### New This Week (Tabular)

<table>
<thead>
<tr>
<th>Category (first appearance)</th>
<th>Title (linked)</th>
<th>Sponsor</th>
<th>Deadline (if multiple, first and last presented)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WEEKLY HIGHLIGHT</td>
<td>Arnold &amp; Mabel Beckman Foundation</td>
<td>Beckman Young Investigator Program</td>
<td>Arnold &amp; Mabel Beckman Foundation</td>
</tr>
<tr>
<td>LIMITED SUBMISSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOUNDATION FUNDING</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Current Limited Submission Opportunities, Columbia University**
<table>
<thead>
<tr>
<th>Limited Submission; Sverige: Sexual Violence Research Initiatives (SVRI); Internal Proposal due 9:00 a.m. on Monday, July 19 [No link provided] Currently available Limited Submission Opportunities at Columbia</th>
<th>SVRI</th>
<th>07/19/2021 (Limited Submission Deadline)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPPH WEEKLY NEWSLETTER</td>
<td>ASPPH Newsletter 07/16/2021 New Format! [please note that the ASPPH Newsletter’s Blog Page will be updated every Friday. All may access it and the url remains constant: <a href="https://www.aspph.org/friday-letter/">https://www.aspph.org/friday-letter/</a>] ASPPH Has Redesigned its Newsletter Page</td>
<td><a href="http://aspph.org">http://aspph.org</a></td>
</tr>
<tr>
<td>ASPPH ANNOUNCEMENTS</td>
<td>ASPPH Policy and Advocacy Newsletter Announcement relative to FY 2020 Budget</td>
<td>ASPPH Policy and Advocacy Newsletter</td>
</tr>
<tr>
<td>REACH FOR THE FIRST R01</td>
<td>Reach for the First R01 ; Columbia Irving Institute for Clinical and Translational Research Application Deadline 09.03.2021</td>
<td><a href="https://www.irvinginstitute.columbia.edu">https://www.irvinginstitute.columbia.edu</a></td>
</tr>
<tr>
<td>EPA PFAS</td>
<td>EPA COLLECTION OF CONCORDANT MULTIMEDIA MEASUREMENTS TO EVALUATE PFAS HUMAN EXPOSURE PATHWAYS Request for Applications (RFA)</td>
<td>EPA</td>
</tr>
<tr>
<td>NIH LOAN REPAYMENT PROGRAM</td>
<td>Extramural Loan Repayment Program for Clinical Researchers (LRP-CR) Extramural Loan Repayment Program for Pediatric Research (LRP-PR) Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR) Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (LRP-IDB)</td>
<td>National Institutes of Health; Office of The Director, National Institutes of Health (OD)</td>
</tr>
</tbody>
</table>
**Extramural Loan Repayment Program for Contraception and Infertility Research (LRP-CIR)**

Extramural Loan Repayment Program for Research in Emerging Areas Critical to Human Health (LRP-REACH)

**NATIONAL SCIENCE FOUNDATION**
Issuance of NSF Proposal and Award Policies and Procedures Guide (NSF 22-1)
National Science Foundation 10/04/2021 (Effective Date)

Statement by NSF Director Sethuraman Panchanathan on the President’s FY22 Budget Request
National Science Foundation (NSF) 05/28/2021 (Release Date)

**CLINICAL TRIALS**
NIA Announces New Policy and Procedures for the Reporting of Human Subjects Enrollment Data for NIA Clinical Research Trials/Studies
National Institute on Aging 06/17/2021 (Release Date)

**BIG DATA**
Columbia Data Science Institute Capstone Project, Updated Link for Submission (Due 07/18/2021)
Archival CU Capstone Project Link provided for reference
Capstone Project Mentor Sign Up Form (Due 07/30/2021) [link will be provided when available]
Data Science Institute; https://datascience.columbia.edu/
datascience@columbia.edu 07/18/2021 (Deadline for Capstone Project); 07/30/2021 (Capstone Project Mentor Sign up Form Deadline)

Request for Information: Developing Consent Language for Future Use of Data and Biospecimens
National Institutes of Health 09/29/2021

NIH Request for Information (RFI) on Streamlining Access to Controlled Data from NIH Data Repositories; Notice Number: NOT-OD-21-157; Key Dates; Release Date: July 9, 2021; Response Date: August 09, 2021
NIH; https://datascience.nih.gov/streamlining-access-to-controlled-data 08/09/2021 (Response Date)

**COVID-19 RETURNING TO CAMPUS**
COVID-19 Campus Safety for Employees and Students
CUMC NA

Research Opportunity Announcement OTA-21-015C REsearching COVID to Enhance Recovery (RECOVER) Initiative: Mobile Health Platform (MHP) ROA
NIH 07/30/2021

Updated Process for Submission of Federal Financial Reports for Closed Payment Management System Subaccounts
National Institutes of Health 06/01/2021 (Release Date)
### Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)

National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases

<table>
<thead>
<tr>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/16/2021</td>
<td>02/16/2022; 06/16/2022; 02/16/2024; 06/16/2024; 09/08/2024 (Expiration)</td>
</tr>
</tbody>
</table>

---

### NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed) [This is a Limited Submission Opportunity, link provided for reference]

Currently Available CU Limited Submission Opportunities

National Institute of General Medical Sciences

<table>
<thead>
<tr>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/13/2022</td>
<td>07/14/2022 (Expiration)</td>
</tr>
</tbody>
</table>

---

### Limited Submission; Gabrielle’s Angel Foundation for Cancer Research – Medical Research Grants; Internal Proposal Deadline 07.21.2021; Sponsor Deadline 08.27.2021

Gabrielle’s Angel Foundation

<table>
<thead>
<tr>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/21/2021 (Limited Submission, Internal Deadline); 08/27/2021 (Sponsor Deadline)</td>
<td></td>
</tr>
</tbody>
</table>

---

### DIVERSITY

Limited Submission; NIH Resource Center for the Support for Research Excellence (SuRE) Program (U24 - Clinical Trial Not Allowed); Internal Deadline 9:00 a.m. on Thursday, July 8 [This is a Limited Submission Opportunity, Sponsor/NIH posting provided for reference] Currently Available Limited Submission Opportunities, Columbia University

National Institutes of Health (NIH); National Institute of General Medical Sciences (NIGMS)

<table>
<thead>
<tr>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/08/2021 (Internal/CU Limited Submission Deadline); 09/24/2021 (Sponsor Deadline); 09/25/2021 (Expiration)</td>
<td></td>
</tr>
</tbody>
</table>

---

### NATIVE AMERICANS

Notice of Participation of NINR in PAR-20-125, Native American Research Centers for Health (NARCH) (S06 Clinical Trials Optional)

Native American Research Centers for Health (NARCH) (S06 Clinical Trial Optional)

National Institute of Nursing Research

<table>
<thead>
<tr>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/24/2021 (Expiration, PAR-20-125)</td>
<td></td>
</tr>
</tbody>
</table>

---

### HEALTHCARE ASSOCIATED INFECTIONS (HAI)

Large Health Services Research Demonstration and Dissemination Projects for Prevention of Healthcare-Associated Infections (R18)

Agency for Healthcare Research and Quality

<table>
<thead>
<tr>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard dates ; 05/27/2025 (Expiration)</td>
<td></td>
</tr>
</tbody>
</table>

Large Research Projects for Prevention of Healthcare-Associated Infections (R01)

Agency for Healthcare Research and Quality

<table>
<thead>
<tr>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard dates ; 05/27/2025 (Expiration)</td>
<td></td>
</tr>
</tbody>
</table>

---

### ARTIFICIAL INTELLIGENCE (AI)

Notice Announcing Data Generation Projects for the NIH Bridge to Artificial Intelligence

Office of Strategic Coordination (Common Fund)

<table>
<thead>
<tr>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>05/26/2021 (Release Date); 07/20/2021</td>
<td></td>
</tr>
</tbody>
</table>

---
<p>| <strong>Intelligence (Bridge2AI) Program (OT2) Other Transaction Opportunity Announcement</strong> | <strong>(Data Generation Project Letter of Intent (LOI) Due Date (Required)); 08/20/2021 (Full Proposal Deadline(s))</strong> |
| <strong>Integration, Dissemination, and Evaluation (BRIDGE) Center for the NIH Bridge to Artificial Intelligence (Bridge2AI) Program (U54 Clinical Trial Not Allowed)</strong> | <strong>Office of Strategic Coordination (Common Fund) 08/20/2021; 08/21/2021 (Expiration)</strong> |
| <strong>Columbia Center of Artificial Intelligence Technology (CAIT)</strong> | <strong><a href="https://cait.engineering.columbia.edu/">https://cait.engineering.columbia.edu/</a> 09/10/2021</strong> |
| <strong>NEW NIH BIOGRAPHICAL SKETCH AND OTHER SUPPORT FORMAT PAGE</strong> | <strong>Announcing New Inbox for Inquiries Related to Changes to Biographical Sketch and Other Support Format Page Effective as of this announcement, please send inquiries related to changes to the biographical sketch and other support templates to <a href="mailto:nihosbiosketch@nih.gov">nihosbiosketch@nih.gov</a> Updated Other Support resources, including FAQs and sample Other Support format pages Implementation of Changes to the Biographical Sketch and Other Support Format Page Upcoming Changes to the Biographical Sketch and Other Support Format Page for Due Dates on or after May 25, 2021 Reminders of NIH Policies on Other Support and on Policies related to Financial Conflicts of Interest and Foreign Components</strong> | <strong>National Institutes of Health 05/18/2021 (Release Date)</strong> |
| <strong>Archival 05.19.2021 SPA Town Hall on the Revised NIH Other Support Format Pages Archival 05.10.2021 SPA Town Hall on NIH Biographical Sketches and Other Support Pages NIH Researcher Disclosure Requirements Reminders of NIH Policies on Other Support and on Policies related to Financial Conflicts of Interest and Foreign Components</strong> | <strong>SPA 05/19/2021 (Event Date); For NIH Submissions 05/25/2021, 01/25/2022 and after; You may continue to use the current biosketch and other support format pages, however, the new formats will be required for</strong> |</p>
<table>
<thead>
<tr>
<th><strong>SPA Project Officer</strong></th>
<th><strong>Publication of the Revised NIH Grants Policy Statement (Rev. April 2021) for Fiscal Year 2021</strong></th>
<th>National Institutes of Health</th>
<th>applications, JIT requests, and RPPRs due on or after 1/25/2022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WEBINAR</strong></td>
<td><strong>Expanding Requirement for eRA Commons IDs to All Senior/Key Personnel</strong></td>
<td>National Institutes of Health; Agency for Healthcare Research and Quality; Food and Drug Administration</td>
<td>04/20/2021 (Release Date)</td>
</tr>
<tr>
<td><strong>WEBINAR</strong></td>
<td><strong>Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjögren’s Syndrome (UC2 Clinical Trial Optional) Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed)</strong></td>
<td>National Institute of Arthritis and Musculoskeletal and Skin Diseases</td>
<td>07/15/2021; 07/16/2021 (Expiration)</td>
</tr>
<tr>
<td><strong>WEBINAR</strong></td>
<td><strong>NIDDK Short-Term Research Experience Program to Unlock Potential (STEP-UP) (R25 Clinical Trial Not Allowed)</strong></td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases</td>
<td>09/01/2021; 09/02/2021 (RFA)</td>
</tr>
<tr>
<td><strong>WEBINAR</strong></td>
<td><strong>Notice of Informational Webinar on the Intramural NIGMS Postdoctoral Research Associate Training (PRAT) Program and Fi2 Application Process</strong></td>
<td>National Institute of General Medical Sciences</td>
<td>06/22/2021 (2PM, Event Date)</td>
</tr>
<tr>
<td><strong>WEBINAR</strong></td>
<td><strong>Notice of a Pre-Application Informational Webinar for PAR-21-168 &quot;Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)&quot; Webinar Registration Archival posting after the event</strong></td>
<td>National Institute of Neurological Disorders and Stroke; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; National Institute on Drug Abuse; National Institute of Environmental Health Sciences</td>
<td>07/27/2021 (Webinar Date)</td>
</tr>
<tr>
<td><strong>DIABETES</strong></td>
<td><strong>Comprehensive Care for Adults with Type 2 Diabetes Mellitus from</strong></td>
<td>National Institute on Minority Health and Health Disparities;</td>
<td>10/05/2021; 02/05/2022;</td>
</tr>
<tr>
<td>Topic</td>
<td>Funding Agency</td>
<td>Expiration Dates</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------</td>
<td>--------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Populations with Health Disparities</td>
<td>National Eye Institute; National Institute of Diabetes and Digestive and Kidney Diseases; Office of Research on Women's Health</td>
<td>02/05/2024; 06/05/2024; 09/08/2024 (Expiration)</td>
<td></td>
</tr>
<tr>
<td>Characterization of Islet-derived Extracellular Vesicles for Improved Detection, Monitoring, Classification, and Treatment of Type 1 Diabetes (R01 Clinical Trial Not Allowed)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases</td>
<td>11/03/2021; 11/04/2021 (Expiration)</td>
<td></td>
</tr>
<tr>
<td>Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes Clinical Centers (U01 Clinical Trial Not Allowed)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases</td>
<td>03/03/2022; 03/04/2022 (Expiration)</td>
<td></td>
</tr>
<tr>
<td>Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes Biostatistics Research Center (U01 Clinical Trial Not Allowed)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases</td>
<td>03/03/2022; 03/04/2022 (Expiration)</td>
<td></td>
</tr>
<tr>
<td>SMALL RESEARCH GRANTS</td>
<td>NICHD Small Research Grant Program (R03 Clinical Trial Required)</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
<td>10/16/2021; 02/16/2022; 06/16/2022; 10/16/2022; 02/16/2023; 06/16/2023; 10/16/2023; 02/16/2024; 05/08/2024 (Expiration)</td>
</tr>
<tr>
<td></td>
<td>NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
<td>10/16/2021; 02/16/2022; 06/16/2022; 10/16/2022; 02/16/2023; 06/16/2023; 10/16/2023; 02/16/2024; 05/08/2024 (Expiration)</td>
</tr>
<tr>
<td>RESEARCH ADMINISTRATION FORUMS</td>
<td>Research Administration Forums</td>
<td>SPA</td>
<td>04/12/2021; (Event Date)</td>
</tr>
<tr>
<td>ENVIRONMENTAL EPIDEMIOLOGY CLIMATE</td>
<td>At this point in time E2C2 plans to reconvene in the Fall. If there is interest we will meet over the summer so</td>
<td>Research Resources and the Departments of</td>
<td>At this point in time E2C2 plans reconvene in the Fall;</td>
</tr>
</tbody>
</table>
### CONNECTIONS (E2C2)

- Colleagues may practice presentations. Opportunities and announcements will be forwarded to the group.
- Environmental Health Sciences and Epidemiology may schedule meetings so colleagues may practice SER (06/08), ISEE (08/10) (or other) presentations. Otherwise, we'll reconvene in the fall. Opportunities and announcements will be forwarded to the group when appropriate. (Meeting dates, [usually the 2nd and 4th] Tuesdays of each month] 4PM-5PM)

### NIH DIRECTOR’S PIONEER AWARD

- NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
- [https://commonfund.nih.gov/pioneer](https://commonfund.nih.gov/pioneer)
- [https://commonfund.nih.gov/highrisk](https://commonfund.nih.gov/highrisk)
- 09/10/2021; 09/11/2021 (Expiration)

### OUTSTANDING INVESTIGATOR AWARD

- NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
- National Heart, Lung, and Blood Institute
- 02/15/2022; 02/15/2023; 02/15/2024; 04/26/2024 (Expiration)

### EARLY INVESTIGATOR

- NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
- National Heart, Lung, and Blood Institute
- 02/15/2022; 02/15/2023; 02/15/2024; 04/26/2024 (Expiration)

### AUTOIMMUNITY

- Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases (AMP AIM) program
- National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; National Institute of Dental and Craniofacial Research; Office of Research on Women’s Health
- 07/15/2021; 07/16/2021 (Expiration)
<table>
<thead>
<tr>
<th>Category</th>
<th>Title</th>
<th>Principal Investigator</th>
<th>Due Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>P GRANTS</td>
<td>Notice of Intent to Publish the Reissuance of PAR-18-420, NINDS Exploratory Clinical Trials (U01 - Clinical Trial Required)</td>
<td>National Institute of Neurological Disorders and Stroke</td>
<td>06/05/2021 (Estimated First Application Due Date)</td>
</tr>
<tr>
<td>SUMMER RESEARCH</td>
<td>NINDS Program Project Grant (P01 Clinical Trial Optional)</td>
<td>National Institute of Neurological Disorders and Stroke</td>
<td>05/25/2021 (First Application Due Date); 01/25/2024; 05/08/2024 (Expiration)</td>
</tr>
<tr>
<td></td>
<td>Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)</td>
<td>National Institute of Neurological Disorders and Stroke</td>
<td>03/17/2022; 03/17/2023; 03/19/2024; 05/08/2024 (Expiration)</td>
</tr>
<tr>
<td>CLINICIAN SCIENTISTS</td>
<td>Research Experiences to Enhance Clinician-Scientists' Participation in NIDCDs Research (R25 Clinical Trial Not Allowed)</td>
<td>National Institute on Deafness and Other Communication Disorders</td>
<td>09/24/2021; 01/27/2022; 05/27/2022; 09/21/2022; 01/27/2023; 05/26/2023; 09/26/2023; 01/29/2024; 01/30/2024 (Expiration)</td>
</tr>
<tr>
<td></td>
<td>Limited Competition: Clinical and Translational Science Awards (CTSA) Consortium-Wide Centers: Resources for Rapid Demonstration and Dissemination (U24 Clinical Trials Not Allowed)</td>
<td>National Center for Advancing Translational Sciences</td>
<td>06/21/2022; 06/21/2023; 06/22/2023 (Expiration)</td>
</tr>
<tr>
<td>PHYSICAL ACTIVITY</td>
<td>Notice of Special Interest (NOSI): Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being</td>
<td>Office of Disease Prevention; National Center for Complementary and Integrative Health; National Cancer Institute; National Institute on Aging; National Institute of Arthritis and Musculoskeletal and Skin</td>
<td>06/05/2021 (First Available Due Date); 02/16/2024 (Expiration)</td>
</tr>
<tr>
<td>PCORI</td>
<td>Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research; Office of Behavioral and Social Sciences Research; Office of Research on Women's Health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health</td>
<td>Office of Behavioral and Social Sciences Research; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; <em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research; Office of Disease Prevention; Office of Research on Women's Health</td>
<td>05/07/2021 (First Available Due Date); 06/08/2024 (Expiration Date)</td>
<td></td>
</tr>
<tr>
<td>Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 Clinical Trials Not Allowed)</td>
<td>NIH Basic Behavioral and Social Science Opportunity Network; National Cancer Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; <em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development</td>
<td>02/05/2022; 02/05/2023; 05/08/2023 (Expiration)</td>
<td></td>
</tr>
<tr>
<td>Field</td>
<td>Description</td>
<td>Institution(s)</td>
<td>Dates</td>
</tr>
<tr>
<td>---------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td><strong>Dyadic Interpersonal Processes and Biopsychosocial Outcomes; (R01 Basic Experimental Studies with Humans)</strong></td>
<td>NIH</td>
<td>03/05/2022; 03/08/2022 (Expiration)</td>
<td></td>
</tr>
<tr>
<td><strong>Microbiology</strong></td>
<td>Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institute of Allergy and Infectious Diseases; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences</td>
<td>10/20/2021; 06/22/2022; 10/20/2022; 06/22/2023; 10/19/2023; 10/20/2023 (Expiration)</td>
</tr>
<tr>
<td><strong>Psychology</strong></td>
<td>Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional)</td>
<td>National Institute of Mental Health</td>
<td>11/01/2021; 11/01/2022; 11/01/2023; 11/02/2023 (Expiration)</td>
</tr>
<tr>
<td></td>
<td>Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional)</td>
<td>National Institute of Mental Health</td>
<td>11/01/2021; 11/01/2022; 11/01/2023; 11/02/2023 (Expiration)</td>
</tr>
<tr>
<td><strong>Cancer</strong></td>
<td>Elsa U. Pardee Foundation</td>
<td>Cancer Research <a href="https://pardeefoundation.org">https://pardeefoundation.org</a></td>
<td>08/31/2021</td>
</tr>
<tr>
<td></td>
<td>Policy, Insurance in Access, Prevention, Detection Treatment of cancer</td>
<td><a href="https://www.cancer.org">https://www.cancer.org</a></td>
<td>10/15/2021</td>
</tr>
<tr>
<td></td>
<td>AGA-Augustyn Award in Digestive Cancer</td>
<td><a href="https://gastro.org">https://gastro.org</a></td>
<td>07/21/2021</td>
</tr>
<tr>
<td>Clinical Res. Professor American Cancer Society</td>
<td><a href="https://www.cancer.org">https://www.cancer.org</a></td>
<td>08/01/2021 (LOI); 10/01/2021 (Application)</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Metastatic Breast Cancer addressing disparities for people of color</td>
<td><a href="https://cdn.pfizer.com">https://cdn.pfizer.com</a></td>
<td>08/04/2021</td>
<td></td>
</tr>
<tr>
<td>Clinical Investigator Career Development Lymphoma Res. Foundation</td>
<td><a href="https://lymphoma.org">https://lymphoma.org</a></td>
<td>09/08/2021</td>
<td></td>
</tr>
<tr>
<td>Smith Charitable Trust Heart, Cancer and AIDS Research</td>
<td><a href="http://www.wwsmithcharitabletrust.org">http://www.wwsmithcharitabletrust.org</a></td>
<td>07/15/2021</td>
<td></td>
</tr>
<tr>
<td>Damon Runyon Cancer Research Foundation Fellowship Award</td>
<td><a href="https://www.damonrunyon.org">https://www.damonrunyon.org</a></td>
<td>08/16/2021</td>
<td></td>
</tr>
<tr>
<td>Tina’s Wish Tina Brozman Foundation for Ovarian Cancer Research</td>
<td>Tina Bozman Foundation</td>
<td>06/10/2021 (LOI); 08/16/2021 (Invited Applicant Deadline)</td>
<td></td>
</tr>
<tr>
<td>AGA–Funderburg Research Award in Gastric Cancer</td>
<td><a href="https://gastro.org">https://gastro.org</a></td>
<td>07/21/2021</td>
<td></td>
</tr>
<tr>
<td>Young Investigator Grants Breast Cancer Alliance</td>
<td><a href="https://breastcanceralliance.org">https://breastcanceralliance.org</a></td>
<td>04/01/2021 (LOI); 07/23/2021 (Application)</td>
<td></td>
</tr>
<tr>
<td>AACR-St. Baldrick’s Award for Achievement in Pediatric Cancer</td>
<td><a href="https://www.aacr.org">https://www.aacr.org</a></td>
<td>08/31/2021</td>
<td></td>
</tr>
<tr>
<td>Pilot &amp; Exploratory Projects Palliative Care of Cancer patients</td>
<td><a href="https://www.cancer.org">https://www.cancer.org</a></td>
<td>10/15/2021</td>
<td></td>
</tr>
<tr>
<td>Columbia University VeloCity Ride to End Cancer</td>
<td>Columbia</td>
<td>10/03/2021 (Event Date)</td>
<td></td>
</tr>
<tr>
<td>Request for Information (RFI): Input for National Cancer Institute (NCI) Pediatric Immunotherapy Network</td>
<td>National Cancer Institute</td>
<td>07/10/2021 (Response Date)</td>
<td></td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): New Information Technology-Enabled Care Delivery Models to Improve Depression Care in Cancer</td>
<td>National Cancer Institute</td>
<td>10/05/2021 (First Available Due Date); 03/08/2024 (Expiration Date)</td>
<td></td>
</tr>
<tr>
<td>Cancer Genomics and Epigenomics Program Translational Clinical Trials Pilot Projects; Deadline: August 15</td>
<td>Cancer Genomics and Epigenomics (CGE) Program at the Herbert Irving Comprehensive Cancer Center</td>
<td>08/15/2021</td>
<td></td>
</tr>
<tr>
<td>The Basser Global Prize; Deadline: August 27</td>
<td><a href="https://www.basser.org">https://www.basser.org</a></td>
<td>08/27/2021</td>
<td></td>
</tr>
<tr>
<td>Cancer Research Institute Postdoctoral Fellowships; Deadline: October 1</td>
<td>CRI; <a href="https://www.cancerresearch.org">https://www.cancerresearch.org</a></td>
<td>10/01/2021</td>
<td></td>
</tr>
</tbody>
</table>
| **DEPARTMENT OF DEFENSE** | **Pancreatic Cancer Research Program Idea Development Award**  
**Translational Research Partnership Award**  
**Informative Webinar**  
**PCRP Application Instructions** | **Department of Defense** | **07/01/2021 (Pre-Application); 10/07/2021 (Application)** |
|---|---|---|---|
| **PIVOT** | [1] Pivot, New Dashboard!  
[3] Pivot Overview-Find Funding and Collaborators-Webinar 02.17.2021 Slides  
https://pivot.proquest.com;  
the Augustus C. Long Health Sciences Library, in collaboration with Sponsored Projects Administration | **NA** |
| **NIH REPORTER** | **NIH Extramural Nexus, NIH Reporter,**  
**Keeping on Top of NIH-Funded Research You Care the Most About Just Got Easier** | **https://grants.nih.gov/grants/oer.htm** | **02/16/2021 (Release Date)** |
| **NSF-BSF JOINT FUNDING OPPORTUNITIES** | **NSF-BSF Joint Funding Opportunities by Program**  
**NSF-BSF Foundational Research in Robotics**  
**NSF-BSF Cyber-Physical Systems**  
**NSF-BSF Mathematical and Scientific Foundations of Deep Learning** | **U.S.-Israel Binational Science Foundation (BSF); www-bsf.org;  
https://www.bsf.org.il/funding-opportunities/nsf-bsf-joint-research-grants/about/** | **Please see individual opportunities** |
| **DoD/CDMRP - COVID-19 Impact on Research Awards [No Link Provided]** | **CDMRP continues to be concerned about the impacts of COVID-19 on Service Members and the public. We are aware of the challenges it poses and are tracking some of the impacts to current awardees and ongoing research. While not every program will have financial resources available to assist, awareness of any significant unresolved issues affecting current research awards is important. The intent of this notice is to remind recipients of the requirements in 32 CFR** | **Department of Defense** | **NA** |
Part 1134, Subpart E Other Reporting. This provision specifies the requirement for recipients to disclose significant developments as soon as they become known. These include problems, delays, or adverse conditions that will materially impair your ability to meet the objectives of your awards.; Disclosures of significant developments may be made on your next interim performance report or at any point between scheduled performance reporting dates by contacting the Science Officer or Grant Specialist assigned to your award. This disclosure must include a statement of the action taken, or contemplated, and any assistance needed to resolve the situation.

<table>
<thead>
<tr>
<th>FY21 Department of Defense; Alcohol and Substance Abuse Disorders Research Program ASADRP Consortium Award Tuberous Sclerosis Complex Research Program TSCRP Deadline Extended</th>
<th>Department of Defense</th>
</tr>
</thead>
<tbody>
<tr>
<td>Department of Defense; FY21; Duchenne Muscular Dystrophy (DMDRP) Application Instructions; Department of Defense; FY21; Duchenne Muscular Dystrophy (DMDRP) Department of Defense; FY21; Duchenne Muscular Dystrophy (DMDRP); Idea Development Award Department of Defense; FY21; Duchenne Muscular Dystrophy</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>08/18/2021 (Pre-Application); 09/08/2021 (Application) [Alcohol and Substance Abuse Disorders Research Program Consortium Award]; 07/08/2021 (Pre-Application); 07/29/2021 (Application) [Tuberous Sclerosis Complex Research Program TSCRP Deadline Extended]</td>
<td>08/11/2021 (Pre-Application); 12/01/2021 (Application) [Department of Defense; FY21; Duchenne Muscular Dystrophy (DMDRP); Deadlines]</td>
</tr>
<tr>
<td>Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP)</td>
<td>Department of Defense</td>
</tr>
</tbody>
</table>
| Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP); Application Instructions | Department of Defense | [
<p>| Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP); Early Investigator Research Award | | Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP); Investigator-Initiated Research Award |
| Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP); Synergistic Idea Award | | Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP)] |
| JUST RELEASED! FY21 DoD BCRP, BMFRP, and LRP Program Announcements and DMDRP Pre-announcement DOD CDMRP website DOD FY21 Breast Cancer Research Program (BCRP) Bone Marrow Failure Research Program (BMFRP) Lupus Research Program (LRP) Duchenne Muscular Dystrophy (DMDRP) CDMRP Webinar Series | Department of Defense | Weekly DOD update; 04/30/2021 |
| Fiscal Year 2021 (FY21) Peer Reviewed Cancer Research Program (PRCRP) | Department of Defense | Later April, Early May (Pre-Applications); Please see piecemeal opportunities |
| Fiscal Year 2021 (FY21) Peer Reviewed Orthopaedic Research Program (PRORP) | | |
| Fiscal Year 2021 (FY21) Prostate Cancer Research Program (PCRP) | | |
| Fiscal Year 2021 (FY21) Spinal Cord Injury Research Program (SCIRP) | | |
| Fiscal Year 2021 (FY21) Tick-Borne Disease Research Program (TBDRP) | | |
| Fiscal Year 2021 (FY21) Tuberous Sclerosis Complex Research Program (TSCRP) | | |
| Subscribe to the DOD ListServ | | |
| SPA Project Officer | | |
| Fiscal Year 2021 (FY21) Autism Research Program (ARP) | Department of Defense | 05/07/2021 (Pre-Application); 08/19/2021 |
| Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program (PRMRP) | | |
| Fiscal Year 2021 (FY21) Amyotrophic Lateral Sclerosis Research Program (ALSRP) | | |
| Fiscal Year 2021 (FY21) Breast Cancer Research Program (BCRP) | | |
| Fiscal Year 2021 (FY21) Combat Casualty Care Research Program (JPC-6) | | |
| Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP) | | |
| Fiscal Year 2021 (FY21) Lung Cancer Research Program (LCRP) | | |
| Fiscal Year 2021 (FY21) Ovarian Cancer Research Program (OCRP) | | |
| Fiscal Year 2021 (FY21) Peer Reviewed Cancer Research Program (PRCRP) | | |
| Fiscal Year 2021 (FY21) Tick-Borne Disease Research Program (TBDRP) | | |
| Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); Research Advancement Award | Department of Defense 06/08/2021 (Pre-Application, MBRP); 09/30/2021 (Application MPRP); 07/08/2021 (Pre-Application, NFRP); 07/22/2021 (Application, NFRP) |
| Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); Clinical Evaluation Award | |
| Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); Therapeutic Biomarker Trial Award | |
| Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); New Investigator Award | |
| Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); Application Instructions | |
| Currently Available Department of Defense DOD FY21 Funding Opportunities CDMRP Webinar Series | |
| Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); New Investigator Award | |
| Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); Application Instructions | |
| Department of Defense FY21 Military Burn Research Program (MBRP) Department of Defense FY21 Neurofibromatosis Research Program (NFRP) | Department of Defense 05/05/2021 (Pre-Application); 07/28/2021 (Application) [LCRP Idea Development Award; LCRP Investigator-Initiated Translational Research Award]; 07/14/2021 (Pre-Application); 07/28/2021 (Application) [LCRP Clinical Translational Research Partnership Award] |
| Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); New Investigator Award | |
| Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); Application Instructions | |</p>
<table>
<thead>
<tr>
<th>Currently Available Department of Defense DOD FY21 Funding Opportunities</th>
<th>CDMRP Webinar Series Department of Defense</th>
<th>05/13/2021 (Pre-Application); 08/26/2021 (Application)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program (PRMRP); Clinical Trial Award</td>
<td>Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program (PRMRP);</td>
<td>Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program (PRMRP) Focused Program Award</td>
</tr>
<tr>
<td>Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program (PRMRP);</td>
<td>Department of Defense</td>
<td>04/28/2021 (Pre-Application); 09/02/2021 (Application)</td>
</tr>
<tr>
<td>Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program (PRMRP);</td>
<td>Investigator-Initiated Research Award</td>
<td>PRMRP Peer Reviewed Medical Research Program (PRMRP) Technology Therapeutic Development Award</td>
</tr>
<tr>
<td>Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program (PRMRP);</td>
<td>04/28/2021 (Pre-Application); 09/02/2021 (Application)</td>
<td></td>
</tr>
<tr>
<td>Technology/Therapeutic Development Award</td>
<td>PRMRP Peer Reviewed Medical Research Program (PRMRP)</td>
<td></td>
</tr>
<tr>
<td>Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program (PRMRP);</td>
<td>05/13/2021 (Pre-Application); 08/26/2021 (Application)</td>
<td></td>
</tr>
<tr>
<td>PRMRP Application Instructions</td>
<td>[PRMRP Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award]</td>
<td></td>
</tr>
<tr>
<td>Currently Available Department of Defense DOD FY21 Funding Opportunities</td>
<td>For Pre-Announcements (NA); 03/31/2021 (Department of Defense FY21 Combat Casualty and Care Research Program (JPC-6) En Route Care Award Pre-Application);</td>
<td></td>
</tr>
<tr>
<td>[1] FY21 Department of Defense DOD Current Funding opportunities</td>
<td>06/23/2021 (Department of Defense FY21 Combat Casualty and Care Research Program (JPC-6) En Route Care Award Application)</td>
<td></td>
</tr>
<tr>
<td>[2] FY21 Department of Defense DOD Amyotrophic Lateral Sclerosis Research Program (ALSRP) Funding Announcements</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[4] FY21 Department of Defense DOD Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[5] FY21 Department of Defense DOD Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[6] FY21 Department of Defense DOD Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Development Award</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[7] FY21 Department of Defense DOD Amyotrophic Lateral Sclerosis Research Program (ALSRP)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Department of Defense**

<p>| Currently Available FY21 DOD Funding Opportunities | NA re the SCIRP Pre-Announcements; 04/09/2021 (ALSRP Pre-Application); 07/15/2021 (ALSRP Applications) |
| Department of Defense FY21 Pre-Announcements | |
| Department of Defense, CDMRP Webinar Series | |
| Department of Defense FY21 Pre-Announcements | |</p>
<table>
<thead>
<tr>
<th>Therapeutic Biomarker Pilot Trial Award</th>
<th>Department of Defense</th>
<th>Please see piecemeal programs and their individual opportunities for Deadlines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current, FY 2020 Department of Defense Funding Opportunities</td>
<td>Department of Defense</td>
<td>Please see piecemeal programs and their individual opportunities for Deadlines</td>
</tr>
<tr>
<td>Your Questions Answered: COVID-19 Vaccines, Archival Webinar 04.08.2021, with Drs. Kellie Bryant and Gary Miller</td>
<td>Office of the Dean</td>
<td>04/08/2021 (Archival posting, Event Date)</td>
</tr>
<tr>
<td>NIH COVID-19 RESEARCH WEBSITE</td>
<td>NIH's COVID-19 Research Website</td>
<td>NIH</td>
</tr>
<tr>
<td>NIH COVID-19 RESEARCH WEBSITE</td>
<td>NIH's COVID-19 Research Website - NEXUS</td>
<td>NA</td>
</tr>
<tr>
<td>NIH Funding Opportunities Specific to COVID-19 Webpage</td>
<td>NIH Funding Opportunities Webpage</td>
<td>NIH</td>
</tr>
<tr>
<td>NIH Funding Opportunities Specific to COVID-19 Webpage</td>
<td>NIH Funding Opportunities Webpage</td>
<td>NA, 07/08/2020 (Release Date)</td>
</tr>
<tr>
<td>DEDICATED CU WEBSITE, COVID-19: FAQs AND RESOURCES RELATING TO RESEARCH</td>
<td>CU Website Dedicated to COVID-19: FAQs and Resources Relating to Research</td>
<td><a href="https://research.columbia.edu">https://research.columbia.edu</a></td>
</tr>
<tr>
<td>DEDICATED CU WEBSITE, COVID-19: FAQs AND RESOURCES RELATING TO RESEARCH</td>
<td>CU Website Dedicated to COVID-19: FAQs and Resources Relating to Research</td>
<td>NA</td>
</tr>
<tr>
<td>VIROLOGY</td>
<td>Promoting Bunyavirales Basic Science Research (R01 Clinical Trial Not Allowed)</td>
<td>National Institute of Allergy and Infectious Diseases</td>
</tr>
<tr>
<td>VIROLOGY</td>
<td>Promoting Bunyavirales Basic Science Research (R01 Clinical Trial Not Allowed)</td>
<td>National Institute of Allergy and Infectious Diseases</td>
</tr>
<tr>
<td>SUMMER 2021 SKILLS FOR HEALTH AND RESEARCH PROFESSIONALS (SHARP) TRAINING AT CU</td>
<td>Registration for Summer 2021 Skills for Health and Research Professionals (SHARP) Training at Columbia University is now open</td>
<td>Columbia University, Mailman School of Public Health, Precision Prevention</td>
</tr>
<tr>
<td>SUMMER 2021 SKILLS FOR HEALTH AND RESEARCH PROFESSIONALS (SHARP) TRAINING AT CU</td>
<td>Registration for Summer 2021 Skills for Health and Research Professionals (SHARP) Training at Columbia University is now open</td>
<td>Registration remains open either until classes are filled, or up until a few weeks before classes begin, Summer 2021</td>
</tr>
<tr>
<td>PILOT</td>
<td>Second annual of the SEAS-HICCC joint seed grant funding opportunity SEAS-HICCC Joint Seed Grants RFA; [extended deadline 07/30/2021 is not reflected in the rfa] Apply SEAS-HICCC Joint Seed Grants</td>
<td>Columbia’s School of Engineering and Applied Science (SEAS) and the Herbert Irving Comprehensive Cancer Center (HICCC)</td>
</tr>
<tr>
<td>PILOT</td>
<td>Second annual of the SEAS-HICCC joint seed grant funding opportunity SEAS-HICCC Joint Seed Grants RFA; [extended deadline 07/30/2021 is not reflected in the rfa] Apply SEAS-HICCC Joint Seed Grants</td>
<td>07/30/2021 [Extended Deadline]</td>
</tr>
<tr>
<td>MENTAL HEALTH DISORDERS</td>
<td>Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>MENTAL HEALTH DISORDERS</td>
<td>Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)</td>
<td>10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023;</td>
</tr>
<tr>
<td>Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)</td>
<td>National Institute of Mental Health</td>
<td>10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)</td>
</tr>
<tr>
<td>NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)</td>
<td>National Institute of Mental Health</td>
<td>10/16/2021; 10/16/2023; 02/16/2024; 05/08/2024 (Expiration)</td>
</tr>
<tr>
<td>Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)</td>
<td>National Institute of Mental Health</td>
<td>10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)</td>
</tr>
<tr>
<td>Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)</td>
<td>National Institute of Mental Health</td>
<td>10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)</td>
</tr>
<tr>
<td>First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)</td>
<td>National Institute of Mental Health</td>
<td>10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)</td>
</tr>
<tr>
<td><strong>Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)</strong></td>
<td><strong>National Institute of Mental Health</strong></td>
<td>10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)</td>
</tr>
<tr>
<td><strong>Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)</strong></td>
<td><strong>National Institute of Mental Health</strong></td>
<td>10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)</td>
</tr>
<tr>
<td><strong>Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33-Clinical Trial Required)</strong></td>
<td><strong>National Institute of Mental Health</strong></td>
<td>10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)</td>
</tr>
<tr>
<td><strong>Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)</strong></td>
<td><strong>National Institute of Mental Health</strong></td>
<td>10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)</td>
</tr>
<tr>
<td>Category</td>
<td>Description</td>
<td>Agency</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------</td>
</tr>
<tr>
<td>INTERVENTIONS</td>
<td>Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)</td>
<td>National Center for Complementary and Integrative Health</td>
</tr>
<tr>
<td></td>
<td>NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)</td>
<td>National Center for Complementary and Integrative Health</td>
</tr>
<tr>
<td></td>
<td>Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)</td>
<td>National Center for Complementary and Integrative Health</td>
</tr>
<tr>
<td></td>
<td>Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)</td>
<td>National Center for Complementary and Integrative Health</td>
</tr>
<tr>
<td>MATERNAL AND CHILD HEALTH</td>
<td>Announcement of Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellows Extramural Nexus How do I request childcare costs in my fellowship application</td>
<td>NIH</td>
</tr>
<tr>
<td></td>
<td>Notice of Special Interest (NOSI): Using Systems Science Methodologies to Protect and Improve Child and Reproductive Population Health</td>
<td>  Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; Office of Disease Prevention</td>
</tr>
<tr>
<td></td>
<td>Prevention of Perinatal Depression: Improving Intervention Delivery for At-</td>
<td>NIH, National Institute of Mental Health (NIMH)</td>
</tr>
<tr>
<td>Risk Individuals (R01 Clinical Trial Required)</td>
<td>NIH, National Institute of Mental Health (NIMH)</td>
<td>11/09/2021; 11/10/2021 (Expiration)</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R34 Clinical Trial Required)</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
<td>07/29/2021; 07/30/2021 (Expiration)</td>
</tr>
<tr>
<td>Developmental Mechanisms of Human Structural Birth Defects (P01 Clinical Trial Not Allowed)</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
<td>06/05/2021 (First Available Due Date); 05/31/2024 (Expiration Date)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Reproductive Health, Pregnancy, and Parenting among Women with Disabilities</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
<td>06/05/2021; 02/05/2025; 05/08/2025 (Expiration)</td>
</tr>
<tr>
<td>Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs</td>
<td>06/16/2021 (First Available Due Date); 05/08/2023 (Expiration Date)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Reduction of Sudden Unexpected Infant Death and Sudden Infant Death Syndrome</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>Notice of Information: NIMH High-Priority Areas for Research on Women's Mental Health during the Perinatal Period</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
</tr>
<tr>
<td>Proposal Title</td>
<td>Institution</td>
<td>Dates</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>10/19/2021; 02/17/2022; 06/17/2022; 10/18/2022; 02/17/2023; 06/19/2023; 10/17/2023; 10/18/2023 (Expiration)</td>
</tr>
<tr>
<td>Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Project (U01 Clinical Trial optional)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>08/16/2021; 08/17/2021 (Expiration)</td>
</tr>
<tr>
<td>Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Administrative Resource (U24) (Clinical Trial Not Allowed)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>08/16/2021; 08/17/2021 (Expiration)</td>
</tr>
<tr>
<td>Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Diagnostic-Telemedicine Resource (U24 Clinical Trial Not Allowed)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>08/16/2021; 08/17/2021 (Expiration)</td>
</tr>
<tr>
<td>Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Data Coordination Resource (U24 Clinical Trial Not Allowed)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>08/16/2021; 08/17/2021 (Expiration)</td>
</tr>
<tr>
<td>Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Developmental Project (UH2 Clinical Trial Optional)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>08/16/2021; 08/17/2021 (Expiration)</td>
</tr>
<tr>
<td>Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional)</td>
<td>National Institute on Drug Abuse</td>
<td>08/13/2021; 08/14/2021 (Expiration)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Partnership between Research Centers in Minority Institutions (RCMI) and Alcohol Research Centers (U54 Clinical Trial Optional)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>12/15/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research</td>
<td>National Institute on Drug Abuse</td>
<td>10/05/2021 (First Available Due Date); 09/08/2024 (Expiration Date)</td>
</tr>
<tr>
<td>HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)</td>
<td>National Institute on Drug Abuse; National Center for Complementary and Integrative Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases</td>
<td>10/19/2021; 10/20/2021 (Expiration)</td>
</tr>
<tr>
<td>HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 - Clinical Trial Not Allowed) (RFA-DA-22-031)</td>
<td>National Institutes of Health (NIH); Components of Participating Organizations: National Institute on Drug Abuse (NIDA); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Complementary and Integrative Health (NCCIH)</td>
<td>10/19/2021; 10/20/2021 (Expiration)</td>
</tr>
<tr>
<td>HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional) (RFA-DA-19-019)</td>
<td>National Institutes of Health (NIH); Components of Participating Organizations: National Institute on Drug Abuse (NIDA); National Center for Advancing Translational Sciences (NCATS)</td>
<td>09/08/2021; 09/09/2021 (Expiration)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for the NIH HEAL Initiative: Preventing Opioid Misuse and other Drug Use by Intervening on Social Determinants (R01 Clinical Trials Optional)</td>
<td>National Institute on Drug Abuse; Office of Behavioral and Social Sciences Research</td>
<td>01/07/2022 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional)</td>
<td>National Institute of Neurological Disorders and Stroke</td>
<td>11/01/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>10/16/2021; 02/16/2022; 02/16/2024;</td>
</tr>
<tr>
<td>Request for Information (RFI): Inviting Input on NIAAAs 2022-2026 Strategic Plan Outline</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>07/30/2021 (Response Date)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>HEAL Initiative: Planning Studies for Initial Analgesic Development [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed)</td>
<td>National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
<td>07/19/2021; 10/13/2021; 06/09/2022; 10/11/2022; 06/09/2023; 10/10/2023; 10/11/2023 (Expiration)</td>
</tr>
<tr>
<td>NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)</td>
<td>National Institute on Drug Abuse</td>
<td>07/26/2021; 03/02/2022; 07/26/2022; 03/02/2023; 07/26/2023; 03/04/2024; 03/05/2024 (Expiration)</td>
</tr>
<tr>
<td>PEDIATRICS</td>
<td>Recompetition of the Pediatric Scientist Development Program (PSDP) (K12 Clinical Trial Not Allowed)</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
</tr>
<tr>
<td></td>
<td>Pediatric Immune System Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed)</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
</tr>
</tbody>
</table>
### BRAIN INITIATIVE

<table>
<thead>
<tr>
<th>Project Description</th>
<th>Funders</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)</td>
<td>National Institute of Mental Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Neurological Disorders and Stroke</td>
<td>05/08/2024 (Expiration)</td>
</tr>
<tr>
<td>BRAIN Initiative: Pilot resources for brain cell type-specific access and manipulation across vertebrate species (U01 Clinical Trial Not Allowed)</td>
<td>NIH</td>
<td>10/15/2021; 06/10/2022; 10/14/2022; 06/09/2023; 10/13/2023; 06/07/2024; 06/08/2024 (Expiration)</td>
</tr>
<tr>
<td>BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)</td>
<td>NIH</td>
<td>10/19/2021; 10/20/2021</td>
</tr>
<tr>
<td>BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)</td>
<td>National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice</td>
<td>10/29/2021; 05/02/2022; 10/28/2022; 05/01/2023; 10/27/2023; 10/28/2023 (Expiration)</td>
</tr>
<tr>
<td>Project Description</td>
<td>Institutions</td>
<td>Dates</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>BRAIN Initiative: Optimization of Transformative Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed)</strong></td>
<td>Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; Office of Behavioral and Social Sciences Research</td>
<td>10/29/2021; 05/02/2022; 10/28/2022; 05/01/2023; 10/27/2023; 10/28/2023 (Expiration)</td>
</tr>
<tr>
<td><strong>BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional)</strong></td>
<td>National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; Office of Behavioral and Social Sciences Research</td>
<td>10/13/2021; 10/11/2022; 10/11/2023; 10/12/2023 (Expiration)</td>
</tr>
<tr>
<td>K-AWARDS</td>
<td>Project Description</td>
<td>Participating Organizations</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</td>
<td>National Institutes of Health (NIH); Components of Participating Organizations; National Institute of Neurological Disorders and Stroke (NINDS); National Eye Institute (NEI); National Institute on Aging (NIA); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Biomedical Imaging and Bioengineering (NIBIB); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Deafness and Other Communication Disorders (NIDCD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH); National Center for Complementary and Integrative Health (NCCIH)</td>
<td>10/06/2021; 02/10/2022; 06/08/2022; 10/11/2022</td>
</tr>
<tr>
<td>BRAIN Initiative: Targeted BRAIN Circuits Planning Projects - TargetedBCPP (R34 Clinical Trial Not Allowed)</td>
<td>NIH</td>
<td></td>
</tr>
<tr>
<td>NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00 Clinical Trial Not Allowed)</td>
<td>National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging</td>
<td></td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE) (U24 Clinical Trial Not Allowed)</td>
<td>National Institute of Mental Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute of Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; Office of Behavioral and Social Sciences Research</td>
<td>11/09/2021 (First Estimated Due Date)</td>
</tr>
<tr>
<td>BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)</td>
<td>National Institute of Mental Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute of Neurological Disorders and Stroke</td>
<td>10/08/2021; 10/07/2022; 10/06/2023; 10/07/2023 (Expiration)</td>
</tr>
<tr>
<td>Area</td>
<td>Description</td>
<td>Institute(s)</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>ADHD</td>
<td>Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required)</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>ALZHEIMER'S DISEASE</td>
<td>Role of Adaptive Immunity in Etiology of Alzheimers Disease and Alzheimers Disease-Related Dementias (R01 Clinical Trial Optional)</td>
<td>National Institute on Aging; National Institute of Neurological Disorders and Stroke</td>
</tr>
<tr>
<td></td>
<td>Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Alzheimer's Disease and Related Dementias (R25 - Clinical Trial Not Allowed)</td>
<td>National Institute on Aging</td>
</tr>
<tr>
<td></td>
<td>Alzheimer's Disease Research Center (ADRC) Research Education Scholar beginning in Fall 2021</td>
<td><a href="http://www.neurology.columbia.edu">www.neurology.columbia.edu</a></td>
</tr>
<tr>
<td></td>
<td>Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimers Disease and Related Dementias (AD/ADRD) (R01 Clinical Trial Optional)</td>
<td>National Institute on Aging</td>
</tr>
<tr>
<td></td>
<td>Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimers Disease and Related Dementias</td>
<td>National Institute on Aging</td>
</tr>
<tr>
<td>Topic</td>
<td>Description</td>
<td>Reference</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>(AD/ADRD) (R61/R33 Clinical Trial Required)</strong></td>
<td>Notice of Special Interest (NOSI): Administrative Supplements to Promote Diversity for NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Awardees</td>
<td>National Institute of Neurological Disorders and Stroke</td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s Drug Discovery Foundation</td>
<td>Alzheimer’s Drug Discovery Foundation</td>
</tr>
<tr>
<td></td>
<td>Harrington Scholar Program</td>
<td>Harrington Scholar Program</td>
</tr>
<tr>
<td></td>
<td>Primary Care-Based Screening and Intervention Development for Prevention of Abuse in Older and Vulnerable Adults in the Context of Alzheimer’s Disease and Related Dementias (R61/R33 Clinical Trial Required)</td>
<td>National Institute on Aging</td>
</tr>
<tr>
<td><strong>PARKINSON’S DISEASE</strong></td>
<td>Michael J. Fox Foundation</td>
<td>Michael J. Fox Foundation</td>
</tr>
<tr>
<td></td>
<td>Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research</td>
<td>Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research</td>
</tr>
<tr>
<td><strong>NEUROSCIENCE</strong></td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Joint NINDS and NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)</td>
<td>National Institute of Neurological Disorders and Stroke; National Institute of Mental Health</td>
</tr>
<tr>
<td></td>
<td>Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)</td>
<td>National Institute of Neurological Disorders and Stroke; National Institute of Mental Health</td>
</tr>
<tr>
<td></td>
<td>Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)</td>
<td>National Institute of Neurological Disorders and Stroke</td>
</tr>
<tr>
<td></td>
<td>Translational Neural Devices (U44 Clinical Trial Optional)</td>
<td>National Institute of Neurological Disorders and Stroke</td>
</tr>
</tbody>
</table>
### NEUROLOGY

| Solicitation of Nominations for the 2022 National Institute of Neurological Disorders and Stroke (NINDS) Landis Award for Outstanding Mentorship Details | National Institute of Neurological Disorders and Stroke | 12/15/2021 |

| Notice of Special Interest: Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders | National Institute of Neurological Disorders and Stroke; Eunice Kennedy Shriver National Institute of Child Health and Human Development | 10/05/2021 (First Available Due Date); 07/17/2024 (Expiration Date) |

### AUTISM

| Research on Autism Spectrum Disorders (R03 Clinical Trial Optional) | National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences | 10/16/2021; 02/16/2022; 02/16/2024; 03/17/2024 (Expiration) |

| Research on Autism Spectrum Disorders (R21 Clinical Trial Optional) | National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences; National Institute of Neurological Disorders and Stroke | 10/16/2021; 02/16/2024; 03/17/2024 (Expiration) |

<p>| Research on Autism Spectrum Disorders (R01 Clinical Trial Optional) | National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Neurological Disorders and Stroke | 10/05/2021; 02/05/2024; 03/06/2024 (Expiration) |</p>
<table>
<thead>
<tr>
<th>AGING</th>
<th>Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Aging (R25 - Clinical Trial Not Allowed)</th>
<th>National Institute on Aging</th>
<th>10/04/2021; 10/05/2021 (Expiration)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; Office of Behavioral and Social Sciences Research</td>
<td>06/05/2021 (First Available Due Date); 01/08/2024 (Expiration Date)</td>
</tr>
<tr>
<td></td>
<td>High Resolution Mapping of Biomolecules in Brain Cells in Aging and Alzheimers Disease (R01 Clinical Trial Not Allowed)</td>
<td>National Institute on Aging</td>
<td>10/28/2021; 10/29/2021 (Expiration)</td>
</tr>
<tr>
<td></td>
<td>Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)</td>
<td>John E. Fogarty International Center; National Center for Complementary and Integrative Health; National Institute on Alcohol Abuse and Alcoholism; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke Office of Disease Prevention; Office of Research on Women's Health</td>
<td>08/13/2021; 07/13/2022; 07/13/2023; 07/14/2023</td>
</tr>
<tr>
<td></td>
<td>Notice of Participation of the National Institute on Aging (NIA) in PAR-21-230</td>
<td>National Institute on Aging</td>
<td>08/13/2021; 07/13/2022;</td>
</tr>
<tr>
<td>Topic</td>
<td>Details</td>
<td>Dates</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Chronic, Non-Communicable Diseases and Disorders Across the Lifespan:</td>
<td>Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)*</td>
<td>07/13/2023; 07/14/2023 (Expiration, PAR-21-230)</td>
<td></td>
</tr>
<tr>
<td>Notice of Change to Key Dates and Application Types Allowed for PAR-21-156 The Midlife in the United States Study (U19 Clinical Trial Not Allowed)</td>
<td></td>
<td>National Institute on Aging 08/16/2021; 02/01/2022 (Updated / New Application Due Dates PAR—21-156) 02/02/2022 (New Expiration Date, PAR-21-156)</td>
<td></td>
</tr>
<tr>
<td>Notice of Change to Key Dates for PAR-21-157 The Midlife in the United States Study - Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed)</td>
<td></td>
<td>National Institute on Aging 08/16/2021; 02/01/2022 (Updated / New Application Due Dates PAR—21-157) 02/02/2022 (New Expiration Date, PAR-21-157)</td>
<td></td>
</tr>
<tr>
<td>Rollout of Redesigned eRA Commons Home and Landing Screens in January 2021 New eRA Commons Login and Landing Screens Take a Sneak Peek: Redesigned eRA Commons Home Screen Coming in 2021</td>
<td></td>
<td>NIH era commons 01/12/2021 (Rollout Date)</td>
<td></td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI) to add harassment as an area of interest to Research to Understand and Inform Interventions that Promote the Research Careers of Individuals in the Biomedical Sciences</td>
<td></td>
<td>Office of Research on Women's Health; National Cancer Institute; National Eye Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of General 10/15/2021 (First Available Due Date); 01/08/2022 (Expiration Date)</td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>Organization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2021 NIAID Omnibus Broad Agency Announcement HHS-NIH-NIAID-BAA2021-1 Now Available</td>
<td>National Institute of Allergy and Infectious Diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reminder Regarding Recipient and Applicant Grants Policy Related Inquiries</td>
<td>National Institutes of Health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Request for Information (RFI): National Institute of Dental and Craniofacial Research (NIDCR) Strategic Plan Fiscal Years 2021-2026</td>
<td>National Institute of Dental and Craniofacial Research</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Updated Guidelines for Enhancing Diversity and Creating Safe Environments in Conferences Supported by NIH Grants and Cooperative Agreements</td>
<td>Office of The Director, National Institutes of Health (OD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximizing Access to Research Careers (T34 - Clinical Trial Not Allowed)</td>
<td>National Institute of General Medical Sciences</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIM-AHEAD Coordinating Center: Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity read the full ROA</td>
<td>NIH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)</td>
<td>National Institutes of Health; John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Due dates vary by awarding IC. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
<table>
<thead>
<tr>
<th>Programme</th>
<th>Institute</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25 - Independent Clinical Trial Not Allowed)</td>
<td>National Institute on Aging</td>
<td>05/25/2022; 05/25/2023; 05/26/2023 (Expiration)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Understanding and Addressing the Impact of Structural Racism and Discrimination on Biomedical Career Progression and the Biomedical Research Enterprise</td>
<td>National Institute of General Medical Sciences</td>
<td>05/17/2021 (First Available Due Date); 10/04/2022 (Expiration Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for New Investigators to Promote Workforce Diversity in Genomics and other Health-Related Research (R01 Clinical Trial Optional)</td>
<td>National Human Genome Research Institute</td>
<td>08/03/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Project Description</td>
<td>NIH Institute(s)</td>
<td>Due Date</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)</td>
<td><a href="https://www.nimhd.nih.gov/">https://www.nimhd.nih.gov/</a></td>
<td>08/24/2021; 08/25/2021 (Expiration)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Research Opportunity Announcement for AIM-AHEAD: Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity</td>
<td>National Institutes of Health</td>
<td>07/07/2021 (Release Date)</td>
</tr>
<tr>
<td>Network of the National Library of Medicine All of Us Program Center (U24) (Clinical Trial Optional)</td>
<td>National Library of Medicine</td>
<td>09/17/2021; 09/18/2021 (Expiration)</td>
</tr>
<tr>
<td>NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Optional)</td>
<td>Office of Strategic Coordination (Common Fund)</td>
<td>09/24/2021; 09/25/2021 (Expiration)</td>
</tr>
<tr>
<td>HEALTH DISPARITIES Notice of Intent to Publish a Funding Opportunity Announcement for Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional)</td>
<td>National Institute on Minority Health and Health Disparities; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research;</td>
<td>08/20/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)</td>
<td>National Institute on Minority Health and Health Disparities; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research</td>
<td>08/24/2021; 08/25/2021</td>
</tr>
<tr>
<td>CTSA CENTER FOR LEADING INNOVATION AND COLLABORATION</td>
<td>R2 ANNOUNCEMENTS</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)</td>
<td>We are segueing over to CU / Uni PW login protected file storage and access (Newsletters and files linked within), e.g. the R2eport 07/09/2021 [Sharepoint file requiring CU/Uni login]</td>
<td></td>
</tr>
<tr>
<td>Agency for Healthcare Research and Quality</td>
<td>Please let us (R2/ckk7) know if anyone is submitting a training grant (of any sort, T32, R25, D43, etc) between now and June 2021</td>
<td></td>
</tr>
<tr>
<td><a href="https://www.nimhd.nih.gov/">https://www.nimhd.nih.gov/</a></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Research resources is pleased to coordinate grant type specific grant writing groups, pending faculty/researcher interest. Please let us know (via email to prf1@cumc.columbia.edu and/or ckk7@cumc.columbia.edu) if you are interested in such groups, along with the type of grant and proposed due date(s). We are planning to coordinate a writing group for this fall’s NIH deadlines. Please join us.

### RIGOR AND REPRODUCIBILITY

<table>
<thead>
<tr>
<th>Event/Opportunity</th>
<th>Details</th>
<th>Date/Posting</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH Rigor and Reproducibility Webinar</td>
<td>NIH Rigor and Reproducibility Slides</td>
<td>01/08/2021; Archival</td>
</tr>
<tr>
<td>Office for Research</td>
<td>Vagelos College of Physicians and Surgeons (columbia.edu)</td>
<td>01/08/2021 (Event Date, Archival Posting)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Creating an Educational Nexus for Training in Experimental Rigor (CENTER) (UC2 Clinical Trial Not Allowed)</td>
<td>National Institute of Neurological Disorders and Stroke</td>
<td>10/21/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Materials to Enhance Training in Experimental Rigor (METER) (UE5 Clinical Trial Not Allowed)</td>
<td>National Institute of Neurological Disorders and Stroke</td>
<td>10/21/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI)</td>
<td>National Institute on Drug Abuse</td>
<td>04/01/2021 (First Available Due Date); 03/31/2022 (Expiration Date)</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>----------------------------------</td>
<td>---------------------------------------------------------------------</td>
</tr>
<tr>
<td>Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus</td>
<td>National Institute of Mental Health; <em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development</td>
<td>06/05/2021 (First Available Due Date); 09/08/2022 (Expiration Date)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children</td>
<td>National Institutes of Health</td>
<td>03/26/2021 (Release Date)</td>
</tr>
<tr>
<td>Updated Reporting Requirements for RADx-rad Grant Recipients</td>
<td>National Institutes of Health</td>
<td>04/30/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish Funding Opportunity Announcements for the RADx-UP Initiative (Phase II)</td>
<td>Office of The Director, National Institutes of Health (OD)</td>
<td>03/29/2021 (Release Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish Funding opportunity RADx-UP Return to School Diagnostic Testing Approaches</td>
<td>Columbia University Biobank</td>
<td><a href="https://www.ps.columbia.edu/research/core-and-shared-facilities/core-facilities-category/columbia-university-biobank">https://www.ps.columbia.edu/research/core-and-shared-facilities/core-facilities-category/columbia-university-biobank</a></td>
</tr>
<tr>
<td>FDA Notice of Special Interest (NOSI) to add COVID-19 Capacity Building Grants to PAR-18-604 Vet-LIRN Network Capacity-Building Projects (Vet-LIRN)</td>
<td>Food and Drug Administration</td>
<td>04/26/2021 (Release Date)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Research on the Impact of the Covid 19 Pandemic and Risks for Abuse and Injury Among Vulnerable Children and Youth</td>
<td><em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development</td>
<td>06/05/2021 (First Available Due Date); 05/08/2024 (Expiration Date)</td>
</tr>
<tr>
<td>Notice of Information: NCATS to Issue an Emergency Competitive Revision Sole Source Award in Support of ACTIV-6</td>
<td>National Center for Advancing Translational Sciences</td>
<td>NA</td>
</tr>
<tr>
<td><strong>ADMINISTRATIVE SUPPLEMENTS</strong></td>
<td>National Institutes of Health; John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Cancer Institute; National Eye Institute; National Human Genome Research Institute;</td>
<td>Due dates may vary by awarding IC. See the awarding IC’s web site or applicable Notice of Special Interest (NOSI) for appropriate Application Due</td>
</tr>
<tr>
<td>Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resource</td>
<td>Description</td>
<td>Date</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>------</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Office of Behavioral and Social Sciences Research; Office of Research on Women's Health</td>
<td>Dates. Applicants may also contact their respective awarding IC; 07/24/2023 (Expiration)</td>
<td></td>
</tr>
<tr>
<td>Extended Guidance for Applicants Preparing Applications During the COVID-19 Pandemic</td>
<td>Office of The Director, National Institutes of Health (OD)</td>
<td>11/04/2020 (Release Date)</td>
</tr>
<tr>
<td>NIH Implementation of the Revised Federal-wide Research Terms and Conditions</td>
<td>National Institutes of Health</td>
<td>11/17/2020 (Release Date)</td>
</tr>
<tr>
<td>SINGLE IRB</td>
<td>AHRQ Guide Notice on Exception to the Use of the Single IRB Review Requirements During the Coronavirus</td>
<td>Agency for Healthcare Research and Quality</td>
</tr>
<tr>
<td>Program</td>
<td>Institution</td>
<td>Dates</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-------------------------------------------------------</td>
<td>-----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Disease 2019 (COVID-19) Public Health Emergency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)</td>
<td>National Cancer Institute</td>
<td>Standard dates; 03/15/2024 (Expiration)</td>
</tr>
<tr>
<td>NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00)</td>
<td>National Human Genome Research Institute</td>
<td>08/08/2021; 12/08/2021; 04/08/2022; 08/08/2022; 12/08/2022; 04/08/2023; 08/08/2023; 12/08/2023; 04/08/2024; 04/09/2024 (Expiration)</td>
</tr>
<tr>
<td>Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Independent Basic Experimental Studies with Humans Required)</td>
<td>National Institute of Environmental Health Sciences</td>
<td>Standard dates; 05/08/2024 (Expiration)</td>
</tr>
<tr>
<td>Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Required)</td>
<td>National Institute of Environmental Health Sciences</td>
<td>Standard dates; 05/08/2024 (Expiration)</td>
</tr>
<tr>
<td>Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Not Allowed)</td>
<td>National Institute of Environmental Health Sciences</td>
<td>Standard dates; 05/08/2024 (Expiration)</td>
</tr>
<tr>
<td>The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required)</td>
<td>National Cancer Institute</td>
<td>Standard dates; 03/15/2024 (Expiration)</td>
</tr>
<tr>
<td>NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)</td>
<td>National Institute of Neurological Disorders and Stroke</td>
<td>Standard dates; Standard AIDS dates; 05/08/2024 (Expiration)</td>
</tr>
<tr>
<td>NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)</td>
<td>National Institute of Neurological Disorders and Stroke</td>
<td>Standard dates; Standard AIDS dates; 05/08/2024 (Expiration)</td>
</tr>
<tr>
<td>Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career</td>
<td>Participating Organization(s): National Institutes of Health (NIH); Components of</td>
<td>Standard dates; 11/15/2022 (Expiration)</td>
</tr>
<tr>
<td>Project Title</td>
<td>Participating Organizations</td>
<td>Dates</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)</td>
<td>National Institute of General Medical Sciences (NIGMS); National Institute of Biomedical Imaging and Bioengineering (NIBIB); National Institute of Nursing Research (NINR); National Institute on Minority Health and Health Disparities (NIMHD); National Human Genome Research Institute (NHGRI); National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Heart, Lung and Blood Institute (NHLBI); National Institute of Environmental Health Sciences (NIEHS); National Institute on Deafness and Other Communication Disorders (NIDCD)</td>
<td></td>
</tr>
<tr>
<td>NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 No Independent Clinical Trials)</td>
<td>National Institute of Mental Health</td>
<td>Standard dates; 09/08/2024 (Expiration)</td>
</tr>
<tr>
<td>Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environmental Health Sciences; National Institutes of Health</td>
<td>10/08/2021; 08/08/2022; 03/08/2023; 03/09/2023 (Expiration)</td>
</tr>
<tr>
<td>Data Enhancements and Analyses to Clarify the Relationship between Education and Cognitive Function</td>
<td>National Institute on Aging</td>
<td>10/20/2021; 10/21/2021 (Expiration)</td>
</tr>
<tr>
<td>(including AD/ADRD) (R01 Clinical Trial Not Allowed)</td>
<td>Leveraging Existing Large Databases and Cohorts to Better Understand the Risks and Benefits of Long-Term Osteoporosis Therapy and Drug Holiday (R01 Clinical Trial Not Allowed)</td>
<td>National Institute on Aging; National Institute of Arthritis and Musculoskeletal and Skin Diseases</td>
</tr>
<tr>
<td>Notice of Modifications to PAR-21-075, &quot;Research Experience in Genomic Research for Data Scientists (R25)&quot; Research Experience in Genomic Research for Data Scientists (R25)</td>
<td>National Human Genome Research Institute</td>
<td>05/25/2022; 05/25/2023; 05/26/2023 (Expiration, PAR-2-075)</td>
</tr>
<tr>
<td>Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed)</td>
<td>National Institute of Allergy and Infectious Diseases</td>
<td>02/17/2022; 07/01/2022; 02/17/2023; 07/06/2023; 07/07/2023 (Expiration)</td>
</tr>
<tr>
<td>Enhancement or Sustainment of Data Science Tools for Infectious and Immune-Mediated diseases (U24 Clinical Trial Not Allowed)</td>
<td>National Institute of Allergy and Infectious Diseases</td>
<td>02/17/2022; 07/01/2022; 02/17/2023; 07/06/2023; 07/07/2023 (Expiration)</td>
</tr>
<tr>
<td>Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed)</td>
<td>National Institute of Allergy and Infectious Diseases</td>
<td>02/17/2022; 07/01/2022; 02/17/2023; 07/06/2023; 07/07/2023 (Expiration)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24)</td>
<td>National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Mental Health</td>
<td>08/18/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating and Data Management Center for Translational and Basic Science Research in Early Lesions (TBEL) (U24 Clinical Trial Not Allowed)</td>
<td>National Cancer Institute</td>
<td>10/01/2021 (First Estimated Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Research Opportunity Announcement for the Data Generation Projects of the NIH Bridge to Artificial Intelligence (Bridge2AI) Program (OT2)</td>
<td>Office of Strategic Coordination (Common Fund)</td>
<td>08/20/2021 (Estimated First Application Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for NIH Bridge2AI Integration, Dissemination, and Evaluation (BRIDGE) Center (U54 Clinical Trial Not Allowed)</td>
<td>Office of Strategic Coordination (Common Fund)</td>
<td>08/20/2021 (Estimated First Application Due Date)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)</td>
<td>National Heart, Lung, and Blood Institute</td>
<td>10/05/2021 (First Available Due Date); 05/08/2023 (Expiration Date)</td>
</tr>
<tr>
<td>Transformative Artificial Intelligence and Machine Learning Based Strategies to Identify Determinants of Exceptional Health and Life Span (R21/R33 Clinical Trial Not Allowed)</td>
<td>National Institute on Aging</td>
<td>10/28/2021; 10/29/2021 (Expiration)</td>
</tr>
<tr>
<td>New York State Department of Health/Health Research, Inc. Comprehensive Cancer Control Program</td>
<td>Health Research, Inc (HRI) and the New York State Department of Health (NYSDOH)</td>
<td>Applications will be accepted starting immediately and will be reviewed and awarded in the order received on a rolling basis until funds are no longer available.</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54 Clinical Trial Not Allowed)</td>
<td>National Cancer Institute</td>
<td>10/01/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (DRCC) (U24 Clinical Trial Not Allowed)</td>
<td>National Cancer Institute</td>
<td>10/01/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)</td>
<td>National Cancer Institute</td>
<td>11/01/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI):</td>
<td>National Cancer Institute</td>
<td>06/05/2021 (First Available Due Date); 01/08/2024 (Expiration Date)</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI):</td>
<td>National Cancer Institute</td>
<td>06/05/2021 (First Available Due Date); 03/08/2024 (Expiration Date)</td>
</tr>
<tr>
<td>Telehealth in Cancer Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI):</td>
<td>National Cancer Institute</td>
<td>06/18/2021 (First Available Due Date); 06/19/2021 (Expiration Date)</td>
</tr>
<tr>
<td>Administrative Supplement for Modifiable Factors Potentially affecting the Cost of Cancer Treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notice of Special Interest: National Cancer Institute Administrative Supplement Opportunity for Strategies to Optimize Recruitment and Retention of Cancer Prevention and Symptom Management Clinical Trial Participants</td>
<td>National Cancer Institute</td>
<td>06/15/2021 (June 15, 2021); 05/08/2023 (Expiration Date)</td>
</tr>
<tr>
<td>Expanding Cancer Control Research in Persistent Poverty Areas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U01 Clinical Trial Required)</td>
<td>National Cancer Institute</td>
<td>07/14/2021; 07/15/2021 (Expiration)</td>
</tr>
<tr>
<td>Coordinating Center for Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U24 Clinical Trial Not Allowed)</td>
<td>National Cancer Institute</td>
<td>07/14/2021; 07/15/2021 (Expiration)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01 - Clinical Trial Not Allowed)</td>
<td>National Cancer Institute</td>
<td>11/01/2021 (Estimated First Application Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish: Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium</td>
<td>National Cancer Institute</td>
<td>11/01/2021 (Estimated First Application Due Date)</td>
</tr>
<tr>
<td>Topic</td>
<td>Details</td>
<td>Date/Status</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Coordinating and Data Management Center (PSRC CDMC) (U24 - Clinical Trial Not Allowed)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Early-life Factors and Cancer Development Later in Life</td>
<td>National Cancer Institute</td>
<td>06/05/2021 (First Available Due Date); 03/08/2024 (Expiration Date)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Integration of Individual Residential Histories in Cancer Research</td>
<td>National Cancer Institute</td>
<td>10/05/2021 (First Available Due Date); 03/08/2024 (Expiration Date)</td>
</tr>
<tr>
<td>Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional)</td>
<td>National Cancer Institute</td>
<td>10/06/2021; 10/07/2021 (Expiration)</td>
</tr>
<tr>
<td>Coordinating Center for the Metabolic Dysregulation and Cancer Risk Program: A Transdisciplinary Approach to Obesity-Associated Cancer Research (U24 Clinical Trial Not Allowed)</td>
<td>National Cancer Institute</td>
<td>10/06/2021; 10/07/2021 (Expiration)</td>
</tr>
<tr>
<td>NIH Extramural Nexus New Policy for Data Management and Sharing Final NIH Policy for Data Management and Sharing</td>
<td>Office of The Director, National Institutes of Health (OD) [Announcement]; <a href="https://grants.nih.gov/grants/oer.htm">https://grants.nih.gov/grants/oer.htm</a> [Extramural Nexus; Office of Extramural Research]</td>
<td>10/29/2020 (Release Date); 01/25/2023 (Effective Date)</td>
</tr>
<tr>
<td>Final NIH Policy for Data Management and Sharing</td>
<td>National Institutes of Health</td>
<td>10/29/2020 (Release Date); 01/25/2023 (Effective Date)</td>
</tr>
<tr>
<td>Reminder: NIH Policy on Use of Hypertext in NIH Grant Applications Reminder - No Hyperlinks and URLs in NIH Proposals The Do's &amp; Don'ts of Hyperlinks in Grant Applications NIH formatting instructions</td>
<td>NIH National Institutes of Health; Office of The Director, National Institutes of Health (OD)</td>
<td>NA; 09/16/2020 (Release Date)</td>
</tr>
</tbody>
</table>
## RETURNING TO CAMPUS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mailman School: Returning to Campus [provided for reference; please note the updated phone number for Covid-19 testing, below]</td>
</tr>
<tr>
<td>2</td>
<td>Appointment for Covid-19 Testing [Please note the New Phone Number 212-854-7426]</td>
</tr>
<tr>
<td>3</td>
<td>Returning to Campus Update 09.18.2020</td>
</tr>
</tbody>
</table>

Mailman School

NA; page updated regularly

## RASCAL IRB 2.1

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rascal IRB 2.1</td>
</tr>
</tbody>
</table>

The Columbia University Human Research Protection Office (HRPO)

09/20/2020 (Release Date)

## COVID-19 OPPORTUNITIES CURATED IN PIVOT

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Coronavirus Funding Opportunities Curated by SPA in PIVOT [this regularly updated link may require PIVOT registration (see below for instructions)]</td>
</tr>
<tr>
<td>2</td>
<td>Pivot is a Funding Opportunity Database, as a one-stop shop to identify COVID-19 opportunities from federal, private, and global sponsors</td>
</tr>
<tr>
<td>3</td>
<td>Pivot Instructions</td>
</tr>
<tr>
<td>4</td>
<td>COVID-19: FAQs and Resources Relating to Research [Columbia Research and SPA]</td>
</tr>
<tr>
<td>5</td>
<td>COVID-19 Research Opportunities and other resources to support researchers</td>
</tr>
<tr>
<td>6</td>
<td>COVID-19 Research Funding Opportunities Curated by SPA and Research at Columbia</td>
</tr>
<tr>
<td>7</td>
<td>Pivot, New Dashboard!</td>
</tr>
<tr>
<td>8</td>
<td>Pivot Quick Guide</td>
</tr>
</tbody>
</table>

Columbia Research

https://research.columbia.edu ;

SPA https://spa.columbia.edu/

[brought to our attention by]

Stephanie Scott [Director of Policy and Research Development] Columbia |

Research; Sponsored Projects Administration;

sfs2110@cumc.columbia.edu ;

Website: https://spa.columbia.edu/

Please note that effective May 01, 2020 (05/01/2020) SPA will continue to support the funding opportunity database Pivot, and will no longer support InfoEd SPIN / SMARTS
<table>
<thead>
<tr>
<th>CU REMOTE LEARNING</th>
<th>Center &amp; Institute Initiative to Enhance Remote Learning and Teaching</th>
<th>the Center for Science and Society, the Center for the History and Ethics of Public Health, the Institute for Religion, Culture and Public Life, the Institute for Comparative Literature and Society, the Center for Justice, the Center for American Studies, and the Institute for the Study of Human Rights</th>
<th>Open until filled</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 Early Treatment Fund: Outpatient Clinical Trials for Effective Early Treatment for COVID-19, Using Existing Drugs, Rolling Deadline</td>
<td>Foundation Funding Opportunities brought to our attention by the Columbia University Office of Alumni Development</td>
<td>Pfizer: COVID-19 Vaccine Grants</td>
<td>Please see piecemeal announcements</td>
</tr>
<tr>
<td>DDCF COVID-19 Fund to Retain Clinical Scientists RFA DDCF Fund to Retain Clinical Scientists</td>
<td>Doris Duke Charitable Foundation website</td>
<td>DDCF COVID-19 Fund to Retain Clinical Scientists</td>
<td>06/22/2021 (LOI); 07/20/2021 (Application)</td>
</tr>
<tr>
<td>CU TEACHING AND LEARNING GRANTS</td>
<td>Columbia University Center for Teaching and Learning, Office of the Provost; Teaching and Learning Grants Presented by Consortium of Institutes &amp; Centers</td>
<td>Columbia University Center for Teaching and Learning, Office of the Provost; Teaching and Learning Grants Presented by Consortium of Institutes &amp; Centers</td>
<td>Open; Applications for the grants are open via rolling submission throughout the 2020-21 academic year</td>
</tr>
<tr>
<td>Policy Update - Results Information Reporting for Applicable Clinical Trials (ACTs)</td>
<td>National Institutes of Health; General Notices</td>
<td>Policy Update - Results Information Reporting for Applicable Clinical Trials (ACTs)</td>
<td>07/28/2020 (Release Date)</td>
</tr>
<tr>
<td>FORMS-F</td>
<td>eRA Information: Changes in HSS Post-Submission Updates with FORMS-F Starting June 13 NIH Policy and Guidelines on the Inclusion of Individuals Across the Lifespan as Participants in Research Involving Human Subjects High-level Grant Application Form Change Summary: FORMS-F</td>
<td>NIH eRA</td>
<td>06/13/2020 (Effective Date); 06/15/2020 (Release Date)</td>
</tr>
<tr>
<td>Section</td>
<td>Description</td>
<td>Agency</td>
<td>Date</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Reminder of Upcoming FORMS-F and Inclusion Across the Lifespan Requirements for NIH Applicants and Recipients Submitting Post-Submission Updates Using the Human Subjects System (HSS)</td>
<td></td>
<td>National Institutes of Health</td>
<td>06/17/2020 (Release Date)</td>
</tr>
<tr>
<td>Reminder: Required use of FORMS-F application forms for application submission</td>
<td></td>
<td>National Institutes of Health</td>
<td>04/14/2021 (Release Date)</td>
</tr>
<tr>
<td>DATA TABLES FOR TRAINING GRANTS</td>
<td>[1] Data Tables for FORMS-F required institutional training grant proposals; required for applications due May 25th, 2020 or later [2] Data Tables Changes from FORMS-E to FORMS-F</td>
<td>NIH, SPA</td>
<td>05/25/2020 (Forms-F, required for applications due 05/25/2020 or later)</td>
</tr>
<tr>
<td>SPA TRAINING GRANT RPPRS AND SURVEY</td>
<td>Training Grant RPPRs and Survey</td>
<td>SPA/HICCC</td>
<td>10/01/2020 (Release Date)</td>
</tr>
<tr>
<td>NIH Summary Statement Available to the Signing Officials (SO) through the eRA Commons</td>
<td></td>
<td>National Institutes of Health</td>
<td>06/18/2020 (Release Date)</td>
</tr>
<tr>
<td>Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic</td>
<td>National Institutes of Health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>This Notice extends the special exception for post-submission material (see NOT-OD-20-123) to applications submitted for the May 2021 Council round. For applications submitted for the May 2021 council (beginning with applications submitted for the September 25, 2020 due date for Spring 2021 review meetings), the NIH, AHRQ, and NIOSH will accept a one-page update with preliminary data as post-submission materials for applications submitted under all activity codes, ONLY if the Funding Opportunity Announcement (FOA) used for submission allowed preliminary data in the application. One page of preliminary data will be accepted for single component applications or for each component of a multi-component application. The deadline for submitting all post-submission materials, including preliminary</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### INFLUENZA

**Systems Approach to Understand Mechanisms of Heterogeneous Response to Influenza (R01 Clinical Trial Not Allowed)**

National Institute of Allergy and Infectious Diseases

09/08/2021; 09/09/2021 (Expiration)

### F-AWARDS

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>[1]</td>
<td>Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) PA-21-051</td>
</tr>
<tr>
<td>[3]</td>
<td>All NIH Fellowship Parent Announcements [F32 Posting on this link pending, as of 10.27.2020]</td>
</tr>
</tbody>
</table>

National Institutes of Health (NIH)

Standard dates; Standard AIDS dates; 09/08/2023 (Expiration [F31 and F32])

### Notice of Participation of NINR in PA-21-050, Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

National Institute of Nursing Research

06/08/2021 (Release Date)
<table>
<thead>
<tr>
<th>Notice of Change to NOT-NR-21-001: “Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards”</th>
<th>National Institute of Nursing Research</th>
<th>Standard dates; Standard AIDS dates; 09/08/2023 (Expiration)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruth L. Kirschstein National Research Service Award (NRS) Stipends, Tuition/Fees and Other Budgetary Levels Effective for Fiscal Year 2021</td>
<td>National Institutes of Health; Agency for Healthcare Research and Quality; Health Resources and Services Administration</td>
<td>01/27/2021 (Release Date)</td>
</tr>
<tr>
<td><strong>T32 TRAINING GRANTS</strong></td>
<td>Notices for changes in T32 submission instructions; Reminder: Changes to Forms and Instructions for Research Training Grant, Fellowship, and Career Development Award Applications for Applications Due on or After May 25, 2020 [NOT-OD-090]</td>
<td>NIH; NIEHS</td>
</tr>
<tr>
<td>T32 Training Program for Institutions That Promote Diversity (T32 Clinical Trial Not Allowed)</td>
<td>National Heart, Lung, and Blood Institute</td>
<td>09/13/2021; 02/28/2022; 09/13/2022; 02/28/2023; 09/13/2023; 02/28/2024; 02/29/2024 (Expiration)</td>
</tr>
<tr>
<td>National Institute of General Medical Sciences Institutional Predoctoral Research Training Grant (T32 - Clinical Trial Not Allowed)</td>
<td>National Institute of General Medical Sciences</td>
<td>Standard dates; 05/26/2023 (Expiration)</td>
</tr>
<tr>
<td>NIHDS Institutional Research Training Program (T32 - Clinical Trial Not Allowed)</td>
<td>National Institute of Neurological Disorders and Stroke</td>
<td>05/25/2022; 05/25/2023; 05/26/2023 (Expiration)</td>
</tr>
<tr>
<td><strong>COLUMBIA PUBLIC HEALTH NOW PODCASTS</strong></td>
<td>Columbia Public Health Now Podcasts</td>
<td>Mailman</td>
</tr>
<tr>
<td>HEALTH POLICY AND MANAGEMENT VIRTUAL EVENTS</td>
<td>Health and Policy Management Virtual Events</td>
<td>Health Policy and Management; <a href="https://www.mailman.columbia.edu/academics/departments/health-policy-and-management">https://www.mailman.columbia.edu/academics/departments/health-policy-and-management</a></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>FREE LISTS OF GRANTS AND FELLOWSHIPS AROUND THE WORLD AVAILABLE ONLINE</td>
<td>Three searchable databases provide information on global opportunities for graduate students, postdocs and junior faculty members</td>
<td>Curated by Johns Hopkins University</td>
</tr>
<tr>
<td>HICCC FUNDING OPPORTUNITIES</td>
<td>HICCC Funding Opportunities</td>
<td>HICCC</td>
</tr>
<tr>
<td>RESEARCH SUPPORT SERVICES</td>
<td>Update on Research Support Services, Spring 2019; we are pleased to expand the Research Support Services to also include resubmissions of otherwise eligible R01, P, K, Center and T32 grants Grant Review Submission Form (updated Spring 2019)</td>
<td>Mailman School</td>
</tr>
<tr>
<td>RWJF Evidence for Action: Investigator-Initiated Research to Build a Culture of Health</td>
<td><a href="https://www.rwjf.org">https://www.rwjf.org</a></td>
<td>Open</td>
</tr>
<tr>
<td>Subscribe to RWJF Funding Alerts</td>
<td>RWJF</td>
<td>NA</td>
</tr>
<tr>
<td>American Association of Cancer Research</td>
<td><a href="https://www.aacr.org">https://www.aacr.org</a></td>
<td>06/29/2021 (LOI); 09/30/2021 (Application)</td>
</tr>
<tr>
<td>Amazon Web Services</td>
<td><a href="https://aws.amazon.com">https://aws.amazon.com</a></td>
<td>07/31/2021</td>
</tr>
<tr>
<td>Donaghue Foundation</td>
<td><a href="https://donaghue.org">https://donaghue.org</a></td>
<td>04/26/2021; 07/30/2021 (Invited Applications)</td>
</tr>
<tr>
<td>Foundation for Opioid Response Efforts</td>
<td><a href="https://www.foundationforsafehealthcare.org">https://www.foundationforsafehealthcare.org</a></td>
<td>07/19/2021</td>
</tr>
<tr>
<td>ONK_Challenge 2021</td>
<td>Foundation for Opioid Response Efforts</td>
<td>07/19/2021</td>
</tr>
<tr>
<td>Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities</td>
<td>Russel Sage Foundation</td>
<td>07/28/2021</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Russel Sage Foundation Various core programs and special initiatives Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities</td>
<td>Russel Sage Foundation</td>
<td>07/28/2021</td>
</tr>
<tr>
<td>BrightFocus Foundation</td>
<td>Macular Degeneration Research Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities</td>
<td>BrightFocus Foundation</td>
</tr>
<tr>
<td>Cures Within Reach</td>
<td>Repurposing Research Led by a US-Based Racial/Ethnic Minority Principle Investigator Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities</td>
<td>Cures Within Reach</td>
</tr>
<tr>
<td>IBM's Call for Code</td>
<td>Call for Code Global Challenge Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities</td>
<td>IBM</td>
</tr>
<tr>
<td>Society of Critical Care Medicine</td>
<td>Research Grants Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities</td>
<td>Society of Critical Care Medicine</td>
</tr>
<tr>
<td>The Barbara McDowell and Gerald S. Hartman Foundation</td>
<td>Social Justice Litigation Grants Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities</td>
<td>The Barbara McDowell and Gerald S. Hartman Foundation</td>
</tr>
<tr>
<td>William T. Grant Foundation</td>
<td>Research Grants, Reducing Inequality Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities</td>
<td>William T. Grant Foundation</td>
</tr>
<tr>
<td>William T. Grant</td>
<td>Research Grants, Improving the Use of Research Evidence</td>
<td>William T. Grant Foundation</td>
</tr>
<tr>
<td>Funding Opportunities</td>
<td>Agency/Program</td>
<td>Effective Date</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>FIREARM INJURY AND MORTALITY PREVENTION</td>
<td>Office of Behavioral and Social Sciences Research</td>
<td>06/01/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish Funding Opportunity Announcements for Research on Firearm Injury and Mortality Prevention</td>
<td>RWJF; Pioneering Ideas: Exploring the Future to Build a Culture of Health</td>
<td>Open</td>
</tr>
<tr>
<td>Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure</td>
<td>National Institute of Mental Health</td>
<td>05/08/2021 (First Available Due Date); 05/09/2024 (Expiration Date)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV</td>
<td>National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Institute of Mental Health</td>
<td>09/07/2021 (First Available Due Date); 05/08/2024 (Expiration Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional)</td>
<td>National Cancer Institute</td>
<td>09/05/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies</td>
<td>National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse</td>
<td>06/17/2021 (First Available Due Date); 09/05/2021 (Expiration Date)</td>
</tr>
<tr>
<td>HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)</td>
<td>John E. Fogarty International Center; National Cancer Institute; National Institute on Aging; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney</td>
<td>12/08/2021; 12/08/2022; 12/09/2022 (Expiration)</td>
</tr>
<tr>
<td>Title</td>
<td>Institution</td>
<td>Dates</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Organoid Modeling of Neural Stimulants and HIV Comorbidity of Human Brain (R01 - Clinical Trial Optional)</td>
<td>National Institute on Drug Abuse</td>
<td>11/17/2021; 11/18/2021 (Expiration)</td>
</tr>
<tr>
<td>Innovative Models for Delivering PrEP and STI Services to Stop HIV in the United States (R61/R33 Clinical Trial Optional)</td>
<td>National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Institute of Mental Health</td>
<td>10/13/2021; 10/14/2021 (Expiration)</td>
</tr>
<tr>
<td>PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional)</td>
<td>National Institute on Drug Abuse</td>
<td>11/12/2021; 11/13/2021 (Expiration)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Administrative Supplements to NIMHD Awards for Research on HIV/AIDS in Populations that Experience Health Disparities (Admin Supp Clinical Trial Optional)</td>
<td>National Institute on Minority Health and Health Disparities</td>
<td>07/15/2021 (First Available Due Date); 07/16/2021 (Expiration Date)</td>
</tr>
<tr>
<td>Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R01 Clinical Trial Optional)</td>
<td>National Institute of Mental Health; National Institute of Neurological Disorders and Stroke</td>
<td>08/27/2021; 08/28/20212 (Expiration)</td>
</tr>
<tr>
<td>Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R21 Clinical Trial Optional)</td>
<td>National Institute of Mental Health; National Institute of Neurological Disorders and Stroke</td>
<td>08/27/2021; 08/28/20212 (Expiration)</td>
</tr>
<tr>
<td>Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)</td>
<td>National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Institute of Mental Health</td>
<td>07/30/2021; 07/31/2021 (Expiration)</td>
</tr>
<tr>
<td>Multidisciplinary Treatment Approaches to End the HIV Epidemic (R01 Clinical Trial Optional)</td>
<td>National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Institute of Mental Health</td>
<td>08/04/2021; 08/05/2021 (Expiration)</td>
</tr>
<tr>
<td>Prevention Strategies to End the HIV Epidemic (R01 Clinical Trial Optional)</td>
<td>National Institute of Allergy and Infectious Diseases; National Institute on Drug</td>
<td>07/30/2021; 07/31/2021 (Expiration)</td>
</tr>
<tr>
<td>Project Title</td>
<td>Funding Agencies</td>
<td>Start Dates</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Understanding HIV Reservoir Dynamics (P01, Clinical Trial Not Allowed)</td>
<td>National Institute of Allergy and Infectious Diseases; National Institute of Mental Health</td>
<td>07/30/2021; 07/31/2021</td>
</tr>
<tr>
<td>Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Mental Health</td>
<td>08/04/2021; 08/05/2021</td>
</tr>
<tr>
<td>Development and Testing of Novel Interventions to improve HIV Prevention,</td>
<td>National Institute of Allergy and Infectious Diseases; National Institute of Mental Health</td>
<td>09/07/2021; 01/07/2022; 05/07/2022; 09/07/2022; 01/07/2024; 05/07/2024; 05/08/2024 (Expiration)</td>
</tr>
<tr>
<td>Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trial Required)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and</td>
<td>National Institute of Dental and Craniofacial Research; National Cancer Institute</td>
<td>11/18/2021; 11/19/2021</td>
</tr>
<tr>
<td>Persistence in People Living with HIV (R01 Clinical Trial Not Allowed)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and</td>
<td>National Institute of Dental and Craniofacial Research; National Cancer Institute</td>
<td>11/18/2021; 11/19/2021</td>
</tr>
<tr>
<td>Persistence in People Living with HIV (R21 Clinical Trial Not Allowed)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Identification of Biomarkers of HIV</td>
<td>National Institute on Drug Abuse</td>
<td>06/05/2021 (First Available Due Date); 09/08/2024 (Expiration Date)</td>
</tr>
<tr>
<td>Pathogenesis and Substance Use Disorder Comorbidity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notice of Special Interest: Advanced Computational Approaches to Elucidate</td>
<td>National Institute on Drug Abuse</td>
<td>10/05/2021 (First Available Due Date); 01/08/2025 (Expiration Date)</td>
</tr>
<tr>
<td>Disease Pathology and Identify Novel Therapeutics for Addiction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol,</td>
<td>National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism</td>
<td>10/16/2021; 02/16/2022; 06/16/2022; 10/16/2023; 02/16/2024;</td>
</tr>
<tr>
<td>and Tobacco Use Disorders (R34 - Clinical Trial Optional)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notice of Special Interest: Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes</td>
<td>National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; National Institute on Drug Abuse</td>
<td>05/08/2024 (Expiration)</td>
</tr>
<tr>
<td>Mechanistic studies on the impact of social inequality on the substance use trajectory (R21 - Clinical Trial Not Allowed)</td>
<td>National Institute on Drug Abuse</td>
<td>10/14/2021; 10/15/2021 (Expiration)</td>
</tr>
<tr>
<td>Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Clinical Trial Not Allowed)</td>
<td>National Institute on Drug Abuse</td>
<td>10/14/2021; 10/15/2021 (Expiration)</td>
</tr>
<tr>
<td>Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation (R01 Clinical Trial Optional)</td>
<td>National Institute on Drug Abuse</td>
<td>08/05/2021; 08/06/2021 (Expiration)</td>
</tr>
<tr>
<td>Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Basic Experimental Studies with Humans Required)</td>
<td>National Institute on Drug Abuse</td>
<td>10/14/2021; 10/15/2021 (Expiration)</td>
</tr>
<tr>
<td>Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Basic Experimental Studies with Humans Required)</td>
<td>NIH/NIDA</td>
<td>10/14/2021; 10/15/2021 (Expiration)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Research Project Sites (U01)</td>
<td>National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Mental Health</td>
<td>08/17/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Administrative Resource (U24)</td>
<td>National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Mental Health</td>
<td>08/18/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Abuse and Alcoholism</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>08/15/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Topic</td>
<td>Funding Opportunity Announcement</td>
<td>Due Date</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Spectrum Disorders (CIFASD), Research Project (U01 Clinical Trial optional)</td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Administrative Core (U24) (Clinical Trial Not Allowed)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
</tr>
<tr>
<td>NOTICE OF INTENT TO PUBLISH A FUNDING OPPORTUNITY ANNOUNCEMENT FOR COLLABORATIVE INITIATIVE ON FETAL ALCOHOL SPECTRUM DISORDERS (CIFASD), DIAGNOSTIC-TELEMEDICINE CORE (U24 CLINICAL TRIAL NOT ALLOWED)</td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Diagnostic-Telemedicine Core (U24 Clinical Trial Not Allowed)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
</tr>
<tr>
<td>NOTICE OF INTENT TO PUBLISH A FUNDING OPPORTUNITY ANNOUNCEMENT FOR COLLABORATIVE INITIATIVE ON FETAL ALCOHOL SPECTRUM DISORDERS (CIFASD), DATA COORDINATION CORE (U24 CLINICAL TRIAL NOT ALLOWED)</td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Data Coordination Core (U24 Clinical Trial Not Allowed)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
</tr>
<tr>
<td>NOTICE OF INTENT TO PUBLISH A FUNDING OPPORTUNITY ANNOUNCEMENT FOR COLLABORATIVE INITIATIVE ON FETAL ALCOHOL SPECTRUM DISORDERS (CIFASD), DEVELOPMENTAL PROJECT (UH2 CLINICAL TRIAL OPTIONAL)</td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Developmental Project (UH2 Clinical Trial Optional)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
</tr>
<tr>
<td>HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)</td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Developmental Project (UH2 Clinical Trial Optional)</td>
<td>National Institute of Neurological Disorders and Stroke; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects</td>
<td>National Institute on Drug Abuse</td>
<td>06/05/2021 (First Available Due Date); 09/08/2024 (Expiration)</td>
</tr>
<tr>
<td>——</td>
<td>——</td>
<td>——</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Administrative Supplements for research on fentanyl and derivatives</td>
<td>National Institute on Drug Abuse</td>
<td>04/01/2021 (First Available Due Date); 04/01/2022 (Expiration)</td>
</tr>
<tr>
<td>[1] Other NIH NIDA Funding Opportunities</td>
<td>NIH, NIDA; <a href="https://www.drugabuse.gov">https://www.drugabuse.gov</a></td>
<td>Please see piecemeal opportunities</td>
</tr>
<tr>
<td>[2] National Institute of Drug Abuse NIDA Funding Opportunities; NIDA Notices</td>
<td>——</td>
<td>——</td>
</tr>
<tr>
<td>[3] National Institute of Drug Abuse NIDA Funding Opportunities; NIDA Notices of Special Interest</td>
<td>——</td>
<td>——</td>
</tr>
<tr>
<td>[4] National Institute of Drug Abuse NIDA Funding Opportunities; Active NIDA Requests for Applications, RFAs</td>
<td>——</td>
<td>——</td>
</tr>
<tr>
<td>[5] National Institute of Drug Abuse NIDA Funding Opportunities; Active NIDA Program Announcements, PAs</td>
<td>——</td>
<td>——</td>
</tr>
<tr>
<td>Special Emphasis Notice (SEN): AHRQ Announces Interest in Health Services</td>
<td>Agency for Healthcare Research and Quality</td>
<td>04/03/2021 (Release Date)</td>
</tr>
<tr>
<td>Research to Address Substance Use Disorder Epidemic</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>11/15/2021; 11/16/2021 (Expiration)</td>
</tr>
<tr>
<td>----------------------------------------------------</td>
<td>--------------------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Specialized Alcohol Research Centers (P50 Clinical Trial Optional)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>11/15/2021; 11/16/2021 (Expiration)</td>
</tr>
<tr>
<td>Comprehensive Alcohol Research Centers (P60 Clinical trial Optional)</td>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>11/15/2021; 11/16/2021 (Expiration)</td>
</tr>
<tr>
<td>Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R43/R44 - Clinical Trial Not Allowed)</td>
<td>National Institute on Drug Abuse</td>
<td>08/10/2021; 08/11/2021 (Expiration)</td>
</tr>
<tr>
<td>Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed)</td>
<td>National Institute on Drug Abuse</td>
<td>08/10/2021; 08/11/2021 (Expiration)</td>
</tr>
<tr>
<td>Exploratory Studies to Investigate the Mechanisms of Interrelationship between Sleep and Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans Required)</td>
<td>National Institute on Drug Abuse</td>
<td>10/14/2021; 10/15/2021 (Expiration)</td>
</tr>
<tr>
<td>PAIN MANAGEMENT Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)</td>
<td>National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; National Institute of Mental Health</td>
<td>04/27/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Planning Studies for Initial</td>
<td>National Institute of Neurological Disorders and Stroke; National Center for</td>
<td>04/27/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Category</td>
<td>Description</td>
<td>Institutions</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Analgesic Development</td>
<td>Initial Translational Efforts [Small Molecules and Biologics]</td>
<td>Complementary and Integrative Health; National Eye Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; National Institute of Mental Health</td>
</tr>
<tr>
<td>Suicide Prevention</td>
<td>Notice of Special Interest (NOSI) in Reducing Suicide Risk in Young People in Low- and Middle-Income Countries and Low-Resource Settings</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td></td>
<td>Notice of Change to NOT-MH-21-090, “Notice of Special Interest (NOSI) in Reducing Suicide Risk in Young People in Low- and Middle-Income Countries and Low-Resource Settings”</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>Countermeasures Against Chemical Threats</td>
<td>Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)</td>
<td>National Institute of Neurological Disorders and Stroke; National Eye Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of Environmental Health Sciences</td>
</tr>
<tr>
<td></td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for NIH Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award</td>
<td>National Institute of Neurological Disorders and Stroke; National Eye Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse</td>
</tr>
<tr>
<td>NIH Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award (R21 Clinical Trial Not Allowed)</td>
<td>National Institute of Neurological Disorders and Stroke; National Eye Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of Environmental Health Sciences</td>
<td>07/27/2021; 07/28/2021 (Expiration)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>COOPERATIVE AGREEMENT</td>
<td>NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases</td>
</tr>
<tr>
<td></td>
<td>NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases</td>
</tr>
<tr>
<td></td>
<td>NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases</td>
</tr>
<tr>
<td>IMPLEMENTATION RESEARCH</td>
<td>[1] Dissemination and Implementation Research in Health R01 Clinical Trial Optional</td>
<td>National Institutes of Health (NIH); Components of Participating Organizations: National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Human Genome Research Institute (NHGRI); National Institute on Aging (NIA); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Eunice Kennedy Shriver National Institute of Child Health and Development</td>
</tr>
<tr>
<td></td>
<td>[2] Dissemination and Implementation Research in Health R21 Clinical Trial Optional</td>
<td></td>
</tr>
<tr>
<td></td>
<td>[3] Dissemination and Implementation Research in Health R03 Clinical Trial Not Allowed</td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td>Description</td>
<td>Institution</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>RARE DISEASES</td>
<td>Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)</td>
<td>Human Development (NICHD); National Institute on Deafness and Other Communication Disorders (NIDCD); National Institute of Dental and Craniofacial Research (NIDCR); National Institute on Drug Abuse (NIDA); National Institute of Environmental Health Sciences (NIEHS); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Nursing Research (NINR); National Institute on Minority Health and Health Disparities (NIMHD); National Center for Complementary and Integrative Health (NCCIH); All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP); Office of Behavioral and Social Sciences Research (OBSSR); Office of Research on Women’s Health (ORWH)</td>
</tr>
<tr>
<td>FOOD AND DRUG ADMINISTRATION</td>
<td>Efficient and Innovative Natural History Studies Addressing Unmet Needs in Food and Drug Administration</td>
<td>National Center for Advancing Translational Sciences</td>
</tr>
<tr>
<td><strong>FOOD AND DRUG ADMINISTRATION</strong></td>
<td>Rare Diseases (R01) Clinical Trials Not Required</td>
<td>02/14/2024 (Expiration)</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td><strong>SMALL BUSINESS</strong></td>
<td>The FDA's Cooperative Agreement Program for States and Territories to Implement a National Produce Safety Program (U2F) Clinical Trials Not Allowed</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td></td>
<td>NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)</td>
<td>NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)</td>
</tr>
<tr>
<td></td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for PHS 2021 Omnibus Solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications</td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for PHS 2021 Omnibus Solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications</td>
</tr>
<tr>
<td></td>
<td>NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional)</td>
<td>NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional)</td>
</tr>
<tr>
<td></td>
<td>NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R41/R42 Clinical Trial Optional)</td>
<td>NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R41/R42 Clinical Trial Optional)</td>
</tr>
<tr>
<td></td>
<td>NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurship Enhancement Award (R25 Clinical Trial Not Allowed)</td>
<td>NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurship Enhancement Award (R25 Clinical Trial Not Allowed)</td>
</tr>
<tr>
<td></td>
<td>NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award (K01 Clinical Trial Not Allowed)</td>
<td>NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award (K01 Clinical Trial Not Allowed)</td>
</tr>
</tbody>
</table>
PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

<p>| National Institutes of Health; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Division of AIDS | Standard dates; 04/06/2022 (Expiration) |</p>
<table>
<thead>
<tr>
<th>Title</th>
<th>Institution</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHS 2021-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)</td>
<td>National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; <em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research</td>
<td>Standard dates; 04/06/2022 (Expiration)</td>
</tr>
<tr>
<td>PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)</td>
<td>National Institutes of Health; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute</td>
<td>Standard dates; 04/06/2022 (Expiration)</td>
</tr>
<tr>
<td>PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)</td>
<td>National Institutes of Health; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research</td>
<td>Standard dates; 04/06/2022 (Expiration)</td>
</tr>
<tr>
<td>Growing Great Ideas: Research Education Course in Product Development and Entrepreneurship for Life Science Researchers (UE5 Clinical Trial Not Allowed)</td>
<td>National Institute on Drug Abuse</td>
<td>11/18/2021; 11/19/2021 (Expiration)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Biomarker Research to Support Fertility Regulation Development by Small Business (R43 Clinical Trial Optional)</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</td>
<td>07/29/2021; 07/30/2021 (Expiration)</td>
</tr>
<tr>
<td>SUPPORT FOR RESEARCH EXCELLENCE (SURE) Notice of Intent to Publish a Funding Opportunity Announcement for Support for Research Excellence (SuRE)</td>
<td>National Institute of General Medical Sciences</td>
<td>05/25/2021 (First Estimated Application Due Date)</td>
</tr>
</tbody>
</table>
**Notice of Intent to Publish a Funding Opportunity Announcement for Support for Research Excellence - First Independent Research Support & Transition (SuRE-First)**

**National Institute of General Medical Sciences**

| 09/25/2021 (First Estimated Application Due Date) |

**Notice of Intent to Publish a Funding Opportunity Announcement for a National Resource Center for the Support for Research Excellence (SuRE) Program**

**National Institute of General Medical Sciences**

| 09/25/2021 (First Estimated Application Due Date) |

**SuRE R16 Program Funding Announcements and Upcoming Webinar Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)**

**NIH**

| 05/26/2022; 05/26/2023; 09/08/2023 (Expiration) [Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)]; 09/28/2021; 09/28/2022; 09/28/2023; 01/08/2024 (Expiration) [Support for Research Excellence - First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)] |

**AHRQ Policy on the Inclusion of Priority Populations in Research**

**Agency for Healthcare Research and Quality**

| 05/18/2021 (Release Date) |

**New Investigators to Promote Workforce Diversity in Genomics and other Health-Related Research (R01 Clinical Trial Optional)**

**National Human Genome Research Institute; National Institute of Biomedical Imaging and Bioengineering; Office of the Director, NIH**

| 08/03/2021; 02/22/2022; 02/22/2023; 02/23/2023 (Expiration) |

**Research on Interventions that Promote the Careers of Individuals in the Biomedical Research Enterprise (R01 Clinical Trial Not Allowed)**

**National Institute of General Medical Sciences**

| 10/13/2021; 10/13/2022; 10/13/2023; 10/14/2023 (Expiration) |

**Mentored Career Development Award to Promote Faculty Diversity in**

**National Heart, Lung, and Blood Institute**

<p>| 10/14/2021; 02/11/2022; |</p>
<table>
<thead>
<tr>
<th>Biomedical Research (K01 Independent Clinical Trial Required)</th>
<th>10/13/2022; 02/14/2023; 10/13/2023; 02/13/2024; 05/08/2024 (Expiration)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Not Allowed)</td>
<td>National Heart, Lung, and Blood Institute 10/14/2021; 02/11/2022; 10/13/2022; 02/14/2023; 10/13/2023; 02/13/2024; 05/08/2024 (Expiration)</td>
</tr>
<tr>
<td>NIDDK Short-Term Research Experience Program to Unlock Potential (STEP-UP) (R25 Clinical Trial Not Allowed)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases 09/01/2021; 09/02/2021 (Expiration)</td>
</tr>
<tr>
<td>Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)</td>
<td>National Heart, Lung, and Blood Institute 08/09/2021; 02/23/2022; 08/09/2022; 02/23/2023; 08/09/2023; 02/23/2024; 02/24/2024 (Expiration)</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): NIH Research Project Grant (R01) Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities</td>
<td>National Institute of Neurological Disorders and Stroke; National Institute on Drug Abuse 06/05/2021 (First Available Due Date); 05/08/2023 (June 05, 2021)</td>
</tr>
<tr>
<td>CONFERENCE AND MEETING SUPPORT</td>
<td>Standard dates: 12/15/2025 (Expiration)</td>
</tr>
<tr>
<td>NIOSH Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)</td>
<td>National Institute for Occupational Safety and Health</td>
</tr>
<tr>
<td>NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and... standard due dates: 01/07/2024; 01/08/2024 (Expiration)</td>
</tr>
<tr>
<td><strong>GENDER INCLUSIVE EXCELLENCE</strong></td>
<td><strong>Notice of Intent to Publish a Funding Opportunity Announcement for Advancing Gender Inclusive Excellence (AGIE) Coordinating Center (U54)</strong></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
</tbody>
</table>

Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
<table>
<thead>
<tr>
<th><strong>VACCINE HESITANCY</strong></th>
<th>Notice of Special Interest (NOSI): Urgent Competitive Revisions and Administrative Supplements for Research at NiMHD Research Centers in Minority Institutions (RCMI U54s) on SARS-CoV-2 Vaccine Hesitancy, Uptake, and Implementation</th>
<th>National Institute on Minority Health and Health Disparities</th>
<th>03/05/2021 (First Available Due Date); 05/04/2024 (Expiration Date)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DIGITAL HEALTHCARE</strong></td>
<td>Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
<td>09/08/2021 (First Available Due Date); 05/08/2024 (Expiration Date)</td>
</tr>
<tr>
<td><strong>MINE EVACUATION TECHNOLOGIES</strong></td>
<td>Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)</td>
<td>Agency for Healthcare Research and Quality</td>
<td>Standard dates; 06/18/2024 (Expiration)</td>
</tr>
<tr>
<td><strong>MINE EVACUATION TECHNOLOGIES</strong></td>
<td>Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)</td>
<td>Agency for Healthcare Research and Quality</td>
<td>Standard dates; 07/18/2024 (Expiration)</td>
</tr>
<tr>
<td><strong>INFECTION DISEASE</strong></td>
<td>Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)</td>
<td>John E. Fogarty International Center; National Institute of Allergy and Infectious Diseases</td>
<td>08/03/2021; 08/03/2022; 08/03/2023; 08/04/2024 (Expiration)</td>
</tr>
<tr>
<td><strong>TOBACCO</strong></td>
<td>Tobacco Regulatory Science (R01 Clinical Trial Optional)</td>
<td>National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environmental Health Sciences</td>
<td>07/14/2021; 02/15/2022; 07/14/2022; 02/14/2023; 02/15/2023 (Expiration)</td>
</tr>
<tr>
<td><strong>TOBACCO</strong></td>
<td>Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism</td>
<td>10/08/2021; 08/08/2022; 03/08/2023; 03/09/2023 (Expiration)</td>
</tr>
<tr>
<td>POINT OF CARE</td>
<td>Notice of Correction to NOT-OD-21-065 &quot;Notice of Intent to Publish a Research Opportunity Announcement for RADx-UP Return to School Diagnostic Testing Approaches (OT2 Clinical Trial Required)&quot; for Clinical Trial Requirements</td>
<td>National Institutes of Health</td>
<td>NA</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>-----</td>
</tr>
<tr>
<td>RESPIRATORY</td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for the ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (U01 Clinical Trial Not Allowed)</td>
<td>National Heart, Lung, and Blood Institute; National Institute of General Medical Sciences</td>
<td>06/17/2022 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td></td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for the ARDS, Pneumonia, and Sepsis Phenotyping Consortium Coordinating Center (U01)</td>
<td>National Heart, Lung, and Blood Institute; National Institute of General Medical Sciences</td>
<td>06/17/2022 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>BEHAVIORAL</td>
<td>Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to</td>
<td>National Heart, Lung, and Blood Institute</td>
<td>10/05/2021 (First Available Due Date); 09/08/2024 (Expiration Date)</td>
</tr>
<tr>
<td>DIRECTORS EARLY INDEPENDENCE AWARDS</td>
<td>Limited Submission: NIH Directors Early Independence Awards (DP5 Clinical Trial Optional); 07.22.2021 (Internal Deadline) Limited Submission NIH Directors Early Independence Awards (DP5 Clinical Trial Optional); Sponsor Announcement, 09.03.2021 (Sponsor Deadline) Notice of Pre-Application Webinars for the High-Risk, High-Reward Research Program's Pioneer (RFA-RM-21-015), New Innovator (RFA-RM-21-016), Transformative Research (RFA-RM-21-017), and Early Independence (RFA-RM-21-018) Awards</td>
<td>Office of Strategic Coordination (Common Fund)</td>
<td>06/28/2021 (Pre-Application Webinar); 07/22/2021 (Internal, Limited Submission Deadline); 09/03/2021 (Sponsor Deadline); 09/04/2021 (Expiration)</td>
</tr>
<tr>
<td>DIRECTORS NEW INNOVATOR AWARD</td>
<td>NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional)</td>
<td>Office of Strategic Coordination (Common Fund)</td>
<td>08/20/2021; 08/21/2021 (Expiration)</td>
</tr>
<tr>
<td>EARLY DETECTION</td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for The Early Detection Research Network: Biomarker Characterization Centers (U2C Clinical Trial Not Allowed)</td>
<td>National Cancer Institute</td>
<td>08/31/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td></td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement: Early Detection Research Network (EDRN) Clinical Validation Centers</td>
<td>National Cancer Institute</td>
<td>08/31/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td></td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement: Early Detection Research Network (EDRN) Data Management and Coordinating Center</td>
<td>National Cancer Institute</td>
<td>08/31/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td></td>
<td>The Early Detection Research Network: Clinical Validation Centers (U01 Clinical Trial Optional)</td>
<td>National Cancer Institute</td>
<td>09/09/2021; 09/10/2021 (Expiration)</td>
</tr>
<tr>
<td></td>
<td>The Early Detection Research Network: Data Management and Coordinating Center (U24 Clinical Trial Not Allowed)</td>
<td>National Cancer Institute</td>
<td>09/09/2021; 09/10/2021 (Expiration)</td>
</tr>
<tr>
<td></td>
<td>The Early Detection Research Network: Biomarker Characterization Centers (U2C Clinical Trial Not Allowed)</td>
<td>National Cancer Institute</td>
<td>09/09/2021; 09/10/2021 (Expiration)</td>
</tr>
<tr>
<td>Category</td>
<td>Program Description</td>
<td>Agency</td>
<td>Dates</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>---------------------------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>RESEARCH TRAINING</td>
<td>Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed)</td>
<td>National Institute of General Medical Sciences</td>
<td>10/14/2021; 10/14/2022; 10/13/2023; 10/14/2023 (Expiration)</td>
</tr>
<tr>
<td>POST-ACUTE INTERVENTIONS</td>
<td>Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)</td>
<td>National Institute of Mental Health</td>
<td>10/05/2021; 03/06/2024 (Expiration)</td>
</tr>
<tr>
<td>OBESITY</td>
<td>Nutrition Obesity Research Centers (P30 Clinical Trial Optional)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases</td>
<td>10/20/2021; 10/21/2021 (Expiration)</td>
</tr>
<tr>
<td>POPULATION DYNAMICS</td>
<td>Population Dynamics Centers Research Infrastructure Program FY 2022 (P2C Clinical Trial Not Allowed)</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
<td>07/29/2021; 07/30/2021 (Expiration)</td>
</tr>
<tr>
<td></td>
<td>Coordinating Center for the NICHD Population Dynamics Centers Research Infrastructure Program FY 2022 (R24 Clinical Trial Not Allowed)</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
<td>07/29/2021; 07/30/2021 (Expiration)</td>
</tr>
<tr>
<td></td>
<td>Notice of Information: NICHD Population Dynamics Centers Research Infrastructure Program FY2023 and FY2024</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development</td>
<td>06/08/2021 (Release Date)</td>
</tr>
<tr>
<td>TRANSLATIONAL</td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed)</td>
<td>National Cancer Institute</td>
<td>10/01/2021 (First Estimated Due Date)</td>
</tr>
<tr>
<td></td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional)</td>
<td>National Institute of Environmental Health Sciences</td>
<td>02/01/2022 (First Available Due Date)</td>
</tr>
<tr>
<td>ANTIVIRALS</td>
<td>Notice of Intent to Publish a Funding Opportunity Announcement for Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern (U19 Clinical Trial Not Allowed)</td>
<td>National Institute of Allergy and Infectious Diseases</td>
<td>10/15/2021 (First Estimated Application Due Date)</td>
</tr>
<tr>
<td>Category</td>
<td>Program Description</td>
<td>Awarding Agency</td>
<td>Deadline Details</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>CHRONIC LUNG DISEASE</td>
<td>Notice of Change in Key Dates and Award Information for RFA-HL-21-013 &quot;Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)&quot;</td>
<td>National Heart, Lung, and Blood Institute</td>
<td>06/02/2022 (Revised/updated application due date); 06/03/2022 (Expiration)</td>
</tr>
<tr>
<td>DOWN SYNDROME</td>
<td>Notice of Special Interest (NOSI): Use of Digital Technology and Mobile Health (mHealth) to Improve Diagnosis, Assessments, Interventions, Management and Outcomes for Individuals with Down Syndrome Across the Lifespan (R21 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research</td>
<td>10/16/2021 (First Available Due Date); 11/17/2023 (Expiration Date)</td>
</tr>
<tr>
<td></td>
<td>Small Research Grants for Analyses of Down Syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed)</td>
<td>NIH</td>
<td>11/03/2021; 11/04/2021 (Expiration)</td>
</tr>
<tr>
<td>CONTRACEPTION</td>
<td>Contraception Development Research Center Program (P50, Clinical Trial Optional)</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</td>
<td>11/29/2021; 11/30/2021 (Expiration)</td>
</tr>
<tr>
<td>VISION RESEARCH</td>
<td>NEI Vision Research Epidemiology Grant (UG1 Clinical Trial Not Allowed)</td>
<td>National Eye Institute</td>
<td>09/25/2021; 01/25/2022; 05/25/2024; 09/08/2024 (Expiration)</td>
</tr>
</tbody>
</table>
TABLE OF CONTENTS:
NEW THIS WEEK (TABULAR) .......................................................... 1
NEW THIS WEEK [NTW] .................................................................. 91
COVID-19 AND TELECOMMUTING ............................................. 257
ANNOUNCEMENTS (NIH AND OTHER) ....................................... 273
REQUEST FOR INFORMATION ..................................................... 310
Courses ......................................................................................... 310
LISTINGS ....................................................................................... 311
NIH Director’s Awards Program ...................................................... 311
Cuimc Medical Library And Systematic Review .............................. 311
Skills Development ....................................................................... 311
National Cancer Institute ................................................................ 311
Center Grants ............................................................................... 311
Research Project Grants And Program Project Grants .................. 311
Health Profession Opportunity Grant ............................................. 311
K-Awards, F-Awards ...................................................................... 312
Evidence-Based Practices .............................................................. 325
New Access Points ......................................................................... 325
Small Market Awards .................................................................... 325
Transportation ............................................................................... 325
Clinical Research Scholars ............................................................. 325
Humanitarian Emergencies, Public Health Emergencies ............... 325
Migration/Refugees ....................................................................... 325
Telehealth / Mobile Health (Mhealth) / Health Apps / Health Technology .............................................................................. 325
National Service ........................................................................... 325
Health Care Access ........................................................................ 325
Sustainable Goals .......................................................................... 325
Physiology ..................................................................................... 325
Primary Care .................................................................................. 325
Organ Donations ........................................................................... 325
Accreditation ................................................................................ 325
Physical Education ......................................................................... 325
Biotechnology And Technology ....................................................... 325
Attention Deficit Disorder .............................................................. 325
Clinical Practices And Education Articles ....................................... 326
Social Sciences ............................................................................... 326
Caregiver Health ........................................................................... 326
Columbia, Research Resources And SPA Announcements ............ 326
Life Course .................................................................................... 326
Food And Drug Administration And Food Safety .......................... 327
Birth Defects .................................................................................. 327
Global Health ................................................................................ 327
Research Supplements, Continuity Of Research ............................. 327
Mentoring, Career Transition ........................................................... 327
Re-Entry, Reentry, To Research Careers ......................................... 327

COLUMBIA | Mailman School of Public Health
mailman.columbia.edu/r2

Page 83/439
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Center For Disease Control</td>
<td>328</td>
</tr>
<tr>
<td>Smallpox</td>
<td>328</td>
</tr>
<tr>
<td>Chemistry</td>
<td>328</td>
</tr>
<tr>
<td>Climate And Climate Change</td>
<td>328</td>
</tr>
<tr>
<td>Precision Medicine</td>
<td>328</td>
</tr>
<tr>
<td>Anxiety Disorders</td>
<td>329</td>
</tr>
<tr>
<td>Disorders Of Sexual Development</td>
<td>329</td>
</tr>
<tr>
<td>Generic Drugs</td>
<td>329</td>
</tr>
<tr>
<td>Radioactivity</td>
<td>329</td>
</tr>
<tr>
<td>Thyroid</td>
<td>329</td>
</tr>
<tr>
<td>Tuskegee</td>
<td>329</td>
</tr>
<tr>
<td>Other Announcements</td>
<td>329</td>
</tr>
<tr>
<td>Small Business</td>
<td>330</td>
</tr>
<tr>
<td>Social Work</td>
<td>330</td>
</tr>
<tr>
<td>Mental Health Disorders</td>
<td>330</td>
</tr>
<tr>
<td>Behavioral Sciences</td>
<td>331</td>
</tr>
<tr>
<td>Small Research Grants / Projects</td>
<td>332</td>
</tr>
<tr>
<td>Toxicants</td>
<td>332</td>
</tr>
<tr>
<td>Lead</td>
<td>332</td>
</tr>
<tr>
<td>Prevention</td>
<td>332</td>
</tr>
<tr>
<td>Disease Prevention</td>
<td>333</td>
</tr>
<tr>
<td>Violence Prevention, Injury Prevention</td>
<td>333</td>
</tr>
<tr>
<td>And Injury Control</td>
<td></td>
</tr>
<tr>
<td>Multimorbidity</td>
<td>333</td>
</tr>
<tr>
<td>Gun Violence</td>
<td>333</td>
</tr>
<tr>
<td>Fall Prevention</td>
<td>333</td>
</tr>
<tr>
<td>Resiliency</td>
<td>333</td>
</tr>
<tr>
<td>Hispanic Health Services</td>
<td>333</td>
</tr>
<tr>
<td>US Department Of Labor</td>
<td>333</td>
</tr>
<tr>
<td>United Stated Department Of Justice</td>
<td>333</td>
</tr>
<tr>
<td>Usdoj And Criminal Justice</td>
<td></td>
</tr>
<tr>
<td>Displaced Persons And Homelessness</td>
<td>334</td>
</tr>
<tr>
<td>Sleep And Sleep Disorders</td>
<td>334</td>
</tr>
<tr>
<td>Undiagnosed Diseases</td>
<td>334</td>
</tr>
<tr>
<td>Chronic Diseases And Chronic Conditions</td>
<td>334</td>
</tr>
<tr>
<td>Research Project Grants</td>
<td>334</td>
</tr>
<tr>
<td>Pharmaceuticals And Dosing</td>
<td>334</td>
</tr>
<tr>
<td>Quality Control, Quality Assurance</td>
<td>334</td>
</tr>
<tr>
<td>Population Health And Dynamics</td>
<td>334</td>
</tr>
<tr>
<td>Allergies And Infectious Diseases</td>
<td>334</td>
</tr>
<tr>
<td>And Emerging Infections</td>
<td></td>
</tr>
<tr>
<td>Malaria</td>
<td>335</td>
</tr>
<tr>
<td>Zika</td>
<td>335</td>
</tr>
<tr>
<td>Ebola And Zoonotic Disease</td>
<td>335</td>
</tr>
<tr>
<td>Human Animal Interactions, HAI</td>
<td>336</td>
</tr>
<tr>
<td>Rare Diseases</td>
<td>336</td>
</tr>
<tr>
<td>APHA</td>
<td>337</td>
</tr>
<tr>
<td>ASPPH Announcements</td>
<td>337</td>
</tr>
<tr>
<td>ASPPH Weekly Newsletter</td>
<td>337</td>
</tr>
<tr>
<td>Title</td>
<td>Page</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Service Area Competitions</td>
<td>346</td>
</tr>
<tr>
<td>Graduate Medical Education</td>
<td>346</td>
</tr>
<tr>
<td>Research Education</td>
<td>346</td>
</tr>
<tr>
<td>P Grants Program Project Grants</td>
<td>346</td>
</tr>
<tr>
<td>Training Grants, T32s, T35s Etc.</td>
<td>346</td>
</tr>
<tr>
<td>Undergraduate, Predoctoral, Postdoctoral, Postbaccalaureate Fellowships, Internships, Training Grants</td>
<td>347</td>
</tr>
<tr>
<td>New Items From The NIH</td>
<td>351</td>
</tr>
<tr>
<td>NIH Esmission Items Of Interest</td>
<td>352</td>
</tr>
<tr>
<td>NIH Revised Submission Rules</td>
<td>352</td>
</tr>
<tr>
<td>NIH Guide for Grants And Contracts</td>
<td>352</td>
</tr>
<tr>
<td>Travel / Conference / Meeting Support</td>
<td>353</td>
</tr>
<tr>
<td>Federal Funding Travel Policy</td>
<td>353</td>
</tr>
<tr>
<td>Main Page Funding Links For HUD, CDC, DOE</td>
<td>354</td>
</tr>
<tr>
<td>US Department Of Education</td>
<td>354</td>
</tr>
<tr>
<td>Research Exchanges</td>
<td>354</td>
</tr>
<tr>
<td>Team Healthcare And Collaborations</td>
<td>354</td>
</tr>
<tr>
<td>Outstanding Investigator</td>
<td>354</td>
</tr>
<tr>
<td>Self-Advocacy</td>
<td>354</td>
</tr>
<tr>
<td>Awards / Prizes</td>
<td>354</td>
</tr>
<tr>
<td>Outcomes</td>
<td>355</td>
</tr>
<tr>
<td>Health Information Technology</td>
<td>355</td>
</tr>
<tr>
<td>PCORI Patient-Centered Outcomes Research Institute</td>
<td>355</td>
</tr>
<tr>
<td>Pay For Success</td>
<td>355</td>
</tr>
<tr>
<td>Maximizing Investigator's Research Award</td>
<td>355</td>
</tr>
<tr>
<td>Limited Competition, Limited Submission</td>
<td>355</td>
</tr>
<tr>
<td>Young Investigator Early Investigator Early Career</td>
<td>355</td>
</tr>
<tr>
<td>Reproducibility, Rigor And Transparency</td>
<td>356</td>
</tr>
<tr>
<td>Ethics / Bioethics</td>
<td>356</td>
</tr>
<tr>
<td>Research Training</td>
<td>356</td>
</tr>
<tr>
<td>STEM Science, Technology, Engineering, And Math</td>
<td>356</td>
</tr>
<tr>
<td>Language And Literacy</td>
<td>356</td>
</tr>
<tr>
<td>Dissemination And Implementation Research In Health</td>
<td>356</td>
</tr>
<tr>
<td>Education And Diversity</td>
<td>358</td>
</tr>
<tr>
<td>Institutional Development Award</td>
<td>363</td>
</tr>
<tr>
<td>Voice Disorders</td>
<td>363</td>
</tr>
<tr>
<td>Tuberculosis Tb And Its Prevention</td>
<td>363</td>
</tr>
<tr>
<td>New Innovator Award</td>
<td>363</td>
</tr>
<tr>
<td>Serious Adverse Drug Reactions</td>
<td>364</td>
</tr>
<tr>
<td>Poison Center</td>
<td>364</td>
</tr>
<tr>
<td>Substance Use Disorders, Opioids And Addiction</td>
<td>364</td>
</tr>
<tr>
<td>Center Core, Program Project And P Grants</td>
<td>372</td>
</tr>
<tr>
<td>Patient Safety</td>
<td>372</td>
</tr>
<tr>
<td>Antimicrobial, Antibacterial Resistance &amp;/Or Multidrug Resistance</td>
<td>373</td>
</tr>
<tr>
<td>Columbia Technology Ventures (Ctv)</td>
<td>373</td>
</tr>
<tr>
<td>Natural Products</td>
<td>373</td>
</tr>
</tbody>
</table>
Basic Research, Evidence Based Research, Exploratory Research, Pre-Clinical, Interdisciplinary, Multidisciplinary And Translative, And Translational Research ............................................. 374
Healthcare Associated Infections ......................................................................... 375
Blood Pressure And Sodium .................................................................................. 375
Skin Diseases / Dermatology ................................................................................ 375
Complementary And Integrative Medicine ............................................................ 375
Epidemiology .......................................................................................................... 376
Public Health Institutes ......................................................................................... 376
Quality Of Care ...................................................................................................... 376
World Trade Center ............................................................................................... 376
The Robert Wood Johnson Foundation ................................................................ 376
Young, Foreign Born Biomedical Scientists ......................................................... 376
Emergency Management Responses/Preparedness And Chemical Threats/Fema/Dhs/Department Of Homeland Security .......... 376
Radiation ................................................................................................................. 377
Nanomaterials And Nanotechnology ..................................................................... 377
Environmental And Occupational Health And Safety ............................................ 377
Cardiovascular Disease / Cardiovascular / Heart Disease Or Stroke ..................... 377
Transdisciplinary .................................................................................................... 378
Lung / Pulmonary Disease ...................................................................................... 378
NIH Research Evaluation And Commercialization Hub Awards ......................... 378
Vision, Eye Disease, Ophthalmology ..................................................................... 378
Important Extramural Funding Opportunities ....................................................... 378
The Health Research Board Funding Opportunity .............................................. 378
Epidemiology Cohort ............................................................................................. 378
Transformative ........................................................................................................ 378
Air Pollution ........................................................................................................... 378
Preneoplasia ........................................................................................................... 378
Leukemia / Lymphoma ........................................................................................... 378
Cancer / Oncology .................................................................................................. 379
Foundation Funding ............................................................................................... 386
Adolescent Health/Teens ....................................................................................... 387
Menopause .............................................................................................................. 387
Fertility, Reproductive Health, Contraception ....................................................... 387
Gynecology ............................................................................................................. 388
Pregnancy ................................................................................................................ 388
Adolescents ............................................................................................................ 388
Home Visiting ........................................................................................................ 389
School Based Health Services ................................................................................ 389
Women’s Health ..................................................................................................... 389
Human Milk ............................................................................................................. 389
Maternal And Child Health And Pediatrics ............................................................ 389
USDA ...................................................................................................................... 392
Omics ....................................................................................................................... 392
Down Syndrome .................................................................................................... 392
Genetics .................................................................................................................. 393
Electronic Health Records ..................................................................................... 393
Informationist Services ................................................................. 393
Biostatistics .................................................................................. 393
Mathematical Modeling Of Living Systems (MMLS) ......................... 393
Big Data, Informatics, Health Information Systems And Genomics .... 393
Disabilities .................................................................................... 400
Learning / Developmental Disabilities ........................................... 400
Autism Spectrum Disorders ........................................................... 400
Defense Health Agency ................................................................ 401
Veterans Administration ................................................................ 401
Department Of Defense (DOD), And Defense Advanced Research Projects Agency (Darpa) ......................................................... 401
US Department Of State ................................................................ 403
USAID .......................................................................................... 403
Renal/Kidney Research ................................................................. 403
Cannabis / Cannabinoids ............................................................... 403
Lupus And Autoimmunity ............................................................... 403
Immunity ...................................................................................... 403
Tobacco, Nicotine And E-Cigarettes ............................................. 404
Hepatitis ...................................................................................... 405
Lyme Disease / Tickborne Diseases ............................................... 405
Palliative / End Of Life Care / Hospices / Survivorship .................... 405
Muskuloskeletal Issues/Orthopedics/Arthritis .................................. 405
Pain And Pain Management ........................................................... 405
Anorexia Nervosa And Bulimia ...................................................... 407
Food, Digestive, Nutrition, Metabolites, Obesity, Dietary, Supplements, Safety ................................................................. 407
Asthma ......................................................................................... 408
New York City .............................................................................. 408
NYC Department Of Health And Mental Hygiene ......................... 408
New York State Energy Research And Development Authority (NYSERDA) ........................................................................ 408
New York State Grants Management ........................................... 408
New York State Department Of Health .......................................... 408
Vaccines / Immunizations ............................................................ 408
Alzheimer’s Disease / Dementia ..................................................... 409
Pathology ..................................................................................... 411
Clinical Trials ............................................................................ 411
Lymphatics ................................................................................... 412
Cholesterol ................................................................................. 412
Inflammation .............................................................................. 412
Blood / Hematologic / Cardiology Heart, Lung, Blood .................... 412
Sickle Cell Disease ...................................................................... 413
Hemophilia .................................................................................. 413
Influenza / Flu ............................................................................ 413
Swine Research .......................................................................... 413
Sex Differences ........................................................................... 413
Sex And Gender .......................................................................... 413
LGBTI And Sexual And Gender Minorities .................................... 414
Diet/Physical Activity .................................................................. 414
<table>
<thead>
<tr>
<th>Category</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suicide Prevention</td>
<td>431</td>
</tr>
<tr>
<td>Transfusions</td>
<td>432</td>
</tr>
<tr>
<td>Veterinary Medicine</td>
<td>433</td>
</tr>
<tr>
<td>Health Care Providers</td>
<td>433</td>
</tr>
<tr>
<td>Affordable Care Act And Exchanges</td>
<td>433</td>
</tr>
<tr>
<td>Medicare Medicaid</td>
<td>433</td>
</tr>
<tr>
<td>Centers Of Excellence</td>
<td>433</td>
</tr>
<tr>
<td>Age / Aging</td>
<td>433</td>
</tr>
<tr>
<td>Students</td>
<td>435</td>
</tr>
<tr>
<td>Notices From Columbia University</td>
<td>435</td>
</tr>
<tr>
<td>Urology, Kidney</td>
<td>436</td>
</tr>
<tr>
<td>CONTACT US</td>
<td>439</td>
</tr>
<tr>
<td>END</td>
<td>439</td>
</tr>
</tbody>
</table>
NEW THIS WEEK [NTW]

Funding opportunities and announcements listed in the “New this Week” section will be moved to the main body of the newsletter in the following weeks. They are presented and hyperlinked (in the posted .pdf version of the newsletter) in the following order:

WEEKLY HIGHLIGHT

LIMITED SUBMISSION
FUNDATION FUNDING
ASPPH
EPA
PFAS
NIH LOAN REPAYMENT PROGRAM
CLINICAL TRIALS
BIG DATA
COVID-19
RETURNING TO CAMPUS
NSF
ALZHEIMER'S DISEASE
DIVERSITY
NATIVE AMERICANS
HIV
WEBINAR
ARTIFICIAL INTELLIGENCE
NEW NIH BIOGRAPHICAL SKETCH AND OTHER SUPPORT FORMAT PAGE
NIH ANNOUNCEMENTS
WEBINAR
DIABETES
SMALL RESEARCH GRANTS
RA FORUMS
ENVIRONMENTAL EPIDEMIOLOGY CLIMATE CONNECTIONS (E2C2)
NASA
COMMUNITY INTEGRATED HEALTH NETWORKS
DRINKING WATER
MENTOR OF THE YEAR AWARD
CALDERONE HEALTH EQUITY AWARDS
EQUITY
NIH DIRECTOR'S PIONEER AWARD
OUTSTANDING INVESTIGATOR AWARD
EARLY INVESTIGATOR R35
AUTOIMMUNITY
P GRANTS

SUMMER RESEARCH
CLINICIAN SCIENTISTS
PHYSICAL ACTIVITY OUTCOMES
MICROBIOLOGY
PSYCHOLOGY
ETHICS
CANCER
EARTH INSTITUTE
PIVOT
COLUMBIA STARTUP LAB
NIH REPORTER
COLUMBIA SUMMER RESEARCH INSTITUTE
NSF-BSF JOINT FUNDING OPPORTUNITIES
DEPARTMENT OF DEFENSE INSTRUMENTATION
NIH COVID-19 RESEARCH WEBSITE
DEDICATED CU WEBSITE, COVID-19: FAQS AND RESOURCES RELATING TO RESEARCH
VIROLOGY
SUMMER 2021 SKILLS FOR HEALTH AND RESEARCH PROFESSIONALS (SHARP) TRAINING AT CU PILOT
PROSTATE CANCER
EARLY CAREER
MENTAL HEALTH DISORDERS
WOMEN'S HEALTH INTERVENTIONS
MATERNAL AND CHILD HEALTH
SUBSTANCE USE DISORDERS
PEDIATRICS
BRAIN INITIATIVE
ADHD
K-AWARDS
AZLEMIER'S DISEASE
PARKINSON'S DISEASE
NEUROSCIENCE
AUTISM

AGING
SLEEP RESEARCH
HEALTH DISPARITIES
CTSA CENTER FOR LEADING INNOVATION AND COLLABORATION
TL1 TRAINING PROGRAM
R2 ANNOUNCEMENTS
RIGOR AND REPRODUCIBILITY
COLUMBIA UNIVERSITY
BIOBANK
PROVOST
ADMINISTRATIVE SUPPLEMENTS
SINGLE IRB
US DEPARTMENT OF STATE ARTIFICIAL INTELLIGENCE SOFTWARE
GENOMICS
RESTARTING RESEARCH COVID-19 OPPORTUNITIES CURATED IN PIVOT
CU REMOTE LEARNING
SPA COVID-19 TOWN HALL
CU TEACHING AND LEARNING GRANTS
FORMS-F DATA TABLES TRAINING GRANT
SPA TRAINING GRANT RPPRS AND SURVEY
HIGH PERFORMANCE COMPUTING
NIH GUIDE FOR GRANTS AND CONTRACTS
F-AWARDS
T32 TRAINING GRANTS
COLUMBIA PUBLIC HEALTH NOW PODCASTS
HEALTH POLICY AND MANAGEMENT VIRTUAL EVENTS
FREE LISTS OF GRANTS AND FELLOWSHIPS AROUND THE WORLD AVAILABLE ONLINE
HICCC FUNDING OPPORTUNITIES
RSRCH SUPPORT SERVICES

FIREARM INJURY AND MORTALITY PREVENTION
TRAUMA
TELOMERES
HIV
PAIN MANAGEMENT
SUICIDE PREVENTION
ENVIRONMENTAL PROTECTION AGENCY
COUNTERMEASURES AGAINST CHEMICAL THREATS COOPERATIVE AGREEMENT IMPLEMENTATION RESEARCH RARE DISEASES
FOOD AND DRUG ADMINISTRATION
SMALL BUSINESS
SUPPORT FOR RESEARCH EXCELLENCE (SURE) CONFERENCE MTG SUPPORT
DRUG RESISTANCE
VACCINE HESITANCY
DIGITAL HEALTHCARE
MINE EVACUATION TECHNOLOGIES
INFECTIOUS DISEASE
TOBACCO
POINT OF CARE
RESPIRATORY
BEHAVIORAL
OCCUPATIONAL HEALTH DIRECTORS EARLY INDEPENDENCE AWARDS
INNOVATOR AWARD
EARLY DETECTION RESEARCH TRAINING POST-ACUTE INTERVENTIONS
OBESITY
POPULATION DYNAMICS
CHRONOMEDICINE
TRANSLATIONAL ANTIVIRALS
CHRONIC LUNG DISEASE
DOWN SYNDROME
CONTRACTEPION
STANDARD DUE DATES
[NTW] [WEEKLY HIGHLIGHT/LIMITED SUBMISSION/FOUNDATION FUNDING]
Arnold & Mabel Beckman Foundation | Beckman Young Investigator Program LOI due 07.20.2021

Current Limited Submission Opportunities, Columbia University

**Sponsor:** Office of University Corporate and Foundation Relations; Arnold & Mabel Beckman Foundation

**Deadline(s):** 07/20/2021 (LOI); Arnold and Mabel Beckman Foundation - Beckman Young Investigators; Completed LOI due 9:00 a.m. on Tuesday, July 20 to obtain required Institutional Endorsements; The Arnold and Mabel Beckman Foundation requires two Institutional Endorsements for Letter of Intent (LOI) submissions to the Beckman Young Investigators program. One from the applicant’s dean and the other from the provost. To obtain the required Institutional Endorsements please send the completed LOI to researchinitiatives@columbia.edu by 9:00 a.m. on Tuesday, July 20; Applicants who have completed these steps will receive additional instructions.; Questions should be sent to researchinitiatives@columbia.edu 08/03/2021 (Sponsor Deadline)

**Contact:** Arnold and Mabel Beckman Foundation - Beckman Young Investigators; Completed LOI due 9:00 a.m. on Tuesday, July 20 to obtain required Institutional Endorsements; The Arnold and Mabel Beckman Foundation requires two Institutional Endorsements for Letter of Intent (LOI) submissions to the Beckman Young Investigators program. One from the applicant’s dean and the other from the provost. To obtain the required Institutional Endorsements please send the completed LOI to researchinitiatives@columbia.edu by 9:00 a.m. on Tuesday, July 20; Applicants who have completed these steps will receive additional instructions.; Questions should be sent to researchinitiatives@columbia.edu

**Link(s):** https://www.beckman-foundation.org/programs/beckman-young-investigator/
https://mailchi.mp/039e9bb7a43b/fe1sebg38
https://columbia.infoready4.com/#limitedsubmissions

**Additional Information:** [Originally brought to our attention by the Office of University Corporate and Foundation Relations, the Beckman Young Investigator Program is a Limited Submission Opportunity with an internal deadline of July 20, 2021]; New Funding Opportunities; July 2021; Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines.; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions.; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here.; -Dimitra; Limited Submission Beckman Young Investigators; Limitedsubmissions@columbia.edu ; Arnold and Mabel Beckman Foundation - Beckman Young Investigators; Completed LOI due 9:00 a.m. on Tuesday, July 20 to obtain required Institutional Endorsements; The Arnold and Mabel Beckman Foundation requires two Institutional Endorsements for Letter of Intent (LOI) submissions to the Beckman Young Investigators program. One from the applicant’s dean and the other from the provost. To obtain the required Institutional Endorsements please send the completed LOI to researchinitiatives@columbia.edu by 9:00 a.m. on Tuesday, July 20; Applicants who have completed these steps will receive additional instructions.; Questions should be sent to researchinitiatives@columbia.edu.; Eligibility; The BYI program funds promising young scientists early in their careers who have not yet received a major award from another organization. Proposals that already have substantial funding will not be considered for the BYI award (see eligibility for more information).; Applicants can have no more than $225,000 in direct, annualized external funding grants during any BYI Program Year (Aug-July) at time of application. Start-up funds, department-wide instrumentation grants, and "Transition" grants received as a postdoc (such as NIH K99/R00) are not counted toward this total.; The BYI program is open to those within the first four years of a tenure-track position, or an equivalent independent research appointment, at a United States academic or non-profit institution that conducts research in chemical and life sciences.; Tenure-Track dates for the 2021 program must start after 1/1/2017 AND before 8/2/2021.; Applicants must have no more than 10 years post terminal degree; and no more than 5 years’ experience
in a non-tenure track (not including postdoc position) or industry position.; Example, post terminal degree was received in any month of 2011, they are eligible to apply in August 2021 for the 2022 program; similarly applies for non-tenure track or industry position which occurred in 2016, they are eligible to apply in August 2021 for the 2022 program.; Program Guidelines: https://www.beckman-foundation.org/programs/beckman-young-investigator/; Research Initiatives; Office of the Executive Vice President for Research; Columbia University in the City of New York; To view current limited submission programs please visit: https://columbia.infoready4.com/#limitedsubmissions

[NTW] [LIMITED SUBMISSION]
Limited Submission; Sverige: Sexual Violence Research Initiatives (SVRI); Internal Proposal due 9:00 a.m. on Monday, July 19 [No link provided]
Currently available Limited Submission Opportunities at Columbia
Sponsor: SVRI
Deadline(s): 07/19/2021 (Limited Submission Deadline)
Contact: Questions should be sent to Greg Culler at gcc19@columbia.edu; Anyone who is planning to submit a proposal to this program must send the information requested below limitedsubmissions@columbia.edu by 9:00 a.m. on Monday, July 19
Link(s): https://columbia.infoready4.com/#limitedsubmissions
Additional Information: Limited Submission; Sverige: Sexual Violence Research Initiatives (SVRI); Internal Proposal due 9:00 a.m. on Monday, July 19; Anyone who is planning to submit a proposal to this program must send the information requested below limitedsubmissions@columbia.edu by 9:00 a.m. on Monday, July 19. “SVRI” should appear in the subject line of the email.; Please send the following: PI – Name, department, and email; Co-PIs – Name, department, and institution; Participating Institutions; Program Summary – The Summary (2-page maximum) should provide an overview of the partnerships, proposed research, and location of proposed project.; CV – Short CV for the PI; Please note the following sponsor preferences for this program: Preference will be given to proposals submitted and led by organizations based in Low- and Middle-Income Countries (LMICs); Preference will be given to academic/researcher – practitioner partnerships.; Grant applications that are proposing work on behalf of UN Agencies, the World Bank Group or other multi-lateral agencies will not be considered.; Questions should be sent to Greg Culler at gcc19@columbia.edu.; Research Initiatives; Office of the Executive Vice President for Research; Columbia University in the City of New York; To view current limited submission programs please visit: https://columbia.infoready4.com/#limitedsubmissions

[NTW] [ASPPH WEEKLY NEWSLETTER]
ASPPH Newsletter 07/16/2021 New Format
[please note that the ASPPH Newsletter’s Blog Page will be updated every Friday. All may access it and the url remains constant]
ASPPH has Redesigned its Newsletter Page
Sponsor: http://aspph.org
Deadline(s): NA
Contact: submissions@aspph.org; ASPPH 1900 m Street NW, Suite 710 Washington, DC 20036;
Link(s): https://www.aspph.org/friday-letter/
https://mailchi.mp/aspph/exciting-friday-letter-changes-5220979?e=52be84a6f5

[NTW] [ASPPH ANNOUNCEMENTS]

Columbia Mailman School of Public Health
Research Resources
mailman.columbia.edu/2
ASPPH Policy and Advocacy Newsletter Announcement relative to FY 2020 Budget

Sponsor: ASPPH Policy and Advocacy Newsletter
Deadline(s): FY 2020
Contact: NA
Link(s): http://go.pardot.com/webmail/497911/155448232/c9e160ea813908cbd2e96d0eae0ee6demand8af563aaf7586c7375d26406000ca67a60#FY2020

[NTW] [REACH FOR THE FIRST R01]
Reach for the First R01; Columbia Irving Institute for Clinical and Translational Research Application Deadline 09.03.2021

Sponsor: https://www.irvinginstitute.columbia.edu/services
Deadline(s): 09/03/2021
Contact: Training and Education (TRANSFORM) ctsa_edu@cumc.columbia.edu
Link(s): https://www.irvinginstitute.columbia.edu/services/reach-first-r01-workshop

Additional Information: Apply Now: Reach for the First R01 & Other NIH Opportunities; Columbia | Irving Institute for Clinical and Translational Research; Accepting Applications; Reach for the First R01 Call for Applications; The Reach for the First R01 Workshop is available twice a year to promising junior faculty. Up to six junior investigators are selected for this workshop each term (fall and spring), across all departments. Successful applicants will receive: Five free hours of biostatistical consulting; Access to other Irving Institute services and programs; Two expert pre-reviews on an early draft of their R01 application; Bimonthly, closely-monitored meetings to ensure structure and timeliness in completing the tasks required to successfully submit a first R01 application. These resources are intended to enhance, rather than replace, appropriate mentoring. An applicant without excellent mentoring cannot be seen as competitive for this workshop.; Speaker: R.T. Ogden, PhD; Professor of Biostatistics; Speaker: Mary Beth Terry, PhD; Professor of Epidemiology; 2021 Course Sessions (In-Person) Friday afternoons, 3:00pm - 4:30pm; Sept. 24 – Intro. Session; · Oct. 8 – Aims; · Oct. 22 – Significance/Innovation; · Nov. 5 – Budget Justification / Biosketch; · Dec. 3 – Approach; · Dec. 17 – Mock Study Session; Application Deadline: Friday, September 3rd; 5:00PM EST; Details and Application; Provided by the TRANSFORM Resource at Irving Institute for Clinical and Translational Research

[NTW] [EPA/PFAS]
EPA COLLECTION OF CONCORDANT MULTIMEDIA MEASUREMENTS TO EVALUATE PFAS HUMAN EXPOSURE PATHWAYS Request for Applications (RFA) | Research Grants | US EPA deadline 08.23.2021

EPA Research Grants

Sponsor: EPA
Deadline(s): 08/23/2021 (Application)
Contact: https://www.epa.gov/research-grants/forms/contact-us-about-research-grants
https://www.epa.gov/research-grants/water-research-grants [sswr epa]
https://www.epa.gov/research-grants [epa research grants]

Additional Information: EPA Request for Applications now Open; Products that Contain PFAs; Collection of Concordant Multimedia Measurements to Evaluate PFAS Human Exposure Pathways Request for Applications (RFA); Collection of
Concordant Multimedia Measurements to Evaluate PFAS Human Exposure Pathways Request for Applications (RFA) and Informational Webinar; URL: COLLECTION OF CONCORDANT MULTIMEDIA MEASUREMENTS TO EVALUATE PFAS HUMAN EXPOSURE PATHWAYS Request for Applications (RFA) | Research Grants | US EPA; Open Date: July 7, 2021; Close Date: August 23, 2021; Informational Webinar: Learn more about this RFA and the application process.; Background: PFAS are a large group of several thousand industrial chemicals that are used in many consumer products and industrial and manufacturing applications. The pervasive nature of PFAS-containing products, their resistance to metabolic and environmental degradation, their mobility, and their potential for bioaccumulation and toxicity present serious environmental health challenges. Measurement data on the nature and level of PFAS in the residential environment and diet is required to understand and mitigate important pathways for human exposure.; With this RFA, EPA seeks to advance common exposure measurement protocols that can be implemented across PFAS cohort studies to generate important exposure data for priority pathways. The Agency is soliciting research that proposes and evaluates innovative protocols for measuring human exposure to PFAS chemicals in cohorts where biomonitoring is being conducted. Responsive proposals should include a collection of environmental and personal exposure measures and analysis for a common set of PFAS chemicals (e.g., those measured in NHANES) as well as Total Organic Fluorine (TOF). In addition, the data developed should enable or improve interpretation of PFAS biomonitoring data and inform understanding of the important sources and pathways related to personal exposures to PFAS chemicals.; For information on eligibility, project specifications, or how to apply, visit COLLECTION OF CONCORDANT MULTIMEDIA MEASUREMENTS TO EVALUATE PFAS HUMAN EXPOSURE PATHWAYS Request for Applications (RFA); Learn more about the Safe and Sustainable Water Resources (SSWR) Research Program. Learn more about EPA Research Grants.; Informational Webinar for Applicants Join us for an informational webinar on the Collection of Concordant Multimedia Measurements to Evaluate PFAS Human Exposure Pathways RFA. The webinar covers application information and provides an overview of research areas information provided in the RFA.; Date: Wednesday, July 21, 2021; Time: 11:30 a.m. - 12:30 p.m. EST; Register: Informational Webinar Event Page; Webinar Objectives: Share general information and information on research areas for the RFA; Learn about the administrative, submission, eligibility, and peer review processes; Question & answer session

[NTW] [NIH LOAN REPAYMENT PROGRAM]
Extramural Loan Repayment Program for Clinical Researchers (LRP-CR)
Extramural Loan Repayment Program for Pediatric Research (LRP-PR)
Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR)
Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (LRP-IDB)
Extramural Loan Repayment Program for Contraception and Infertility Research (LRP-CIR)
Extramural Loan Repayment Program for Research in Emerging Areas Critical to Human Health (LRP-REACH)

Sponsor: National Institutes of Health; Office of The Director, National Institutes of Health (OD)
Deadline(s): 09/01/2021 - 11/18/2021 (submission window)
Contact: Additional detailed information about the NIH Loan Repayment Programs is provided at https://www.lrp.nih.gov/eligibility-programs. Applicants are strongly encouraged to discuss their career interests with an NIH Institute or Center scientific liaison provided at this site: https://www.lrp.nih.gov/contact-engage.

https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-140.html [Extramural Loan Repayment Program for Pediatric Research (LRP-PR)]
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-142.html [Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (LRP-IDB)]

Additional Information: NIH Loan Repayment Program 2022; The National Institutes of Health (NIH) released six separate program announcements for the 2022 application cycle of the NIH Loan Repayment Program (LRP). The LRP may repay up to $50,000 of qualified student loan debt per year to outstanding health professionals who commit at least two years to conduct biomedical, behavioral, social, or clinical research, and who agree to engage in such research for an average of at least 20 hours per week based on a 40-hour work week. This includes most undergraduate, graduate, and medical school loans. Loan repayment benefits are in addition to the institutional salary received for research. LRP awards are based on an applicant’s potential to build and sustain a research career.; New – the application process is different this year! All applications must be submitted through the Application Submission System & Interface for Submission Tracking (ASSIST), and not the LRP website. We will provide more explicit instructions on how to apply through ASSIST as it becomes available. ASSIST will begin accepting applications on September 1st, 2021 through November 18, 2021, 8pm EST.; Potential applicants should carefully read the general eligibility requirements, plus the eligibility requirements and application instructions under each funding announcement. Questions concerning eligibility should be discussed with NIH staff. Find the appropriate contact at the Contact and Engage page.; The six program announcements are: NOT-OD-21-139 – LRP for Clinical Researchers (LRP-CR); NOT-OD-21-140 – LRP for Pediatric Research (LRP-PR); NOT-OD-21-141 – LRP for Health Disparities Research (LRP-HDR); NOT-OD-21-142 – Clinical Research LRP for Individuals from Disadvantaged Backgrounds (LRP-IDB); NOT-OD-21-143 – LRP for Contraception and Infertility Research (LRP-CIR); NOT-OD-21-144 – LRP for Research in Emerging Areas Critical to Human Health (LRP-REACH) – New; Please note: Recipients of Ruth L. Kirschstein National Research Service Award (NRSA) support from an individual postdoctoral fellowship (F32) or an institutional research training grant (T32) will be eligible for loan repayment during the second year of NRSA support if a formal extension of the NRSA service payback is granted (see NIH Training Payback). Concurrent fulfillment of LRP and NRSA service obligations is prohibited. You must request a deferral of NRSA payback service prior to acceptance into the LRP. A deferral form can be obtained by contacting the LRP Help Line at 866-849-4047. It is important to note, though, that NRSA recipients may continue to receive their stipends from the NRSA.; All general questions should be directed to the LRP Information Center at (866) 849-4047 or lrp@nih.gov.; [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia University; Columbia University Irving Medical Center; Main Campus: (212) 854-0606; sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu/
**[NTW] [NATIONAL SCIENCE FOUNDATION]**

**Issuance of NSF Proposal and Award Policies and Procedures Guide (NSF 22-1)**

**Sponsor:** National Science Foundation

**Deadline(s):** 10/04/2021 (Effective Date)

**Contact:** If you have any questions regarding these changes, please contact the DIAS/Policy Office at policy@nsf.gov.; Regards, Jean Feldman; Head, Policy Office; Division of Institution and Award Support; Office of Budget, Finance & Award Management; CU SPA Project Officer

**Link(s):**
- https://nsfpolicyoutreach.com/get-notified/

**Additional Information:** Issuance of NSF Proposal and Award Policies and Procedures Guide (NSF 22-1); See below announcement from NSF. They have released the latest version of the NSF Proposal & Award Policies & Procedures Guide (PAPPG) (NSF 22-1), effective for proposals submitted or due on or after October 4, 2021. While this version of the PAPPG becomes effective on October 4, 2021, in the interim, the guidelines contained in the current PAPPG (NSF 20-1) continue to apply.; A listing of significant changes can be found here, and a condensed list of major changes are below. NSF will be hosting a webinar to review the significant changes, date to be determined. However, you can sign up here to be notified immediately when registration for the webinar is open. I’ll also provide that information once it becomes available.; One thing I’d like to highlight is that NSF will be increasing the page limit for the biographical sketch from two to three pages, effective for proposals submitted or due on or after October 4, 2021. Stay tuned for more information about that.; As always, feel free to contact your SPA Project Officer should you have any questions, and we’ll keep you posted of new developments.; [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; sfs2110@columbia.edu; Website: https://spa.columbia.edu/; Dear Colleagues: We are pleased to announce that a revised version of the NSF Proposal & Award Policies & Procedures Guide (PAPPG) (NSF 22-1) has been issued.; The new PAPPG will be effective for proposals submitted or due on or after October 4, 2021. Significant changes include: A new section covering requests for reasonable and accessibility accommodations regarding the proposal process or requests for accessibility accommodations to access NSF’s electronic systems, websites and other digital content; A table entitled, NSF Pre-award and Post-award Disclosures Relating to the Biographical Sketch and Current and Pending Support. This table identifies where pre- and post-award current and pending support disclosure information must be provided. Proposers and awardees may begin using this table immediately; Increasing the page limit for the biographical sketch from two to three pages; Updates to the current and pending support section of NSF proposals to require that information on objectives and overlap with other projects is provided to help NSF and reviewers assess overlap/duplication; Adding planning proposals and Career-Life Balance supplemental funding requests as new proposal types; Updates to travel proposals will require that AORs certify that prior to the proposer’s participation in the meeting for which NSF travel support is being requested, the proposer will assure that the meeting organizer has a written policy or code-of-conduct addressing harassment.; You are encouraged to review the by-chapter summary of changes provided in the Introduction section of the PAPPG.; NSF plans to conduct a webinar covering these changes. Visit the NSF policy outreach website to sign up for notifications about this and other outreach events.; While this version of the PAPPG becomes effective on October 4, 2021, in the interim, the guidelines contained in the current PAPPG (NSF 20-1) continue to apply.; If you have any questions regarding these changes, please contact the DIAS/Policy Office at policy@nsf.gov.; Regards, Jean Feldman; Head, Policy Office; Division of Institution and Award Support; Office of Budget, Finance & Award Management
[NTW] [CLINICAL TRIALS]
NIA Announces New Policy and Procedures for the Reporting of Human Subjects Enrollment Data for NIA Clinical Research Trials/Studies

Sponsor: National Institute on Aging  
Deadline(s): 06/17/2021 (Release Date)  
Contact: Holly Massett, Ph.D.; Senior Advisor, Clinical Research Recruitment & Engagement; Division of Extramural Activities; National Institute on Aging; Email: NIAclinicalresearch@nia.nih.gov


Additional Information: The purpose of this Notice is to inform the research community of the National Institute on Aging (NIA) new policy and procedures for reporting enrollment data for clinical research trials/studies funded through an NIA funding mechanism (including grants, contracts, and cooperative agreements). This Notice details the new requirements, expectations of NIA-funded investigators, and impetus for the policy change.

[NTW] [BIG DATA]
Columbia Data Science Institute Capstone Project, Updated Link for Submission (Due 07/18/2021)

Archival CU Capstone Project Link provided for reference

Capstone Project Mentor Sign Up Form (Due 07/30/2021)

Sponsor: Data Science Institute; https://datascience.columbia.edu; datascience@columbia.edu

Deadline(s): 07/18/2021 (Deadline for Capstone Project) ; 07/30/2021 (Capstone Project Mentor Sign Up Form)

Contact: datascience@columbia.edu

Link(s): https://docs.google.com/forms/d/e/1FAIpQLSckhNG-1slwVVYYxaRW8QK_tWckv69JA3_iBp9OXlWFfUnA/viewform  
https://docs.google.com/forms/d/e/1FAIpQLSf-13MASXELM5yn7141TAEQ0xVlmtpx4UCQhMy6et-I04vQ/viewform [Mentor sign up form]


Additional Information: UPDATED LINK FOR SUBMISSION. Education is one of the pillars of the Data Science Institute. Through educational activities, we strive to create a community in Data Science at Columbia. The capstone project is one of the most lauded elements of our MS in Data Science program. As a final step during their study at Columbia, our MS students work on a project sponsored by a DSI industry affiliate or a faculty member over the course of a semester. There are two levels of engagement for DSI faculty in the capstone program: (1) The first is through faculty-sponsored capstone projects, where a DSI faculty member proposes a research project and advises a team of students working on this project. This is a great way to run a research project with enthusiastic students, eager to try out their newly acquired data science skills in a research setting.

Interested faculty should submit a Capstone Project Proposal by July 18th, 2021. This is especially a good opportunity for developing and accelerating interdisciplinary collaboration.; SUBMIT CAPSTONE PROJECT PROPOSAL HERE; (2) The second way a DSI faculty member can contribute is by serving as a faculty mentor, who will mentor a team of students working on a project proposed by an industry affiliate. While the students work with industry mentors, we have found that timely advising from a faculty member is absolutely crucial for the success of these projects. The faculty mentor will be jointly mentoring the students with the project’s industry mentor. This is a great way to participate in DSI’s industry affiliates program and network with data scientists from industry. As a faculty mentor you also gain a first-hand and close look at the MS in Data Science students’ skill set-- a nice opportunity for someone who might be looking for future research assistants with data science skills or who might want to propose a capstone project in the future. Interested faculty should fill out this form - Capstone project mentor sign-up
form (deadline July 30th, 2021) [link will be provided when available]; Specifically, to the center chairs/co-chairs on this list: Each DSI’s center or working group represents a unique focused area of data science, whose intellectual activities attract faculty and students across campus. There is a lot of potential for the centers and working groups to contribute to DSI’s educational mission, which is a great way to build up the center/working group’s research-education integration/convergence profile. We would like to increase the engagement from centers in our educational initiatives of DSI. We are hoping all the centers will help us recruit capstone project proposals and faculty mentors from your center’s members.; All submissions are subject to review and approval by the capstone committee. For capstone project proposals, the committee will do their best to provide timely feedback on how to make it fit with the mission of the capstone project.

[NTW] [BIG DATA]
Request for Information: Developing Consent Language for Future Use of Data and Biospecimens

**Sponsor:** National Institutes of Health  
**Deadline(s):** 09/29/2021  
**Contact:** NIH Office of Science Policy; OD/Division of Clinical and Healthcare Research Policy; Telephone: 301-496-9838; Email: SciencePolicy@mail.nih.gov  

[NTW] [BIG DATA]
NIH Request for Information (RFI) on Streamlining Access to Controlled Data from NIH Data Repositories; Notice Number: NOT-OD-21-157; Key Dates; Release Date: July 9, 2021; Response Date: August 09, 2021

**Sponsor:** NIH; [https://datascience.nih.gov/streamlining-access-to-controlled-data](https://datascience.nih.gov/streamlining-access-to-controlled-data)  
**Deadline(s):** 08/09/2021 (Response Date)  
**Contact:** Please direct all inquiries to: Vivian OTA WANG PhD; Office of Data Science Strategy; Division of Program Coordination, Planning, and Strategic Initiatives; Office of the Director; Email: streamingdata-rfi@nih.gov  
[https://datascience.nih.gov/streamlining-access-to-controlled-data](https://datascience.nih.gov/streamlining-access-to-controlled-data)  

**Additional Information:** NIH Request for Information (RFI) on Streamlining Access to Controlled Data from NIH Data Repositories; **Notice Number:** NOT-OD-21-157; **Key Dates; Release Date:** July 9, 2021; **Response Date:** August 09, 2021; **Related Announcements:** None; **Issued by:** Office of The Director, National Institutes of Health (**OD**); **Purpose:** NIH is requesting input on strategies for harmonizing, simplifying, and streamlining mechanisms for accessing data in NIH-supported controlled-access data repositories that continue to uphold robust data privacy and security protections. In particular, NIH would like to understand better researchers’ experiences in finding and accessing controlled access data housed in NIH-supported repositories and the extent to which existing NIH policies address aggregation and linkage of controlled access data.; This Notice is part of several NIH activities to engage stakeholders on this topic. Interested parties may find additional information at: [https://datascience.nih.gov/streamlining-access-to-controlled-data](https://datascience.nih.gov/streamlining-access-to-controlled-data); **Background:** NIH stores and facilitates access to many datasets, both open and controlled, with the goal of accelerating new discoveries, thereby maximizing taxpayer return on investment in the collection of these datasets. Data derived from humans that are shared through controlled-access mechanisms
in particular, reflect NIH’s commitment to protect sensitive data from and honor the informed consent provided by research participants in NIH-supported studies; NIH has supported multiple controlled-access data repositories that uphold appropriate data protections (for both human data and other sensitive data) while meeting the needs of various researcher communities. However, as data access requests increase, new repositories are established, and new mechanisms of providing access to data are developed, it is apparent that opportunities remain to improve efficiency and harmonization among repositories to make NIH-supported controlled-access data more Findable, Accessible, Interoperable, and Reusable (FAIR) and to ensure appropriate oversight when data from different resources are combined. While these trends are enabling datasets and datatypes to be combined in new ways that advance the science, datasets and datatypes that may or may not be controlled may, when combined, create inadvertent re-identification risks.; **Request for Information:** NIH is requesting input on issues that are relevant to users of NIH-supported controlled-access data repositories (hereinafter “repositories”). NIH notes that the scope of this RFI is intended to cover strategies generalizable to all NIH-supported controlled-access data repositories, and all data types featured therein and is not specific to particular data repositories. This RFI is not intended to identify specific repository access challenges, but rather to help NIH understand users’ experiences and potentially workable solutions to streamlining access to controlled data. Prior RFIs sought community input on opportunities and challenges associated with particular repositories, (for example with dbGaP in 2017[1]); While elements of this RFI touch on informed consent in the sense of ensuring a common understanding and vocabulary to describe how data may or may not be used, NIH has released another RFI on sample informed consent language for data and biospecimen sharing.[2] Respondents interested in consent for data and biospecimen sharing may wish to review and comment in response to that RFI.; **The NIH seeks comments on any or all of, but not limited to, the following topics:** General opportunities for streamlining access to controlled data; Identify the minimum data elements necessary for review of requests to access controlled data from a repository and envision how they may be standardized across repositories.; Describe methods to streamline access requests for researchers from one or more institutions collaborating on a single project, while mindful of oversight and accountability.; Describe experiences with Institutional Signing Official (ISO) involvement and envision what could be automated to support ISO involvement.; Identify potential opportunities to automate elements of data access requests. Describe whether or the extent to which such automation might inherently increase the risk that a request is approved (or recommended for approval) that otherwise should not have been.; Making controlled-access data readily findable and accessible Suggest how to make metadata[3] consistent across repositories to facilitate findability, and how to encourage standard definitions. Describe how frequently standard metadata may need to be updated.; Describe your experiences and any barriers that you have experienced with data descriptors such as vocabularies, search ontologies, etc.; Describe what benefits may accrue through the use of standardized data use agreement terms across repositories.; Current trends toward “general research use” informed consent language support subsequent broad accessibility of data. However, some research requires more restrictive consents, thus limiting downstream data access. Describe approaches to foster standardized consent language expectations that lead to a common understanding of limitations of data use across repositories. Describe any barriers to researcher acceptance of approaches that might exist.; Addressing oversight, governance, and privacy issues in linking controlled access data from different resources; Describe processes for identifying and addressing risks of unanticipated re-identification that may emerge when linking information about a specific person, drawn from two or more datasets from the same, or different repositories with different access processes. Consider whether processes and risk mitigation strategies would differ when the original datasets are controlled vs. open.; Describe optimal policy strategies for addressing such risks.; Describe processes to ensure there are no gaps in oversight for projects that involve data governed by multiple repositories.; Describe strategies that would increase transparency to the public in how data are used. ; **How to Submit a Response:** All comments must be submitted electronically on the Web Portal; at: https://datascience.nih.gov/streamlining-access-to-controlled-data-rfi-submission.; **Responses;** Responses must be received by 11:59:59 pm (ET) on **08/09/21.**; Responses to this RFI are voluntary and may be submitted anonymously. You may voluntarily include your name and contact information with your response. If you choose to provide NIH with this information, NIH will not share your name and contact information outside of NIH unless required by law.; Other than your name and contact information, please do not include any personally identifiable information or any
information that you do not wish to make public. Proprietary, classified, confidential, or sensitive information should not be included in your response. The Government will use the information submitted in response to this RFI at its discretion. Other than your name and contact information, the Government reserves the right to use any submitted information on public websites, in reports, in summaries of the state of the science, in any possible resultant solicitation(s), grant(s), or cooperative agreement(s), or in the development of future funding opportunity announcements. This RFI is for informational and planning purposes only and is not a solicitation for applications or an obligation on the part of the Government to provide support for any ideas identified in response to it. Please note that the Government will not pay for the preparation of any information submitted or for use of that information. We look forward to your input and hope that you will share this RFI opportunity with your colleagues; Reference: [1] https://grants.nih.gov/grants/guide/notice-files/NOT-od-17-044.html; [2] https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-131.html; [3] Data that provide additional information intended to make scientific data interpretable and reusable (e.g., date, independent sample and variable construction and description, methodology, data provenance, data transformations, any intermediate or descriptive observational variables). See NIH Policy for Data Management and Sharing; at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-013.html; Inquiries: Please direct all inquiries to: Vivian OTA WANG PhD; Office of Data Science Strategy; Division of Program Coordination, Planning, and Strategic Initiatives; Office of the Director; Email: streamliningdata-rfi@nih.gov

[NTW] [COVID-19/RETURNING TO CAMPUS]
COVID-19 Campus Safety for Employees and Students
Sponsor: CUMC
Deadline(s): NA
Contact: If you have further questions or requests after reading this guide, please email cumchr@cumc.columbia.edu (link sends e-mail) or your Senior Human Resources Business Partner. If you have any COVID-19 specific questions, please email covid19questions@cumc.columbia.edu (link sends e-mail).
Additional Information: CUIMC is focused on the safety of our health care providers, our staff, students and the patients we serve. In charting a path forward, CUIMC is committed to continuing our missions of providing the finest clinical care, cutting edge research, and educating the next generation of leaders in science and medicine.

[NTW] [COVID-19]
Research Opportunity Announcement OTA-21-015C REsearching COVID to Enhance Recovery (RECOVER) Initiative: Mobile Health Platform (MHP) ROA
Sponsor: NIH
Deadline(s): 07/30/2021
Contact: Proposals must be submitted via eRA ASSIST under OTA-21-015 and simultaneously emailed to NHLBI_OTA@mail.nih.gov no later than 5 PM EDT on July 30, 2021. The ROA # OTA-21-015 should be entered into the system when submitting via ASSIST.
Additional Information: Researching COVID to Enhance Recovery (RECOVER) initiative: Mobile Health Platform (MHP) ROA; A Mobile Health Platform ROA (OTA-21-015C) soliciting proposals for the adaptation and support of a scalable, configurable, and integrated Mobile Health Platform (MHP) to provide RECOVER Initiative studies with customized mobile applications and for enabling secure collection of PASC digital health measures.; Full Proposals must be received by 5:00 pm, ET, July 30, 2021; View Mobile Health Platform ROA
[NTW] [NIH ANNOUNCEMENTS]
Updated Process for Submission of Federal Financial Reports for Closed Payment Management System Subaccounts

Sponsor: National Institutes of Health
Deadline(s): 06/01/2021 (Release Date)
Contact: Please direct all system policy inquiries to: Systems Policy Branch; Office of Policy for Extramural Research Administration; OPERAsystemspolicy@nih.gov; Please direct inquiries for NIH Office of Financial Management (OFM) to: Don Geiger, OFM-GAB Branch Chief; don.geiger@nih.gov; (301) 402-5130
Additional Information: The purpose of this Notice is to provide instructions to NIH recipients who need to submit an SF-425 Federal Financial Report (FFR) for a closed subaccount (e.g. “C" status) in the HHS Payment Management System (PMS). The subaccount corresponds to the award document number in Section I of the Notice of Award.

[NTW] [NATIONAL SCIENCE FOUNDATION (NSF)]
Statement by NSF Director Sethuraman Panchanathan on the President’s FY22 Budget Request

Sponsor: NSF
Deadline(s): 05/28/2021 (Release Date)
Contact: https://www.nsf.gov/help/contact.jsp
https://www.whitehouse.gov/omb/budget/
https://beta.nsf.gov/budget

Additional Information: May 28, 2021; Statement by NSF Director Sethuraman Panchanathan on the President’s FY22 Budget Request; President proposes Crucial Investments to Advance the Frontiers of U.S. Science and Technology; The Biden-Harris Administration today submitted to Congress the President’s Budget for fiscal year 2022. As the Administration continues to make progress defeating the pandemic and getting our economy back on track, the Budget makes historic investments that will help the country build back better and lay the foundation for shared growth and prosperity for decades to come; “This request will bolster the U.S. economy and our leadership in critical and emerging areas of research and technological advancements, which are essential to our long-term economic and national security,” said NSF Director Sethuraman Panchanathan. “NSF’s mission is unique in supporting research across all fields of science, technology, engineering, and mathematics, and all levels of STEM education. Seven decades of experience building the necessary partnerships between federal, state, and local government, academia, and industry have produced remarkable results for the country. With this budget, we can rapidly scale our investments and build even stronger bridges between discovery, innovation, and commercialization.”; The Budget includes more details on what is proposed in the two historic plans the President has already put forward — the Americans Jobs Plan and the American Families Plan – and reinvests in education, research, public health, and other foundations of our country’s strength. At the U.S. National Science Foundation, the Budget would: Enhance Fundamental Research and Development. $9.43 billion, an increase of $1.55 billion above 2021 enacted level will support research across the spectrum of science, engineering and technology. This includes biological sciences; computer and information sciences; engineering; geosciences; math and physical sciences; social, behavioral, and economic sciences; and education. With this additional funding, NSF will continue to be the champion of basic
and fundamental research and will strengthen it at speed and scale; **Strengthen U.S. Leadership in Emerging Technologies.** Includes the establishment of a new directorate for technology, innovation and partnerships within NSF to help translate research into practical applications. The directorate will work with programs across NSF and with other federal and non-federal entities to expedite technology development in emerging areas that are crucial for the United States’ technological leadership.; **Advances Equity in Science and Engineering.** $100 million, an increase of about 50 percent, in funding for programs that aim to increase participation in science and engineering of individuals from racial and ethnic groups underrepresented in these fields. Funding will support curriculum design, research on successful recruitment and retention methods, development of outreach or mentorship programs, fellowships, and building science and engineering research and education capacity at historically black colleges and universities, and other minority-serving institutions.; **Advances Climate Science and Sustainability Research.** $1.2 billion for climate and clean energy-related research will fund a broad portfolio of research related to climate science and clean energy, including research on atmospheric composition, water and carbon cycles, modeling climate systems, renewable energy technologies, materials sciences, and social, behavioral, and economic research on human responses to climate change.; **Continues Construction of Forefront Research Infrastructure.** Invests in the continued construction of major NSF research facilities, including long-term upgrades of NSF’s major Antarctic infrastructure. It also supports construction of the Vera C. Rubin Observatory to enable astronomy research. In addition, the budget request seeks funding for the construction and procurement of smaller research facilities and equipment across the nation.; Enacting the Budget policies into law this year would strengthen our Nation’s economy and lay the foundation for shared prosperity, while also improving our Nation’s long-term fiscal health.; For more information on the President’s FY22 Budget, please visit: [https://www.whitehouse.gov/omb/budget/](https://www.whitehouse.gov/omb/budget/); For more information on the NSF budget, please visit: [https://beta.nsf.gov/budget](https://beta.nsf.gov/budget); *-NSF- [brought to our attention by Stephanie Scott / SPA]*

**[NTW] [LIMITED COMPEITION]**

**Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)**

**Sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases

**Deadline(s):** 10/16/2021; 02/16/2022; 06/16/2022; 02/16/2024; 06/16/2024; 09/08/2024 (Expiration)

**Contact:** Scientific/Research Contact(s); Hung Tseng PhD; National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS); Telephone: 301-496-0810; Email: tsengh@mail.nih.gov


**[NTW] [LIMITED SUBMISSION]**

**NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)** [This is a Limited Submission Opportunity, link provided for reference]

**Currently Available CU Limited Submission Opportunities**

**Sponsor:** National Institute of General Medical Sciences

**Deadline(s):** 07/13/2022; 07/14/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Tony Beck, Ph.D.; National Institute of General Medical Sciences (NIGMS);

Email: beckl@mail.nih.gov [NIH Reference, this is a limited submission opportunity and questions should be directed to] Greg Culler at limitedsubmissions@columbia.edu
[NTW] [LIMITED SUBMISSION/FOUNDATION FUNDING]
Limited Submission; Gabrielle’s Angel Foundation for Cancer Research – Medical Research Grants; Internal Proposal Deadline 07.21.2021; Sponsor Deadline 08.27.2021

Sponsor: Gabrielle’s Angel Foundation
Deadline(s): 07/21/2021 (Limited Submission, Internal Deadline); 08/27/2021 (Sponsor Deadline)
Contact: Questions should be sent to Greg Culler at limitedsubmissions@columbia.edu.
Link(s): https://columbia.infoready4.com/#competitionDetail/1846373

Additional Information: Gabrielle’s Angel Foundation for Cancer Research – Medical Research Grants; Limited Submission; Internal Proposal due 9:00 a.m. on July 21; Program: Gabrielle’s Angel Foundation Medical Research Awards provide support to junior investigators whose cutting-edge, creative scientific proposals have the greatest potential of broadening understanding of, and treatment for, blood cancers. The Foundation focuses on projects for cancer prevention, detection, and treatment; Tracks: Proposals may be submitted in two areas – Mainstream / Conventional Medicine Integrative Medicine; Award: Projects will be funded for a three-year period at $75,000.00 per year--overhead (i.e. indirect) costs cannot exceed 10% of the total grant award, Eligibility: To be eligible for the Medical Research Awards, candidates must: Hold a tenure-track Assistant Professor position Associate Professors may only apply for Integrative Medicine; Have independent research projects as well as independent resources; Have preliminary results and/or publications from their independent laboratory; For Mainstream/Conventional Medicine: Have held their current position no longer than five years; Start date after August 27, 2016.; Deadlines: Internal Proposal due 9:00 a.m. on Wednesday, July 21; Final Sponsor Proposal – August 27; Internal Application: For more information on how to apply, please view the internal announcement webpage – https://columbia.infoready4.com/#competitionDetail/1846373; Questions should be sent to Greg Culler at limitedsubmissions@columbia.edu.
[NTW] [LIMITED SUBMISSION/DIVERSITY]

Limited Submission; NIH Resource Center for the Support for Research Excellence (SuRE) Program (U24 - Clinical Trial Not Allowed); Internal Deadline 9:00 a.m. on Thursday, July 8 [This is a Limited Submission Opportunity, Sponsor/NIH posting provided for reference]

Currently Available Limited Submission Opportunities, Columbia University

Sponsor: National Institutes of Health (NIH); National Institute of General Medical Sciences (NIGMS)

Deadline(s): 07/08/2021 (Internal/CU Limited Submission Deadline); 09/24/2021 (Sponsor Deadline); 09/25/2021 (Expiration)

Contact: Scientific/Research Contact(s); Irina Krasnova, Ph.D.; National Institute of General Medical Sciences (NIGMS); Email: irina.krasnova@nih.gov [NIH Contact provided for reference, this is a Limited Submission opportunity]; Questions should be sent to Greg Culler at limitedsubmissions@columbia.edu

https://columbia.infoready4.com/#limitedsubmissions

Additional Information: NIH Resource Center for the Support for Research Excellence (SuRE) Program (U24 - Clinical Trial Not Allowed); Limited Submission; NIH Resource Center for the Support for Research Excellence (SuRE) Program (U24 - Clinical Trial Not Allowed); Internal Deadline 9:00 a.m. on Thursday, July 8; Anyone who is planning to submit a proposal to this program must send the information requested below to limitedsubmissions@columbia.edu by 9:00 a.m. on Thursday, July 8. “NIH SuRE” should appear in the subject line of the email; Please provide the following: PI – Name, department, and email; Co-PIs – Name, department, and Institution; Participating Institutions; Resource Center Overview – A one-page synopsis of the vision and functions of the proposed center; Questions should be sent to Greg Culler at limitedsubmissions@columbia.edu ; FOA: https://grants.nih.gov/grants/guide/pa-files/PAR-21-227.html ; Funding Opportunity Purpose - This funding opportunity announcement encourages applications for a Resource Center as part of the Support for Research Excellence (SuRE) program to develop and sustain research excellence at U.S. higher education institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research (see NOT-OD-20-031). The Resource Center will: (1) assist SuRE-eligible institutions to build research capacity, (2) conduct outreach and training to their professional staff and faculty, and (3) collect and report data relevant to the goals of the R16 SuRE programs; Research Initiatives; Office of the Executive Vice President for Research; Columbia University in the City of New York; To view current limited submission programs please visit: https://columbia.infoready4.com/#limitedsubmissions

[NTW] [NATIVE AMERICANS]

Notice of Participation of NINR in PAR-20-125, Native American Research Centers for Health (NARCH) (S06 Clinical Trials Optional)

Native American Research Centers for Health (NARCH) (S06 Clinical Trial Optional)

Sponsor: National Institute of Nursing Research

Deadline(s): 06/24/2021; 07/24/2021 (Expiration, PAR-20-125)

Contact: Please direct all inquiries to: Lynn S. Adams, PhD; National Institute of Nursing Research (NINR); Telephone: 301-594-8911; Email: lynn.adams@nih.gov

Additional Information: Related Announcements: PAR-20-125 - Native American Research Centers for Health (NARCH) (S06 Clinical Trial Optional)

[NTW] [HEALTHCARE ASSOCIATED INFECTIONS (HAI)]
Large Health Services Research Demonstration and Dissemination Projects for Prevention of Healthcare-Associated Infections (R18)

Sponsor: Agency for Healthcare Research and Quality
Deadline(s): Standard dates; 05/27/2025 (Expiration)
Contact: James Cleeman, MD; Division of Healthcare-Associated Infections; Center for Quality Improvement and Patient Safety; Agency for Healthcare Research and Quality; Telephone: (301) 427-1330; E-mail: james.cleeman@ahrq.hhs.gov

[NTW] [HEALTHCARE ASSOCIATED INFECTIONS]
Large Research Projects for Prevention of Healthcare-Associated Infections (R01)

Sponsor: Agency for Healthcare Research and Quality
Deadline(s): Standard dates; 05/27/2025 (Expiration)
Contact: Scientific/Research Contact(s); James Cleeman, MD; Division of Healthcare-Associated Infections; Center for Quality Improvement and Patient Safety; Agency for Healthcare Research and Quality; Telephone: (301) 427-1330; E-mail: james.cleeman@ahrq.hhs.gov

[NTW] [ARTIFICIAL INTELLIGENCE (AI)]
Notice Announcing Data Generation Projects for the NIH Bridge to Artificial Intelligence (Bridge2AI) Program (OT2) Other Transaction Opportunity Announcement

Sponsor: Office of Strategic Coordination (Common Fund)
Deadline(s): 05/26/2021 (Release Date); 07/20/2021 (Data Generation Project Letter of Intent (LOI) Due Date (Required)); 08/20/2021 (Full Proposal Deadline(s))
Contact: Please direct all inquiries to the Bridge2AI program staff who will respond to inquiries sent to this email: bridge2AI@od.nih.gov.
Additional Information: The Bridge2AI Program seeks to bridge the biomedical and behavioral research communities with the rapidly growing community of experts developing AI/ML models by producing flagship datasets that adhere to the FAIR principles (Findable, Accessible, Interoperable, Reproducible) and critically integrate ethical considerations in preparing data for computation. The program will use biomedical and behavioral research grand challenges to drive the development of ethics, standards, tools, data sets, and skills and workforce development strategies for linking scientific workflows, protocols, and other information about the data collection process into computable knowledge. Data sets may be linked to existing clinical, environmental and surveillance data as required by the chosen grand challenges. The overall goal of the Bridge2AI Program is to generate flagship datasets and best practices for the collection and preparation of AI/ML-ready data to address biomedical and behavioral research grand challenges. The Bridge2AI program will require multiple scientific domains to come together with data science, data management and analytic experts to unlock the potential of AI/ML for the scientific community.
[NTW] [ARTIFICIAL INTELLIGENCE]
Integration, Dissemination, and Evaluation (BRIDGE) Center for the NIH Bridge to Artificial Intelligence (Bridge2AI) Program (U54 Clinical Trial Not Allowed)

**Sponsor:** Office of Strategic Coordination (Common Fund)

**Deadline(s):** 08/20/2021; 08/21/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Shurjo K. Sen, Ph.D.; National Human Genome Research Institute (NHGRI); Telephone: 301-827-7028; Email: bridge2ai@od.nih.gov


[NTW] [ARTIFICIAL INTELLIGENCE]
Columbia Center of Artificial Intelligence Technology (CAIT)

**Sponsor:** [https://cait.engineering.columbia.edu/](https://cait.engineering.columbia.edu/)

**Deadline(s):** 09/10/2021

**Contact:** Please send all questions related to this opportunity to Libby Goss, Program Manager of CAIT, at lg3182@columbia.edu

**Link(s):** [https://cait.engineering.columbia.edu/](https://cait.engineering.columbia.edu/)  
[https://cait.engineering.columbia.edu/content/2021-funded-projects-fellows](https://cait.engineering.columbia.edu/content/2021-funded-projects-fellows)

Subscribe to the CAIT mailing list

**Additional Information:** Sending this on behalf of the Columbia Center of Artificial Intelligence Technology (CAIT), in the Fu Foundation School of Engineering and Applied Science (SEAS), in collaboration with Amazon. This is a very broad opportunity, open to all departments in SEAS, but also other Columbia schools and disciplines. The Center encourages collaborations among the School of Engineering and other schools and disciplines. See below for full details. Deadline for proposals is September 10, 2021. Please send all questions related to this opportunity to Libby Goss, Program Manager of CAIT, at lg3182@columbia.edu. You can also open this opportunity in your browser [here](https://cait.engineering.columbia.edu/). 2022 Call for Project Proposals; Columbia University Center of AI Technology in Collaboration with Amazon; Dear Colleagues, The Columbia Center of AI Technology in collaboration with Amazon is pleased to announce its 2022 Call for Research Project Proposals.; Columbia faculty members, from all departments in SEAS and other Columbia schools, will be eligible to submit proposals. Collaborations led by Columbia faculty involving faculty from other universities and institutions in the greater New York City metropolitan area are welcome. The Center encourages collaborations among the School of Engineering and other schools and disciplines.; A list of the 2021 Funded Research Projects can be found on the [CAIT website](https://cait.engineering.columbia.edu/).; Founded in 2020, the Center is a collaborative effort between Columbia and Amazon with a mission to better society through the development and adoption of advanced AI technology contributing to a more secure, connected, creative, sustainable, healthy and equitable humanity. Each year, the Center funds approximately 5 research projects through generous support from Amazon.; In the 2022 cycle, the Center will award projects in the following research focus areas: Foundations of AI and Machine Learning; Conversational AI/Natural Language Processing; Multisensory Multimodal AI; Fairness, Explainability, and Accountability in AI; AI for Human-Agent and Human-Robot Interaction; AI for Information Security; Cloud and Computing Systems for AI; Computer Vision; Operations Research and Optimization; Search and Information Retrieval; Information and Knowledge Management; AI/ML Sustainability; To learn more about the Center, projects, and how to apply, please review the sections below.; All proposals are due by September 10th, 2021.; Questions can be sent to CAIT program manager Libby Goss libby.goss@columbia.edu.; The Center of AI Technology; Founded in 2021, the Center of AI Technology (CAIT) is a collaborative effort between Columbia and Amazon with a mission to better society through the development and adoption of advanced AI technology contributing to a more secure, connected, creative, sustainable, healthy and equitable humanity.; Amazon has made significant investments in AI, developing cutting-edge technologies to address the opportunities and challenges across a broad spectrum of applications and customer needs. Amazon and Columbia have had...
productive collaborations through successful research awards and the participation of several Columbia faculty members in the Amazon Scholars program. With the launch of the Center of AI Technology, Columbia Engineering and Amazon further aim to advance research and technology development, knowledge discovery, and talent training to achieve beneficial societal impact. This partnership will also benefit from and contribute to the vibrant and rapidly expanding AI tech ecosystem in New York City. The Center’s yearly activities include funded research projects and fellows as well as a number of events and programs including the CAIT Distinguished Lecture Series, the Annual CAIT Research Showcase, and the Annual CAIT Symposium. More information about the Center can be found at the CAIT website. The Center is pleased to invite research project proposals from Columbia affiliates across the university. There are two types of funding mechanisms associated with the project proposals. One is a Sponsored Research Project (SRP), which may involve direct collaboration with Amazon researcher(s). The other mechanism is a Gift-Funded Research Project (GFRP) for more exploratory projects. The Center will support up to 3 SRPs and 1-3 GFRPs annually. All submitted proposals will be considered for both the SRP and GFRP categories. Accepted proposals will be informed of their award type at the time of notification by the Center. Columbia faculty members, from all departments in SEAS and other Columbia schools, will be eligible to submit proposals. Collaborations led by Columbia faculty involving faculty from other universities and institutions in the greater New York City metropolitan area are welcome. Groups receiving funding for the 2021 cycle are eligible to submit new proposals or renewal proposals for expanded continued research. All proposals will be considered together and equally with new proposals submitted for the 2022 cycle. A list of the 2021 Funded Research Projects can be found on the CAIT website; Funding amount: up to $150,000 for each SRP (including 35% indirect costs, with 50% tuition rate); up to $105,000 for each GFRP (no indirect costs, with full tuition rate); Submitters will be prompted to submit an SRP budget. If a proposal is selected and awarded GFRP funding, the proposal budget will be revised according to University policies on gifts, and the funding amount will be up to $105,000 with no indirect costs; Funding Timeline: Projects are expected to commence on November 1, 2021; As a 6-month progress report, funded project teams are expected to present their progress at the Annual CAIT Research Showcase; Projects should be completed by October 31st, 2022; Projects must submit a final report by November 12, 2022; Proposal Requirements: All proposal materials should be submitted in InfoReady. The system will prompt submitters to include the following: A completed application in the InfoReady system; A project proposal (4 pages maximum not including references, single-spaced, 12-font, Times New Roman); A project budget in Excel; CV’s for Faculty/Collaborators (2 page NSF or NIH style format); All proposals are due by September 10, 2021; The mission of the Columbia University Center of Artificial Intelligence Technology in Collaboration with Amazon is to better society through the development and adoption of advanced AI technology contributing to a more secure, connected, creative, sustainable, healthy and equitable humanity. Visit the CAIT website; Subscribe to the CAIT mailing list [NTW] [CHANGES TO BIOGRAPHICAL SKETCH AND OTHER SUPPORT PAGES] Announcing New Inbox for Inquiries Related to Changes to Biographical Sketch and Other Support Format Page Effective as of this announcement, please send inquiries related to changes to the biographical sketch and other support templates to nihosbiosketch@nih.gov Updated Other Support resources, including FAQs and sample Other Support format pages Implementation of Changes to the Biographical Sketch and Other Support Format Page Upcoming Changes to the Biographical Sketch and Other Support Format Page for Due Dates on or after May 25, 2021
Reminders of NIH Policies on Other Support and on Policies related to Financial Conflicts of Interest and Foreign Components

Sponsor: National Institutes of Health

Deadline(s): 05/18/2021 (Release Date)

Contact: Please direct all inquiries to: Office of Policy for Extramural Research Administration (OPERA); nihosbiosketch@nih.gov

https://grants.nih.gov/grants/forms/biosketch.htm

Additional Information: This announcement informs the research community of the creation of a central email inbox for inquiries related to changes to the biographical sketch and other support templates in response to the high volume of inquiries received.; Effective as of this announcement, please send inquiries related to changes to the biographical sketch and other support templates to nihosbiosketch@nih.gov.; NIH is diligently working to ensure complete and timely responses to inquiries received to date via existing email inboxes. The research community may elect to forward inquiries that are pending a response to the new central email inbox, as needed.; NIH encourages the research community to review the currently available resources related to this effort: Updated Biosketch resources, including FAQs and sample Biosketch format pages can be found here.; Additional resources, including training videos and other materials will be posted on the pages above as they become available.; Related Announcements: NOT-OD-21-110 - Implementation of Changes to the Biographical Sketch and Other Support Format Page; NOT-OD-21-073 - Upcoming Changes to the Biographical Sketch and Other Support Format Page for Due Dates on or after May 25, 2021; NOT-OD-19-114 - Reminders of NIH Policies on Other Support and on Policies related to Financial Conflicts of Interest and Foreign Components; It is important for all NIH applicants and awardees, including PIs, senior/key personnel, and grants administrators, to read it in its entirety.; The updated Biographical Sketch and Other Support format pages will be required for applications and Research Performance Progress Reports (RPPRs) submitted for due dates on or after May 25, 2021. It is advisable that you bookmark these pages: NIH Biosketch format pages and instructions and FAQs; NIH Other Support format pages and FAQs; Please note: PIs and senior/key personnel will be required to certify that their Other Support information is true, complete and accurate to the best of their knowledge.; Our office is in the process of reviewing the updated forms and instructions. We are scheduling webinars in the coming weeks to provide an overview of these changes. NIH is also planning to release additional resources and training materials in the coming weeks. If you are in the process of creating either a Biosketch or Other Support format page for applications and RPPRs due on or after May 25, 2021; Updated Biosketch resources, including FAQs and sample Biosketch format pages can be found here.; Updated Other Support resources, including FAQs and sample Other Support format pages can be found here.; One of the most important changes in the Biosketch instructions is Section B: “List in reverse chronological order all positions and scientific appointments both domestic and foreign, including affiliations with foreign entities or governments. This includes titled academic, professional, or institutional appointments whether or not remuneration is received, and whether full-time, part-time, or voluntary (including adjunct, visiting, or honorary).”; This is critical. The senior/key personnel, and mentors for training grants, have to include all positions and appointments, not just select ones, or ones relevant to the proposal. It’s not just the heading of Section B that changed, it’s the instructions to Section B.; The changes as outlined in the announcement are as follows:

<table>
<thead>
<tr>
<th>Format Page</th>
<th>Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Biographical Sketch Format Page | Section B ‘Positions and Honors’ has been renamed ‘Positions, Scientific Appointments, and Honors’.  
For the non-Fellowship Biosketch, Section D has been removed.  
For the Fellowship Biosketch, Section D has been updated to remove ’Research Support.’  
As applicable, all applicants may include details on ongoing and completed research projects from the past three years that they want to draw attention to within the personal statement, Section A. |
|---|---|
| Other Support Format Page | The format page has been re-organized to separate funded projects from in-kind contributions.  
Signature block added, for Program Director/Principal Investigator or Other Senior/Key Personnel to certify the accuracy of the information submitted. Each PD/PI or senior/key personnel must electronically sign their respective Other Support form as a PDF prior to submission. |
Additional Information: The slides from today’s town hall on the revised NIH other support format pages are available here (included in the NIH Researcher Disclosure Requirements webpage). Key takeaways: You may continue to use the current biosketch and other support format pages, however, the new formats will be required for applications, JIT requests, and RPPRs due on or after 1/25/2022. Regardless of which format you use, applicants and recipients remain responsible for disclosing all research endeavors. Other Support: As a reminder (see NIH announcement NOT-OD-19-114, July 10, 2019), regardless of the format used, you must ensure to include: completed projects (past three years); consulting that involves the conduct of research; and in-kind contributions. We will continue to schedule future town halls and develop tools to assist you. For immediate questions, please contact your SPA Project Officer. [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu/

[NTW] [NIH ANNOUNCEMENTS]
Publication of the Revised NIH Grants Policy Statement (Rev. April 2021) for Fiscal Year 2021
Sponsor: National Institutes of Health
Deadline(s): 04/20/2021 (Release Date)
Contact: NIH Office of Policy for Extramural Research Administration; Division of Grants Policy; grantspolicy@nih.gov. As always, contact your SPA Project Officer should you have any NIH policy-related questions

Additional Information: NIH announced the publication of the revised NIH Grants Policy Statement (NIHGPS, rev. April 2021). See: NIH Grants Policy Statement (both HTML and PDF format); Significant Changes Document, revisions since December 2019; Per NIH’s announcement, “This revision is applicable to all NIH grants and cooperative agreements with budget periods beginning on or after October 1, 2020. This revision supersedes, in its entirety, the NIHGPS dated December 2019. Previous versions of the NIHGPS remain applicable as standard terms and conditions of award for all NIH grants and cooperative agreements with budget periods that began prior to October 1, 2020.”; For more information about these changes, see NIH’s full announcement at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-107.html.; As always, contact your SPA Project Officer should you have any NIH policy-related questions; Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research Sponsored Projects Administration; Columbia University; Columbia University Irving Medical Center; sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu/

[NTW] [NIH ANNOUNCEMENTS]
Expanding Requirement for eRA Commons IDs to All Senior/Key Personnel
Sponsor: National Institutes of Health; Agency for Healthcare Research and Quality; Food and Drug Administration
Deadline(s): 04/20/2021 (Release Date)
Contact: Please direct all eRA technical inquiries to: eRA Service Desk; Submit a web ticket: https://grants.nih.gov/support/index.html; Toll-free:1-866-504-9552; Phone:301-402-7469
[NTW] [WEBINAR]
Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjögren’s Syndrome (UC2 Clinical Trial Optional)

Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases  
**Deadline(s):** 07/15/2021; 07/16/2021 (Expiration)  
**Contact:** AMP_AIM@mail.nih.gov (Webinar); Scientific/Research Contact(s); Ricardo Cibotti, Ph.D.; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Telephone: (301) 451-5888; Email: ricardo.cibotti@nih.gov [rfas]

**Link(s):**  
https://www.niams.nih.gov/grants-funding/niams-supported-research-programs/accelerating-medicines-partnership-amp  

**Additional Information:** Related announcements: RFA-AR-21-015 - Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjögren's Syndrome (UC2 Clinical Trial Optional); RFA-AR-21-016 - Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed)

[NTW] [DIVERSITY]

NIDDK Short-Term Research Experience Program to Unlock Potential (STEP-UP) (R25 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases  
**Deadline(s):** 09/01/2021; 09/02/2021 (RFA)  
**Contact:** Robert Clay Rivers, PhD; Office of Minority Health Research Coordination; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Email: niddkstepup@mail.nih.gov [webinar]

**Link(s):**  
https://nih.zoomgov.com/webinar/register/WN_PU8O_7CmQ_alTpdsM2eB0g  

**Additional Information:** RFA-DK-21-023 - NIDDK Short-Term Research Experience Program to Unlock Potential (STEP-UP) (R25 Clinical Trial Not Allowed)

[NTW] [DIVERSITY]

Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)

**Sponsor:** National Heart, Lung, and Blood Institute  
**Deadline(s):** 08/09/2021; 02/23/2022; 08/09/2022; 02/23/2023; 08/09/2023; 02/23/2024; 02/24/2024 (Expiration)
[NTW] [WEBINAR]
Notice of a Pre-Application Informational Webinar for PAR-21-168 "Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)"

Webinar Registration
Archival posting after the event

Sponsor: National Institute of Neurological Disorders and Stroke; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; National Institute on Drug Abuse; National Institute of Environmental Health Sciences

Deadline(s): 07/27/2021 (Webinar Date)

Contact: Please direct all inquiries to: Lauren Ullrich, PhD; National Institute of Neurological Disorders and Stroke (NINDS);
Telephone: 301-451-7964; Email: lauren.ullrich@nih.gov


Additional Information: Related Announcement: PAR-21-168 - Summer Research Education Experience Program (R25 Clinical Trial Not Allowed) ; Webinar Information; The webinar will be hosted through WebEx.; Date: Tuesday, July 27, 2021; Time: 2:00-3:00 pm EDT; Prospective applicants are required to register in advance at: https://nih.webex.com/nih/onstage/g.php?MTID=e1b0859e442514b8bd151cc1c5fa87b; Participants requiring sign language interpretation and/or other reasonable accommodations should contact lauren.ullrich@nih.gov at least 5 days prior to the event.; The recording and slides will be posted on the NINDS website after the event: https://www.ninds.nih.gov/Funding/Training-Career-Development/Award/R25-Summer-Research-Experience-High-School-Undergraduate.

[NTW] [DIABETES]
Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)

Sponsor: National Institute on Minority Health and Health Disparities; National Eye Institute; National Institute of Diabetes and Digestive and Kidney Diseases; Office of Research on Women's Health

Deadline(s): 10/05/2021; 02/05/2022; 02/05/2024; 06/05/2024; 09/08/2024 (Expiration)

Contact: Scientific/Research Contact(s); Larissa Aviles-Santa, MD, MPH; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-827-6924; Email: avilesanta@mail.nih.gov


[NTW] [DIABETES]
Characterization of Islet-derived Extracellular Vesicles for Improved Detection,
Monitoring, Classification, and Treatment of Type 1 Diabetes (R01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases  
**Deadline(s):** 11/03/2021; 11/04/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Olivier Blondel, Ph.D.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-451-7334; Email: blondelol@niddk.nih.gov  

[NTW] [DIABETES] 
Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes Clinical Centers (U01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases  
**Deadline(s):** 03/03/2022; 03/04/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Barbara Linder, M.D., Ph.D.; Division of Diabetes, Endocrinology and Metabolic Diseases; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-594-0021; Email: linderb@mail.nih.gov  

[NTW] [DIABETES] 
Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes Biostatistics Research Center (U01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases  
**Deadline(s):** 03/03/2022; 03/04/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Barbara Linder, M.D., Ph.D.; Division of Diabetes, Endocrinology and Metabolic Diseases; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-594-0021; Email: linderb@mail.nih.gov  

[NTW] [SMALL RESEARCH GRANTS] 
NICHD Small Research Grant Program (R03 Clinical Trial Required)

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development  
**Deadline(s):** 10/16/2021; 02/16/2022; 06/16/2022; 10/16/2022; 02/16/2023; 06/16/2023; 10/16/2023; 02/16/2024; 05/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); NICHD Referral Office; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Email: NICHDReferral@mail.nih.gov  
**R2eport**

**Friday Newsletter 07/16/2021**

**[NTW] [SMALL RESEARCH GRANTS]**

**NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development  
**Deadline(s):** 10/16/2021; 02/16/2022; 06/16/2022; 10/16/2022; 02/16/2023 06/16/02023; 10/16/2023; 02/16/2024; 05/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); NICHD Referral Office; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Email: NICHDReferral@mail.nih.gov  
**Link(s):** [https://grants.nih.gov/grants/guide/notice-ntw-21-007.html](https://grants.nih.gov/grants/guide/notice-ntw-21-007.html)

**[NTW] [RESEARCH ADMINISTRATION FORUMS]**

**Research Administration Forums**

**Research Administration Forum Part I 04.12.2021 Archival**

**Sponsor:** SPA  
**Deadline(s):** 04/12/2021; 04/19/2021 (Event Dates)  
**Contact:** Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia University; sfs2110@cumc.columbia.edu; Website: [https://spa.columbia.edu/](https://spa.columbia.edu/)  
**Link(s):** [https://research.columbia.edu/research-administration-forums](https://research.columbia.edu/research-administration-forums)  
**Email:** mailman.columbia.edu/r2

**Additional Information:** The Research Administration Forum is an interactive opportunity to hear from key central Columbia University offices on updates in policies and procedures that may directly impact proposal preparation or the management of sponsored projects. We invite researchers, grants administrators, and financial administrators to join us to learn the latest sponsored projects news and have an opportunity to ask questions. Slides will be available after the forums. Below are draft agendas. You must register for each part separately; The Forum Part I; Research Administration Forum Part I 04.12.2021 Archival; Please register here using a Columbia-affiliated email address; Agenda will include: Sponsored Projects Administration (SPA) updates; Update on Science & Security and Researcher Disclosure Requirements; Note: Additional webinars are being scheduled to provide more indepth training on the new NIH Biosketch and Other Support format pages; Sponsor-specific updates concerning NIH and NSF; Updated Policy: Distinguishing Gifts from Sponsored Projects; Human Research Protection Office (HRPO)/IRB – new guidance documents; Audit: FY20 Uniform Guidance (UG) Single Audit Debriefing; The Forum Part II will take place on Monday, April 19, 2021 from 11:00 am – 12:30 pm EST; Please register here using a Columbia-affiliated email address; Agenda will include: Sponsored Projects Finance (SPF) - Overruns and Receivables; Payments and Operational Guidance Updates, and Fiscal Year End 2021; Office of Research Compliance & Training (ORCT); International Shipping (Biologics); Sanctions Update; Prohibition on Certain Chinese-origin Telecommunications Equipment or Services (NDAA 889); Procurement Policy Updates - Competitive Procurement; Purchase Requisitions and Purchase Orders; and the Procurement Mechanism guide; The slides from 04/12/2021’s Research Administration Forum – Part I are available here. These slides, plus all past Forum slides, are available on our Research Administration Forums website.; To register for the Research Administration Forum – Part II, taking place Monday, April 19 at 11am – 12:30pm, click here using a Columbia-affiliated email address.; Today we also held a session on SciENcv. Those slides, plus all other Columbia presentations related to the new NIH Biosketch and Other Support format pages are available at [https://research.columbia.edu/nih-researcher-disclosure-requirements](https://research.columbia.edu/nih-researcher-disclosure-requirements); To register for an upcoming session on the new NIH Biosketches, Other Support format pages, and SciENcv, see our Town Hall schedule.; Feel free to send me any questions at sfs2110@cumc.columbia.edu. Thank you; Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia University; sfs2110@cumc.columbia.edu; Website: [https://spa.columbia.edu/](https://spa.columbia.edu/).
[NTW] [ENVIRONMENTAL EPIDEMIOLOGY CLIMATE CONNECTIONS (E2C2)]
At this point in time E2C2 plans reconvene in the Fall; if there is interest, we may schedule meetings so colleagues may practice SER (06/08), ISEE (08/10) (or other) presentations. Otherwise, we’ll reconvene in the fall. Opportunities and announcements will be forwarded to the group when appropriate; (Meeting Dates, [usually the 2nd and 4th] Tuesdays [of each month] 4PM-5PM)

Register Here for any of our currently scheduled Environmental Epidemiology Climate Connections (E2C2) meetings!

**Sponsor:** Research Resources and the Departments of Environmental Health Sciences and Epidemiology

**Deadline(s):** At this point we plan on reconvening the E2C2 journal club in the fall. Opportunities will be distributed to the group as appropriate, over the summer.

**Contact:** ckk7@cumc.columbia.edu

**Link(s):**
https://columbiacuimc.zoom.us/meeting/register/tJwrfuyvrDsoH9Hf5CPQk-VBuE7hfEHKcT [Zoom Registration Link for any of our currently scheduled meetings]

**Additional Information:** Environmental Epidemiology Climate Connections, E2C2, formerly EEC: Join faculty, students, postdocs, and staff to informally discuss relevant topics in the field of environmental and climate epidemiology today. Led by Marianthi-Anna Kiousourtoglou, Jeanette Stingone, Robbie Parks, and Anne Nigra. We plan on meeting virtually via Zoom from 4PM - 5PM defaulting to the second and fourth Tuesdays of each month. At this point we plan on reconvening in the Fall. We will reach out to the group with announcements and opportunities, as appropriate.

[NTW] [NIH DIRECTOR’S PIONEER AWARD]

NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)


**Deadline(s):** 09/10/2021; 09/11/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Ravi Basavappa, Ph.D.; Office of the Director (OD)

Telephone: 301-435-7204; Email: PioneerAwards@mail.nih.gov


**Additional Information:** NIH Director's Pioneer Award Program; Deadline: September 10; The NIH has just re-announced their Director's Pioneer Award Program (DP1); RFA-RM-21-015; [https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-015.html](https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-015.html); This is a Common Fund initiative in which all NIH Institutes and Centers participate.; [https://commonfund.nih.gov/pioneer](https://commonfund.nih.gov/pioneer); The NIH Director's Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's research program or elsewhere. The NIH Director's Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.”; The award supports scientists with outstanding records of creativity pursuing new research directions to develop pioneering approaches to major challenges in biomedical, social science, and behavioral research.; Open to all career
stages; Single PI only; No preliminary data required; Must be new scientific research direction; Minimum of 51% research effort in first 3 years; 3 Letters of Reference required; $700,000 in direct costs per year for up to 5 years; NIH intends to commit approximately $8,000,000 in FY 2022 to fund approximately 7 awards. The project period is limited to five years.; Application Deadline: September 10, 2021; Earliest Start Date: July 2022

**[NTW] [OUTSTANDING INVESTIGATOR AWARD]**

**NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)**

**Sponsor:** National Heart, Lung, and Blood Institute

**Deadline(s):** 02/15/2022; 02/15/2023; 02/15/2024; 04/26/2024 (Expiration)

**Contact:** Scientific/Research Contact(s); Division of Cardiovascular Sciences; Narasimhan Danthi, Ph.D.; Telephone: 301-451-5170; Email: ndanthi@nhlbi.nih.gov


**[NTW] [EARLY INVESTIGATOR]**

**NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)**

**Sponsor:** National Heart, Lung, and Blood Institute

**Deadline(s):** 02/15/2022; 02/15/2023; 02/15/2024; 04/26/2024 (Expiration)

**Contact:** Scientific/Research Contact(s); Division of Cardiovascular Sciences; Narasimhan Danthi, Ph.D.; Telephone: 301-451-5170; Email: ndanthi@nhlbi.nih.gov


**[NTW] [EARLY STAGE INVESTIGATOR]**

**Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional)**

**Sponsor:** National Cancer Institute

**Deadline(s):** 07/07/2021 (First Application Due Date); 12/02/2024 (Expiration)

**Contact:** Scientific/Research Contact(s); For any scientific or research-related questions on this extension request opportunity, please contact the Program Officer listed on the NoA of the most recent parent award.


**Additional Information:** The first Application Due Date is July 7, 2021. NCI ESI MERIT Award Extension requests are due during the penultimate award year, either on March 1, July 1, or November 1. For more details, refer to the deadlines table for the NCI ESI MERIT Awards. Recipients are encouraged to contact the NCI program director and grants management specialist assigned to the R37 award for details. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
NTW [AUTOIMMUNITY]

Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases (AMP AIM) program

Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjögren's Syndrome (UC2 Clinical Trial Optional)

**Sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; National Institute of Dental and Craniofacial Research; Office of Research on Women’s Health

**Deadline(s):** 07/15/2021; 07/16/2021 (Expiration)

**Contact:** Ricardo Cibotti, Ph.D.; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Telephone: (301) 451-5888; Email: ricardo.cibotti@nih.gov


[https://www.niams.nih.gov/grants-funding/niams-supported-research-programs/accelerating-medicines-partnership-amp](https://www.niams.nih.gov/grants-funding/niams-supported-research-programs/accelerating-medicines-partnership-amp)

**Additional Information:** New NIH AMP AIM Program Supports Autoimmune Disease Research; NIH recently published two funding opportunities to establish the Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases (AMP AIM) program. AMP AIM will deepen the current understanding of autoimmune diseases—such as rheumatoid arthritis, lupus, psoriatic spectrum diseases, and Sjögren’s syndrome—which afflict more than 25 million Americans. These diseases can cause profound abnormalities in immune responses and can result in persistent damage to multiple tissues and organ systems. The AMP AIM network will consist of four distinct, highly interactive, and complementary components: **Disease Teams (DTs).** Each DT will lead the development of the research agenda and research priorities for one disease (rheumatoid arthritis, lupus, psoriatic spectrum diseases, or Sjögren’s syndrome). DTs will identify critical opportunities and select, recruit, and deep phenotype the most informative patient populations for the AMP AIM program. Individual DTs will work together with the TACs (see below) to analyze tissue and other biospecimens. For more information, see [RFA-AR-21-015](https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-21-015.html); **Technology and Analytics Cores (TACs).** TACs will test, optimize, and apply innovative technologies to interrogate and analyze human biopsy tissue and biosamples. For more information, see [RFA-AR-21-016](https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-21-016.html); **Research Management Unit (RMU).** The RMU will provide centralized management and operational support to the network, including providing and/or overseeing clinical monitoring for the entire AMP AIM program. For more information, see [RFA-AR-21-016](https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-21-016.html); **Knowledge Portal (KP).** The KP will provide an interface for storage, analysis aggregation, and visualization of all data generated by the DTs and TACs.; Letters of intent for [RFA-AR-21-015](https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-21-015.html) and [RFA-AR-21-016](https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-21-016.html) are due June 15, 2021.

NTW [CLINICAL TRIALS]

Notice of Intent to Publish the Reissuance of PAR-18-420, NINDS Exploratory Clinical Trials (U01 - Clinical Trial Required)

**Sponsor:** National Institute of Neurological Disorders and Stroke

**Deadline(s):** 06/05/2021 (Estimated First Application Due Date)

**Contact:** Please direct all inquiries to: Jeremy Brown, MD; National Institute of Neurological Disorders and Stroke (NINDS); 301-496-9135; Jeremy.brown@nih.gov

[NTW] [CLINICAL TRIALS]
NIA Announces New Policy and Procedures for the Reporting of Human Subjects Enrollment Data for NIA Clinical Research Trials/Studies

Sponsor: National Institute on Aging
Deadline(s): 06/17/2021 (Release Date)
Contact: Holly Massett, Ph.D.; Senior Advisor, Clinical Research Recruitment & Engagement; Division of Extramural Activities; National Institute on Aging; Email: NIAclinicalresearch@nia.nih.gov

Additional Information: The purpose of this Notice is to inform the research community of the National Institute on Aging (NIA) new policy and procedures for reporting enrollment data for clinical research trials/studies funded through an NIA funding mechanism (including grants, contracts, and cooperative agreements). This Notice details the new requirements, expectations of NIA-funded investigators, and impetus for the policy change.

[NTW] [P GRANTS]
NINDS Program Project Grant (P01 Clinical Trial Optional)

Sponsor: National Institute of Neurological Disorders and Stroke
Deadline(s): 05/25/2021 (First Application Due Date); 01/25/2024; 05/08/2024 (Expiration)
Contact: Scientific/Research Contact(s); David Owens, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-9248; Email: do47h@nih.gov

[NTW] [SUMMER RESEARCH]
Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)

Sponsor: National Institute of Neurological Disorders and Stroke; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; National Institute on Drug Abuse; National Institute of Environmental Health Sciences
Deadline(s): 03/17/2022; 03/17/2023; 03/19/2024; 05/08/2024 (Expiration)
Contact: Laura E. Kwako, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-451-8507; Email: laura.kwako@nih.gov

[NTW] [CLINICIAN SCIENTISTS]
Research Experiences to Enhance Clinician-Scientists’ Participation in NIDCDs Research (R25 Clinical Trial Not Allowed)

Sponsor: National Institute on Deafness and Other Communication Disorders
Deadline(s): 09/24/2021; 01/27/2022; 05/27/2022; 09/21/2022; 01/27/2023; 05/26/2023; 09/26/2023; 01/29/2024; 01/30/2024 (Expiration)
Contact: Scientific/Research Contact(s); Alberto L. Rivera-Rentas, Ph.D.; National Institute on Deafness and Other Communication Disorders (NIDCD); Telephone: 301-496-1804
Email: riverara@nidcd.nih.gov
Link(s): https://grants.nih.gov/grants/guide/files/PAR-21-188.html

[NTW] [LIMITED COMPETITION]
Limited Competition: Clinical and Translational Science Awards (CTSA) Consortium-Wide Centers: Resources for Rapid Demonstration and Dissemination (U24 Clinical Trials Not Allowed)
Sponsor: National Center for Advancing Translational Sciences
Deadline(s): 06/21/2022; 06/21/2023; 06/22/2023 (Expiration)
Contact: Scientific/Research Contact(s); Audie Atienza, PhD; National Center for Advancing Translational Sciences (NCATS); Telephone: 301-435-0198; Email: Audie.Atienda@nih.gov

[NTW] [PHYSICAL ACTIVITY]
Notice of Special Interest (NOSI): Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being
Sponsor: Office of Disease Prevention; National Center for Complementary and Integrative Health; National Cancer Institute; National Institute on Aging; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research; Office of Behavioral and Social Sciences Research; Office of Research on Women’s Health
Deadline(s): 06/05/2021 (First Available Due Date); 02/16/2024 (Expiration)
Contact: Scientific/Research Contact(s); Bramaramba Kowtha MS, RDN, LDN; Office of Disease Prevention (ODP); Telephone: 301-435-8052; Email: bramaramba.kowtha@nih.gov

[NTW] [PCORI]
[1] Engagement Award Special Cycle: Building Capacity for PCOR/CER for Topics Related to COVID-19
[3] Broad PCORI Funding Announcements -- Cycle 1 2021
[4] Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes -- Cycle 1 2021
R²report
Friday Newsletter 07/16/2021

[6] Broad PCORI Funding Announcements -- Cycle 2 2021
[8] Broad PCORI Funding Announcements -- Cycle 3 2021
[9] Improving Methods for Conducting Patient-Centered Outcomes Research -- Cycle 3 2021


06/01/2021 (LOI); 08/31/2021 (Application); [4] [Broad PCORI Funding Announcements -- Cycle 2 2021]; [5] [Improving Methods for Conducting Patient-Centered Outcomes Research -- Cycle 2 2021]
10/05/2021 (LOI); 01/11/2022 (Application); [6] [Broad PCORI Funding Announcements -- Cycle 3 2021]; [7] [Improving Methods for Conducting Patient-Centered Outcomes Research -- Cycle 3 2021]

Contact: https://help.pcori.org/hc/en-us

Contact: ea@pcori.org


https://www.pcori.org/funding-opportunities/announcement/improving-methods-cycle-1-2021 [3]

[NTW] [OUTCOMES]
Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health
Sponsor: Office of Behavioral and Social Sciences Research; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research; Office of Disease Prevention; Office of Research on Women's Health

Deadline(s): 05/07/2021 (First Available Due Date); 06/08/2024 (Expiration Date)

Contact: Scientific/Research Contact(s); Wendy Nelson, PhD, MPH; National Cancer Institute (NCI); Telephone: 240-276-6971; Email: nelsonw@mail.nih.gov

Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-100.html

[NTW] [OUTCOMES]

Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 Clinical Trials Not Allowed)

Sponsor: NIH Basic Behavioral and Social Science Opportunity Network; National Cancer Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; Office of Behavioral and Social Sciences Research; Office of Research on Women's Health

Deadline(s): 02/05/2022; 02/05/2023; 05/08/2023 (Expiration)

Contact: William Elwood, PhD; Office of Behavioral and Social Sciences Research (OBSSR); Telephone: 301-402-0116; Email: william.elwood@nih.gov


Additional Information: This FOA invites basic and/or methodological research projects that seek to illuminate or measure independent and interdependent health-related effects within dyads. For the purpose of this FOA, a dyad is a unit of two individuals whose interactions and influences on one another are nested within larger social contexts and networks. Both animal and human subjects research projects are welcome. Types of projects submitted under this FOA include but are not limited to, observational studies involving humans, or existing/synthesized datasets studies. Researchers proposing basic science experimental studies involving human participants (i.e., experimentally manipulate independent variables) should consider the companion FOA PAR-21-280 “Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 Basic Experimental Studies with Humans).”

[NTW] [OUTCOMES]

Dyadic Interpersonal Processes and Biopsychosocial Outcomes; (R01- Basic Experimental Studies with Humans)

Sponsor: NIH

Deadline(s): 03/05/2022; 03/08/2022 (Expiration)

Contact: William Elwood, PhD; Office of Behavioral and Social Sciences Research (OBSSR); Telephone: 301-402-0116; Email: william.elwood@nih.gov

**Additional Information:** This FOA invites basic and/or methodological research projects that illuminate and/or measure independent and interdependent health-related effects within dyads across relationships and settings. For the purpose of this FOA, a dyad is a unit of two individuals whose interactions and influences on one another are nested within larger social contexts and networks. Dyads are social relationships that extend beyond the individual and have strong bidirectional influences on physical and mental health. For the purpose of this FOA, independent effects are those effects that affect each member of the dyad individually (i.e., by nature of being part of the dyad), whereas interdependent effects are those that affect one member of the dyad contingent upon the other member of the dyad (i.e., not only because the individual is part of a dyad but also because being part of the dyad has an effect on the other individual within the dyad as well).

**[NTW] [MICROBIOLOGY]**

**Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)**

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institute of Allergy and Infectious Diseases; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences

**Deadline(s):** 10/20/2021; 06/22/2022; 10/20/2022; 06/22/2023; 10/19/2023; 10/20/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Padma Maruvada; National Institute of Diabetes, and Digestive and Kidney Diseases (NIDDK); Telephone: 301-594-8884; Email: maruvadp@mail.nih.gov


**[NTW] [PSYCHOLOGY]**

**Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional)**

**Sponsor:** National Institute of Mental Health

**Deadline(s):** 11/01/2021; 11/01/2022; 11/01/2023; 11/02/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Michele Ferrante, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-435-6782

Email: michele.ferrante@nih.gov


**[NTW] [PSYCHOLOGY]**

**Computationally Defined Behaviors in Psychiatry (R21 Clinical Trial Optional)**

**Sponsor:** National Institute of Mental Health

**Deadline(s):** 11/01/2021; 11/01/2022; 11/01/2023; 11/02/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Siavash Vaziri, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-1576

Email: siavash.vaziri@nih.gov

[NTW] [FOUNDATION FUNDING/CANCER]
Elsa U. Pardee Foundation | Cancer Research

**Sponsor:** https://pardeefoundation.org  
**Deadline(s):** 08/31/2021  
**Contact:** https://pardeefoundation.org/contact  
**Link(s):** https://pardeefoundation.org/how-to-apply/  
**Additional Information:** [brought to our attention by the Office of University Corporate and Foundation Relations]; Dimitra Koutsantoni, Director, University Corporate and Foundation Relations; dk2617@columbia.edu with any questions; you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here.

[NTW] [FOUNDATION FUNDING/CANCER]
Policy, Insurance in Access, Prevention, Detection Treatment of cancer

**Sponsor:** https://www.cancer.org  
**Deadline(s):** 10/15/2021  
**Contact:** For questions about this mechanism please contact Chanda Felton, Program Manager of the Clinical and Cancer Control Research program, at chanda.felton@cancer.org  
**Link(s):** https://www.cancer.org/research/we-fund-cancer-research/apply-research-grant/grant-types/rfa-role-healthcare-insurance-cancer.html

[NTW] [FOUNDATION FUNDING/CANCER]
AGA-Augustyn Award in Digestive Cancer

**Sponsor:** https://gastro.org  
**Deadline(s):** 07/21/2021  
**Contact:** https://gastro.org/about-aga/contact-us/  
**Link(s):** https://gastro.org/research-and-awards/apply-for-awards/award/aga-caroline-craig-augustyn-damian-augustyn-award-in-digestive-cancer/

[NTW] [FOUNDATION FUNDING/CANCER]
Clinical Res. Professor American Cancer Society

**Sponsor:** https://www.cancer.org  
**Deadline(s):** 08/01/2021 (LOI); 10/01/2021 (Application)  
**Contact:** https://www.cancer.org/about-us/online-help/contact-us.html ; Ellie Daniels, MD, MPH; Interim Vice President of Extramural Discovery Science; American Cancer Society Office of Cancer Research & Implementation; ellie.daniels@cancer.org  
**Link(s):** https://www.cancer.org/research/we-fund-cancer-research/apply-research-grant/grant-types/clinical-research-professor-grant.html

[NTW] [FOUNDATION FUNDING/CANCER]
Metastatic Breast Cancer addressing disparities for people of color

**Sponsor:** https://cdn.pfizer.com  
**Deadline(s):** 08/04/2021
Contact: If you have questions regarding this RFP, please direct them in writing to Conquer Cancer Scientific Review Officer, Andrew L. Smith, PhD Andrew.Smith@conquer.org or Pfizer Grant Officer, Dewayne Brumlow Dewayne.Brumlow@Pfizer.com with the subject line 2021 Equitable Care of mBC Patients, 06.04.21

Link(s): https://cdn.pfizer.com/pfizercom/2021-06/GMG_2021-Oncology_EquitableCareMetastaticBreastCancerPatients.pdf

[NTW] [FOUNDATION FUNDING/CANCER]

Clinical Investigator Career Development Lymphoma Res. Foundation

Sponsor: https://lymphoma.org
Deadline(s): 09/08/2021
Contact: researchgrants@lymphoma.org

[NTW] [FOUNDATION FUNDING/CANCER]

Smith Charitable Trust Heart, Cancer and AIDS Research

Sponsor: http://www.wsmithcharitabletrust.org
Deadline(s): 07/15/2021
Contact: http://www.wsmithcharitabletrust.org/contact.html
Link(s): http://www.wsmithcharitabletrust.org/medical.html

[NTW] [FOUNDATION FUNDING/CANCER]

Damon Runyon Cancer Research Foundation Fellowship Award

Sponsor: https://www.damonrunyon.org
Deadline(s): 08/16/2021
Contact: awards@damonrunyon.org
Link(s): https://www.damonrunyon.org/for-scientists/application-guidelines/fellowship

Additional Information: Damon Runyon Fellowship Award; Deadline: August 16; The Foundation encourages all theoretical and experimental research relevant to the study of cancer and the search for cancer causes, mechanisms, therapies and prevention. Candidates must apply for the fellowship under the guidance of a Sponsor—a scientist capable of providing mentorship and able to foster the development of the Fellow’s overall knowledge, technical and analytical skills, and capacity for scientific inquiry. The Sponsor is also expected to assist the Fellow in attaining their career goals. Assistant Professors with limited mentorship are strongly encouraged to identify a more established scientist to co-sponsor the candidate.; Application must be submitted through proposalCENTRAL by 4:00 PM Eastern Time on August 16, 2021. Application instructions and relevant forms are available on proposalCENTRAL.; For eligibility requirements, more information and to apply, click the button below. Damon Runyon Fellowship Award

[NTW] [FOUNDATION FUNDING/CANCER]

Tina’s Wish Tina Brozman Foundation for Ovarian Cancer Research

Sponsor: Tina Bozman Foundation
Deadline(s): 06/10/2021 (LOI); 08/16/2021 (Invited Applicant Deadline)
Contact: Please contact Venessa Manzano at vgm2109@cumc.columbia.edu for questions and to apply
Additional Information: Tina’s Wish Tina Brozman Foundation for Ovarian Cancer Research; LOI Deadline: June 10; Tina’s Wish is pleased to announce the Individual Investigators Awards for 2022-2023. They are annual grants to support researchers proposing new ideas and concepts specifically for the early detection or prevention of ovarian cancer. The award is for $300,000 over two years with no more than 10% in indirect costs; To apply, forward a description of your project to Venessa Manzano at vgm2109@cumc.columbia.edu containing the following: Cover page with name and project title; Brief Proposed Research Plan: briefly describe the background, hypothesis and approach for the proposed research (800 words); Innovation: briefly describe how the proposed research is innovative in the context of early detection or prevention of ovarian cancer.; Impact: briefly describe how the proposed research will impact a critical problem or question in early detection or prevention of ovarian cancer research.; NIH Formatted Biosketch; Please contact Venessa Manzano at vgm2109@cumc.columbia.edu for questions and to apply: Tina’s Wish Request for LOI

[NTW] [FOUNDATION FUNDING/CANCER]
AGA- Funderburg Research Award in Gastric Cancer
Sponsor: https://gastro.org
Deadline(s): 07/21/2021
Contact: awards@gastro.org

[NTW] [FOUNDATION FUNDING/CANCER]
Young Investigator Grants Breast Cancer Alliance
Sponsor: https://breastcanceralliance.org
Deadline(s): 04/01/2021 (LOI); 07/23/2021 (Application)
Contact: researchgrants@breastcanceralliance.org
Link(s): https://breastcanceralliance.org/how-to-apply

[NTW] [FOUNDATION FUNDING/CANCER]
AACR-St. Baldrick’s Award for Achievement in Pediatric Cancer
Sponsor: https://www.aacr.org
Deadline(s): 08/31/2021
Contact: Please direct all inquiries pertaining to this award or any other AACR scientific achievement award or lecture to Michael J. Powell, PhD, Deputy Director of Scientific Programs, at michael.powell@aacr.org or by phone at (215) 440-9373.
Link(s): https://www.aacr.org/awards/aacr-st-baldricks-foundation-award-for-outstanding-achievement-in-pediatric-cancer-research/

[NTW] [FOUNDATION FUNDING/CANCER]
Pilot & Exploratory Projects Palliative Care of Cancer patients
[NTW] [CANCER]
Columbia University VeloCity Ride to End Cancer
Sponsor: Columbia
Deadline(s): 10/03/2021 (Event Date)
Contact: Nicole Sumner at 646.784.5295 or ns3423@cumc.columbia.edu
Link(s): https://www.velocityride.org/

[NTW] [CANCER]
Notice of Special Interest (NOSI): New Information Technology-Enabled Care Delivery Models to Improve Depression Care in Cancer
Sponsor: National Cancer Institute
Deadline(s): 10/05/2021 (First Available Due Date); 03/08/2024 (Expiration Date)
Contact: Scientific/Research Contact(s): Gurvaneet S. Randhawa, M.D., M.P.H.; National Cancer Institute; Telephone: (240) 276-6940; Email: Gurvaneet.Randhawa@nih.gov

[NTW] [CANCER]
Cancer Genomics and Epigenomics Program Translational Clinical Trials Pilot Projects; Deadline: August 15
Sponsor: Cancer Genomics and Epigenomics (CGE) Program at the Herbert Irving Comprehensive Cancer Center
Deadline(s): 08/15/2021
Contact: Questions: contact Dr. Jean Gautier at jg130@cumc.columbia.edu or Dr. Tanisha Jackson at tj2325@cumc.columbia.edu
Link(s): https://columbia.infoready4.com/#competitionDetail/1846647

Additional Information: The Cancer Genomics and Epigenomics (CGE) Program at the Herbert Irving Comprehensive Cancer Center is seeking to support translational clinical trials – from bench to bedside and back to bench – that align with its focus on cancer genomics and epigenomics. The goal of this funding opportunity is to support translational clinical trials pilot projects leading to larger clinical trials. Thus, successful applicants will be expected to apply for national funding as a result of pilot support.; Up to 2 pilot proposals will be funded at $50,000 per award for one year. At least one of the selected proposals will be therapeutic in focus. Awards will be made to support innovative ideas stemming from research conceived by the co-principal investigators. We encourage that the majority of funds be utilized for project specific study experiments, although a smaller portion of the funds may be used towards salary support for research personnel (e.g., post-doctorate researchers, graduate students or technician). Funds may not be used towards PI salary, capital equipment or travel. Indirect costs will not be allowed.; Eligibility requirements For this request for applications: Proposal may involve therapeutic or prospective trials; Teams should have at least 2 co-PIs: one basic scientist and a clinician; additional collaborators are allowed; One of the co-PIs should be a CGE
program member; Questions: contact Dr. Jean Gautier at jg130@cumc.columbia.edu or Dr. Tanisha Jackson at tj2325@cumc.columbia.edu; For application requirements and to apply, click the button below.; Apply Cancer Genomics and Epigenomics Program Pilot

[NTW] [CANCER]
The Basser Global Prize; Deadline: August 27
Sponsor: https://www.basser.org
Deadline(s): 08/27/2021
Contact: https://www.basser.org/contact
Link(s): https://www.basser.org/basser-global-prize
Additional Information: The Basser Global Prize; Deadline: August 27; The Basser Global Prize was established to honor a visionary scientist who has conceptually advanced BRCA1/2 related research that has led to improvements in clinical care. The prize will be considered for a broad range of basic, translational and clinical BRCA1/2 cancer researchers worldwide. Outstanding candidates will be those whose research has produced seminal advances in the field and who continue to drive BRCA1/2 related research towards the ultimate goal of mitigating the adverse impact of deleterious BRCA1/2 mutations. The Basser Global Prize provides $100,000 in unrestricted support of the awardee's innovative BRCA1/2 related research efforts. The Awardee will give the keynote address at the annual Basser Center for BRCA Scientific Symposium in May 2023, where they will also be awarded the Basser Trophy and a personal $10,000 prize.; For more information and to apply, click the button below.; Apply Basser Global Prize

[NTW] [CANCER]
Cancer Research Institute Postdoctoral Fellowships; Deadline: October 1
Sponsor: CRI; https://www.cancerresearch.org
Deadline(s): 10/01/2021
Contact: https://www.cancerresearch.org/en-us/about-cdi/stay-informed/contact; info@cancerresearch.org
Link(s): https://www.cancerresearch.org/en-us/scientists/fellowships/grants
Additional Information: Cancer Research Institute Postdoctoral Fellowships; Deadline: October 1; The CRI Irvington Postdoctoral Fellowship Program furthers career development and supports laboratory research for promising young scientists working under the mentorship of leading immunologists. The CRI Irvington Postdoctoral Fellowship Program provides critical financial support and continued career training to the most promising young scientists in basic and tumor immunology as part of our lifesaving work in cancer immunotherapy research.; Fellows receive up to $175,500 over three years to cover the cost of salary, insurance, and other research-related expenses, such as travel to conferences and meetings.; For more information and to apply, follow the link below.; Apply Cancer Research Institute Postdoctoral Fellowship

[NTW] [DEPARTMENT OF DEFENSE]
Pancreatic Cancer Research Program
Idea Development Award
Translational Research Partnership Award
informative webinar
PCRP Application Instructions
Sponsor: Department of Defense
Deadline(s): 07/01/2021 (Pre-Application); 10/07/2021 (Application)
Contact: help@ebrap.org
Link(s): https://cdmrp.army.mil/funding/pcarp
https://www.youtube.com/watch?v=TuWcdyACWic

Additional Information: Two funding opportunities are now available through the Pancreatic Cancer Research Program at the Department of Defense's (DoD) Congressionally Directed Medical Research Program (CDMRP): $15 million in research funds will be available through the research program this year, thanks to Congress and the tireless advocacy efforts of dedicated PanCAN supporters; Funding opportunities include: Idea Development Award; Pre-Application (Preproposal) due: July 1, 2021; Translational Research Partnership Award; Pre-Application (Preproposal) due: July 1, 2021; In partnership with the CDMRP, PanCAN sponsored an informative webinar for prospective applicants to learn more about the program and funding mechanisms, as well as the application process and requirements.; For more information and to apply, click the button below; DoD Pancreatic Cancer Research Program

[NTW] [PIVOT]
[1] Pivot, New Dashboard!
[3] Pivot Overview-Find Funding and Collaborators-Webinar 02.17.2021 Slides
Sponsor: Pivot, Medical Library; https://pivot.proquest.com; the Augustus C. Long Health Sciences Library, in collaboration with Sponsored Projects Administration
Deadline(s): NA
Contact: Please feel free to contact us should you have any questions or need assistance at Pivot-Help@columbia.edu.; Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu/
Link(s): https://columbia.hosted.panopto.com/Panopto/Pages/Viewer.aspx?id=9c10497e-c077-43d1-a734-acd20135e7f2 [Pivot Webinar, AV]
https://research.columbia.edu/find-funding-using-pivot
https://pivot.proquest.com
https://pivot.proquest.com/dashboard [Pivot, New Dashboard]
https://research.columbia.edu/find-funding-using-pivot [Pivot, Quick Guide]

Additional Information: Thank you to all who attended yesterday's webinar on Pivot, a funding opportunity and profile database. Slides, the full webinar recording, and a Quick Start Guide are available: Webinar - Pivot Overview-Find Funding and Collaborators, 9-16-2020; Webinar Slides; Pivot Quick Start Guide ; We have additional training materials on our website at Find Funding Using Pivot. To access Pivot, go to https://pivot.proquest.com/, click "Use login from my institution", select Columbia University from the drop-down menu, and enter your UNI and password.; If you have any questions, feel free to email Pivot-Help@columbia.edu.
[NTW] [NIH REPORTER]

NIH Extramural Nexus, NIH Reporter, Keeping on Top of NIH-Funded Research You Care the Most About Just Got Easier

**Sponsor:** https://grants.nih.gov/grants/oer.htm  
**Deadline(s):** 02/16/2021 (Release Date)  
**Contact:** If you have any feedback or questions, please contact the RePORT team by email at RePORT@mail.nih.gov  
**Link(s):** https://nexus.od.nih.gov/all/2021/02/16/keeping-on-top-of-nih-funded-research-you-care-the-most-about-just-got-easier/

**Additional Information:** Keeping on Top of NIH-Funded Research You Care the Most About Just Got Easier; See article below on new functionality in NIH RePORTER. You can now create email alerts of newly awarded projects, or new publications linked to specific projects. If you have trouble seeing the full article below, you can read it here; [brought to our attention by Stephanie Scott] ; NIH Extramural Nexus; Posted on: Tuesday, February 16, 2021; Author: Mike Lauer; Subject: Keeping on Top of NIH-Funded Research You Care the Most About Just Got Easier

[NTW] [NIH ANNOUNCEMENTS/COVID-19]

Requesting Extensions for Early Career Scientists Whose Career Trajectories Have Been Significantly Impacted by COVID-19

**Sponsor:** Office of The Director, National Institutes of Health (OD)  
**Deadline(s):** 02/02/2021 (Release Date)  
**Contact:** Please direct all inquiries to: Direct all inquiries and requests for funded extensions to the Grants Management and Program Officials listed on the Notice of Award; For general inquiries about fellowships and career development programs please contact: Division of Biomedical Research Workforce; Office of Extramural Research; Website: https://researchtraining.nih.gov ; Email: NIHTrain@mail.nih.gov ; For general policy questions please contact: NIH Office of Policy for Extramural Research Administration; Division of Grants Policy; Email: grantspolicy@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-052.html

**Additional Information:** Requesting Extensions for Early Career Scientists Whose Career Trajectories Have Been Significantly Impacted by COVID-19; Please see announcement from NIH for recipients of NIH Fellowship (“F”) and NIH Career Development (“K”) awards who have been impacted by COVID-19: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-052.html ; NIH is providing opportunities for no cost extensions and funded extensions for recipients of individual fellowships and K-awards impacted by COVID-19. Please read the notice carefully for specifics. Funded extensions are being considered on a case-by-case basis, and it is advised to speak with the Program Official named on the Notice of Award, and your SPA Project Officer, prior to submitting such a request.; As always, please reach out to your SPA Project Officer should you have any questions. [brought to our attention by] Stephanie F. Scott, MS, CRA, Director of Policy and Research Development, Columbia | Research, Sponsored Projects Administration; sf2110@columbia.edu; Website: https://spa.columbia.edu/

[NTW] [NSF-BSF JOINT FUNDING OPPORTUNITIES]

NSF-BSF Joint Funding Opportunities by Program

NSF-BSF Foundational Research in Robotics
NSF-BSF Cyber-Physical Systems
NSF-BSF Mathematical and Scientific Foundations of Deep Learning
Friday Newsletter 07/16/2021

Sponsor: U.S.-Israel Binational Science Foundation (BSF); www.bsf.org; https://www.bsf.org.il/funding-opportunities/nsf-bsf-joint-research-grants/about/
Deadline(s): Please see individual opportunities
Contact: Please see individual announcements
Link(s): https://www.bsf.org.il/funding-opportunities/nsf-bsf-joint-research-grants/the-programs
https://www.bsf.org.il/funding-opportunities/

Additional Information: Quarterly overview of the NSF-BSF programs; Dear Colleague, BSF is pleased to make to announce three new, interdisciplinary NSF-BSF programs are welcoming joint applications: Foundational Research in Robotics. This program has no deadline. You can find more details in our call for proposals here; http://files.bsf.org.il/data/FormsToDownload/BSF-NSF_Robotics_Program_Call_for_Proposal.pdf; Cyber-Physical Systems- This program has no deadline. You can find more details in our call for proposals here; http://files.bsf.org.il/data/FormsToDownload/BSF-NSF_CNS_Call.pdf; Mathematical and Scientific Foundations of Deep Learning. Deadline for application by the U.S. partner to the NSF is May 12, 2021 and by the Israeli partner to the BSF is May 18, 2021. You can find more details in our call for proposals here; http://files.bsf.org.il/data/FormsToDownload/BSF-NSF_SCALE%20MoDL_Program_Call_for_Proposal.pdf; We also would like to draw your attention to a couple of changes in our budget regulation; BSF will not approve requests for equipment that exceed 20% of the total budget.; In following a BSF Board of Governors decision, travel requests will be approved for visiting the partner lab only. BSF will no longer support PI/student travel to conferences and workshops; Please check our regulations for both BSF regulation; We will be glad to see you among the applicants to any of these programs and we stand ready to provide assistance in answering your questions regarding proposal preparation, submission etc.; [brought to our attention by] Anton Post, PhD; Executive Director; U.S. – Israel Binational Science Foundation; www.bsf.org

[NTW] [DEPARTMENT OF DEFENSE]
DoD/CDMRP - COVID-19 Impact on Research Awards
[No Link Provided]
CDMRP continues to be concerned about the impacts of COVID-19 on Service Members and the public. We are aware of the challenges it poses and are tracking some of the impacts to current awardees and ongoing research. While not every program will have financial resources available to assist, awareness of any significant unresolved issues affecting current research awards is important.; The intent of this notice is to remind recipients of the requirements in 32 CFR Part 1134, Subpart E Other Reporting, This provision specifies the requirement for recipients to disclose significant developments as soon as they become known. These include problems, delays, or adverse conditions that will materially impair your ability to meet the objectives of your awards.; Disclosures of significant developments may be made on your next interim performance report or at any point between scheduled performance reporting dates by contacting the Science Officer or Grant Specialist assigned to your award. This disclosure must include a statement of the action taken, or contemplated, and any assistance needed to resolve the situation
Sponsor: Department of Defense
Deadline(s): NA
Contact: For questions concerning this notice, please contact the Grants Specialist and Science Officer or Grants Officer's Representative listed in your award
Link(s): No Link Provided

Additional Information: DoD/CDMRP - COVID-19 Impact on Research Awards; I wanted to pass along this important announcement from the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP). See below. They are stressing the importance of disclosing significant developments impacting research awards, including problems, delays and other events impacting your ability to meet the award objectives; As always, please reach out to your SPA Project Officer should you have questions or concerns about your awards.; [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; sfs2110@cumc.columbia.edu
Friday Newsletter 07/16/2021

Website: https://spa.columbia.edu/; COVID-19 Impact on Research Awards; CDMRP continues to be concerned about the impacts of COVID-19 on Service Members and the public. We are aware of the challenges it poses and are tracking some of the impacts to current awardees and ongoing research. While not every program will have financial resources available to assist, awareness of any significant unresolved issues affecting current research awards is important.; The intent of this notice is to remind recipients of the requirements in 32 CFR Part 1134, Subpart E Other Reporting. This provision specifies the requirement for recipients to disclose significant developments as soon as they become known. These include problems, delays, or adverse conditions that will materially impair your ability to meet the objectives of your awards; Disclosures of significant developments may be made on your next interim performance report or at any point between scheduled performance reporting dates by contacting the Science Officer or Grant Specialist assigned to your award. This disclosure must include a statement of the action taken, or contemplated, and any assistance needed to resolve the situation.; For questions concerning this notice, please contact the Grants Specialist and Science Officer or Grants Officer’s Representative listed in your award.

[NTW] [DEPARTMENT OF DEFENSE]
FY21 Department of Defense; Alcohol and Substance Abuse Disorders Research Program ASDARP Consortium Award

Tuberous Sclerosis Complex Research Program  TSCRP Deadline Extended

Sponsor: Department of Defense
Deadline(s): 08/18/2021 (Pre-Application); 09/08/2021 (Application) [Alcohol and Substance Abuse Disorders Research Program Consortium Award]; 07/08/2021 (Pre-Application); 07/29/2021 (Application) [Tuberous Sclerosis Complex Research Program  TSCRP Deadline Extended]

Contact: help@ebrap.org
Link(s): https://cdmrp.army.mil/pubs/Webinars/webinar_series
https://cdmrp.army.mil/
https://www.grants.gov/
https://eBRAP.org
https://cdmrp.army.mil/funding/asadrp
https://cdmrp.army.mil/funding/tscrp

Additional Information: JUST RELEASED! FY21 DOD Funding Opportunity and TSCRP Deadline Extended; This e-mail is to notify the research community of recently released Fiscal Year 2021 (FY21) funding opportunity for the Alcohol and Substance Abuse Disorders Research Program and modified funding opportunity for the Tuberous Sclerosis Complex Research Program and managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP); FY21 funding opportunity released: Alcohol and Substance Abuse Disorders Research Program: Consortium Award; Tuberous Sclerosis Complex Research Program: New Pre-Application and Application Deadlines!!!; Clinical Translational Research Award; Exploration – Hypothesis Development Award ; Idea Development Award ; A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Funding Opportunities/Program Announcements and General Application Instructions which can be found on the Grants.gov website https://Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.; For email notification when CDMRP funding opportunities are released, subscribe to program-specific news and updates under
“Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the CDMRP-administered programs, please visit the CDMRP website https://cdmrp.army.mil; For more information on types of funding opportunities offered and application strategies review the CDMRP Webinar Series: https://cdmrp.army.mil/pubs/Webinars/webinar_series.

[NTW] [DEPARTMENT OF DEFENSE]

<table>
<thead>
<tr>
<th>Department of Defense; FY21; Duchenne Muscular Dystrophy (DMDRP) Application Instructions; Department of Defense; FY21; Duchenne Muscular Dystrophy (DMDRP) Department of Defense; FY21; Duchenne Muscular Dystrophy (DMDRP); Idea Development Award Department of Defense; FY21; Duchenne Muscular Dystrophy (DMDRP); Translational Research Award</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor:</strong> Department of Defense</td>
</tr>
<tr>
<td><strong>Deadline(s):</strong> 08/11/2021 (Pre-Application); 12/01/2021 (Application) Department of Defense; FY21; Duchenne Muscular Dystrophy (DMDRP); Deadlines</td>
</tr>
<tr>
<td><strong>Contact:</strong> <a href="mailto:help@ebrap.org">help@ebrap.org</a></td>
</tr>
</tbody>
</table>
| **Additional Information:** EXTERNAL] JUST RELEASED! FY21 DMDRP and NETP Program Announcements; This e-mail is to notify the research community of the recently released Fiscal Year 2021 (FY21) funding opportunities for the Department of Defense (DoD) Duchenne Muscular Dystrophy Research Program (DMDRP) and the Neurotoxin Exposure Treatment Parkisons’s (NETP) program managed by the office of Congressionally Directed Medical Research Programs (CDMRP). Detailed descriptions of funding opportunities, evaluation criteria, and submission requirements can be found in the specific Program Announcements. The Program Announcements are available electronically for downloading from the Grants.gov website http://www.grants.gov, the CDMRP website https://cdmrp.army.mil/funding/prgdefault and the electronic Biomedical Research Application Portal (eBRAP) https://eBRAP.org.; Additional information about applying to CDMRP programs, as well as tips for successfully preparing applications for different types of CDMRP award mechanisms, are available in the CDMRP Webinar Series https://cdmrp.army.mil/pubs/Webinars/webinar_series.; All CDMRP funding opportunities, both recently and previously released, are available on the CDMRP website https://cdmrp.army.mil.; Subsequent notifications will be sent when additional funding opportunities are released. A listing of all open CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.; Submission is a two-step process requiring both pre-application submission and full application submission. All pre-applications must be submitted through eBRAP https://eBRAP.org./; Full applications from extramural organizations (non-DoD organizations) must be submitted through Grants.gov http://www.grants.gov. Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov. Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP and Grants.gov. For detailed information on the submission process, refer to Section II.D. of the Program Announcement/Funding Opportunity.; eBRAP is a multifunctional web-based...
system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance. A key feature of eBRAP is the ability of an organization’s representatives and PIs to view and modify the Grants.gov application submissions associated with them. eBRAP will validate Grants.gov application files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity.

[NTW] [DEPARTMENT OF DEFENSE]
Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP)
Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP); Application Instructions
Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP); Early Investigator Research Award
Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP); Investigator-Initiated Research Award
Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP); Synergistic Idea Award

Sponsor: Department of Defense
Deadline(s): 09/08/2021 (Pre-Application); 09/28/2021 (Application) [Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP)]
Contact: help@ebrap.org
Link(s): https://cdmrp.army.mil/funding/netp [Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP)]
https://cdmrp.army.mil/funding/pa/FY21-NETP-GAI.pdf [Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP); Application Instructions]
https://cdmrp.army.mil/funding/pa/FY21-NETP-EIRA.pdf [Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP); Early Investigator Research Award]
https://cdmrp.army.mil/funding/pa/FY21-NETP-IIRA.pdf [Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP); Investigator-Initiated Research Award]
https://cdmrp.army.mil/funding/pa/FY21-NETP-SIA.pdf [Department of Defense; FY21; Neurotoxin Exposure Treatment Parkinson’s (NETP); Synergistic Idea Award]
Additional Information: EXTERNAL] JUST RELEASED! FY21 DMDRP and NETP Program Announcements; This e-mail is to notify the research community of the recently released Fiscal Year 2021 (FY21) funding opportunities for the Department of Defense (DoD) Duchenne Muscular Dystrophy Research Program (DMDRP) and the Neurotoxin Exposure Treatment Parkisons's (NETP) program managed by the office of Congressionally Directed Medical Research Programs (CDMRP); Detailed descriptions of funding opportunities, evaluation criteria, and submission requirements can be found in the specific Program Announcements. The Program Announcements are available electronically for downloading from the Grants.gov website http://www.grants.gov, the CDMRP website https://cdmrp.army.mil/funding/prgdefault and the electronic Biomedical Research Application Portal (eBRAP) https://eBRAP.org. ; Additional information about applying to CDMRP programs, as well as tips for successfully preparing applications for different types of CDMRP award mechanisms, are available in the CDMRP Webinar Series.
https://cdmrp.army.mil/pubs/Webinars/webinar_series; All CDMRP funding opportunities, both recently and previously released, are available on the CDMRP website https://cdmrp.army.mil; Subsequent notifications will be sent when additional funding opportunities are released. A listing of all open CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.; Submission is a two-step process requiring both pre-application submission and full application submission. All pre-applications must be submitted through eBRAP https://eBRAP.org/. Full applications from extramural organizations (non-DoD organizations) must be submitted through Grants.gov http://www.grants.gov. Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov. Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP and Grants.gov. For detailed information on the submission process, refer to Section II.D. of the Program Announcement/Funding Opportunity.; eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance. A key feature of eBRAP is the ability of an organization's representatives and PIs to view and modify the Grants.gov application submissions associated with them. eBRAP will validate Grants.gov application files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity.

[NTW] [DEPARTMENT OF DEFENSE]
JUST RELEASED! FY21 DoD BCRP, BMFRP, and LRP Program Announcements and DMDRP Pre-announcement

DOD CDMRP website
DOD FY21 Breast Cancer Research Program (BCRP)
Bone Marrow Failure Research Program (BMFRP)
Lupus Research Program (LRP)
Duchenne Muscular Dystrophy (DMDRP)

CDMRP Webinar Series

Sponsor: Department of Defense
Deadline(s): Weekly DOD update; 04/30/2021

Contact: help@ebrap.org
Link(s): https://cdmrp.army.mil/funding/prgdefault
https://cdmrp.army.mil/funding/bcrp;
https://cdmrp.army.mil/funding/bmfrp
https://cdmrp.army.mil/funding/lrp;

Additional Information: JUST RELEASED! FY21 DoD BCRP, BMFRP, and LRP Program Announcements and DMDRP Pre-announcement; This e-mail is to notify the research community of the recently released Fiscal Year 2021 (FY21) funding opportunities for the Department of Defense (DoD) Breast Cancer Research Program (BCRP), Bone Marrow Failure Research Program (BMFRP), and Lupus Research Program (LRP) and the pre-announcement for the Duchenne Muscular Dystrophy Research Program (DMDRP) managed by the office of Congressionally Directed Medical Research Programs (CDMRP); Descriptions of each of the anticipated funding opportunities, eligibility, key mechanism elements, and funding can be found in the Program pre-announcement. FY21 pre-announcements can be found in the CDMRP home page features
at https://cdmrp.army.mil. Subsequent notifications will be sent when the program announcements/funding opportunities are released.; Detailed descriptions of funding opportunities, evaluation criteria, and submission requirements can be found in the specific Program Announcements. The Program Announcements are available electronically for downloading from the Grants.gov website http://www.grants.gov, the CDMRP website https://cdmrp.army.mil/funding/prgdefault and the electronic Biomedical Research Application Portal (eBRAP) https://eBRAP.org.; Additional information about applying to CDMRP programs, as well as tips for successfully preparing applications for different types of CDMRP award mechanisms, are available in the CDMRP Webinar Series https://cdmrp.army.mil/pubs/Webinars/webinar_series; All CDMRP funding opportunities, both recently and previously released, are available on the CDMRP website https://cdmrp.army.mil.; Subsequent notifications will be sent when additional funding opportunities are released. A listing of all open CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.; Submission is a two-step process requiring both pre-application submission and full application submission. All pre-applications must be submitted through eBRAP https://eBRAP.org/. Full applications from extramural organizations (non-DoD organizations) must be submitted through Grants.gov http://www.grants.gov. Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov. Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP and Grants.gov. For detailed information on the submission process, refer to Section II.D. of the Program Announcement/Funding Opportunity.; eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance. A key feature of eBRAP is the ability of an organization’s representatives and PIs to view and modify the Grants.gov application submissions associated with them. eBRAP will validate Grants.gov application files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity.; Please do not respond directly to this message. To be added or removed from this email list please use the “Subscribe/unsubscribe” to program specific news and updates at https://ebrap.org/; FY21 Program Announcements Released: Breast Cancer Research Program (BCRP) at https://cdmrp.army.mil/funding/bcpr; Bone Marrow Failure Research Program (BMFRP) at https://cdmrp.army.mil/funding/bmfrp; Idea Development Award; Investigator-Initiated Research Award; Lupus Research Program (LRP) at https://cdmrp.army.mil/funding/lrp; Idea Award; Impact Award; Transformative Vision Award; FY21 Pre-Announcement Released: Duchenne Muscular Dystrophy (DMDRP) at https://cdmrp.army.mil/pubs/press/2021/21dmdrppreann; Idea Development Award; Translational Research Award

[NTW] [DEPARTMENT OF DEFENSE]

DoD/CDMRP Funding Opportunities update - 4/23/2021
Fiscal Year 2021 (FY21) Epilepsy Research Program (ERP)
Fiscal Year 2021 (FY21) Orthotics and Prosthetics Outcomes Research Program (OPORP)
Fiscal Year 2021 (FY21) Peer Reviewed Alzheimer’s Research Program (PRARP)
Fiscal Year 2021 (FY21) Peer Reviewed Cancer Research Program (PRCRP)
Fiscal Year 2021 (FY21) Peer Reviewed Orthopaedic Research Program (PRORP)
Fiscal Year 2021 (FY21) Prostate Cancer Research Program (PCRP)
Fiscal Year 2021 (FY21) Spinal Cord Injury Research Program (SCIRP)
Fiscal Year 2021 (FY21) Tick-Borne Disease Research Program (TBDRP)
Fiscal Year 2021 (FY21) Tuberous Sclerosis Complex Research Program (TSCRCP)
Subscribe to the DOD ListServ
SPA Project Officer
Sponsor: Department of Defense
Deadline(s): Please see individual opportunities
Contact: Feel free to contact your SPA Project Officer with any questions
Link(s): https://cdmrp.army.mil/funding/prgdefault
https://ebrap.org/eBRAP/programSubscription/Subscribe.htm
Additional Information: DoD/CDMRP Funding Opportunities update - 4/23/21; This is an update of the latest Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) that were officially released. The most recently released FY2021 funding opportunities are highlighted below in yellow.; For all CDMRP funding opportunities, application instructions, and deadlines, go to https://cdmrp.army.mil/funding/prgdefault.; You can also subscribe to their listserv to be notified of other opportunities in your area of interest at https://ebrap.org/eBRAP/programSubscription/Subscribe.htm.; The following list are all CDMRP FY2021 funding opportunities released to date: Amyotrophic Lateral Sclerosis Research Program; Autism Research Program; Breast Cancer Research Program; Combat Casualty Care Research Program (JPC-6); Epilepsy Research Program; Gulf War Illness Research Program; Lung Cancer Research Program; Orthotics and Prosthetics Outcomes Research Program; Ovarian Cancer Research Program; Peer Reviewed Alzheimer’s Research Program; Peer Reviewed Cancer Research Program; Peer Reviewed Medical Research Program; Peer Reviewed Orthopaedic Research Program; Prostate Cancer Research Program; Spinal Cord Injury Research Program; Tick-Borne Disease Research Program; Tuberous Sclerosis Complex Research Program; Feel free to contact your SPA Project Officer with any questions.; [brought to our attention by]; Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; Columbia University; Columbia University Irving Medical Center; sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu/

[NTW] [DEPARTMENT OF DEFENSE]
Current, FY 2020 Department of Defense Funding Opportunities
Sponsor: Department of Defense
Deadline(s): Please see piecemeal programs and their individual opportunities for Deadlines
Contact: CDMRP Help Desk, help@ebrap.org
Link(s): https://cdmrp.army.mil/funding/prgdefault
Additional Information: Research Resources regularly posts funding opportunity announcements from the Department of Defense. The https://cdmrp.army.mil/funding/prgdefault link defaults to all current opportunities. Please see piecemeal programs and their individual opportunities for Deadlines.; Detailed descriptions of funding opportunities, evaluation criteria, and submission requirements can be found in the specific Program Announcements. The Program Announcements are available electronically for downloading from the Grants.gov website http://www.grants.gov, the CDMRP website https://cdmrp.army.mil/funding/prgdefault and the electronic Biomedical Research Application Portal (eBRAP) https://eBRAP.org.; All CDMRP funding opportunities, both recently and previously released, are available on the CDMRP website https://cdmrp.army.mil.; Subsequent notifications will be sent when additional funding opportunities are released. A listing of all open CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.; Submission is a two-step process requiring both pre-application submission and full application submission. All pre-applications must be submitted through eBRAP https://eBRAP.org.; Full applications from extramural organizations (non-DoD organizations) must be submitted through Grants.gov http://www.grants.gov/. Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov. Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP and Grants.gov. For detailed information on the submission process, refer to Section II.D. of the Program Announcement/Funding
Opportunity.

eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance. A key feature of eBRAP is the ability of an organization’s representatives and PIs to view and modify the Grants.gov application submissions associated with them. eBRAP will validate Grants.gov application files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity.

[NTW] [DEPARTMENT OF DEFENSE]

Fiscal Year 2021 (FY21) Autism Research Program (ARP)
Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program (PRMRP)
Fiscal Year 2021 (FY21) Amyotrophic Lateral Sclerosis Research Program (ALSRP)
Fiscal Year 2021 (FY21) Breast Cancer Research Program (BCRP)
Fiscal Year 2021 (FY21) Combat Casualty Care Research Program (JPC-6)
Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP)
Fiscal Year 2021 (FY21) Lung Cancer Research Program (LCRP)
Fiscal Year 2021 (FY21) Ovarian Cancer Research Program (OCRP)
Fiscal Year 2021 (FY21) Peer Reviewed Cancer Research Program (PRCRP)
Fiscal Year 2021 (FY21) Tick-Borne Disease Research Program (TBDRP)

**Sponsor:** Department of Defense

**Deadline(s):** Later April, Early May (Pre-Applications); Please see piecemeal opportunities

**Contact:** help@ebrap.org

**Link(s):** https://cdmrp.army.mil/funding/prgdefault
https://cdmrp.army.mil/funding/prmrp

**Additional Information:** DoD/CDMRP Funding Opportunities update; This is an update of the latest Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) that were officially released. The Autism Research Program and the Peer Reviewed Medical Research Program (PRMRP) were the most recently released funding opportunities;
For all CDMRP funding opportunities, application instructions, and deadlines, go to https://cdmrp.army.mil/funding/prgdefault. ; You can also subscribe to their listserv to be notified of other opportunities in your area of interest at https://ebrap.org/eBRAP/programSubscription/Subscribe.htm.; The following list are all CDMRP FY2021 funding opportunities released to date: Amyotrophic Lateral Sclerosis Research Program; Autism Research Program; Breast Cancer Research Program; Combat Casualty Care Research Program (JPC-6); Gulf War Illness Research Program; Lung Cancer Research Program; Ovarian Cancer Research Program; Peer Reviewed Medical Research Program; Feel free to contact your SPA Project Officer with any questions.; [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; Email: sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu/; DoD Peer Review Medical Research Program Funding Opportunities released The official opportunities for the DoD Peer Review Medical Research Program Funding Opportunities were released: https://cdmrp.army.mil/funding/prmrp; Most of the pre-applications/letters of intent are due late April or early May. Point of Contact; CDMRP Public Affairs; usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil
[NTW] [DEPARTMENT OF DEFENSE]
Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP)
Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); Idea Award
Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); Research Advancement Award
Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); Clinical Evaluation Award
Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); Therapeutic Biomarker Trial Award
Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); New Investigator Award
Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP); Application Instructions
Currently Available Department of Defense DOD FY21 Funding Opportunities
CDMRP Webinar Series
Sponsor: Department of Defense
Deadline(s): 05/07/2021 (Pre-Application); 08/19/2021 (Application) [GWIRP]
Contact: help@ebrap.org
Link(s): https://cdmrp.army.mil/funding/gwirp [Fiscal Year 2021 (FY21) Gulf War Illness Research Program (GWIRP)]
https://cdmrp.army.mil/funding/pa/FY21-GWIRP-TBTA.pdf [GWIRP Therapeutic/Biomarker Trial Award]
https://cdmrp.army.mil/funding/pa/FY21-GWIRP-NIA.pdf [GWIRP New Investigator Award]
https://cdmrp.army.mil/funding/pa/FY21-GWIRP-GAI.pdf [GWIRP Application Instructions]
https://cdmrp.army.mil/funding/prgdefault [Current DOD FY21 announcements]
Additional Information: JUST RELEASED! FY21 GWIRP Program Announcements; This e-mail is to notify the research community of the recently released Fiscal Year 2021 (FY21) funding opportunities for the Department of Defense (DoD) Gulf War Illness Research Program (GWIRP) managed by the office of Congressionally Directed Medical Research Programs.; Detailed descriptions of funding opportunities, evaluation criteria, and submission requirements can be found in the specific Program Announcements. The Program Announcements are available electronically for downloading from the Grants.gov website http://www.grants.gov, the CDMRP website https://cdmrp.army.mil/funding/prgdefault and the electronic Biomedical Research Application Portal (eBRAP) https://eBRAP.org.; Additional information about applying to CDMRP programs, as well as tips for successfully preparing applications for different types of CDMRP award mechanisms, are available in the CDMRP Webinar Series https://cdmrp.army.mil/pubs/Webinars/webinar_series.; All CDMRP funding opportunities, both recently and previously released, are available on the CDMRP website https://cdmrp.army.mil; Subsequent notifications will be sent when additional funding opportunities are released. A listing of all open CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.; Submission is a two-step process requiring both pre-application submission and full application submission. All pre-applications must be submitted through eBRAP https://eBRAP.org/. Full applications from extramural organizations (non-DoD organizations) must be submitted through Grants.gov http://www.grants.gov/. Intramural DoD
organizations may submit full applications to either eBRAP or Grants.gov. Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP and Grants.gov. For detailed information on the submission process, refer to Section II.D. of the Program Announcement/Funding Opportunity.; eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance. A key feature of eBRAP is the ability of an organization's representatives and PIs to view and modify the Grants.gov application submissions associated with them. eBRAP will validate Grants.gov application files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity.; Please do not respond directly to this message. To be added or removed from this email list please use the “Subscribe/unsubscribe” to program specific news and updates at https://ebrap.org.

[NTW] [DEPARTMENT OF DEFENSE]
Fiscal Year 2021 (FY21) Lung Cancer Research Program (LCRP)
Fiscal Year 2021 (FY21) Lung Cancer Research Program (LCRP); Idea Development Award
Fiscal Year 2021 (FY21) Lung Cancer Research Program (LCRP); Investigator-Initiated Translational Research Award
Fiscal Year 2021 (FY21) Lung Cancer Research Program (LCRP); Clinical Translational Research Partnership Award
Fiscal Year 2021 (FY21) Lung Cancer Research Program (LCRP); LCRP Application Instructions
Currently Available Department of Defense DOD FY21 Funding Opportunities
CDMRP Webinar Series

Sponsor: Department of Defense
Deadline(s): 05/05/2021 (Pre-Application); 07/28/2021 (Application) [LCRP Idea Development Award; LCRP Investigator-Initiated Translational Research Award]; 07/14/2021 (Pre-Application); 07/28/2021 (Application) [LCRP Clinical Translational Research Partnership Award]
Contact: help@ebrap.org

Link(s): https://cdmrp.army.mil/funding/lcrp [Lung Cancer Research Program (LCRP)]
https://cdmrp.army.mil/funding/pa/FY21-LCRP-GAI.pdf (LCRP Application Instructions)
https://cdmrp.army.mil/funding/prgdefault [Current DOD FY21 announcements]

Additional Information: JUST RELEASED! FY21 GWIRP, LCRP and PRMRP Program Announcements; This e-mail is to notify the research community of the recently released Fiscal Year 2021 (FY21) funding opportunities for the Department of Defense (DoD) Lung Cancer Research Program (LCRP), managed by the office of Congressionally Directed Medical Research
Programs.; Detailed descriptions of funding opportunities, evaluation criteria, and submission requirements can be found in the specific Program Announcements. The Program Announcements are available electronically for downloading from the Grants.gov website http://www.grants.gov, the CDMRP website https://cdmrp.army.mil/funding/prgdefault and the electronic Biomedical Research Application Portal (eBRAP) https://eBRAP.org.; Additional information about applying to CDMRP programs, as well as tips for successfully preparing applications for different types of CDMRP award mechanisms, are available in the CDMRP Webinar Series https://cdmrp.army.mil/pubs/Webinars/webinar_series.; All CDMRP funding opportunities, both recently and previously released, are available on the CDMRP website https://cdmrp.army.mil; Subsequent notifications will be sent when additional funding opportunities are released. A listing of all open CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.; Submission is a two-step process requiring both pre-application submission and full application submission. All pre-applications must be submitted through eBRAP https://eBRAP.org/. Full applications from extramural organizations (non-DoD organizations) must be submitted through Grants.gov http://www.grants.gov. Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov. Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP and Grants.gov. For detailed information on the submission process, refer to Section II.D. of the Program Announcement/Funding Opportunity.; eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance. A key feature of eBRAP is the ability of an organization’s representatives and PIs to view and modify the Grants.gov application submissions associated with them. eBRAP will validate Grants.gov application files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity.; Please do not respond directly to this message. To be added or removed from this email list please use the “Subscribe/unsubscribe” to program specific news and updates at https://ebrap.org.
**Sponsor:** Department of Defense

**Deadline(s):** 05/13/2021 (Pre-Application); 08/26/2021 (Application) [PRMRP Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award]

04/29/2021 (Pre-Application); 05/13/2021 (Application) [PRMRP Peer Reviewed Medical Research Program (PRMRP) Discovery Award]

05/13/2021 (Pre-Application); 08/26/2021 (Application) [PRMRP Peer Reviewed Medical Research Program (PRMRP) Focused Program Award]

04/28/2021 (Pre-Application); 09/02/2021 (Application) [PRMRP Peer Reviewed Medical Research Program (PRMRP) Investigator-Initiated Research Award]

04/28/2021 (Pre-Application); 09/02/2021 (Application) [PRMRP Peer Reviewed Medical Research Program (PRMRP) Technology Therapeutic Development Award]

**Contact:** help@ebrap.org

**Link(s):**
- https://cdmrp.army.mil/funding/pa/FY21-PRMRP-CTA.pdf [PRMRP Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award]
- https://cdmrp.army.mil/funding/pa/FY21-PRMRP-DA.pdf [PRMRP Peer Reviewed Medical Research Program (PRMRP) Discovery Award]
- https://cdmrp.army.mil/funding/pa/FY21-PRMRP-FPA.pdf [PRMRP Peer Reviewed Medical Research Program (PRMRP) Focused Program Award]
- https://cdmrp.army.mil/funding/pa/FY21-PRMRP-TTTA.pdf [PRMRP Peer Reviewed Medical Research Program (PRMRP) Technology Therapeutic Development Award]
- https://cdmrp.army.mil/funding/prgdefault [Current DOD FY21 announcements]

**Additional Information:** JUST RELEASED! FY21 GWIRP, LCRP and PRMRP Program Announcements; This e-mail is to notify the research community of the recently released Fiscal Year 2021 (FY21) funding opportunities for the Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP) managed by the office of Congressionally Directed Medical Research Programs.; Detailed descriptions of funding opportunities, evaluation criteria, and submission requirements can be found in the specific Program Announcements. The Program Announcements are available electronically for downloading from the Grants.gov website http://www.grants.gov, the CDMRP website https://cdmrp.army.mil/funding/prgdefault and the electronic Biomedical Research Application Portal (eBRAP) https://eBRAP.org.; Additional information about applying to CDMRP programs, as well as tips for successfully preparing applications for different types of CDMRP award mechanisms, are available in the CDMRP Webinar Series https://cdmrp.army.mil/pubs/Webinars/webinar_series.; All CDMRP funding opportunities, both recently and previously released, are available on the CDMRP website https://cdmrp.army.mil; Subsequent notifications will be sent when additional funding opportunities are released. A listing of all open CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.; Submission is a two-step process requiring both pre-application submission and full application submission. All pre-applications must be submitted through eBRAP https://eBRAP.org/. Full applications from extramural organizations (non-DoD organizations) must be submitted through Grants.gov http://www.grants.gov. Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov. Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP and Grants.gov. For detailed information on the submission process, refer to Section II.D. of the Program Announcement/Funding Opportunity.; eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance. A key feature of eBRAP is the ability of an organization's representatives and
PIs to view and modify the Grants.gov application submissions associated with them. eBRAP will validate Grants.gov application files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity. Please do not respond directly to this message. To be added or removed from this email list please use the "Subscribe/unsubscribe" to program specific news and updates at https://ebrap.org.

[NTW] [DEPARTMENT OF DEFENSE]


[4] Department of Defense FY21 Combat Casualty and Care Research Program (JPC-6) En Route Care Award

[5] Department of Defense FY21 Combat Casualty and Care Research Program (JPC-6) En Route Care Award Application Instructions

[6] Currently Available FY21 DOD Funding Opportunities

[7] Department of Defense FY21 Pre-Announcements

[8] Department of Defense FY21 Funding Opportunities

[9] Department of Defense, CDMRP Webinar Series

[10] Department of Defense FY21 Pre-Announcements

**Sponsor:** Department of Defense

**Deadline(s):** For Pre-Announcements (NA); 03/31/2021 (Department of Defense FY21 Combat Casualty and Care Research Program (JPC-6) En Route Care Award Pre-Application); 06/23/2021 (Department of Defense FY21 Combat Casualty and Care Research Program (JPC-6) En Route Care Award Application)

**Contact:** help@ebrap.org

**Link(s):**

https://cdmrp.army.mil/funding/jpc6 [Department of Defense Fiscal Year 2021 (FY21) Combat Casualty Care Research Program (JPC-6)]


https://cdmrp.army.mil/funding/oa/FY21-DMRDP-JPC6-ERCA.pdf [Department of Defense FY21 Combat Casualty and Care Research Program (JPC-6) En Route Care Award]

https://cdmrp.army.mil/funding/oa/FY21-DMRDP-JPC6-GAI.pdf [Department of Defense FY21 Combat Casualty and Care Research Program (JPC-6) En Route Care Award Application Instructions]


**Additional Information:** JUST RELEASED! FY21 DoD Pre-Announcements and Funding Opportunities; This e-mail is to notify the research community of recently released Fiscal Year 2021 (FY21) pre-announcements and funding opportunities for the
Department of Defense (DoD) programs managed by the office of Congressionally Directed Medical Research Programs (CDMRP). CDMRP understands that applicants are impacted by COVID-19. Submission deadlines for pre-applications and full applications will incorporate the maximum time that is feasible for each FY21 program. Thank you for your efforts during this challenging time; A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Funding Opportunities/Program Announcements and General Application Instructions which can be found on the Grants.gov website https://Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.; For email notification when CDMRP funding opportunities are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the CDMRP-administered programs, please visit the CDMRP website https://cdmrp.army.mil; For more information on types of funding opportunities offered and application strategies review the CDMRP Webinar Series: https://cdmrp.army.mil/pubs/Webinars/webinar_series; FY21 Pre-announcements released: Peer Reviewed Cancer Research Program; Behavioral Health Science Award; Career Development Award – Fellow Option; Idea Award; Impact Award; Translational Team Science Award; FY21 Funding Opportunities released: Defense Medical Research and Development Program; Joint Program Committee 6 (JPC-6)/Combat Casualty Care Research Program (CCCRP) En Route Care Award

[NTW] [DEPARTMENT OF DEFENSE]
Department of Defense FY21 Military Burn Research Program (MBRP)
Department of Defense FY21 Neurofibromatosis Research Program (NFRP)
Sponsor: Department of Defense
Deadline(s): 06/08/2021 (Pre-Application, MBRP); 09/30/2021 (Application MPRP); 07/08/2021 (Pre-Application, NFRP); 07/22/2021 (Application, NFRP)
Contact: help@ebrap.org
Link(s): https://cdmrp.army.mil/funding/mbrp [Military Burn Research Program (MBRP)]
https://cdmrp.army.mil/funding/nfrp [Neurofibromatosis Research Program (NFRP)]
Additional Information: JUST RELEASED! FY21 MBRP and NFRP Program Announcements; This e-mail is to notify the research community of the recently released Fiscal Year 2021 (FY21) funding opportunities for the Department of Defense (DoD) Military Burn Research Program (MBRP) and Neurofibromatosis Research Program (NFRP) managed by the office of Congressionally Directed Medical Research Programs (CDMRP). Detailed descriptions of funding opportunities, evaluation criteria, and submission requirements can be found in the specific Program Announcements. The Program Announcements are available electronically for downloading from the Grants.gov website http://www.grants.gov, the CDMRP website https://cdmrp.army.mil/funding/prgdefault and the electronic Biomedical Research Application Portal (eBRAP) https://eBRAP.org; additional information about applying to CDMRP programs, as well as tips for successfully preparing applications for different types of CDMRP award mechanisms, are available in the CDMRP Webinar Series https://cdmrp.army.mil/pubs/Webinars/webinar_series; All CDMRP funding opportunities, both recently and previously released, are available on the CDMRP website https://cdmrp.army.mil; Subsequent notifications will be sent when additional funding opportunities are released. A listing of all open CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.; Submission is a two-step process requiring both pre-application submission and full application submission. All pre-applications must be submitted through eBRAP https://eBRAP.org. Full applications from extramural organizations (non-DoD organizations) must be submitted through Grants.gov http://www.grants.gov. Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov. Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP
and Grants.gov. For detailed information on the submission process, refer to Section II.D. of the Program Announcement/Funding Opportunity.; eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance. A key feature of eBRAP is the ability of an organization’s representatives and PIs to view and modify the Grants.gov application submissions associated with them. eBRAP will validate Grants.gov application files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity.; **FY21 Program Announcements Released:** Military Burn Research Program (MBRP) at [https://cdmrp.army.mil/funding/mbrp](https://cdmrp.army.mil/funding/mbrp); Clinical Translational Research Award; Idea Development Award; Neurofibromatosis Research Program (NFRP) at [https://cdmrp.army.mil/funding/nfrp](https://cdmrp.army.mil/funding/nfrp); Clinical Trial Award; Early Investigator Research Award; Exploration - Hypothesis Development Award; Investigator-Initiated Research Award; New Investigator Award; Synergistic Idea Award; Clinical Trials Consortium (Pending Release)

**[NTW] [NIH COVID-19 RESEARCH WEBSITE]**

**NIH’s COVID-19 Research Website**

**NIH’s COVID-19 Research Website - NEXUS**

**Sponsor:** NIH  
**Deadline(s):** NA  
**Contact:** ExtramuralNexus@mail.nih.gov  
**Link(s):** [https://covid19.nih.gov/](https://covid19.nih.gov/)  
**Additional Information:** NIH’s New COVID-19 Research Website; Below is an announcement from Dr. Mike Lauer of NIH announcing their new NIH COVID-19 website. See below for more details; We are pleased to announce that the new NIH COVID-19 website launched earlier this week. The site provides a central location for trusted, up-to-date, accurate information about NIH research and our strategic role in COVID-19 research. The site complements information made available on our COVID-19: Information for NIH Applicants and Recipients of NIH Funding webpage.; The new site includes information about key programs such as the Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership and the Rapid Acceleration of Diagnostics initiative to develop state-of-the-science diagnostic tests for COVID-19. Users are also able to search information on funded research by state, institution, Congressional district, and more.; [https://nexus.od.nih.gov/all/wp-content/uploads/2021/01/cov2.png](https://nexus.od.nih.gov/all/wp-content/uploads/2021/01/cov2.png); To support ongoing efforts to direct the public to critical information on COVID-19, the website also includes links to information on: Vaccines, treatments, and testing; Clinical trials and how to participate; How to donate plasma; Resources from NIH’s Community Engagement Alliance Against COVID-19 Disparities and Federal agencies such as the Centers for Disease Control and Prevention and Department of State; [https://nexus.od.nih.gov/all/wp-content/uploads/2021/01/cov2.jpg](https://nexus.od.nih.gov/all/wp-content/uploads/2021/01/cov2.jpg); View article...
[NTW] [COVID-19]
Your Questions Answered: COVID-19 Vaccines, Archival Webinar 04.08.2021, with Gary Miller and Kellie Bryant

Sponsor: Office of the Dean
Deadline(s): 04/08/2021 (Archival Event Date)
Contact: Lauren Sagnella, Associate Director of Special Events, 212-305-9737; las2336@cumc.columbia.edu
Link(s): https://www.youtube.com/watch?v=XWWKe9HF0A
Additional Information: Kellie Bryant, DNP, WHNP, CHSE, Columbia School of Nursing and Gary W. Miller, PhD Columbia Mailman School of Public Health discuss Covid-19 Vaccines

[NTW] [COVID-19]
NIH Funding Opportunities Specific to COVID-19 Webpage
CU RESEARCH SPA COVID-19 Funding Opportunities Webpage

Sponsor: NIH
Deadline(s): NA, 07/08/2020 (Release Date)
Contact: [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; sfs2110@cumc.columbia.edu
Website: https://spa.columbia.edu/
Additional Information: New NIH dedicated COVID-19 funding opportunities webpage. Columbia Research has compiled a list of funding opportunities offered by federal and non-federal sources for COVID-19 research.; I just wanted to bring to your attention that today NIH launched a new dedicated NIH Funding Opportunities Specific to COVID-19 webpage, which allows applicants to quickly differentiate active and expired opportunities.; This link has also been added to our CU RESEARCH SPA COVID-19 Funding Opportunities webpage. Feel free to contact me should you have any questions.

[NTW] [DEDICATED CU WEBSITE, COVID-19: FAQS AND RESOURCES RELATING TO RESEARCH]
CU Website Dedicated to COVID-19: FAQs and Resources Relating to Research

Sponsor: https://research.columbia.edu
Deadline(s): NA
Contact: Contact COVID19_research@columbia.edu for all research-related questions.
Link(s): https://research.columbia.edu/COVID-19_Research
Additional Information: COVID-19: FAQs and Resources Relating to Research; The Offices of the Executive Vice President for Research are continuing to monitor the impact of COVID-19 on research activities. See our new dedicated website COVID-19: FAQs and Resources Relating to Research. This website is updated daily. Contact COVID19_research@columbia.edu for all research-related questions.

[NTW] [VIROLOGY]
Promoting Bunyavirales Basic Science Research (R01 Clinical Trial Not Allowed)
**NTW [SUMMER 2021 SKILLS FOR HEALTH AND RESEARCH PROFESSIONALS (SHARP) TRAINING AT CU]**

Registration for Summer 2021 Skills for Health and Research Professionals (SHARP) Training at Columbia University is now open

**Sponsor:** Columbia University, Mailman School of Public Health, Precision Prevention

**Deadline(s):** Registration remains open either until classes are filled, or up until a few weeks before classes begin, Summer 2021

**Contact:** Please see piecemeal class announcements for contact information; for general contact information for the SHARP program, please email Abby Welbourn, MA; Associate Director, Special Projects; Department of Environmental Health Sciences; Columbia University Mailman School of Public Health; aj2730@cumc.columbia.edu

**Link(s):** [https://www.publichealth.columbia.edu/research/precision-prevention/training-workshops](https://www.publichealth.columbia.edu/research/precision-prevention/training-workshops)

**Additional Information:** Short, intensive (2 – 3 day, virtual, live-stream) boot camps (18 hot topics in research and education) led by field experts to teach in-demand research skills and methods to investigators at all career levels and from any organization.

**NTW [PILOT]**

Second annual of the SEAS-HICCC joint seed grant funding opportunity

**SEAS-HICCC Joint Seed Grants RFA:** [extended deadline 07/30/2021 is not reflected in the rfa]

**Apply SEAS-HICCC Joint Seed Grants**

**Sponsor:** Columbia’s School of Engineering and Applied Science (SEAS) and the Herbert Irving Comprehensive Cancer Center (HICCC)

**Deadline(s):** 07/30/2021 [Extended Deadline]

**Contact:** If you need assistance identifying potential collaborators in SEAS or HICCC, please contact Eric Vieira (Director of Strategic Collaborations @ SEAS; evm2144@columbia.edu) or Emer Smyth (Director, Cancer Research Alliances @ HICCC; es3551@cumc.columbia.edu). Questions: contact Dr. Tanisha Jackson at tj2325@cumc.columbia.edu

**Link(s):** [https://mcusercontent.com/62dee4a9ce60631ed27b1d57/files/c33aaf0c-8684-aec4-529a-b84f214a9d72/2012_SEAS_HICCC_Joint_Pilot_Award_RFP_1_.pdf](https://mcusercontent.com/62dee4a9ce60631ed27b1d57/files/c33aaf0c-8684-aec4-529a-b84f214a9d72/2012_SEAS_HICCC_Joint_Pilot_Award_RFP_1_.pdf)

**Additional Information:** Extended Deadline: July 30, 2021; Columbia’s School of Engineering and Applied Science (SEAS) and the Herbert Irving Comprehensive Cancer Center (HICCC) are excited to announce the second annual of the SEAS-HICCC joint seed grant funding opportunity. These resources have been developed by leadership in response faculty requests for funding to initiate and support interdisciplinary and collaborative research. Thus, a SEAS-HICCC joint seed grant proposal should include collaboration between SEAS and HICCC with faculty from both organizations represented. Up to two (2) projects will be funded at the level of up to $80,000 for 12-months; Following a successful Frontiers in Engineering and Medicine: Cancer + Biosensors workshop in May 2021, we seek proposals that explore the development and utility of biosensors for cancer research, diagnosis, and treatment. If you need assistance identifying potential collaborators in SEAS or HICCC, please contact Eric Vieira (Director of Strategic Collaborations @ SEAS; evm2144@columbia.edu) or Emer Smyth (Director, Cancer Research Alliances...
Questions: contact Dr. Tanisha Jackson at tj2325@cumc.columbia.edu For more information, eligibility requirements, and to apply, click the links below. SEAS-HICCC Joint Seed Grants RFA ; Apply SEAS-HICCC Joint Seed Grants

[NTW] [MENTAL HEALTH DISORDERS]
Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)
Sponsor: National Institute of Mental Health
Deadline(s): 10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)
Contact: For Studies involving therapeutic and preventive interventions: Joel Sherrill, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-2477; Email: jsherril@mail.nih.gov

[NTW] [MENTAL HEALTH DISORDERS]
Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)
Sponsor: National Institute of Mental Health
Deadline(s): 10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)
Contact: For Studies involving therapeutic and preventive interventions: Joel Sherrill, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-2477; Email: jsherril@mail.nih.gov

[NTW] [MENTAL HEALTH DISORDERS]
NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)
Sponsor: National Institute of Mental Health
Deadline(s): 10/16/2021; 10/16/2023; 02/16/2024; 05/08/2024 (Expiration)
Contact: Scientific/Research Contact(s); Division of Neuroscience and Basic Behavioral Science; Susan Koester, Ph.D.; National Institute of Mental Health (NIMH); Telephone: (301) 443-3563; Email: koesters@mail.nih.gov

[NTW] [MENTAL HEALTH DISORDERS]
Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)
Sponsor: National Institute of Mental Health
Deadline(s): 10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)
Contact: For Studies involving therapeutic and preventive interventions: Joel Sherrill, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-2477; Email: jsherril@mail.nih.gov

[NTW] [MENTAL HEALTH DISORDERS]
Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)
Sponsor: National Institute of Mental Health
Deadline(s): 10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)
Contact: Scientific/Research Contact(s); Adam Haim, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-435-3593; Email: haima@mail.nih.gov

[NTW] [MENTAL HEALTH DISORDERS]
First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)
Sponsor: National Institute of Mental Health
Deadline(s): 10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)
Contact: Questions about first in human and Phase I studies of novel therapeutic drug candidates should be directed to: Enrique Michelotti, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-5415; Email: michelotti@nlm.nih.gov

[NTW] [MENTAL HEALTH DISORDERS]
Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
Sponsor: National Institute of Mental Health
Deadline(s): 10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)
Contact: Scientific/Research Contact(s); Alexander Talkovsky, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-827-7614; Email: alexander.talkovsky@nih.gov
Link(s): https://grants.nih.gov/grants/guide/pa-files/PAR-21-134.html
[NTW] [MENTAL HEALTH DISORDERS]
Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)

Sponsor: National Institute of Mental Health
Deadline(s): 10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)
Contact: Scientific/Research Contact(s): Alexander Talkovsky, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-827-7614; Email: alexander.talkovsky@nih.gov

[NTW] [MENTAL HEALTH DISORDERS]
Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

Sponsor: National Institute of Mental Health
Deadline(s): 10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)
Contact: Scientific/Research Contact(s): For Pediatric Studies: Margaret Grabb, Ph.D.
National Institute of Mental Health (NIMH); Telephone: 301-443-3563; Email: mgrabb@mail.nih.gov

[NTW] [MENTAL HEALTH DISORDERS]
Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

Sponsor: National Institute of Mental Health
Deadline(s): 10/15/2021; 02/15/2022; 06/15/2022; 10/14/2022; 02/15/2023; 06/15/2023; 10/17/2023; 02/15/2024; 02/16/2024 (Expiration)
Contact: Scientific/Research Contact(s): For Pediatric Studies: Margaret Grabb, Ph.D.
National Institute of Mental Health (NIMH); Telephone: 301-443-3563; Email: mgrabb@mail.nih.gov
Link(s): https://grants.nih.gov/grants/guide/pa-files/PAR-21-137.html

[NTW] [INTERVENTIONS]
Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)

Sponsor: National Center for Complementary and Integrative Health
Deadline(s): 07/20/2021; 10/20/2021; 02/18/2022; 10/20/2023; 02/20/2024; 03/12/2024 (Expiration)
Contact: Scientific/Research Contact(s): Peter Murray, Ph.D.; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-496-4054; Email: peter.murray@nih.gov
[NTW] [INTERVENTIONS]
NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
Sponsor: National Center for Complementary and Integrative Health
Deadline(s): 07/20/2021; 10/20/2021; 02/18/2022; 10/20/2023; 02/20/2024; 03/12/2024 (Expiration)
Contact: Scientific/Research Contact(s); Della White, Ph.D.; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-827-6538; Email: della.white@nih.gov

[NTW] [INTERVENTIONS]
Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)
Sponsor: National Center for Complementary and Integrative Health
Deadline(s): 10/20/2021; 02/18/2022; 10/20/2023; 02/20/2024; 03/12/2024 (Expiration)
Contact: Scientific/Research Contact(s); Lanay Mudd, Ph.D.; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-594-9346; Email: lanay.mudd@nih.gov

[NTW] [INTERVENTIONS]
Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)
Sponsor: National Center for Complementary and Integrative Health
Deadline(s): 10/20/2021; 02/18/2022; 10/20/2023; 02/20/2024; 03/12/2024 (Expiration)
Contact: Scientific/Research Contact(s); Lanay Mudd, Ph.D.; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-594-9346; Email: lanay.mudd@nih.gov

[NTW] [MATERNAL AND CHILD HEALTH]
Announcement of Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellows
Extramural Nexus
How do I request childcare costs in my fellowship application
Sponsor: NIH
Deadline(s): 03/15/2021 (Release Date)
Contact: Please direct all grants policy inquiries to: NIH Office of Policy for Extramural Research Administration; Division of Grants Policy; Email: granteepolicy@nih.gov; For general inquiries about fellowships and career development programs please contact: Division of Biomedical Research Workforce; Office of Extramural Research; Website: https://researchtraining.nih.gov; Email: NIHTrain@mail.nih.gov
Each fellow is eligible to receive $2,500 per budget period for childcare costs. See FAQs for more details. If you have any questions regarding how to make the request in a fellowship application, RPPR, or administrative supplement, please contact your SPA Project Officer. We'll provide you with any updates brought to our attention by [brought to our attention by] Stephanie Scott, Announcement of Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) Supported Individual Fellows; This week NIH announced a new policy to allow for childcare support costs to recipients of NRSA individual fellowships (i.e., F31, F32, etc). These costs must be specifically requested in new, continuation applications or through administrative supplements beginning on or after April 8, 2021. Please read the full announcement at NOT-OD-21-069, the FAQs, and supplementary information below.; Some key takeaways: The policy applies to full-time NIH-NRSA supported individual fellowship applicants and awardees. However, additional information is forthcoming later this year regarding expanding the policy to trainees on institutional training grants, anticipated for FY2022.; Each fellow is eligible to receive $2,500 per budget period for childcare costs. The childcare cost amount is not determined by number of children.; Childcare costs are permitted for dependent children living in the eligible fellow’s home from birth under the age of 13, or children who are disabled and under age 18.; Eligible childcare is care that is licensed and/or regulated by state and/or local authorities. See FAQs for more details.; At a minimum, recipients must obtain and retain documentation verifying that a childcare provider is licensed and/or regulated by state and/or local authorities, and must document that the fellow is eligible to receive the childcare costs and has eligible dependents.; The childcare cost is restricted for that purpose and cannot be rebudgeted without prior written approval from the NIH awarding IC.; If you have any questions regarding how to make the request in the fellowship application, RPPR, or administrative supplement, please contact your SPA Project Officer. The announcement NOT-OD-21-069, and the FAQs, provide instructions on how to make the childcare support request.; We’ll provide further guidance on these new costs at a later date.;

Feed: blog – NIH Extramural Nexus; Posted on: Tuesday, March 2, 2021 11:40 AM; Author: Mike Lauer; Subject: Announcement of Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) Supported Individual Fellows; View article.; Subsequently, NIH posted this blog, with screen shot, to assist applicants with the request for childcare costs. If you have any questions regarding how to make the request in a fellowship application, RPPR, or administrative supplement, please contact your SPA Project Officer. We’ll provide you with any updates.

Notice of Special Interest (NOSI): Using Systems Science Methodologies to Protect and Improve Child and Reproductive Population Health

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; Office of Disease Prevention

Deadline(s): 06/05/2021 (First Available Due Date); 05/08/2024 (Expiration Date)

Contact: Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: Regina M. Bures, Ph.D.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-496-9485; Email: regina.bures@nih.gov

[NTW] [MATERNAL AND CHILD HEALTH]

Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R01 Clinical Trial Required)

Sponsor: NIH, National Institute of Mental Health (NIMH)
Deadline(s): 11/09/2021; 11/10/2021 (Expiration)
Contact: Scientific/Research Contact(s); Eve E. Reider, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-827-1496; Email: ereider@mail.nih.gov

Additional Information: The purpose of this FOA is to encourage research addressing major gaps identified in the United States Preventive Services Task Force (USPSTF) recommendation statement concerning interventions to prevent perinatal depression, with an emphasis on populations experiencing mental health disparities. The research scope for this FOA includes: 1) strategies for identifying women at risk for perinatal depression; 2) developing and testing tools for selecting those most likely to benefit from preventive interventions; 3) testing service-ready efficacious preventive interventions that are of appropriate intensity/dose, and are scalable, such that they can be delivered with fidelity by setting providers; and, 4) testing strategies that can be used to train providers and to support delivery of evidence-based approaches with fidelity across diverse health care and community settings. This FOA is intended to support effectiveness research trials that are statistically powered to provide a definitive answer regarding the effectiveness of the intervention. Support for pilot effectiveness is provided via a companion R34 FOA RFA-MH-21-241 that supports pilot effectiveness studies in preparation for the larger-scale, fully powered studies described in this FOA.

[NTW] [MATERNAL AND CHILD HEALTH]

Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R34 Clinical Trial Required)

Sponsor: NIH, National Institute of Mental Health (NIMH)
Deadline(s): 11/09/2021; 11/10/2021 (Expiration)
Contact: Scientific/Research Contact(s); Eve E. Reider, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-827-1496; Email: ereider@mail.nih.gov

Additional Information: The purpose of this FOA is to encourage research addressing major gaps identified in the United States Preventive Services Task Force (USPSTF) recommendation statement concerning interventions to prevent perinatal depression, with an emphasis on populations experiencing mental health disparities. The research scope for this FOA includes: 1) refining and pilot testing strategies for identifying women at risk for perinatal depression; 2) developing and testing tools for selecting those most likely to benefit from preventive interventions; 3) refining and testing service-ready efficacious preventive interventions that are of appropriate intensity/dose, and are scalable, such that they can be delivered with fidelity by setting providers; and, 4) optimizing and testing strategies that can be used to train providers and to support delivery of evidence-based approaches with fidelity across diverse health care and community settings. This FOA is intended to support pilot effectiveness research trials. Support for larger-scale effectiveness research trials that are statistically powered to provide a definitive answer regarding the effectiveness of the intervention is provided via a companion R01 FOA (RFA-MH-21-240).

[NTW] [MATERNAL AND CHILD HEALTH]

Developmental Mechanisms of Human Structural Birth Defects (P01 Clinical Trial Not
Allowed

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Deadline(s):** 07/29/2021; 07/30/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Reiko Toyama, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Email: toyamar@mail.nih.gov


[NTW] [MATERNAL AND CHILD HEALTH]

**Notice of Special Interest (NOSI): Reproductive Health, Pregnancy, and Parenting among Women with Disabilities**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Deadline(s):** 06/05/2021 (First Available Due Date); 05/31/2024 (Expiration Date)

**Contact:** Scientific/Research Contact(s); *For Preconception and Gynecologic Health Topics*; Rosalind King, Ph.D.; Telephone: 301-435-6986; Email: kingros@mail.nih.gov


[NTW] [MATERNAL AND CHILD HEALTH]

**Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** 02/05/2025; 05/08/2025 (Expiration)

**Contact:** Scientific/Research Contact(s); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Mahua Mukhopadhyay, Ph.D.; Telephone: 301-435-6886; Email: mukhopam@mail.nih.gov


[NTW] [MATERNAL AND CHILD HEALTH]

**Notice of Special Interest (NOSI): Reduction of Sudden Unexpected Infant Death and Sudden Infant Death Syndrome**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Deadline(s):** 06/16/2021 (First Available Due Date); 05/08/2023 (Expiration Date)

**Contact:** Scientific/Research Contact(s); Marion Koso-Thomas M.D, MPH; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6873; Email: kosomari@mail.nih.gov

[NTW] [MATERNAL AND CHILD HEALTH]
Notice of Information: NIMH High-Priority Areas for Research on Women’s Mental Health during the Perinatal Period

Sponsor: National Institute of Mental Health
Deadline(s): 06/23/2021 (Release Date)
Contact: Tamara Lewis Johnson, MPH, MBA; National Institute of Mental Health (NIMH); Telephone: (301) 594-7963; Email: tamara.lewisjohnson@nih.gov

Additional Information: The purpose of this notice is to outline high priority areas of research related to women's mental health during the perinatal period. NIMH is interested in receiving applications that will provide new knowledge in perinatal mental disorders and that will test strategies for translating this knowledge into improved diagnostics, therapies, and services to improve women's mental health during the perinatal period. This Notice of Information applies broadly to most but not all Funding Opportunity Announcements (FOAs) that are aligned with NIMH research priorities.

[NTW] [MATERNAL AND CHILD HEALTH]
Notice of Special Interest (NOSI): High Priority Areas in Placental Research for Healthy Pregnancies

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development
Deadline(s): 10/05/2021 (First Available Due Date); 10/06/2024 (Expiration Date)
Contact: Scientific/Research Contact(s); General scientific inquires (including contacts for areas of particular scientific interest): Areas 1 & 2; John V. Ilekis, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Pregnancy and Perinatology Branch; Telephone: 301-435-6895; Email: ilekisj@nih.gov

[NTW] [SUBSTANCE USE DISORDERS/MATERNAL AND CHILD HEALTH]
Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)

Sponsor: National Institute on Alcohol Abuse and Alcoholism
Deadline(s): 10/19/2021; 02/17/2022; 06/17/2022; 10/18/2022; 02/17/2023; 06/19/2023; 10/17/2023; 10/18/2023 (Expiration)
Contact: Scientific/Research Contact(s); Preclinical Studies and Medical Care; William Dunty, PhD; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-443-7351; Email: duntyw@mail.nih.gov
Link(s): https://grants.nih.gov/grants/guide/pa-files/PAR-21-097.html [*]

[NTW] [SUBSTANCE USE DISORDERS/MATERNAL AND CHILD HEALTH]
Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)

Sponsor: National Institute on Alcohol Abuse and Alcoholism
Deadline(s): 10/19/2021; 02/17/2022; 06/17/2022; 10/18/2022; 02/17/2023; 06/19/2023; 10/17/2023; 10/18/2023

Contact: Scientific/Research Contact(s); Preclinical Studies and Medical Care; William Dunty, PhD
National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-443-7351; Email: duntyw@mail.nih.gov

Link(s): https://grants.nih.gov/grants/guide/pa-files/PAR-21-098.html [*]

[NTW] [SUBSTANCE USE DISORDERS/MATERNAL AND CHILD HEALTH]
Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Project (U01 Clinical Trial optional)
Sponsor: National Institute on Alcohol Abuse and Alcoholism
Deadline(s): 08/16/2021; 08/17/2021 (Expiration)
Contact: Scientific/Research Contact(s); H. Joe Wang, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA);
Telephone: 301-451-0747; Email: joe.wang1@nih.gov

[NTW] [SUBSTANCE USE DISORDERS/MATERNAL AND CHILD HEALTH]
Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Administrative Resource (U24) (Clinical Trial Not Allowed)
Sponsor: National Institute on Alcohol Abuse and Alcoholism
Deadline(s): 08/16/2021; 08/17/2021 (Expiration)
Contact: Scientific/Research Contact(s); H. Joe Wang, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA);
Telephone: 301-451-0747; Email: joe.wang1@nih.gov

[NTW] [SUBSTANCE USE DISORDERS/MATERNAL AND CHILD HEALTH]
Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Diagnostic-Telemedicine Resource (U24 Clinical Trial Not Allowed)
Sponsor: National Institute on Alcohol Abuse and Alcoholism
Deadline(s): 08/16/2021; 08/17/2021 (Expiration)
Contact: Scientific/Research Contact(s); H. Joe Wang, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA);
Telephone: 301-451-0747; Email: joe.wang1@nih.gov

[NTW] [SUBSTANCE USE DISORDERS/MATERNAL AND CHILD HEALTH]
Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Data Coordination Resource (U24 Clinical Trial Not Allowed)
Sponsor: National Institute on Alcohol Abuse and Alcoholism
Deadline(s): 08/16/2021; 08/17/2021 (Expiration)
[NTW] [SUBSTANCE USE DISORDERS/MATERNAL AND CHILD HEALTH]
Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CiFASD), Developmental Project (UH2 Clinical Trial Optional)
Sponsor: National Institute on Alcohol Abuse and Alcoholism
Deadline(s): 08/16/2021; 08/17/2021 (Expiration)
Contact: Scientific/Research Contact(s); H. Joe Wang, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-451-0747; Email: joe.wang1@nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional)
Sponsor: National Institute on Drug Abuse
Deadline(s): 08/13/2021; 08/14/2021 (Expiration)
Contact: Scientific/Research Contact(s); Leonardo Angelone, PhD; National Institute on Drug Abuse (NIDA); Telephone: 301-827-5946; Email: leonardo.angelone@nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Partnership between Research Centers in Minority Institutions (RCMI) and Alcohol Research Centers (U54 Clinical Trial Optional)
Sponsor: National Institute on Alcohol Abuse and Alcoholism
Deadline(s): 12/15/2021 (First Estimated Application Due Date)
Contact: Abraham P. Bautista, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); bautista@mail.nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research
Sponsor: National Institute on Drug Abuse
Deadline(s): 10/05/2021 (First Available Due Date); 09/08/2024 (Expiration Date)
Contact: Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements; Steve Gust, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-402-1118; Email: sgust@nida.nih.gov


[NTW] [SUBSTANCE USE DISORDERS]

HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)

Sponsor: National Institute on Drug Abuse; National Center for Complementary and Integrative Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases

Deadline(s): 10/19/2021; 10/20/2021 (Expiration)

Contact: Sam Ananthan, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-435-2199; Email: sam.ananthan@nih.gov


[NTW] [SUBSTANCE USE DISORDERS]

HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 - Clinical Trial Not Allowed) (RFA-DA-22-031)

Sponsor: National Institutes of Health (NIH); Components of Participating Organizations: National Institute on Drug Abuse (NIDA); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Complementary and Integrative Health (NCCIH)

Deadline(s): 10/19/2021; 10/20/2021 (Expiration)

Contact: Scientific/Research Contact(s); Sam Ananthan, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-435-2199; Email: sam.ananthan@nih.gov


[NTW] [SUBSTANCE USE DISORDERS]

HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional) (RFA-DA-19-019)

Sponsor: National Institutes of Health (NIH); Components of Participating Organizations: National Institute on Drug Abuse (NIDA); National Center for Advancing Translational Sciences (NCATS)

Deadline(s): 09/08/2021; 09/09/2021 (Expiration)

Contact: Scientific/Research Contact(s); Elena Koustova, PhD, MBA; National Institute on Drug Abuse (NIDA); Telephone:301-496-8768; Email: NIDASBIR@mail.nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
Notice of Intent to Publish a Funding Opportunity Announcement for the NIH HEAL Initiative: Preventing Opioid Misuse and other Drug Use by Intervening on Social Determinants (R01 Clinical Trials Optional)

Sponsor: National Institute on Drug Abuse; Office of Behavioral and Social Sciences Research
Deadline(s): 01/07/2022 (First Estimated Application Due Date)
Contact: Aria Davis Crump, Sc.D.; National Institute on Drug Abuse; 301-435-0881; aria.crump@nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional)

Sponsor: National Institute of Neurological Disorders and Stroke
Deadline(s): 11/01/2021 (First Estimated Application Due Date)
Contact: Eric Hudak, PhD; National Institute of Neurological Disorders and Stroke; 301-496-1779; NINDS-Devices@nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional)

Sponsor: National Institute on Alcohol Abuse and Alcoholism
Deadline(s): 10/16/2021; 02/16/2022; 02/16/2024; 06/16/2024; 09/08/2024 (Expiration)
Contact: Scientific/Research Contact(s); Elizabeth Powell, PhD; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-443-0786; Email: elizabeth.powell3@nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
Request for Information (RFI): Inviting Input on NIAAAs 2022-2026 Strategic Plan Outline

Sponsor: National Institute on Alcohol Abuse and Alcoholism
Deadline(s): 07/30/2021 (Response Date)
Contact: Please direct all inquiries to: NIAAA Strategic Planning Team; National Institute on Alcohol Abuse and Alcoholism; Email: NIAASciencePolicyBranch@nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
HEAL Initiative: Planning Studies for Initial Analgesic Development [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed)
Sponsor: National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; National Institute of Mental Health

Deadline(s): 07/19/2021; 10/13/2021; 06/09/2022; 10/11/2022; 06/09/2023; 10/10/2023; 10/11/2023 (Expiration)

Contact: Scientific/Research Contact(s); Michael L. Oshinsky, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-9964; Email: michael.oshinsky@nih.gov


[NTW] [SUBSTANCE USE DISORDERS]

NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)

Sponsor: National Institute on Drug Abuse

Deadline(s): 07/26/2021; 03/02/2022; 07/26/2022; 03/02/2023; 07/26/2023; 03/04/2024; 03/05/2024 (Expiration)

Contact: Scientific/Research Contact(s); Amy C. Lossie, PhD; National Institute on Drug Abuse (NIDA); Telephone: 301-827-6092; Email: lossieac@mail.nih.gov

Link(s): https://grants.nih.gov/grants/guide/pa-files/PAR-21-244.html

[NTW] [PEDIATRICS]

Recompetition of the Pediatric Scientist Development Program (PSDP) (K12 Clinical Trial Not Allowed)

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Deadline(s): 07/29/2021; 07/30/2021 (Expiration)

Contact: Scientific/Research Contact(s); Karen K. Winer, MDEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6877; Email: winerk@mail.nih.gov


[NTW] [PEDIATRICS]

Pediatric Immune System Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed)

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Deadline(s): 10/05/2021; 02/05/2022; 10/05/2022; 02/05/2023; 10/05/2023; 02/05/2024; 05/08/2024 (Expiration)

Contact: Scientific/Research Contact(s); Sai Majji, PhD; Maternal and Pediatric Infectious Disease Branch; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-661-9816; Email: sai.majji@nih.gov


[NTW] [BRAIN INITIATIVE]

BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)
**Sponsor**: National Institute of Mental Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Neurological Disorders and Stroke

**Deadline(s)**: 10/15/2021; 06/10/2022; 10/14/2022; 06/09/2023; 10/13/2023; 06/07/2024; 06/08/2024 (Expiration)

**Contact**: Scientific/Research Contact(s): Ming Zhan, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-827-3678; Email: ming.zhan@nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-135.html

---

**[NTW] [BRAIN INITIATIVE]**

**BRAIN Initiative: Pilot resources for brain cell type-specific access and manipulation across vertebrate species (U01 Clinical Trial Not Allowed)**

**Sponsor**: NIH

**Deadline(s)**: 10/19/2021; 10/20/2021

**Contact**: Scientific/Research Contact(s): Douglas S. Kim, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-827-6463; Email: douglas.kim@nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-556.html

---

**[NTW] [BRAIN INITIATIVE]**

**BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)**

**Sponsor**: NIH

**Deadline(s)**: 10/29/2021; 05/02/2022; 10/28/2022; 05/01/2023; 10/27/2023; 10/28/2023 (Expiration)

**Contact**: Scientific/Research Contact(s): Martha Flanders, Ph.D; National Eye Institute (NEI); Telephone: 301-451-2020; Email: BRAIN-FOAs@nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide/rfa-files/RFA-EY-21-001.html

---

**[NTW] [BRAIN INITIATIVE]**

**BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)**

**Sponsor**: National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; Office of Behavioral and Social Sciences Research

**Deadline(s)**: 10/29/2021; 05/02/2022; 10/28/2022; 05/01/2023; 10/27/2023; 10/28/2023 (Expiration)

**Contact**: Scientific/Research Contact(s): Edmund (Ned) Talley, PhD; Sahana N. Kukke, PhD

National Institutes of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1917, 301-496-1447; Email: BRAIN-FOAs@nih.gov
[NTW] [BRAIN INITIATIVE]
BRAIN Initiative: Optimization of Transformative Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed)

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; Office of Behavioral and Social Sciences Research

**Deadline(s):** 10/29/2021; 05/02/2022; 05/01/2023; 10/28/2022; 10/28/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Edmund (Ned) Talley, PhD; Sahana N. Kukke, PhD
National Institutes of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1917, 301-496-1447; Email: BRAIN-FOAs@nih.gov


[NTW] [BRAIN INITIATIVE]
BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Neurological Disorders and Stroke

**Deadline(s):** 10/13/2021; 10/11/2022; 10/11/2023; 10/12/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); James Churchill, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-3621; Email: james.churchill@nih.gov


[NTW] [BRAIN INITIATIVE/K-AWARDS]
BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health (NIH); Components of Participating Organizations; National Institute of Neurological Disorders and Stroke (NINDS); National Eye Institute (NEI); National Institute on Aging (NIA); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Biomedical Imaging and Bioengineering (NIBIB); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Deafness and Other Communication Disorders (NIDCD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH); National Center for Complementary and Integrative Health (NCCIH)

**Deadline(s):** 10/06/2021; 02/10/2022; 06/08/2022; 10/11/2022
**Contact**: Scientific/Research Contact(s); For project relevance or scientific questions: Edmund (Ned) Talley, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1917; Email: BRAINDIVERSITYK99R00@nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-043.html [*]

---

**[NTW] [BRAIN]**

**BRAIN Initiative: Targeted BRAIN Circuits Planning Projects - TargetedBCPP (R34 Clinical Trial Not Allowed)**

**Sponsor**: NIH

**Deadline(s)**: 11/10/2021; 11/11/2021 (Expiration)

**Contact**: Scientific/Research Contact(s); Karen K David, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-9964; Email: BRAINCircuits@NIH.GOV

**Link(s)**: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-014.html

---

**[NTW] [BRAIN]**

**NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00 Clinical Trial Not Allowed)**

**Sponsor**: National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; Office of Behavioral and Social Sciences Research

**Deadline(s)**: 12/15/2021; 04/15/2022; 12/15/2022; 04/14/2023; 12/15/2023; 12/16/2023 (Expiration)

**Contact**: Scientific/Research Contact(s); Michelle Jones-London, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-451-7966; Email: jonesmiche@ninds.nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-012.html

---

**[NTW] [BRAIN]**

**Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE) (U24 Clinical Trial Not Allowed)**

**Sponsor**: National Institute of Mental Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Neurological Disorders and Stroke
**Deadline(s):** 11/09/2021 (First Estimated Due Date)

**Contact:** Please direct all inquiries to: Yong Yao, Ph.D.; National Institute of Mental Health (NIMH); 301-443-6102; yyao@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-21-262.html

---

**[NTW] [BRAIN]**

**BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)**

**Sponsor:** National Institute of Mental Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Neurological Disorders and Stroke; Office of Behavioral and Social Sciences Research

**Deadline(s):** 10/08/2021; 10/07/2022; 10/06/2023; 10/07/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Douglas S. Kim, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-827-6463; Email: douglas.kim@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-175.html

---

**[NTW] [ADHD]**

**Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required)**

**Sponsor:** National Institute of Mental Health

**Deadline(s):** 03/01/2022; 03/02/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Mary Rooney, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-827-1325; Email: mary.rooney@nih.gov


---

**[NTW] [ALZHEIMER'S DISEASE]**

**Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Alzheimer's Disease and Related Dementias (R25 - Clinical Trial Not Allowed)**

**Sponsor:** National Institute on Aging

**Deadline(s):** 10/04/2021; 10/05/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Georageanne E. Patmios; National Institute on Aging (NIA); Phone: 301-402-8788; Email: patmiosg@nia.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-010.html

---

**[NTW] [ALZHEIMER'S DISEASE]**

**Role of Adaptive Immunity in Etiology of Alzheimers Disease and Alzheimers Disease-
Related Dementias (R01 Clinical Trial Optional)

**Sponsor:** National Institute on Aging; National Institute of Neurological Disorders and Stroke  
**Deadline(s):** 10/28/2021; 10/29/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s): Miroslaw ‘Mack’ Mackiewicz, Ph.D.; Division of Neuroscience; National Institute on Aging (NIA); Telephone: 301-594-7636; Email: miroslaw.mackiewicz@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-017.html

[NTW] [ALZHEIMER’S DISEASE]

Alzheimer’s Disease Research Center (ADRC) Research Education Scholar beginning in Fall 2021

**Sponsor:** www.neurology.columbia.edu  
**Deadline(s):** 08/01/2021  
**Contact:** Please direct all questions to Allison Heaps at ah3788@cumc.columbia.edu  
**Link(s):** https://www.neurology.columbia.edu/research/research-programs-and-partners/alzheimers-disease-research-center-adrc/investigators/our-cores/research-education-core-rec

**Additional Information:** On behalf of the Alzheimer’s Disease Research Center. Please direct all questions to Allison Heaps at ah3788@cumc.columbia.edu. Details about this program are below. Please forward to anyone you think might be interested;  
**ELIGIBILITY REQUIREMENTS** – postdoctoral or junior faculty level whose goals are to become leaders in the field of ADRD;  
**BUDGET:** $12,000 in direct costs will be awarded each year, up to 3 years;  
**APPLICATION DEADLINE:** August 1, 2021;  
**PROJECT START DATE:** September 1, 2021;  
**SUBMIT PROPOSALS VIA EMAIL ONLY** in Word format using this form;  
**Taub Institute for Research on Alzheimer’s Disease and the Aging Brain; RESEARCH EDUCATION SCHOLAR; in THE ALZHEIMER’S DISEASE RESEARCH CENTER:** The Alzheimer’s Disease Research Center (ADRC) has funds to support a Research Education Scholar beginning in Fall 2021.  
**The Research Education Component (REC) of the ADRC supports the development of future research leaders in the Alzheimer’s disease and related disorders (ADRD) through training and research support.**  
**Training:** Each year, the REC provides 5 scholars with a breadth of training in ADRD through monthly seminars, tailored didactics, and professional development activities. Group didactics, spanning a wide variety of topics in ADRD, are complemented by individual training plans to fill gaps in specific skills or knowledge areas unique to each scholar.  
**Research Support:** The REC provides $12,000 per year, for up to 3 years, to support a mentored pilot study.  
**ELIGIBILITY REQUIREMENTS** – The REC Program is designed for investigators at the postdoctoral or junior faculty level whose goals are to become leaders in the field of ADRD.  
Priority will be given to applicants: 1) who self-identify as members of underrepresented groups in health-related sciences Populations Underrepresented in the Extramural Scientific Workforce | SWD at NIH; and 2) whose research project is focused specifically on Alzheimer’s disease.  
**PROPOSAL FORMAT** – 1) Attached 3-page application; 2) CV; 3) Letter of support from an identified research mentor;  
**BUDGET:** $12,000 in direct costs will be awarded each year;  
**APPLICATION DEADLINE:** August 1, 2021;  
**PROJECT START DATE:** September 1, 2021;  
**SUBMIT PROPOSALS VIA EMAIL ONLY** in Word format; Allison Heaps, M.S.; Taub Institute for Research on Alzheimer’s Disease and the Aging Brain; ah3788@cumc.columbia.edu;  
**THESE FUNDS ARE AVAILABLE THROUGH NIH GRANT AG066462-01; FOR THE ALZHEIMER’S DISEASE RESEARCH CENTER, SCOTT A. SMALL, MD, PI;** Applications can be found here: https://www.neurology.columbia.edu/research/research-programs-and-partners/alzheimers-disease-research-center-adrc/investigators/our-cores/research-education-core-rec;  
**If you experience difficulty accessing the application, please email.** ah3788@cumc.columbia.edu.
**[NTW] [ALZHEIMER’S DISEASE]**

Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias (AD/ADRD) (R01 Clinical Trial Optional)

**Sponsor:** National Institute on Aging

**Deadline(s):** 09/15/2021; 01/26/2022; 01/27/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Luke Stoeckel, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-3136; Email: luke.stoeckel@nih.gov


---

**[NTW] [ALZHEIMER’S DISEASE]**

Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias (AD/ADRD) (R61/R33 Clinical Trial Required)

**Sponsor:** National Institute on Aging

**Deadline(s):** 09/15/2021; 09/16/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Luke Stoeckel, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-3136; Email: luke.stoeckel@nih.gov


---

**[NTW] [ALZHEIMER’S DISEASE]**

Notice of Special Interest (NOSI): Administrative Supplements to Promote Diversity for NINDS Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) Awardees

**Sponsor:** National Institute of Neurological Disorders and Stroke

**Deadline(s):** 11/15/2021

**Contact:** Roderick Corriveau, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS); Email: roderick.corriveau@nih.gov


---

**[NTW] [ALZHEIMER’S DISEASE]**

Primary Care-Based Screening and Intervention Development for Prevention of Abuse in Older and Vulnerable Adults in the Context of Alzheimer's Disease and Related Dementias (R61/R33 Clinical Trial Required)

**Sponsor:** National Institute on Aging

**Deadline(s):** 10/20/2021; 10/21/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Melissa S. Gerald, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-3136; Email: melissa.gerald@nih.gov
[NTW] [FOUNDATION FUNDING/PARKINSON'S DISEASE]
Michael J. Fox Foundation | Promoting Diversity, Equity and Inclusion in Parkinson's Disease Research
Sponsor: https://www.michaeljfox.org
 Deadline(s): 04/21/2021 (Pre-Proposals); 08/05/2021 (Invited Proposals)
Contact: Contact grants@michaeljfox.org with questions about the RFA, application process, or these policies
Link(s): https://www.michaeljfox.org/grant/promoting-diversity-equity-and-inclusion-parkinsons-disease-research
Additional Information: [brought to our attention by the Office of University Corporate and Foundation Relations]; Dimitra Koutsantoni, Director, University Corporate and Foundation Relations; dk2617@columbia.edu with any questions; you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here.

[NTW] [NEUROSCIENCE]
Notice of Intent to Publish a Funding Opportunity Announcement for Joint NINDS and NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
Sponsor: National Institute of Neurological Disorders and Stroke; National Institute of Mental Health
Deadline(s): 06/16/2021 (First Estimated Application Due Date)
Contact: Karrah Benson; National Institute of Neurological Disorders and Stroke (NINDS); 301-496-0838; Karrah.Benson@nih.gov

[NTW] [NEUROSCIENCE]
Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
Sponsor: National Institute of Neurological Disorders and Stroke; National Institute of Mental Health
Deadline(s): 10/16/2021; 10/16/2023; 02/16/2024; 05/08/2024 (Expiration)
Contact: Scientific/Research Contact(s); Karrah Benson; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-0838; Email: Karrah.benson@nih.gov

[NTW] [NEUROLOGY]
Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)
Sponsor: National Institute of Neurological Disorders and Stroke
Deadline(s): 10/20/2021; 10/18/2023; 02/20/2024; 02/21/2024 (Expiration)
Contact: Scientific/Research Contact(s); Nick Langhals, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1779; Email: NINDS-Devices@nih.gov
Translational Neural Devices (U44 Clinical Trial Optional)

**Sponsor:** National Institute of Neurological Disorders and Stroke

**Deadline(s):** 10/20/2021; 02/18/2022; 06/20/2022; 10/18/2022; 02/21/2023; 06/19/2023; 10/18/2023; 02/20/2024; 02/21/2024 (Expiration)

**Contact:** Scientific/Research Contact(s); Eric Hudak, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS);
Telephone: 301-496-1779; Email: NINDS-Devices@nih.gov


Solicitation of Nominations for the 2022 National Institute of Neurological Disorders and Stroke (NINDS) Landis Award for Outstanding Mentorship

**Details**

**Sponsor:** National Institute of Neurological Disorders and Stroke

**Deadline(s):** 12/15/2021

**Contact:** Please direct all inquiries to: Stephen Korn, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS);
Telephone: 301-496-4188; Email: korns@ninds.nih.gov


Notice of Special Interest: Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders

**Sponsor:** National Institute of Neurological Disorders and Stroke; Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Deadline(s):** 10/05/2021 (First Available Due Date); 07/17/2024 (Expiration Date)

**Contact:** Scientific/Research Contact(s); Adam L. Hartman, MD; National Institute of Neurological Disorders and Stroke;
Telephone: 301-496-9135; Email: adam.hartman@nih.gov


Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences

**Deadline(s):** 10/16/2021; 02/16/2022; 02/16/2024; 03/17/2024 (Expiration)

**Contact:** Lisa Gilotty, Ph.D.; National Institute of Mental Health (NIMH); Phone: 301-443-3825; E-mail: gilottyl@mail.nih.gov

[NTW] [AUTISM]
Research on Autism Spectrum Disorders (R21 Clinical Trial Optional)
**Sponsor:** National Institute of Mental Health; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences; National Institute of Neurological Disorders and Stroke
**Deadline(s):** 10/16/2021; 02/16/2024; 03/17/2024 (Expiration)
**Contact:** Lisa Gilotty, Ph.D.; National Institute of Mental Health (NIMH); Phone: 301-443-3825; E-mail: gilottyl@mail.nih.gov

[NTW] [AUTISM]
Research on Autism Spectrum Disorders (R01 Clinical Trial Optional)
**Sponsor:** National Institute of Mental Health; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences; National Institute of Neurological Disorders and Stroke
**Deadline(s):** 10/05/2021; 02/05/2024; 03/06/2024 (Expiration)
**Contact:** Lisa Gilotty, Ph.D.; National Institute of Mental Health (NIMH); Phone: 301-443-3825; E-mail: gilottyl@mail.nih.gov

[NTW] [AGING]
Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Aging (R25 - Clinical Trial Not Allowed)
**Sponsor:** National Institute on Aging
**Deadline(s):** 10/04/2021; 10/05/2021 (Expiration)
**Contact:** Scientific/Research Contact(s); Georgeanne E. Patmios; National Institute on Aging (NIA); Phone: 301-402-8788; Email: patmiosg@nia.nih.gov

[NTW] [AGING]
Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition
**Sponsor:** *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; Office of Behavioral and Social Sciences Research
**Deadline(s):** 06/05/2021 (First Available Due Date); 01/08/2024 (Expiration Date)
**Contact:** Scientific/Research Contact(s); Sonia Lee, PhD; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD); Telephone: 301-594-4783; Email: leesonia@mail.nih.gov
Additional Information: The purpose of this Notice of Special Interest (NOSI) is to encourage applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged. The ultimate goal is to improve care quality and patient and family outcomes during and after HCT.

[NTW] [AGING]
High Resolution Mapping of Biomolecules in Brain Cells in Aging and Alzheimers Disease (R01 Clinical Trial Not Allowed)
Sponsor: National Institute on Aging
Deadline(s): 10/28/2021; 10/29/2021 (Expiration)
Contact: Scientific/Research Contact(s): J. Austin Yang, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-9350; Fax: 301-496-1494; Email: austin.yang@nih.gov

[NTW] [AGING]
Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)
Sponsor: John E. Fogarty International Center; National Center for Complementary and Integrative Health; National Institute on Alcohol Abuse and Alcoholism; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; Office of Disease Prevention; Office of Research on Women's Health
Deadline(s): 08/13/2021; 07/13/2022; 07/13/2023; 07/14/2023
Contact: Scientific/Research Contact(s): Kathleen Michels, Ph.D.; Fogarty International Center (FIC); Telephone: 301-496-1653; Email: FIC-NCD@mail.nih.gov; Email: michelsk@nih.gov

[NTW] [AGING]
Notice of Participation of the National Institute on Aging (NIA) in PAR-21-230 "Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)"
Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)
Sponsor: National Institute on Aging
Deadline(s): 08/13/2021; 07/13/2022; 07/13/2023; 07/14/2023 (Expiration, PAR-21-230)
Contact: Please direct all inquiries to: Damali Martin, Ph. D., MPH; National Institute on Aging (NIA)
Phone: 301-402-8310; Email: martinda@mail.nih.gov
Additional Information: PAR-21-230 - Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional).

[NTW] [AGING]
Notice of Change to Key Dates and Application Types Allowed for PAR-21-156 The Midlife in the United States Study (U19 Clinical Trial Not Allowed)

**Sponsor:** National Institute on Aging  
**Deadline(s):** 08/16/2021; 02/01/2022 (Updated / New Application Due Dates PAR—21-156) 02/02/2022 (New Expiration Date, PAR-21-156)  
**Contact:** Dana Jeffrey Plude, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-3136; Email: dana.plude@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AG-21-026.html  
**Additional Information:** PAR-21-156 “The Midlife in the United States Study (U19 Clinical Trial Not Allowed).”

[NTW] [AGING]
Notice of Change to Key Dates for PAR-21-157 The Midlife in the United States Study - Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed)

**Sponsor:** National Institute on Aging  
**Deadline(s):** 08/16/2021; 02/01/2022 (Updated / New Application Due Dates PAR—21-157) 02/02/2022 (New Expiration Date, PAR-21-157)  
**Contact:** Dana Jeffrey Plude, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-3136; Email: dana.plude@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AG-21-025.html  
**Additional Information:** PAR-21-157 “The Midlife in the United States Study - Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed).”

[NTW] [NIH ANNOUNCEMENTS]
Rollout of Redesigned eRA Commons Home and Landing Screens in January 2021  
New eRA Commons Login and Landing Screens  
Take a Sneak Peek: Redesigned eRA Commons Home Screen Coming in 2021

**Sponsor:** NIH era commons  
**Deadline(s):** 01/12/2021 (Rollout Date)  
**Contact:** eRA Service Desk; Submit a web ticket: https://grants.nih.gov/support/index.html  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-028.html  
**Additional Information:** eRA Reminder: New eRA Commons Login and Landing Screens Coming January 12; Watch for New Navigation Once Logged In; Please see information below about new eRA Commons login and landing screens coming January 12.; In addition, NIH is phasing in **two-factor authentication (2FA) in order to use the eRA Commons, Commons Mobile, IAR, and ASSIST.** NIH is encouraging all users of eRA Commons, ASSIST, IAR and Commons Mobile to switch to 2FA through
**Notice of Special Interest (NOSI) to add harassment as an area of interest to Research to Understand and Inform Interventions that Promote the Research Careers of Individuals in the Biomedical Sciences**

**Sponsor:** Office of Research on Women’s Health; National Cancer Institute; National Eye Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of General Medical Sciences; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** 10/15/2021 (First Available Due Date); 01/08/2022 (Expiration Date)

**Contact:** Scientific/Research Contact(s); Lynn Morin; Office of Research on Women’s Health; Telephone: 301-451-2730; Email: lynn.morin@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-068.html

**Additional Information:** This Broad Agency Announcement is soliciting proposals that possess the research and development (R&D) expertise necessary for successfully carrying out research toward meeting the program objectives of the Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH.
[NTW] [NIH ANNOUNCEMENTS]
Reminder Regarding Recipient and Applicant Grants Policy Related Inquiries

**Sponsor:** National Institutes of Health

**Deadline(s):** 07/13/2021 (Release Date)

**Contact:** Please direct all inquiries from the AOR to: NIH Office of Policy for Extramural Research Administration (OPERA); Division of Grants Policy; grantspolicy@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-151.html
https://www.ninds.nih.gov/Funding/About-Funding/landis-award-for-outstanding-mentorship

**Additional Information:** The purpose of this notice is to remind the extramural research community of best practices regarding submission of grants policy related inquiries to NIH.

[NTW] [NIH ANNOUNCEMENTS]
Request for Information (RFI): National Institute of Dental and Craniofacial Research (NIDCR) Strategic Plan Fiscal Years 2021-2026

**Sponsor:** National Institute of Dental and Craniofacial Research

**Deadline(s):** 08/27/2021 (Response Date)

**Contact:** NIDCRstrategicPlan@niddcr.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DE-21-007.html

[NTW] [NIH ANNOUNCEMENTS/DIVERSITY]
Updated Guidelines for Enhancing Diversity and Creating Safe Environments in Conferences Supported by NIH Grants and Cooperative Agreements

**Sponsor:** Office of The Director, National Institutes of Health (OD)

**Deadline(s):** 01/22/2021 (Release Date)

**Contact:** Please direct all policy-related inquiries to: Office of Policy for Extramural Research Administration (OPERA); Division of Grants Policy; GrantsPolicy@OD.NIH.GOV

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-053.html

**Additional Information:** This new policy notice, which provides updated guidance on enhancing the diversity of conferences supported by NIH under the R13 and U13 activity codes. Per the notice, “Conference grant applicants (R13/U13) must include plans to enhance diversity during the selection of organizing committees, speakers, other invited participants, such as session chairs and panel discussants, and attendees. Plans to enhance diversity will be assessed during the scientific and technical merit review of the application. Though the proposed plans will not be scored individually, they will be considered in the overall impact score.” Please read the full notice for more details.

[NTW] [DIVERSITY]
Maximizing Access to Research Careers (T34 - Clinical Trial Not Allowed)

**Sponsor:** National Institute of General Medical Sciences

**Deadline(s):** 05/26/2022; 05/26/2023; 05/27/2023 (Expiration)
[NTW] [DIVERSITY]
AIM-AHEAD Coordinating Center: Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity
read the full ROA

**Sponsor:** NIH  
**Deadline(s):** 07/22/2021 (LOI); 08/03/2021 (Invited Applications)  
**Contact:** If you have questions related to the OT award mechanism or other financial-related questions, please contact Financial/Agreements Officer Dede Rutberg at rutbergd@mail.nih.gov; Erin Walker, MBA; Communications Specialist; Office of Data Science Strategy; Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI); Office of the Director, National Institutes of Health; erin.walker@nih.gov  
https://datascience.nih.gov/artificial-intelligence/aim-ahead

**Additional Information:** Dear SRP Community, Passing along this research opportunity announcement for, AIM-AHEAD Coordinating Center: Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity, that might be of interest. Please note there is an informational webinar tomorrow. If you have any questions related to this opportunity, please submit your question using AIM-AHEAD_ROA@od.nih.gov. See the note below for additional information. Kind regards, Michelle [brought to our attention by] Michelle Heacock, Ph.D.; Hazardous Substances Research Branch; Superfund Research Program; National Institute of Environmental Health Sciences; AIM-AHEAD Research Opportunity Announced! Hi all—please see below for an exciting announcement! We appreciate any help spreading the word broadly to colleagues and communities who may be interested; I wanted to let you know that the Research Opportunity Announcement (ROA) titled “AIM-AHEAD Coordinating Center: Artificial Intelligence / Machine Learning Consortium to Advance Health Equity and Researcher Diversity” (OTA-21-017) was published late yesterday. The Coordinating Center will build a consortium comprising four main cores (Leadership/Administration, Data Science Training, Data and Research, Infrastructure), and applicants may address one or more of these cores. We encourage you to read the full ROA and register for tomorrow’s optional informational webinar. Also, please note these important dates: July 15: Informational webinar; July 22: Letters of Intent due; Aug. 3: Proposals due; Sept. 8: Earliest start date; The funding instrument for this ROA is the Other Transactions (OT) Award mechanism. OT awards are not grants, cooperative agreements, or contracts, and use an Other Transactions Authority, provided by law. Policies and terms for individual OT awards may vary between awards. Each award is issued with a specific agreement, which is negotiated with the recipient and details specific terms and conditions for that award. We will discuss the opportunity and this funding mechanism at tomorrow’s webinar. A recording of the webinar will be available on Friday, July 16 on the AIM-AHEAD webpage. If you have any questions about this opportunity, please contact AIM-AHEAD_ROA@od.nih.gov. If you have questions related to the OT award mechanism or other financial-related questions, please contact Financial/Agreements Officer Dede Rutberg at rutbergd@mail.nih.gov; Erin Walker, MBA; Communications Specialist; Office of Data Science Strategy; Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI); Office of the Director, National Institutes of Health; erin.walker@nih.gov; https://datascience.nih.gov

[NTW] [DIVERSITY]
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** Due dates vary by awarding IC. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts


[NTW] [DIVERSITY]

**NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25 - Independent Clinical Trial Not Allowed)**

**Sponsor:** National Institute on Aging

**Deadline(s):** 05/25/2022; 05/25/2023; 05/26/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); NIA Training Office; National Institute on Aging (NIA); Email: NIAtraining@nih.gov


[NTW] [DIVERSITY]

**Notice of Special Interest (NOSI): Understanding and Addressing the Impact of Structural Racism and Discrimination on Biomedical Career Progression and the Biomedical Research Enterprise**

**Sponsor:** National Institute of General Medical Sciences

**Deadline(s):** 05/17/2021 (First Available Due Date); 10/04/2022 (Expiration Date)

**Contact:** Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.


[NTW] [DIVERSITY]

**Notice of Intent to Publish a Funding Opportunity Announcement for New Investigators to Promote Workforce Diversity in Genomics and other Health-Related Research (R01 Clinical Trial Optional)**
[NTW] [DIVERSITY]
Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)

**Sponsor:** National Human Genome Research Institute  
**Deadline(s):** 08/03/2021 (First Estimated Application Due Date)  
**Contact:** Jyoti Dayal, M.S.; 301-480-2307; jyotig@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HG-21-024.html

Additional Information: NIH webinar will answer questions on new minority health and discrimination study FOA; NIH National Institutes of health; Office of Research on Women's Health; NIMHD to Host Webinar on Funding Opportunity to Study Impact of Racism and Discrimination on Minority Health; On May 26, 2021, the National Institute on Minority Health and Health Disparities (NIMHD) will host a pre-application technical assistance webinar relating to RFA-MD-21-004, Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities. During the webinar, NIH program and review staff will provide an overview of the RFA—including objectives, application instructions, and review criteria—and will be available to answer questions. Participants are encouraged to submit questions in advance to Jennifer Alvidrez jennifer.alvidrez@nih.gov. The initiative will support observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, as well as intervention research that addresses SRD to improve minority health or reduce health disparities.

[NTW] [DIVERSITY]
Notice of Intent to Publish a Research Opportunity Announcement for AIM-AHEAD: Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity

**Sponsor:** National Institutes of Health  
**Deadline(s):** 07/07/2021 (Release Date)  
**Contact:** Please direct all inquiries to: AIM-AHEAD_ROA@od.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-156.html

[NTW] [DIVERSITY]
Network of the National Library of Medicine All of Us Program Center (U24) (Clinical Trial Optional)

**Sponsor:** National Library of Medicine  
**Deadline(s):** 09/17/2021; 09/18/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s): Alan VanBiervliet, MA, PhD; National Library of Medicine (NLM); Telephone: 301-594-4882; Email: alan.vanbiervliet@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/RFA-LM-21-002.html
[NTW] [DIVERSITY]

NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Optional)

**Sponsor**: Office of Strategic Coordination (Common Fund)
**Deadline(s)**: 09/24/2021; 09/25/2021 (Expiration)
**Contact**: Scientific/Research Contact(s); Sanya A. Springfield, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-6170; Email: FIRST NIH@nih.gov
**Link(s)**: https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-025.html

[NTW] [HEALTH DISPARITIES]

Notice of Intent to Publish a Funding Opportunity Announcement for Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional)

**Sponsor**: National Institute on Minority Health and Health Disparities; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; Office of Behavioral and Social Sciences Research
**Deadline(s)**: 08/20/2021 (First Estimated Application Due Date)
**Contact**: Jennifer Alvidrez, PhD; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-594-9567; Email: jennifer.alvidrez@nih.gov
**Link(s)**: https://grants.nih.gov/grants/guide/notice-files/NOT-MD-21-016.html

[NTW] [HEALTH DISPARITIES]

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)

**Sponsor**: National Institute on Minority Health and Health Disparities; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National
Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; Office of Behavioral and Social Sciences Research; Office of the Director, NIH; Office of Disease Prevention; Office of Research on Women's Health

**Deadline(s):** 08/24/2021; 08/25/2021

**Contact:** Scientific/Research Contact(s): Jennifer Alvidrez, PhD; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-594-9567; Email: jennifer.alvidrez@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-21-004.html

**[NTW] [HEALTH DISPARITIES] Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)**

**Sponsor:** https://www.nimhd.nih.gov/

**Deadline(s):** 08/24/2021; 08/25/2021 (Expiration)

**Contact:** Participants are encouraged to submit questions in advance to Jennifer Alvidrez jennifer.alvidrez@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-21-004.html

**Additional Information:** NIH webinar will answer questions on new minority health and discrimination study FOA; NIH National Institutes of health; Office of Research on Women’s Health; NIMHD to Host Webinar on Funding Opportunity to Study Impact of Racism and Discrimination on Minority Health; On May 26, 2021, the National Institute on Minority Health and Health Disparities (NIMHD) will host a pre-application technical assistance webinar relating to RFA-MD-21-004, Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities. During the webinar, NIH program and review staff will provide an overview of the RFA—including objectives, application instructions, and review criteria—and will be available to answer questions. Participants are encouraged to submit questions in advance to Jennifer Alvidrez jennifer.alvidrez@nih.gov. The initiative will support observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, as well as intervention research that addresses SRD to improve minority health or reduce health disparities.

**[NTW] [HEALTH DISPARITIES] Addressing Social Determinants of Health to Eliminate Oral Health Disparities (UG3/UH3 Clinical Trials Optional)**

**Sponsor:** National Institute of Dental and Craniofacial Research; Office of Behavioral and Social Sciences Research; Office of Disease Prevention; Office of Research on Women’s Health

**Deadline(s):** 07/08/2021; 07/21/2021 (Expiration)

**Contact:** Hiroko Iida, DDS, MPH; National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-594-7404; Email: hiroko.iida@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-22-002.html

**[NTW] [HEALTH DISPARITIES] Special Emphasis Notice (SEN): AHRQ Announces Interest in Health Services Research to Advance Health Equity**

**Sponsor:** Agency for Healthcare Research and Quality

**Deadline(s):** 08/29/2021 (Release Date)
[NTW] [CTSA CENTER FOR LEADING INNOVATION AND COLLABORATION]

The Center for Leading Innovation & Collaboration across all CTSA hubs

Sponsor: Irving Institute; https://www.irvinginstitute.columbia.edu/
Deadline(s): NA
Contact: https://clic-ctsa.org/contact
Link(s): https://clic-ctsa.org/

Additional Information: CLIC has a new website; The Center for Leading Innovation & Collaboration across all CTSA hubs has a new platform for sharing and collaborating; CLIC has also collected stories from 60+ CTSA Program hubs (including the Irving Institute) as they brought testing, treatment and prevention to people during the COVID-19 pandemic. The stories will be featured on a new CLIC webpage. Watch the trailer HERE.

[NTW] [R2 ANNOUNCEMENTS]

We are also segueing over to CU / Uni PW login protected file storage and access (Newsletters and files linked within), e.g. the R2eport 07/09/2021 [Sharepoint file requiring CU/Uni login]

Please let us (R2/ckk7) know if anyone is submitting a training grant (of any sort, T32, R25, D43, etc) between now and June 2021

Research resources is pleased to coordinate grant type specific grant writing groups, pending faculty / researcher interest. Please let us know (via email to prf1@cumc.columbia.edu and or ckk7@cumc.columbia.edu) if you are interested in such groups, along with the type of grant and proposed due date(s). We are planning to coordinate a writing group for this fall's NIH deadlines. Please join us.

[NTW] [RIGOR AND REPRODUCIBILITY]

NIH Rigor and Reproducibility Webinar; 01/08/2021; Archival
NIH Rigor and Reproducibility Slides; 01/08/2021; Archival

Sponsor: Office for Research | Vagelos College of Physicians and Surgeons (columbia.edu); https://www.ps.columbia.edu/research/office-research
Deadline(s): 01/08/2021 (Event Date, Archival Posting)
Contact: For more information, please email ps-officeforresearch@cumc.columbia.edu.
Link(s): https://columbia.hosted.panopto.com/Panopto/Pages/Viewer.aspx?id=ce8bf5b7-3fc8-425f-ab91-aaca0140d2f1 [Webinar, accessible via CU UNI pw login]
https://research.columbia.edu/system/files/RCT%20content/ReaDI%20Program/20200106_RR_Share.pdf [Slides]
[NTW] [RIGOR AND REPRODUCIBILITY]
Notice of Intent to Publish a Funding Opportunity Announcement for Creating an Educational Nexus for Training in Experimental Rigor (CENTER) (UC2 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Neurological Disorders and Stroke
**Deadline(s):** 10/21/2021 (First Estimated Application Due Date)
**Contact:** Shai Silberberg; National Institute of Neurological Disorders and Stroke (NINDS); 301-496-1917; SilberbS@ninds.nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-074.html

**Additional Information:** The purpose of this Notice is to alert the community that the National Institute of Neurological Disorders and Stroke (NINDS) plans to publish a Funding Opportunity Announcement (FOA) to solicit applications for Creating an Educational Nexus for Training in Experimental Rigor (CENTER), which will build, evaluate, and disseminate a user-friendly, harmonized, and openly accessible educational resource to promote awareness, understanding, and utilization of the principles of rigorous biomedical research.

[NTW] [RIGOR AND REPRODUCIBILITY]
Notice of Intent to Publish a Funding Opportunity Announcement for Materials to Enhance Training in Experimental Rigor (METER) (UE5 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Neurological Disorders and Stroke
**Deadline(s):** 10/21/2021 (First Estimated Application Due Date)
**Contact:** Shai Silberberg; National Institute of Neurological Disorders and Stroke (NINDS); 301-496-1917; SilberbS@ninds.nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-075.html

[NTW] [COVID-19]


**Sponsor:** https://covid19.columbia.edu
**Deadline(s):** beginning 12/23/2020
**Contact:** covid19.columbia.edu
**Link(s):** https://covid19.columbia.edu/content/columbia-university-test-and-trace-program-spring-2021-plan
https://secure.health.columbia.edu

**Additional Information:** Dear Fellow Members of the Columbia Community. As we approach 2021, I write to update you about an important requirement for Spring Term 2021 SARS-CoV-2 Gateway testing. Effective January 4, 2021, a NEW gateway test is required for all faculty, staff, and students accessing Columbia campuses and other facilities. This includes individuals who have been on a campus throughout 2020 and who previously complied with the requirements of the gateway testing program. This gateway test must be administered by Columbia University’s COVID Testing Program starting January 4, 2021 through January 25, 2021. Due to our stringent quality and data management systems, the only acceptable tests will be conducted by Columbia’s COVID Testing Program at one of our five approved testing sites (Monday to Friday in Morningside Lerner Hall & CUIMC Black Building Schaeffer Gallery; Select dates at West 51st St., Lamont Doherty Earth Observatory, or Tarrytown Columbia Doctors). Tests submitted from other locations, including NYP or WHS, will not be accepted. Access to all
Columbia campuses and facilities via the ReOpenCU app (symptom checker app) and Columbia University ID card swipe system will only be permitted for those faculty, staff, and students who have completed the repeat gateway test requirement by January 25, 2021. Register for this gateway test online beginning December 23rd, 2020. The schedule opens 10-14 days in advance. During the gateway period, there will be more than sufficient schedule capacity in the Morningside and CUIMC locations to accommodate all those requiring testing; however, schedule availability in each site will depend on the demand for specific appointment dates and time slots. We encourage you to plan ahead, schedule in advance, and consider all testing sites if a particular date and time is preferred. For those who do not complete a new SARS-CoV-2 PCR test between January 4th and January 25th, access to the campuses and facilities will be reinstated within 48-72 hours of completion of a gateway test at an approved site. More information regarding the testing plan for the Spring Term can be found online. We thank you for your continuing commitment to participating in the University testing program and the steps you take each and every day to keep our community safe. With care for our community, Melanie J Bernitz, MD, MPH; Associate Vice President & Medical Director, Columbia Health; Associate Clinical Professor of Medicine (in the Center for Family and Community Medicine). More Information: covid19.columbia.edu

[NTW] [COVID-19]
Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)

**Sponsor:** National Institute on Aging; National Eye Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; Office of Behavioral and Social Sciences Research; Office of Research on Women’s Health

**Deadline(s):** 11/08/2021; 11/09/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); John W.R. Phillips, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-3136; Email: John.Phillips@nih.gov


[NTW] [COVID-19]
Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 04/01/2021 (First Available Due Date); 03/31/2022 (Expiration Date)

**Contact:** Scientific/Research Contact(s); MeLisa Creamer, PhD, MPH; Division of Epidemiology, Services, and Prevention Research; National Institute on Drug Abuse (NIDA); Telephone: 301-402-1933; Email: melisa.creamer@nih.gov


[NTW] [COVID-19]
**Updated Reporting Requirements for RADx-rad Grant Recipients**

**Sponsor:** National Institutes of Health  
**Deadline(s):** 03/26/2021 (Release Date)  
**Contact:** NIH Office of Policy for Extramural Research Administration; Division of Grants Policy; grantspolicy@nih.gov  
**Link(s):** [Notices of Interest to Publish Funding Opportunity Announcements for the RADx-UP Initiative (Phase II)](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-064.html)

**Notice of Intent to Publish Funding opportunity RADx-UP Return to School Diagnostic Testing Approaches**

**Sponsor:** Office of The Director, National Institutes of Health (OD)  
**Deadline(s):** 03/29/2021 (Release Date)  
**Contact:** Please direct all inquiries to: RADx-UPR2Sinfo@nih.gov  
**Link(s):** [Notice of Intent to Publish Funding opportunity RADx-UP Return to School Diagnostic Testing Approaches](https://grants.nih.gov/sites/default/files/RADx-UP-LOI.pdf)
and the letter of interest requirements on Thursday, April 1, 2021 from 11:00 AM to 12:00 PM EST. Questions can be pre-submitted at RADx-UPR2Info@nih.gov by 11:59 local time on Wednesday, March 31, 2021. Register and learn more about this webinar at: https://deloitte.zoom.us/webinar/register/WN_FyFYH5ALTWChie2OWSQZKQ.

**[NTW] [COVID-19/COLUMBIA UNIVERSITY BIOBANK]**

**Columbia University Biobank**

**Sponsor:** https://www.ps.columbia.edu/research/core-and-shared-facilities/core-facilities-category/columbia-university-biobank  
**Deadline(s):** NA  
**Contact:** General questions: Danielle Pendrick, dp2657@cumc.columbia.edu; Researchers can contact - PS-Officeforresearch@cumc.columbia.edu; Participants can contact - CUBiobankCOVID19@cumc.columbia.edu  
**Link(s):** https://www.ps.columbia.edu/research/core-and-shared-facilities/core-facilities-category/columbia-university-biobank  
**Additional Information:** An Update from the Columbia University Biobank (CUB) and COVID-19 research; This message is sent on behalf of the Columbia University Biobank (CUB) from Dr. Muredach Reilly, Director, Irving Institute for Clinical and Translational Research, and Dr. Michael Shelanski, Senior Vice Dean for Research, at the Columbia University Irving Medical Center;  
For questions, contact: General questions: Danielle Pendrick, dp2657@cumc.columbia.edu; Researchers can contact - PS-Officeforresearch@cumc.columbia.edu; Participants can contact - CUBiobankCOVID19@cumc.columbia.edu; As you will remember, the Columbia University Biobank (CUB) quickly pivoted in April 2020 in response to the urgent needs surrounding the coronavirus pandemic. Since then CUB has collected biospecimens from Columbia University Irving Medical Center/NewYork-Presbyterian Hospital (CUIMC/NYP) patients who tested positive for SARS-CoV-2, and re-distributed samples to researchers across campus.  
Currently we have over 90,000 biospecimens banked from more than 14,000 patients (both COVID-19 positive, and negative) including DNA, RNA, serum, plasma, urine, and other tissue samples. Given the number of patients treated for COVID-19 at CUIMC/NYP and the diversity of our patient population, Columbia’s COVID-19 biobank is arguably the largest and most distinct in the United States. Additionally, CUB has consented more than 2,400 patients for genomic research and future research studies to further advance our understanding of COVID-19 and its devastating clinical consequences; Since our last update, whole exome sequencing data has been generated on more than 1,000 patients diagnosed with SARS-CoV-2, and is currently available in AWS for download with the appropriate IRB and CUB approvals. Host and virome RNA sequencing and microbiome data generation is ongoing, and will soon be available to investigators with CUB approval. We are also excited to announce that Dr. David Goldstein has partnered with Vanda Pharmaceuticals to perform whole genome sequencing on 1,000 COVID+ patients. Once generated, this data will also be available to CUIMC researchers for their own analyses; Dr. Krzysztof Kiryluk in the Department of Medicine is spearheading an effort to generate SARS-CoV-2 genome-focused clinical phenotypes, which will then be combined with sequencing data generated by the Institute for Genomic Medicine, into a single dataset that will be available centrally through CUB. We hope that this data will be useful to any Columbia investigator performing genetics and genomics analyses to address SARS-CoV-2-related research. Additionally, the CUB Clinical Phenotype Committee (CPC), led by Dr. Mitchell Elkind, has been established to oversee efforts related to the generation of broader COVID-19 clinical phenotypes. The CPC is a multidisciplinary working group which includes experts from the Departments of Anesthesiology, Surgery, Pediatrics, Emergency Medicine, Biomedical Informatics, Obstetrics and Gynecology, and Medicine (Pulmonary, Cardiology, Nephrology and Transplant). The CPC has focused initial efforts on standardizing, validating, and refining core SARS-CoV-2 related phenotype definitions, which will be made widely available when completed; As of October 2020, over 140 requests to the biobank were reviewed by the CUB Sample and Data Committee, and more than 22,000 samples have been disbursed to support a wide range of research studies across the CUIMC community. With assistance from Drs. Kevin Roth, Eldad Hod, and Susan Whittier in the Department of Pathology and Cell Biology, we are able to continue residual clinical sample collections, which will be critical as the coronavirus continues to spread; While CUB has initially focused on COVID-19 due to obvious needs, it
continues to look past the pandemic and begin University-wide recruitment efforts with multiple partners and across multiple domains towards the ultimate goal of enrolling all CUIMC/NYP patients. To this end, we are excited to be partnering with the IGM’s All of Us team. The Columbia University Biobank is now being offered to All of Us participants during their enrollment and retention activities. CUB looks forward to applying the lessons learned from the All of Us Research Program to the CUB recruitment efforts.

We encourage you to use the research resources offered through the CUB website. As we enter another chapter in the COVID-19 pandemic and again brace ourselves for potential challenges ahead, it is with great thanks that we acknowledge the strength of the Columbia community. Having the Columbia University Biobank now in full operation will significantly benefit the vital research yet to come.

Stay safe,
Muredach Reilly, MBBCh; Director, Irving Institute for Clinical and Translational Research; Michael Shelanski, MD, PhD; Senior Vice Dean for Research; On behalf of the Columbia University Biobank

[NTW] [COVID-19]

FDA Notice of Special Interest (NOSI) to add COVID-19 Capacity Building Grants to PAR-18-604 Vet-LIRN Network Capacity-Building Projects (Vet-LIRN)

Sponsor: Food and Drug Administration
Deadline(s): 04/26/2021 (Release Date)
Contact: Rene Vasquez; Grants Management Specialist; Office of Operations, Office of Finance Budget & Acquisitions; Office of Acquisitions and Grants Services, HFA-500; U.S. Food and Drug Administration; Tel: 301-796-3546; rene.vasquez@fda.hhs.gov

[NTW] [COVID-19]

Notice of Special Interest (NOSI): Research on the Impact of the Covid 19 Pandemic and Risks for Abuse and Injury Among Vulnerable Children and Youth

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development
Deadline(s): 06/05/2021 (First Available Due Date); 05/08/2024 (Expiration Date)
Contact: Scientific/Research Contact(s); Valerie Maholmes, Ph.D., CAS; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-496-1514; Email: maholmev@mail.nih.gov

[NTW] [COVID-19]

Notice of Information: NCATS to Issue an Emergency Competitive Revision Sole Source Award in Support of ACTIV-6

Sponsor: National Center for Advancing Translational Sciences
Deadline(s): NA
Contact: Please direct all inquiries to: Stacia Fleisher, MPP; National Center for Advancing Translational Research (NCATS); Phone: 301-435-0851; Email: stacia.fleisher@nih.gov
[NTW] [ADMINISTRATIVE SUPPLEMENTS]

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

**Sponsor:** National Institutes of Health; John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Office of Behavioral and Social Sciences Research; Office of Research on Women's Health

**Deadline(s):** Due dates may vary by awarding IC. See the awarding IC’s web site or applicable Notice of Special Interest (NOSI) for appropriate Application Due Dates. Applicants may also contact their respective awarding IC; 07/24/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); For any scientific or research-related questions on this administrative supplement notice please contact the Program Officer listed on the NoA of the most recent parent award.

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html

[NTW] [NIH ANNOUNCEMENTS/COVID-19]

Extended Guidance for Applicants Preparing Applications During the COVID-19 Pandemic

**Sponsor:** Office of The Director, National Institutes of Health (OD)

**Deadline(s):** 11/04/2020 (Release Date)

**Contact:** Please direct all inquiries to: Sally A. Amero, Ph.D.; NIH Review Policy Officer; ReviewPolicyOfficer@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-026.html

**Additional Information:** Extended Guidance for Applicants Preparing Applications During the COVID-19 Pandemic; The NIH issued the following notice: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-026.html; Per announcement: “The NIH is committed to supporting the biomedical research enterprise as the nation implements the President's Guidelines for Re-Opening America Again. The purpose of this Notice is to extend the guidance below for applicants preparing applications during the COVID-19 pandemic (NOT-OD-21-122) until further notice.; NIH grant applications should NOT include contingency plans that would outline steps needed to recover from temporary, emergency situations, or institutional return-to-the-workplace plans, resulting from the COVID-19 pandemic.; Contingency plans will not be considered in peer review but, if needed, COVID-19 contingency plans will be requested and carefully considered by NIH staff before funding.; Reviewers will continue to receive instruction to assume that temporary, emergency problems arising from the COVID-19 pandemic will be resolved and complications related to COVID-19 should not affect their scores. Reviewers will be instructed to disregard situations due to the COVID-19 pandemic, e.g., temporary declines in productivity, availability of key personnel, proposed patient populations, animal facility shutdowns, etc.”; Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu/
[NTW] [NIH ANNOUNCEMENTS]
NIH Implementation of the Revised Federal-wide Research Terms and Conditions

**Sponsor:** National Institutes of Health  
**Deadline(s):** 11/17/2020 (Release Date)  
**Contact:** Please direct all inquiries to: Division of Grants Policy; Office of Policy for Extramural Research Administration; grantspolicy@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-029.html

[NTW] [NIH ANNOUNCEMENTS/SINGLE IRB]

**Sponsor:** Agency for Healthcare Research and Quality  
**Deadline(s):** 11/05/2020 (Release Date)  
**Contact:** Please direct all inquiries to: Hope Hongzhu He, JD, MPA, MA; Human Protections Administrator; Agency for Healthcare Research and Quality; Telephone: (301) 427-1905; E-mail: HopeHongzhu.He@ahrq.hhs.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HS-21-002.html  
**Additional Information:** The purpose of this Notice is to provide information to the extramural research community regarding AHRQ's implementation of the Department of Health and Human Services (HHS) Office for Human Research Protections (OHRP)'s determination of Exception to the Single IRB Review Requirements for Certain HHS-Conducted or -Supported Cooperative Research Activities Subject to the 2018 Requirements During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency.

[NTW] [K-AWARDS]
The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)

**Sponsor:** National Cancer Institute  
**Deadline(s):** Standard dates; 03/15/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); Sonia B. Jakowlew, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-5630; Email: jakowles@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-111.html

[NTW] [K-AWARDS]
NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00)

**Sponsor:** National Human Genome Research Institute  
**Deadline(s):** 08/08/2021; 12/08/2021; 04/08/2022; 08/08/2022; 12/08/2022; 04/08/2023; 08/08/2023; 12/08/2023; 04/08/2024; 04/09/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); Tina Gatlin, Ph.D.; National Human Genome Research Institute (NHGRI); Telephone: 301-480-2280; Email: gatlincl@nih.gov
[NTW] [K-AWARDS]
Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institute of Environmental Health Sciences  
**Deadline(s):** Standard dates; 05/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); Carol Shreffler, PhD; National Institute of Environmental Health Sciences (NIEHS); Telephone: 984-287-3322; Email: shreffl1@niehs.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-143.html

[NTW] [K-AWARDS]
Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Required)

**Sponsor:** National Institute of Environmental Health Sciences  
**Deadline(s):** Standard dates; 05/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); Carol Shreffler, PhD; National Institute of Environmental Health Sciences (NIEHS); Telephone: 984-287-3322; Email: shreffl1@niehs.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-170.html

[NTW] [K-AWARDS]
Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Environmental Health Sciences  
**Deadline(s):** Standard dates; 05/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); Carol Shreffler, PhD; National Institute of Environmental Health Sciences (NIEHS); Telephone: 984-287-3322; Email: shreffl1@niehs.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-172.html

[NTW] [K-AWARDS]
The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Cancer Institute  
**Deadline(s):** Standard dates; 03/15/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); Sonia B. Jakowlew, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-5630; Email: jakowles@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-318.html
[NTW] [K-AWARDS]
NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)

**Sponsor:** National Institute of Neurological Disorders and Stroke  
**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); Michelle Jones-London, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-451-7966; Email: jonesmiche@ninds.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-152.html

[NTW] [K-AWARDS]
NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)

**Sponsor:** National Institute of Neurological Disorders and Stroke  
**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); Michelle Jones-London, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-451-7966; Email: jonesmiche@ninds.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-153.html

[NTW] [K-AWARDS]
Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)

**Sponsor:** Participating Organization(s): National Institutes of Health (NIH); Components of Participating Organizations: National Institute of General Medical Sciences (NIGMS); National Institute of Biomedical Imaging and Bioengineering (NIBIB); National Institute of Nursing Research (NINR); National Institute on Minority Health and Health Disparities (NIMHD); National Human Genome Research Institute (NHGRI); National Institute on Aging (NIA); National Library of Medicine (NLM); National Institute of Mental Health (NIMH); National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Heart, Lung and Blood Institute (NHLBI); National Institute of Environmental Health Sciences (NIEHS); National Institute on Deafness and Other Communication Disorders (NIDCD)

**Deadline(s):** Standard dates; 11/15/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Carol Shreffler, PhD; National Institute of Environmental Health Sciences (NIEHS); Telephone: 984-257-3322; Email: shreffl1@niehs.nih.gov  

**Additional Information:** Postdoctoral Career Transitions Award to Promote Diversity (K99/R00); Dear NIEHS T32 Training Directors; NIEHS is reaching out to Principal Investigators who have grants which support diversity trainees at the postdoctoral level (either on T32 training grants or research grants) to make sure they are aware of this Pathways to Independence program specifically designed for them. This is the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00). The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored, postdoctoral research
positions to independent, tenure-track or equivalent faculty positions at research-intensive institutions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity Awards funded by the National Institute of General Medical Sciences. The announcement is at: [https://grants.nih.gov/grants/guide/pa-files/par-19-343.html](https://grants.nih.gov/grants/guide/pa-files/par-19-343.html) - [brought to our attention by] Carol Shreffler, PhD; Program Officer; Exposure, Response, and Technology Branch; Division of Extramural Research and Training; Phone: 984-287-3322; Shreff1@niehs.nih.gov

[NTW] [K-AWARDS]

**NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 No Independent Clinical Trials)**

**Sponsor:** National Institute of Mental Health

**Deadline(s):** Standard dates; 09/08/2024 (Expiration)

**Contact:** Scientific/Research Contact(s); Ashlee Van’t Veer, PhD; National Institute of Mental Health (NIMH); Telephone: 301-443-3107; Email: dnbbstrainingbranch@mail.nih.gov


[NTW] [BIG DATA]

**Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)**

**Sponsor:** National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environmental Health Sciences; National Institutes of Health

**Deadline(s):** 10/08/2021; 08/08/2022; 03/08/2023; 03/09/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Rachel Grana Mayne, PhD; National Cancer Institute (NCI) Telephone: 240-276-5899; Email: granar@nih.gov


[NTW] [BIG DATA]

**Data Enhancements and Analyses to Clarify the Relationship between Education and Cognitive Function (including AD/ADRD) (R01 Clinical Trial Not Allowed)**

**Sponsor:** National Institute on Aging

**Deadline(s):** 10/20/2021; 10/21/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Amelia Karraker, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-3136; Email: Amelia.Karraker@nih.gov

[NTW] [BIG DATA]
Leveraging Existing Large Databases and Cohorts to Better Understand the Risks and Benefits of Long-Term Osteoporosis Therapy and Drug Holiday (R01 Clinical Trial Not Allowed)
**Sponsor:** National Institute on Aging; National Institute of Arthritis and Musculoskeletal and Skin Diseases
**Deadline(s):** 10/28/2021; 10/29/2021 (Expiration)
**Contact:** Scientific/Research Contact(s): Lyndon Joseph, Ph.D.; National Institute on Aging (NIA)
Telephone: 301-496-6761; Fax: 301-402-1784; Email: lyndon.joseph@nih.gov

[NTW] [BIG DATA]
Notice of Modifications to PAR-21-075, "Research Experience in Genomic Research for Data Scientists (R25)"
Research Experience in Genomic Research for Data Scientists (R25)
**Sponsor:** National Human Genome Research Institute
**Deadline(s):** 05/25/2021; 05/25/2022; 05/25/2023; 05/26/2023 (Expiration, PAR-2-075)
**Contact:** Please direct all inquiries to: Shurjo K. Sen, Ph.D.; National Human Genome Research Institute (NHGRI); Phone: 301-827-7028; Email: sensh@mail.nih.gov
**Additional Information:** Related, PAR-21-075 - Research Experience in Genomic Research for Data Scientists (R25)

[NTW] [BIG DATA]
Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed)
**Sponsor:** National Institute of Allergy and Infectious Diseases
**Deadline(s):** 02/17/2022; 07/01/2022; 02/17/2023; 07/06/2023; 07/07/2023 (Expiration)
**Contact:** Scientific/Research Contact(s); Steve Tsang, PhD; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3330; Email: AI-DSFOAinquiries@nih.gov

[NTW] [BIG DATA]
Enhancement or Sustainment of Data Science Tools for Infectious and Immune-mediated diseases (U24 Clinical Trial Not Allowed)
**Sponsor:** National Institute of Allergy and Infectious Diseases
**Deadline(s):** 02/17/2022; 07/01/2022; 02/17/2023; 07/06/2023; 07/07/2023 (Expiration)
**Contact:** Scientific/Research Contact(s); Steve Tsang, PhD; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3330; Email: AI-DSFOAinquiries@nih.gov
[NTW] [BIG DATA]
Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Allergy and Infectious Diseases

**Deadline(s):** 02/17/2022; 07/01/2022; 02/17/2023; 07/06/2023; 07/07/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Steve Tsang, PhD; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3330; Email: AI-DSFOInquiries@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-021.html

[NTW] [BIG DATA]
Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24)

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Mental Health

**Deadline(s):** 08/18/2021 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Abraham P. Bautista, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); bautista@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AA-21-018.html

[NTW] [BIG DATA]
Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating and Data Management Center for Translational and Basic Science Research in Early Lesions (TBEL) (U24 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute

**Deadline(s):** 10/01/2021 (First Estimated Due Date)

**Contact:** Christos Patriotis, Ph.D.; Division of Cancer Prevention National Cancer Institute (NCI); patriotisc@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-061.html

[NTW] [BIG DATA]
Notice of Intent to Publish a Funding Opportunity Announcement for Research Opportunity Announcement for the Data Generation Projects of the NIH Bridge to Artificial Intelligence (Bridge2AI) Program (OT2)

**Sponsor:** Office of Strategic Coordination (Common Fund)
Deadline(s): 08/20/2021 (Estimated First Application Due Date)
Contact: Please direct all inquiries to: Shurjo Sen, Ph.D.; National Human Genome Research Institute (NHGRI); 301 827-7028; bridge2ai@od.nih.gov

[NTW] [BIG DATA]
Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)
Sponsor: National Heart, Lung, and Blood Institute
Deadline(s): 10/05/2021 (First Available Due Date); 05/08/2023 (Expiration Date)
Contact: James Luo, Ph.D.; Division of Cardiovascular Sciences; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-0533
Email: luoja@nih.gov
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-HL-21-017.html

[NTW] [ARTIFICIAL INTELLIGENCE]
Notice of Intent to Publish a Funding Opportunity Announcement for NIH Bridge2AI Integration, Dissemination, and Evaluation (BRIDGE) Center (U54 Clinical Trial Not Allowed)
Sponsor: Office of Strategic Coordination (Common Fund)
Deadline(s): 08/20/2021 (Estimated First Application Due Date)
Contact: Please direct all inquiries to: Shurjo Sen, Ph.D.; National Human Genome Research Institute (NHGRI); 301 827-7028; bridge2ai@od.nih.gov

[NTW] [ARTIFICIAL INTELLIGENCE]
Transformative Artificial Intelligence and Machine Learning Based Strategies to Identify Determinants of Exceptional Health and Life Span (R21/R33 Clinical Trial Not Allowed)
Sponsor: National Institute on Aging
Deadline(s): 10/28/2021; 10/29/2021 (Expiration)
Contact: Nalini Raghavachari, Ph.D.; National Institute on Aging (NIA); Division of Geriatrics and Clinical Gerontology (DGCG); Phone: 301-496-6942; Email: nraghavachari@mail.nih.gov
Additional Information: Transformative Artificial Intelligence and Machine Learning Based Strategies to Identify Determinants of Exceptional Health and Life Span; This Funding Opportunity Announcement (FOA) will use the NIH Phased Innovation Award mechanism (R21/R33) to develop novel transformative artificial intelligence/machine learning (AI/ML) strategies and computer automation to integrate, extract, and interpret multi-omic (i.e., genome, epigenome, transcriptome, proteome, metabolome, microbiome, phenome) data sets from human exceptional longevity (EL) cohorts and multiple non-
human species that display wide variation in life span and decipher the relationships between DNA, RNA, proteins, metabolites, and other cell variables, as well as links to disease risks and exceptionally healthy aging.

[NTW] [CANCER]
New York State Department of Health/Health Research, Inc. Comprehensive Cancer Control Program

**Sponsor:** Health Research, Inc (HRI) and the New York State Department of Health (NYSDOH)

**Deadline(s):** Applications will be accepted starting immediately and will be reviewed and awarded in the order received on a rolling basis until funds are no longer available.

**Contact:** Please click on the link to the Community Project Application below to apply: Community Project Application


**Additional Information:** New York State Department of Health/Health Research, Inc. Comprehensive Cancer Control Program; Health Research, Inc (HRI) and the New York State Department of Health (NYSDOH) Comprehensive Cancer Control Program are soliciting applications from organizations to conduct projects in support of the New York State Comprehensive Cancer Control Plan and the work of the New York State Cancer Consortium (Consortium) action teams. The Consortium is a voluntary network of individuals and organizations that collaborate to address New York’s cancer burden. The Consortium recommends statewide and local interventions to: prevent skin cancer, promote the human papillomavirus (HPV) vaccine, promote programs and services to increase quality of life for cancer survivors, and prevent and promote early detection of colorectal cancer. ; The purpose of this funding opportunity is to support local interventions to address the burden of cancer in communities and across the state.; This funding will support awards, valued at $1,000 each to implement one of the six (6) community interventions listed in the attached solicitation.; Applications will be accepted beginning November 18, 2020, and will be reviewed and awarded in the order received on a rolling basis until funds are no longer available. ; **Eligible applicants:** Nonprofit organizations and municipal organizations located in New York State including, but not limited to: local government and public health agencies, local educational agencies, academic institutions, community-based organizations, faith-based organizations, health care systems, primary care networks, professional associations, public and private schools, and volunteer associations.; **Applications will be accepted starting immediately and will be reviewed and awarded in the order received on a rolling basis until funds are no longer available.** ; Please click on the link to the Community Project Application below to apply: Community Project Application

[NTW] [CANCER]
Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute

**Deadline(s):** 10/01/2021 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Shizuko Sei, M.D.; Division of Cancer Prevention; National Cancer Institute (NCI); 240-276-5005; seis@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-079.html
[NTW] [CANCER]
Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (DRCC) (U24 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 10/01/2021 (First Estimated Application Due Date)  
**Contact:** Please direct all inquiries to: Shizuko Sei, M.D.; Division of Cancer Prevention; National Cancer Institute (NCI); 240-276-5005; seis@nih.gov  

[NTW] [CANCER]
Notice of Intent to Publish a Funding Opportunity Announcement for Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 11/01/2021 (First Estimated Application Due Date)  
**Contact:** Edward Sauter, M.D., Ph.D.; Division of Cancer Prevention; National Cancer Institute (NCI); 240-276-7657; Email: edward.sauter@nih.gov  

[NTW] [CANCER]
Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers

**Sponsor:** National Cancer Institute  
**Deadline(s):** 06/05/2021 (First Available Due Date); 01/08/2024 (Expiration Date)  
**Contact:** Natalie Abrams, PhD; National Cancer Institute (NCI); Telephone: (240) 474-7336; Email: natalie.abrams@nih.gov  

[NTW] [CANCER]
Notice of Special Interest (NOSI): Telehealth in Cancer Care

**Sponsor:** National Cancer Institute  
**Deadline(s):** 06/05/2021 (First Available Due Date); 03/08/2024 (Expiration Date)  
**Contact:** Scientific/Research Contact(s): Gurvaneet Randhawa, M.D., M.P.H.; National Cancer Institute  
Telephone: (240) 276-6940; Email: Gurvaneet.Randhawa@nih.gov  
**Link(s):** [https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-043.html](https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-043.html)

[NTW] [CANCER]
Notice of Special Interest: National Cancer Institute Administrative Supplement
Opportunity for Strategies to Optimize Recruitment and Retention of Cancer Prevention and Symptom Management Clinical Trial Participants

**Sponsor:** National Cancer Institute  
**Deadline(s):** 06/15/2021 (First Available Due Date); 05/16/2023 (Expiration Date)  
**Contact:** Please direct all inquiries to: Ellen Richmond, MS, GNP-BC; Division of Cancer Prevention; National Cancer Institute; Telephone: 240-276-7043; E-mail: richmone@mail.nih.gov  

**[NTW] [CANCER]**  
Notice of Special Interest (NOSI): Expanding Cancer Control Research in Persistent Poverty Areas

**Sponsor:** National Cancer Institute  
**Deadline(s):** 09/24/2021 (First Available Due Date); 05/08/2023 (Expiration Date)  
**Contact:** Scientific/Research Contact(s): Shobha Srinivasan, Ph.D.; Division of Cancer Control and Population Sciences; National Cancer Institute; Telephone: 240-276-6938; Email: sriniva2@mail.nih.gov  

**[NTW] [CANCER]**  
Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U01 Clinical Trial Required)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 07/14/2021; 07/15/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s): Frank M. Perna, Ed.D., Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-6782; Email: pernafm@mail.nih.gov  

**[NTW] [CANCER]**  
Notice of Intent to Publish a Funding Opportunity Announcement for Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01 - Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 11/01/2021 (Estimated First Application Due Date)  
**Contact:** Peter Ujhazy, MD, PhD; Division of Cancer Treatment & Diagnosis; National Cancer Institute (NCI); Telephone: 240-276-5686; Email: pu5s@nih.gov  
[NTW] [CANCER]
Notice of Intent to Publish: Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium Coordinating and Data Management Center (PSRC CDMC) (U24 - Clinical Trial Not Allowed)
Sponsor: National Cancer Institute
Deadline(s): 11/01/2021 (Estimated First Application Due Date)
Contact: Peter Ujhazy, MD, PhD; Division of Cancer Treatment & Diagnosis; National Cancer Institute (NCI); Telephone: 240-276-5686; Email: pu5s@nih.gov

[NTW] [CANCER]
Notice of Special Interest (NOSI): Early-life Factors and Cancer Development Later in Life
Sponsor: National Cancer Institute
Deadline(s): 06/05/2021 (First Available Due Date); 03/08/2024 (Expiration Date)
Contact: Scientific/Research Contact(s); Somdat Mahabir, Ph.D., M.P.H.; National Cancer Institute (NCI); Telephone: (240) 276-6941; Email: mahabir@mail.nih.gov

[NTW] [CANCER]
Notice of Special Interest (NOSI): Integration of Individual Residential Histories in Cancer Research
Sponsor: National Cancer Institute
Deadline(s): 10/05/2021 (First Available Due Date); 03/08/2024 (Expiration Date)
Contact: Scientific/Research Contact(s); Zaria Tatalovich, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-6976; Email: tatalovichzp@mail.nih.gov

[NTW] [CANCER]
Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional)
Sponsor: National Cancer Institute
Deadline(s): 10/06/2021; 10/07/2021 (Expiration)
Contact: Tram Kim Lam, Ph.D, MPH; Division of Cancer Control and Population Sciences (NCI); Telephone: 240-276-6967; Email: lamt@mail.nih.gov
[NTW] [CANCER]
Coordinating Center for the Metabolic Dysregulation and Cancer Risk Program: A Transdisciplinary Approach to Obesity-Associated Cancer Research (U24 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute

**Deadline(s):** 10/06/2021; 10/07/2021 (Expiration)

**Contact:** Tram Kim Lam, PhD, MPH; Division of Cancer Control and Population Sciences (NCI); Telephone: 240-276-6967; Email: lamt@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-022.html

[NTW] [NIH ANNOUNCEMENTS]

NIH Extramural Nexus New Policy for Data Management and Sharing

**Final NIH Policy for Data Management and Sharing**

**Sponsor:** Office of The Director, National Institutes of Health (OD) [Announcement]; https://grants.nih.gov/grants/oer.htm [Extramural Nexus; Office of Extramural Research]

**Deadline(s):** 10/29/2020 (Release Date); 01/25/2023 (Effective Date);

**Contact:** ExtramuralNexus@mail.nih.gov [Extramural Nexus]; Please direct all inquiries to: NIH Office of Science Policy; SciencePolicy@od.nih.gov


**Additional Information:** NIH Extramural Guest Post by Carrie Wolinetz, Ph.D., NIH Associate Director for Science Policy

[NTW] [BIG DATA]

Final NIH Policy for Data Management and Sharing

**Sponsor:** National Institutes of Health

**Deadline(s):** 10/29/2020 (Release Date); 01/25/2023 (Effective Date)

**Contact:** Please direct all inquiries to: NIH Office of Science Policy; SciencePolicy@od.nih.gov


[NTW] [NIH ANNOUNCEMENTS]

Reminder: NIH Policy on Use of Hypertext in NIH Grant Applications

Reminder - No Hyperlinks and URLs in NIH Proposals

**The Do’s & Don’ts of Hyperlinks in Grant Applications**

**NIH formatting instructions**

**Sponsor:** NIH National Institutes of Health; Office of The Director, National Institutes of Health (OD)

**Deadline(s):** NA; 09/16/2020 (Release Date)

**Contact:** Division of Grants Policy; Office of Policy for Extramural Research Administration (OPERA); GrantsPolicy@OD.NIH.gov; As always feel free to reach out to your SPA Project Officer if you have any questions. [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu/
[NTW] [RESTARTING RESEARCH]

[2] Restart Survey Requested for All Projects

**Sponsor:** Mailman School, Research Resources

**Deadline(s):** 09/11/2020 (Event Date)

**Contact:** msph_research@cumc.columbia.edu; https://health.columbia.edu/content/make-appointment [Appointment for Covid-19 Testing; Please also note the NEW phone number 212-854-7426]

**Link(s):**
- https://health.columbia.edu/content/make-appointment [Appointment for Covid-19 Testing; Please also note the NEW phone number 212-854-7426]
- https://cumc.co1.qualtrics.com/jfe/form/SV_3ZVrNGSjy7qmyqh [Restart survey requested for all projects]
- https://covid19.columbia.edu/content/guidelines-planning-resumption-field-research [Guidelines for Resumption of Field Research (International Studies)]
- https://covid19.columbia.edu/sites/default/files/content/Documents%2020%20Resumption%20of%20Field%20Research%20Guidance%20for%20International%20Studies%20Resumption_FINAL.pdf [Guidelines for Resumption of Field Research (International Studies)]

**Additional Information:**

As noted on slide 4: **COVID-19 Testing – New:** Effective July 20, 2020, all employees are required to be tested prior to arrival on campus. https://health.columbia.edu/content/make-appointment To arrange for a test call: (212)-854-7426 *note new number*

As noted on slide 7, applicable to All Studies: All investigators MUST complete the restarting research survey so we can track the restarts https://cumc.co1.qualtrics.com/jfe/form/SV_3ZVrNGSjy7qmyqh One survey for each project please.

As noted on slide 10, relative to International Studies: We are also required to inform the Provost that this research will be restarted (not for approval, just notification). There is a form that must be completed and sent (with the other documentation) to
msph_research@cumc.Columbia.edu. We will send the form to the provost’s office. The link to the downloadable form can be found here.

[NTW] [RETURNING TO CAMPUS]
[1] Mailman School; Returning to Campus [provided for reference; please note the updated phone number for Covid-19 testing, below]
[3] Returning to Campus Update 09.18.2020
Sponsor: Mailman School
Deadline(s): NA; page updated regularly
Contact: Please see Returning to Campus link for multiple sources, and contacts
Link(s): https://www.publichealth.columbia.edu/coronavirus-updates/returning-campus

[NTW] [IRB RESEARCH REMINDER]
Survey Required to Resume Un-Paused IRB-Approved Projects
Sponsor: Mailman School
Deadline(s): ASAP
Contact: msph_research@cumc.columbia.edu
Link(s): https://cumc.co1.qualtrics.com/jfe/form/SV_3ZVrNGSJy7qmyqh
Additional Information: IRB Research Reminder. Remember, in order to resume un-paused IRB-approved projects investigators must complete the following survey to receive School - level approval. https://cumc.co1.qualtrics.com/jfe/form/SV_3ZVrNGSJy7qmyqh. This is necessary to assure that the research conforms with the CUIMC requirements for building occupancy and participant and worker safety.

[NTW] [RASCAL IRB 2.1]
Rascal IRB 2.1
Sponsor: The Columbia University Human Research Protection Office (HRPO)
Deadline(s): 09/20/2020 (Release Date)
Contact: rascal@columbia.edu
Link(s): www.rascal.columbia.edu/irb
Additional Information: Rascal IRB 2.1 Open Hours - Last Call!; Dear Members of the Columbia Research Community, The Columbia University Human Research Protection Office (HRPO) released an updated version of the IRB module in Rascal, “Rascal IRB 2.1”, on September 20. The majority of the changes affect the "review" side of Rascal. However, there are some changes on the “researcher” side that you should be aware of. These are presented in the Rascal IRB 2.1 training video for researchers that is accessible to you on the main Rascal IRB page www.rascal.columbia.edu/irb via the link labeled “New Rascal 2.1 updates! View tutorial here”; The last of our "open" hours was hosted on Zoom on Thursday, October 15. Rascal 2.1 questions [were fielded], or any other questions you have about the IRB process. If you are unable to attend this session, then we welcome your questions during our Monthly Investigator Meeting next week on October 22nd. Event details will be sent out soon.; If you are experiencing issues with any of the new functions in Rascal, please send an email to rascal@columbia.edu. ; Thank you for all your efforts in this process,
as we continue to improve the efficiency and quality of the Human Research Protection Program here at Columbia. Best regards, Rascal IRB 2.1 Planning Team

[NTW] [COVID-19 OPPORTUNITIES CURATED IN PIVOT]
Resources to access COVID-19 Funding Opportunities and New Website:
[1] Coronavirus Funding Opportunities Curated by SPA in PIVOT [this regularly updated link may require PIVOT registration (see below for instructions)]
[2] Pivot is a Funding Opportunity Database, as a one-stop shop to identify COVID-19 opportunities from federal, private, and global sponsors
[3] Pivot Instructions
[5] COVID-19 Research Opportunities and other resources to support researchers
[6] COVID-19 Research Funding Opportunities Curated by SPA and Research at Columbia
[7] Pivot, New Dashboard!
[8] Pivot Quick Guide

Sponsor: Columbia Research https://research.columbia.edu; SPA https://spa.columbia.edu/ [brought to our attention by] Stephanie Scott [Director of Policy and Research Development] Columbia | Research; Sponsored Projects Administration; sfs2110@cumc.columbia.edu ; Website: https://spa.columbia.edu/

Deadline(s): Please note that effective May 01, 2020 (05/01/2020) SPA will continue to support the funding opportunity database Pivot, and will no longer support InfoEd SPIN / SMARTS

Contact: Please continue to email questions to COVID19_research@columbia.edu; we will make sure your questions are routed to the right person so you receive a timely answer. For questions concerning Pivot, email Pivot-Help@columbia.edu

[2] https://research.columbia.edu/COVID-19_Research/Researchers [COVID-19 Research opportunities, as well as other resources to support researchers]
[3] https://pivot.proquest.com/funding_main [Pivot, a funding opportunity database, as a one-stop shop to identify COVID-19 opportunities from federal, private, and global sponsors]

Additional Information: Please note that effective May 01, 2020 (05/01/2020) SPA will continue to support the funding opportunity database Pivot, and will no longer support InfoEd SPIN / SMARTS
**[NTW] [CU REMOTE LEARNING]**

**Center & Institute Initiative to Enhance Remote Learning and Teaching**

**Sponsor:** The Center for Science and Society, the Center for the History and Ethics of Public Health, the Institute for Religion, Culture and Public Life, the Institute for Comparative Literature and Society, the Center for Justice, the Center for American Studies, and the Institute for the Study of Human Rights

**Deadline(s):** Open until filled

**Contact:** scienceandsociety@columbia.edu

**Link(s):** [https://scienceandsociety.columbia.edu/content/call-enhance-learning](https://scienceandsociety.columbia.edu/content/call-enhance-learning)

**Additional Information:** CALL FOR APPLICATIONS: Center & Institute Initiative to Enhance Remote Learning and Teaching; Dear Colleagues, Please find below information about brand new grants offered by a consortium of Columbia centers and institutes, including the Center for Science and Society. We hope you will help us spread the word among your students and colleagues who may be eligible to apply. We encourage you to apply if you are teaching/taking classes online this academic year and have ideas for activities and initiatives that can improve the online teaching/learning experience. I am also attaching a PDF document with all the information about the grants.; **Eligibility:** All Columbia and Barnard faculty, instructors, undergraduate and graduate students, TAs, research fellows and postdocs (if teaching or taking a class in the 2020-21 academic year) are eligible to apply.; **Amount:** Funding of up to $1,500 per proposal is available.; **Deadline:** Applications for the grants are open via rolling submission throughout the 2020-21 academic year.; **Description:** With a challenging academic year ahead, a consortium of Centers and Institutes will offer funding for proposals that cultivate student engagement and enhance the online learning experience for Columbia students and instructors. As many universities and colleges grapple with the reality of online and hybrid instruction in the wake of the COVID-19 pandemic, faculty members, teaching assistants, instructors, and students prepare to learn and teach in unprecedented ways. Structuring engaging online or hybrid courses is not a simple task.; To help ameliorate some of the challenges, the Center for Science and Society, the Center for the History and Ethics of Public Health, the Institute for Religion, Culture and Public Life, the Institute for Comparative Literature and Society, the Center for Justice, the Center for American Studies, and the Institute for the Study of Human Rights will offer funds throughout the 2020-21 academic year to proposals that aim to improve the online classroom experience and promote student engagement. We welcome proposals from any member of any course offered in the 2020-21 academic year - instructor, TA, or student. Successful proposals will lay out course activities (to be carried out inside or outside class sessions) that will enhance the teaching and learning experiences of remote learning; they can also suggest innovative pedagogical strategies and tools. They can be proposed at any time during an ongoing, or in advance of a future, course. This funding opportunity aims to make resources available quickly so that students and teachers can respond rapidly to class dynamics, ideas, and opportunities.; Activities might include forming online student-instructor groups, special events, public outreach activities or webinars, journal/book clubs, outdoor activities, in-home activities or demonstrations, financial support for assistance in the classroom, special speaker honoraria, etc.; We look forward to receiving innovative proposals, especially from students and TAs. Visit the Center for Science and Society website to apply.; Best, Jozef; [brought to our attention by] Jozef Sulik; Senior Project Manager; Presidential Scholars in Society and Neuroscience; The Center for Science and Society; Columbia University in the City of New York; presidentscholars.columbia.edu; scienceandsociety.columbia.edu

---

**[NTW] [SPA COVID-19 TOWN HALL]**

**SPA COVID TOWN HALLS [ARCHIVAL]**

**Sponsor:** SPA

**Deadline(s):** NA, Archival Postings

**Contact:** We encourage you to submit any questions in advance to SPA-TownHall@columbia.edu.

**Link(s):** [https://research.columbia.edu/SPA-TownHalls](https://research.columbia.edu/SPA-TownHalls) [SPA Town Halls, Archival]
[NTW] [COVID-19]
Columbia Public Health’s Free Online Course COVID-19 from Virus to Vaccine: Biological, Clinical, and Public Health Dimensions (Archival)

**Sponsor:** Columbia Mailman School of Public Health.

**Deadline(s):** Archival

**Contact:** Register Here to Access to Columbia Public Health’s Covid-19 Course (Archival)

**Link(s):** [https://mailchi.mp/cumc/covid-19-course?mc_cid=69e04428cb&mc_eid=17b4454a9b](https://mailchi.mp/cumc/covid-19-course?mc_cid=69e04428cb&mc_eid=17b4454a9b)

**Additional Information:** Register here to access Columbia Public Health’s free online course, COVID-19 from Virus to Vaccine: Biological, Clinical, and Public Health Dimensions. Through lectures and virtual labs, world-class scientific experts and leaders explore a broad range of topics related to COVID-19 including understanding the science of the virus; who is particularly vulnerable to the virus and why; developing and implementing tests, treatments and vaccines; modeling projections of the pandemic’s spread; and advancing strategies to contain the pandemic.

[NTW] [COVID-19/FOUNDATION FUNDING]
Pfizer: COVID-19 Vaccine Grants

**Sponsor:** [https://www.pfizer.com](https://www.pfizer.com)

**Deadline(s):** Not Specified

**Contact:** [https://www.pfizer.com/contact](https://www.pfizer.com/contact)

**Link(s):** [https://www.pfizer.com/purpose/independent-grants/covid-19-vaccine](https://www.pfizer.com/purpose/independent-grants/covid-19-vaccine)

[NTW] [COVID-19/FOUNDATION FUNDING]
COVID-19 Early Treatment Fund: Outpatient Clinical Trials for Effective Early Treatment for COVID-19, Using Existing Drugs, Rolling Deadline

**Sponsor:** Foundation Funding Opportunities brought to our attention by the Columbia University Office of Alumni Development

**Deadline(s):** Please see piecemeal announcements

**Contact:** Please see piecemeal announcements

**Link(s):** [https://mailchi.mp/039e9bb7a43b/fet1sebg38](https://mailchi.mp/039e9bb7a43b/fet1sebg38) [Register for monthly CFR Opportunities Newsletter]

**Additional Information:** Foundation Funding Opportunities brought to our attention by the Columbia University Office of Alumni Development; Corporate and Foundation Relations; New Funding Opportunities, November 2020; Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines.; Please share these opportunities with colleagues and faculty as appropriate, and please feel free to reach out to me at dk2617@columbia.edu with any questions.; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here. – Dimitra; [brought to our attention by] Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu | (212) 851-9924

[NTW] [COVID-19/FOUNDATION FUNDING]
DDCF COVID-19 Fund to Retain Clinical Scientists RFA
DDCF Fund to Retain Clinical Scientists

**Sponsor:** Doris Duke Charitable Foundation website

**Deadline(s):** 06/22/2021 (LOI); 07/20/2021 (Application)

**Contact:** Questions: Contact Jennifer Williamson at jlw61@cumc.columbia.edu

**Link(s):** https://www.ddcf.org/what-we-fund/medical-research/goals-and-strategies/encourage-and-develop-clinical-research-careers/fund-to-retain-clinical-scientists

**Additional Information:** The Doris Duke Charitable Foundation; New Institutional Grant Opportunity: COVID-19 Fund to Retain Clinical Scientists Institutional award; LOI Deadline: June 22; The Doris Duke Charitable Foundation (DDCF), together with the Burroughs Wellcome Fund, Rita Allen Foundation and Walder Foundation, is pleased to announce this funding opportunity to bolster medical schools’ wider efforts to support a research workforce with family caregiving responsibilities in light of the impacts of COVID-19.; Building on the promising outcomes of the Doris Duke Charitable Foundation Fund to Retain Clinical Scientists program, DDCF is jointly allocating up to $10 million to offer the COVID-19 Fund to Retain Clinical Scientists grant opportunity for U.S. medical schools that are evolving to strengthen policies, practices, and processes to support the research productivity and retention of early-career faculty with family caregiving responsibilities.; The COVID-19 Fund to Retain Clinical Scientists will provide supplemental, flexible research funds to early-career physician scientists working on clinical research projects and facing extra-professional demands of caregiving increased by COVID-19.; In 2021, DDCF and its partners will award grants of $500,000 total cost plus 10% indirect costs over 2 years to support U.S. medical schools in providing individual research supplements to eligible faculty with family caregiving responsibilities exacerbated by COVID-19.; $500K +10% indirects over 2 years, aim to support awards of $20-50K for clinician researchers who hold K award or equivalent for human subjects research support (ie, tech salary, data analyst, etc); For additional details, visit the Doris Duke Charitable Foundation website; Application Deadlines; Letters of Intent Due: June 22, 2021; Full Proposals Due: July 20, 2021; Award Start Date: October 15, 2021; Questions: Contact Jennifer Williamson at jlw61@cumc.columbia.edu. Click the buttons below for more details.; DDCF COVID-19 Fund to Retain Clinical Scientists RFA ; DDCF Fund to Retain Clinical Scientists

---

**[NTW] [CU TEACHING AND LEARNING GRANTS]**

**Columbia University Center for Teaching and Learning, Office of the Provost; Teaching and Learning Grants Presented by Consortium of Institutes & Centers**

**Sponsor:** Columbia University Center for Teaching and Learning, Office of the Provost; https://scienceandsociety.columbia.edu

**Deadline(s):** Open; Applications for the grants are open via rolling submission throughout the 2020-21 academic year

**Contact:** For questions, please contact scienceandsociety@columbia.edu.

**Link(s):** https://scienceandsociety.columbia.edu/content/call-applications-enhance-learning

**Additional Information:** Call for Applications: Teaching and Learning Grants Presented by Columbia Institutes & Centers; Call for Applications: Teaching and Learning Grants Presented by Consortium of Institutes & Centers; A consortium of Columbia Centers and Institutes are offering funding of up to $1,500 for projects that cultivate student engagement and enhance the online learning experience for Columbia students and instructors. All Columbia and Barnard faculty, instructors, undergraduate and graduate students, TAs, research fellows and postdocs who are teaching or taking a class in the 2020-21 academic year are eligible to apply.; Proposals are now being accepted on a rolling submission throughout the 2020-21 academic year by the Center for Science and Society, the Center for the History and Ethics of Public Health, the Institute for Religion, Culture and Public Life, the Institute for Comparative Literature and Society, and the Center for Justice; each is seeking proposals related to their areas of expertise. This funding opportunity aims to make resources available quickly so that students and
teachers can respond rapidly to class dynamics, ideas, and opportunities during this challenging academic year; Successful proposals will lay out course activities (to be carried out inside or outside class sessions) that will enhance the teaching and learning experiences of remote learning for current or future courses; they can also suggest innovative pedagogical strategies and tools. Activities may include (but are not limited to) forming online student-instructor groups, special events, public outreach activities or webinars, journal/book clubs, outdoor activities, in-home activities or demonstrations, financial support for assistance in the classroom, or special speaker honoraria.

[NTW] [NIH ANNOUNCEMENTS/CLINICAL TRIALS]

Policy Update - Results Information Reporting for Applicable Clinical Trials (ACTs)

**Sponsor:** National Institutes of Health; General Notices

**Deadline(s):** 07/28/2020 (Release Date)

**Contact:** Please direct all inquiries to: NIH Office of Policy for Extramural Research Administration; Division of Grants Compliance and Oversight; Telephone: 301-435-0949; Email: grantscompliance@od.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-147.html

**Additional Information:** The purpose of this notice is to inform the extramural community that a Federal court has held that Section 801 of the Food and Drug Administration Amendments Act of 2007 ("FDAAA") requires submission of results information for any "applicable clinical trial" ("ACT"), as defined in section 402(j)(1)(A) of the Public Health Service ("PHS") Act, that was initiated after September 27, 2007, or that was ongoing as of December 26, 2007, if the ACT studied a product that is approved, licensed, or cleared by FDA at any time, including after the ACT's primary completion date.

[NTW] [FORMS-F]

eRA Information: Changes in HSS Post-Submission Updates with FORMS-F Starting June 13

NIH Policy and Guidelines on the Inclusion of Individuals Across the Lifespan as Participants in Research Involving Human Subjects

High-level Grant Application Form Change Summary: FORMS-F

**Sponsor:** NIH eRA

**Deadline(s):** 06/13/2020 (Effective Date); 06/15/2020 (Release Date)

**Contact:** NIH Office of Extramural Research; Questions? Please contact the eRA Service Desk. Check out self-help resources on the Help page before submitting an online ticket; or call Toll-free: 1-866-504-9552, Phone: 301-402-7469. The eRA Service Desk hours are Mon-Fri, 7 a.m. to 8 p.m. ET.; Help us improve our communications; send your suggestions and feedback to eRACommunications@mail.nih.gov or call 301-435-8185.; To read other recent articles and messages, please visit our Latest News page at https://era.nih.gov/news

https://www.youtube.com/watch?v=iHYrdlPfKV0&feature=youtu.be
https://era.nih.gov/help-tutorials/hss/overview.htm
https://grants.nih.gov/support/index.html
https://era.nih.gov/news

Participant-level Data Template
**R²report**

**Friday Newsletter 07/16/2021**

**Additional Information:** [SPA News] FW: eRA Information: Changes in HSS Post-Submission Updates with FORMS-F Starting June 13; NIH sent this announcement yesterday after they had already made the changes in their Human Subjects System (HSS). Please see below, it outlines the changes made to the HSS and its integration with the updated FORMS-F PHS Human Subjects and Clinical Trials Form. [brought to our attention by] Stephanie Scott ; eRA Information: Changes in HSS Post-Submission Updates with FORMS-F Starting June 13; **eRA Information: Changes in HSS Post-Submission Updates with FORMS-F Starting June 13; Monday, June 15, 2020**; As of Saturday, June 13, 2020, all applicants and recipients submitting post-submission updates in the Human Subjects System (HSS) will use the updated FORMS-F PHS Human Subjects and Clinical Trials Information Form. These updates address new requirements for participant-level data on sex/gender, race, ethnicity, and age at enrollment for projects subject to the NIH Policy and Guidelines on the Inclusion of Individuals Across the Lifespan as Participants in Research Involving Human Subjects.

Users with records currently in progress will need to modify the records to meet new FORMS-F requirements.; The changes listed below include items released by eRA in March and items released on June 13.; Key FORMS-F Changes to the PHS Human Subjects and Clinical Trials Information Form; [*] A new Inclusion Enrollment Report title field is now available. The human subjects study title will appear by default for all existing studies and may be changed by the user. For new studies and those with a work in progress study, the title will be blank and need to be filled by the grantee. See Figure 1.; **Figure 1: Inclusion Enrollment Report Title Field;** [*] For clinical trials, the “Brief Summary” field will no longer appear in Section 4. Information in this field prior to June 13, 2020 will continue to be available in the PDF images of applications and Research Performance Progress Reports (RPPRs) submitted prior to this change.; [*] Question 1.4.a. “Does the study involve human subjects/participants” now has a default value of yes and cannot be changed unless the user changes their response to the question “Are Human Subjects Involved?” on the Other Projects Information form. As a study record should be completed only for research involving human participants, the “No” option is no longer available for this question. See Figure 2.; **Figure 2: Question 1.4.a of the Clinical Trial Post Submission Study Record;** [*] In Section 2.8 of the Study Record: PHS Human Subjects and Clinical Trials Information screen, the language has been changed from ‘Enrollment of First Subject’ to ‘Enrollment of First Participant.’; [*] A new question has been added to the Study Record: PHS Human Subjects and Clinical Trials Information screen — Section 4.6 asks ‘Is this an applicable clinical trial under FDAAA.’; [*] For a full list of significant FORMS-F changes, see the High-level Grant Application Form Change Summary: FORMS-F PDF; Key Inclusion Across the Lifespan Changes; [*] Recipients reporting actual enrollment progress for a grant application submitted for due dates January 25, 2019 or later must provide participant-level data on sex/gender, race, ethnicity, and age at enrollment in the Inclusion Enrollment Report of the PHS Human Subjects and Clinical Trials Information Form using HSS; [*] Users must use the spreadsheet template available in HSS to submit participant-level data. The column titles must not be altered, and data should be provided using the values modeled in the template. Changes to the template may result in a submission error. See Figure 3.; **Figure 3: Download Participant Level Data Template button on the Inclusion Enrollment Report;** [*] Participant-level data must be uploaded in .csv format. Users do not need to separately enter the individual numerical fields in the Actual (Cumulative) Inclusion Enrollment Report table once the .csv file is successfully uploaded. The data provided will populate the actual (cumulative) enrollment table within the system. See Figure 4.; **Figure 4: Upload Participant Level Data Attachment button on the Inclusion Enrollment Report;** [*] For more information on the requirement of individual-level participant data on sex/gender, race, ethnicity, and age at enrollment in progress reports for research supported by NIH projects, please see NOT-OD-18-116; For more information, see: [*] Entering Inclusion Data Using the Participant Level Data Template (video and transcript); Participant-level Data Template ; [*] The eRA Human Subjects System (HSS) information page; [*] Information about the PHS Human Subjects and Clinical Trials Information form; electronic Research Administration (eRA); NIH Office of Extramural Research; Questions? Please contact the eRA Service Desk. Check out self-help resources on the Help page before submitting an online ticket; or call Toll-free: 1-866-504-9552, Phone: 301-402-7469. The eRA Service Desk hours are Mon-Fri, 7 a.m. to 8 p.m. ET.; Help us improve our communications; send your suggestions and feedback to eRACommunications@mail.nih.gov or call 301-435-8185.; To read other recent articles and messages, please visit our Latest News page at https://era.nih.gov/news

---

R²report

Friday Newsletter 07/16/2021

**Additional Information:** [SPA News] FW: eRA Information: Changes in HSS Post-Submission Updates with FORMS-F Starting June 13; NIH sent this announcement yesterday after they had already made the changes in their Human Subjects System (HSS). Please see below, it outlines the changes made to the HSS and its integration with the updated FORMS-F PHS Human Subjects and Clinical Trials Form. [brought to our attention by] Stephanie Scott ; eRA Information: Changes in HSS Post-Submission Updates with FORMS-F Starting June 13; **eRA Information: Changes in HSS Post-Submission Updates with FORMS-F Starting June 13; Monday, June 15, 2020**; As of Saturday, June 13, 2020, all applicants and recipients submitting post-submission updates in the Human Subjects System (HSS) will use the updated FORMS-F PHS Human Subjects and Clinical Trials Information Form. These updates address new requirements for participant-level data on sex/gender, race, ethnicity, and age at enrollment for projects subject to the NIH Policy and Guidelines on the Inclusion of Individuals Across the Lifespan as Participants in Research Involving Human Subjects.

Users with records currently in progress will need to modify the records to meet new FORMS-F requirements.; The changes listed below include items released by eRA in March and items released on June 13.; Key FORMS-F Changes to the PHS Human Subjects and Clinical Trials Information Form; [*] A new Inclusion Enrollment Report title field is now available. The human subjects study title will appear by default for all existing studies and may be changed by the user. For new studies and those with a work in progress study, the title will be blank and need to be filled by the grantee. See Figure 1.; **Figure 1: Inclusion Enrollment Report Title Field;** [*] For clinical trials, the “Brief Summary” field will no longer appear in Section 4. Information in this field prior to June 13, 2020 will continue to be available in the PDF images of applications and Research Performance Progress Reports (RPPRs) submitted prior to this change.; [*] Question 1.4.a. “Does the study involve human subjects/participants” now has a default value of yes and cannot be changed unless the user changes their response to the question “Are Human Subjects Involved?” on the Other Projects Information form. As a study record should be completed only for research involving human participants, the “No” option is no longer available for this question. See Figure 2.; **Figure 2: Question 1.4.a of the Clinical Trial Post Submission Study Record;** [*] In Section 2.8 of the Study Record: PHS Human Subjects and Clinical Trials Information screen, the language has been changed from ‘Enrollment of First Subject’ to ‘Enrollment of First Participant.’; [*] A new question has been added to the Study Record: PHS Human Subjects and Clinical Trials Information screen — Section 4.6 asks ‘Is this an applicable clinical trial under FDAAA.’; [*] For a full list of significant FORMS-F changes, see the High-level Grant Application Form Change Summary: FORMS-F PDF; Key Inclusion Across the Lifespan Changes; [*] Recipients reporting actual enrollment progress for a grant application submitted for due dates January 25, 2019 or later must provide participant-level data on sex/gender, race, ethnicity, and age at enrollment in the Inclusion Enrollment Report of the PHS Human Subjects and Clinical Trials Information Form using HSS; [*] Users must use the spreadsheet template available in HSS to submit participant-level data. The column titles must not be altered, and data should be provided using the values modeled in the template. Changes to the template may result in a submission error. See Figure 3.; **Figure 3: Download Participant Level Data Template button on the Inclusion Enrollment Report;** [*] Participant-level data must be uploaded in .csv format. Users do not need to separately enter the individual numerical fields in the Actual (Cumulative) Inclusion Enrollment Report table once the .csv file is successfully uploaded. The data provided will populate the actual (cumulative) enrollment table within the system. See Figure 4.; **Figure 4: Upload Participant Level Data Attachment button on the Inclusion Enrollment Report;** [*] For more information on the requirement of individual-level participant data on sex/gender, race, ethnicity, and age at enrollment in progress reports for research supported by NIH projects, please see NOT-OD-18-116; For more information, see: [*] Entering Inclusion Data Using the Participant Level Data Template (video and transcript); Participant-level Data Template ; [*] The eRA Human Subjects System (HSS) information page; [*] Information about the PHS Human Subjects and Clinical Trials Information form; electronic Research Administration (eRA); NIH Office of Extramural Research; Questions? Please contact the eRA Service Desk. Check out self-help resources on the Help page before submitting an online ticket; or call Toll-free: 1-866-504-9552, Phone: 301-402-7469. The eRA Service Desk hours are Mon-Fri, 7 a.m. to 8 p.m. ET.; Help us improve our communications; send your suggestions and feedback to eRACommunications@mail.nih.gov or call 301-435-8185.; To read other recent articles and messages, please visit our Latest News page at https://era.nih.gov/news

---

COLUMBIA

Mailman School of Public Health

RESEARCH RESOURCES

mailman.columbia.edu/r2
[NTW] [FORMS-F]
Reminder of Upcoming FORMS-F and Inclusion Across the Lifespan Requirements for NIH Applicants and Recipients Submitting Post-Submission Updates Using the Human Subjects System (HSS)

**Sponsor:** National Institutes of Health  
**Deadline(s):** 06/17/2020 (Release Date)  
**Contact:** For questions about this notice, contact: Office of Policy for Extramural Research Administration; Telephone: 301-435-0949; Email: grantspolicy@mail.nih.gov; For requests for technical assistance using HSS, contact the eRAService Desk.  


[NTW] [FORMS-F]
Reminder: Required use of FORMS-F application forms for application submission

**Sponsor:** National Institutes of Health  
**Deadline(s):** 04/14/2021 (Release Date)  
**Contact:** NIH Office of Policy for Extramural Research Administration (OPERA); Systems Policy Branch; Email: OPERAsystemspolicy@nih.gov  

[NTW] [DATA TABLES FOR TRAINING GRANTS]
[1] Data Tables for FORMS-F required institutional training grant proposals; required for applications due May 25th, 2020 or later
[2] Data Tables Changes from FORMS-E to FORMS-F

**Sponsor:** NIH, SPA  
**Deadline(s):** 05/25/2020 (Forms-F, required for applications due 05/25/2020 or later)  
**Contact:** [https://grants.nih.gov/support/index.html](https://grants.nih.gov/support/index.html) ; SPA  
**Link(s):** [https://grants.nih.gov/grants/forms-f/data-tables.htm](https://grants.nih.gov/grants/forms-f/data-tables.htm)  

**Additional Information:** Data Tables for training grants; NIH just posted the latest Data Tables for FORMS-F required institutional training grant proposals. These tables will be required for applications due May 25th, 2020 or later. Go to: [https://grants.nih.gov/grants/forms-f/data-tables.htm](https://grants.nih.gov/grants/forms-f/data-tables.htm); They did not post a significant changes document yet, so I took the instructions from the previous tables and did a comparison to the new tables. See attached “Changes from FORMS-E to FORMS-F”; I have an email to NIH to clarify the significant changes, and any impact they may have in xTRACT. Upon first glance, the changes appear to be more of clarifications of the instructions, rather than anything drastically different; I know a number of you are preparing training grant proposals for May. Please feel free to take a look at these changes, and let me know if you have questions. This
way I can collect them all and send them to NIH for clarification. As every training grant program is different, you may also need to go to your Program Officials for direction on how they want the table completed for your specific set of circumstances. As soon as I have more information from NIH I will pass it along.\footnote{\textit{brought to our attention by} Stephanie F. Scott, MS, CRA; Director of Policy and Research Development}

\[NTW\] \textbf{[SPA TRAINING GRANT RPPRS AND SURVEY]}

\textbf{Training Grant RPPRs and Survey}

\textbf{Sponsor:} SPA/HICCC

\textbf{Deadline(s):} 10/01/2020 (Release Date)

\textbf{Contact:} \footnote{\textit{brought to our attention by} Stephanie Scott, SPA}, sfs2110@cumc.columbia.edu ; If you have any questions about it, please contact Stuart Fischer at sgf2@cumc.columbia.edu ; For inquiries concerning the policy described in the NOT-OD-20-178 Notice, contact: NIHTrain@mail.nih.gov


https://cumc.co1.qualtrics.com/jfe/form/SV_dnlpKJH JoJQk5kp

\textbf{Additional Information:} Training Grant RPPRs and survey; Training Grant RPPRs and survey; Hello, Training Grant PIs and Administrators. This is just a quick reminder to please take the very survey below from HICCC, available here: https://cumc.co1.qualtrics.com/jfe/form/SV_dnlpKJH JoJQk5kp ; For background, see below and attached. If you have any questions about it, please contact Stuart Fischer at sgf2@cumc.columbia.edu Thank you! We will be contacting folks individually if we don’t hear from you.; Steph; Dear Training Grant Directors and Administrators, We have two important updates regarding Research Performance Progress Reports (RPPRs); To follow up on the TGA meeting we held on August 12 (see attached slides), we’d like to request that PIs complete the following Qualtrics survey indicating your willingness to share your next RPPR with the Herbert Irving Comprehensive Cancer Center (HICCC) administration. Go to https://cumc.co1.qualtrics.com/jfe/form/SV_dnlpKJH JoJQk5kp to complete the survey.; Background: HICCC is an NCI-designated Comprehensive Cancer Center. Its Cancer Center Support Grant with Dr. Anil Rustgi as Principal Investigator was recently renewed for a period of five years. Starting this year, as required by NCI, a new dedicated Cancer Research Career Enhancement (CRCE) Core, with Dr. Wendy Chung as Director, was established in the HICCC to coordinate education and training activities and provide educational opportunities at all levels, from high school to faculty.; CRCE serves all HICCC members, some of whom may be mentors on your active institutional grants. The NCI requires that HICCC collect data and submit reports on the education and training activities of HICCC members who are mentors on your grants. During our meeting on August 12, we discussed your willingness to share your RPPRs with the HICCC in order to meet NCI’s mandate. Attendees on the call were amenable to the idea. The information will be used solely for the purposes of enabling the CRCE Core to meet the NCI’s requirement and will allow CRCE to enhance the programming focused on trainees in cancer research.; SPA will provide a copy of the RPPR to HICCC if you select YES to the following statement: "As the P.I of this training grant, I am willing to share the Research Performance Progress Report of this training grant with the Herbert Irving Comprehensive Cancer Center administration." If you are unwilling to provide the RPPR to HICCC, please email Stuart Fischer at sgf2@cumc.columbia.edu and we will connect with you separately.; New Requirement for Trainee Diversity Report, beginning October 30, 2020; See full NIH announcement at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-178.html ; NIH is integrating the Trainee Diversity Report into xTrain, which will now be generated electronically using trainees’ demographic data from their
eRA Commons Personal Profiles. This electronically generated report must be included with the RPRR. RPRRs lacking an electronically generated report will not be accepted. We are waiting for more specific instructions on how this will work, so stay tuned and we’ll provide you with more information.; If you have any questions about the Qualtrics survey, please reach out to Stuart Fischer at sgf2@cumc.columbia.edu; Thank you!; Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu/

**[NTW] [NIH ANNOUNCEMENTS]**

**NIH Summary Statement Available to the Signing Officials (SO) through the eRA Commons**

**Sponsor:** National Institutes of Health  
**Deadline(s):** 06/18/2020 (Release Date)  
**Contact:** Please direct all inquiries to: System Policy Branch; Office of Policy for Extramural Research Administration; Office of Extramural Research; Email: OPERAsystemspolicy@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-126.html

**Additional Information:** To facilitate award management and communications with applicant organizations via Authorized Organization Representatives (AORs), NIH has modified the system of records by adding a new routine use to clarify that information may be shared with applicant organizations.; Effective June 24, 2020, the overall impact score and the NIH Summary Statement will be made available in the eRA Commons to the Authorized Organization Representatives (AORs) of the applicant organization with the Signing Official (SO) user role in the eRA Commons.

**[NTW] [COVID-19/HIGH PERFORMANCE COMPUTING]**

SRCPAC Major players offering Access to High Performance Computing for COVID-19 Research

1. **Covid-19 High Performance Computing HPC Consortium**
2. **Covid-19 HPC High Performance Computing Webinar Presentation**
3. **All Active Projects, Covid-19 HPC High Performance Computing Consortium**

**Deadline(s):** Please see all active projects  
**Contact:** Questions: George Garrett, Manager, Research Computing Services shinobu@columbia.edu  

**Additional Information:** A unique public-private consortium, spearheaded by The White House, the U.S. Department of Energy, and IBM, which includes government, industry, and academic leaders, have volunteered free compute time and resources on their machines to provide COVID-19 researchers worldwide with access to the world’s most powerful high-performance computing resources that can significantly advance the pace of scientific discovery in the fight to stop the virus.; Key takeaways from Webinar (slides attached): [*] The COVID-19 HPC Consortium provides free HPC resources in support of high impact COVID-19
research; [*] Projects approved typically within days (extremely rapid turnaround); [*] The website has a list of all active projects and taxonomies which can be filtered by research area; [*] There are currently 46 up and running COVID-19 projects that have been matched; [*] Proposals can be submitted here: https://www.xsede.org/covid19-hpc-consortium

[NTW] [NIH GUIDE FOR GRANTS AND CONTRACTS]
[1] NIH Guide for Grants and Contracts (this week’s)
[3] Subscribe to Weekly NIH Funding Opportunities and Notices

**Sponsor:** NIH

**Deadline(s):** Accrued and posted throughout the week (usually available no later than Monday AMs), Distributed weekly, usually Friday afternoons and archivally available

**Contact:** https://grants.nih.gov/grants/guide/listserv_dev.htm [subscribe to receive weekly updates]

**Link(s):** https://grants.nih.gov/grants/guide/WeeklyIndexMobile.cfm?WeekEnding=07-16-2021 [NIH Funding Opps; 07/16/2021]
https://grants.nih.gov/grants/guide/WeeklyIndexMobile.cfm?WeekEnding=MM-DD-YYYY [generic format that may be modified weekly to access the Guide]

**Additional Information:** NIH Guide for Grants and Contracts; Weekly NIH Funding Opportunities and Notices are distributed, usually on Friday afternoons (e.g. ~ 3PM, occasionally at other times, later or earlier in the day); The opportunities and notices are updated throughout the week, usually starting no later than the Monday AM; you may access these opps and notices any given week by updating the MM-DD-YYYY in the url; a generic url that may be modified weekly; MM = month, 2 digits; DD = Day, 2 digits; YYYY = Year; 4 digits; https://grants.nih.gov/grants/guide/WeeklyIndexMobile.cfm?WeekEnding=MM-DD-YYYY; NIH Funding Opps; 07/16/2021: https://grants.nih.gov/grants/guide/WeeklyIndexMobile.cfm?WeekEnding=07-16-2021;
https://grants.nih.gov/grants/guide/YearlyIndex/AllYearsIndex.cfm [archival NIH Funding opportunity postings]
https://grants.nih.gov/funding/searchguide/index.html#/ [Generic format that may be modified weekly to access the Guide]

[NTW] [COVID-19]

**Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic**

**Sponsor:** National Institutes of Health

**Deadline(s):** This Notice extends the special exception for post-submission material (see NOT-OD-20-123) to applications submitted for the May 2021 Council round; For applications submitted for the May 2021 council (beginning with applications submitted for the September 25, 2020 due date for Spring 2021 review meetings), the NIH, AHRQ, and NIOSH will accept a one-page update with preliminary data as post-submission materials for applications submitted under all activity codes, ONLY if the Funding Opportunity Announcement (FOA) used for submission allowed preliminary data in the application. One page of preliminary data will be accepted for single component applications or for each component of a multi-component application.; The deadline for submitting all post-submission materials, including preliminary data, will be 30 days before the study section meeting. Because applications for emergency competitive revisions and urgent competitive revisions undergo expedited review, post-submission materials will not be accepted for those applications.; All other materials listed in NOT-OD-19-083 as acceptable post-submission materials will continue to be accepted if submitted 30 days before the study section meeting.

[NTW] [COVID-19]
Contact: Please direct all inquiries to: Sally A. Amero, Ph.D.; NIH Review Policy Officer; ReviewPolicyOfficer@mail.nih.gov


Additional Information: Related Announcements: NOT-OD-20-123 - Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic; NOT-OD-19-083 - Update to the NIH/AHRQ/NIOSH Policy on Post-Submission Materials

[NTW] [INFLUENZA]

Systems Approach to Understand Mechanisms of Heterogeneous Response to Influenza (R01 Clinical Trial Not Allowed)

Sponsor: National Institute of Allergy and Infectious Diseases

Deadline(s): 09/08/2021; 09/09/2021 (Expiration)

Contact: Scientific/Research Contact(s): Marciela DeGrace, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3460; Email: InfluenzaAI21017@nih.gov

Link(s): https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-017.html

[NTW] [F-AWARDS]

[1] Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) PA-21-051


[3] All NIH Fellowship Parent Announcements [F32 Posting on this link pending, as of 10.27.2020]

Sponsor: National Institutes of Health (NIH)

Deadline(s): Standard dates ; Standard AIDS dates ; 09/08/2023 (Expiration [F31 and F32])

Contact: Table of IC-Specific Information, Requirements, and Staff Contacts [F32 Scientific / Research Contacts]; Table of IC-Specific Information, Requirements, and Staff Contacts [F31 Scientific / Research Contacts]


Additional Information: NIH re-issued Parent F31 and F32; NIH has re-issued several of the individual fellowship Funding Opportunity Announcements (FOAs), including: Individual Predoctoral Fellowship (Parent F31) PA-21-051 ; Individual Postdoctoral Fellowship (Parent F32): PA-21-048 ; All fellowship parent announcements can be located at https://grants.nih.gov/grants/guide/parent_announcements.htm#el ; It appears the new F32 is not appearing on the Parent list just yet, but should be soon. You may wish to check back to the link above as they continue to update the F-series FOAs. If you have any questions, reach out to your SPA Project Officer. [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; Columbia University; Columbia University Irving Medical Center; sfs2110@cumc.columbia.edu ; Website: https://spa.columbia.edu/

[NTW] [F-AWARDS]

Notice of Participation of NINR in PA-21-050, Ruth L. Kirschstein National Research
Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

**Sponsor:** National Institute of Nursing Research  
**Deadline(s):** 06/08/2021 (Release Date)  
**Contact:** David Banks, Ph.D., M.P.H., M.S.S.W., R.N.; National Institute of Nursing Research (NINR); Telephone: 301-496-9558; Email: david.banks@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NR-21-004.html  
**Additional Information:** Related Announcements: PA-21-050 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30); NOT-NR-21-001 - Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards

**[NTW] [F-AWARDS]**

Notice of Change to NOT-NR-21-001: "Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards"

**Sponsor:** National Institute of Nursing Research  
**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2023 (Expiration)  
**Contact:** David Banks, PhD, MPH, MSSW, RN; National Institute of Nursing Research (NINR); Telephone: 301-496-9558; Email: david.banks@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NR-21-006.html  
**Additional Information:** This Notice informs applicants of the addition of PA-21-050: "Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)" to NOT-NR-21-001: "Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards."

**[NTW] [NIH ANNOUNCEMENTS]**

Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels Effective for Fiscal Year 2021

**Sponsor:** National Institutes of Health; Agency for Healthcare Research and Quality; Health Resources and Services Administration  
**Deadline(s):** 01/27/2021 (Release Date)  
**Contact:** See Frequently Asked Questions Related to NRSA Tuition, Fees, and Health Insurance Policies: https://grants.nih.gov/training/nrsa_tuition_q&a.htm.; Specific questions concerning this notice or other policies relating to training grants or fellowships should be directed to the grants management office in the appropriate NIH Institute or Center, AHRQ, or HRSA.; General inquiries concerning NRSA stipend and tuition policies should be directed to: Division of Biomedical Research Workforce; Office of Extramural Research; Website: https://researchtraining.nih.gov ; Email: NIHTrain@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-049.html

**[NTW] [T32 TRAINING GRANTS]**

Notices for changes in T32 submission instructions ; Reminder: Changes to Forms and
Instructions for Research Training Grant, Fellowship, and Career Development Award Applications for Applications Due on or After May 25, 2020 [NOT-OD-090]

**Sponsor:** NIH; NIEHS

**Deadline(s):** 05/25/2020 (for Research Training Grant, Fellowship, and Career Development Award Applications for Applications Due on or After May 25, 2020)

**Contact:** Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Research; National Institutes of Health; E-mail: NIHTrain@mail.nih.gov [NOT-OD-090]

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-090.html

**Additional Information:** Notices for changes in T32 submission instructions; Dear Training Directors: This announcement of interest was published Friday.; https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-090.html; [brought to our attention by] Carol Shreffler, PhD; Program Officer; Exposure, Response, and Technology Branch; Division of Extramural Research and Training; Phone: 984-287-3322; Shreffl1@niehs.nih.gov; Related Announcements; NOT-OD-20-077; NOT-OD-20-033

[NTW] [T32]

**T32 Training Program for Institutions That Promote Diversity (T32 Clinical Trial Not Allowed)**

**Sponsor:** National Heart, Lung, and Blood Institute

**Deadline(s):** 09/13/2021; 02/28/2022; 09/13/2022; 02/28/2023; 09/13/2023; 02/28/2024; 02/29/2024 (Expiration)

**Contact:** Scientific/Research Contacts; Traci Mondoro, PhD; National Heart, Lung, And Blood Institute (NHLBI); Telephone: 301-435-0050; E-mail: NHLBI_Blood_Training@nhlbi.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/RFA-HL-22-001.html

[NTW] [T32s]

**National Institute of General Medical Sciences Institutional Predoctoral Research Training Grant (T32 - Clinical Trial Not Allowed)**

**Sponsor:** National Institute of General Medical Sciences

**Deadline(s):** Standard dates; 05/26/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); For general information, contact Dr. Alison Gammie or Dr. Shiva Singh. For specific information about an area of training or questions about the application process, contact the relevant NIGMS Program Director.

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-20-213.html

[NTW] [T32]

**NINDS Institutional Research Training Program (T32 - Clinical Trial Not Allowed)**

**Sponsor:** National Institute of Neurological Disorders and Stroke

**Deadline(s):** 05/25/2022; 05/25/2023; 05/26/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Stephen Korn, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS); Email: korns@ninds.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-149.html
[NTW] [TRAINING GRANTS]
Columbia University Research SPA Training Grant Sessions and Resources
Columbia University Research SPA NIH Institutional Training Grant Information Sessions

**Sponsor:** [https://research.columbia.edu/](https://research.columbia.edu/) ; [https://spa.columbia.edu/](https://spa.columbia.edu/)

**Deadline(s):** NA, updated regularly

**Contact:** Stephanie Scott; Director of Policy and Research Development; Sponsored Projects Administration; sfs2110@columbia.edu

**Link(s):** [https://research.columbia.edu/nih-institutional-training-grants](https://research.columbia.edu/nih-institutional-training-grants)
[https://columbia.hosted.panopto.com/Panopto/Pages/Sessions/List.aspx#folderID=%22d092e80a-486f-4b1a-a3e6-a9e9012f5ed4%22](https://columbia.hosted.panopto.com/Panopto/Pages/Sessions/List.aspx#folderID=%22d092e80a-486f-4b1a-a3e6-a9e9012f5ed4%22)

[NTW] [COLUMBIA PUBLIC HEALTH NOW PODCASTS]
Columbia Public Health Now Podcasts

**Sponsor:** Mailman

**Deadline(s):** NA

**Contact:** Care to share your comments and questions? Contact the Columbia Public Health Now podcast team at publichealthnow@cumc.columbia.edu.


[NTW] [HEALTH POLICY AND MANAGEMENT VIRTUAL EVENTS]
Health and Policy Management Virtual Events

**Sponsor:** Health Policy and Management; [https://www.mailman.columbia.edu/academics/departments/health-policy-and-management](https://www.mailman.columbia.edu/academics/departments/health-policy-and-management)

**Deadline(s):** ongoing and archived

**Contact:** [brought to our attention by] Becca Schoenfeld; Events & Administrative Manager; Department of Health Policy & Management; Columbia University Mailman School of Public Health; Email: rs3665@columbia.edu


**Additional Information:** Click here to view HPM virtual events, then click “watch live” listed under each panel. Live webinars will begin at 4:30pm EST.

[NTW] [FREE LISTS OF GRANTS AND FELLOWSHIPS AROUND THE WORLD AVAILABLE ONLINE]
Three searchable databases provide information on global opportunities for graduate students, postdocs and junior faculty members

**Sponsor:** Curated by Johns Hopkins University

**Deadline(s):** NA

**Contact:** RDT@jhu.edu

**Link(s):** [https://research.jhu.edu/rdt/funding-opportunities/graduate/](https://research.jhu.edu/rdt/funding-opportunities/graduate/) [JHU curated Graduate Student Funding Opportunities]
Additional Information: The databases — one for graduate students, one for postdoctoral researchers and one for junior faculty members — are produced and posted by Johns Hopkins University (JHU) in Baltimore, Maryland. These are continuously updated repositories of federal and private funding opportunities that are intended for graduate students, postdoctorals and early career researchers. The opportunities are pre-sorted chronologically and alphabetically, and can be searched by funding amount and subject matter; [brought to our attention by] https://www.nature.com/articles/d41586-020-00599-z

[NTW] [HICCC FUNDING OPPORTUNITIES]
HICCC Funding Opportunities

Sponsor: HICCC
Deadline(s): NA, site updated regularly
Contact: https://cancer.columbia.edu/patientresourcesgroup/contact-us
Link(s): https://cancer.columbia.edu/events/funding

[NTW] [RESEARCH SUPPORT SERVICES]
Update on Research Support Services, Spring 2019; we are pleased to expand the Research Support Services to also include resubmissions of otherwise eligible R01, P, K, Center and T32 grants
Grant Review Submission Form (updated Spring 2019)

Sponsor: Mailman School
Deadline(s): relative to upcoming NIH Grant Submission Deadline(s): 5 weeks prior to submission deadline (Inform R2 of intent to utilize services); 4 weeks prior to submission deadline (science draft for external review); 2 weeks prior to submission deadline (submission for editing services)
Contact: Pam Factor-Litvak (Associate Dean, Research Resources, and Professor of Epidemiology) prf1@cumc.columbia.edu; Craig Kandell (Project Coordinator, Research Resources) ckk7@cumc.columbia.edu
Link(s): https://r2eport.files.wordpress.com/2015/05/updatesofgrantsupportservicesspring2019cpdf.pdf
https://r2eport.files.wordpress.com/2015/05/mailmanschoolgrantreviewsubmissionformwordgenericspring2019_04-09-19d.docx [Grant Review Submission Form (updated Spring 2019)]

Additional Information:

Dear Mailman School faculty,

I want to give you an update on Research Support Services—the School’s new program for pre-submission external review and final editing. As Dean Fried wrote in October, the program is geared “to support faculty in preparing grant applications with the highest chance of success.”

I’m happy to report that those using the services this fall have found them valuable. Katherine Keyes in Epidemiology spoke enthusiastically at the recent Assembly: “It was a great experience. I got to focus on the science without having to deal with any of the administrative aspects. I got really good feedback. I will be using these services again.”
In my estimation, all the grants were greatly improved by these services. Of course, the ultimate test is how they are scored and funded. As soon I have that information, I will share it with you.

I encourage everyone to take advantage of Research Support Services to give your grants a competitive advantage. Please keep in mind the following deadlines:

- **5 weeks prior to submission deadline**—Inform Research Resources (via Craig Kandell at ckk7@cumc.columbia.edu) if you plan on using Research Support Services with information about the type of grant at least five weeks prior to the grant due date. If you seek external review, please provide the name and contacts of at least three potential reviewers so we can reach out to them in your order of preference.

- **4 weeks prior to submission deadline**—Send us your science draft for external review three to four weeks prior to submission. We will forward it to the external reviewer. Generally, they provide feedback within a week.

- **2 weeks prior to submission deadline**—For editorial services, send us your manuscript at least 10 days ahead of the deadline. We will make arrangements with the editor. Comments will be returned to Craig and the PI for finalization and submission within a few days.

Please keep in mind that it may take you a day or two to incorporate comments and edits. For best results, get in touch with us prior to these deadlines.

Research Support Services cover first-time submissions, and we are pleased to expand the service to encompass resubmissions of R01, P, K, Center, T32, or other complex NIH proposals by full-time faculty with primary appointments in the School. I am available to provide feedback for grants that utilize this service and also for other grant types that are ineligible for the services.

If you have any questions about your eligibility or the above process, please visit Research Resources online or contact me at prf1@cumc.columbia.edu.

Best wishes,

Pam Factor-Litvak

[NTW] [FOUNDATION FUNDING]
**RWJF Evidence for Action: Investigator-Initiated Research to Build a Culture of Health**

*Sponsor:* https://www.rwjf.org

*Deadline(s):* Open

*Contact:* evidenceforaction@ucsf.edu


[NTW] [FOUNDATION FUNDING]
**Subscribe to RWJF Funding Alerts**

*Sponsor:* RWJF

*Deadline(s):* NA

*Contact:* https://www.rwjf.org/en/contact.html
Additional Information: Subscribe to RWJF emails. Enter your email address on the link provided to have RWJF news and funding alerts delivered directly to your inbox.

[NTW] [FOUNDATION FUNDING]
American Association of Cancer Research | AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Program

Sponsor: https://www.aacr.org
Deadline(s): 06/29/2021 (LOI); 09/30/2021 (Application)
Contact: aacr@aacr.org
Link(s): https://www.aacr.org/grants/aacr-mpm-oncology-grants/

Additional Information: Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions.; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here.; -Dimitra

[NTW] [FOUNDATION FUNDING]
Amazon Web Services | Diagnostic Development Initiative

Sponsor: https://aws.amazon.com
Deadline(s): 07/31/2021
Contact: https://aws.amazon.com/contact-us

Additional Information: Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions.; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here.; -Dimitra

[NTW] [FOUNDATION FUNDING]
Facebook Research | 2021 Towards Trustworthy Products in AR, VR, and Smart Devices
Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities

Sponsor: Office of University Corporate and Foundation Relations; Facebook
Deadline(s): 07/14/2021
Contact: For any questions, further information, or content suggestions please contact: Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu | (212) 851-9924; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here. See rfa for granting agency contact
**R²eport**  
**Friday Newsletter 07/16/2021**

**Link(s):**  
https://mailchi.mp/039e9bb7a43b/fet1sebg38

**Additional Information: New Funding Opportunities; July 2021:** Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter [here](https://mailchi.mp/039e9bb7a43b/fet1sebg38). -Dimitra

---

**[NTW] [FOUNDATION FUNDING]**

**Foundation for Opioid Response Efforts | 2021 Opioid Crisis Innovation OK_Challenge 2021**

**Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities**

**Sponsor:** Office of University Corporate and Foundation Relations; Foundation for Opioid Response Efforts  
**Deadline(s):** 07/19/2021  
**Contact:** For any questions, further information, or content suggestions please contact: Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu | (212) 851-9924; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter [here](https://mailchi.mp/039e9bb7a43b/fet1sebg38).  
**Link(s):**  
https://forefdn.org/wp-content/uploads/2021/05/Innovation_RFP_FINAL.pdf  
https://mailchi.mp/039e9bb7a43b/fet1sebg38

**Additional Information: New Funding Opportunities; July 2021:** Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter [here](https://mailchi.mp/039e9bb7a43b/fet1sebg38). -Dimitra

---

**[NTW] [FOUNDATION FUNDING]**

**Russel Sage Foundation Various core programs and special initiatives Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities**

**Sponsor:** Office of University Corporate and Foundation Relations; Russel Sage Foundation  
**Deadline(s):** 07/28/2021  
**Contact:** For any questions, further information, or content suggestions please contact: Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu | (212) 851-9924; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter [here](https://mailchi.mp/039e9bb7a43b/fet1sebg38).  
**Link(s):**  
https://www.russellsage.org/how-to-apply/application-deadlines  
https://mailchi.mp/039e9bb7a43b/fet1sebg38

**Additional Information: New Funding Opportunities; July 2021:** Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach
out to me at dk2617@columbia.edu with any questions.; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here. ;-Dimitra

[NTW] [FOUNDATION FUNDING]
BrightFocus Foundation | Macular Degeneration Research
Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities

**Sponsor:** Office of University Corporate and Foundation Relations; BrightFocus Foundation
**Deadline(s):** 07/29/2021
**Contact:** For any questions, further information, or content suggestions please contact: Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu | (212) 851-9924; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here.; info@brightfocus.org
**Link(s):** https://www.brightfocus.org/research/macular-degeneration-research-program
https://mailchi.mp/039e9bb7a43b/fet1sebg38

**Additional Information:** New Funding Opportunities; July 2021; Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines.; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions.; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here. ;-Dimitra

[NTW] [FOUNDATION FUNDING]
Cures Within Reach | Repurposing Research Led by a US-Based Racial/Ethnic Minority Principle Investigator
Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities

**Sponsor:** Office of University Corporate and Foundation Relations; Cures Within Reach
**Deadline(s):** 07/30/2021
**Contact:** For any questions, further information, or content suggestions please contact: Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu | (212) 851-9924; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here.; info@cureaccelorator.org
https://mailchi.mp/039e9bb7a43b/fet1sebg38

**Additional Information:** New Funding Opportunities; July 2021; Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines.; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions.; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here. ;-Dimitra
[NTW] [FOUNDATION FUNDING]
IBM's Call for Code | Call for Code Global Challenge
Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities

**Sponsor:** Office of University Corporate and Foundation Relations; IBM

**Deadline(s):** 07/31/2021

**Contact:** For any questions, further information, or content suggestions please contact: Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu | (212) 851-9924; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here.; https://callforcode.org/contact/

**Link(s):** https://callforcode.org/global-challenge/
https://mailchi.mp/039e9bb7a43b/fet1sebg38

**Additional Information:** New Funding Opportunities; July 2021; Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions.; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here. ;-Dimitra

[NTW] [FOUNDATION FUNDING]
Society of Critical Care Medicine | Research Grants
Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities

**Sponsor:** Office of University Corporate and Foundation Relations; Society for Critical Care Medicine

**Deadline(s):** 08/01/2021

**Contact:** For any questions, further information, or content suggestions please contact: Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu | (212) 851-9924; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here.; https://www.sccm.org/Research/Grants

**Link(s):** https://www.sccm.org/Research/Grants
https://mailchi.mp/039e9bb7a43b/fet1sebg38

**Additional Information:** New Funding Opportunities; July 2021; Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions.; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here. ;-Dimitra

[NTW] [FOUNDATION FUNDING]
The Barbara McDowell and Gerald S. Hartman Foundation | Social Justice Litigation Grants
Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities

**Sponsor:** Office of University Corporate and Foundation Relations; The Barbara McDowell and Gerald S. Hartman Foundation
**R2eport**

**Friday Newsletter 07/16/2021**

**Deadline(s):** 08/01/2021  
**Contact:** For any questions, further information, or content suggestions please contact: **Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu | (212) 851-9924**; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter [here.](https://mailchi.mp/039e9bb7a43b/fet1sebg38)

**Link(s):** [https://mailchi.mp/039e9bb7a43b/fet1sebg38](https://mailchi.mp/039e9bb7a43b/fet1sebg38)

**Additional Information: New Funding Opportunities; July 2021:** Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter [here.](https://mailchi.mp/039e9bb7a43b/fet1sebg38) - Dimitra

---

**[NTW] [FOUNDATION FUNDING]**

**William T. Grant Foundation | Research Grants, Reducing Inequality**  
**Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities**

**Sponsor:** Office of University Corporate and Foundation Relations; William T. Grant Foundation  
**Deadline(s):** 08/04/2021  
**Contact:** For any questions, further information, or content suggestions please contact: **Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu | (212) 851-9924**; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter [here.](http://wtgrantfoundation.org/contact)

**Link(s):** [http://wtgrantfoundation.org/grants/research-grants-reducing-inequality](http://wtgrantfoundation.org/grants/research-grants-reducing-inequality)  
https://mailchi.mp/039e9bb7a43b/fet1sebg38

**Additional Information: New Funding Opportunities; July 2021:** Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter [here.](https://mailchi.mp/039e9bb7a43b/fet1sebg38) - Dimitra

---

**[NTW] [FOUNDATION FUNDING]**

**William T. Grant | Research Grants, Improving the Use of Research Evidence**  
**Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities**

**Sponsor:** Office of University Corporate and Foundation Relations; William T. Grant Foundation  
**Deadline(s):** 08/04/2021  
**Contact:** For any questions, further information, or content suggestions please contact: **Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu | (212) 851-9924**; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter [here.](http://wtgrantfoundation.org/contact)

**Link(s):** [http://wtgrantfoundation.org/grants/research-grants-improving-use-research-evidence](http://wtgrantfoundation.org/grants/research-grants-improving-use-research-evidence)
**Additional Information: New Funding Opportunities; July 2021**; Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions.; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here. ; -Dimitra

[NTW] [FOUNDATION FUNDING]
John Templeton Foundation | Psychological Cross-Training for Christian Theology
Office of University Corporate and Foundation Relations Compiled Foundation Funding Opportunities

**Sponsor:** Office of University Corporate and Foundation Relations; John Templeton Foundation

**Deadline(s):** 08/20/2021

**Contact:** For any questions, further information, or content suggestions please contact: Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu | (212) 851-9924; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here.; https://www.templeton.org/contact

**Link(s):** https://www.templeton.org/internal-competition-fund/psychological-science-cross-training-for-christian-theology
https://mailchi.mp/039e9bb7a43b/ef1sebg38

**Additional Information: New Funding Opportunities; July 2021**; Dear colleagues, Compiled by the Office of University Corporate and Foundation Relations, this monthly newsletter shares a selection of corporate and foundation opportunities that span a range of disciplines; Please share these opportunities with colleagues and faculty as appropriate, and feel free to reach out to me at dk2617@columbia.edu with any questions.; If you were forwarded this email, you can subscribe to the Corporate and Foundation Funding Opportunities newsletter here. ; -Dimitra

[NTW] [FIREARM INJURY AND MORTALITY PREVENTION]
Notice of Intent to Publish Funding Opportunity Announcements for Research on Firearm Injury and Mortality Prevention

**Sponsor:** Office of Behavioral and Social Sciences Research

**Deadline(s):** 06/01/2021 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Dara R. Blachman-Demner, Ph.D.; Office of Behavioral and Social Sciences Research; 301-496-8522; dara.blachman-demner@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-059.html

**Sponsor:** RWJF

**Deadline(s):** Open

**Contact:** pioneeringideas@rwjf.org

**Additional Information:** What can we do today to create a better, more equitable tomorrow? Through this new funding opportunity, RWJF seeks to understand and anticipate what dramatic changes we might see in the next five to 15 years in four areas: 1) Future of Evidence; 2) Future of Social Interaction; 3) Future of Food; and Future of Work. Additionally, this call for proposals seeks to support unconventional approaches and breakthrough ideas outside of these areas that could improve health equity and well-being for generations to come. We welcome proposals from scientists, anthropologists, artists, urban planners, community leaders—anyone, anywhere who has a cutting edge idea that could alter the trajectory of health and increase opportunities for everyone in the United States to live their healthiest life possible. Please note, while this CFP is focused on broader and longer-term societal trends and shifts that were evolving prior to the COVID-19 outbreak, we recognize the unique circumstances and learning created by the COVID-19 pandemic may inform your response. It is at your discretion whether you propose a project related to the pandemic directly or indirectly.

[NTW] [HIV]
**Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure**
*Sponsor:* National Institute of Mental Health  
**Deadline(s):** 05/08/2021 (First Available Due Date); 05/09/2024 (Expiration Date)  
**Contact:** Scientific/Research Contact(s); Collene Lawhorn, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-828-7186; Email: collene.lawhorn@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-21-105.html

[NTW] [HIV]
**Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV**
*Sponsor:* National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Institute of Mental Health  
**Deadline(s):** 09/07/2021 (First Available Due Date); 05/08/2024 (Expiration Date)  
**Contact:** Scientific/Research Contact(s); Rosemary McKaig, M.P.H, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3214; Email: rm434n@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-054.html

[NTW] [HIV]
**Notice of Intent to Publish a Funding Opportunity Announcement for Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional)**
*Sponsor:* National Cancer Institute  
**Deadline(s):** 09/05/2021 (First Estimated Application Due Date)  
**Contact:** Vidya Vedham, Ph.D.; National Cancer Institute (NCI); 240-276-7272; vidya.vedham@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-084.html
Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies

**Sponsor:** National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse

**Deadline(s):** 06/17/2021 (First Available Due Date); 09/05/2021 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Usha Sharma, PhD; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: (240) 292-4809; Email: usharma@niaid.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-056.html

**Additional Information:** Related Announcements: PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed); PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed); RFA AI-21-020 - Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed); RFA AI-21-021 - Enhancement or Sustainment of Data Science Tools for Infectious and Immune-Mediated diseases (U24 Clinical Trial Not Allowed); RFA AI-21-035 - Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed); PA 20-265 - PHS 2020-20 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed); PA-20-260 - PHS 2020 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)

**Sponsor:** John E. Fogarty International Center; National Cancer Institute; National Institute on Aging; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Mental Health

**Deadline(s):** 12/08/2021; 12/08/2022; 12/09/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Geetha P. Bansal, Ph.D.; Fogarty International Center (FIC); Telephone: 301-496-1492 Email: geetha.bansal@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-246.html

Organon Modeling of Neural Stimulants and HIV Comorbidity of Human Brain (R01-Clinical Trial Optional)

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 11/17/2021; 11/18/2021 (Expiration)

**Contact:** Scientific/Research Contact(s): Da-Yu Wu, PhD; National Institute on Drug Abuse (NIDA); Telephone: 301-435-4649; Email: wudy@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-009.html
[NTW] [HIV]
Innovative Models for Delivering PrEP and STI Services to Stop HIV in the United States (R61/R33 Clinical Trial Optional)
Sponsor: National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Institute of Mental Health
Deadline(s): 10/13/2021; 10/14/2021 (Expiration)
Contact: Scientific/Research Contact(s); Dale Burwen, M.D., M.P.H.; National Institute of Allergy and Infectious Disease (NIAID); Telephone: 240-669-2867; Email: dale.burwen@nih.gov

[NTW] [HIV]
PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional)
Sponsor: National Institute on Drug Abuse
Deadline(s): 11/12/2021; 11/13/2021 (Expiration)
Contact: Scientific/Research Contact(s); Richard A. Jenkins PhD; National Institute on Drug Abuse (NIDA); Telephone: 301-443-1923; Email: jenkinsri@mail.nih.gov
Link(s): https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-017.html

[NTW] [HIV]
Notice of Special Interest (NOSI): Administrative Supplements to NIMHD Awards for Research on HIV/AIDS in Populations that Experience Health Disparities (Admin Supp Clinical Trial Optional)
Sponsor: National Institute on Minority Health and Health Disparities
Deadline(s): 07/15/2021 (First Available Due Date); 07/16/2021 (Expiration Date)
Contact: Scientific/Research Contacts: Jennifer Alvidrez, PhD; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-594-9567; Email: jennifer.alvidrez@nih.gov

[NTW] [HIV]
Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R01 Clinical Trial Optional)
Sponsor: National Institute of Mental Health; National Institute of Neurological Disorders and Stroke
Deadline(s): 08/27/2021; 08/28/20212 (Expiration)
Contact: Scientific/Research Contact(s); Jeymohan Joseph, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 240-627-3869; Email: jiejeymoha@mail.nih.gov
[NTW] [HIV]  
Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R21 Clinical Trial Optional)  
**Sponsor:** National Institute of Mental Health; National Institute of Neurological Disorders and Stroke  
**Deadline(s):** 08/27/2021; 08/28/20212 (Expiration)  
**Contact:** Scientific/Research Contact(s); Jeymohan Joseph, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 240-627-3869; Email: jjeymoha@mail.nih.gov  

[NTW] [HIV]  
Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)  
**Sponsor:** National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Institute of Mental Health  
**Deadline(s):** 07/30/2021; 07/31/2021 (Expiration)  
**Contact:** Rosemary McKaig, PhD; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3214; Email: rmckaig@niaid.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-023.html

[NTW] [HIV]  
Multidisciplinary Treatment Approaches to End the HIV Epidemic (R01 Clinical Trial Optional)  
**Sponsor:** National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Institute of Mental Health  
**Deadline(s):** 08/04/2021; 08/05/2021 (Expiration)  
**Contact:** Tia Morton, R.N., M.S.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 301-222-7795; Email: frazierti@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-024.html

[NTW] [HIV]  
Prevention Strategies to End the HIV Epidemic (R01 Clinical Trial Optional)  
**Sponsor:** National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Institute of Mental Health  
**Deadline(s):** 07/30/2021; 07/31/2021 (Expiration)  
**Contact:** Dale Burwen, MD, MPH; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-669-2867; Email: dale.burwen@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-025.html
Understanding HIV Reservoir Dynamics (P01, Clinical Trial Not Allowed)

** Sponsor:** National Institute of Allergy and Infectious Diseases; National Institute of Mental Health  
** Deadline(s):** 07/30/2021; 07/31/2021 (Expiration)  
** Contact:** Scientific/Research Contact(s): Leia Novak, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID);  
Telephone: 301-761-7825; Email: Leia.novak@nih.gov  

Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3/UH3 Clinical Trial Optional)

** Sponsor:** National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Mental Health  
** Deadline(s):** 08/04/2021; 08/05/2021 (Expiration)  
** Contact:** Scientific/Research Contact(s): Gerald B. Sharp, Dr.P.H.; National Institute of Allergy and Infectious Diseases (NIAID);  
Telephone: 240-627-3217; Email: GSharp@niaid.nih.gov  

Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)

** Sponsor:** National Institute on Drug Abuse  
** Deadline(s):** 09/07/2021; 01/07/2022; 05/07/2022; 09/07/2022; 01/07/2024; 05/07/2024; 05/08/2024 (Expiration)  
** Contact:** Scientific/Research Contact(s): Richard A. Jenkins, Ph.D.; National institute on Drug Abuse (NIDA);  
Telephone: 301-443-1923; Email: jenkinsri@mail.nih.gov  

Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV (R01 Clinical Trial Not Allowed)

** Sponsor:** National Institute of Dental and Craniofacial Research; National Cancer Institute  
** Deadline(s):** 11/18/2021; 11/19/2021 (Expiration)  
** Contact:** Scientific/Research Contact(s): Hiroko Iida, DDS, MPH; National Institute of Dental and Craniofacial Research (NIDCR);  
Telephone: 301-594-7404; Email: hiroko.iida@nih.gov  
R2eport
Friday Newsletter 07/16/2021

[NTW] [HIV]
Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV (R21 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Dental and Craniofacial Research; National Cancer Institute
**Deadline(s):** 11/18/2021; 11/19/2021 (Expiration)
**Contact:** Scientific/Research Contact(s); Hiroko Iida, DDS, MPH; National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-594-7404; Email: hiroko.iida@nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-22-004.html

[NTW] [HIV/SUBSTANCE USE DISORDERS]
Notice of Special Interest (NOSI): Identification of Biomarkers of HIV Pathogenesis and Substance Use Disorder Comorbidity

**Sponsor:** National Institute on Drug Abuse
**Deadline(s):** 06/05/2021 (First Available Due Date); 09/08/2024 (Expiration Date)
**Contact:** Lennin F. Greenwood; National Institute on Drug Abuse (NIDA); Telephone: 301-827-6686;
Email: lennin.greenwood@nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-014.html

[NTW] [SUBSTANCE USE DISORDERS]
Notice of Special Interest: Advanced Computational Approaches to Elucidate Disease Pathology and Identify Novel Therapeutics for Addiction

**Sponsor:** National Institute on Drug Abuse
**Deadline(s):** 10/05/2021 (First Available Due Date); 01/08/2025 (Expiration Date)
**Contact:** Scientific/Research Contact(s); Susan Wright, PhD; National Institute on Drug Abuse (NIDA); Telephone: (301) 402-6683; Email: susan.wright@nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-004.html

[NTW] [SUBSTANCE USE DISORDERS]
Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)

**Sponsor:** National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
**Deadline(s):** 10/16/2021; 02/16/2022; 06/16/2022; 10/16/2023; 02/16/2024; 05/08/2024 (Expiration)
**Contact:** Scientific/Research Contact(s); Keisher Highsmith, DrPH; National Institute on Drug Abuse (NIDA);
Email: Keisher.highsmith@nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-21-180.html
Notice of Special Interest: Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes

Sponsor: National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; National Institute on Drug Abuse

Deadline(s): 06/05/2021 (First Available Due Date); 09/08/2024 (Expiration Date)

Contact: Scientific/Research Contact(s); Gregory Bloss, M.A., M.P.P.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Email: Gregory.Bloss@nih.gov


Mechanistic studies on the impact of social inequality on the substance use trajectory (R21 - Clinical Trial Not Allowed)

Sponsor: National Institute on Drug Abuse

Deadline(s): 10/14/2021; 10/15/2021 (Expiration)

Contact: Scientific/Research Contact(s); Vani Pariyadath, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: (301) 443-3209; Email: vani.pariyadath@nih.gov


Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Clinical Trial Not Allowed)

Sponsor: National Institute on Drug Abuse

Deadline(s): 10/14/2021; 10/15/2021 (Expiration)

Contact: Scientific/Research Contact(s); Vani Pariyadath, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: (301) 443-3209; Email: vani.pariyadath@nih.gov


Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation (R01 Clinical Trial Optional)

Sponsor: National Institute on Drug Abuse

Deadline(s): 08/05/2021; 08/06/2021 (Expiration)

Contact: Scientific/Research Contact(s); Yu (Woody) Lin; National Institute on Drug Abuse (NIDA); Telephone: 301-435-1318; Email: ylin1@mail.nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Basic Experimental Studies with Humans Required)

Sponsor: National Institute on Drug Abuse
Deadline(s): 10/14/2021; 10/15/2021 (Expiration)
Contact: Scientific/Research Contact(s); Vani Pariyadath, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: (301) 443-3209; Email: vani.pariyadath@nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Basic Experimental Studies with Humans Required)

Sponsor: NIH/NIDA
Deadline(s): 10/14/2021; 10/15/2021 (Expiration)
Contact: Scientific/Research Contact(s); Vani Pariyadath, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: (301) 443-3209; Email: vani.pariyadath@nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Research Project Sites (U01)

Sponsor: National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Mental Health
Deadline(s): 08/17/2021 (First Estimated Application Due Date)
Contact: Please direct all inquiries to: Abraham P. Bautista, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); bautista@mail.nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Administrative Resource (U24)

Sponsor: National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Mental Health
Deadline(s): 08/18/2021 (First Estimated Application Due Date)
[NTW] [SUBSTANCE USE DISORDERS]
Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CI-FASD), Research Project (U01 Clinical Trial optional)
**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 08/15/2021 (First Estimated Application Due Date)  
**Contact:** H. Joe Wang, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); 301-451-0747  
**Link(s):** [https://grants.nih.gov/grants/guide/notice-files/NOT-AA-21-017.html](https://grants.nih.gov/grants/guide/notice-files/NOT-AA-21-017.html)

[NTW] [SUBSTANCE USE DISORDERS]
Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CI-FASD), Administrative Core (U24) (Clinical Trial Not Allowed)
**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 08/15/2021 (First Estimated Application Due Date)  
**Contact:** Scientific/Research Contact: H. Joe Wang, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); 301-451-0747; joe.wang1@nih.gov  

[NTW] [SUBSTANCE USE DISORDERS]
Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CI-FASD), Diagnostic-Telemedicine Core (U24 Clinical Trial Not Allowed)
**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 08/15/2021 (First Estimated Application Due Date)  
**Contact:** Scientific/Research Contact: H. Joe Wang, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); 301-451-0747; joe.wang1@nih.gov  

[NTW] [SUBSTANCE USE DISORDERS]
Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CI-FASD)
Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Data Coordination Core (U24 Clinical Trial Not Allowed)

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 08/15/2021 (First Estimated Application Due Date)  
**Contact:** Scientific/Research Contact: H. Joe Wang, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); 301-451-0747; joe.wang1@nih.gov  

**[NTW] [SUBSTANCE USE DISORDERS]**  
Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Developmental Project (UH2 Clinical Trial Optional)

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 08/15/2021 (First Estimated Application Due Date)  
**Contact:** Scientific/Research Contact: H. Joe Wang, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); 301-451-0747; joe.wang1@nih.gov  

**[NTW] [SUBSTANCE USE DISORDERS]**  
HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs  
**Deadline(s):** 09/08/2021; 01/06/2022; 04/06/2022; 09/08/2022  
**Contact:** Scientific/Research Contact(s); Stephanie Fertig, MBA; National Institute of Neurological Disorders and Stroke (NINDS); Phone: 301-496-1778; Email: fertigs@ninds.nih.gov  
Notice of Special Interest (NOSI): Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 06/05/2021 (First Available Due Date); 09/08/2024 (Expiration)

**Contact:** Scientific/Research Contact(s); Sam Ananthan, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-435-2199; Email: sam.ananthan@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-028.html

Notice of Special Interest (NOSI): Administrative Supplements for research on fentanyl and derivatives

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 04/01/2021 (First Available Due Date); 04/01/2022 (Expiration)

**Contact:** Aidan Hampson, Ph.D.; National Institute on Drug Abuse; Telephone: 301-827-5925; Email: hampsona@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-032.html

## Other NIH NIDA Funding Opportunities

1. [National Institute of Drug Abuse NIDA Funding Opportunities; NIDA Notices](https://www.drugabuse.gov/funding/nida-funding-opportunities)
2. [National Institute of Drug Abuse NIDA Funding Opportunities; NIDA Notices of Special Interest](https://www.drugabuse.gov/funding/nida-funding-opportunities)
3. [National Institute of Drug Abuse NIDA Funding Opportunities; Active NIDA Requests for Applications, RFAs](https://www.drugabuse.gov/funding/nida-funding-opportunities)
4. [National Institute of Drug Abuse NIDA Funding Opportunities; Active NIDA Program Announcements, PAs](https://www.drugabuse.gov/funding/nida-funding-opportunities)
[NTW] [SUBSTANCE USE DISORDERS]
Special Emphasis Notice (SEN): AHRQ Announces Interest in Health Services Research to Address Substance Use Disorder Epidemic

**Sponsor:** Agency for Healthcare Research and Quality  
**Deadline(s):** 04/03/2021 (Release Date)  
**Contact:** Please direct all inquiries to: Sebastian Tong, MD, MPH; Center for Evidence and Practice Improvement; Agency for Healthcare Research and Quality; Sebastian.Tong@ahrq.hhs.gov  

[NTW] [SUBSTANCE USE DISORDERS]
Specialized Alcohol Research Centers (P50 Clinical Trial Optional)

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 11/15/2021; 11/16/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Gregory Bloss, M.A.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-443-3865; Email: Gregory.Bloss@nih.gov  

[NTW] [SUBSTANCE USE DISORDERS]
Comprehensive Alcohol Research Centers (P60 Clinical trial Optional)

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 11/15/2021; 11/16/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Gregory Bloss, M.A.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-443-3865; Email: Gregory.Bloss@nih.gov  

[NTW] [SUBSTANCE USE DISORDERS]
Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R43/R44 - Clinical Trial Not Allowed)

**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 08/10/2021; 08/11/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Ram Arudchandran, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-827-6889; Email: ramachandran.arudchandran@nih.gov  

[NTW] [SUBSTANCE USE DISORDERS]
Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed)

**Sponsor:** National Institute on Drug Abuse
Deadline(s): 08/10/2021; 08/11/2021 (Expiration)
Contact: Scientific/Research Contact(s): Ram Arudchandran, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-827-6889; Email: ramachandran.arudchandran@nih.gov

[NTW] [SUBSTANCE USE DISORDERS]
Exploratory Studies to Investigate the Mechanisms of Interrelationship between Sleep and Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans Required)
Sponsor: National Institute on Drug Abuse
Deadline(s): 10/14/2021; 10/15/2021 (Expiration)
Contact: Scientific/Research Contact(s); Sunila Nair, PhD; National Institute on Drug Abuse (NIDA); Telephone: 301-827-6832; Email: sunila.nair@nih.gov

[NTW] [PAIN MANAGEMENT]
Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)
Sponsor: National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; National Institute of Mental Health
Deadline(s): 04/27/2021 (First Estimated Application Due Date)
Contact: Please direct all inquiries to: Michael Oshinsky; National Institute of Neurological Disorders and Stroke (NINDS); 301-496-9964; michael.oshinsky@nih.gov

[NTW] [PAIN MANAGEMENT]
Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics]
Sponsor: National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; National Institute of Mental Health
Deadline(s): 04/27/2021 (First Estimated Application Due Date)
Contact: Please direct all inquiries to: Michael Oshinsky; National Institute of Neurological Disorders and Stroke (NINDS); 301-496-9964; michael.oshinsky@nih.gov
[NTW] [SUICIDE PREVENTION]
Notice of Special Interest (NOSI) in Reducing Suicide Risk in Young People in Low- and Middle-Income Countries and Low-Resource Settings

**Sponsor:** National Institute of Mental Health

**Deadline(s):** 06/05/2021 (First Available Due Date); 05/08/2024 (Expiration Date)

**Contact:** Scientific/Research Contact(s); Andrea Horvath Marques, MD, MPH, PhD; National Institute of Mental Health (NIMH); Telephone: 301-646-7320; Email: andrea.horvathmarques@nih.gov


[NTW] [SUICIDE PREVENTION]
Notice of Change to NOT-MH-21-090, "Notice of Special Interest (NOSI) in Reducing Suicide Risk in Young People in Low- and Middle-Income Countries and Low-Resource Settings"

**Sponsor:** National Institute of Mental Health

**Deadline(s):** 06/09/2021 (Release Date)

**Contact:** Andrea Horvath Marques, MD, MPH, PhD; National Institute of Mental Health (NIMH); Telephone: 301-646-7320; Email: andrea.horvathmarques@nih.gov


[NTW] [COUNTERMEASURES AGAINST CHEMICAL THREATS]
Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Eye Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of Environmental Health Sciences

**Deadline(s):** 09/14/2021; 09/13/2022; 09/12/2023; 09/13/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); For questions related to the overall CounterACT program and/or neurological injury research including threat agents of interest: David A. Jett, Ph.D.; National Institute of Neurological Disorder and Stroke (NINDS); Telephone: 301-496-6035; Email: jettd@ninds.nih.gov

[Link(s):](https://grants.nih.gov/grants/guide/pa-files/PAR-20-316.html)

[NTW] [COUNTERMEASURES AGAINST CHEMICAL THREATS/EARLY CAREER]
Notice of Intent to Publish a Funding Opportunity Announcement for NIH Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award
[NTW] [COUNTERMEASURES AGAINST CHEMICAL THREATS]
NIH Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award (R21 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Eye Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of Environmental Health Sciences

**Deadline(s):** 07/27/2021; 07/28/2021 (Expiration)

**Contact:** Scientific/Research Contact(s): Shardell Spriggs, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Email: shardell.spriggs@mail.nih.gov


[NTW] [COOPERATIVE AGREEMENT]

NIH Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award (R21 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Eye Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of Environmental Health Sciences

**Deadline(s):** 06/27/2021 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Shardell M. Spriggs, PhD; National Institute of Neurological Disorders and Stroke (NINDS); 301-443-8189; shardell.spriggs@nih.gov


[NTW] [COOPERATIVE AGREEMENT]

NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases

**Deadline(s):** 02/17/2022; 10/13/2022; 06/08/2023; 02/15/2024; 02/16/2024 (Expiration)

**Contact:** Scientific/Research Contact(s): Tracy Rankin, Ph.D., M.P.H.; Division of Kidney, Urologic and Hematologic Diseases; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-594-4748; Email: rankint@mail.nih.gov


[NTW] [COOPERATIVE AGREEMENT]

NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases

**Deadline(s):** Standard dates; Standard AIDS dates: 01/08/2024 (Expiration)

**Contact:** Scientific/Research Contact(s): Tracy Rankin, Ph.D., M.P.H.; Division of Kidney, Urologic and Hematologic Diseases; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-594-4748; Email: rankint@mail.nih.gov

[NTW] [COOPERATIVE AGREEMENT]
NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases  
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s): Tracy Rankin, Ph.D., M.P.H. ; Division of Kidney, Urologic and Hematologic Diseases; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-594-4748; Email: rankint@mail.nih.gov  

[NTW] [IMPLEMENTATION RESEARCH]

[1] Dissemination and Implementation Research in Health R01 Clinical Trial Optional  
[2] Dissemination and Implementation Research in Health R21 Clinical Trial Optional  
[3] Dissemination and Implementation Research in Health R03 Clinical Trial Not Allowed  

**Sponsor:** National Institutes of Health (NIH); Components of Participating Organizations: National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Human Genome Research Institute (NHGRI); National Institute on Aging (NIA); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Deafness and Other Communication Disorders (NIDCD); National Institute of Dental and Craniofacial Research (NIDCR); National Institute on Drug Abuse (NIDA); National Institute of Environmental Health Sciences (NIEHS); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Nursing Research (NINR); National Institute on Minority Health and Health Disparities (NIMHD); National Center for Complementary and Integrative Health (NCCIH); All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers: Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP); Office of Behavioral and Social Sciences Research (OBSSR); Office of Research on Women’s Health (ORWH)  
**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s): Lindsey Ann Martin, PhD; National Institute of Environmental Health Sciences (NIEHS); Phone: (984) 287-4036; Email: Lindsey.Martin@nih.gov  
**Link(s):** [https://grants.nih.gov/grants/guide/files/PAR-19-274.html](https://grants.nih.gov/grants/guide/files/PAR-19-274.html) (Dissemination and Implementation Research in Health R01 Clinical Trial Optional);  

[NTW] [RARE DISEASES]

Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)  

**Sponsor:** National Center for Advancing Translational Sciences
Deadline(s): 09/13/2021; 01/12/2022; 01/13/2022 (Expiration)
Contact: Scientific/Research Contact(s): P.J. Brooks, Ph.D.; National Center for Advancing Translational Sciences (NCATS);
Telephone: 301-443-0513; Email: pjbrooks@mail.nih.gov

[NTW] [FOOD AND DRUG ADMINISTRATION/RARE DISEASES]
Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01) Clinical Trials Not Required
Sponsor: Food and Drug Administration
Deadline(s): 02/15/2022; 02/13/2024; 02/14/2024 (Expiration)
Contact: Scientific/Research Contact(s): Katherine Needleman; Director, Orphan Products Grants Program; Office of Orphan Products Development; Food and Drug Administration; E-mail: katherine.needleman@fda.hhs.gov

[NTW] [FOOD AND DRUG ADMINISTRATION]
The FDA’s Cooperative Agreement Program for States and Territories to Implement a National Produce Safety Program (U2F) Clinical Trials Not Allowed
Sponsor: Food and Drug Administration
Deadline(s): 03/01/2022; 03/02/2023 (Expiration)
Contact: Program Official Contact(s); Laurie Keppley; Office of Regulatory Affairs (ORA); Office of Management; Telephone: 240-402-7736; Email: Laurie.Keppley@fda.hhs.gov

[NTW] [SMALL BUSINESS]
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
Sponsor: National Institute of Allergy and Infectious Diseases
Deadline(s): 09/13/2021; 01/14/2022; 05/13/2022; 09/13/2022; 01/13/2023; 05/13/2023; 09/14/2023; 01/13/2024; 01/14/2024 (Expiration)
Contact: Scientific/Research Contact(s): Natalia Kruchinin, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID);
Telephone: 240-669-2919; Email: NIAIDU44@mail.nih.gov
Link(s): https://grants.nih.gov/grants/guide/pa-files/PAR-21-082.html

[NTW] [SMALL BUSINESS]
Notice of Intent to Publish a Funding Opportunity Announcement for PHS 2021 Omnibus Solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications
Sponsor: National Institutes of Health
Deadline(s): 09/07/2021 (First Estimated Application Due Date)
Contact: SEED (Small business Education and Entrepreneurial Development); Office of Extramural Research; 301-435-2688;
SEEDinfo@nih.gov

[NTW] [SMALL BUSINESS]
NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional)
Sponsor: National Institute on Aging
Deadline(s): 10/26/2021; 10/27/2021 (Expiration)
Contact: Scientific/Research Contact(s); Saroj Regmi, Ph. D.; National Institute on Aging (NIA)
Phone: 301-480-8964; Email: saroj.regmi@nih.gov

[NTW] [SMALL BUSINESS]
NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R41/R42 Clinical Trial Optional)
Sponsor: National Institute on Aging
Deadline(s): 10/26/2021; 10/27/2021 (Expiration)
Contact: Scientific/Research Contact(s); Saroj Regmi, Ph. D.; National Institute on Aging (NIA)
Phone: 301-480-8964; Email: saroj.regmi@nih.gov

[NTW] [SMALL BUSINESS]
NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurship Enhancement Award (R25 Clinical Trial Not Allowed)
Sponsor: National Institute on Aging
Deadline(s): 10/04/2021; 10/05/2021 (Expiration)
Contact: Scientific/Research Contact(s); Saroj Regmi, Ph.D.; National Institute on Aging (NIA); Phone: 301-480-8964; Email: saroj.regmi@nih.gov

[NTW] [SMALL BUSINESS]
NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award (K01 Clinical Trial Not Allowed)
Sponsor: National Institute on Aging
Deadline(s): 09/29/2021; 09/30/2021 (Expiration)
Contact: Scientific/Research Contact(s); Saroj Regmi, Ph. D.; National Institute on Aging (NIA)
Phone: 301-480-8964; Email: saroj.regmi@nih.gov
[NTW] [SMALL BUSINESS]

**PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)**

**Sponsor:** National Institutes of Health; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** Standard dates; 04/06/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); NIH SEED (Small business Education and Entrepreneurial Development); Telephone: 301-435-2688; Fax: 301-480-0146; Email: SEEDinfo@nih.gov; For Agency, Institute and Center Scientific/Research (Program) contacts, please see middle column here: https://sbir.nih.gov/engage/ic-contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-21-259.html

[NTW] [SMALL BUSINESS]

**PHS 2021-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)**

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research

**Deadline(s):** Standard dates; 04/06/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); NIH SEED (Small business Education and Entrepreneurial Development); Telephone: 301-435-2688; Fax: 301-480-0146; Email: SEEDinfo@nih.gov; For Agency, Institute and Center Scientific/Research (Program) contacts, please see middle column here: https://sbir.nih.gov/engage/ic-contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-21-260.html
[NTW] [SMALL BUSINESS]
PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research

**Deadline(s):** Standard dates; 04/06/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); NIH SEED (Small business Education and Entrepreneurial Development); Telephone: 301-435-2688; Fax: 301-480-0146; Email: SEEDinfo@nih.gov; For Agency, Institute and Center Scientific/Research (Program) contacts, please see middle column here: https://sbir.nih.gov/engage/ic-contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-21-261.html

[NTW] [SMALL BUSINESS]
PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** Standard dates; 04/06/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); NIH SEED (Small business Education and Entrepreneurial Development); Telephone: 301-435-2688; Fax: 301-480-0146; Email: SEEDinfo@nih.gov; For Agency, Institute and Center Scientific/Research (Program) contacts, please see middle column here: https://sbir.nih.gov/engage/ic-contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-21-262.html

[NTW] [SMALL BUSINESS]
Growing Great Ideas: Research Education Course in Product Development and Entrepreneurship for Life Science Researchers (UE5 Clinical Trial Not Allowed)

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 11/18/2021; 11/19/2021 (Expiration)
Contact: Elena Koustova, PhD, MBA; National Institute on Drug Abuse (NIDA); Telephone: 301-496-8768; Email: elena.koustova@nih.gov

[NTW] [SMALL BUSINESS]
Biomarker Research to Support Fertility Regulation Development by Small Business (R43 Clinical Trial Optional)
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Deadline(s): 07/29/2021; 07/30/2021 (Expiration)
Contact: Scientific/Research Contact(s); Christopher C. Lindsey, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6907; Email: chris.lindsey@mail.nih.gov

[NTW] [SUPPORT FOR RESEARCH EXCELLENCE (SURE)]
Notice of Intent to Publish a Funding Opportunity Announcement for Support for Research Excellence (SuRE)
Sponsor: National Institute of General Medical Sciences
Deadline(s): 05/25/2021 (First Estimated Application Due Date)
Contact: Please direct all inquiries to: Irina N. Krasnova, Ph.D.; National Institute of General Medical Sciences (NIGMS); 301-827-7323; irina.krasnova@nih.gov

[NTW] [SUPPORT FOR RESEARCH EXCELLENCE (SURE)]
Notice of Intent to Publish a Funding Opportunity Announcement for Support for Research Excellence - First Independent Research Support & Transition (SuRE-First)
Sponsor: National Institute of General Medical Sciences
Deadline(s): 09/25/2021 (First Estimated Application Due Date)
Contact: Please direct all inquiries to: Irina N. Krasnova, Ph.D.; National Institute of General Medical Sciences (NIGMS); 301-827-7323; irina.krasnova@nih.gov

[NTW] [SUPPORT FOR RESEARCH EXCELLENCE (SURE)]
Notice of Intent to Publish a Funding Opportunity Announcement for a National Resource Center for the Support for Research Excellence (SuRE) Program
Sponsor: National Institute of General Medical Sciences
Deadline(s): 09/25/2021 (First Estimated Application Due Date)
SuRE R16 Program Funding Announcements and Upcoming Webinar

Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
Support for Research Excellence – First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)

SuRE program, please join our informational webinar: Tuesday, April 13, 3:00-4:30 p.m. ET

Sponsor: NIH
Deadline(s): 05/26/2022; 05/26/2023; 09/08/2023 (Expiration) [Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)]; 09/28/2021; 09/28/2022; 09/28/2023; 01/08/2024 (Expiration) [Support for Research Excellence – First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)]
Contact: Scientific/Research Contact(s); Irina N. Krasnova, Ph.D.; National Institute of General Medical Sciences (NIGMS); Email: irina.krasnova@nih.gov

Additional Information: PEPH: Funding Announcements and Upcoming Webinar; Dear PEPH Community, See note below from Toccara Chamberlain regarding a new funding opportunity that may be of interest to many of you. Please share as appropriate; In health, Liam; SuRE R16 Program Funding Announcements and Upcoming Webinar; Good afternoon everyone, I am pleased to announce that two funding opportunities for the new Support for Research Excellence (SuRE) program, which replaces our Support of Competitive Research (SCORE) program, have been issued. SuRE R16 awards support investigator-initiated research projects in all NIH mission areas and are open to faculty at institutions that award science degrees (bachelor and/or graduate degrees), receive limited NIH research support, and serve students from groups underrepresented in biomedical research.; The two opportunities are: [1] SuRE Award. Faculty with prior experience in leading independent research who aren’t currently program directors/principal investigators of active NIH research project grants may apply for a SuRE Award PAR-21-169; Due date -- May 26, 2021 (SuRE Award); [2] SuRE-First Award. Faculty who haven’t had any prior independent research grant support are encouraged to apply for the SuRE-First Award PAR-21-173; Due date -- September 28, 2021 (SuRE-First Award); To learn more about SuRE program, please join our informational webinar: Tuesday, April 13, 3:00-4:30 p.m. ET; During the webinar, we’ll provide a broad overview of the programs and share our expectations for successful applications. You can send questions in advance to irina Krasnova or post them in the chat box during the event.; To join the webinar, visit the Zoom Meeting page and enter the meeting number 160 329 0386 and the passcode 952376. If you’re unable to attend online, you can join by calling 669-254-5252 or 646-828-7666 (United States) and entering the meeting number and passcode.; Slides and a recording of the webinar will be posted on the NIGMS webpage following the event.; Could you please share this information with potential SuRE applicants?; Best regards, Toccara; [brought to our attention by] Toccara Chamberlain, MA; Health Specialist; Population Health Branch; National Institute of Environmental Health Sciences; Email: toccara.chamberlain@nih.gov
AHRQ Policy on the Inclusion of Priority Populations in Research

**Sponsor:** Agency for Healthcare Research and Quality  
**Deadline(s):** 05/18/2021 (Release Date)  
**Contact:** Brenda Harding; AHRQ/Division of Priority Populations; Office of Extramural Research, Education, and Policy; Brenda.harding@ahrq.hhs.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HS-21-015.html

New Investigators to Promote Workforce Diversity in Genomics and other Health-Related Research (R01 Clinical Trial Optional)

**Sponsor:** National Human Genome Research Institute; National Institute of Biomedical Imaging and Bioengineering; Office of the Director, NIH  
**Deadline(s):** 08/03/2021; 02/22/2022; 02/22/2023; 02/23/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Jyoti Dayal, M.S.; National Human Genome Research Institute (NHGRI); Telephone: 301-480-2307; Email: jyotig@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-025.html

Research on Interventions that Promote the Careers of Individuals in the Biomedical Research Enterprise (R01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of General Medical Sciences  
**Deadline(s):** 10/13/2021; 10/13/2022; 10/13/2023; 10/14/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Sydella Blatch, Ph.D.; National Institute of General Medical Sciences (NIGMS); Email: sydella.blatch@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-269.html

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Required)

**Sponsor:** National Heart, Lung, and Blood Institute  
**Deadline(s):** 10/14/2021; 02/11/2022; 10/13/2022; 02/14/2023; 10/13/2023; 02/14/2024; 05/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); Jane D. Scott, ScD, MSN, FAHA; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-0535; Email: scottj2@nhlbi.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-010.html
[NTW] [DIVERSITY]
Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Not Allowed)

**Sponsor:** National Heart, Lung, and Blood Institute  
**Deadline(s):** 10/14/2021; 02/11/2022; 10/13/2022; 02/14/2023; 10/13/2023; 02/13/2024; 05/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); Jane D. Scott, ScD, MSN, FAHA; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-0535; Email: scottj2@nhlbi.nih.gov  

[NTW] [DIVERSITY]
NIDDK Short-Term Research Experience Program to Unlock Potential (STEP-UP) (R25 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases  
**Deadline(s):** 09/01/2021; 09/02/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Rob Rivers, PhD; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-443-8415; Email: riversrc@mail.nih.gov  

[NTW] [DIVERSITY]
Notice of Special Interest (NOSI): NIH Research Project Grant (R01) Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Institute on Drug Abuse  
**Deadline(s):** 06/05/2021 (First Available Due Date); 05/08/2023 (June 05, 2021)  
**Contact:** Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.  

[NTW] [CONFERENCE AND MEETING SUPPORT]
NIOSH Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)

**Sponsor:** National Institute for Occupational Safety and Health  
**Deadline(s):** Standard dates; 12/15/2025 (Expiration)  
**Contact:** Scientific / Research Contact(s); Sharon Chiu, PhD; National Institute for Occupational Safety and Health (NIOSH); Centers for Disease Control and Prevention (CDC); Telephone: 304-285-6029; Email: SChiou@cdc.gov  
[NTW] [CONFERENCE AND MEETING SUPPORT]
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** standard due dates: 01/07/2024; 01/08/2024 (Expiration)

**Contact:** Scientific/Research Contact information is listed in the table at R13 Contacts and Special Interest website.

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-21-151.html

[NTW] [GENDER INCLUSIVE EXCELLENCE]

Notice of Intent to Publish a Funding Opportunity Announcement for Advancing Gender Inclusive Excellence (AGIE) Coordinating Center (U54)

**Sponsor:** Office of Research on Women's Health; National Institute of Diabetes and Digestive and Kidney Diseases

**Deadline(s):** 01/29/2021 (Release Date)

**Contact:** Please direct all inquiries to: Lynn Morin; Office of Research on Women’s Health; 301-451-2730; lynn.morin@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-051.html

[NTW] [VACCINE HESITANCY]

Notice of Special Interest (NOSI): Urgent Competitive Revisions and Administrative Supplements for Research at NIMHD Research Centers in Minority Institutions (RCMI U54s) on SARS-CoV-2 Vaccine Hesitancy, Uptake, and Implementation

**Sponsor:** National Institute on Minority Health and Health Disparities

**Deadline(s):** 03/05/2021 (First Available Due Date); 05/04/2024 (Expiration Date)

**Contact:** Scientific/Research Contact; Deborah E. Linares, Ph.D., M.A.; National Institute on Minority Health and Health Disparities; http://www.nimhd.nih.gov; Telephone: 301-402-2516; Email: deborah.linares@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MD-21-012.html

[NTW] [VACCINES]

Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake
among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development  
**Deadline(s):** 09/08/2021 (First Available Due Date) ; 05/08/2024 (Expiration Date)  
**Contact:** Scientific/Research Contact(s); Regina M. Bures, Ph.D.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Phone: 301-496-9485; Email: regina.bures@nih.gov  

[NTW] [DIGITAL HEALTHCARE]  
**Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)**

**Sponsor:** Agency for Healthcare Research and Quality  
**Deadline(s):** Standard dates; 06/18/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); CDR Derrick L. Wyatt; Agency for Healthcare Research and Quality; Center for Evidence and Practice Improvement (CEPI); Division of Health Information Technology; Telephone: 301-427-1505; Email: DigitalHealthcareResearch@ahrq.hhs.gov (preferred method of contact)  

[NTW] [DIGITAL HEALTHCARE]  
**Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)**

**Sponsor:** Agency for Healthcare Research and Quality  
**Deadline(s):** Standard dates; 07/18/2024 (Expiration)  
**Contact:** CDR Derrick L. Wyatt; Agency for Healthcare Research and Quality; Center for Evidence and Practice Improvement (CEPI); Division of Health Information Technology; Telephone: 301-427-1505; Email: DigitalHealthcareResearch@ahrq.hhs.gov (preferred method of contact)  

[NTW] [MINE EVACUATION TECHNOLOGIES]  
**Underground Mine Evacuation Technologies and Human Factors Research (U60)**

**Sponsor:** National Institute for Occupational Safety and Health  
**Deadline(s):** 02/10/2022; 10/01/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Maria Lioce, MD; Office of Extramural Programs; National Institute for Occupational Safety and Health (NIOSH); Centers for Disease Control and Prevention (CDC); Telephone: 404-498-2575; Email: MLioce@cdc.gov  

[NTW] [INFECTIOUS DISEASE]  
**Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)**
[NTW] [TOBACCO]
Tobacco Regulatory Science (R01 Clinical Trial Optional)
Sponsor: National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environmental Health Sciences
Deadline(s): 02/15/2022; 07/14/2022; 02/14/2023; 02/15/2023 (Expiration)
Contact: Scientific/Research Contact(s); Rachel Grana Mayne, PhD; National Cancer Institute (NCI); Telephone: 240-276-5899; Email: granar@nih.gov

[NTW] [TOBACCO]
Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)
Sponsor: National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environmental Health Sciences
Deadline(s): 10/08/2021; 08/08/2022; 03/08/2023; 03/09/2023 (Expiration)
Contact: Scientific/Research Contact(s); Rachel Grana Mayne, PhD; National Cancer Institute (NCI)
Telephone: 240-276-5899; Email: granar@nih.gov

[NTW] [TOBACCO]
Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Basic Mechanisms of Health Effects
Sponsor: Office of Disease Prevention; National Cancer Institute; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences
Deadline(s): 10/05/2021 (First Available Due Date) ; 05/08/2023 (Expiration Date)
Contact: Ron Johnson, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-6250; Email: rjohnso2@mail.nih.gov

**Sponsor:** Office of Disease Prevention; National Cancer Institute; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute on Minority Health and Health Disparities

**Deadline(s):** 10/05/2021 (First Available Due Date); 05/08/2024 (Expiration Date)

**Contact:** Rachel Grana Mayne, PhD, MPH; National Cancer Institute (NCI); Telephone: 240-276-5899; Email: rachel.mayne@nih.gov


[NTW] [POINT OF CARE]

Notice of Correction to NOT-OD-21-065 "Notice of Intent to Publish a Research Opportunity Announcement for RADx-UP Return to School Diagnostic Testing Approaches (OT2 Clinical Trial Required)" for Clinical Trial Requirements

**Sponsor:** National Institutes of Health

**Deadline(s):** NA

**Contact:** Sonia Lee, Ph.D.; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD); Telephone: 301-594-4783; Email: leeson@nih.gov


[NTW] [RESPIRATORY]

Notice of Intent to Publish a Funding Opportunity Announcement for the ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (U01 Clinical Trial Not Allowed)

**Sponsor:** National Heart, Lung, and Blood Institute; National Institute of General Medical Sciences

**Deadline(s):** 06/17/2022 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Lora Reineck, MD, MS; National Heart, Lung, and Blood Institute (NHLBI); 301-435-0222; lora.reineck@nih.gov


[NTW] [RESPIRATORY]

Notice of Intent to Publish a Funding Opportunity Announcement for the ARDS, Pneumonia, and Sepsis Phenotyping Consortium Coordinating Center (U01)

**Sponsor:** National Heart, Lung, and Blood Institute; National Institute of General Medical Sciences

**Deadline(s):** 06/17/2022 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Lora Reineck, MD, MS; National Heart, Lung, and Blood Institute (NHLBI); 301-435-0222; lora.reineck@nih.gov

[NTW] [BEHAVIORAL]

Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to improve use of Evidence-Based Practices for HLBS conditions

**Sponsor:** National Heart, Lung, and Blood Institute

**Deadline(s):** 10/05/2021 (First Available Due Date); 09/08/2024 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Rebecca A. Roper, MS, MPH; Center for Translation Research and Implementation Science; National Heart, Lung and Blood Institute (NHLBI); Telephone: 301-496-1051; Email: Rebecca.Roper@nih.gov


**Additional Information:** This Notice of Special Interest (NOSI) is intended to stimulate the use of behavioral economics strategies for implementation research (BEIR) in order to develop more effective strategies for implementation of evidence-based practices (EBP) to address heart, lung, blood, and sleep (HLBS) conditions.

[NTW] [DIRECTORS EARLY INDEPENDENCE AWARDS]

Limited Submission: NIH Directors Early Independence Awards (DP5 Clinical Trial Optional); 07.22.2021 (Internal Deadline)

Limited Submission NIH Directors Early Independence Awards (DP5 Clinical Trial Optional); Sponsor Announcement, 09.03.2021 (Sponsor Deadline)

**Sponsor:** Office of Strategic Coordination (Common Fund)

**Deadline(s):** 07/22/2021 (Internal, Limited Submission Deadline); 09/03/2021 (Sponsor Deadline); 09/04/2021 (Expiration)

**Contact:** Scientific/Research Contact(s): Becky Miller, Ph.D.; Office of the Director (OD); Telephone: 301-594-9979; Questions should be sent to Greg Culler at limitedsubmissions@columbia.edu [NIH Contact provided for reference, this is a Limited Submission initiative]; Email: earlyindependence@od.nih.gov

**Link(s):** [https://columbia.infoready4.com/#competitionDetail/1845646](https://columbia.infoready4.com/#competitionDetail/1845646)

**Additional Information:** Limited Submission; NIH Director’s Early Independence Awards (DP5); RFA-RM-21-018; Internal Proposal deadline: 9:00 a.m. on Thursday, July 22; Important - This is not a postdoctoral fellowship/training program.; This program supports exceptionally talented PhD candidates and very recent graduates to begin an independent faculty career bypassing postdoctoral training. Those planning to engage in research supervised by senior PIs will not be considered.; What: The NIH Director’s Early Independence Award Program supports exceptional investigators who wish to pursue independent research directly after completion of their terminal doctoral/research degree or clinical residency, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. Applicants may request as much as $250,000 in direct costs per year, plus applicable Facilities and Administrative costs, for a five-year period. Individuals must commit at least 9.6 person-months (80% effort) to research supported by the Early Independence Award.; Who: The following eligibility terms apply.; Time window for eligibility: Given the focus on early research independence, the receipt date of the terminal doctoral degree or end of post-doctoral clinical training of the PD/PI must be between June 1, 2020 and September 30, 2022. The degree receipt date is that which appears on the official transcript for the degree. The end of post-graduate clinical training includes residency and fellowship periods. The PD/PI must not have served as a post-doctoral fellow for more than twelve months before June 1, 2020.; Research independence at time of...
application: Individuals are eligible only if they, at the time of application submission, do not have research independence. Lack of research independence is defined functionally rather than by position title. Eligible individuals must have all the following characteristics: The PD/PI’s current research agenda is set through concurrence with mentors; The PD/PI’s research is funded primarily through support to other investigators (mentored fellowships such as NIH F31 or F32 Fellowships or NSF Graduate Research Fellowships do not preclude eligibility); The PD/PI does not have any space assigned directly by the institution for the conduct of his/her research; The PD/PI, according to institutional policy, cannot apply for an NIH R01 grant without special waiver or exemption from the institution; When: Internal Proposal deadline – 9:00 a.m. on Thursday, July 22, 2021; NIH Proposal deadline – September 3, 2021; How: For more information, please visit https://columbia.infoready4.com/#competitionDetail/1845646; Questions should be sent to Greg Culler at limitedsubmissions@columbia.edu.; NIH Director’s Early Independence Award (RFA-RM-21-018) – Monday, June 28, 2021 at 11:30 AM EDT To join the webinar, register through WebEx and submit your questions by 11:59 PM local time on Thursday, June 24, 2021 to EarlyIndependence@od.nih.gov.

[NTW] [NEW INNOVATOR AWARD]
NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional)

Sponsor: Office of Strategic Coordination (Common Fund)
Deadline(s): 08/20/2021; 08/21/2021 (Expiration)
Contact: Scientific/Research Contact(s); Ravi Basavappa, Ph.D.; Office of the Director (OD); Telephone: 301-435-7204; Email: NewInnovatorAwards@mail.nih.gov

[NTW] [EARLY DETECTION]
Notice of Intent to Publish a Funding Opportunity Announcement for The Early Detection Research Network: Biomarker Characterization Centers (U2C Clinical Trial Not Allowed)

Sponsor: National Cancer Institute
Deadline(s): 08/31/2021 (First Estimated Application Due Date)
Contact: Sudhir Srivastava, Ph.D., M.P.H.; National Cancer Institute (NCI); 240-276-7028; srivasts@mail.nih.gov

[NTW] [EARLY DETECTION]
Notice of Intent to Publish a Funding Opportunity Announcement: Early Detection Research Network (EDRN) Clinical Validation Centers

Sponsor: National Cancer Institute
Deadline(s): 08/31/2021 (First Estimated Application Due Date)
Contact: Sudhir Srivastava, Ph.D., M.P.H.; National Cancer Institute (NCI); 240-276-7028; srivasts@mail.nih.gov
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-051.html
Notice of Intent to Publish a Funding Opportunity Announcement: Early Detection Research Network (EDRN) Data Management and Coordinating Center

**Sponsor:** National Cancer Institute  
**Deadline(s):** 08/31/2021 (First Estimated Application Due Date)  
**Contact:** Sudhir Srivastava, Ph.D., M.P.H.; National Cancer Institute (NCI); 240-276-7028; srivasts@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-052.html

The Early Detection Research Network: Clinical Validation Centers (U01 Clinical Trial Optional)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 09/09/2021; 09/10/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Sudhir Srivastava, Ph.D., M.P.H.; National Cancer Institute (NCI); Telephone: 240-276-7028; Email: srivasts@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-033.html

The Early Detection Research Network: Data Management and Coordinating Center (U24 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 09/09/2021; 09/10/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Sudhir Srivastava, Ph.D., M.P.H.; National Cancer Institute (NCI); Telephone: 240-276-7028; Email: srivasts@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-034.html

The Early Detection Research Network: Biomarker Characterization Centers (U2C Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 09/09/2021; 09/10/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Sudhir Srivastava, Ph.D., M.P.H.; National Cancer Institute (NCI); Telephone: 240-276-7028; Email: srivasts@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-035.html
[NTW] [RESEARCH TRAINING]
Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed)

**Sponsor:** National Institute of General Medical Sciences

**Deadline(s):** 10/14/2021; 10/14/2022; 10/13/2023; 10/14/2023 (Expiration)

**Contact:** Edgardo Falcón Ph.D.; National Institute of General Medical Sciences (NIGMS); Email: edgardo.falcon@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-196.html

[NTW] [POST-ACUTE INTERVENTIONS]
Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)

**Sponsor:** National Institute of Mental Health

**Deadline(s):** 10/05/2021; 03/06/2024 (Expiration)

**Contact:** Adam Haim, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-435-3593; Email: haima@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-210.html

[NTW] [POST-ACUTE INTERVENTIONS]
Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required)

**Sponsor:** National Institute of Mental Health

**Deadline(s):** 10/16/2021; 03/17/2024 (Expiration)

**Contact:** Adam Haim, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-435-3593; Email: haima@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-211.html

[NTW] [OBESITY]
Nutrition Obesity Research Centers (P30 Clinical Trial Optional)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases

**Deadline(s):** 10/20/2021; 10/21/2021 (Expiration)

**Contact:** Mary E. Evans, Ph.D.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-594-4578; Email: evansmary@niddk.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-015.html

[NTW] [POPULATION DYNAMICS]
Population Dynamics Centers Research Infrastructure Program FY 2022 (P2C Clinical Trial Not Allowed)

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Deadline(s):** 07/29/2021; 07/30/2021 (Expiration)
**Contact**: Scientific/Research Contact(s); Rosalind B. King, PhD; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6986; Email: rozking@mail.nih.gov  

**[NTW] [POPULATION DYNAMICS]**

**Coordinating Center for the NICHD Population Dynamics Centers Research Infrastructure Program FY 2022 (R24 Clinical Trial Not Allowed)**  
**Sponsor**: *Eunice Kennedy Shriver* National Institute of Child Health and Human Development  
**Deadline(s)**: 07/29/2021; 07/30/2021 (Expiration)  
**Contact**: Scientific/Research Contact(s); Rosalind B. King, PhD; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6986; Email: rozking@mail.nih.gov  
**Link(s)**: https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-014.html

**[NTW] [POPULATION DYNAMICS]**

**Notice of Information: NICHD Population Dynamics Centers Research Infrastructure Program FY2023 and FY2024**  
**Sponsor**: *Eunice Kennedy Shriver* National Institute of Child Health and Human Development  
**Deadline(s)**: 06/08/2021 (Release Date)  
**Contact**: Rosalind B. King, PhD; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6986; Email: rozking@mail.nih.gov  
**Link(s)**: https://grants.nih.gov/grants/guide/notice-files/NOT-HD-21-036.html

**[NTW] [TRANSLATIONAL]**

**Notice of Intent to Publish a Funding Opportunity Announcement for Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed)**  
**Sponsor**: National Cancer Institute  
**Deadline(s)**: 10/01/2021 (First Estimated Due Date)  
**Contact**: For Biology Research; Elisa Woodhouse, Ph.D.; Division of Cancer Biology; National Cancer Institute (NCI); Email: woodhousee@mail.nih.gov  
**Link(s)**: https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-060.html

**[NTW] [TRANSLATIONAL]**

**Notice of Intent to Publish a Funding Opportunity Announcement for Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional)**  
**Sponsor**: National Institute of Environmental Health Sciences  
**Deadline(s)**: 02/01/2022 (First Available Due Date)  
**Contact**: Heather Henry, PhD; National Institute of Environmental Health Sciences (NIEHS); 984-287-3268; heather.henry@nih.gov
[NTW] [ANTIVIRALS]

Notice of Intent to Publish a Funding Opportunity Announcement for Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern (U19 Clinical Trial Not Allowed)

Sponsor: National Institute of Allergy and Infectious Diseases
Deadline(s): 10/15/2021 (First Estimated Application Due Date)
Contact: Michael Schaefer, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID); 240-627-3364; MSchaefer@niaid.nih.gov

[NTW] [CHRONIC LUNG DISEASE]

Notice of Change in Key Dates and Award Information for RFA-HL-21-013 "Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)"

Sponsor: National Heart, Lung, and Blood Institute
Deadline(s): 06/02/2022 (Revised/updated application due date); 06/03/2022 (Expiration)
Contact: Please direct all inquiries to: Antonello Punturieri, MD, PhD; Division of Lung Diseases; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-0233; Email: punturieria@nhlbi.nih.gov

[NTW] [DOWN SYNDROME]

Notice of Special Interest (NOSI): Use of Digital Technology and Mobile Health (mHealth) to Improve Diagnosis, Assessments, Interventions, Management and Outcomes for Individuals with Down Syndrome Across the Lifespan (R21 Clinical Trial Not Allowed)

Sponsor: National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research
Deadline(s): 10/16/2021 (First Available Due Date) ; 11/17/2023 (Expiration Date)
Contact: Scientific/Research Contact(s); Sujata Bardhan, Ph.D.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-0471; Email: sujata.bardhan@nih.gov
[NTW] [DOWN SYNDROME]
Small Research Grants for Analyses of Down Syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed)

Sponsor: NIH
Deadline(s): 11/03/2021; 11/04/2021 (Expiration)
Contact: Please direct inquiries related to specific interests of the participating NIH Institutes and Centers (IC) to the IC contacts listed on the INCLUDE Project website.

[NTW] [CONTRACEPTION]
Contraception Development Research Center Program (P50, Clinical Trial Optional)

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Deadline(s): 11/29/2021; 11/30/2021 (Expiration)
Contact: Scientific/Research Contact(s); Christopher. C. Lindsey, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6907; Email: chris.lindsey@nih.gov

[NTW] [VISION RESEARCH]
NEI Vision Research Epidemiology Grant (UG1 Clinical Trial Not Allowed)

Sponsor: National Eye Institute
Deadline(s): 09/25/2021; 01/25/2022; 05/25/2024; 09/08/2024 (Expiration)
Contact: Scientific/Research Contact(s); Sangeeta Bhargava, PhD, National Eye Institute (NEI); Telephone: 301-451-2020 ; Email: bhargavas@mail.nih.gov
Link(s): https://grants.nih.gov/grants/guide/pa-files/PAR-21-204.html

[NTW] [STANDARD DUE DATES]
Standard Due Dates
COVID-19 AND TELECOMMUTING

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

Sponsor: National Institute of General Medical Sciences
Deadline(s): 03/15/2021 (First Available Due Date); 12/16/2021 (Expiration Date)
Contact: Daniel E. Janes, Ph.D.; National Institute of General Medical Sciences (NIGMS); Email: daniel.janes@nih.gov

Notice of Special Interest (NOSI): Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs

Sponsor: National Center for Advancing Translational Sciences
Deadline(s): 01/28/2021 (First Available Due Date); 08/17/2024 (Expiration Date)
Contact: Please contact the program officer on your active award

Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19

Sponsor: National Institute on Drug Abuse
Deadline(s): 05/05/2021 (First Available Due Date); 09/08/2024 (Expiration Date)
Contact: Raul Mandler, MD; NIDA/DTMC/CMB; Telephone: 301-480-2541; Email: mandlerr@nih.gov
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-017.html

Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders

Sponsor: National Institute on Drug Abuse
Deadline(s): 02/03/2021 (First Available Due Date); 05/07/2024 (Expiration Date)
Contact: Raul Mandler, MD; NIDA/DTMC/CMB; Telephone: 301-480-2541; Email: mandlerr@nih.gov

Notice of Special Interest: Administrative Supplements for COVID-19 Impacted NIMH Research

Sponsor: National Institute of Mental Health
Deadline(s): 01/05/2021 (First Available Due Date); 06/02/2023 (Expiration Date)
Contact: Applicants should direct their inquiries to the program officer of the parent award.

NIH Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)

Sponsor: National Institute of Environmental Health Sciences (NIEHS)
Deadline(s): 05/01/2020 (First Available Due Date); 05/04/2021 (Expiration Date)
Contact: Scientific / Research Contacts: Anika Dzierlenga, Ph.D.; Genes, Environment, and Health Branch National Institute of Environmental Health Sciences; Telephone: (984) 287-3125; Email: anika.dzierlenga@nih.gov

Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)

Sponsor: National Institute on Aging
Deadline(s): 03/04/2021 (First Available Due Date); 05/08/2023 (Expiration Date)
Contact: Scientific/Research Contact; Jonathan W. King, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-3136; Email: kingjo@nia.nih.gov

Notice of Special Interest (NOSI): NIDCR Support for
Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)

**Sponsor:** National Institute of Dental and Craniofacial Research

**Deadline(s):** 06/05/2021 (First Available Due Date); 05/08/2023 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Amanda Melillo, Ph.D.; National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-529-7217; Email: amanda.melillo@nih.gov


---

Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 06/05/2021 (First Available Due Date); 09/08/2024 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Raul Mandler, MD; FAAN; FANA: National Institute on Drug Abuse; Telephone: 301-480-2541; Email: mandler@nih.gov


---

Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trials Not Allowed)

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism

**Deadline(s):** 04/15/2021 (First Estimated Due Date)

**Contact:** Please direct all inquiries to: M. Kathy Jung, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); 301-443-8744; jungma@mail.nih.gov


---

Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trials Not Allowed)

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism

**Deadline(s):** 04/15/2021 (First Estimated Due Date)

**Contact:** Please direct all inquiries to: M. Kathy Jung, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); 301-443-8744; jungma@mail.nih.gov


---

Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases

**Sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases

**Deadline(s):** 02/05/2021 (First Available Due Date); 11/19/2021 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Marie Mancini, Ph.D.; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Telephone: 301-594-5032; Email: mancinim2@mail.nih.gov


---

Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

**Sponsor:** National Institute on Minority Health and Health Disparities; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute of Nursing Research; Office of Behavioral and Social Sciences Research; Office of Disease Prevention; Office of Research on Women's Health

**Deadline(s):** 02/05/2021 (First Available Due Date); 01/08/2022 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Integrative Biological and Behavioral Sciences; Deborah E. Linares, Ph.D., M.A.; National Institute on Minority Health and Health Disparities

**Link(s):** [http://www.nimhd.nih.gov](http://www.nimhd.nih.gov); Telephone: 301-402-2516; Email: deborah.linares@nih.gov

Sponsor: Mailman School

Deadline(s): 10/14/2020 (Distribution Date)

Contact: distributed by Sepi Sepasi, Vice Dean, Finance and Administration [ss5827]

Link(s): https://mailchi.mp/cumc.columbia.edu/covid-19-update-bulletin?e=17b4454a9b

Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2

Sponsor: National Institute of Allergy and Infectious Diseases

Deadline(s): 09/01/2020 (First Available Due Date); 09/01/2021 (Expiration Date)

Contact: Scientific/Research Contact(s): Diane Post, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3346; NIAIDCOVID19CTNOSI@mail.nih.gov


Additional Information: Related Announcements: PAR-20-20, PAR-20-183 - NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)

Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic: August/October 2021 Councils

Sponsor: National Institutes of Health

Deadline(s): This Notice extends the special exception for post-submission material (see NOT-OD-20-123 and NOT-OD-20-163) to applications submitted for the August/October 2021 Council round.

The deadline for submitting all post-submission materials, including preliminary data, will be 30 days before the study section meeting.

Contact: Please direct all inquiries to: Sally A. Amero, Ph.D.; NIH Review Policy Officer; Email: ReviewPolicyOfficer@mail.nih.gov


COVID-19/SARS-CoV-2 Small Animal Studies and ABSL-3 Facility [Downloadable .docx application]

Sponsor: Vagelos College of Physicians and Surgeons Office for Research

Deadline(s): Rolling basis

Contact: Noel Manu at nm3091@cumc.columbia.edu

Link(s): https://r2eport.files.wordpress.com/2014/04/application-to-use-the-cumc-animal-biological-safety-level-3-facility_final-1.docx [Downloadable .docx application]
Policy for Charging Personal Protective Equipment to NIH Grants and Cooperative Agreements as Direct Costs
**Sponsor:** National Institutes of Health; Office of The Director, National Institutes of Health (OD)

**Deadline(s):** 09/11/2020 (Release Date)
**Contact:** Please direct all inquiries to: Division of Grants Policy; Office of Policy for Extramural Research Administration; Office of Extramural Research; GrantsPolicy@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide-notice-files/NOT-OD-20-164.html

Notice of Special Interest (NOSI) Research on Rehabilitation Needs Associated with the COVID-19 Pandemic

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Deadline(s):** 02/05/2021 (First Available Due Date); 05/08/2023 (Expiration Date)
**Contact:** Scientific/Research Contact(s): Theresa Cruz, PhD.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-496-9233; Email: cruzth@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide-notice-files/NOT-HD-20-031.html

Notice of Early Expiration of NOT-AI-20-051 “Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

**Sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)

**Deadline(s):** The purpose of this Notice is to inform the extramural community that NOT-AI-20-051, “Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19),” will expire on 09/08/2020; [for reference, its first available due date was 06/16/2020]
**Contact:** Please direct all inquiries to: Diane Post, Ph.D.; Division of Microbiology and Infectious Diseases; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3348; Email: postd@niaid.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide-notice-files/NOT-AI-20-066.html

**Additional Information:** Related Announcements: NOT-AI-20-051 - Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

COVID-19 Early Treatment Fund (CETF)-Outpatient clinical trials for COVID-19

**Sponsor:** http://www.treatearly.org/

**Deadline(s):** open
**Contact:** http://www.treatearly.org/contact (sponsor contact provided for reference); For any questions and further information, please contact: Dimitra Koutsantoni, PhD; Director of University Corporate and Foundation Relations; Office of Alumni and Development; Dk2617@columbia.edu [who brought these opportunities to our attention]

**Link(s):** http://www.treatearly.org/

Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Allergy and Infectious Diseases

**Deadline(s):** Applications for this limited competition FOA will be accepted on a rolling basis, beginning 07/13/2020; 07/08/2021 (Expiration)
**Contact:** Scientific/Research Contact(s); Dr. Andrea Wurster; Division of Extramural Activities; National Institute of Allergy and Infectious Diseases, NIH; Tel: 301-496-7291; Email: NIAID_PPE@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide-pa-files/PAR-20-256.html

Notice of Expiration of PAR-20-178 "Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Allergy and Infectious Diseases

**Deadline(s):** After 08/14/2020, applicants are encouraged to consider applying to PA-19-056, NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
**Contact:** Please direct all inquiries to: Diane Post, Ph.D.; Division of Microbiology and Infectious Diseases; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3348; Email: NIAID.DMID.SARS2.PAR@niaid.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide-notice-files/NOT-AI-20-062.html

Notice of Expiration of PAR-20-177 "Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Allergy and Infectious Diseases

**Deadline(s):** after 08/14/2020; please consider PA-20-195
Contact: Please direct all inquiries to: Diane Post, Ph.D.; Division of Microbiology and Infectious Diseases; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3348; Email: NIAID.DMD.SARS2.PAR@niaid.nih.gov

[1] Oak Ridge Associated Universities (ORAU)'s University Consortium


Sponsor: Oak Ridge Associated Universities (ORAU) University Consortium; https://www.orau.org

Deadline(s): rolling

Contact: Researchers who would like to use the Rapid Access Proposals resources should submit a short rapid access proposal, outlining experiment aims and scope, at https://snsapp1.sns.gov/xprod_ro/f?p=109:26. A facility scientist will contact you regarding your proposal within 2 days. Scientific and technical questions should be sent to Dean Myles at mylesda@ornl.gov.

Link(s): https://www.orau.org/university-partnerships/membership.html
https://www.orau.org/impact/webinar.html

[1] A Message from the Vice Deans of Finance and Administration and Research Strategy and Innovation

[2] Mailman School Virtual Town Hall; Resuming Limited On-Site Operations, 06/24/2020

Sponsor: Vice Deans of Finance and Administration and Research Strategy and Innovation

Deadline(s): 06/24/2020 (Town Hall); 07/01/2020 (Message)

Contact: Sepi Sepasi, Vice Dean, Finance & Administration; Columbia University Mailman School of Public Health [ss5827]; and Gary W. Miller, PhD; Vice Dean for Research Strategy and Innovation; Professor, Department of Environmental Health Sciences; Columbia University Mailman School of Public Health [gm2815]

Link(s): https://mailchi.mp/cumc.columbia.edu/update-returning?e=17b4454a9b [Message]
https://www.youtube.com/watch?v=FFrGSXOk5gk&feature=youtu.be [Town Hall, 06/24/2020]

COVID-19 Early Treatment Fund (CTEF)-Outpatient clinical trials for COVID-19

Sponsor: http://www.treatearly.org/

Deadline(s): Open

Contact: http://www.treatearly.org/contact (sponsor contact provided for reference); For any questions and further information, please contact: Dimitra Koutsanton, PhD; Director of University Corporate and Foundation Relations; Office of Alumni and Development; Dk2617@columbia.edu [who brought these opportunities to our attention]

Link(s): http://www.treatearly.org/

Notice to Extend Eligibility for Submission of Diversity K22 Applications due to COVID related Disruptions

Sponsor: National Institute of Neurological Disorders and Stroke

Deadline(s): NINDS understands that COVID-19 has caused a major disruption in the ability of many individuals to make progress on their research. Though subject to future updates, NINDS now will provide at least a 2-receipt cycle extension (roughly 8 additional months) of eligibility for individuals whose eligibility to apply for the K22, under normal eligibility rules (including resubmission policy as defined in NOT-OD-18-197), is expiring between June/July 2020 and February/March 2021 (inclusive of these dates). In addition, those who normally would have been eligible to apply for the June/July 2021 receipt date will have a 1-receipt cycle (roughly 4 months) extension.

Contact: Please direct all inquiries to: Michelle Jones-London, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS); E-mail: NINDSdiversityTraining@mail.nih.gov


Additional Information: Related Announcements: PAR-18-469 - NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22-No Independent Clinical Trials); PAR-18-468 - NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22-Clinical Trial Required)

NIDCR Announces Availability of Frequently Asked Questions (FAQs) for Coronavirus Disease 2019 (COVID-19)-Related Notices of Special Interest (NOSI) NOT-DE-20-022 and NOT-DE-20-023

Sponsor: National Institute of Dental and Craniofacial Research

Deadline(s): 05/13/2020 (Release Date)

Contact: Please direct all inquiries to: Alicia Chou, M.S.; Division of Extramural Research; National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-594-4874; Email: alicia.chou@nih.gov
Research at Columbia, updated Covid-19 focused FAQs and Links
COVID-19 SPA Town Hall 05/08/2020 (Slides)
COVID-19 Research FAQs
Sponsored Projects Town Halls
What you should know about your Sponsored Projects: A Summary of the SPA COVID Town Hall 5/8/2020
Sponsor: Research @ Columbia
Deadline(s): NA
Contact: Please continue to email questions to COVID19_research@columbia.edu; we will make sure your questions are routed to the right person so you receive a timely answer.

Link(s): [https://research.columbia.edu/sites/default/files/content/SPA/SPA%20Town%20Halls/SPA%20Town%20Halls_2020_05_08.pdf](https://research.columbia.edu/sites/default/files/content/SPA/SPA%20Town%20Halls/SPA%20Town%20Halls_2020_05_08.pdf) [SPA Covid-19 Town Hall, 05/08/2020, 'slides']
[https://research.columbia.edu/sites/default/files/content/SPA/Department%20Assignments/MSPH%20Dept%20Assignments%202020-05-20.pdf](https://research.columbia.edu/sites/default/files/content/SPA/Department%20Assignments/MSPH%20Dept%20Assignments%202020-05-20.pdf) [Columbia Research, MSPH Sponsored Projects Administration, Project Officer Departmental Assignments]

Guide Notice of Information Highlighting Harmonization and Data Sharing Expectations for Supplement and Revision Projects Addressing Social, Behavioral, Economic and Health Impacts of the COVID-19 Public Health Emergency
Sponsor: National Institutes of Health
Deadline(s): 06/10/2020 (Release Date, this is a NOI, Notice of Information)
Contact: Erica Spotts, PhD; Office of Behavioral and Social Sciences Research (OBSSR); Telephone: 301-594-2105; SpottsE@nih.gov

Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic

Sponsor: National Institutes of Health (NIH); Agency for Healthcare Research and Quality (AHRQ); The National Institute for Occupational Safety and Health (NIOSH)
Deadline(s): For applications submitted for the January 2021 council (beginning with applications submitted for the May 25, 2020 due date for Fall 2020 review meetings), the NIH, AHRQ, and NIOSH will accept a one-page update with preliminary data as post-submission materials for applications submitted under all activity codes, ONLY if the Funding Opportunity Announcement (FOA) used for submission allowed preliminary data in the application. One page of preliminary data will be accepted for single component applications or for each component of a multi-component application; The deadline for submitting all post-submission materials, including preliminary data, will be 30 days before the study section meeting. Because applications for emergency competitive revisions and urgent competitive revisions undergo expedited review, post-submission materials will not be accepted for those applications; All other materials listed in NOT-OD-19-083 as acceptable post-submission materials will continue to be accepted if submitted 30 days before the study section meeting.
Contact: Please direct all inquiries to: Sally A. Amero, Ph.D.; NIH Review Policy Officer; ReviewPolicyOfficer@mail.nih.gov; Francis D. Chesley, Jr., M.D.; Agency for Healthcare Research and Quality; Telephone: 301-427-1521; Email: Francis.Chesley@ahrq.hhs.gov; SteveDearwent, Ph.D.; Centers for Disease Control and Prevention; Telephone: 404-498-6382; Email: Sed7@cdc.gov; MichaelGoldcamp, Ph.D.; Centers for Disease Control and Prevention; Telephone: 304-285-5951; Email: ehg8@cdc.gov

NIH Late Application Policy for NIA-Specific FOAs with Application Due Dates in May, June, and July 2020
Sponsor: National Institute on Aging
Deadline(s): Late applications will be accepted by 5:00 PM local time up to two weeks after the application due date for the NIA-specific FOAs listed below. Institutions do not need to request advance permission. While a cover letter may be provided, it is not required to take advantage of this flexibility; please see announcement NOT-AG-20-033
Contact: Please direct all inquiries to: Ramesh Vemuri, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-9666; Email: ramesh.vemuri@nih.gov

Notice of Change in Application Due Date for PAR-19-215 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)
Sponsor: National Institute of Biomedical Imaging and Bioengineering
Deadline(s): It is anticipated that the emergency declaration related to novel coronavirus (COVID-19) will adversely affect many NIH applicants’ ability to submit applications in a timely manner. Hence, the May 28, 2020 due date for Funding Opportunity Announcement PAR-19-215 has been changed to June 29, 2020 by 5:00 PM local time of applicant organization.; 07/29/2020 (Extended Deadline); 05/29/2021 (Expiration)
Contact: Please direct all inquiries to: Joan Greve, Ph.D.; Division of Interdisciplinary Training; National Institute of Biomedical Imaging and Bioengineering; Telephone: 301-451-6649; Email: joan.greve@nih.gov
Additional Information: Related Announcements: PAR-19-215 Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed); NOT-OD-20-082 - NIH LATE APPLICATION POLICY Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19); NOT-OD-20-083 - General Frequently Asked Questions (FAQs) - Proposal Submission and Award Management

[2] Notice of Intent to Publish a Funding Opportunity Announcement for Community Interventions to Address the Consequences of the COVID-19 Pandemic for Health Disparity and Vulnerable Populations (R01 - Clinical Trial Optional)
Sponsor: National Institute of Environmental Health Sciences (NIEHS) [NOT-ES-20-015]

Deadline(s): 05/01/2020 (First Available Due Date) 05/04/2021 (Expiration Date); [NOT-ES-20-015]
07/22/2020 (First Estimated Application Due Date) [NOT-MD-20-023]
Contact: Scientific/Research Contacts: Anika Dzierlenga, Ph.D.; Genes, Environment, and Health Branch; National Institute of Environmental Health Sciences; Telephone: (984) 287-3125; Email: anika.dzierlenga@nih.gov; [NOT-ES-20-015]; Please direct all inquiries to: Jennifer Alvidrez, Ph.D.; National Institute on Minority Health and Health Disparities (NIMHD); 301-594-9567; jennifer.alvidrez@nih.gov; [NOT-MD-20-023]
https://www.nih.gov/health-information/coronavirus

Notice of Intent to Publish a Funding Opportunity Announcement for Digital healthcare interventions to address the secondary health effects related to social, behavioral, and economic impact of COVID-19 (R01 - Clinical Trial Optional)
Sponsor: National Institute of Mental Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Nursing Research; Office of Behavioral and Social Sciences Research; Office of Disease Prevention
Deadline(s): 07/20/2020 (First Estimated Application Due Date)
Contact: Please direct all inquiries to: Adam Haim, Ph.D; National Institute of Mental Health (NIMH); 301-435-3593; haima@mail.nih.gov
Additional Information: The National Institute of Mental Health (NIMH) with other ICs are issuing this Notice of Intent to Publish a Funding Opportunity Announcement to promote new initiatives that will solicit applications to support research to determine the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), wearable devices] to address secondary health effects of the social, behavioral, and economic changes following
the COVID-19 pandemic, particularly among populations who experience health disparities and vulnerable populations.

Notice of Participation of National Institute of Nursing Research (NINR) in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Sponsor: National Institute of Nursing Research

Deadline(s): See the Emergency Notice of Special Interest (NOSI) for any applicable Application Due Dates; Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date; 03/10/2023 (Expiration) [For PA-20-135]

Contact: Please direct all inquiries to: Gregory Greenwood, PhD, MPH; National Institute of Mental Health (NIMH); Telephone: 240-669-5532; Email: gregory.greenwood@nih.gov


Additional Information: Related Announcements: PA-20-135 - Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

Notice of NLM's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Sponsor: National Library of Medicine

Deadline(s): See the Emergency Notice of Special Interest (NOSI) for any applicable Application Due Dates; Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date; 03/10/2023 (Expiration) [For PA-20-135]

Contact: Please direct all inquiries to: Hua-Chuan Sim, MD; National Library of Medicine (NLM); Telephone: 301-594-4882; Email: simh@mail.nih.gov


Additional Information: Related Announcements: PA-20-135 - Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

Notice of NIMH Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Sponsor: National Institute of Mental Health

Deadline(s): See the Emergency Notice of Special Interest (NOSI) for any applicable Application Due Dates; Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date; 03/10/2023 (Expiration) [For PA-20-135]

Contact: Please direct all inquiries to: Partha Bhattacharyya, Ph.D; National Institute on Aging (NIA); Telephone: 301-496-3136; Email: bhattacharyya@nih.gov


Additional Information: Related Announcements: PA-20-135 - Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

Notice of NIDA Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Sponsor: National Institute on Drug Abuse

Deadline(s): 03/10/2023 (Expiration) [PA-20-135]
Notice of NIDCD’s Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

**Sponsor:** National Institute on Deafness and Other Communication Disorders

**Deadline(s):** 03/10/2023 (Expiration) [PA-20-135]

**Contact:** Please direct all inquiries to: Janet L. Cyr, Ph.D.; NIDCD/Division of Scientific Programs; Telephone: 301-402-3458; Email: cyrj@nidcd.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DC-20-010.html

**Additional Information:** Related Announcements: PA-20-135 - Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

Notice of ORWH Participation in PA-20-135, Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement Clinical Trial Optional)

**Sponsor:** Office of Research on Women’s Health

**Deadline(s):** 03/10/2023 (Expiration) [PA-20-135]

**Contact:** Please direct all inquiries to: Rajeev K. Agarwal, Ph.D.; Office of Research on Women’s Health (ORWH); Telephone: 301-451-7058; Email: rajeev.agarwal@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-111.html

**Additional Information:** Related Announcements: PA-20-135 - Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders

**Sponsor:** National Institute on Deafness and Other Communication Disorders

**Deadline(s):** 10/05/2020 (First Available Due Date); 09/08/2022 (Expiration Date)
Deadline(s): NA; please see individual funding opportunities
Contact: https://cancer.columbia.edu/contact-us (HICCC); please see individual opportunities for funding agency contacts
Link(s): https://cancer.columbia.edu/update-nih-funding-covid-research

Notice of NEI's Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"
Sponsor: National Eye Institute
Deadline(s): Earliest start dates may vary by awarding IC. See the Urgent Guide Notices for any applicable Application Due Dates.; 01/25/2022 (Expiration Date)
Contact: Please direct all inquiries to: Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements


NIH Extramural Nexus
New NIH Resource to Analyze COVID-19 Literature: The COVID-19 Portfolio Tool
Sponsor: NIH Office of Extramural Research;
https://grants.nih.gov/grants/oer.htm
Deadline(s): 04/15/2020 (Release Date)
Contact: ExtramuralNexus@mail.nih.gov

NIH COVID-19 Funding and Funding Opportunities
NIH Extramural Nexus
Sponsor: NIH
Deadline(s): 04/13/2020 (Release Date)
Contact: https://nexus.od.nih.gov/all/author/lauerm/ [NIH Extramural Nexus]; ExtramuralNexus@mail.nih.gov
[NIH COVID-19 Funding and Funding Opportunities]

Notice of Change in Eligibility and Activity Codes for NOT-TR-20-011, Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need
Sponsor: National Center for Advancing Translational Sciences
Deadline(s): 05/04/2020 (First Available Due Date); 07/10/2021 (Expiration Date)
Contact: Please direct all inquiries to: Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements


Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials
Sponsor: National Heart, Lung, and Blood Institute
Deadline(s): 05/01/2020 (First Available Due Date); 10/06/2022 (Expiration Date)
Contact: Please direct all inquiries to: Patricia Noel, PhD; National Heart, Lung, and Blood Institute; Division of Lung Diseases; Telephone: 301-435-0202; Email: noelp@nih.gov

Additional Information: Related Announcements: NOT-OD-20-077 ; PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

Notice of Special Interest (NOSI): Data Driven Research on Coronavirus Disease 2019 (COVID-19) (R21)
Sponsor: National Library of Medicine
Deadline(s): 06/16/2020 (First Available Due Date); 06/17/2022 (Expiration Date)
Contact: Scientific/Research Contact(s); Hua-Chuan Sim, MD; National Library of Medicine (NLM); Telephone: 301-594-4882; Email: simh@mail.nih.gov

Notice of Eligibility Change for NIDCD Urgent Competitive Revisions and Administrative Supplements for Research on COVID-19
Sponsor: National Institute on Deafness and Other Communication Disorders
**Deadline(s):** Please see deadlines for piecemeal Supplements, this Notice does not affect their due dates

**Contact:** Please direct all inquiries to: Janet Cyr Ph.D.; National Institute on Deafness and Other Communication Disorders (NIDCD); Telephone: 301-402-3458; Email: cyrj@nidcd.nih.gov

**Columbia University Biobank**

**Sponsor:** https://www.ps.columbia.edu/research/core-and-shared-facilities/core-facilities-category

**Deadline(s):** NA

**Contact:** Researchers: Please contact the VP&S Office for Research with any questions.

Potential participants: Please contact CUBiobankCOVID19@cumc.columbia.edu with any questions.

**Link(s):** https://www.ps.columbia.edu/research/core-and-shared-facilities/core-facilities-category/columbia-university-biobank

[36x286]: [please also see piecemeal / individual opportunities]

**National Science Foundation awards rapid response grants to support coronavirus (COVID-19) research**

**NSF COVID-19 RAPID Awards**

**National Science Foundation Dear Colleague Letter**

**Sponsor:** National Science Foundation

**Deadline(s):** Please see piecemeal / individual opportunities

**Contact:** https://www.nsf.gov/help/contact.jsp [please also see piecemeal / individual opportunities]

**Link(s):**


[1] NIH Extramural Nexus; Temporary, Emergency Situations Due to COVID-19 and Application Scores Received During Peer Review

[2] NIH Coronavirus Update Guidance for Peer Reviewers


**Sponsor:** NIH; NIH Office of Extramural Research; https://grants.nih.gov/grants/oer.htm

**Deadline(s):** 04/21/2020 (Release Date)

**Contact:** Sally Amero, Ph.D., NIH’s Review Policy Officer; and Extramural Research Integrity Liaison Officer [Author]; https://nexus.od.nih.gov/all/author/sally-amero/

**ExtramuralNexus@mail.nih.gov**

**Columbia Researchers Against COVID-19 (The CRAC Team)**

**Sponsor:** https://www.olivelab.org

**Deadline(s):** Ongoing

**Contact:** https://columbiaovid.weebly.com/contact.html

**Link(s):** https://www.olivelab.org/columbia-researchers-against-coronavirus.html

**OBSSRS Updates; COVID-19 Urgent Competitive Revisions and Administrative Supplement Notices of Scientific Interest (NOSIs) Relevant to the Social and Behavioral Sciences**

**Sponsor:** NIH Office of Behavioral and Social Sciences Research

**Deadline(s):** See piecemeal OBSSR_Relevant NOSIs

**Contact:** https://obssr.od.nih.gov/about/contact-us/

**Link(s):** https://obssr.od.nih.gov/research-support/funding-announcements/

**Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus**

**Sponsor:** National Center for Advancing Translational Sciences

**Deadline(s):** 05/15/2020 (First Available Due Date); 01/26/2022 (Expiration Date)

**Contact:** Please direct all inquiries to: Danilo A. Tagle, Ph.D.; National Center for Advancing Translational Sciences (NCATS); Telephone: 301-594-8064; Email: danilo.tagle@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-017.html; Related Announcements; PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

**Notice of Early Expiration of "Notice of Special Interest (NOSI) regarding the NEIHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)"

**Sponsor:** National Institute of Environmental Health Sciences

**Deadline(s):** NA
Flexibilities Available to AHRQ Recipients and Applicants Directly Impacted by the Novel Coronavirus (COVID-19) Due to Loss of Operations

**Sponsor:** Agency for Healthcare Research and Quality (AHRQ)

**Deadline(s):** NA

**Contact:** AHRQ Division of Grants Management; Email: GrantsManagementInbox@AHRQ.HHS.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-010.html

NHLBI Announces Availability of Frequently Asked Questions (FAQs) for NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

**Sponsor:** National Heart, Lung, and Blood Institute

**Deadline(s):** NA

**Contact:** Please direct all inquiries to: Lora Reineck, MD, MS; National Heart, Lung, and Blood Institute (NHLBI); Division of Lung Diseases; Telephone: 301-827-7845; Email: lora.reineck@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-759.html

Notice of NCATS' Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

**Sponsor:** National Center for Advancing Translational Sciences

**Deadline(s):** See the Emergency Notice of Special Interest (NOSI) for any applicable Application Due Dates.; Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.; 03/10/2023 (Expiration)

**Contact:** Please direct all inquiries to: For any scientific or research-related questions on this emergency competitive revisions notice please contact the Program Officer listed on the NoA of the most recent parent award.


Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)

**Sponsor:** National Institute of Environmental Health Sciences

**Deadline(s):** 05/01/2020 (First Available Due Date); 05/04/2021 (Expiration)

**Contact:** Scientific/Research Contacts: Anika Dzierlenga, Ph.D.; Genes, Environment, and Health Branch; National Institute of Environmental Health Sciences; Telephone: (984) 287-3125; Email: anika.dzierlenga@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-015.html


Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus

**Sponsor:** National Center for Advancing Translational Sciences

**Deadline(s):** 05/15/2020 (First Available Due Date); 01/26/2022 (Expiration)

**Contact:** Please direct all inquiries to: Danilo A. Tagle, Ph.D.; National Center for Advancing Translational Sciences (NCATS); Telephone: 301-594-8064; Email: danilo.tagle@nih.gov


Guidance for Cost-Related Flexibilities Available to Support of Competitive Research (SCORE) Award Recipients Affected by COVID-19

**Sponsor:** National Institute of General Medical Sciences

**Deadline(s):** NA, please see Guidance

**Contact:** Please direct all inquiries to: Irina Krasnova, PhD; National Institute of General Medical Sciences (NIGMS); Email: irina.krasnova@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-026.html


**Sponsor:** National Center for Complementary and Integrative Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism

**Deadline(s):** Due dates may vary by awarding IC. See the awarding IC’s web site for any applicable Application Due Dates.

**Contact:** Please direct all inquiries to: Lanay M. Mudd, Ph.D.; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-594-9346; Email: lanay.mudd@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AT-20-011.html
**Additional Information:** Related Announcements; PA-18-591, Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional); PA-18-935, Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional); NOT-OD-20-077, Reminder: FORMS-F Grant Application Forms & Instructions Must be Used for Due Dates On or After May 25, 2020 - New Grant Application Instructions Now Available

**Notice of Special Interest (NOS):** Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities NOT-MD-20-019

**Sponsor:** National Institute on Minority Health and Health Disparities; National Institute on Aging; National Institute of Mental Health

**Deadline(s):** 05/01/2020 (First Available Due Date); 05/01/2021 (Expiration Date)

**Contact:** Scientific/Research Contact(s); Rada K Dagher, Ph.D., M.P.H.; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-451-2187; Email: rada.dagher@nih.gov


---

NIH Update: Responding to Frequent Questions on Flexibilities Related to NIH Funding and COVID-19


[3] Update on COVID-19 Flexibilities for the Research Community; Mike Lauer, NIH Deputy Director for Extramural Research; Video

**Sponsor:** NIH; Office of Extramural Research

**Deadline(s):** 03/26/2020 (Release Date) ; Please read the notice in its entirety. Grant applications submitted late for due dates between March 9, 2020, and May 1, 2020, will be accepted through May 1, 2020

**Contact:** Please feel free to send all your questions related to COVID-19 and research to COVID19_research@columbia.edu. As always, your SPA Project Officer can assist you with questions specific to grant proposals and awards.

**Link(s):** [https://grants.nih.gov/grants/natural_disasters/corona19-frequently-asked-questions.html](https://grants.nih.gov/grants/natural_disasters/corona19-frequently-asked-questions.html) [FAQs on COVID-19 for NIH Awardees due to COVID-19] [COVID19_research@columbia.edu](mailto:COVID19_research@columbia.edu)

---

**COVID-19 FAQ Updates and Pay Continuation on Sponsored Projects**

**Sponsor:** SPA

**Deadline(s):** NA, 03/27/2020 (Release Day)

**Contact:** Please continue to email questions to COVID19_research@columbia.edu; we will make sure your questions are routed to the right person so you receive a timely answer


Covid-19 FAQs added since 03/18/2020:
**General Frequently Asked Questions (FAQs) - Proposal Submission and Award Management Related to COVID-19**

**Sponsor:** NIH; Office of The Director, National Institutes of Health (OD)

**Deadline(s):** 03/10/2020 (Release Date)

**Contact:** Please direct all inquiries to: Division of Grants Policy; Office of Policy for Extramural Research; Administration; Office of Extramural Research; Telephone: 301-435-0949; GrantsPolicy@nih.gov; https://grants.nih.gov/grants/natural_disasters.htm

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-083.html

---

**Notice of National Cancer Institute (NCI) Participation in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)**

**Sponsor:** National Cancer Institute (NCI)

**Deadline(s):** 04/02/2020 (Release Date): 01/25/2022 (Expiration) ; Earliest start dates may vary by awarding IC. See the Urgent Guide Notices for any applicable Application Due Dates.; Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

---

**Notice of NCATS’ Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

**Sponsor:** National Center for Advancing Translational Sciences (NCATS)

**Deadline(s):** Earliest start dates may vary by awarding IC. See the Urgent Guide Notices for any applicable Application Due Dates.; Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.; 01/25/2022 (Expiration, PA-18-935)

**Contact:** Please direct all inquiries to: For any scientific or research-related questions on this urgent competitive revisions notice please contact the Program Officer listed on the NoA of the most recent parent award

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-083.html

---

**COVID-19 research: Notice of Early Expiration of NOT-Al-20-030; Notice of Early Expiration of "Notice of Special**
Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)," NOT-AI-20-030

**Sponsor:** National Institute of Allergy and Infectious Diseases (NIAID); National Institute of General Medical Sciences (NIGMS)

**Deadline(s):** NOT-AI-20-030 is going to expire as of 4/8/2020

**Contact:** Please direct all inquiries to: Diane Post, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3348; Email: postd@niaid.nih.gov; Daniel E. Janes, Ph.D.; National Institute of General Medical Sciences (NIGMS); Email: daniel.janes@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-040.html

**Deadlines:** 03/26/2020 (Release Date)

**Contact:** Please direct all inquiries to Lisa Scott-Morring, MS, MSHS, CRA; Director, Division for Policy, Coordination and Analysis; Office of Extramural Research, Education, and Priority Populations; Agency for Healthcare Research and Quality, HHS; Email: Grant_Queries@ahrq.hhs.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-008.html

FLEXIBILITIES FOR ASSURED INSTITUTIONS FOR ACTIVITIES OF INSTITUTIONAL ANIMAL CARE AND USE COMMITTEES (IACUCs) DUE TO COVID-19

**Sponsor:** National Institutes of Health; Office of The Director, National Institutes of Health (OD)

**Deadline(s):** 03/16/2020 (Release Date)

**Contact:** Please direct all inquiries to: Office of Laboratory Animal Welfare; Telephone: 301-496-7163;

**Email:** olaw@od.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-088.html

**Deadlines:** 03/26/2020 (Release Date)

**Contact:** Please direct all inquiries to: Lisa Scott-Morring, MS, MSHS, CRA; Director, Division for Policy, Coordination and Analysis; Office of Extramural Research, Education, and Priority Populations; Agency for Healthcare Research and Quality, HHS; Email: Grant_Queries@ahrq.hhs.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-008.html

**Deadlines:** 03/25/2020 (Release Date); please see piecemeal opportunities

**Contact:** Questions about this DCL should be directed to sbir@nsf.gov or to the cognizant SBIR/STTR Program Director on your current SBIR/STTR award

**Link(s):** https://www.nsf.gov/pubs/2020/nsf20065/nsf20065.jsp

**Deadlines:** 05/04/2020 (First Available Due Date);

07/10/2021 (Expiration)

**Contact:** Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.


**Deadlines:** 03/26/2020 (Release Date)

**Contact:** Please direct all inquiries to: Office of Laboratory Animal Welfare; Telephone: 301-496-7163;

**Email:** olaw@od.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-088.html

**Deadlines:** 03/26/2020 (Release Date)

**Contact:** Please direct all inquiries to: Lisa Scott-Morring, MS, MSHS, CRA; Director, Division for Policy, Coordination and Analysis; Office of Extramural Research, Education, and Priority Populations; Agency for Healthcare Research and Quality, HHS; Email: Grant_Queries@ahrq.hhs.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-008.html

NSF Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19

**Sponsor:** NSF; https://www.nsf.gov

**Deadline(s):** 03/25/2020 (Release Date); please see piecemeal opportunities

**Contact:** Questions about this DCL should be directed to sbir@nsf.gov or to the cognizant SBIR/STTR Program Director on your current SBIR/STTR award

**Link(s):** https://www.nsf.gov/pubs/2020/nsf20065/nsf20065.jsp

**Deadlines:** 05/04/2020 (First Available Due Date);

07/10/2021 (Expiration)

**Contact:** Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.


**Deadlines:** 03/26/2020 (Release Date)

**Contact:** Please direct all inquiries to Lisa Scott-Morring, MS, MSHS, CRA; Director, Division for Policy, Coordination and Analysis; Office of Extramural Research, Education, and Priority Populations; Agency for Healthcare Research and Quality, HHS; Email: Grant_Queries@ahrq.hhs.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-008.html

**Deadlines:** 03/26/2020 (Release Date)

**Contact:** Please direct all inquiries to Lisa Scott-Morring, MS, MSHS, CRA; Director, Division for Policy, Coordination and Analysis; Office of Extramural Research, Education, and Priority Populations; Agency for Healthcare Research and Quality, HHS; Email: Grant_Queries@ahrq.hhs.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-008.html

**Deadlines:** 03/26/2020 (Release Date)

**Contact:** Please direct all inquiries to Lisa Scott-Morring, MS, MSHS, CRA; Director, Division for Policy, Coordination and Analysis; Office of Extramural Research, Education, and Priority Populations; Agency for Healthcare Research and Quality, HHS; Email: Grant_Queries@ahrq.hhs.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-008.html
R²eport
Friday Newsletter 07/16/2021

Council on Governmental Relations (COGR); Frequently Asked Questions Regarding COVID-19’s Impact on Federal Awards

**Sponsor:** COGR; [https://www.coagr.edu/](https://www.coagr.edu/)

**Deadline(s):** NA, 03/12/2020 (update, Release Date)

**Contact:** please see FAQ link; COGR contact: https://www.coagr.edu/washington-office


[https://www.coagr.edu/faqs REGARDING COVID-19](https://www.coagr.edu/faqs) and [https://www.coagr.edu/washington-office](https://www.coagr.edu/washington-office)

---

**Archived Research Resources Covid-19 Transmission to Faculty 03/18/2020**

**Sponsor:** Research Resources

**Deadline(s):** 03/18/2020 (Transmission Date)

**Contact:** ckk7@cumc.columbia.edu

**Link(s):** [https://r2eport.files.wordpress.com/2014/04/r2covid19transmission03182020-copydpdf.pdf](https://r2eport.files.wordpress.com/2014/04/r2covid19transmission03182020-copydpdf.pdf)

Research Resources Covid-19 Transmission to Faculty 03.23.2020 Archived

**Sponsor:** Research Resource

**Deadline(s):** 03/23/2020 (Transmission Date)

**Contact:** ckk7@cumc.columbia.edu

**Link(s):** [https://r2eport.files.wordpress.com/2014/04/r2covid19transmission03232020-copydpdf.pdf](https://r2eport.files.wordpress.com/2014/04/r2covid19transmission03232020-copydpdf.pdf)

Research Resources Covid-19 Transmission to Faculty 03.23.2020 Archived

**Sponsor:** Research Resources

**Deadline(s):** 03/23/2020 (Transmission Date)

**Contact:** ckk7@cumc.columbia.edu

**Link(s):** [https://r2eport.files.wordpress.com/2014/04/r2covid19transmission03232020-copydpdf.pdf](https://r2eport.files.wordpress.com/2014/04/r2covid19transmission03232020-copydpdf.pdf)

---

Memorandum to the Heads of Executive Departments and Agencies; 03/19/2020; Executive Office of the President Office of Management and Budget

**Sponsor:** Executive Office of the President Office of Management and Budget

**Deadline(s):** 03/19/2020 (Release Date)

**Contact:** To receive the latest information on grants, including COVID-19 update, sign up for the Grants Community of Practice by clicking at: [https://www.performance.gov/CAP/grants/](https://www.performance.gov/CAP/grants/)

Questions regarding the above administrative relief provisions should be directed to Office of Federal Financial Management Grant link at GrantsTeam@omb.eop.gov. OMB will continue to provide updates and additional information as the situation unfolds. For the latest information, sign up for the Grants Community of Practice by clicking at: [https://www.performance.gov/CAP/grants/](https://www.performance.gov/CAP/grants/)

**Link(s):** [https://r2eport.files.wordpress.com/2014/04/covid19-omb-memo-on-grants-and-contracts.pdf](https://r2eport.files.wordpress.com/2014/04/covid19-omb-memo-on-grants-and-contracts.pdf)

---

**Additional Information:** Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly Impacted by the Novel Coronavirus (COVID-19) due to Loss of Operations

R²eport 03/20/2020 Newsletter Preamble; A Message from The Vice Dean for Research Strategy and Innovation

**Sponsor:** Research Resources

**Deadline(s):** R²eport 03/20/2020 Newsletter Preamble

**Contact:** ckk7@cumc.columbia.edu

**Link(s):** [https://r2eport.files.wordpress.com/2014/04/r2covid19newsletterpreamble032020-archivepdf.pdf](https://r2eport.files.wordpress.com/2014/04/r2covid19newsletterpreamble032020-archivepdf.pdf)

Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients

**Sponsor:** NIH

**Deadline(s):** NA, 03/17/2020 (Last updated)

**Contact:** [https://grants.nih.gov/support/index.html](https://grants.nih.gov/support/index.html)

**Link(s):** [https://grants.nih.gov/grants/natural_disasters/coronavirus-virus.htm](https://grants.nih.gov/grants/natural_disasters/coronavirus-virus.htm)

Research Resources Covid-19 Transmission, 03/23/2020

**Sponsor:** Research Resources

**Deadline(s):** NA, Release Date 03/23/2020

**Contact:** Craig Kandell, ckk7@cumc.columbia.edu

**Link(s):** [https://r2eport.files.wordpress.com/2014/04/r2covid19transmission03232020-copydpdf.pdf](https://r2eport.files.wordpress.com/2014/04/r2covid19transmission03232020-copydpdf.pdf)


**Sponsor:** [https://research.columbia.edu](https://research.columbia.edu)

**Deadline(s):** NA; This webpage will continue to be updated frequently as new information is received.

**Contact:** As always, if you have questions about sponsored projects, reach out to your assigned SPA Project Officer. Other research-related matters may be addressed in the FAQs.


Additional Information: [SPA News] COVID-19 FAQs Relating to Research; The Offices of the Executive Vice President for Research have collected FAQs relating to COVID-19 (Novel Coronavirus) and its impact on research activities. These can be found on the Research homepage, or directly at COVID-19 (Novel Coronavirus): Frequently Asked Questions Relating to Research. These FAQs contain
information about COVID-19 as it relates to the conduct of research, research operations, and sponsored projects. This webpage will continue to be updated frequently as new information is received. As always, if you have questions about sponsored projects, reach out to your assigned SPA Project Officer. Other research-related matters may be addressed in the FAQs. We will continue to keep you posted; [brought to our attention by] Stephanie F. Scott, MS, CRA, Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; sfs2110@cumc.columbia.edu ; Website: https://spa.columbia.edu/

[2] NSF Supporting Research to Address Coronavirus Disease

Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19

Sponsor: National Institutes of Health
Deadline(s): 03/16/2020 (Release Date)
Contact: Please direct all inquiries to: Division of Grants Policy; Office of Policy for Extramural Research Administration; Office of Extramural Research; Telephone: 301-435-0949;
GrantsPolicy@nih.gov

NIH Operates Under a Continuing Resolution

Sponsor: National Institutes of Health
Deadline(s): 10/21/2020 (Release Date)
Contact: Questions regarding adjustments applied to individual grant awards may be directed to the Grants Management Specialist identified in the Notice of Award.

NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)

Sponsor: National Library of Medicine
Deadline(s): 02/24/2022; 02/24/2023; 02/25/2023 (Expiration)

---

Deadline(s): 08/13/2020 (Effective Date); 12/11/2020 (Date, Release of Clarification)
Contact: Please direct all inquiries to: OPERA Division of Grants Policy; GrantsPolicy@nih.gov ; Please direct all compliance inquiries to: OPERA Division of Grants Compliance and Oversight grantscompliance@nih.gov

Guidance for Applicants Preparing Applications for the Fall 2020 Due Dates During the COVID-19 Pandemic NIH Review and Award Cycles

President’s Guidelines for Re-Opening America Again

Deadline(s): NIH issued guidance today (07/08/2020) related to preparing proposals for the May 2021 Council round beginning with applications submitted for the September 25, 2020 due date (see Review and Award Cycles)
Contact: Please direct all inquiries to: Sally A. Amero, Ph.D.; NIH Review Policy Officer; ReviewPolicyOfficer@mail.nih.gov [NIH Contact for reference] ; Feel free to ask me, or your SPA Project Officer, any questions.; [brought to our attention by] ; Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; sfs2110@cumc.columbia.edu ; Website: https://spa.columbia.edu/
https://www.whitehouse.gov/openingamerica/

---

ANNOUNCEMENTS (NIH and Other)

Clarification on Prohibition on Expending NIH Grant Funds for Covered Telecommunications Equipment or Services

Sponsor: National Institutes of Health
Successor-in-Interest (Type 6 Parent Clinical Trial Optional)

Sponsor: National Institutes of Health; John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Office of Behavioral and Social Sciences Research; Office of Research on Women’s Health

Deadline(s): A successor-in-interest request must be made before the anticipated start date at the new organization and preferably several months in advance.; 07/24/2023 (Expiration)

Contact: Scientific/Research Contact(s); For any scientific or research-related questions on this Successor-in-Interest announcement please contact the Program Officer listed on the NoA of the most recent award.


SPA Webinar NIH Forms-F and Other Policy Changes

Sponsor: SPA

Deadline(s): 05/20/2020 (Forms-F Webinar Archival Information Release Date)

Contact: [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu/

Link(s): https://research.columbia.edu/nih-proposal-information

Upcoming Mandatory Submission of theFederal Financial Report (FFR) in the Payment Management System

Beginning January 1, 2021

Sponsor: National Institutes of Health

Deadline(s): 06/23/2020 (Release Date); This change to FFR submission requirements does not impact the timeline. Therefore, FFR due dates, as outlined in the NIH Grants Policy Statement, 8.4.1.5.2 and 8.6.1, remain unchanged.

Contact: Please direct all inquiries to: NIH Office of Policy for Extramural Research Administration (OPERA); Systems Policy Branch; Email: OPERAsystemspolicy@nih.gov


Upcoming Changes to the Notice of Award (NoA)

Beginning October 1, 2020

Sponsor: National Institutes of Health

Deadline(s): 07/31/2020 (Release Date)

Contact: Please direct all inquiries to: Office of Policy for Extramural Research Administration (OPERA); Systems Policy Branch; Email: operasystemspolicy@nih.gov
Research Resources has been apprised that the R2eport distribution email to Faculty and other colleagues at times sorts to MS Outlook’s “Other” vs. “Focused” tab when web accessed. You may move an email from the “Other” to “Focused” in box tabs, by selecting Move to Focused if you want only the selected message moved; or you may select Always Move to Focused if you want all future messages from the sender to be delivered to the Focused tab. You may also Turn off Focused In Box when accessing MS Outlook via the web by accessing the settings (cog icon adjacent to your initials), accessing “all outlook settings”, activating the “Don’t sort my messages” button and saving this setting. Rectifying email sorting to Outlook’s Junk folder, may also be addressed. R2eports are posted weekly on our Reports Page

[1] Temporary Extension of Eligibility for the NIH K99/R00 Pathway to Independence Award During COVID-19 Pandemic; NIH just released the following announcement regarding a temporary extension of eligibility for the K99/R00 due to the COVID-19 pandemic
[2] NIH Extramural Nexus relative to this announcement

**Sponsor:** NIH

**Deadline(s):** NIH will be providing up to a two-receipt cycle extension (roughly eight additional months) of eligibility for prospective applicants meeting the requirements for submission of a K99/R00 application from the time period covered by the June/July 2020 due dates through the February/March 2021 due dates

**Contact:** Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Research; Website: https://researchtraining.nih.gov; Email: NIHTrain@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-158.html

---

**Notice of Requirement for Electronic Submission of all Administrative Supplements**

**Sponsor:** National Institutes of Health

**Deadline(s):** [1] Effective immediately, NIH will begin accepting administrative supplement applications for multi-project awards electronically. Since the administrative supplement applies to the parent award as a whole, the single-project application form package used for research grants and cooperative agreements will be used for these submissions (e.g., Competition ID= “FORMS-F-ADMSUPP-RESEARCH.”); [2] Effective July 25, 2020, the streamlined submission method through the eRA Commons will be discontinued and replaced with the option to initiate the administrative supplement application within eRA Commons and leverage technology available in NIH ASSIST.

**Contact:** Please direct all inquiries to: Division of Grants Policy; Website: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-128.html

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-128.html

**Additional Information:** Related Announcements: PA-18-591- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional); PA-18-592- Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed); This Notice alerts the extramural community of three updates to our administrative supplement submission policies.

---

**Guidance Regarding Change in Status, Including Absence of PD/PI and Other Key Personnel Named in the Notice of Award**

**Sponsor:** National Institutes of Health

**Deadline(s):** 06/11/2020 (Release Date)

**Contact:** Please direct all inquiries to: Division of Grants Policy; Office of Extramural Research; Website: https://grants.nih.gov/grants/policy/notice-files/NOT-OD-20-124.html


**Additional Information:** Related Announcements: NOT-OD-18-172- Clarification of NIH’s Policy Regarding a Change in Program Director’s/Principal Investigator’s Status

---

**NIH Center of Scientific Review, Review Matters, Race and Peer Review**

**Sponsor:** NIH, Center of Scientific Review, [https://www.csr.nih.gov](https://www.csr.nih.gov)

**Deadline(s):** 06/12/2020 (Release Date)

**Contact:** Noni Byrnes, Director CSR; If you are interested in participating, please email kramerkm@csr.nih.gov

**Link(s):** [https://www.csr.nih.gov/reviewmatters/2020/06/12/race-peer-review/](https://www.csr.nih.gov/reviewmatters/2020/06/12/race-peer-review/)
**Competition Revisions to Existing NIH Grants and Cooperative Agreements (Clinical Trial Optional)**

**Sponsor:** National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences

**Deadline(s):** See the competitive revision NOSI for any applicable Application Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Open dates may vary by awarding IC on an as-needed rolling basis. See competitive revision NOSI published by an NIH Institute or Center for applicable Application Due Dates; 04/03/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); For any scientific or research-related questions on this competitive revision notice please contact the Program Officer listed on NoA of the most recent parent award.

**Link(s):** [https://grants.nih.gov/grants/guide/notice.html](https://grants.nih.gov/grants/guide/notice.html)

---

**NIH Extramural Nexus_Don’t Forget to Use Updated Grant Application Forms (FORMS-F)**

**Sponsor:** NIH; Extramural Nexus; Office of Extramural Research

**Deadline(s):** 06/03/2020 (Release Date)

**Contact:** As always, please reach out to your SPA Project Officer should you have any questions.; [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia Research; Sponsored Projects Administration; sfs2110@columbia.edu; Website: https://spa.columbia.edu; ExtramuralNexus@mail.nih.gov

**Link(s):** [https://grants.nih.gov/grants/guide/notice.html](https://grants.nih.gov/grants/guide/notice.html)
National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; Application

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Participating NIH Institutes and Centers are listed in "Components of Participating Organizations" in Part 1. Overview; Scientific/Research Contact information is listed on R01 Clinical Trial Required IC-Specific Scientific Interests and Contact website

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html

**Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)**

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Participating NIH Institutes and Centers are listed in "Components of Participating Organizations" in Part 1. Overview; Scientific/Research Contact information is listed on R01 Clinical Trial Required IC-Specific Scientific Interests and Contact website

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html

**NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)**

**Sponsor:** National Institutes of Health; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Biomedical Imaging and Bioengineering; National Institute on Drug Abuse; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Participating NIH Institutes and Centers are listed in "Components of Participating Organizations" in Part 1. Overview; Scientific/Research Contact information is listed on the R03 IC-Specific Scientific Interests and Contact website.

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-200.html
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Eye Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Participating NIH Institutes and Centers are listed in "Components of Participating Organizations" in Part 1. Overview. Scientific/Research Contact information is listed on the R21 IC-Specific Scientific Interests and Contact website.

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-194.html

---

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Participating NIH Institutes and Centers are listed in "Components of Participating Organizations" in Part 1. Overview. Scientific/Research Contact information is listed on the R21 IC-Specific Scientific Interests and Contact website.

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html

---

NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-187.html

---

NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration Date)

**Contact:** Scientific / Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-187.html

---

NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration Date)

**Contact:** Scientific / Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-187.html

---

COLUMBIA Mailman School of Public Health RESEARCH RESOURCES mailman.columbia.edu/r2
Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration Date)

**Contact:** Scientific / Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Links:** https://grants.nih.gov/grants/guide/pa-files/PA-20-188.html

### NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration Date)

**Contact:** Scientific / Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Links:** https://grants.nih.gov/grants/guide/pa-files/PA-20-189.html

### Notice of Participation of NIAAA in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional"

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism

**Deadline(s):** See the Emergency Notice of Special Interest (NOSI) for any applicable Application Due Dates; Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Contact:** Kathy Jung, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Phone: 301-443-8722; Email: jungma@mail.nih.gov

**Links:** https://grants.nih.gov/grants/guide/notice-files/NOT-AA-20-007.html

### Notice of Common Funds Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional"

**Sponsor:** Office of Strategic Coordination (Common Fund); National Center for Complementary and Integrative Health; National Cancer Institute; National Human Genome Research Institute; National Institute of Allergy and Infectious Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute on Minority Health and Health Disparities

**Deadline(s):** See the Emergency Notice of Special Interest (NOSI) for any applicable Application Due Dates; Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date; 03/10/2023 (Expiration)

**Contact:** Mary Ellen Perry, Ph.D.; Office of Strategic Coordination (OSC); Office of the Director (OD); Telephone: 301-435-5082; Email: cfcovid19@od.nih.gov


### Notice of National Institute of Dental and Craniofacial Research (NIDCR) Participation in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional"

**Sponsor:** National Institute of Dental and Craniofacial Research; National Cancer Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child...
Health and Human Development; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities

**Deadline(s):** Earliest start dates may vary by awarding IC. See the Urgent Guide Notices for any applicable Application Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Contact:** Jason Wan, PhD; Division of Extramural Research; National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-594-9898; Email: JasonWan@nidcr.nih.gov


**Revised and Corrected Notice on Policy Regarding Minimum Level of Effort for NCI-Funded Awards**

**Sponsor:** National Cancer Institute

**Deadline(s):** 04/08/2020 (Release date); replaces [NOT-CA-20-033](https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-033.html)

**Contact:** Please direct all inquiries to: Questions regarding NCI’s implementation of this policy should be directed to the NCI Grants Management Specialist for the award. Questions of a programmatic nature should be directed to the NCI Program Official for the award.


**AHRQ Guide Notice on Implementation of the Use of a Single Institutional Review Board (IRB) for Cooperative Research at 45 CFR 46.114 (b)**

**Sponsor:** Agency for Healthcare Research and Quality

**Deadline(s):** 01/10/2020 (Release Date)

**Contact:** Please direct all inquiries to: Hope Hongzhu He, JD, MPA, MA; Human Protections Administrator; Agency for Healthcare Research and Quality; Telephone: (301) 427-1905; Email: HopeHongzhu.He@ahrq.hhs.gov

[Link(s):](https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-005.html)


**Sponsor:** NIH

**Deadline(s):** 01/22/2020 (Release Date)

**Contact:** If you have questions about the application process, you may contact your SPA Project Officer (CU); Please direct all compliance inquiries to: Office of Policy for Extramural Research Administration; Email: grantscompliance@mail.nih.gov


**Reminder:** FORMS-F Grant Application Forms & Instructions Must be Used for Due Dates On or After May 25, 2020; New Grant Application Instructions Now Available

**Sponsor:** Issued by the Office of The Director, National Institutes of Health (OD); Agency for Healthcare Research and Quality (AHRQ)

**Deadline(s):** 03/10/2020 (Release Date); for FORMS-F, required for use for proposals due on or after May 25, 2020

**Contact:** Please direct all inquiries to: NIH Office of Policy for Extramural Research Administration (OPERA); Systems Policy Branch; Email: OPERAsystemspolicy@nih.gov


[1] [NIH video on FORMS-F transition](https://www.youtube.com/watch?v=qxwua8Uy84A&feature=youtu.be)

[2] [Preparing for Updated Application Forms (FORMS-F), NIH Extramural Nexus](https://nexus.od.nih.gov/forms)

**Sponsor:** NIH, [https://grants.nih.gov/aboutoer/intro2oer.htm](https://grants.nih.gov/aboutoer/intro2oer.htm)

**Deadline(s):** for FORMS-F, required for use for proposals due on or after May 25, 2020

**Contact:** [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; sfsc110@columbia.edu; Website: [https://spa.columbia.edu/](https://spa.columbia.edu/)

[Link(s):](https://www.youtube.com/watch?v=qxwua8Uy84A&feature=youtu.be)

[https://grants.nih.gov/aboutoer/intro2oer.htm](https://grants.nih.gov/aboutoer/intro2oer.htm)

[https://nexus.od.nih.gov/forms](https://nexus.od.nih.gov/forms)


**Notice of NIBIB’s Participation in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)”**

**Sponsor:** National Institute of Biomedical Imaging and Bioengineering (NIBIB)

**Deadline(s):** See the Emergency Notice of Special Interest (NOSI) for any applicable Application Due Dates.
New Science & Security Website for the Columbia Community

Sponsor: Executive Vice President for Research
Deadline(s): NA

Contact: https://research.columbia.edu/directory/michelle-avallone; mla25@columbia.edu

Link(s): https://research.columbia.edu/science-security

Harassment and Discrimination Protections in NIH Training Applications
[a New NIH Discrimination and Harassment letter for training grants is accessible via CU Uni and PW and linked in the Additional information section of the posting in the Newsletter]

Sponsor: NIH
Deadline(s): This policy applies to applications submitted for due dates on or after January 25, 2019

Contact: NIH contact; Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Research; Website: https://researchtraining.nih.gov; Email: NIHTrain@mail.nih.gov; if you are applying for a new or competing renewal, you need to include this letter or else your application will be withdrawn by NIH. Please let me or your SPA Project Officer know if you have any questions; [brought to our attention by] Stephanie F. Scott, Director of Policy and Research Development; Columbia | Research, Sponsored Projects Administration; sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu

Link(s): https://research.columbia.edu/science-security

Additional Information: New NIH Discrimination and Harassment letter for training grants; As per NOT-OD-19-029, applications for NIH institutional training grants (T15, T32, T34, T35, T36, T37, T90/R90, TL1, TL4) must include a letter on institutional letterhead signed by a key institutional leader that describes the institutional commitment to ensuring that proper policies, procedures, and oversight are in place to prevent discriminatory harassment and other discriminatory practices.; We just updated this letter and it is available on our website for you to download to include with your Letters of Support into a single PDF file. It is dated January 14, 2020, signed by Deborah Stiles; You can download the letter directly from here, or go to our Institutional Training Grants webpage and download the letter from the Proposal Boilerplate/Template Text/Letters section. You will need your UNI and password to access the letter; If you are applying for a new or competing renewal, you need to include this letter or else your application will be withdrawn by NIH. Please let me or your SPA Project Officer know if you have any questions; [brought to our attention by] Stephanie F. Scott, Director of Policy and Research Development; Columbia | Research, Sponsored Projects Administration; sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu

Broadening the Pool of NIH Reviewers

Sponsor: NIH Center for Scientific Review
Deadline(s): 01/24/2020 (Release Date)

Contact: https://public.csr.nih.gov/AboutCSR/ContactCSR

Link(s): https://www.csr.nih.gov/reviewmatters/2020/01/24/broadening-the-pool-of-nih-reviewers/

Additional Information: The latest Review Matters blog post from the NIH Center for Scientific Review. Check Out the Change: Broadening the Pool of NIH Reviewers.

NIH Announces $1 Million Prize Competition to Target Global Disease Diagnostics

Sponsor: National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Deadline(s): 02/26/2020 (Release Date); No Deadline at this point

Contact: Media Contacts: Raymond A. Macougall, nibibpress@mail.nih.gov


You can use a figure in Specific Aims and the NIH Division of Receipt and Referral (DRR) won’t withdraw your application


Deadline(s): NA, 01/30/2020 (Release date)

Contact: https://www.nih.gov/about-nih/contact-us

Link(s): https://twitter.com/CSRpeerreview/status/1222864918884232966

https://twitter.com/CSRpeerreview?lang=en

Selecting the Correct Budget Format for Your Application

Sponsor: NIH Office of Extramural Research
Deadline(s): 12/03/2019 (Release Date)

Contact: ExtramuralNexus@mail.nih.gov
NEW NCI Policy on Minimum Level of Effort for NCI-Funded Awards

**Sponsor:** NIH, NCI  
**Deadline:** 03/03/2020 (Release Date)  
**Contact:** Questions regarding NCI’s implementation of this policy should be directed to the NCI Grants Management Specialist for the award. Questions of a programmatic nature should be directed to the NCI Program Office for the award.

[https://r2ep.mailman.columbia.edu/r2reports/2020/04/nihihtablepdf.pdf](https://r2ep.mailman.columbia.edu/r2reports/2020/04/nihihtablepdf.pdf)

**Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels Effective for Fiscal Year 2020**

**Sponsor:** National Institutes of Health (NIH); Agency for Healthcare Research and Quality (AHRQ); Health Resources Services Administration (HRSA)  
**Deadline:** 02/07/2020 (Release Date)  
**Contact:** Please direct all inquiries to: See Frequently Asked Questions Related to NRSA Tuition, Fees, and Health Insurance Policies: [https://grants.nih.gov/training/nrsa_tuition_q&a.htm](https://grants.nih.gov/training/nrsa_tuition_q&a.htm); Specific questions concerning this notice or other policies relating to training grants or fellowships should be directed to the grants management office in the appropriate NIH Institute or Center, AHRQ, or HRSA; General inquiries concerning NRSA stipend and tuition policies should be directed to: Division of Biomedical Research Workforce; Office of Extramural Research; Website: [https://researchtraining.nih.gov](https://researchtraining.nih.gov); Email: NIHTrain@mail.nih.gov


**Guidance on Salary Limitation for Grants and Cooperative Agreements FY 2020**

**Sponsor:** Office of The Director, National Institutes of Health (OD)  
**Deadline:** FY 2020  
**Contact:** Questions about specific awards may be directed to the Grants Management Specialist identified on the Notice of Award [NIH]; Please work with your SPA Project Officer if you have any questions [CU]


**Three Important Reminders for NIH-funded Researchers and Applicants:**  
[2] Prior approval for “Foreign Components;”  
[3] Disclosure to Columbia of all Financial Interests related to your institutional responsibilities

**Sponsor:** NIH/SPA  
**Deadline(s):** NA  
**Contact:** If you have questions, please contact the [https://research.columbia.edu/office-research-compliance-and-training](https://research.columbia.edu/office-research-compliance-and-training)

**Link(s):** [https://grants.nih.gov/policy/nihgps/index.htm](https://grants.nih.gov/policy/nihgps/index.htm) [NIH Grants Policy Statement (GPHS) for FY 2020, including other support]  
[https://grants.nih.gov/grants/forms/othersupport.htm](https://grants.nih.gov/grants/forms/othersupport.htm) [NIH Definition of Other Support (not yet updated)]

**NIH Office of Extramural Research Extramural Nexus; NSTC Seeks Insights on the American Research Environment**

**Sponsor:** NIH Office of Extramural Research  
**Deadline:** 12/02/2019 (Release Date)  
**Contact:** ExtramuralNexus@mail.nih.gov

**Link(s):** [https://nexus.od.nih.gov/all/2019/12/02/nstc-seeks-insights-on-the-american-research-environment/](https://nexus.od.nih.gov/all/2019/12/02/nstc-seeks-insights-on-the-american-research-environment/)

**NIH eRA Items of interest and video Tutorials**

**Sponsor:** NIH eRA  
**Deadline:** The eRA Commons is migrating their modules and data to Amazon Web Services (AWS), and will be unavailable from 8 a.m. ET on Friday, April 17 to 8 p.m. ET on Monday, April 20. Please plan ahead if you have proposals due on either of those days.

**Contact:** [https://grants.nih.gov/support/index.html](https://grants.nih.gov/support/index.html)

**Link(s):** [https://era.nih.gov/](https://era.nih.gov/)  
[https://www.youtube.com/watch?v=8E5RX0HLI0M&feature=youtu.be](https://www.youtube.com/watch?v=8E5RX0HLI0M&feature=youtu.be)  

[1] New “All About Grants” Podcast on Notices of Special Interest (NOSIs)  

**Sponsor:** NIH Extramural News (Grants Podcast); NIH Office of Policy for Extramural Research (Video Submissions)  
**Deadline(s):** NA  
**Contact:** ExtramuralNexus@mail.nih.gov (All About Grants podcast queries); Please direct all inquiries to: NIH Office of Policy for Extramural Research Administration (OPERA); Systems Policy Branch; Email: OPERAsystemspolicy@nih.gov (Video Guidance queries)

**NIH and AHRQ Announce Upcoming Changes to Policies, Instructions and Forms for Research Training Grant, Fellowship, and Career Development Award Applications**
Sponsor: National Institutes of Health (NIH); Agency for Healthcare Research and Quality (AHRQ)
Deadline(s): 12/03/2019 (Release Date)
Contact: Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Research National Institutes of Health; E-mail: NIHTrain@mail.nih.gov; or sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu/Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-033.html
https://grants.nih.gov/grants/forms/data-tables.htm
https://research.columbia.edu/pcri
https://research.columbia.edu/ReaDI-Program
https://research.columbia.edu/nih-institutional-training-grants
https://research.columbia.edu/nih
https://research.columbia.edu/Panopto/Pages/View.aspx?id=08ab34-a3b00f71501

Webinar on NIH’s Rigor & Reproducibility Policy
Sponsor: https://research.columbia.edu
Deadline(s): 01/06/2020 ( Archived Webinar Date)
Contact: Please feel free to contact us with any questions.;
Michelle C. Benson, PhD email at mb3852@columbia.edu; Stephanie F. Scott, MS, CRA email at sfs2110@cumc.columbia.edu
Link(s): https://research.columbia.edu/sites/default/files/content/RCT%20content/ReaDI%20Program/20200106_RR_Share.pdf [archived slide]
https://columbia.hosted.panopto.com/Panopto/Pages/View.aspx?id=08aba34-94d4-4186-9675-ab3b00f71501 [archived webinar]

NIH Extramural Nexus; Important Reminders for Fellowship and Career Development Applicants
Sponsor: NIH Office of Extramural Research;
https://grants.nih.gov/grants/oeer.htm
Deadline(s): NA, release date 01/06/2020
Contact: ExtramuralNexus@mail.nih.gov
Link(s): https://nexus.od.nih.gov/all/2020/01/06/important-reminders-for-fellowship-and-career-development-applicants/

Introducing BioRender: A Tool to Make Scientific Figures
Sponsor: VP&S Office of Research
Deadline(s): The VP&S Office for Research is sponsoring a 6-month trial phase for BioRender that will end in September 2019;
09/2019 (End, 6 month trial)
Contact: For questions or comments, please email ps-officeforresearch@cumc.columbia.edu
Link(s): https://www.ps.columbia.edu/research/policies/boilerplate_1

Publication of the Revised NIH Grants Policy Statement (Rev. December 2019) for FY 2020
Sponsor: National Institutes of Health, Office of The Director, National Institutes of Health (OD)
Deadline(s): 12/10/2019 (Release Date)
Contact: Please direct all inquiries to: NIH Office of Policy for Extramural Research Administration (OPERA)
Telephone: 301-435-0949; Email: grantspolicy@mail.nih.gov

NIH and AHRQ Announce Upcoming Changes to Policies, Instructions and Forms for Research Training Grant, Fellowship, and Career Development Award Applications
Sponsor: Issued by: National Institutes of Health (NIH); Agency for Healthcare Research and Quality (AHRQ)
Deadline(s): 12/03/2019 (Release Date); NIH and AHRQ recently announced plans to transition to updated application forms and instructions for due dates on or after May 25, 2020
Contact: Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Research National Institutes of Health; E-mail: NIHTrain@mail.nih.gov

NIH Office of Extramural Research Extramural Nexus; Updated Grant Application Instructions and Forms Coming in Spring 2020
Sponsor: NIH Office of Extramural Research
Deadline(s): 12/03/2019 (Release Date)
Contact: ExtramuralNexus@mail.nih.gov
Link(s): https://nexus.od.nih.gov/all/2019/12/03/updated-grant-application-instructions-and-forms-coming-in-spring-2020/
Additional Information: NIH will require the use of updated application forms and instructions (FORMS-F) for due dates on or after May 25, 2020. In the meantime, continue to use FORMS-E application packages for due dates on or before May 24, 2020 despite the expiration dates noted on each form.

NIH Extramural Nexus; Looking for Submission Policies?
Sponsor: National Institutes of Health; Office of Extramural Research
Deadline(s): NA, Posted on 10/29/2019
Contact: ExtramuralNexus@mail.nih.gov
Link(s): https://nexus.od.nih.gov/all/2019/10/29/looking-for-submission-policies/
Changes to the NIH Early Career Reviewer (ECR) Program

**Sponsor:** NIH Center for Scientific Review  
**Deadline(s):** NA  
**Contact:** Questions should be directed to CSReviewOfficer@mail.nih.gov  
**Link(s):** https://public.csr.nih.gov/ECR/ 

NIH launches new NIH/Gates Foundation collaboration to develop gene-based cures for sickle cell disease and HIV on global scale  
**Sponsor:** NIH, Gates Foundation  
**Deadline(s):** NA  
**Contact:** nhbi_news@nhbi.nih.gov; 301-496-5449; Ask for press officer on duty  

Requirement for ORCID iDs for Individuals Supported by Research Training, Fellowship, Research Education, and Career Development Awards Beginning in FY 2020  
**Sponsor:** National Institutes of Health (NIH); Agency for Healthcare Research and Quality (AHRQ); Centers for Disease Control and Prevention (CDC)  
**Deadline(s):** 07/10/2019 (Release Date)  
**Contact:** Please direct all inquiries to: For inquiries concerning the policy described in this Notice, contact: NIHTrain@mail.nih.gov  

Reminders of NIH Policies on Other Support and on Policies related to Financial Conflicts of Interest and Foreign Components  
**Sponsor:** NIH; Office of The Director, National Institutes of Health (OD); SPA  
**Deadline(s):** 07/10/2019 (Release Date)  
**Contact:** Please direct all inquiries to: Office of Policy for Extramural Research Administration; Division of Grants Compliance Oversight; Telephone: 301-435-0949; Email: grantscompliance@od.nih.gov; [NIH Contact provided for reference]; For questions, please free to reach out to your SPA Project Officer  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-114.html [Full Announcement]  
https://grants.nih.gov/grants/forms/othersupport.htm [Other Support Forms]  

NIH Extramural Nexus Newsletter, May 2019; Sample Grant Applications and Summary Statements  
**Sponsor:** NIH, National Institutes of Health, Office of Extramural Research, Extramural Nexus  
**Deadline(s):** May 2019 (Released)  
**Contact:** ExtramuralNexus@mail.nih.gov  
**Link(s):** https://www.niaid.nih.gov/grants-contacts/sample-applications  
https://public.csr.nih.gov/all/2019/05/13/the-dos-donts-of-hyperlinks-in-grant-applications/  

NIH Extramural Nexus: The Do’s & Don’ts of Hyperlinks in Grant Applications  
**Sponsor:** NIH Office of Extramural Research; https://grants.nih.gov/grants/oer.htm  
**Deadline(s):** NA; 05/13/2019 (Release Date)  
**Contact:** ExtramuralNexus@mail.nih.gov  
**Link(s):** https://nexus.od.nih.gov/all/2019/05/13/the-dos-donts-of-hyperlinks-in-grant-applications/  

NIH FY 19 Salary Cap & FY 19 AHRQ Salary Cap: Guidance on Salary Limitation for Grants and Cooperative Agreements FY 2019  
**Sponsor:** NIH; AHRQ  
**Deadline(s):** 01/06/2019 [Effective Date]  
**Contact:** Questions about specific NIH awards may be directed to the Grants Management Specialist identified on the Notice of Award.; Please direct all AHRQ inquiries to: AHRQ Division of Grants Management Email: GrantsManagementInbox@AHRQ.HHS.gov  

Notice of Data Sharing Policy for the National Institute of Mental Health  
**Sponsor:** National Institute of Mental Health  
**Deadline(s):** NA; 06/17/2019 (Release Date)  
**Contact:** Please direct all inquiries to: For technical assistance with data submission, please contact the NDA help desk
**R2eport**
**Friday Newsletter 07/16/2021**

NDAHelp@mail.nih.gov For other inquiries please contact: Gregory K. Farber, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-435-0778; E-mail: farberg@mail.nih.gov


**Registration for Summer 2020 Skills for Health and Research Professionals (SHARP) Training at Columbia University is now open**

**Sponsor:** Mailman

**Deadline(s):** Organizers hope to leave registration open until capacity is reached, up until a few days before the event. Please note piecemeal event dates and locations.

**Contact:** Please see piecemeal opportunities for contact information

**Link(s):** https://mailman.columbia.edu/SHARP-training
https://www.mailman.columbia.edu/research/precision-prevention/training-workshops

**Notice of Correction to NOT-AG-19-007, "Notice of Special Interest: High-Priority Research Topics for PAR-19-071"

**Sponsor:** National Institute on Aging

**Deadline(s):** NA (Notice)

**Contact:** Please direct all inquiries to: Austin Yang, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-9350; Email: yangj13@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AG-19-019.html

**NIH Early Career Reviewer Program**

**Sponsor:** NIH Center for Scientific Review; https://public.csr.nih.gov

**Deadline(s):** Ongoing

**Contact:** https://grants.nih.gov/about/CSR/ContactCSR; CSREarlyCareerReviewer@mail.nih.gov.

**Link(s):** https://public.csr.nih.gov/ForReviewers/BecomeARReviewer/ECR

**Registration for Summer 2019 Skills for Health and Research Professionals (SHARP) Training at Columbia University is now open**

**Sponsor:** Mailman School

**Deadline(s):** Announcement(s), NA. Please see piecemeal announcements for dates and registration information

**Contact:** please see piecemeal announcements

**Link(s):** https://www.mailman.columbia.edu/research/precision-prevention/sharp-training-skills-health-and-research-professionals


**Update to the NIH/AHRQ/NIOSH Policy on Post-Submission Materials**

**Sponsor:** Center for Scientific Review

**Deadline(s):** 05/25/2019 (Implementation Date)

**Contact:** Please direct all inquiries to: Division of Receipt and Referral; Center for Scientific Review (CSR); National Institutes of Health; Telephone: 301-435-0715; Email: csrdr@mail.nih.gov


**NIH eRA Items of Interest February 2019**

**Sponsor:** NIH Office of Extramural Research; http://Era.nih.gov

**Deadline(s):** NA, released 02/08/2019

**Contact:** https://grants.nih.gov/support/index.html; Electronic Research Administration; NIH Office of Extramural Research: http://Era.nih.gov

**Link(s):** https://era.nih.gov/news_and_events/era-item-February2019.htm

https://public.era.nih.gov/commons/public/quickqueries/index.era [eRA Commons Quick Queries]

**NIH Extramural Nexus: Reminder to Address Inclusion of Individuals Across the Lifespan in Grant Applications**

**Sponsor:** NIH; https://nexus.od.nih.gov

**Deadline(s):** 02/06/2019 (Release Date)

**Contact:** ExtramuralNexus@mail.nih.gov

**Link(s):** https://nexus.od.nih.gov/all/2019/02/06/reminder-to-address-inclusion-of-individuals-across-the-lifespan-in-grant-applications/

**CU Mandatory Facilities and Administrative Costs Faculty and Staff Training**

**Sponsor:** SPA

**Deadline(s):** please complete by 03/16/2019

**Contact:** For questions regarding this training, please contact Sponsored Projects Administration at grants-office@columbia.edu.

**Link(s):** https://mailchi.mp/cumc.columbia.edu/cu-mandatory-facilities-and-administrative-costs-faculty-and-staff-training

**eRA Information: New Validations for HSS Form When Completing an RPPR**

**Sponsor:** http://Era.nih.gov

**Deadline(s):** 01/24/2019 (Release Date)

**Contact:** https://grants.nih.gov/support/index.html

**Link(s):** https://era.nih.gov/node/523

**Summer Research Education Experience Program (Clinical Trials Not Allowed R25)**

**Sponsor:** National Institutes of Health (NIH); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Biomedical Imaging and Bioengineering (NIBIB); National Institute on Drug Abuse (NIDA); National Institute of Environmental Health Sciences (NIEHS); National Institute of Neurological Disorders and Stroke (NINDS)

**Deadline(s):** Standard dates; Standard AIDS dates: 09/08/2021 (Deadline)

**Contact:** Scientific/Research Contact(s); L Lynn Morin; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-402-0176; Email: Lynn.Morin@nih.gov

**COLUMBIA**
**Mailman School of Public Health**
mailman.columbia.edu/r2
Funding and Grantsmanship for Research and Career Development Activities; A Course for Students, Post Doctoral Scientists, Clinical Fellows, New Investigators, Faculty, & Administrators

Sponsor: CUMC

Deadline(s): 01/24/2019 (First Class)

Contact: Please contact me if there are any questions.; Regards;
Jaime Rubin; Course Director; [brought to our attention by]
Jaime S. Rubin, Ph.D.; Vice Chair for Investigator Development;
Professor of Medical Sciences (In Medicine) at CUMC; Department
of Medicine; Columbia University; JSR9@columbia.edu; (212) 342-
3104

Link(s): http://grantscourse.columbia.edu/

Summary of Significant NIH Application Changes for 2019

Sponsor: NIH; SPA

Deadline(s): 01/25/2019 • January 25th, 2019 or later:
Application changes take effect involving the Rigor and Reproducibility Policy, inclusion reporting, and new human subjects exemption criteria. • (02/05/2019) February 5th, 2019
due date or later: Must prepare proposal using the new or re-
issued Parent FOAs.

Contact: Medical Center SPA Office; grants-office@columbia.edu ;
(212) 305-4191; https://research.columbia.edu/content/directory

Link(s): https://research.columbia.edu/new-nih-foas-and-application-
changes-2019
https://r2report.files.wordpress.com/2014/04/2019-nih-proposal-
changes_final_corrected-1-13-19.pdf

NIH Policy for Review and Resubmission of New Investigator R01 Applications

Sponsor: Center for Scientific Review

Deadline(s): 01/25/2019 (Starting with R01 applications submitted for due dates on or after January 25, 2019)

Contact: Please direct all inquiries to: Division of Receipt and Referral; Center for Scientific Review; Telephone: 301-435-0715;
Email: csdrfr@mail.nih.gov


Removal of the Requirement for Institutional Review Board Review of NIH Grant Applications and Contract Proposals Related to Research

Sponsor: National Institutes of Health

Deadline(s): The HHS Office of Human Research Protections (OHRP) published the Final Rule in the Federal Register on (01/19/2017) January 19, 2017 and amended the Final Rule to delay implementation until January 21, 2019 (01/21/2019).

Contact: Inquiries; Please direct all inquiries to: Office of Policy for Extramural Research Administration
Telephone: 301-435-0949; Email: grantspolicy@mail.nih.gov


Final Revisions to the Federal Policy for the Protection of Human Subjects (the Common Rule) Information Sessions, please see accompanying schedule

Sponsor: https://research.columbia.edu/irb

Deadline(s): 01/21/2019 (The general compliance date for the Revised Common Rule is January 21, 2019); (Information Session Dates): 01/08/2019, 12:30-1:30p, HSC LL204; 01/09/2019, 1-
2p, HSC LL204; 01/10/2019, 3-4p, HSC LL204; 01/14/2019, 10-
11a, HSC LL204; 01/15/2019, 11:30-12:30p, HSC LL203;
01/17/2019, 3:30-4:30p, VP&S Amp 1

Contact: If you have questions, please contact:
https://research.columbia.edu/irb; Medical Center Office: Phone:
212.305.5883; e-mail: irboffice@columbia.edu ; Morningside
Office: Phone: 212.851.7040; e-mail: askirb@columbia.edu ;
Columbia | Research; Human Research Protections Office;
Institutional Review Boards

Link(s): https://www.ecfr.gov/cgi-
bin/retrieveECFR?gp=&SID=83cd09e1c05c6937cd9d7513160fc3f&pid=201
80719&n=pt45.1.46&n=PART14&; Email:
https://research.columbia.edu/irb

NIH Implementation of the Final Rule on the Federal Policy for the Protection of Human Subjects (Common Rule)

Sponsor: National Institutes of Health

Deadline(s): 01/02/2019 (Release Date); 01/21/2019 (The
general compliance date for the Revised Common Rule is January
21, 2019)

Contact: Please direct all inquiries to: Office of Policy for Extramural Research Administration; Telephone: 301-435-0949;
Email: grantspolicy@mail.nih.gov


Several updates to the NIH & AHRQ application instructions and review criteria for applications due on January 25, 2019 and beyond; [please also see links in Additional Information]

Sponsor: NIH

Deadline(s): for applications due on January 25, 2019
(01/25/2019) and beyond

Contact: Feel free to reach out to me regarding some of these changes. NIH & AHRQ also has specific contact information: For questions about enhancing reproducibility contact: reproducibility@nih.gov ; For questions about inclusion across the lifespan contact: inclusion@od.nih.gov ; For questions
about NIH protections for human subjects in research
contact: oep-hs@mail.nih.gov ; For questions about AHRQ
protections for human subjects in research
contact: HopeHongzhu.He@ahrq.hhs.gov
Link(s): https://grants.nih.gov/policy/reproducibility/index.htm
https://grants.nih.gov/grants/funding/lifespan/lifespan.htm
https://research.columbia.edu/ReaDI-Program

FY19 NIH NRSA Ruth L. Kirschstein National Research
Service Award (NRSA) Stipends, Tuition/Fees and Other
Budgetary Levels Effective for Fiscal Year 2019
Sponsor: National Institutes of Health (NIH); Agency for
Healthcare Research and Quality (AHRQ); Health Resources
Services Administration (HRSA)
Deadline(s): NA; 11/27/2018 (Release Date); applicable to FY
19
Contact: Please direct all inquiries to: See Frequently Asked
Questions Related to NRSA Tuition, Fees, and Health Insurance
Policies: https://grants.nih.gov/training/nrsa_tuition_q&a.htm ; Specific
questions concerning this notice or other policies relating to training
grants or fellowships should be directed to the grants management
office in the appropriate NIH Institute or Center. AHRQ, or HRSA.;
General inquiries concerning NRSA stipend and tuition policies
should be directed to: Division of Biomedical Research Workforce;
Office of Extramural Research;
Website: https://researchtraining.nih.gov ; Email: NIHTrain@mail.nih.gov
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-
036.html

New (updated) NIH Grants Policy Statement (GPS) Oct
2018
Sponsor: NIH
Deadline(s): NA; 10/23/2018 (Release Date)
Contact: Please direct all inquiries to: NIH Office of Policy for
Extramural Research Administration; Telephone: 301-435-0949;
Email: grantspolicy@mail.nih.gov ; As always, if you have any
questions, please feel free to reach out to your SPA Project Officer
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-
021.html
https://grants.nih.gov/grants/policy/nihgps/Significant_Changes_NIHGPS_Oc
t2018.pdf

NIH Multi-Project Application Resources
Sponsor: NIH
Deadline(s): NA, posted on 11/15/2018
Contact: Please see piecemeal Application Resources in the
Extramural Nexus and / or ExtramuralNexus@mail.nih.gov

Link(s): https://nexus.od.nih.gov/all/2018/11/15/multi-project-application-
resources/

Notice of Fiscal Policies in Effect for FY 2019
Sponsor: National Institutes of Health
Deadline(s): 11/27/2018 (Release Date)
Contact: Please direct all inquiries to: Division of Grants Policy;
National Institutes of Health; Telephone: 301-435-0949;
Email: GrantsPolicy@od.nih.gov
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-
031.html

NIH Research Project Grant (Parent R01 Basic
Experimental Studies with Humans Required)
Sponsor: National Institutes of Health; National Center for
Complementary and Integrative Health; National Institute on
Aging; National Institute on Alcohol Abuse and Alcoholism;
National Institute on Drug Abuse; National Institute on Deafness
and Other Communication Disorders; National Institute of Dental
and Craniofacial Research; National Institute of Environmental
Health Sciences; National Institute of Mental Health; National
Institute on Minority Health and Health Disparities; National
Institute of Neurological Disorders and Stroke; National Institute
of Nursing Research; National Library of Medicine
Deadline(s): Standard dates ; Standard AIDS dates. 01/08/2022
(Expiration)
Contact: Scientific/Research Contact(s): Participating NIH
Institutes and Centers are listed in "Components of Participating
Organizations" in Part 1. Overview. Scientific/Research Contact
information is listed on R01 Basic Experimental Studies with Humans
Required IC-Specific Scientific Interests and Contact website.

NIH Exploratory/Developmental Research Grant Program
(Parent R21 Basic Experimental Studies with Humans
Required)
Sponsor: National Institutes of Health; National Center for
Complementary and Integrative Health; National Institute on
Aging; National Institute on Alcohol Abuse and Alcoholism;
National Institute on Drug Abuse; National Institute on Deafness
and Other Communication Disorders; National Institute of Dental
and Craniofacial Research; National Institute of Environmental
Health Sciences; National Institute of Mental Health; National
Institute on Minority Health and Health Disparities; National
Institute of Nursing Research
Deadline(s): Standard dates ; Standard AIDS dates. 01/08/2022
(Expiration)
Contact: Scientific/Research Contact(s): Participating NIH
Institutes and Centers are listed in "Components of Participating
Organizations" in Part 1. Overview. Scientific/Research Contact
information is listed on R01 Basic Experimental Studies with Humans
Required IC-Specific Scientific Interests and Contact website.
Reminder: NIH Natural Disaster Policy - Hurricane Florence

**Sponsor:** National Institutes of Health

**Deadline(s):** NA

**Contact:** Please direct all inquiries to: Division of Receipt and Referral; Center for Scientific Review; Telephone: 301-435-0715; Email: csrcf@mail.nih.gov


---

Conferees Approve FY 2019 HHS Funding Bill; All ASPPH Priority Accounts Funded; NIH Up $2 Billion

**Sponsor:** House-Senate Conference Committee

**Deadline(s):** NA

**Contact:** NA

**Link(s):**

---

**NIH eSubmission Items of Interest - July 31, 2018**

**Sponsor:** NIH

**Deadline(s):** NA; 07/31/2018 (Release Date)

**Contact:** https://grants.nih.gov/support/index.html

**Link(s):**

---

**Additional Information:** NIH eSubmission Items of Interest - July 31, 2018; NIH sent the newsletter below the other day, which contains a lot of tips on the new PHS Human Subjects and Clinical Trial Information Form. In addition, they address Fellowship applications, and some things to keep in mind if the fellow is seeking clinical research experience. Since the fellowship deadline is next week (August 8th), I wanted to bring this to your attention.; I highlighted what I thought were the key points below. [brought to our attention by] Stephanie Scott; NIH Submission Items of Interest - July 31, 2018; Happy National Mutt Day! Yep, it's a real thing. And, why shouldn't it be? I vividly remember bringing my mutt home from a pet adoption event years ago and introducing her to her new "daddy." "She’s two dogs long and one dog tall and looks like she’s made from spare parts," Jeff said. All true. An emaciated basset-beagle-ish dog with ears longer than her bowed-little-legs isn’t going to win any beauty contests. But, our Dixie is the most lovable hound on the planet and we wouldn’t trade her for the world.; Mutts are amazing, but what do they have to do with grant application submission? Not much actually, but if you love your mutt as much as I love mine, then I’ve at least got your attention. Besides, who passes up the opportunity to celebrate? More wag, less bark!; Hopefully you’ll find this edition to have an interesting mix... not unlike your favorite mutt.; Where Do I Put the Information I Know You’d Want, But Didn’t Ask For?; You want to give staff and reviewers ALL the information you think they need to provide a thorough review of your proposal. There is certainly nothing wrong with that - right? Well, actually it does. The application guide and funding opportunity announcement provide very specific guidance on what to include in your application and, in some cases, **there are page limits** you must stay within to convey the requested information.; If you have information that doesn’t fit in page-limited attachments like your Specific Aims and Research Strategy, rework those attachments until you tell the best story possible within the confines of the page limits. Do not try to stuff that extra information into other non-limited fields of the application forms. Similarly, if you have information that doesn’t have a "natural home" based on our instructions, don’t include it.; There are several form fields with tempting names like "Appendix," "Other Attachments," "Other Requested Information," and "Other Clinical Trial-related Attachments." DO NOT use those fields unless requested to do so in the application guide or announcement.; Why not? Even if you have the best of intentions, you need to resist the temptation to force fit information into your application where it doesn’t belong. The page limits and guidance are there for fairness and you may find your application pulled from consideration if you try to get around them NOT-OD-18-080; The Duplication Balancing Act: The application guide statement "do not duplicate information between the Research Strategy attachment and the PHS Human Subjects and Clinical Trials Information form" appears to be causing some angst in the community. In fact, our new human subjects form invites a certain amount of overlap between the sections. It would be difficult, for example, to provide a "Brief Summary" of a protocol without talking about information captured elsewhere in the application.; The point we were actually trying to make is that we don’t want you to copy and paste blocks of text into multiple places in your application. Your Specific Aims and Research Strategy should include enough human subjects and clinical trial information to tell a cohesive and complete story. The human subjects form is meant to provide structured, supporting details for the study (sorry, it isn’t just extra space to expound on the research strategy). The Brief Summary in the Protocol Synopsis section of the human subjects form aligns with what the public would see in ClinicalTrials.gov without the benefit of the full application. It should hit the key points at a very high level in as close to plain language as possible.; The bottom line is there will be some overlap of information within your application, but reviewers should not be reading blocks of text copied verbatim into multiple sections of the application.; Space-Fill Compulsion: My mother, an interior designer, never saw a horizontal surface she didn’t want to decorate. For years I encouraged her to declutter and often she’d begrudgingly remove a knick-knack from a table of shelf. But the next time I’d visit a new knick-knack was sitting right it its place. My dad calls it space-fill compulsion.; Our new human subjects form has several text fields with large character limits (e.g., Eligibility Criteria - 15,000 characters; Brief Summary - 5,000 characters; Narrative Study Description - 32,000 characters). These character limits match those in...
ClinicalTrials.gov and were set artificially high so the system could accommodate more characters than are actually needed.; Here is a fun little tidbit we’ve learned ... folks who are already funded and entering information into ClinicalTrials.gov tend to be more pithy than folks applying for funding. Could it be that while composing your response you see the character count is well below the available space and assume NIH wants more? Space-fill compulsion, perhaps?: If you’ve covered what you need to say in a few paragraphs, then stop. You don’t need to fill the entire allotted space. Eligibility criteria is typically quite succinct. A Brief Summary typically runs 2,000 characters or less and the Project Narrative typically 5,000 characters or less. It would be unusual to come even close to the character limits for those fields. It’s, OK. Cover the topics using only the space you need.; Remember, this is the supporting detail for your story, not the story itself. Less is more. Don’t bury your main point under unnecessary information.; Do Fellowship Awards Allow Clinical Trials?: We encourage fellows to receive training in clinical research, including clinical trials. NIH-supported fellows just can’t independently lead them. The career stage of a fellow may not yet align with the responsibilities of navigating all the components, complexities and reporting requirements associated with a clinical trial. In addition, fellowship grants do not include sufficient research funds to support the majority of clinical trials. Consequently, all Fellowship opportunities are posted as independent Clinical Trials Not Allowed.; The sponsor is the responsible individual of record for oversight of the trial. He or she is ultimately responsible for tasks like interacting with relevant Institutional Review Board (IRB) staff, reviewing all informed consent documents, reporting potential serious adverse events, and maintaining responsibility for patient safety. But there are no restrictions on the responsibilities the fellow can assume with the sponsor’s oversight.; If you plan on submitting a fellowship application, clearly delineate the roles both the sponsor and the fellow are undertaking. This can be done in the Sponsor and Co-Sponsor attachment for the sponsor and the Research Strategy for the fellow. It needs to be clear that the fellow is not the responsible individual. Overselling their role to the point where it looks like they are leading the trial can hurt more than it helps. It’s fine to show the fellow working side-by-side with his or her sponsor through every aspect of the trial. It’s not OK for them to be off on their own Shouldering all the responsibility themselves.; Dog Days of Summer: “Be the person your dog thinks you are.”; ~ George Elliot aka Mary Ann Evans; Stay cool and if you’re lucky enough to have one, give your mutt an extra hug.; Take care, Sheri; [brought to our attention] by Sheri Cummins; Communications & Outreach; NIH Office of Extramural Research; cumminss@mail.nih.gov

Sponsor: NIH/AHRQ
Deadline(s): NA; 07/23/2018 (Release Date)
Contact: Please direct all inquiries to: Division of Receipt and Referral; Center for Scientific Review; Telephone: 301-435-0715; Email: csdr@mail.nih.gov; Sally A. Amero, Ph.D.; NIH Office of Extramural Research; Email: ReviewPolicyOfficer@mail.nih.gov; Lisa Scott-Morning, M.S., M.S.H.S., C.R.A.; Agency for Healthcare Research and Quality; Telephone: 301-427-1555; Email: Lisa.Scott-Morning@ahrq.hhs.gov

NIH Extramural News: How do you define a “study” for the purposes of providing information on the PHS Human Subject and Clinical Trial form?
Sponsor: NIH; Office of Extramural Research; Extramural News;
Deadline(s): NA; 07/25/2018 (Release Date)
Contact: ExtramuralNexus@mail.nih.gov

NIH Guide Notice on Delayed Enforcement and Short-Term Flexibilities for Some Requirements Affecting Prospective Basic Science Studies Involving Human Participants
Sponsor: National Institutes of Health (NIH)
Deadline(s): NA; 07/20/2018 (Release Date)
Contact: Please direct all inquiries to: NIH Grants Information; Email: grantsinfo@od.nih.gov (preferred method of contact); [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; Email: stephanie.scott@columbia.edu; or sfs2110@cumc.columbia.edu; Website: https://spa.columbia.edu/

Additional Information: NIH Guide Notice on Delayed Enforcement for Some Requirements Affecting Prospective Basic Science Studies Involving Human Participants; As I previously announced a few weeks ago, NIH will be delaying enforcement for some requirements affecting prospective basic science studies that also meet NIH’s definition of a clinical trial. NIH just released the official notice stating this, along with their future plans: https://grants.nih.gov/grants/guide-notice-files/NOT-OD-18-212.html; Please read the notice in its entirety. The Council on Governmental Relations (COGR) provided a summary below. Here are some highlights: (*) Registration and Reporting: NIH still expects the registration and reporting of these prospective basic science studies, but is giving flexibility to allow reporting on existing basic science portals, and expects the data to eventually be transported to ClinicalTrials.gov. Flexibility given through September 24, 2019.

NIH/AHRQ Application Submission/Resubmission Policy;
NIH and AHRQ just issued the following announcement clarifying and consolidating previous policies concerning resubmissions and renewals

COLUMBIA RESEARCH RESOURCES
mailman.columbia.edu/r2

Page 289/439
They are issuing a Request for Information (RFI) to collect stakeholder feedback on this topic; (*) Funding Opportunity Announcements (FOAs): NIH will not administratively reject any proposal application for submission to an incorrect FOA based on study-type designation, and they plan to issue an FOA specifically for prospectively basic science studies in November for due dates starting on January 25th, 2019; (*) The PHS Human Subjects and Clinical Trial Information Form (new in FORMS-E) – they still expect that form for all applications involving prospective basic science studies; (*) Good Clinical Practice (GCP) training is still being enforced for all personnel involved in the conduct, oversight, or management of prospective basic science studies involving human participants. As a reminder, Columbia offers GCP training in Rascal through Course TC3450. For more information, see https://research.columbia.edu/content/good-clinical-practice-training or email NIH-GCP@columbia.edu ; Please read the notice in its entirety for more information, and stay tuned for more updates from me on this topic; [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; Email: stephanie.scott@columbia.edu; or sfs2110@cumc.columbia.edu ; Website: https://spa.columbia.edu/ ; NIH Guide Notice on Delayed Enforcement for Some Requirements Affecting Prospective Basic Science Studies Involving Human Participants; Dear COGR Members, NIH issued the following Guide Notice this morning, Delayed Enforcement and Short-Term Flexibilities for Some Requirements Affecting Prospective Basic Science Studies Involving Human Participants. As you know, COGR and other organizations have expressed concern that the NIH clinical trial case studies broadened the agency’s definition of “clinical trial” to include basic science studies involving human participants. NIH, in response to report language in the Consolidated Appropriations Act of 2018, has released this notice NOT-OD-18-212 which delays enforcement of registration and reporting policies for prospective basic science studies involving human participants under NOT-OD-16-149. Per the notice, “through September 24, 2019, NIH will continue to expect registration and reporting for prospective basic science studies involving human participants, with additional flexibility to allow reporting on existing basic science portals, with the expectation that data will eventually be transported to ClinicalTrials.gov.” NIH will issue a Request for Information (RFI) to seek additional input “on registration and results reporting standards best suited for prospective basic science studies involving human participants.”; The notice also provides a period of “tenancy for applications submitted to the incorrect FOA based on the study type designation” during which time NIH will not “administratively reject any application for submission to an incorrect FOA based on study-type designation.” The notice also indicates that the agency “plans to issue FOAs specifically for prospective basic science studies involving human participants.” Please see the notice for details. ; Lisa Nichols, Ph.D.; Council on Governmental Relations; 1200 New York Avenue, N.W., Suite 460; Washington, D.C. 20005; l nichols@cogr.edu; 202-289-6655

Clarification: Assignment Deadlines for Applications Submitted Under the NIH Continuous Submission Policy; Notice NOT-OD-18-178 from the NIH Guide for Grants and Contracts

Sponsor: NIH
Deadline(s): 06/22/2018 (Release Date)
Contact: If you have any questions, you can reach out to your assigned SPA Project Officer; Please direct all inquiries to: Frequently Asked Questions and answers have been prepared; (see https://grants.nih.gov/grants/peer/faq_continuous_submission.htm ).
Any remaining issues/appeals may be directed to a NIH Continuous Submission Committee by emailing CSR.cont.sub.comm@csr.nih.gov


Additionally, please see the following notice, which clarifies the NIH application receipt date deadlines for applicants eligible under NIH’s Continuous Submission Policy: The key point stated in the notice is, “Eligible applications may be submitted at any time, but they will be assigned to Advisory Council rounds based on the schedule in the table” that is provided in the link above; If you have any questions, you can reach out to your assigned SPA Project Officer.; [brought to our attention by] Stephanie Scott

Now Available: Delegate Tasks When Working on Interim or Final RPPRs

Sponsor: NIH
Deadline(s): 05/21/2018 (posted on date)
Contact: ExtramuralNexus@mail.nih.gov ; https://grants.nih.gov/support/index.html
Link(s): https://nexus.od.nih.gov/all/2018/05/21/now-available-delegate-tasks-when-working-on-interim-or-final-rpprs.html
https://grants.nih.gov/rgs/rppr/index.htm

June 9th, 2018-NEW NIH Human Subjects System (HSS); NIH announced last week that they are retiring the Inclusion Management System (IMS) and replacing it with a new Human Subjects System (HSS) as of June 9th, 2018

Sponsor: NIH
Deadline(s): 06/09/2018 (Effective Date)
Contact: https://grants.nih.gov/support/index.html
Link(s): https://era.nih.gov/hss_overview.cfm

NIH Announces Stipend and Benefit Increases for National Research Service Award Recipients

Sponsor: NIH
Contact: Inquiries; Please direct all inquiries to: See Frequently Asked Questions Related to NRSA Tuition, Fees, and Health Insurance Policies; https://grants.nih.gov/training/nrsa_tuition_q&a.htm ;
Specific questions concerning this notice or other policies relating to training grants or fellowships should be directed to
the grants management office in the appropriate NIH Institute or Center, AHRQ, or HRSA; General inquiries concerning NRSA stipend and tuition policies should be directed to: Division of Biomedical Research Workforce; Office of Extramural Research; Website: https://researchtraining.nih.gov; Email: NIHTrain@mail.nih.gov
NA, posted on 05/16/2018

Clarification of NIH’s Policy Regarding a Change in Program Director’s/Principal Investigator’s Status
Sponsor: National Institutes of Health (NIH)
Deadline(s): 05/01/2018 (Release Date)
Contact: Please direct all inquiries to: Office of Policy for Extramural Research Administration
Telephone: 301-435-0949; Email: grantspolicy@mail.nih.gov

Provision of Table 3 for PIs to be included in NIH and AHRQ institutional training grant proposals
Sponsor: NIH/SPA
Deadline(s): Announcement, NA
Contact: The form is an excel file with two tabs. You should make sure to include the first and last names of all participating faculty, along with their UNIs (not email addresses) and departments. The completed form should be sent to SPA-eBiz@columbia.edu.
Link(s): https://research.columbia.edu/content/nih-institutional-training-grants

National Science Foundation - National Institutes of Health NSF-NIH Interagency Initiative: Smart and Connected Health
Sponsor: Office of the Director, NIH; National Cancer Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Library of Medicine
Deadline(s): 03/09/2018 (Release Date)

NIH Salary Cap: Guidance on Salary Limitation for Grants and Cooperative Agreements FY 2018
Sponsor: National Institutes of Health (NIH)
Deadline(s): 03/07/2018 (Release Date)
Contact: Questions about specific awards may be directed to the Grants Management Specialist identified on the Notice of Award.

Additional Information: NIH Salary Cap: Guidance on Salary Limitation for Grants and Cooperative Agreements FY 2018; NIH issued guidance on the use of a new NIH salary cap, to increase from $187,000 to $189,600. See https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-137.html. The effective date of this increase is January 7th, 2018.; NIH has not received the final Fiscal Year (FY) 2018 appropriation and is operating under a continuing resolution through March 23rd, 2018 (see NOT-OD-18-136 also a very important notice). However, NIH issued this guidance until a budget is passed.; In summary, this is how the $189,600 salary cap can be applied: (*) NIH proposal budgets may be submitted using the new cap; (*) Active NIH awards may rebudget to the new cap if restricted to Executive Level II, and adequate funds are available, and the salary cap increase is consistent with the institutional base salary. The new cap should be prorated for the applicable months: (**) Cap is $187,000 through 1/6/18; (**) Cap is $189,600 from 1/7/18 – present.; if you have any questions, please feel free to reach out to your SPA Project Officer. We will keep you posted on any developments. Please note I am currently out of the office, returning on Monday; Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu

NICHID Policy on Early T32 Renewal Applications
Sponsor: NIH/NICHD
Deadline(s): 05/25/2018 (Effective Date)
Contact: Please direct all inquiries to: NICHD Referral Officer; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-3371; Email: NICHDReferral@mail.nih.gov

Outsourcing of IRB Review for NIH Single IRB Policy
Sponsor: NIH/IRB OFFICE AT COLUMBIA
Deadline(s): Now in effect; 01/25/2018 (Effective Date)
Contact: Please contact the HRPO at (212) 305-5883 or by email at irboffice@columbia.edu if you have any questions

xTRACT will be required in FY2020
Sponsor: National Institutes of Health (NIH); Agency for Healthcare Research and Quality (AHRQ)
Deadline(s): xTRACT will be required in FY2020
Contact: Please direct all inquiries to: NIHTrain@mail.nih.gov

Update on Research Support Services, Spring 2018; we are pleased to expand the Research Support Services to also include resubmissions of otherwise eligible R01, P, K, Center and T32 grants (if the services have not yet been utilized)
Sponsor: Mailman School
Deadline(s): relative to upcoming NIH Grant Submission

Deadlines: 5 weeks prior to submission deadline (Inform R2 of intent to utilize services); 4 weeks prior to submission deadline (science draft for external review); 2 weeks prior to submission deadline (submission for editing services)

Contact: Pam Factor-Litvak (Associate Dean, Research Resources, and Professor of Epidemiology) prf1@columbia.edu; Craig Kandell (Project Coordinator, Research Resources) ckk7@cumc.columbia.edu

Link(s):
https://r2report.files.wordpress.com/2015/05/updateofgrantsupportservicespring2018gpdf.pdf

Additional Information:

Dear Mailman School faculty,

I want to give you an update on Research Support Services—the School’s new program for pre-submission external review and final editing. As Dean Fried wrote in October, the program is geared “to support faculty in preparing grant applications with the highest chance of success.”

I’m happy to report that those using the services this fall have found them valuable. Katherine Keyes in Epidemiology spoke enthusiastically at the recent Assembly: “It was a great experience. I got to focus on the science without having to deal with any of the administrative aspects. I got really good feedback. I will be using these services again.”

In my estimation, all the grants were greatly improved by these services. Of course, the ultimate test is how they are scored and funded. As soon I have that information, I will share it with you.

I encourage everyone to take advantage of Research Support Services to give your grants a competitive advantage. Please keep in mind the following deadlines:

- **5 weeks prior to submission deadline**—Inform Research Resources (via Craig Kandell at ckk7@cumc.columbia.edu) if you plan on using Research Support Services with information about they the type of grant at least five weeks prior to the grant due date. If you seek external review, please provide the name and contacts of at least three potential reviewers so we can reach out to them in your order of preference.

- **4 weeks prior to submission deadline**—Send us your science draft for external review three to four weeks prior to submission. We will forward it to the external reviewer. Generally, they provide feedback within a week.

- **2 weeks prior to submission deadline**—For editorial services, send us your manuscript at least 10 days ahead of the deadline. We will make arrangements with the editor. Comments will be returned to Craig and the PI for finalization and submission within a few days.

Please keep in mind that it may take you a day or two to incorporate comments and edits. For best results, get in touch with us prior to these deadlines.

Research Support Services cover first-time submissions, and we are pleased to expand the service to encompass resubmissions (if the support services have not been utilized for the grant) of R01, P, K, Center, T32, or other complex NIH proposals by full-time faculty with primary appointments in the School. I am available to provide feedback for grants that utilize this service and also for other grant types (such as R21s) that are ineligible for the services.

If you have any questions about your eligibility or the above process, please visit Research Resources online or contact me at prf1@columbia.edu.

Best wishes,

Pam Factor-Litvak

NIH eSubmission Items of Interest – February 14, 2018

**Sponsor**: NIH/SPA

**Deadline(s)**: NA/Announcement(s)

**Contact**: [NIH] Sheri Cummins; Communications & Outreach; NIH Office of Extramural Research; cumminsas@mail.nih.gov; just reach out to the eRA Service Desk; [CU] If you have any questions, please feel free to reach out to your SPA Project Officer.

**Link(s)**:
https://grants.nih.gov/grants/ElectronicReceipt/esub_items_interest_02142018.htm
https://grants.nih.gov/grants/guide/parent_announcements.htm
https://grants.nih.gov/policy/clinical-trials/definition.htm

NIH Single IRB Policy Reminder

**Sponsor**: NIH

**Deadline(s)**: Effective for NIH Funding submissions whose due dates are 01/25/2018 or after

**Contact**: If you have questions, please contact:
https://research.columbia.edu/irb; Medical Center Office: Phone: 212.305.5883; e-mail: irboffice@columbia.edu; Morningside Office: Phone: 212.851.7040; e-mail: askirb@columbia.edu; Columbia | Research; Human Research Protection Office; Institutional Review Boards

**Link(s)**: https://research.columbia.edu/content/single-irb-review-multi-site-research
NIH single IRB (sIRB) policy

**Sponsor:** NIH

**Deadline(s):** (for NIH application submissions on or after)
01/25/2018

**Contact:** If you are preparing an NIH application due on or soon after January 25th, 2018, you should contact the Human Research Protection Office (HRPO) immediately at irboffice@columbia.edu if your application proposes to: (*) Conduct non-exempt human subjects research; AND; (*) The same research protocol will be conducted at multiple domestic sites

**Link(s):** https://grants.nih.gov/grants/policy/clinical-trials/single-irb-policy-multisite-research.htm

**Additional Information:** The NIH single IRB (sIRB) policy applies to the domestic sites of new and competing renewal applications/proposals with due dates of January 25, 2018 and beyond for NIH-funded multi-site studies where each site will conduct the same protocol involving non-exempt human subjects research, whether supported through grants, cooperative agreements, contracts, or the NIH Intramural Research Program;

If you are preparing an NIH application due on or soon after January 25th, 2018, you should contact the Human Research Protection Office (HRPO) immediately at irboffice@columbia.edu if your application proposes to: (*) Conduct non-exempt human subjects research; AND; (*) The same research protocol will be conducted at multiple domestic sites;

If Columbia University is being proposed as one of the participating sites in an application to be submitted this month or soon after by another applicant organization, you must also contact the HRPO immediately. Moving forward, it is recommended that you contact the HRPO as soon as a decision is made to participate in a multi-site study to which the NIH sIRB Policy applies; An official process that details the requirements for addressing the NIH sIRB Policy is being finalized, to be released shortly. In the meantime, PIs and/or departments can reach out to irboffice@columbia.edu to inform the HRPO about these applications. Upon receipt of your email, HRPO will send you an online form to be completed, and you will be provided with next steps; in addition, we are offering several options to learn more about the sIRB process. Note: Protocols that address the same research questions, involve the same methodologies, and evaluate the same outcomes are considered to be the “same research protocol.” Additionally, sites that are accruing research participants for studies that are identical except for variations due to local context consideration would be considered to be conducting the “same research protocol.”; If you have any questions, please contact irboffice@columbia.edu; Our website contains resources to help you while you get accustomed to all of the policy changes impacting proposal preparation. We have an Excel checklist to help you complete the new PHS NIH Human Subjects and Clinical Trials Information Form. We also have a one-page reference guide (thank you Katherine Rochmat of School of Social Work for the initial template); https://research.columbia.edu/content/nih-proposal-information; As always, feel free to contact your SPA Project Officer should you have any questions about NIH proposal preparation.; [brought to our attention by] Stephanie F. Scott, Director of Policy & Research Development, SPA; Columbia | Research; Sponsored Projects Administration; Phone: (212) 854-0606; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu; and Alan Teller, Director of Operations, HRPO. At2059@cumc.columbia.edu

Successor-in-Interest (Type 6 Parent Clinical Trial Optional)

**Sponsor:** National Institutes of Health; John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Office of Behavioral and Social Science Research; Office of Research on Women’s Health; The Common Fund/Office of Strategic Coordination

**Deadline(s):** A successor-in-interest request must be made before the anticipated start date at the new organization and preferably several months in advance; 01/26/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); For any scientific or research-related questions on this Successor-in-Interest announcement please contact the Program Officer listed on the NOA of the most recent award.

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-18-589.html

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp - Clinical Trial Optional)

**Sponsor:** National Institutes of Health; John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and
Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Office of Behavioral and Social Science Research; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs; Office of Research on Women’s Health; The Common Fund/Office of Strategic Coordination

**Deadline(s):** Due dates may vary by awarding IC. See the awarding IC web site for any applicable Application Due Dates.

**Contact:** Scientific/Research Contact(s); For any scientific or research-related questions on this administrative supplement please contact the Program Officer listed on the NoA of the most recent parent award.


---

**Change of Grantee Organization (Type 7 Parent Clinical Trial Optional)**

**Sponsor:** National Institutes of Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Office of Behavioral and Social Science Research; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs; Office of Research on Women’s Health; The Common Fund/Office of Strategic Coordination

**Deadline(s):** A change of grantee organization request must be made before the anticipated start date at the new organization and preferably several months in advance.

**Contact:** Scientific/Research Contact(s); For any scientific or research-related questions on this Change of Grantee Organization announcement please contact the Program Officer listed on NoA of the most recent award.

**Link(s):** [https://research.columbia.edu/irb](https://research.columbia.edu/irb)

---

**Improving Odds of Success for Young Researchers**

**Sponsor:** NICHD, [https://www.nichd.nih.gov/about/od](https://www.nichd.nih.gov/about/od)

**Deadline(s):** 01/16/2018 (Date Posted)

**Contact:** [https://www.nichd.nih.gov/contact](https://www.nichd.nih.gov/contact);

**Link(s):** [NICHD_information_resource_center@mail.nih.gov](mailto:NICHD_information_resource_center@mail.nih.gov)

---

**Updates from the Human Research Protection Office (HRPO) on recent new or revised policies, regulations or requirements that may affect IRB activities and requirements**

**Sponsor:** Columbia | Research Human Research Protection Office; Institutional Review Boards; [https://research.columbia.edu/irb](https://research.columbia.edu/irb)

**Deadline(s):** NA

**Contact:** We look forward to hearing from you;

**Link(s):** [https://research.columbia.edu/sites/default/files/content/HRPO/IRB%20SOP%20-%205.0%2001.18.pdf](https://research.columbia.edu/sites/default/files/content/HRPO/IRB%20SOP%20-%205.0%2001.18.pdf)

---

**Additional Information:** HRPO and IRB Updates; Dear colleagues, This email provides updates from the Human Research Protection Office (HRPO) on recent new or revised policies, regulations or requirements that may affect IRB activities and requirements.; [Status of the Revised Common Rule]: The Final (revised) Common Rule, i.e., revisions to Subpart A of the DHHS regulations for the Protection of Human Subjects (45 CFR 46), were published on January 19, 2017, with an effective and compliance date of January 19, 2018 for the majority of the revisions. On January 17, 2018, an Interim Final Rule was released that delays the effective date for 6 months, to July 19, 2018. Certain federal departments and agencies are in the process of developing a proposed rule to further delay implementation.; The HRPO is developing guidance for preparing for the transition to the Revised Common Rule. Stay tuned for more information...; [Revised Policies]: Revisions have been made to the new IRB Policy on the Privacy Rule and the Use of Health Information in Research (IRB HIPAA & Research Policy) and the IRB Data Security Plans Involving the Use, Storage or Transmission of Electronic Research Data Constituting Sensitive Data (IRB Data Security Policy). The IRB HIPAA & Research Policy, which was released on November 1,
2017, was revised to provide clarifications of definitions, scope, and when a Data Use Agreement is necessary. In addition, several case studies were added to assist with implementation of this policy. The IRB Data Security Policy was revised to include new terminology and definitions that are included in the IRB HIPAA & Research Policy. Sessions to explain the policy and review the examples will be scheduled. In addition, please let us know if you would like to have us come to your departmental meeting to review the policy!

**Revised Standard Operating Procedures (SOPs):** Version 5.0 of the IRB’s SOPs were recently released. Included in this version: (*) Comprehensive information on Expanded Access; (*) Incorporation of Columbia’s Institutional Conflict of Interest Policy; (*) Clarifications on when Unanticipated Problems are reported to federal agencies; (*) Updates to the sections regarding recruitment of impatient at NYP; (*) Addition of the new SingleIRB processes; (*) Clarification on the process for IRB disapproval; **Process for Implementing the NIH Single IRB Policy:** The NIH Single IRB (sIRB) Policy is applicable to new and competing renewal applications/proposals for NIH funding that are due on or after January 25, 2018, and contract solicitations issued on or after January 25, 2018. It is applicable to NIH-funded multi-site domestic studies involving non-exempt human subjects research, whether supported through grants, cooperative agreements, contracts, or the NIH Intramural Research Program; If you are preparing an NIH application that is due on or before March 5, 2018, it is important that you contact the HRPO immediately at irboffice@columbia.edu if your application proposes to: (*) Conduct non-exempt human subjects research; AND (*) The same research protocol will be conducted at multiple domestic sites; The HRPO and SPA have developed tools to facilitate implementation of this policy. These tools, including an overview of our process and template language that can be used in your grant applications, can be accessed here. The HRPO’s web page will continue to be updated with additional resources as more information becomes available to facilitate compliance with this policy; **Upcoming HRPO Education Sessions:** Monthly IRB Investigation Monthly Meetings: (*) February 22, 3:30-4:30pm, P&S Amphitheatre 1; (*) March 22, 3:30-4:30pm, P&S Amphitheatre 1; (*) April 26, 3:30-4:30pm, P&S Amphitheatre 1; (*) May 24, 3:30-4:30pm, P&S Amphitheatre 1; **We want to hear from you!** Please send us your questions as well as suggestions for topics for future education sessions; We look forward to hearing from you! [https://research.columbia.edu/irb](https://research.columbia.edu/irb)

- Medical Center Office: Phone: 212.305.5883; e-mail: irboffice@columbia.edu; Morningside Office: Phone: 212.851.7040; e-mail: askirb@columbia.edu
- Columbia | Research Human Research Protection Office; Institutional Review Boards

| Assuring the Integrity of Peer Review |
| Sponsor: NIH |
| **Deadline(s):** 12/22/2017 (Release Date) |
| **Contact:** Please direct all inquiries to: Sally A. Amero, Ph.D.; NIH Review Policy Officer; ReviewPolicyOfficer@mail.nih.gov |

A few questions as you prepare your NIH proposals and Clinical Trials

**Sponsor:** NIH

- **Deadline(s):** NA
- **Contact:** [Brought to our attention] by Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; Phone: (212) 854-0606; Cell Phone: (646) 248-8573; Email: sfs2110@columbia.edu;
- **Website:** [http://spa.columbia.edu/](http://spa.columbia.edu/);
- **Link(s):** [https://grants.nih.gov/ct-decision/index.htm](https://grants.nih.gov/ct-decision/index.htm)

Update: Notice of NIH’s Interest in Diversity

**Sponsor:** National Institutes of Health

- **Deadline(s):** 01/03/2018 (Release Date)
- **Contact:** Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Research; Website: [https://researchtraining.nih.gov](https://researchtraining.nih.gov);

Further Refining Case Studies and FAQs about the NIH Definition of a Clinical Trial in Response to Your Questions

**Sponsor:** NIH Office of Extramural Research (OER) at NIH; [https://grants.nih.gov/aboutoer/intro2oer.htm](https://grants.nih.gov/aboutoer/intro2oer.htm)

- **Deadline(s):** NA; posted on 01/04/2018
- **Contact:** Dr. Michael Lauer is NIH’s Deputy Director for Extramural Research, serving as the principal scientific leader and advisor to the NIH Director on the NIH extramural research program.; [ExtramuralNexus@mail.nih.gov](mailto:ExtramuralNexus@mail.nih.gov)

NIH ANNOUNCEMENTS: On December 31, 2017

Grants.gov will no longer allow grant applicants to download an entire application form package as a single PDF for offline data entry and later submission

**Sponsor:** NIH

- **Deadline(s):** 12/31/2017 (Effective Date)
- **Contact:** Sheri Cummins; Communications & Outreach; NIH Office of Extramural Research; cummingsa@mail.nih.gov

**Additional Information:** NIH grant applicants: Grants.gov downloadable forms submission option retiring Dec. 31; NIH grant applicants: Grants.gov downloadable forms submission option retiring Dec. 31; NIH Grant Applicant, On December 31, 2017
Grants.gov will no longer allow grant applicants to download an entire application form package as a single PDF for offline data entry and later submission. Since you were involved in a grant application submitted using downloadable forms in 2017, we wanted to provide a final reminder to switch to one of the following submission options for 2018 submissions: (1) NIH’s ASSIST (learn more); (2) Institutional system-to-system solution (if your institution has one); (3) Grants.gov Workspace (learn more).

Our submission options page can help you compare features and considerations for each option. Ultimately your office of sponsored research or other group responsible for grant application submissions will decide which option is the best fit for you and your organization. If there is no business reason to choose one option over another, give NIH’s ASSIST a try. It’s a user-friendly, online solution optimized for NIH applications. Although Grants.gov will stop presenting their legacy downloadable forms package as an option at the end of this year, Grants.gov and NIH systems will continue to process previously downloaded application packages through March 2018. If you plan to submit a downloaded application package after December 31, 2017, you might want to consider downloading an extra copy of the forms package for the opportunity before Dec 31 just in case you run into a technical difficulty with the original. Hope you have a great holiday season! Sheri; Sheri Cummins; Communications & Outreach; NIH Office of Extramural Research; cummins@mail.nih.gov

Changes to NIH policies and procedures related to human subjects research
Sponsor: NIH

Deadline(s): These proposal application changes in effect for proposals due January 25th, 2018 or later; 01/25/2018 (Effective Date)

Contact: [brought to our attention by] Meredith D. Temple-O’Connor, Ph.D.; Senior Policy Advisor for Clinical Research; Division of Extramural Research; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institutes of Health / DHHS; Bethesda, MD 20892; NICDHTrials@nih.gov; [and] Stephanie Scott; Director of Policy and Research Development; Sponsored Projects Administration; sfs2110@cumc.columbia.edu

Link(s): https://grants.nih.gov/ct-decision/index.htm
https://grants.nih.gov/policy/clinical-trials.htm

Additional Information: I wanted to pass along this email we received from NICHD. Regardless of whether you receive funding from NICHD, I thought it was a great summary of the recent NIH policies concerning human subjects research and the definition of a clinical trial. It also highlights contacting the NIH Program Officials when you are uncertain if your study meets the NIH clinical trial definition; I promise you will see more communications from me as we prepare you for these proposal application changes in effect for proposals due January 25th, 2018 or later.; Stephanie Scott; Changes to NIH policies and procedures related to human subjects research; Dear NICHD Investigator, NIH has broadened its definition of clinical trial, and it may impact your future applications (new, resubmission, or revision) and awards.; NIH’s definition of clinical trial now includes some research approaches not traditionally considered clinical trials. For example, many behavioral or biobehavioral studies that focus on underlying mechanisms of development may now be considered clinical trials. Also, conducting experiments that involve human subjects may be considered a clinical trial. If you are conducting studies involving human subjects, it is very important that you understand this definition and determine whether it applies to your research.; How do I know if my study is a clinical trial?; NIH has four questions that researchers need to answer to determine whether their study is a clinical trial. These questions may use terminology that has a different meaning than the typical meanings understood by certain research communities. It’s important to review the FAQs and case studies provided by the NIH Office of Extramural Research. If you answer “yes” to each of these four questions, your research will be considered a clinical trial by NIH: (1) Does the study involve human participants?; (2) Are the participants prospectively assigned to an intervention?; (3) Is the study designed to evaluate the effect of the intervention on the participants?; (4) Is the effect being evaluated a health-related biomedical or behavioral outcome?; Here is a link that can help you determine if your research is a clinical trial: https://grants.nih.gov/policy/clinical-trials/index.htm.; Why is this important? What are the implications if my study is considered a clinical trial?; Beginning with applications submitted on or after January 25, 2018, if your application involves a clinical trial, you must: (*) Submit the application through a Funding Opportunity Announcement (FOA) that accepts clinical trials; (**) Provide additional information in the application, which will be subject to different and distinct review criteria for clinical trials; If selected for funding, you will need to designate individual(s) to serve as the responsible party for the trial and to register and post results in the ClinicalTrials.gov system.; NIH has also issued other policy updates involving Good Clinical Practice training requirements and the use of Single Institutional Review Board (sIRB) approaches for domestic, multisite human subjects research. Details about all updates/changes are available at https://grants.nih.gov/policy/clinical-trials.htm.; Note: These policy updates/changes also apply to individuals conducting research through contracts.; Why is NIH making these changes?; As stewards of public funding, NIH is implementing these changes in support of our scientific and ethical obligation to ensure that the burden and risk that volunteers assume as research participants ultimately contributes to scientific knowledge. In addition, these changes facilitate transparency in how NIH conducts and supports human subjects and clinical trials research and increases dissemination of data and conclusions derived from NIH-conducted or -supported clinical trials. More discussion of the reasons for the policy changes is at: https://grants.nih.gov/policy/clinical-trials/why-changes.htm.; We know this is a lot to process, but we are here to answer your
questions. Please contact your Program Officer with any questions. If you're uncertain who your Program Officer is, this information is available in your Commons account; Kind regards, Meredith D. Temple-O'Connor, Ph.D.; Senior Policy Advisor for Clinical Research; Division of Extramural Research; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institutes of Health / DHHS; Bethesda, MD 20892; NICHDTrials.nih.gov; Doing human subjects research? New policies will impact you! Learn more; Updated application forms (FORMS-E) are required for due dates of January 25, 2018 and beyond - includes new Human Subject and Clinical Trial Information Form. Take a tour of the new form.

Be Careful to Pick the Right Funding Opportunity Announcement (FOA)
Sponsor: NIH, Extramural Nexus, National Institutes of Health, Office of Extramural Research
Deadline(s): 12/07/2017 (Released/Posted)
Contact: ExtramuralNexus@mail.nih.gov
Link(s): https://nexus.od.nih.gov/all/2017/12/07/be-careful-to-pick-the-right-funding-opportunity-announcement-foa/
Additional Information: Be Careful to Pick the Right Funding Opportunity Announcement (FOA); In follow-up to the announcement I sent last night, Update: NIH FOAs with FORMS-E, Dr. Mike Lauer of NIH just wrote a blog on the importance of selecting the correct Funding Opportunity Announcement (FOA). See full blog post; *Key takeaways:* (*) If any part of your study (the specific aims, components, studies, etc) meets NIH’s definition of a clinical trial, then you must select an FOA that allows for clinical trials.; (*) If none of the aims or studies within your project meet the definition, select an FOA that says “Clinical trials not allowed” or “Clinical trials optional”; (*) “The participating organizations may vary between the “clinical trial not allowed” parent FOA and the “clinical trial required” parent FOA for the same activity code. Read the details of each FOA carefully.; (*) “Note that some institutes that participate on a “Clinical Trial Required” parent may limit their participation to mechanistic studies.”; If you are unsure whether your study meets the definition of a clinical trial, I highly encourage you to reach out to the Program Official named on the FOA to help you make the appropriate determination, and to clarify the appropriate FOA to be selected. Include in your application cover letter the name of the Program Official who assisted you, and confirmed, the selection of the FOA; [brought to our attention by] Stephanie Scott, sfs2110@cumc.columbia.edu

New IRB Policy on the Privacy Rule and the Use of Health Information in Research
Sponsor: CU IRB
Deadline(s): 11/01/2017 (Effective Date)
Contact: Questions about the policy may be directed to the HRPO by email at irboffice@columbia.edu.

Link(s):
https://research.columbia.edu/sites/default/files/content/HRPO/HIPAAandResearchPolicy2017.docx

RPPRs and the Project Outcomes Section; NIH will make the Project Outcomes Section of all Interim and Final RPPRs submitted on or after October 1, 2017 available to the general public via the NIH RePORTER
Sponsor: NIH
Deadline(s): 10/01/2017 (Effective Date)
Contact: Please direct all inquiries to: Division of Grants Policy; Office of Policy for Extramural Research Administration; Office of Extramural Research; Email: grantspolicy@od.nih.gov

Statement on Article Publication Resulting from NIH Funded Research
Sponsor: NIH
Deadline(s): 11/03/2017 (Release Date)
Contact: Office of Extramural Research;
Email: PublicAccess@nih.gov ; Website: http://publicaccess.nih.gov

Opportunity to meet with the New York City Housing Authority
Sponsor: Columbia | Research
Deadline(s): NA/ASAP
Contact: Michael Shelter; Executive Assistant to Victoria Hamilton, Executive Director of Research Initiatives; Executive Assistant to Adrian Hill, Executive Director of University Research Planning and Development; Columbia | Research; Office of the Executive Vice President for Research; Columbia University in the City of New York; 409A Low Library, MC 4312; 535 West 116th Street; New York, NY 10027; Phone: 212-854-6841; Cell: 646-599-7865; Email: ms5595@columbia.edu
Link(s): https://r2eport.files.wordpress.com/2014/04/townandgown_did-someone-at-your-agency-mention-an-academic-research-need-10-23-17pdf.pdf
https://doodle.com/poll/mc4kkzvfnspcppayd (please fill out this Doodle Poll with your availability if you are interested in attending the meeting)

Research Data at Columbia
Sponsor: https://research.columbia.edu
Deadline(s): NA, Announcement
Contact: Questions regarding the Guidance on Retention of Research Data may be directed to the Office of Research Compliance and Training: research-compliance@columbia.edu

COLUMBIA
Mailman School of Public Health
research.columbia.edu/2
Human Subjects and Clinical Trials: A Summary of Policies Impacting NIH-funded studies

**Sponsor:** NIH

**Deadline(s):** NA

**Contact:** [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; Phone: (212) 854-0606; Cell Phone: (646) 248-8573; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/

**Link(s):**
- [https://grants.nih.gov/grants/policy/review_templates.htm](https://grants.nih.gov/grants/policy/review_templates.htm)
- [https://grants.nih.gov/grants/guide/notice-od-17-121.html](https://grants.nih.gov/grants/guide/notice-od-17-121.html)
- [https://grants.nih.gov/grants/policy/review_templates.htm](https://grants.nih.gov/grants/policy/review_templates.htm)

**New NIH Review Criteria for K’s, F’s, & T’s; The NIH Announces New Review Criteria for Career Development Award Applications Involving Clinical Trials**

**Sponsor:** NIH

**Deadline(s):** NA

**Contact:** [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; Phone: (212) 854-0606; Cell Phone: (646) 248-8573; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/

**Link(s):**
- [https://grants.nih.gov/grants/policy/review_templates.htm](https://grants.nih.gov/grants/policy/review_templates.htm)
- [https://grants.nih.gov/grants/policy/review_templates.htm](https://grants.nih.gov/grants/policy/review_templates.htm)
- [https://grants.nih.gov/grants/policy/review_templates.htm](https://grants.nih.gov/grants/policy/review_templates.htm)

**New NIH Review Criteria for K’s, F’s, & T’s; The NIH Announces New Review Criteria for Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship Applications Involving Research Experiences in Clinical Trials**

**Sponsor:** NIH

**Deadline(s):** NA

**Contact:** [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; Phone: (212) 854-0606; Cell Phone: (646) 248-8573; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/

**Link(s):**
- [https://grants.nih.gov/grants/policy/review_templates.htm](https://grants.nih.gov/grants/policy/review_templates.htm)
- [https://grants.nih.gov/grants/policy/review_templates.htm](https://grants.nih.gov/grants/policy/review_templates.htm)
- [https://grants.nih.gov/grants/policy/review_templates.htm](https://grants.nih.gov/grants/policy/review_templates.htm)

**New NIH Review Criteria for K’s, F’s, & T’s; The NIH Announces New Review Criteria for Institutional Research Training Grants Involving Research Experiences in Clinical Trials**

**Sponsor:** NIH

**Deadline(s):** NA

**Contact:** [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; Phone: (212) 854-0606; Cell Phone: (646) 248-8573; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/

**Link(s):**
- [https://grants.nih.gov/grants/policy/review_templates.htm](https://grants.nih.gov/grants/policy/review_templates.htm)
- [https://grants.nih.gov/grants/policy/review_templates.htm](https://grants.nih.gov/grants/policy/review_templates.htm)
- [https://grants.nih.gov/grants/policy/review_templates.htm](https://grants.nih.gov/grants/policy/review_templates.htm)
Columbia | Research; Sponsored Projects Administration; Phone: (212) 854-0606; Cell Phone: (646) 248-8573; Email: sfs2110@columbia.edu; Website: http://spaff.columbia.edu/

**Sponsor**: NIH Policy and Application Instructions
**Reminder**: NIH Applications Must Be Complete and Compliant With NIH Policy and Application Instructions At Time Of Submission

**Deadline(s)**: 09/12/2017 (Release Date)
**Contact**: Please direct all inquiries to: Office of Policy for Extramural Research Administration (OPERA)
Office of Extramural Research (OER); Division of Grants Policy; National Institutes of Health; Telephone: 301-435-0949; Email: grantspolicy@od.nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-105.html

**Notice of Assistance Available to Institutions Impacted by Hurricane Harvey**
**Sponsor**: National Institutes of Health

**Deadline(s)**: NA; 09/11/2017 (Release Date)
**Contact**: Please direct all inquiries to: Division of Grants Policy; Office of Policy for Extramural Research Administration; Office of Extramural Research; Telephone: 301-435-0949; NIHGR@nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-111.html

**FY 2019 Administration Research and Development Budget Priorities**
**Sponsor**: [forwarded to our attention by] Tony Mazzaschi | Senior Director, Policy and Research; Association of Schools and Programs of Public Health (ASPPH) | www.aspph.org; 1900 M Street NW, Suite 710 | Washington, DC 20036; Tel: 202-296-1099, ext. 132 | Email: tmazzaschi@aspph.org

**Deadline(s)**: NA; released 08/17/2017
**Contact**: [forwarded to our attention by] Tony Mazzaschi | Senior Director, Policy and Research; Association of Schools and Programs of Public Health (ASPPH) | www.aspph.org; 1900 M Street NW, Suite 710 | Washington, DC 20036; Tel: 202-296-1099, ext. 132 | Email: tmazzaschi@aspph.org

**Link(s)**: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-114.html

**Announcing New Research Support Services**
**Sponsor**: Mailman School

**Deadline(s)**: relative to the upcoming 10/05/2017 NIH Grant Submission: Initial Request form (5 weeks prior to the Grant Due Date): 09/01/2017
Science Draft Submission (for those seeking external review): Three (3) to Four (4) weeks prior to submission 09/14/2017 (3 weeks) or 09/07/2017 (4 weeks)
(Final) Scientific Editing (an outside company that has already been used by several departments will be engaged as needed); 10 to 14 days prior to submission (09/21/2017 – 09/25/2017)
**Contact**: If you have any questions about your eligibility or the above process, please contact Pam Factor-Litvak, Associate Dean Research Resources prfl@columbia.edu
Please submit the submission form and documents to Craig Kandell at ckk7@cumc.columbia.edu
Dear Mailman Faculty,

In acknowledgement of the increasingly competitive federal funding environment, the School’s administrative and academic leadership teams have been working to develop new resources to support faculty in preparing grant applications with the highest chance of success. In the fall, we will announce and begin rolling out a suite of such supports: (*) To ensure taking advantage of these new services and that you find them helpful; With best wishes, Linda P. Fried, MD, MPH; Dean and DeLamar Professor of Public Health; Mailman School of Public Health; Senior Vice President; Columbia University Medical Center; Professor of Epidemiology and Medicine

Updated Appendix Policy Eliminates Clinical Trial-Related Materials for NIH/AHRQ/NIOSH Applications Submitted to Due Dates on or After January 25, 2018

Sponsor: NIH/AHRQ/NIOSH; National Institutes of Health (NIH); Agency for Health Research and Quality (AHRQ); National Institute for Occupational Safety and Health (NIOSH)

For Applications Submitted to Due Dates on or After

Deadline(s): 01/25/2018

Contact: Please direct all inquiries to: Division of Receipt and Referral; Center for Scientific Review; Telephone: 301-435-0715; Email: csrdrn@mail.nih.gov; Sally A. Amero, Ph.D.; NIH Office of Extramural Research; Email: ReviewPolicyOfficer@mail.nih.gov; Lisa Scott-Morring, M.S., M.S.H.S., C.R.A.; Agency for Healthcare Research and Quality; Telephone: 301-427-1555; Email: Lisa.Scott@ahrq.hhs.gov; Vij Potula, Ph.D.; National Institute for Occupational Safety and Health; Centers for Disease Control and Prevention; Telephone: 404-498-2551; Email: vbp6@cdc.gov


Additional Guidance on Full-Time Training for Ruth L. Kirschstein National Research Service Awards

Sponsor: National Institutes of Health; Agency for Healthcare Research and Quality

Deadline(s): Release Date 07/24/2017; NA

Contact: Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Programs; Office of Extramural Research; Website: https://researchtraining.nih.gov; Email: NIHTrain@mail.nih.gov


Consolidating NIH eRA Commons accounts

Sponsor: NIH

Deadline(s): NA; 06/29/2017 (Release Date)
migration to Microsoft 365 email begins late Sunday night (July 23/24)

Sponsor: NIH Office of Extramural Research

Deadline(s): NA; migration to Microsoft 365 email begins late Sunday night (July 23/24)

Contact: Based on how the pilot migration went, this should go very smoothly. However, all techs will be on hand Monday at 8 am to provide support if you cannot access your mail. Please just open a ticket with msph-tickets@cumc.columbia.edu and someone will be assigned to work with you.; Best, Mailman IT

Link(s): https://www.mailman.columbia.edu/information-for/administrative-offices/information-technology

Additional Information: To update your UPN, please find the type of device you have and follow these instructions below;

(**) Android: http://www.cumc.columbia.edu/it/howto/email/android-remove.html;
(**)Mac: http://www.cumc.columbia.edu/it/howto/email/mac-username.html;
(**)PC: http://www.cumc.columbia.edu/it/howto/email/win-username.html;
(**) iPhone/iPad: http://www.cumc.columbia.edu/it/howto/email/ios-remove.html; Based on how the pilot migration went, this should go very smoothly. However, all techs will be on hand Monday at 8am to provide support if you cannot access your mail. Please just open a ticket with msph-tickets@cumc.columbia.edu and someone will be assigned to work with you.; Best, Mailman IT

NIH Extramural News; NIH Update: Grant Reporting Responsibilities; eRA Account Emails; Training Tables & XTRACT; Next Generation Researchers Initiative

Sponsor: NIH Office of Extramural Research

Deadline(s): Release Date 06/2017

Contact: ExtramuralNexus@mail.nih.gov

Link(s): https://nexus.od.nih.gov/all/2017/06/16/nih-next-generation-researchers-initiative/?utm_source=nexus&utm_medium=email&utm_content=nihupdate&utm_campaign=jun17

https://nexus.od.nih.gov/all/2017/06/29/important-era-account-emails-headed-your-way/?utm_source=nexus&utm_medium=email&utm_content=nihupdate&utm_campaign=jun17


NIH’S Next Generation Researchers Initiative

Sponsor: NIH, Office of Extramural Research

Deadline(s): 06/16/2017 (Release Date)

Contact: https://nexus.od.nih.gov/all/author/lauerm; publicinput@od.nih.gov

Link(s): https://nexus.od.nih.gov/all/2017/06/16/nih-next-generation-researchers-initiative/

Fringe Benefits Rates for Fiscal Year Beginning July 1, 2017 (FY 2018)

Sponsor: Sponsored Projects Administration

NA, FY2018 Announcements, brought to our attention on Deadline(s): 07/06/2017

Contact: Any questions about the government fringe rate should be directed to AskRPIC@columbia.edu.

Link(s): http://finance.columbia.edu/content/fringe-benefit-rates http://spa.columbia.edu/proposals/institutional-information

Additional Information: To Principal Investigators, Sponsored Projects Administrators; From: Barbara Hough, Vice President, Controller and Treasurer, Rudi Odeh-Ramadan, Associate Vice President for Research Administration; We are writing to inform you that, based on the approval obtained from the Federal government, the fringe rate applicable to government grants and contracts will increase from 28.9% to 30.3%, effective July 1, 2017. For all funding sources other than government grants and contracts, the fringe benefit rate will be 29.75%. The increase in the rate is primarily driven by the significant increase in medical costs the University has experienced over the past several years.; Please note that you may wish to take this opportunity to review the impact the change in the fringe benefits recovery rate may have on the allocation of personnel related costs for the
remainder of the grant life cycle; For information regarding student employees working during the academic year or summer, refer to http://finance.columbia.edu/content/fringe-benefit-rates. ; For grants administrators: FY17 Cost Transfers involving sponsored projects will continue to be processed with the FY17 fringe rates through the July 7th deadline. The new FY18 fringe rates will be introduced with FY18 payroll runs.; The rate agreement is available on the SPA website on the Institutional Information page and on the Finance Gateway at http://finance.columbia.edu/content/fringe-benefit-rates. ; Any questions about the government fringe rate should be directed to AskRPIC@columbia.edu.

NIH Fiscal Policy for Grant Awards - FY 2017  
**Sponsor:** National Institutes of Health  
**Deadline(s):** 06/30/2017 (Release Date)  
**Contact:** Please direct all inquiries to: Questions about specific awards may be directed to the Grants Management Specialist identified in the Notice of Award.  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-086.html  
**Additional Information:** Additional details on Fiscal Operations, including specific funding strategies for ICs will be posted at https://grants.nih.gov/grants/financial/index.htm.

Ruth L. Kirschstein National Research Service Awards (NRSA) Predoctoral Stipends, Training Related Expenses, Institutional Allowance, and Tuition/Fees Effective for Fiscal Year 2017  
**Sponsor:** NIH: Agency for Healthcare Research and Quality  
**Deadline(s):** 06/27/2017 (Release Date)  
**Contact:** Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Programs; Office of Extramural Research; Website: https://researchtraining.nih.gov ; Email: NIHTrain@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-084.html

NIH Drops “Grant Support Index” Proposal; Adopts an Even Larger Initiative to Support Early- and Mid-Career Investigators  
**Sponsor:** NIH  
**Deadline(s):** NA  
**Contact:** publicinput@od.nih.gov  
**Link(s):** https://www.nih.gov/about-nih/who-we-are.nih-director/statements/launching-next-generation-researchers-initiative-strengthen-biomedical-research-enterprise  
https://nexus.od.nih.gov/all/2017/05/02/nih-grant-support-index/  

Notice of Legislative Mandates in Effect for FY 2017  
**Sponsor:** National Institutes of Health  
**Deadline(s):** 06/09/2017 (Release Date)  

**Contact:** Please direct all inquiries to: Division of Grants Policy; Office of Policy for Extramural Research Administration (OPERA); Office of Extramural Research; National Institutes of Health; Telephone: 301-435-0949; Email: grantspolicy@od.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-075.html

National Institutes of Health (NIH) Office of Science Policy (OSP) Launches New Website  
**Sponsor:** National Institutes of Health (NIH) Office of Science Policy (OSP)  
**Deadline(s):** NA  
**Contact:** NIH Office of Science Policy; 6705 Rockledge Drive, Suite 750 Bethesda, MD 20892; Phone: (301) 496-9838; Fax: (301) 496-9839; OSP Directory ; General Inquiries: SciencePolicy@mail.nih.gov ; Subscribe to the OSP News Listserv by clicking here.  
**Link(s):** https://osp.od.nih.gov/  

1 NIH Rigor and Reproducibility Policy; Reminder: Authentication of Key Biological and/or Chemical Resources  
2 NIH Rigor and Reproducibility Policy; Reminder: Authentication of Key Biological and/or Chemical Resources; slide presentation  
**Sponsor:** NIH  
**Deadline(s):** 05/31/2017 (Release Date)  
**Contact:** Dr. Michelle Benson [Assistant Director for Research Integrity and Compliance]; mb3852@columbia.edu and Stephanie Scott [sfs2110@columbia.edu] continue to be points of contacts for questions concerning the NIH Rigor and Reproducibility Policy;  
**For reference:** NIH Contact: Reproducibility@NIH.Gov  

NIH Next Generation Researchers Initiative  
**Sponsor:** NIH  
**Deadline(s):** NA  
**Contact:** publicinput@od.nih.gov  
**Link(s):** https://www.nih.gov/about-nih/who-we-are/nih-director/statements/launching-next-generation-researchers-initiative-strengthen-biomedical-research-enterprise  
https://grants.nih.gov/grants/ngri.htm  
https://acd.od.nih.gov/meetings.html  
**Additional Information:** Next Generation Researchers Initiative; Dear ACD Colleagues, Today, NIH issued an NIH Director’s statement and launched a new webpage on the Next Generation Researchers Initiative to enhance funding to early-stage and mid-career investigators and help stabilize and strengthen the
NIH Reminds Recipients to Submit Complete, Timely and Accurate Progress and Financial Reports

The Privacy Paradox

NIH to Limit Total Grant Support to PIs

Notice Announcing the Availability of Common Data Elements for Research Related to Early Psychosis

New NIH Policies on Appendices to Grant Applications
Deadline(s): Effective for grant submissions submitted on or after 01/25/2017

Contact: Please direct all inquiries to: Division of Receipt and Referral; Center for Scientific Review (CSR); National Institutes of Health; Telephone: 301-435-0715; Email: csdr@mail.nih.gov; Sally A. Amero, Ph.D.; NIH Review Policy Officer; Email: ReviewPolicyOfficer@mail.nih.gov; Francis D. Chesley, Jr., M.D.; Director, Office of Extramural Research, Education, and Priority Populations; Agency for Healthcare Research and Quality; Telephone: 301-427-1521; Email: Francis.Chesley@ahrq.hhs.gov; Viji Potula, Ph.D.; Office of Extramural Programs; National Institute for Occupational Safety and Health; Centers for Disease Control and Prevention; Telephone: 404-498-2551; Email: VPotula@cdc.gov; Sincerely, Nora Volkow, M.D.; Director, National Institute on Drug Abuse

Final Research Performance Progress Report (F-RPPR) Interim-RPPR While A Renewal Application Is Under Consideration (I-RPPR)

Sponsor: NIH

Deadline(s): NA

Contact: Should you have any questions, please feel free to reach out to your SPA Project Officer or myself [brought to our attention by] Stephanie F. Scott, MS, CRA; Communications and Outreach Director; Columbia | Research; Sponsored Projects Administration; Phone: (212) 854-6066; Cell Phone: (646) 248-8573; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/

Final Research Performance Progress Report (F-RPPR) Interim-RPPR While A Renewal Application Is Under Consideration (I-RPPR)

Sponsor: NIH

Deadline(s): NA

Contact: Should you have any questions, please feel free to reach out to your SPA Project Officer.

Additional Information: Please also note the highlighted final research report requirement below; Several updates to ASSIST happened [01.19.17], you can read about those updates below.; In addition, you may recall that NIH now requires the use of a Final Research Performance Progress Report (FRPPR). See NOT-OD-17-022. Section D.1 in the Participants section will now be included, per the email below regarding eRA Commons updates.; I’ll need to provide more information on the FRPPR separately. It appears NIH just posted some FAQs on the FRPPR and Interim RPPR. See https://grants.nih.gov/grants/rppr/faqs.htm#5038. I’ll provide a separate email with this information.; Should you have any questions, please feel free to reach out to your SPA Project Officer, [brought to our attention by] Stephanie Scott; eRA Enhancements: eRA Commons Upcoming Release and Scheduled Downtime for Wednesday, January 18; eRA Enhancements: eRA Commons Upcoming Release and Scheduled Downtime for Wednesday, January 18; Friday, January 13, 2017; Scheduled Downtime for the January Release: eRA Commons and ASSIST will be unavailable beginning at 9 p.m. ET Wednesday, January 18 and will return to service by 7 a.m. ET Thursday, January 19, 2017. When the system is available again, you will see new features and functionality have been added to the system.; Highlights of ASSIST’s January Software Release; (*) New Access Maintainer Role; (**) A new role called “ASSIST_ACCESS_MAINTAINER_ROLE” with Access Maintainer Privileges has been added to the Account Management System (AMS).; (**) Only the Signing Official (SO) has the authority to provide this role to whomever they want to manage access to applications in ASSIST on behalf of the organization.; (**) By providing this role, the SO is delegating the authority to manage access to all applications at the organization level, rather than application by application level.; (**) Access Management within ASSIST for individual applications has not changed.; (*) Multi-Employment Functionality; (**) Senior Key Persons who are affiliated with multiple organizations will be able to select from their current employments so they can choose the most appropriate organization as it relates to their application.; (**) When the user provides their eRA Commons User ID and multiple active employments are associated with the account, the system displays the organization, the state, the city of each employment organization. The user can select the appropriate appointment and click the “Select” button.; (*) New Link for SOs from ASSIST to Commons Status Screen; (**) When SOs access the Application Information page, they will find a new link titled “To view Commons post submission actions” in the Agency section of the page.; (**) The link will take them to the Commons Status search page. From here they can search for the application under the Recent/Pending Submissions option so they can quickly reject the application if so desired/needed.; (**) This link is only available to Signing Officials.; (*) A Warning if Appendix Material is Submitted in Applications; (**) Per the policy outlined in NOT-OD-16-129, the submission of most appendix materials has been eliminated from NIH applications.; (**) If the system detects the submission of appendix materials, a new warning will advise the applicant to closely review the Funding Opportunity Announcement to confirm that these materials are requested as part of the application.; (*) Form Lock Message Includes User Name; (**) When a user opens a form screen in ASSIST to edit or add information, the system locks that form so others cannot simultaneously edit the same form.; (**) ASSIST displays a message indicating the form you are trying to access is locked by another user and now includes the
name of the user who holds the lock; Highlights of eRA Commons January Software Release; (*) Final RPPR Section D.1 Added; (**) As part of the transition to the use of the Final Research Performance Progress Report (FRPPR), Section D.1 of Participants is now included; (***) § Section D.1 asks “What individuals have worked on the project?” This information will be the list of people who have worked on the project since the previous progress report. It does not include all the individuals during the lifetime of the award; (*) New Design of the Status Information Screen for PIs and SOs; The Status Information screen will have a new look and feel. The screen is an important source of information for Principal Investigators (PIs) and Signing Officials (SOs) for such things as scores, summary statements, NIH contacts, reference letter status, etc.; [a] provided picture has been linked at; https://2report.files.wordpress.com/2014/04/nihannouncemntpicinpddformat.pdf; New Status Information screen with some sections expanded, other collapsed.; (*) The new design is similar to other updated screens, such as the Personal Profile and the Institution Profile; (*) Categories of information are organized into collapsible/expandable sections; ($ ) Expand All (default view) and Collapse All buttons show and hide the information on the screen; (*) New Text Filter; ($) A new field will allow you to enter text and display the results on those sections with matches; ($) Matching text will be highlighted, allowing you to quickly locate the information; (*) Important information is displayed along the left side; ($ ) Warnings; ($) Contact information; (*) Scientific Review Officer (SRO); (*) Grants Management Specialist (GMS); (*) Program Official (PO); ($) Latest Updates; ($) eRA Service Desk contact information; (*) New Print Capabilities; ($) New formatting capabilities allow you to print all the information with the click of a single button; ($) Organized by category; ($) Includes warnings; ($) Includes NIH contacts; NOTE: The ability to submit help tickets online will not be available during the downtime listed above: Joe Schumaker; eRA Communications; Division of Communications and Outreach; NIH Office of Extramural Research; Questions? Please contact the eRA Service Desk. Check out self-help resources on the Help page before submitting an online ticket; or call Toll-free: 1-866-504-9552. Phone: 301-402-7469. The Service Desk hours are Mon-Fri, 7 a.m. to 8 p.m. ET; Help us improve our communications; send your suggestions and feedback to eRACommunications@mail.nih.gov or call 301-435-8185.; To read other recent articles and messages, please visit our Latest News page at http://era.nih.gov/news_and_events/index.cfm.;

Notice of Clarification on the Publication of the Final Rule on the Federal Policy for the Protections of Human Subjects (Common Rule)

**Sponsor**: National Institutes of Health

**Deadline(s)**: 01/23/2017 (Release Date)

**Contact**: Inquiries about the final rule should be directed to: Office for Human Research Protections

OHRP@hhs.gov; Please direct inquiries about this Notice to: National Institutes of Health

Office of Science Policy; SciencePolicy@od.nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-040.html

**Notice Announcing the Availability of Common Data Elements for Research Related to Early Psychosis**

**Sponsor**: National Institute of Mental Health

**Deadline(s)**: 01/25/2017 (Release Date)

**Contact**: Please direct all inquiries to: Gregory K. Farber, Ph.D.; National Institute of Mental Health; Telephone: 301-435-0778; Email: farberg@mail.nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide/notice-files/NOT-MH-009.html

**New Appendix policy for NIH/AHRQ/NIOSH Applications submitted for Due Dates On or after January 25, 2017**

**Sponsor**: NIH

**Deadline(s)**: NA; 01/25/2017 (Effective Date)

**Contact**: Please direct all inquiries to: Division of Receipt and Referral; Center for Scientific Review; Telephone: 301-435-0715; Email: csdr@mail.nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-035.html

**NIH & AHRQ Update Font Guidelines for Applications to Due Dates On or after January 25, 2017**

**Sponsor**: NIH; AHRQ

**Deadline(s)**: 01/25/2017 (Effective Date)

**Contact**: Please direct all inquiries to: NIH Grants Information; Email: grantsinfo@od.nih.gov (preferred method of contact); Telephone: 301-945-7573

**Link(s)**: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-030.html

**New Good Clinical Practice Training Requirement for NIH-funded Clinical Trials**

**Sponsor**: NIH; Columbia

**Deadline(s)**: NA; 01/01/2017 (Effective Date)

**Contact**: For questions, please email: NIH-GCP@columbia.edu;

**Link(s)**: http://www.columbia.edu/cu/compliance/docs/training/Good_Clinical_Practi ce/index.html


**Change to Standard Due Dates for Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowships to Promote Diversity in Health Related Research (F31 - Diversity)**

**Sponsor**: NIH

**Deadline(s)**: standard application due dates for F31 - Diversity applications will be the same as all other F Series Fellowship applications – 12/08/2017
Friday Newsletter 07/16/2021

Contact: Please direct all inquiries to: NIH Grants Information; Email: grantsinfo@od.nih.gov (preferred method of contact); Telephone: 301-710-0267;  

Ruth L. Kirschstein National Research Service Awards (NRSA) Postdoctoral Stipends, Training Related Expenses, Institutional Allowance and Tuition/Fees Effective for Fiscal Year 2017  
Sponsor: NIH  
Deadline(s): NA; 12/15/2016 (Release Date)  
Contact: Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Programs; Office of Extramural Research; Website: https://researchtraining.nih.gov; Email: NIHTrain@mail.nih.gov  
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-003.html

New HHS Regulation and NIH Policy on Trial Registration in ClinicalTrials.gov  
Sponsor: NIH  
Deadline(s): Please see below  
Contact: Forwarding this important announcement on behalf of the Clinical Trials Office (CTO). For questions, please contact ClinicalTrialsGov@columbia.edu; For questions regarding the new requirements, please contact ClinicalTrialsGov@columbia.edu or the University PRS Administrators: Jane Cho; Email: jc2050@columbia.edu; Telephone: (212) 342-2763; Cindy Han; Email: ch2919@columbia.edu; Telephone: (212) 342-1643; Diana Kim; Email: ddk2133@columbia.edu; Telephone: (212) 342-1643  
www.clinicaltrials.gov

Revised SF424 (R&R) Application Guides and Supplemental Instructions Available  
Sponsor: National Institutes of Health  
Deadline(s): NA; 12/15/2016 (Release Date)  
Contact: NIH Grants Information; Email: grantsinfo@od.nih.gov (preferred method of contact); Telephone: 301-435-0714  
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-023.html

New to the NIH Grants Process? NIH Announces 2017 NIH Regional Seminar Locations in New Orleans, LA and Baltimore, MD  
Sponsor: National Institutes of Health

Deadline(s): NA; 12/15/2016 (Release Date)  
Contact: Please direct all inquiries to: NIHRegionalSeminars@mail.nih.gov.  

Final Research Performance Progress Report (Final RPPR)  
Sponsor: NIH  
Deadline(s): 11/2016 (Released); 01/2017 (Effective)  
Contact: Please direct all inquiries to: Division of Grants Policy; Office of Policy for Extramural Research Administration; Office of Extramural Research; grantspolicy@od.nih.gov  
Link(s): http://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-022.html

Publication of the Revised NIH Grants Policy Statement (Rev. November 2016) for FY 2017  
Sponsor: NIH  
Deadline(s): Effective November 2016  
Contact: As always, your SPA Project Officer should be your first point of contact should you have any such questions. [brought to our attention by] Stephanie F. Scott, MS, CRA; Communications and Outreach Director; Columbia | Research; Phone: (212) 854-0606; Cell Phone: (646) 248-8573; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/ Please direct all inquiries to: Division of Grants Policy; Office of Policy for Extramural Research Administration (OPERA); Telephone: 301-435-0949; Email: GrantsPolicy@od.nih.gov  
Link(s): https://grants.nih.gov/policy/nihgps/index.htm

eRA Information: Please Update Your Browsers by Nov. 30 to Use eRA Modules; New Security Mandated For Websites  
Sponsor: NIH  
Deadline(s): must implement by 11/30/2016  
Contact: Questions? If you have a question about this email, please contact the eRA Service Desk at http://grants.nih.gov/support/ (preferred method of contact) or call 1-866-504-9552/301.402.7469.  
Link(s): https://era.nih.gov/browser_support_ext.cfm

Final Progress Report for Closeout  
Sponsor: NIH  
Deadline(s): NA  
Contact: If you have a question, please contact the eRA Service Desk at http://grants.nih.gov/support/ (preferred method of contact) or call 1-866-504-9552/301.402.7469.  
Link(s): https://era.nih.gov/news_and_events/era_item_November_2016.htm#final
https://era.nih.gov/news_and_events/era_items.cfm

Please Update Your Browsers by Nov. 30 to Use eRA Modules; New Security Mandated For Websites
R²report
Friday Newsletter 07/16/2021

Sponsor: NIH
Deadline(s): NA
Contact: Questions? If you have a question about this email, please contact the eRA Service Desk at http://grants.nih.gov/support/ (preferred method of contact) or call 1-866-504-9552/301.402.7469.

NIH Operates Under a Continuing Resolution
Sponsor: NIH
Deadline(s): NA
Contact: Questions regarding adjustments applied to individual grant awards may be directed to the Grants Management Specialist identified on the Notice of Award;
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-001.html

NIH Announces How It Will Operate Under the Current Continuing Resolution; AHRQ Discontinues COLAs
Sponsor: NIH
Deadline(s): NA
Contact: Questions regarding adjustments applied to individual grant awards may be directed to the Grants Management Specialist identified on the Notice of Award; Questions may be directed to the AHRQ Grants Management Inbox (AHRQ) GrantsManagementinbox@ahrq.hhs.gov.
Link(s): http://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-001.html

IRB Liaison Service
Sponsor: Columbia | Research; Human Research Protection Office; Institutional Review Boards;
https://research.columbia.edu/content/human-research-protection-office-and-irbs
Deadline(s): 09/07/17 (service begins for the semester)
Contact: To learn more or to request an appointment outside walk-in hours, contact Rui Ferreira, IRB Specialist, by phone (212-342-5136) or email r2554@cumc.columbia.edu
Link(s): https://research.columbia.edu/content/human-research-protection-office-and-irbs

Who At NIH Can Answer my Question About….?
Sponsor: NIH
Deadline(s): NA (Announcement/Information)
Contact: Please see posting for individual contact links
Link(s): https://grants.nih.gov/grants/how-to-apply-application-guide/resources/contacting-nih-staff.htm
Additional Information: Contacting Staff at the NIH Institutes and Centers; In today’s NIH Extramural News blog, the NIH staff posted a handy chart of the major roles of NIH staff: Program Officials, Scientific Review Officers, Grants Management Officials, and staff of the Division of Receipt and Referral in NIH’s Center of Scientific Review. It explains each role’s responsibility, when it is appropriate to contact them, and where to find their contact information; See Who At NIH Can Answer my Question About….?
Remember that your Sponsored Projects Administration (SPA) Project Officer must communicate with NIH staff directly when submitting proposals, negotiating awards, submitting just-in-Time information, submitting formal requests for prior approval, submitting progress reports, clarifying NIH policies, and discussing financial or administrative issues. However, there may be times when contacting NIH directly is appropriate, for example, to identify the right type of grant program and/or funding opportunity for you and your research, or to verify that your idea fits within the mission and priorities of an NIH Institute or Center. When in doubt, reach out to your SPA Project Officer; [brought to our attention by] Stephanie F. Scott, M.S., CRA; Communications and Outreach Director; Columbia | Research; Sponsored Projects Administration; Phone: (212) 854-0606; Cell Phone: (646) 248-8573; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/

The Fringe Rate Applicable to Government Grants and Contracts will Increase from 27.1% to 28.9%, effective July 1, 2016
Sponsor: NA
Deadline(s): 07/01/2016 (effective)
Contact: Any questions about the government fringe rate should be directed to Carl Sparano at email cs16@columbia.edu or voice 212-854-1049.
Link(s): http://spa.columbia.edu/proposals/institutional-information
Additional Information: To: Principal Investigators, Sponsored Projects Administrators; From: Anne Sullivan, Executive Vice President for Finance; Rudi Odoh-Ramadan, Associate Vice President for Research Administration; We are writing to inform you that, based on the approval obtained from the Federal government, the fringe rate applicable to government grants and contracts will increase from 27.1% to 28.9%, effective July 1, 2016. For all funding sources other than government grants and contracts, the fringe benefit rate will be 29.5%. The increase in the rate is primarily driven by the significant increase in medical costs the University has experienced over the past year.; Please note that you may wish to take this opportunity to review the impact the change in the fringe benefits recovery rate may have on the allocation of personal related costs for the remainder of the grant life cycle.; With respect to students, the fringe benefit rate applicable to salaries funded by government projects will not change and will remain at 8.15%. For all funding sources other than government projects, the fringe benefit rate will be 8.15%; For grants administrators: FY16 Cost Transfers involving sponsored projects will continue to be processed with the FY16 fringe rates through the July 15 deadline. The new FY17 fringe rates will be introduced with FY17 payroll runs.; The rate
agreement is available on the SPA website on the Institutional Information page. It will be posted on the Finance website shortly. Any questions about the government fringe rate should be directed to Carl Sparano at email cs16@columbia.edu or voice 212-854-1049.

Two items NIH fellowship applicants should be aware of

**Sponsor:** NIH  
**Deadline(s):** NA  
**Contact:** If you have any questions, please contact Grants Information at grantsinfo@od.nih.gov; Sheri; Sheri Cummins; Chief, Grants Information; Division of Communications and Outreach; NIH Office of Extramural Research; cumminss@mail.nih.gov; 301-496-3405;  

**Additional Information:** Please pass this on to anyone you know whom may be preparing an NIH individual fellowship application (pre- or postdoc). Anyone who started a grant application for any of these fellowship opportunities prior to June 8, 2016 must return to the funding opportunity announcement and begin again. There were problems in the fellowship forms packages attached to the funding announcements. NIH has since corrected the problem. See below for details, and https://grants.nih.gov/grants/guide/notices/NOT-OD-16-106.html. Impacts the Parent fellowship funding announcements as well as PA-16-130 from NIGMS and PAR-16-210 from NIDCD. [forwarded to our attention by] Stephanie Scott, SPA Communications and Outreach Director, sfs2110; NIH Fellowship applicants, I’d like to bring two issue to your attention: (1) Anyone who started a fellowship application between June 3 and June 7 must return to their funding opportunity announcement to get an updated application package (NOT-OD-16-106); (2) If you use Grants.gov downloadable forms or Workspace to prepare your application, be aware that the “View Attachment” button associated with the 23. Resource Sharing Plan attachment on the PHS Fellowship Supplemental form displays the 22. Select Agent Research attachment instead of the expected one. This is simply an issue with the Grants.gov form interface. It does not impact how the attachments are sent to NIH or how we assemble your application image in eRA Commons; We are working with Grants.gov to address the issue. In the meantime, do not rely on the “View Attachment” feature for the Resource Sharing Plan. Instead, carefully check your attachments prior to uploading them and again when viewing your application image in eRA Commons.; This issue only impacts the PDF version of the form. If you use ASSIST or a system-to-system solution to prepare your application, then you are not impacted.; If you have any questions, please contact Grants Information at grantsinfo@od.nih.gov.; Sheri; Sheri Cummins; Chief, Grants Information; Division of Communications and Outreach; NIH Office of Extramural Research; cumminss@mail.nih.gov; 301-496-3405;

**Protecting Data, Promoting Access: Improving Our Toolbox;**  
**Sponsor:** NIH  
**Deadline(s):** NA published on 05/02/2016;  
**Contact:** NA author information; http://osp.od.nih.gov/under-the-poliscope/wolinetz-bio;  
**Carrie D. Wolinetz, Ph.D.;** Associate Director for Science Policy; National Institutes of Health; carrie.wolinetz@nih.gov;  

**NEW NIH Pilot Program to Find Private Support for Unfunded Applications;**  
**Sponsor:** NIH/Leidos Life Sciences;  
**Deadline(s):** NA  
**Contact:** For more information about OnPAR please contact OnPAR@leidos.com; http://onpar.leidosweb.com/onpar/contactUs.php; http://onpar.leidosweb.com/onpar/apply.php;  
**Link(s):** http://onpar.leidosweb.com/onpar/index.php; links to similar/related initiatives: https://www.nih.gov/research-training/accelerating-medicines-partnership-amp; http://stm.sciencemag.org/content/8/331/331ed3; Extramural News/Mike Lauer comments about this opportunity: http://nexus.od.nih.gov/all/2016/03/23/a-pilot-partnership-to-find-private-support-for-unfunded-applications/;  

**NIH STRATEGIC PLAN 2016-2020;**  
**Sponsor:** NIH  
**Deadline(s):** NA  
**Contact:** NA  
**Link(s):** NIH STRATEGIC PLAN: https://r2eport.files.wordpress.com/2014/04/nih_strategic_plan-fy2016-2020-508.pdf;  
**Additional Information:** The NIH strategic plan is linked at https://r2eport.files.wordpress.com/2014/04/nih_strategic_plan-fy2016-2020-508.pdf;  

3 Concept Papers;  
**Sponsor:** Potential NYC DOH Program Opportunities;  
**Deadline(s):** Please see 3 papers;  
**Contact:** Michael Santangelo, Esq.; Contract Manager; New York City Department of Health and Mental Hygiene; 42-09 28th Street, CN 30A; Queens, New York 11101; rfp@health.nyc.gov; Please indicate in the Subject Line the Concept Paper you are addressing: (1) Public Health Diversion Center Concept Paper; (2) Increasing Social
Connectedness Concept Paper; (3) Open Airways Concept Paper;

Increasing Social Connectedness among NYC's Older Adults Concept Paper;
Open Airways for Schools Concept Paper;

Guidance on Changes That Involve Human Subjects in Active Awards and That Will Require Prior NIH Approval: Updated Notice;
[Sponsor: National Institutes of Health; Deadline(s): NA Contact: Office of Extramural Programs; Office of Extramural Research; National Institutes of Health; 6705 Rockledge Dr., Suite 300; Email: OEPmailbox@mail.nih.gov; Link(s): (NOT-OD-15-128);]

NIH Fiscal Policy for Grant Awards – FY 2014; NIH Operates Under a Continuing Resolution;
[Sponsor: NIH; Deadline(s): Please see announcements; Contact: Questions about specific awards may be directed to the Grants Management Specialist identified in the Notice of Award.; See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-055.html#shash.hDCW959Z.dpufl; Link(s): NOT-OD-14-055; NIH; FY 2006 – 2014; NOT-OD-14-053; NOT-OD-14-046; NOT-OD-14-052; H.J. Res. 124; http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-001.html#shash.Ab1QXRcn.dpufl;]

Important Information Regarding Federal Grant Proposals;
<table>
<thead>
<tr>
<th>REQUEST FOR INFORMATION</th>
<th>Courses</th>
</tr>
</thead>
<tbody>
<tr>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>
LISTINGS

NIH DIRECTOR’S AWARDS PROGRAM

NA

CUIMC MEDICAL LIBRARY AND SYSTEMATIC REVIEW

Covidence, Systematic Review Demonstration, 01.26.2021, Archival posting pending
Cochrane Interactive Learning, Systematic Review Demonstration, 02.02.2021, Archival posting pending
Sponsor: The Knowledge Center; Columbia University Irving Medical Center; Covidence and Cochrane Interactive Learning
Deadline(s): 01/26/2021, 11AM (Covidence Demo; Archival posting TBD); 02/02/2021, 10AM (Cochrane Interactive Demo; Archival posting TBD)
Contact: Marian LaForest, MPH; Informationist; The Knowledge Center; Columbia University Irving Medical Center; ml4338@cumc.columbia.edu
Link(s): https://www.covidence.org/ [Covidence] https://training.cochrane.org/interactivelearning [Cochrane Interactive Learning]

SKILLS DEVELOPMENT

NA

NATIONAL CANCER INSTITUTE

NA

CENTER GRANTS

NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)
Sponsor: National Institute on Deafness and Other Communication Disorders
Deadline(s): 10/06/2021; 10/07/2021 (Expiration)
Contact: Scientific/Research Contact(s); Lana Shekim, Ph.D.; National Institute on Deafness and Other Communication Disorders (NIDCD); Telephone: 301-496-5061; Email: shekiml@nidcd.nih.gov

RESEARCH PROJECT GRANTS AND PROGRAM PROJECT GRANTS

HEALTH PROFESSION OPPORTUNITY GRANT

NA

EARLY CAREER, EARLY RESEARCHER, YOUNG RESEARCHER

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)
Sponsor: National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs; Office of Research on Women's Health
Deadline(s): 09/28/2021; 01/26/2022; 05/26/2022; 09/27/2022; 01/26/2023; 05/26/2023; 09/26/2023; 12/29/2023 (Expiration)
Contact: Scientific/Research Contact(s); Katz R01 Award Clinical Trial Not Allowed IC-Specific Scientific Interests and Contacts website

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Humans Required)
Sponsor: National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National...
Established Investigators (K18 Clinical Trial Required)
NIDCD Research
https://www.fic.nih.gov/Programs/Pages/research
https://grants.nih.gov/grants/guide/pa-
Link(s)
Telephone: 301

International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed (PAR-21-104)
International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Required (PAR-21-105)
Sponsor: NIH, Fogarty
Deadline(s): 03/09/2022; 03/08/2023; 03/09/2023 (Expiration)
Contact: Scientific/Research Contact(s): Christine Jessup, PhD; Fogarty International Center (FIC)
Telephone: 301-496-1653; Email: Christine.Jessup@nih.gov
Link(s): https://grants.nih.gov/grants/guide/pa-files/PAR-21-104.html
https://www.fic.nih.gov/Programs/Pages/research-scientists.aspx

NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)

K-AWARDS, F-AWARDS
K Award Development Seminars; 2020 – 2021
Sponsor: CUIMC
Deadline(s): 10/15/2020 05/20/2021 (Course Dates)
Contact: https://www.surveymonkey.com/r/X5K8893
Link(s): https://www.surveymonkey.com/r/X5K8893

Introducing the Stephen I. Katz Early Stage Investigator Research Grant Program
Sponsor: NIH
Deadline(s): 11/09/2020 (Release Date)
Contact: ExtramuralNexus@mail.nih.gov
Link(s): https://nexus.od.nih.gov/all/2020/11/09/introducing-the-stephen-i-katz-early-stage-investigator-research-grant-program/

Sponsor: National Institute on Deafness and Other Communication Disorders
Deadline(s): 10/08/2021; 02/08/2022; 06/07/2022; 10/07/2022; 02/08/2023; 06/08/2023; 10/10/2023; 01/08/2024 (Expiration)
Contact: Scientific / Research Contact(s): Alberto L. Rivera-Rentas, Ph.D.; National Institute on Deafness and Other Communication Disorders (NIDCD); Telephone: 301-496-1804;
Email: riverara@nidcd.nih.gov

NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)
Sponsor: National Institute on Deafness and Other Communication Disorders
Deadline(s): 10/08/2021; 02/08/2022; 06/07/2022; 10/07/2022; 02/08/2023; 06/08/2023; 10/10/2023; 01/08/2024 (Expiration)
Contact: Scientific / Research Contact(s): Alberto L. Rivera-Rentas, Ph.D.; National Institute on Deafness and Other Communication Disorders (NIDCD); Telephone: 301-496-1804;
Email: riverara@nidcd.nih.gov

NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)
Sponsor: National Institute on Deafness and Other Communication Disorders
Deadline(s): 02/08/2022; 06/07/2022; 10/07/2022; 02/08/2023; 06/08/2023; 10/10/2023; 01/08/2024 (Expiration)
Contact: Scientific / Research Contact(s): Alberto L. Rivera-Rentas, Ph.D.; National Institute on Deafness and Other Communication Disorders (NIDCD); Telephone: 301-496-1804;
Email: riverara@nidcd.nih.gov

NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)
Sponsor: National Institute on Aging
Deadline(s): Standard dates ; Standard AIDS dates ; 05/08/2024 (Expiration)
Contact: Scientific/Research Contact(s); NIA Training Office; National Institute on Aging (NIA); Email: NIAtraining@nih.gov
R2report
Friday Newsletter 07/16/2021


NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00 Independent Clinical Trial Not Allowed)
Sponsor: National Institute of Dental and Craniofacial Research
Deadline(s): Standard dates; Standard AIDS dates; 01/08/2024
Expiration
Contact: Scientific/Research Contact(s); Leslie A. Frieden, Ph.D.; National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-496-4263; Email: leslie.frieden@nih.gov

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)
Sponsor: National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Deadline(s): Standard dates; Standard AIDS dates; 09/08/2023
Expiration
Contact: Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)
Sponsor: National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Deadline(s): Standard dates; Standard AIDS dates; 09/08/2023
Expiration
Contact: Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts
Notice to Extend Eligibility for Submission to PAR-19-371, NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed) due to COVID-related Disruptions

**Sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration) [for PAR-19-371]; Though subject to future updates, NIAID now will provide at least a 2-receipt cycle extension (roughly 8 additional months) of eligibility for individuals whose eligibility to apply for the K22, under normal eligibility rules (including the resubmission policy as defined in NOT-OD-18-197), is expiring between June/July 2020 and February/March 2021 (inclusive of these dates). In addition, those who normally would have been eligible to apply for the June/July 2021 receipt date will have a 1-receipt cycle (roughly 4 months) extension.

**Contact:** Please direct all inquiries to: Deborah Philp, Ph.D.; Office of Research Training and Special Programs; National Institute of Allergy and Infectious Diseases (NIAID); Email: AITrainingHelpDesk@niaid.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-067.html

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Library of Medicine; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration) [for PAR-19-371]; Though subject to future updates, NIAID now will provide at least a 2-receipt cycle extension (roughly 8 additional months) of eligibility for individuals whose eligibility to apply for the K22, under normal eligibility rules (including the resubmission policy as defined in NOT-OD-18-197), is expiring between June/July 2020 and February/March 2021 (inclusive of these dates). In addition, those who normally would have been eligible to apply for the June/July 2021 receipt date will have a 1-receipt cycle (roughly 4 months) extension.

**Contact:** Please direct all inquiries to: Deborah Philp, Ph.D.; Office of Research Training and Special Programs; National Institute of Allergy and Infectious Diseases (NIAID); Email: AITrainingHelpDesk@niaid.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-051.html
Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates ; 05/08/2023

**Contact:** If you have any questions, please feel free to reach out to your SPA Project Officer.; [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; sfsc10@cumc.columbia.edu;

Website: https://spa.columbia.edu/; NIH; Scientific/Research Contact(s): Table of IC-Specific Information, Requirements, and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-242.html

**Additional Information:** [SPA News] NIH Re-issued Parent F32 now available; NIH just posted the Parent F32 for individual postdoc fellowships. See PA-20-242. The next upcoming standard F32 deadline is August 8th. You may want to review the webinar I conducted a few weeks ago related to FORMS-F, as it covers significant changes to individual fellowships concerning the NIH Rigor and Reproducibility Policy. See: [*] Slides ; [*] Discussion Guide for Career Development and Fellowship Applicants on Rigor & Reproducibility skills.; [*] Also see ReadI Program for more information and resources.; [*] FORMS-F Checklists - courtesy of the VP&S Office for Research

---

**Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 No Independent Clinical Trials)**

**Sponsor:** NIH Basic Behavioral and Social Science Opportunity Network; National Center for Complementary and Integrative Health; National Institute on Alcohol Abuse and Alcoholism; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; Office of Behavioral and Social Sciences Research

**Deadline(s):** 03/17/2022; 03/17/2023; 03/18/2023

**Contact:** William Elwood, PhD; Office of Behavioral and Social Sciences Research (OBSSR); Telephone: 301-402-0116; Email: william.elwood@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-211.html

---

**Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 Basic Experimental Studies with Humans Required)**

**Sponsor:** NIH Basic Behavioral and Social Science Opportunity Network; National Center for Complementary and Integrative Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; Office of Behavioral and Social Sciences Research

**Deadline(s):** Standard dates; Standard AIDS dates ; 05/08/2023

**Contact:** If you have any questions, please feel free to reach out to your SPA Project Officer.; [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research; Sponsored Projects Administration; sfsc10@cumc.columbia.edu;

Website: https://grants.nih.gov/grants/guide/pa-files/PA-20-211.html

**Additional Information:** Related Announcements; PA-20-197 Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)

**Sponsor:** National Cancer Institute

**Deadline(s):** Standard dates; Standard AIDS dates ; 05/08/2023

**Contact:** Please direct all inquiries to: Sonia B. Jakowlew, Ph.D., National Cancer Institute (NCI); Telephone: 240-276-5630; Email: jakowlew@email.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-063.html

**Additional Information:** Related Announcements; PA-20-198 Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)

**Sponsor:** National Cancer Institute

**Deadline(s):** Standard dates; Standard AIDS dates ; 05/08/2023

**Contact:** Please direct all inquiries to: Sonia B. Jakowlew, Ph.D., National Cancer Institute (NCI); Telephone: 240-276-5630; Email: jakowlew@email.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-064.html

**Additional Information:** Related Announcements; PA-20-198 Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institute of Allergy and Infectious Diseases

---

**NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)**

**Sponsor:** National Institute of Allergy and Infectious Diseases

---
NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)

**Sponsor**: National Institute of Allergy and Infectious Diseases

**Deadline(s)**: Standard dates; Standard AIDS dates: 01/08/2023 (Expiration)

**Contact**: Scientific/Research Contact(s); Deborah Philip, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 301-761-7776; Email: AITrainingHelpDesk@niaid.nih.gov


Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)

**Sponsor**: National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke

**Deadline(s)**: Standard dates; Standard AIDS dates: 01/08/2023 (Expiration)

**Contact**: Scientific/Research Contact(s); Deborah Philip, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 301-761-7776; Email: AITrainingHelpDesk@niaid.nih.gov


Mentored Clinical Scientist Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)

**Sponsor**: National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke

**Deadline(s)**: Standard dates; Standard AIDS dates: 01/08/2023 (Expiration)

**Contact**: Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts


Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)

**Sponsor**: National Institutes of Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke

**Deadline(s)**: Standard dates; Standard AIDS dates: 01/08/2023 (Expiration)

**Contact**: Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-205.html

Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-204.html

Notice of NCI's Participation on PA-20-199, "Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration) [for PA-20-199]

**Contact:** Please direct all inquiries to: Sonia B. Jakowlew, Ph.D., National Cancer Institute (NCI); Telephone: 240-276-5630; Email: jakowles@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-062.html

**Additional Information:** Related Announcements: PA-20-199 Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)

Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts There must be a contact for all participating ICs.

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-186.html

Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-206.html
Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-193.html

Mentored Research Scientist Development Award (Parent K01 Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-191.html

Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-191.html
Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-197.html

---

Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-198.html

---

Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-199.html

---

Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Neurological Disorders and Stroke

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements, and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-171.html

---

Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Neurological Disorders and Stroke

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements, and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-173.html

---

Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Neurological Disorders and Stroke

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements, and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-174.html
Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)

**Sponsor:** Participating Organization(s): National Institutes of Health (NIH); Components of Participating Organizations: National Institute of General Medical Sciences (NIGMS); National Institute of Biomedical Imaging and Bioengineering (NIBIB); National Institute of Nursing Research (NINR); National Institute on Minority Health and Health Disparities (NIMHD); National Human Genome Research Institute (NHGRI); National Institute on Aging (NIA); National Library of Medicine (NLM); National Institute of Mental Health (NIMH); National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Heart, Lung and Blood Institute (NHLBI); National Institute of Environmental Health Sciences (NIEHS); National Institute on Deafness and Other Communication Disorders (NIDCD)

**Deadline(s):** Standard dates; 11/15/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Carol Shreffler, PhD; National Institute of Environmental Health Sciences (NIEHS); Telephone: 984-257-3322; Email: shreffl1@niehs.nih.gov


Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)

**Sponsor:** NIH

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022

**Contact:** Scientific/Research Contact(s): See Table of IC-Specific Information, Requirements and Staff Contacts


Notice of Special Interest: Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development (K) Award Recipients and Scholars

**Sponsor:** National Institutes of Health; John E. Fogarty International Center; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** 03/05/2022 (First Available due date); 03/06/2023 (Expiration)

**Contact:** Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Research; Website: [https://researchtraining.nih.gov](https://researchtraining.nih.gov); Email: NIHTrain@mail.nih.gov


AHRQ Mentored Research Scientist Career Development Award (K01)

**Sponsor:** Agency for Healthcare Research and Quality

**Deadline(s):** Standard dates; 11/14/2022 (Expiration)

**Contact:** Direct your questions about general FOA issues, including information on the inclusion of priority populations to: Tamara Willis, PhD, MPH; Agency for Healthcare Research and Quality (AHRQ); Office of Extramural Research, Education, and Priority Populations; Division of Research Education

Telephone: (301) 427-1011; E-mail: Tamara.Willis@ahrq.hhs.gov

**Link(s):** [https://grants.nih.gov/grants/guide/notice-files/PA-20-067.html](https://grants.nih.gov/grants/guide/notice-files/PA-20-067.html)

NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)

**Sponsor:** National Institute of Allergy and Infectious Diseases

**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Shawn Drew Gaillard, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3857; Email: Shawn.Gaillard@nih.gov


[1] Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)


**Sponsor:** NIH; National Institute of General Medical Sciences (NIGMS)

**Deadline(s):** Standard dates; 11/15/2022 (Expiration)

**Contact:** [for Webinar] Please direct all inquiries to: Kenneth D. Gibbs, Jr., Ph.D; National Institute of General Medical Sciences (NIGMS); Email: kenneth.gibbs@nih.gov
Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-117.html

Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-118.html

Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-119.html

Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-121.html

Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Nursing Research
Mentored Quantitative Research Development Award (Parent K25 - Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts


Mentored Research Scientist Development Award (Parent K25 - Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-125.html

Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute on Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute of Nursing Research; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-126.html

NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts
# NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts


---

# Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Neurological Disorders and Stroke

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts


---

# Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Neurological Disorders and Stroke

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts


---

# Mentored Research Scientist Development Award (Parent K01 - Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements and Staff Contacts


---

# Independent Scientist Award (Parent K02 - Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Neurological Disorders and Stroke

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements and Staff Contacts


---

# Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Neurological Disorders and Stroke

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements and Staff Contacts

Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-087.html

Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-088.html

Mentored Quantitative Research Development Award (Parent K25 - Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-089.html

NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-090.html

K01 Mentored Research Scientist Development Award

**Sponsor:** Centers for Disease Control and Prevention

**Deadline(s):** Standard dates; 11/18/2023 (Expiration)

**Contact:** Scientific/Research Contact; Linda West, MSPH; National Institute for Occupational Safety and Health; Centers for Disease Control and Prevention; Telephone: 404-498-5767; Email: LWest@cdc.gov


CDC: Mentored Research Scientist Development Award (K01)

**Sponsor:** Department of Health and Human Services; Centers for Disease Control and Prevention – ERA

**Deadline(s):** 12/01/2023 (Archive)

**Contact:** Steve Dearwent; (404) 639-7091; sed7@cdc.gov; CDC Procurement and Grants Office (PGO) Technical Information Management Section (TIMS) Phone: 770-488-2700 Email: pgolim@cdc.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-13-245.html

http://www.grants.gov/web/grants/view-opportunity.html?oppId=237453

CDC: Mentored Research Scientist Development Award (K01)

**Sponsor:** Department of Health and Human Services; Centers for Disease Control and Prevention – ERA

**Deadline(s):** 12/01/2023 (Archive)

**Contact:** Steve Dearwent; (404) 639-7091; sed7@cdc.gov
EVIDENCE-BASED PRACTICES

NA

NEW ACCESS POINTS

NA

SMALL MARKET AWARDS

NA

TRANSPORTATION

TRB: National Cooperative Highway Research Program

Sponsor: Transportation Research Board

Deadline(s): Closing Date: TBD

Contact: Address inquiries to: Christopher J. Hedges; Manager, National Cooperative Highway Research Program;
Transportation Research Board; chedges@nas.edu

Link(s): http://www.trb.org/NCHRP/NCHRP.aspx

CLINICAL RESEARCH SCHOLARS

NA

HUMANITARIAN EMERGENCIES, PUBLIC HEALTH EMERGENCIES

NA

MIGRATION/REFUGEES

NA

TELEHEALTH / MOBILE HEALTH (MHEALTH) / HEALTH APPS / HEALTH TECHNOLOGY

Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)

Sponsor: National Center for Complementary and Integrative Health

Deadline(s): Standard dates; Standard AIDS dates; 05/08/2023

Contact: Scientific/Research Contact(s); Lanay Mudd, Ph.D;
National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-594-9346;
Email: lanay.mudd@mail.nih.gov


Additional Information: Weekly NIH Funding Opportunities and Notices; Funding Opportunities

NATIONAL SERVICE

NA

HEALTH CARE ACCESS

NA

SUSTAINABLE GOALS

NA

PHYSIOLOGY

NA

PRIMARY CARE

NA

ORGAN DONATIONS

NA

ACCREDITATION

NA

PHYSICAL EDUCATION

NA

BIOTECHNOLOGY AND TECHNOLOGY

NA

ATTENTION DEFICIT DISORDER

NA
CLINICAL PRACTICES and Education

NA

ARTICLES

From The New York Times: Why the Medical Research Grant System Could Be Costing Us Great Ideas
Sponsor: NY Times Article
Deadline(s): NA, published on 06/18/2018
Contact: NA

The Leiden Manifesto for research metrics;
Sponsor: Nature Magazine; Diana Hicks, Paul Wouters et al.
Deadline(s): NA
Contact: Nature, 520, 04/23/2015; pp. 429;
Link(s): http://www.nature.com/polopoly_fs/1.17351!/menu/main/topColumns/topLeftColumn/pdf/520429a.pdf

Additional Information: An interesting link for faculty, which talks about evaluation of faculty research;

SOCIAL SCIENCES

NA

CAREGIVER HEALTH

NA

COLUMBIA, RESEARCH RESOURCES AND SPA ANNOUNCEMENTS

New Research Data and Integrity ReaDI Program and Research Data and Integrity ReaDI October 2019 eNewsletter
Sponsor: Research and Data Integrity (ReaDI) Program
Deadline(s): NA
Contact: For questions about the ReaDI Program or the eNewsletter, feel free to reach out to Michelle C. Benson, Ph.D., Asst. Director for Research Integrity & Compliance at mb3852@columbia.edu.
Link(s): https://research.columbia.edu/ReaDI-Program [ReaDI Program]
https://research.columbia.edu/sites/default/files/content/RCT%20content/ReaDI%20Program/2019-October.pdf [ReaDI E-Newsletter]

NYT Article on Data Security
Sponsor: New York Times
Deadline(s): NA
Contact: NA

Link(s):

Sponsor: Columbia
Deadline(s): NA
Contact: Piecemeal, per publication
Link(s): http://evpr.columbia.edu/content/selected-resources pw protected, you will be prompted to log in.

2016 HIPAA Privacy and Information Security Briefing
Sponsor: http://www.cumc.columbia.edu/hipaa/index.html
Deadline(s): NA; Annual Webinar
Contact: Karen Pagliaro-Meyer; Privacy Officer; kpagliaro@columbia.edu
Link(s): https://wind.columbia.edu/login?destination=https://a2learning.cumc.columbia.edu:8443/ess/echo/presentation/39ba7003-f6d6-44e5-b23f-7b5dd6838a69&service=cumc-modauth you will be prompted for you uni and pw
http://www.cumc.columbia.edu/hipaa/index.html

Additional Information: Dear Colleagues, We were pleased to see so many faculty and staff members at the annual HIPAA Privacy and Information Security Briefing. Those of you who were unable to attend the briefing can watch a video of it here: 2016 HIPAA Privacy and Information Security Briefing. The slides and video link are also on the CUMC HIPAA website under HIPAA Educational Information. Although the session was not mandatory, it outlined important information about CUMC’s privacy and information security programs. We encourage you to familiarize yourself with the material.; Thank you for your commitment to safeguarding Protected Health Information at the medical center. Your partnership in this endeavor helps make CUMC one of the nation’s leading medical centers.; Sincerely, Karen Pagliaro-Meyer; Privacy Officer; Columbia University Medical Center

Internal Process for Dealing with Multiple PI Grants
Sponsor: SPA Announcement
Deadline(s): NA
Contact: Individual Departmental Administrators; Departmental administrators have had training on this and should be able to answer any questions you have
http://grants.nih.gov/grants/multi_pi/sample_leadership_plans.pdf

LIFE COURSE

NA
FOOD AND DRUG ADMINISTRATION AND FOOD SAFETY

Notice to Extend the 2020 Application Due Date for PAR-20-124 “NARMS Cooperative Agreement Program to Enhance and Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens (U01)”

**Sponsor:** Food and Drug Administration

**Deadline(s):** 05/03/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Claudine Kabera; Center for Veterinary Medicine (CVM); Telephone: 240-402-5430; Email: Claudine.Kabera@fda.hhs.gov


Notice of 2nd deadline extension for the 2020 Application Due Date for PAR-20-091 "Revision Applications - FSMA Human Foods Preventive Controls Implementation Expansion Supplement to RFA-FD-18-001 (U18 Clinical Trials Not Allowed)"

**Sponsor:** Food and Drug Administration

**Deadline(s):** 03/25/2022 [Extended Deadlines]

**Contact:** Please direct all inquiries to: Daniel Lukash; Grants Management Specialist; Office of Acquisitions & Grants Services (OAGS); Food and Drug Administration; Telephone: 240-402-7596; Email: daniel.lukash@fda.hhs.gov


BIRTH DEFECTS

NA

GLOBAL HEALTH

Protecting Life in Global Health Assistance

**Sponsor:** National Institutes of Health

**Deadline(s):** 06/23/2017 (Release Date)

**Contact:** Division of Grants Compliance and Oversight; Office of Policy for Extramural Research Administration (OER); Telephone: 301-435-0938; Email: GrantsCompliance@od.nih.gov


RESEARCH SUPPLEMENTS, CONTINUITY OF RESEARCH

MENTORING, CAREER TRANSITION

NA

RE-ENTRY, REENTRY, TO RESEARCH CAREERS

Notice to Extend the Submission Period to the National Cancer Institute (NCI) for PA-18-592, Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute

**Deadline(s):** 09/08/2021 (Expiration)

**Contact:** Please direct all inquiries to: Alison Lin, PhD; National Cancer Institute (NCI); Telephone: 240-276-6177; Email: alison.lin@nih.gov


Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed)

**Sponsor:** Department of Health and Human Services; National Institutes of Health; National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; *Eunice Kennedy Shriver* National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs; Office of Research on Women's Health; The Common Fund/Office of Strategic Coordination
Due dates may vary by awarding IC. See Table of IC-Specific Information, Requirements and Staff Contacts for more details.

**Deadline(s):** 09/07/2021; 10/13/2021 (Archive)
**Contact:** Scientific/Research Contact(s); Before submitting an application for a research supplement, applicants are strongly encouraged to contact their program official to discuss the program (see Table of IC-Specific Information, Requirements and Staff Contacts).


---

**Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp) Grant;**

**Sponsor:** National Institutes of Health; John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Office of Dietary Supplements; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs; Office of Research on Women’s Health; The Common Fund/Organization of Strategic Coordination;

**Deadline(s):** Application Receipt/Submission Date(s); Due dates may vary by awarding IC. See Table of IC-Specific Information, Requirements and Staff Contacts for more details.
**Contact:** [FBOWwebmaster@OD.NIH.GOV](mailto:FBOWwebmaster@OD.NIH.GOV); Scientific/Research Contact(s); Before submitting an application for a research supplement, applicants are strongly encouraged to contact their program official to discuss the program (see Table of IC-Specific Information, Requirements and Staff Contacts). Application Receipt/Submission Date(s); Due dates may vary by awarding IC. See Table of IC-Specific Information, Requirements and Staff Contacts for more details;


---

**CENTER FOR DISEASE CONTROL**

**2015 CDC Funding Opportunities; Workforce Improvement Projects (WIPs) Overview;**

**CDC;**

**Deadline(s):** Varies, please see individual announcements;
**Contact:** Varies, please see individual announcements;
**Link(s):** Please see individual announcements;

- 2015-N-01; NCBDDD; Population-based Surveillance of Venous Thromboembolism;
- 2015-N-02; NCBDDD; Population-based Surveillance of Venous Thromboembolism;
- 2015-N-03; NCHHSTP; Navigation for Improved Outcomes for HIV-infected Persons with Depression and/or Substance Use Disorders;
- 2015-N-04; NCHHSTP; Public Health Surveillance Training for DSTDP/Field Staff Employees;
- 2015-N-05; NCHHSTP; Health Equity Training for FSB Field Staff Employees;

**SMALLPOX**

- NA; at this time;

**CHEMISTRY**

- NA; at this time;

**CLIMATE AND CLIMATE CHANGE**

- NA

**PRECISION MEDICINE**

**Notice of Intent to Publish a Funding Opportunity Announcement for Nutrition for Precision Health, powered by the All of Us Research Program: Artificial Intelligence for Multimodal Data Modeling and Bioinformatics Center (U54 Clinical Trial Not Allowed)**

**Sponsor:** Office of Strategic Coordination (Common Fund)

**Deadline(s):** 04/06/2021 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Christopher M. Hartshorn, Ph.D.; National Cancer Institute (NCI); 240-781-3315; christopher.hartshorn@nih.gov


**Notice of Intent to Publish a Funding Opportunity Announcement for Nutrition for Precision Health, powered by the All of Us Research Program: Metabolomics and Clinical Assays Center (U24)**
Notice of Intent to Publish a Funding Opportunity Announcement for Nutrition for Precision Health, powered by the All of Us Research Program: Microbiome and Metagenomics Center (U24 Clinical Trial Not Allowed)

**Sponsor:** Office of Strategic Coordination (Common Fund)
**Deadline(s):** 04/06/2021 (First Estimated Application Due Date)
**Contact:** Pothur R. Srinivas, Ph.D., M.P.H.; National Cancer Institute (NCI); 240-276-7620; srinivap@mail.nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-RM-21-002.html

Notice of Intent to Publish a Funding Opportunity Announcement for Nutrition for Precision Health, powered by the All of Us Research Program: Dietary Assessment Center (U24 Clinical Trial Optional)

**Sponsor:** Office of Strategic Coordination (Common Fund)
**Deadline(s):** 04/06/2021 (First Estimated Application Due Date)
**Contact:** Padma Maruvada, Ph.D.; National Institute of Diabetes, and Digestive and Kidney Diseases (NIDDK) 301-594-8884; maruvadp@mail.nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-RM-21-003.html

Notice of Intent to Publish a Funding Opportunity Announcement for Nutrition for Precision Health, powered by the All of Us Research Program: Clinical Centers (UG1 Clinical Trial Required)

**Sponsor:** Office of Strategic Coordination (Common Fund)
**Deadline(s):** 04/06/2021 (First Estimated Application Due Date)
**Contact:** Please direct all inquiries to: Ashley J. Vargas, Ph.D., M.P.H.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); 301-827-6030; ashley.vargas@nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-RM-21-007.html

Notice of Intent to Publish a Funding Opportunity Announcement for Nutrition for Precision Health, powered by the All of Us Research Program: Research Coordinating Center (U24 Clinical Trial Not Allowed)

**Sponsor:** Office of Strategic Coordination (Common Fund)
**Deadline(s):** 04/06/2021 (First Estimated Application Due Date)
**Contact:** Please direct all inquiries to: Ashley J. Vargas, Ph.D., M.P.H.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); 301-827-6030; ashley.vargas@nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-RM-21-008.html

Funding opportunities issued for the NIH Precision Medicine Initiative Cohort Program;

**Sponsor:** National Institutes of Health;
**Deadline(s):** Please see individual announcements;
**Contact:** Irene Haas; PMI Cohort Program Agreements Officer; Email: PMICPFOInquiries@mail.nih.gov;

ANXIETY DISORDERS

NA

DISORDERS OF SEXUAL DEVELOPMENT

NA

GENERIC DRUGS

NA

RADIOACTIVITY

NA

THYROID

NA

TUSKEGEE

NA

OTHER ANNOUNCEMENTS
HIPAA Privacy and Information Security Briefing 2015 (Presentation .pdf and video);
Sponsor: COLUMBIA UNIVERSITY/HIPAA;
Deadline(s): 06/30/2015 Security Briefing
Contact: Karen Pagliaro-Meyer; Privacy Officer;
kpagliaro@columbia.edu; 212-305-7315; Brian Smith-Sweeney;
Chief Information Security Officer; bs2931@cumc.columbia.edu; 212-342-0268;
Link(s): http://www.cumc.columbia.edu/hipaa/index.html;
Security Briefing: Presentation in .pdf format:
http://www.cumc.columbia.edu/hipaa/pdf/secured/hipaa_privacy_and_information_security_briefing_2015.pdf?ticketid=3sMpMMKIm9j3MBHqskQPY9wBT5q2yJN6qk7Mz7;
Presentation in video format:
http://a2learning.cumc.columbia.edu:8080/ess/echo/presentation/4c47338-b5f5-49b8-a564-6ea3b7d128db?ticketid=Z85wMsPbcSLHfVTSXgf5hvK5QyKgkJBJDYlVvKcogj; you may be required to log in with your uni and pw;

Provost’s Year-End Report;
Sponsor: Columbia University Office of the Provost;
https://provost.columbia.edu/;
Deadline(s): NA
Contact: NA
Link(s): http://www.columbia.edu/cu/provost/docs/newsletter/SinglePage.pdf;

SMALL BUSINESS

Notice of Change to Award Budget for PHS 2020-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications
Sponsor: National Institutes of Health
Deadline(s): 12/15/2020 (Release Date)
Contact: Please direct all inquiries to: Stephanie Fertig, MBA; HHS Small Business Program Lead; SEED (Small Business Education and Entrepreneurial Development) - Office of Extramural Research

NCCIH Policy Change to Budget Limit and Grant Durations for SBIR/STTR Phase I and Phase II Applications
Sponsor: National Center for Complementary and Integrative Health
Deadline(s): 07/29/2020 (Release Date)
Contact: Merav Sabri, Ph.D.; National Center for Complementary and Integrative Health (NCCIH); Phone: 301-496-2583;
Email: merav.sabri@nih.gov
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-AT-20-017.html

Social Work

MENTAL HEALTH DISORDERS

Notice of Intent to Publish a Funding Opportunity Announcement for ALACRITY Centers for Practice-Based Effectiveness and Services Research with Near-Term Impact (P50 Clinical Trial Optional)
Sponsor: National Institute of Mental Health
Deadline(s): 05/17/2021 (First Estimated Application Due Date)
Contact: Please direct all inquiries to: Joel Sherrill, Ph.D.; National Institute of Mental Health (NIMH); (301)-443-2477; jshemi@mail.nih.gov
Additional Information: Related Announcements: NOT-MH-20-065

Notice of Interest in Advancing Research on FMR1-Associated Conditions
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Advancing Translational Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke
Deadline(s): 06/05/2020 (Release Date)
Contact: Please direct all inquiries to: Tracy King, M.D., M.P.H.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-402-1822; Email: tracy.king@nih.gov
Additional Information: Related Announcements: RFA-HD-20-003 - Centers for Collaborative Research in Fragile X and FMR1-related Associated Conditions

Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia (R01 Basic Experimental Studies with Humans Required)
Sponsor: National Institute of Mental Health
Deadline(s): Standard dates: 05/08/2023 (Expiration)
Contact: Scientific/Research Contact(s): Andrew Rossi; National Institute of Mental Health (NIMH); Telephone: 301-443-1576; Email: rossia@mail.nih.gov

Notice of Interest in Advancing Research on FMR1-Related Associated Conditions
Associated Conditions (P50 Clinical Trial Optional); NOT-HD-17-033 - Request for Information (RFI): Future Directions in Research on Fragile X Syndrome and FMR1-Related Conditions

NIMH Short Courses for Mental Health Related Research (R25 -Independent Clinical Trial Not Allowed)

**Sponsor:** National Institute of Mental Health/NIH/DHHS

**Deadline(s):** 05/25/2021; 05/25/2022

**Contact:** Tamara Lewis Johnson, MPH, MBA; National Institute of Mental Health (NIMH); Telephone: 301-443-3267; Email: tamara.lewisjohnson@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/PAR-20-096.html

Notice of Special Interest in High Priority Research Areas for Sex and Gender Influences on the Adolescent Brain and the Mental Health of Girls and Young Women (Ages 12-24)

**Sponsor:** National Institute of Mental Health

**Deadline(s):** 05/18/2022 (Expiration)

**Contact:** Please direct all inquiries to: Scientific / Research Contact: Anjené Addington (genomics studies); National Institute of Mental Health (NIMH); Telephone: 301-443-6653; Email: anjene.addington@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-19-039.html

Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health

**Deadline(s):** Standard dates; Standard dates; 09/08/2022

**Contact:** Scientific/Research Contact(s); Anjené Addington (genomics studies); National Institute of Mental Health (NIMH); Telephone: 301-443-6653; Email: anjene.addington@nih.gov


Notice of Intent to Publish a Funding Opportunity Announcement for Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders

**Sponsor:** National Institute of Mental Health

**Deadline(s):** 01/28/2020 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: David McMullen; National Institute of Mental Health (NIMH); 301-451-0180; david.mcmullen@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-022.html

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)

**Sponsor:** National Institute of Mental Health

**Deadline(s):** Standard dates; 05/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Susan T. Azrin, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-3267; Email: susan.azrin@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-18-031.html

BEHAVIORAL SCIENCES

[1] Limited Submission; HRSA Behavioral Health Workforce Education and Training (BHMET) Program for Professionals; Funding Opportunity Number: HRSA-21-089; 11/16/2020 (Limited Submission Due Date) [This is the CU Limited Submission site]


[3] HRSA Behavioral Health Workforce Education and Training (BHMET) Sponsor Link Provided for Reference, this is a Limited Submission Opportunity

**Sponsor:** HRSA

**Deadline(s):** 11/16/2020 (Internal Deadline)

**Contact:** limitedsubmissions@columbia.edu

**Link(s):** https://research.columbia.edu/content/limitedsubmissions#table-6029#table-6029

https://www.hrsa.gov/grants/find-funding/hrsa-21-089
https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.hrsa.gov_2010_Web2External_Interface_Common_EHBDisplayAttachment.aspx-3Fdm-5Frtc-3D16-26dm-5Fatid-3D4e3e9799-2D47e1-2D47e1-2D9aa2-
Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions

**Sponsor:** Office of Behavioral and Social Sciences Research; National Center for Complementary and Integrative Health; National Cancer Institute; National Institute on Aging; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute of Nursing Research

**Deadline(s):** 07/23/2020 (First Available Due Date); 09/26/2022 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Will M. Aklin, Ph.D.; National Institutes on Drug Abuse (NIDA); Telephone: 301-827-5909; Email: aklinwm@mail.nih.gov


NIH Releases Protocol Template for Behavioral and Social Sciences Research Involving Humans

**Sponsor:** National Institutes of Health

**Deadline(s):** 03/26/2019 (Release Date)

**Contact:** Please direct all inquiries to: NIH Office of Science Policy

**SciencePolicy@od.nih.gov**


**Additional Information:** Purpose: The National Institutes of Health (NIH) has released a clinical trial protocol template with instructional and example text for NIH funded investigators to use in writing protocols for behavioral and social sciences clinical trials. This template was developed in response to changes in NIH policies that expanded the requirements associated with clinical trials beyond FDA-regulated clinical trials to those studies including behavioral or social interventions. Use of the template is recommended, but not required.

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)

**Sponsor:** National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Science Research

**Deadline(s):** 07/23/2021; 03/23/2022; 03/24/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Will M. Aklin, Ph.D.; National Institutes on Drug Abuse (NIDA); Telephone: 301-827-5909; Email: aklinwm@mail.nih.gov


Development and Optimization of Tasks and Measures for Functional Domains of Behavior (R01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism

**Deadline(s):** Standard dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Sarah Morris, Ph.D.; National Institute of Mental Health (NIMH)

Telephone: 301-443-9233; Email: sarah.morris@nih.gov


**SMALL RESEARCH GRANTS / PROJECTS**

**NA**

**TOXICANTS**

**NA**

**LEAD**

**NA**

**MINIMAL RISK STUDIES**

**NA**

**PREVENTION**

**NA**
DISEASE PREVENTION

Coming Soon: Grants Using Data Analytics to Support Chronic Disease Prevention and Management by Engaging Patient Navigators to Improve Population Health

**Sponsor:** Agency for Healthcare Research and Quality  
**Deadline(s):** NA, 11/26/2018 (Release Date); AHRQ intends to publish a Request for Applications (RFA) in fiscal year 2019  
**Contact:** Please direct all inquiries to: Cindy Brach, M.P.P.; Agency for Healthcare Research and Quality; Telephone: 301-427-1444; Email: Cindy.Brach@ahrq.hhs.gov  

VIOLENCE PREVENTION, INJURY PREVENTION AND INJURY CONTROL

NA

Multimorbidity

**Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)**

**Sponsor:** Office of Disease Prevention; National Center for Complementary and Integrative Health; National Cancer Institute; National Institute on Aging; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research  
**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); David L. Tilley, MPH, MS, CPH; Office of Disease Prevention (ODP); Telephone: 301-827-6014; Email: david.tilley@nih.gov  

**Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)**

**Sponsor:** Office of Disease Prevention; National Center for Complementary and Integrative Health; National Cancer Institute; National Institute on Aging; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research; Office of Behavioral and Social Sciences Research  
**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); David L. Tilley, MPH, MS, CPH; Office of Disease Prevention (ODP); Telephone: 301-827-6014; Email: david.tilley@nih.gov  

GUN VIOLENCE

**NIH awards grants for firearm injury and mortality prevention research**

**Sponsor:** NIH  
**Deadline(s):** NA (Announcement of Awards Granted)  
**Contact:** [https://obssr.od.nih.gov/about/contact-us/](https://obssr.od.nih.gov/about/contact-us/)  

**Gun Violence Research Collaborative to Release First Request for Research Proposals in January**

**Sponsor:** [http://rand.org](http://rand.org)  
**Deadline(s):** NA; Gun Violence Research Collaborative to Release First Request for Research Proposals in January  
**Contact:** Researchers who would like to suggest areas of focus for gun-policy research funding can contact us at ncgvr@rand.org  

FALL PREVENTION

NA

RESILIENCY

NA

HISPANIC HEALTH SERVICES

NA

US DEPARTMENT OF LABOR

NA

UNITED STATE DEPARTMENT OF JUSTICE USDOJ AND CRIMINAL JUSTICE

NA

COLUMBIA Mailman School of Public Health  
mailman.columbia.edu/r2
DISPLACED PERSONS AND HOMELESSNESS
NA

SLEEP AND SLEEP DISORDERS

Notice of Special Interest (NOSI): Heart, lung, blood and sleep focused ancillary studies to large ongoing clinical trials
Sponsor: National Heart, Lung, and Blood Institute
Deadline(s): 05/08/2022 (Expiration Date)
Contact: Please direct all inquiries to: Division of Cardiovascular Sciences; Jue Chen, Ph.D.; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-0550; Email: jue.chen@nih.gov

Mechanisms and Consequences of Sleep Disparities in the U.S. (R01 - Clinical Trial Not Allowed)
Sponsor: National Institute on Minority Health and Health Disparities; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Neurological Disorders and Stroke
Deadline(s): 07/14/2022; 07/15/2022 (Expiration)
Contact: Scientific/Research Contact(s); Rina Das, Ph.D.; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-496-3996; Email: dasr2@mail.nih.gov

RESEARCH PROJECT GRANTS
NA

PHARMACEUTICALS AND DOSING
NA

QUALITY CONTROL, QUALITY ASSURANCE

Pre Solicitation Notice: Clinical Pharmacology Quality Assurance (CPQA) Program, RFP: 75N93021R00003
Sponsor: National Institute of Allergy and Infectious Diseases
Deadline(s): 12/17/2020 (Release Date)
Contact: Please direct all inquiries to: Shane Sarchiapone; Contract Specialist; AIDS Research Contracts Branch; Office of Acquisitions; Division of Extramural Activities; National Institute of Allergy & Infectious Diseases; National Institutes of Health, DHHS; Email: shane.sarchiapone@nih.gov

POPULATION HEALTH AND DYNAMICS

RFP – Population Health Research Support
Sponsor: NIH/DHHS; The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Division of Intramural Population Health Research (DIPHR) plans to compete and award a contract for population health research centers.
Deadline(s): NA, this is a Notice of Intent
Contact: Jacquelin Jones, Contracting Officer; 301-435-6965; jacquelin.jones@nih.gov;
Links: https://www.fbo.gov/index?s=opportunity&mode=form&id=a8f3828c5bcf66599f2b3689c10e21&tab=core&_cview=0

ALLERGIES AND INFECTIOUS DISEASES AND EMERGING INFECTIONS

[1] Limited Submission; CDC Strengthening Public Health Research and Implementation Science (Operations Research) to Control and Eliminate Infectious Diseases Globally; RFA-GH-21-006
Sponsor: Department of Health and Human Services; Centers for Disease Control and Prevention - ERA
Global Infectious Disease Research Administration
Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Allergy and Infectious Diseases

**Deadline(s):** 07/28/2021; 07/28/2022; 07/28/2023; 07/29/2023 (Expiration)

**Contact:** Scientific / Research Contact(s): Paula S. Strickland, Ph.D., MPH; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-669-2922; Email: pstricklan@mail.nih.gov


Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)

**Sponsor:** John E. Fogarty International Center

**Deadline(s):** 08/03/2021; 08/03/2022; 08/04/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Barbara Sina Ph.D.; Fogarty International Center (FIC); Telephone: 301-402-9467; Email: sinab@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/files/NOT-FD-20-014.html

NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Allergy and Infectious Diseases

**Deadline(s):** 01/11/2022; 06/10/2022; 09/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); For the Division of AIDS (DAIDS): Martin Gutierrez, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-292-4844; Email: mgutierrez@niaid.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/files/PAR-20-072.html

Ecology and Evolution of Infectious Diseases (EEID)

**Sponsor:** Directorate for Biological Sciences/NSF

**Deadline(s):** 12/16/2022 (Archive)

**Contact:** Katharina Dittmar; 703-292-7799; kdittmar@nsf.gov

**Link(s):** https://www.grants.gov/grants/apply/files/PAR-20-072.html

**Notice of Intent to Publish a Funding Opportunity Announcement for Zika Virus (ZIKV) Complications (R21)**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Eye Institute; National Institute of Allergy and Infectious Diseases; National Institute of Biomedical Imaging and Bioengineering; National Institute of Dental and Craniofacial Research; National Institutes of Health; National Institute of Neurological Disorders and Stroke

**Deadline(s):** NA

**Contact:** Please direct all inquiries to: Nahida Chakhtoura MD, MsGH; *Eunice Kennedy Shriver National Institute of Child Health and Human Development* (NICHD); Telephone: 301-435-6872; Email: nahida.chakhtoura@nih.gov

**Link(s):** http://grants.nih.gov/grants/guide/notice-files/NICHD-2021-022.html

NIH seeks research applications to study Zika in pregnancy, developing fetus; 

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development;

**Deadline(s):** NA

**Contact:** NICHD Press Office; nichdpress@mail.nih.gov; 301-496-5133;

**Link(s):** http://grants.nih.gov/grants/guide/notice-files/PAR-20-072.html

**Additional Information:** NIH recently announced its research priorities for studies to investigate how Zika virus infection affects reproduction, pregnancy, and the developing fetus. The virus has been linked to a spike in cases of microcephaly—an abnormally small head resulting from an underdeveloped or damaged brain—among newborn babies;

**EBOLA and ZOONOTIC DISEASE**

**Message from President Bollinger relative to Ebola;**

**Sponsor:** Columbia University;

**Deadline(s):** NA

**Contact:** If you or anyone has any concerns, please visit the University’s Ebola Preparedness site or the New York City Department of Health Ebola update page. You may also contact Student Health
Services at 212-854-2284 or Workforce Health and Safety for Faculty/Staff with Hospital Responsibilities at 212-305-7590; [Link(s):] If you or anyone has any concerns, please visit the University’s Ebola Preparedness site or the New York City Department of Health Ebola update page; [Additional Information:]

Dear fellow members of the Columbia community: As you may have seen in the media, Dr. Craig Spencer is being treated for Ebola at Bellevue Hospital in Manhattan. Dr. Spencer, an emergency department physician at NewYork-Presbyterian/Columbia University Medical Center, recently returned from a humanitarian mission with Doctors Without Borders to one of the outbreak areas in Western Africa. We admire and appreciate all of those willing to do this vital and selfless public health work around the globe; it’s critical to bear in mind what our public health and infectious disease experts have emphasized—that the risk to people in New York City and at Columbia remains extremely low. If you or anyone has any concerns, please visit the University’s Ebola Preparedness site or the New York City Department of Health Ebola update page. You may also contact Student Health Services at 212-854-2284 or Workforce Health and Safety for Faculty/Staff with Hospital Responsibilities at 212-305-7590; We must keep Dr. Spencer in our thoughts and wish him a full and speedy recovery, as we do the vulnerable populations he serves. We will also continue to keep the Columbia community informed as we learn more from City, State, and Federal health officials.; Sincerely, Lee C. Bollinger;

Note from Dean Fried; [Deadline(s):] NA [Sponsor: Dean’s Office] [Link(s):] NA [Additional Information:]

Dear Colleagues, By now, many of you have learned that a New York Presbyterian physician, Dr. Craig Spencer, who recently returned from treating patients in Guinea, has tested positive for Ebola. I ask you all to keep Dr. Spencer, who is a 2013 Mailman School graduate, in your thoughts, and to acknowledge that the extraordinary efforts of our alumni, current students, and faculty continue to play a critical role in the containment, treatment, and understanding of this outbreak. At a moment of global distress, public health knowledge is vital. It is important to recognize that this crisis will continue, and that all available scientific information suggests the risk of transmission here is extremely low.; Dr. Spencer’s commitment is among many noteworthy examples of our colleagues passing seamlessly from science to service. As we move through this global crisis, we must all take pride in that commitment.; Sincerely, Linda; Linda P. Fried, MD, MPH; Dean and DeLamar Professor of Public Health; Mailman School of Public Health; Senior Vice President; Columbia University Medical Center; Professor of Epidemiology and Medicine;

Video FAQs in both English and Spanish to address concerns about Ebola; [Sponsor: Communications, P&S and Mailman;] [Deadline(s):] NA [Contact:] Doug Levy, CUMC Chief Communications Officer; dl2674@columbia.edu; [Link(s):] English: http://bit.ly/CUMC_Ebola_FAQ_Video or http://youtu.be/ENYhL1a58sc?list=PLB_2Zzj38aDjrt0ej6UzTW8CO9bMftbO8; Spanish: http://bit.ly/Ebola_Video_Espanol; or directly at http://youtu.be/QRTliVtcIVk?list=PLB_2Zzj38aDheL.NqRDFb25_h2cpndJSIS;

HUMAN ANIMAL INTERACTIONS, HAI

Human-Animal Interaction (HAI) Research (R03 Clinical Trial Optional) [Sponsor: National Institutes of Health (NIH);] [Components of Participating Organizations;] [Deadline(s):] 11/30/2021; 12/21/2021 (Expiration) [Contact: Layla Esposito, PhD;] [Deadline(s):] 11/30/2021; 12/21/2021 (Expiration) [Contact: Scientific/Research Contact(s):] [Link(s):] https://grants.nih.gov/grants/guide/pa-files/PAR-20-032.html

RARE DISEASES

Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) [Sponsor: National Institutes of Health (NIH);] [Components of Participating Organizations;] [Deadline(s):] 10/25/2021; 10/26/2021 (Expiration) [Contact: Alice Chen, M.D.;] [Deadline(s):] 10/25/2021; 10/26/2021 (Expiration) [Contact: Scientific/Research Contact(s):] [Link(s):] https://grants.nih.gov/grants/guide/pa-files/PAR-18-953.html

Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed) [Sponsor: National Institutes of Health (NIH);] [Components of Participating Organizations;] [Deadline(s):] 10/25/2021; 10/26/2021 (Expiration) [Contact: Alice Chen, M.D.;] [Deadline(s):] 10/25/2021; 10/26/2021 (Expiration) [Contact: Scientific/Research Contact(s):] [Link(s):] https://grants.nih.gov/grants/guide/pa-files/PAR-18-953.html
ASPPH, is the official journal of the U.S. Public Health Service and
Deadline(s)
Association of Schools & Programs Of Public Health; Sponsor:
Sponsor
in the Fiscal Year 2016 Omnibus Appropriations Agreement;
Deadline(s)
ASPPH has Redesigned its Newsletter
Deadline(s)
Association of Schools and Programs of Public Health (ASPPH) |
Deadline(s)

ASPPH Newsletter 07/16/2021


APHA
NA

ASPPH Announcements

ASPPH Policy & Advocacy - December 16, 2015 Special Appropriations Edition; ASPPH Funding Priorities Reflected in the Fiscal Year 2016 Omnibus Appropriations Agreement; Sponsor: www.aspph.org; Deadline(s): NA

Contact: Tony Mazzaschi | Senior Director, Policy and Research; Association of Schools and Programs of Public Health (ASPPH) | www.aspph.org; 1900 M Street NW, Suite 710 | Washington, DC 20036; Tel: 202-296-1099, ext. 132 | Fax: 202-296-1252 | Email: tmazzaschi@aspph.org; Link(s): The text of the 2,009-page bill: http://docs.house.gov/billtextweek/20151214/CPRT-114-HPRTRU00-SAHR2029-AMNT1final.pdf; Report on Division H (Labor-HHS-Education): http://docs.house.gov/meetings/RU/RR00/20151216/104298/HMSGOVHPRT-114-RU00-20151216-SD009.pdf; Updated ASPPH appropriations priorities: https://s3.amazonaws.com/ASPPH_Media_Files/Docs/ASPPH+Priorities+12.16.15.pdf;

ASPPH Weekly Newsletter
Weekly Newsletter Submission Guidelines Link: http://www.aspph.org/friday-letter-submission-guidelines/

Sponsor: ASPPH; Association of Schools & Programs Of Public Health; Links to Friday Newsletter; Association of Schools & Programs Of Public Health; Deadline(s): NA

Contact: To share updates, email submissions@aspph.org. View submission guidelines: Public Health Reports, published by ASPPH, is the official journal of the U.S. Public Health Service and the U.S. Surgeon General, since 1878.; ASPPH 1900 M Street NW, Suite 710 Washington, DC 20036

ASPPH Weekly Newsletter (continued):

https://www.aspph.org/friday-letter/ [henceforth, this link will be updated weekly with the contents of the ASPPH Friday Letter]; ASPPH Newsletter 07/09/2021 New Format; ASPPH has Redesigned its Newsletter Page; ASPPH Newsletter 07/02/2021; ASPPH Newsletter 06/25/2021; ASPPH Newsletter 06/18/2021; ASPPH Newsletter 06/11/2021; ASPPH Newsletter 06/04/2021; ASPPH Newsletter 05/28/2021; ASPPH Newsletter 05/21/2021; ASPPH Newsletter 05/14/2021; ASPPH Newsletter 05/07/2021; ASPPH Newsletter 04/30/2021; ASPPH Newsletter 04/23/2021; ASPPH Newsletter 04/16/2021; ASPPH Newsletter 04/09/2021; ASPPH Newsletter 04/02/2021; ASPPH Newsletter 03/26/2021; ASPPH Newsletter 03/19/2021; ASPPH Newsletter 03/12/2021; ASPPH Newsletter 03/05/2021; ASPPH Newsletter 02/26/2021; ASPPH Newsletter 02/19/2021; ASPPH Newsletter 02/12/2021; ASPPH Newsletter 02/05/2021; ASPPH Newsletter 01/29/2021; ASPPH Newsletter 01/22/2021; ASPPH Newsletter 01/15/2021; ASPPH Newsletter 01/08/2021; ASPPH Newsletter 01/01/2021; ASPPH Newsletter 12/25/2020; ASPPH Newsletter 12/18/2020; ASPPH Newsletter 12/11/2020; ASPPH Newsletter 12/04/2020; ASPPH Newsletter 11/27/2020; ASPPH Newsletter 11/20/2020; ASPPH Newsletter 11/13/2020; ASPPH Newsletter 11/06/2020; ASPPH Newsletter 10/30/2020; ASPPH Newsletter 10/23/2020; ASPPH Newsletter 10/16/2020; ASPPH Newsletter 10/09/2020; ASPPH Newsletter 10/02/2020; ASPPH Newsletter 09/25/2020; ASPPH Newsletter 09/18/2020; ASPPH Newsletter 09/11/2020 ASPPH Newsletter 09/04/2020; ASPPH Newsletter 08/28/2020; ASPPH Newsletter 08/21/2020; ASPPH Newsletter 08/14/2020; ASPPH Newsletter 08/07/2020; ASPPH Newsletter 07/31/2020; ASPPH Newsletter 07/24/2020; ASPPH Newsletter 07/17/2020; ASPPH Newsletter 07/10/2020; ASPPH Newsletter 07/03/2020; ASPPH Newsletter 06/26/2020; ASPPH Newsletter 06/19/2020; ASPPH Newsletter 06/12/2020; ASPPH Newsletter 06/05/2020; ASPPH Newsletter 05/29/2020; ASPPH Newsletter 05/22/2020; ASPPH Newsletter 05/15/2020; ASPPH Newsletter 05/08/2020; ASPPH Newsletter 05/01/2020; ASPPH Newsletter 04/24/2020; ASPPH Newsletter 04/17/2020; ASPPH Newsletter 04/10/2020; ASPPH Newsletter 04/03/2020; ASPPH Newsletter 03/27/2020; ASPPH Newsletter 03/20/2020; ASPPH Newsletter 03/13/2020; ASPPH Newsletter 03/06/2020; ASPPH Newsletter 02/28/2020; ASPPH Newsletter 02/21/2020; ASPPH Newsletter 02/14/2020; ASPPH Newsletter 02/07/2020; ASPPH Newsletter 01/31/2020; ASPPH Newsletter 01/24/2020; ASPPH Newsletter 01/17/2020; ASPPH Newsletter 01/10/2020; ASPPH Newsletter 01/03/2020; ASPPH Newsletter 12/27/2019; ASPPH Newsletter 12/20/2019; ASPPH Newsletter 12/13/19; ASPPH Newsletter 12/06/19; ASPPH Newsletter 11/29/2019; ASPPH Newsletter 11/22/2019; ASPPH Newsletter 11/15/2019; ASPPH Newsletter 11/08/19; ASPPH Newsletter 11/01/19; ASPPH Newsletter 10/25/19; ASPPH Newsletter 10/18/19; ASPPH Newsletter 10/11/19; ASPPH Newsletter 10/04/19; ASPPH Newsletter 09/27/19; ASPPH Newsletter 09/20/19; ASPPH Newsletter 09/13/19; ASPPH Newsletter 09/06/2019; ASPPH Newsletter 08/30/2019; ASPPH Newsletter 08/23/2019; ASPPH Newsletter 08/16/2019; ASPPH Newsletter 08/09/2019; ASPPH Newsletter 08/02/2019; ASPPH Newsletter 07/26/2019; ASPPH Newsletter 07/19/2019; ASPPH Newsletter 07/12/2019; ASPPH Newsletter 07/05/2019; ASPPH Newsletter 06/28/2019; ASPPH Newsletter 06/21/2019; ASPPH Newsletter 06/14/2019; ASPPH Newsletter 06/07/2019; ASPPH Newsletter 05/31/2019; ASPPH Newsletter 05/24/2019; ASPPH Newsletter 05/17/19; ASPPH Newsletter 05/10/19; ASPPH Newsletter 05/03/19; ASPPH Newsletter 04/26/19; ASPPH Newsletter 04/19/19; ASPPH Newsletter 04/12/19; ASPPH Newsletter 04/05/19; ASPPH Newsletter 03/29/19; ASPPH Newsletter 03/22/19; ASPPH Newsletter 03/15/19; ASPPH Newsletter 03/08/19; ASPPH Newsletter 03/01/19; ASPPH Newsletter 02/22/19; ASPPH Newsletter 02/15/19; ASPPH Newsletter 02/08/19; ASPPH Newsletter 02/01/19; ASPPH Newsletter 01/25/19; ASPPH Newsletter 01/18/19; ASPPH Newsletter 01/11/19; ASPPH Newsletter 01/04/19; ASPPH Newsletter

COLUMBIA
RESEARCH RESOURCES
mailman.columbia.edu/ir2
AFFORDABLE MEDICAL TECHNOLOGIES
NA
CAPITAL EQUIPMENT, SHARED INSTRUMENTATION, HIGH END INSTRUMENTATION
NA
DENGUE FEVER
NA
TROPICAL MEDICINE
NA
NATIVE AMERICAN HEALTH / INDIGENOUS PEOPLES
Research to Improve Native American Health (R21 Clinical Trials Optional)
**Sponsor:** National Institute on Drug Abuse; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Minority Health and Health Disparities; National Library of Medicine; Office of Behavioral and Social Sciences Research
**Deadline(s):** 05/17/2022; 05/17/2023; 09/08/2023 (Expiration)
**Contact:** Scientific/Research Contact(s); Kathy Etz, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-402-1749; Email: Ketz@nih.gov

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)
**Sponsor:** National Institute on Drug Abuse; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research; National Library of Medicine; Office of Behavioral and Social Sciences Research
**Deadline(s):** 05/17/2022; 05/17/2023; 09/08/2023 (Expiration)
**Contact:** Scientific/Research Contact(s); Kathy Etz, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-402-1749; Email: Ketz@nih.gov
**Link(s):** [https://grants.nih.gov/grants/guide/pa-files/PAR-20-238.html](https://grants.nih.gov/grants/guide/pa-files/PAR-20-238.html)

Native American Research Centers for Health (NARCH) (S06 Clinical Trial Optional)
**Sponsor:** National Institutes of Health (NIH); Indian Health Service (IHS)
**Deadline(s):** 06/24/2021; 07/24/2021 (Expiration)
**Contact:** Scientific/Research Contact(s); Sheila A. Caldwell, PhD; National Institute of General Medical Sciences (NIGMS); Email: caldwells@mail.nih.gov

Notice of Change to Application Due Dates and Foreign Components Eligibility in PAR-20-125 "Native American Research Centers for Health (NARCH) (S06 Clinical Trials Optional)"
**Sponsor:** National Institute of General Medical Sciences
**Deadline(s):** 07/23/2021; 07/24/2021 (Expiration)
**Contact:** Please direct all inquiries to: Sheila A. Caldwell, PhD; National Institute of General Medical Sciences (NIGMS); Email: caldwells@mail.nih.gov

Additional Information: Related Announcements: PAR-20-125

Notice of NICHD Participation in PAR 20-125 "Native American Research Centers for Health (NARCH) (S06 Clinical Trials Optional)"
**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
**Deadline(s):** 07/23/2021; 07/24/2021 [Expiration [Native American Research Centers for Health (NARCH) (S06 Clinical Trials Optional [PAR-20-125])]]
**Contact:** Scientific/Research Contact(s); Juanita J. Chinn, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Human Development (NICHD); Telephone: 301-827-4901; Email: juanita.chinn@nih.gov
[Related Announcement]

EMERGING AND PARASITIC INFECTIONS
NA

METABOLOMICS
NA

CENTRAL AMERICA
NA

ORGAN FIBROSIS / WOUND HEALING
NA

POLIO
NA

HEALTH DISPARITIES AND MINORITY HEALTH

Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01 Clinical Trial Optional)

Sponsor: National Institute on Minority Health and Health Disparities; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Environmental Health Sciences; Office of Behavioral and Social Sciences Research

Deadline(s): Standard dates; Standard AIDS dates; 01/08/2023 (Expiration)

Contact: Scientific/Research Contact(s); Rina Das, Ph.D.; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-496-3996; Email: dasr2@mail.nih.gov

[Related Announcement]

Health Services Research on Minority Health and Health Disparities (R01- Clinical Trial Optional)

Sponsor: National Institute on Minority Health and Health Disparities ; National Institute on Alcohol Abuse and Alcoholism;

National Institute on Drug Abuse; Office of Behavioral and Social Sciences Research; Office of Disease Prevention; Office of Research on Women’s Health

Deadline(s): 11/17/2021; 03/17/2022; 11/17/2022

02/17/2023; 03/28/2023 (Expiration)

Contact: Scientific/Research Contact(s); Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: NIMHD; Rada Dagher, PhD; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-451-2187; rada.dagher@nih.gov [please see rfa for other agency’s scientific contacts]

[Related Announcement]

NLM Information Resource Grants to Reduce Health Disparities (G08 Clinical Trial Not Allowed)

Sponsor: National Library of Medicine; Office of Research on Women’s Health

Deadline(s): 10/22/2021; 10/21/2022; 10/22/2022 (Expiration)

Contact: Scientific/Research Contact(s): Alan VanBiervliet, PhD; National Library of Medicine (NLM); Telephone: 301-594-4882; Email: vanbiervlietag@mail.nih.gov

[Related Announcement]

Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities

Sponsor: National Institute on Minority Health and Health Disparities; National Cancer Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of Mental Health; National Library of Medicine; Office of Behavioral and Social Sciences Research; Office of Disease Prevention

Deadline(s): 10/05/2020 (First Available Due Date); 05/08/2023 (Expiration Date)

Contact: Scientific/Research Contact(s): Rada Dagher, Ph.D., M.P.H.; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-451-2187; Email: rada.dagher@nih.gov

[Related Announcement]

Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations

Sponsor: National Institute on Minority Health and Health Disparities; National Cancer Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of Mental Health; National Library of Medicine; Office of Behavioral and Social Sciences Research; Office of Disease Prevention

Deadline(s): 11/17/2021; 03/17/2022; 11/17/2022

02/17/2023; 03/28/2023 (Expiration)

Contact: Scientific/Research Contact(s); Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: NIMHD; Rada Dagher, PhD; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-451-2187; rada.dagher@nih.gov [please see rfa for other agency’s scientific contacts]

[Related Announcement]
**Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional)**

**Sponsor:** National Institute on Minority Health and Health Disparities; National Cancer Institute; National Institute on Aging; National Institute on Drug Abuse

**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Larissa Avilés-Santa, MD, MPH; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-827-6924; Email: avilledsanta@nih.gov


**Notice of Participation of the National Institute on Minority Health and Health Disparities (NIMHD) in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)**

**Sponsor:** National Institute on Minority Health and Health Disparities (NIMHD)

**Deadline(s):** 01/25/2022 (Expiration, PA-18-935); Earliest start dates may vary by awarding IC. See the Urgent Guide Notices for any applicable Application Due Dates.

**Contact:** Please direct all inquiries to: Nathan Stinson Jr, PhD, MD; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-594-8704; Email: stinsonn@mail.nih.gov


**Notice of Special Interest: Health Services Research on Minority Health and Health Disparities (R01- Clinical Trial Optional)**

**Sponsor:** National Institute on Minority Health and Health Disparities; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; Office of Behavioral and Social Sciences Research

**Deadline(s):** 06/05/2020 (First Available Due Date); 09/08/2022 (Expiration)

**Contact:** Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: Scientific/Research Contact for NIMHD; Rada Dagher, PhD; National Institute on Minority Health and Health Disparities NIMHD/http://www.nimhd.nih.gov/; Telephone: 301-451-2187; rada.dagher@nih.gov


**Surgical Disparities Research (R01 - Clinical Trial Optional)**

**Sponsor:** National Institute on Minority Health and Health Disparities; National Cancer Institute

**Deadline(s):** New Applications: 06/05/2021; 06/05/2022; Resubmission/revision applications: 07/05/2021; 07/05/2022; 07/06/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Benyam Hailu, MD, MPH; National Institute on Minority Health and Health Disparities (NIMHD); Telephone:301-594-8696; Email: Benyam.Hailu@nih.gov


**Social Epigenomics Research Focused on Minority Health and Health Disparities (R01-Clinical Trial Not Allowed)**

**Sponsor:** National Institute on Minority Health and Health Disparities; National Institute on Aging

**Deadline(s):** 11/08/2021; 11/09/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Lucia Hindorff, Ph.D.; National Human Genome Research Institute; Phone: 240-271-1509; Email: hindorff@mail.nih.gov


**MEDICAL MONITORING**

**NA**

**BIOSPECIMENS, MOLECULAR ANALYSIS**
Notice of Special Interest (NOSI): Innovative Molecular Analysis Technologies for Low-Resource Settings Globally

**Sponsor:** National Cancer Institute  
**Deadline(s):** 02/22/2021 (First Available Due Date); 09/30/2021 (Expiration Date)  
**Contact:** Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements; Scientific/Research Contact(s): Paul C. Pearlman, Ph.D.; Center for Global Health; National Cancer Institute (NCI); Telephone: 240-276-6429; Email: paul.pearlman@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-025.html

Notice of Intent to Publish a Funding Opportunity Announcement for Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)

**Sponsor:** Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environmental Health Sciences  
**Deadline(s):** 10/08/2021 (First Estimated Application Due Date)  
**Contact:** Please direct all inquiries to: Tobacco Regulatory Science Program; Office of Disease Prevention; 301-451-7464; TRSP@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-044.html

BASIC SCIENCES

NA

HEALTH AND POLICY MANAGEMENT HPM

Request for Information: Soliciting Input for the National Center for Complementary and Integrative Health’s New Strategic Plan;  
**Sponsor:** National Center for Complementary and Integrative Health  
**Deadline(s):** NA

Contact: Please direct all inquiries to: Karin Lohman, Ph.D.; National Center for Complementary and Integrative Health (NCCIH); Email: NCCIH_StrategicPlan2016@mail.nih.gov;  
**Link(s):** (NOT-AT-15-006)

Understanding and Promoting Health Literacy; (R01, R03, R21); Understanding and Promoting Health Literacy (R03)  
**Sponsor:** NIH; Department of Health and Human Services  
**Deadline(s):** http://grants.nih.gov/grants/funding/submissionschedule.htm; Standard Dates;  
http://grants.nih.gov/grants/funding/submissionschedule.htm#AIDS; Standard AIDS Dates;  
**Contact:** William Elwood, PhD; Office of Behavioral and Social Sciences Research (OBSSR); Telephone: 301-401-0116; Email: elwoodwi@od.nih.gov;  

POINT OF CARE TECHNOLOGIES

NA

COMMUNITIES / COMMUNITY HEALTH

NA

ACCOUNTABLE HEALTH COMMUNITIES

NA

FAMILY PLANNING AND TEEN PREGNANCY PREVENTION

NA

RURAL HEALTH CARE

NA

NONINTERVENTIONAL

NA

INTERVENTIONS

NA

EARLY DETECTION

NA
ORTHOPEDICS

Notice of Special Interest: Promoting Research on Mechanisms of Pathogenesis and Pathophysiology of Atypical Femoral Fracture (AFF) and Osteonecrosis of the Jaw (ONJ)

**Sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Aging; National Institute of Dental and Craniofacial Research; Office of Research on Women’s Health

**Deadline(s):** 06/05/2020 (First Available Due Date); 07/18/2023 (Expiration Date)

**Contact:** Scientific/Research Contact(s); Faye Chen, Ph.D.; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Telephone: 301-594-5055; Email: chenf1@mail.nih.gov


AMBULATORY CARE

NA

PIONEERING, TRANSFORMATIVE, NOVEL & EXPLORATORY INNOVATIONS

NA

TECHNOLOGICAL INNOVATION

NA

SCHOLASTIC / SCHOLARLY

Click Here For Standard Budget Spreadsheets To Be Used By All Departments And Pls For Grant Submissions, Provided By MSPH/SPA: (1) New Budget Proposal Template; (2) Genetic Detail Budget Template;

The Columbia University Medical Center IRB Office has a standing "IRB Consultation Hour". This service provides an opportunity for researchers to stop in at the IRB office and meet with an IRB professional to discuss regulatory, policy, and procedural questions. The sessions are scheduled for every Tuesday from 10 am to 11 am. No appointment is necessary. The IRB office is located at 154 Haven Avenue, 1st Floor. Attendees should sign in at the IRB receptionist desk, and will meet with IRB staff in the order of arrival. If situations warrant, individual consultations may be limited to 15 minutes. Important Note: If you have questions about a protocol that has already been submitted to the IRB, please contact the staff members who administer the IRB to which the protocol is assigned rather than bringing those questions to a Consultation Hours session. Staff contact information may be obtained on the IRB website: [http://www.cumc.columbia.edu/dept/irb/](http://www.cumc.columbia.edu/dept/irb/). Researchers may also call in during these times, to the IRB main number, for consultation: 212.305.5883. Email: irboffice@columbia.edu;

TAY-SACHS DISEASE

NA

COOPERATIVE AGREEMENTS

NA

ENVIRONMENTAL HEALTH SCIENCES

Outstanding New Environmental Scientist (ONES) Award (R01 Clinical Trial Optional)

**Sponsor:** National Institute of Environmental Health Sciences

**Deadline(s):** 02/24/2023; 02/25/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Carol A. Shreffler, Ph.D.; National Institute of Environmental Health Sciences (NIEHS); Telephone: 984-287-3322; Email: shreffl1@niehs.nih.gov


NIEHS Research Intensive Short Courses and Educational Opportunities (NIEHS RISE) (R25 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Environmental Health Sciences

**Deadline(s):** 11/29/2021; 11/28/2022; 11/29/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Amanda E. Garton, Sc.M., M.S.P.P.; National Institute of Environmental Health Sciences (NIEHS); Telephone: 984-287-3260; Email: amanda.garton@nih.gov

R2eport
Friday Newsletter 07/16/2021

Notice of Special Interest (NOSI): Stimulating Intervention Research to Reduce Cardiopulmonary Impacts of Particulate Matter in Air Pollution among High-Risk Populations

**Sponsor:** National Heart, Lung and Blood Institute; National Institute of Environmental Health Sciences

**Deadline(s):** 10/05/2020 (First Available Due Date); 09/08/2025 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Lawrence J. Fine, MD, DrPH; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-0305; Email: Lawrence.Fine@NIH.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-788.html

Notice of Participation of the Environmental Influences on Child Health Outcomes (ECHO) in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

**Sponsor:** National Institutes of Health

**Deadline(s):** Earliest start dates may vary by awarding IC. See the Urgent Guide Notices for any applicable Application Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.; 01/25/2022 (Expiration) for PA-18-935

**Contact:** Please direct all inquiries to: Manjit Hanspal, PhD; Environmental Influences on Child Health Outcomes (ECHO), Office of The Director, NIH (OD); Telephone: 301-435-5008; Email: manjit.hanspal@nih.gov


**Additional Information:** Related Announcements: PA-18-935 - Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

**Partnerships for Environmental Public Health (PEPH) Funding Opportunities**

**Sponsor:** https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm

**Deadline(s):** Please see piecemeal announcements on regularly updated page

**Contact:** https://www.niehs.nih.gov/research/supported/translational/peph/contactus/index.cfm

**Link(s):**
- https://www.niehs.nih.gov/research/supported/translational/peph/newsletter/2020/02/index.cfm#step4 [PEPH Newsletter, 02/2020, Funding Opportunities]
- https://www.niehs.nih.gov/research/supported/translational/peph/newsletter/2020/02/index.cfm [PEPH Newsletter, 02/2020]

**Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)**

**Sponsor:** National Institutes of Health (NIH); National Institute of Environmental Health Sciences (NIEHS)

**Deadline(s):** 12/02/2019; [monthly through] 10/03/2022; 10/04/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Martha I. Barnes, M.S.; National Institute of Environmental Health Sciences (NIEHS); Telephone: 984-207-3235; Email: barnes@niehs.nih.gov


**Superfund Hazardous Substance Research and Training**

**Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)**

**Current Limited Submission Opportunities, CU**

**Sponsor:** National Institute of Environmental Health Sciences

**Deadline(s):** 09/25/2020 (Limited Submission Deadline); 02/15/2021; 02/16/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Heather Henry, Ph.D; National Institute of Environmental Health Sciences (NIEHS); Telephone: 984-287-3268; Email: heather.henry@nih.gov [NIH/Sponsor Contact Provided for reference; this is a Limited Submission Opportunity];

Anyone who plans to submit a proposal to this program must send the information requested below to limitedsubmissions@columbia.edu by 9:00 a.m. on Friday, September 25. “NIH Superfund P42” should appear in subject line of the email, with items as stipulated below in our Additional Information section, submitted.

**Link(s):**
- https://research.columbia.edu/content/limitedsubmissions#table-6029 [current, Limited Submission opportunities, CU]

**Notice of Intent to Publish a Funding Opportunity Announcement for Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)**

**Sponsor:** National Institute of Environmental Health Sciences

**Deadline(s):** 02/15/2021 (First Estimated Application Date)
**Contact**: Please direct all inquiries to: Heather Henry, Ph.D.; National Institute of Environmental Health Sciences (NIEHS); 984-287-3268; heather.henry@nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-021.html

**ENVIRONMENTAL ISSUES**

**Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21)**

**Sponsor**: Participating Organization(s): National Institutes of Health (NIH); Components of Participating Organizations: National Institute of Environmental Health Sciences (NIEHS)

**Deadline(s)**: 10/03/2022; 10/04/2022 (Expiration) (RFA-ES-19-011)

**07/31/2019** (New Expiration Date for RFA-ES-16-005); per issuance of RFA-ES-19-011

**Contact**: Scientific/Research Contact(s): Martha I. Barnes, MS; National Institute of Environmental Health Sciences (NIEHS); Telephone: 984-287-3235; Email: barnes@niehs.nih.gov


**supplants**


**WATER QUALITY AND DROUGHT**

NA;

**IRVING INSTITUTE**

**Call for Applications: Irving Institute Pilot Awards**

**Sponsor**: Irving Institute

Please see individual Pilots

**Contact**: http://irvinginstitute.columbia.edu/people/contact.html

**Link(s)**: http://irvinginstitute.columbia.edu/research_ops/pilot_funding.html

**EXPLORATORY, SMALL GRANT, DEVELOPMENTAL AND PILOT PROJECTS**

**Pilot Services Research Grants Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)**

**Sponsor**: National Institute of Mental Health

**Deadline(s)**: 01/08/2022 (Expiration)

**Contact**: Scientific/Research Contact(s): Denise Juliano-Bult, M.S.W.; National Institute of Mental Health (NIMH); Telephone: 301-443-1638; Email: djuliano@mail.nih.gov


**ADDITIONAL INFORMATION REQUIRED FOR F GRANT APPLICATIONS**

**REMINDER & Clarification: New NIH Requirement for Fellowship Applications**

**Sponsor**: NIH;

**Deadline(s)**: Standard Dates;

**Contact**: Stephanie F. Scott, M.S., CRA; Communications and Outreach Director; Sponsored Projects Administration (SPA); Columbia University; Morningside Campus Ph: 212-854-0606; Medical Center (CUMC) Ph: 212-305-1641; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu;

**Link(s)**: NIH Notice of Clarification (F31s); NIH Notice of Clarification (F32s); NIH Notice of Clarification (Parent F31-Diversity); NIH Notice of Clarification (F30); FAQs for Fellowships; http://www.postdocs.columbia.edu/funding.html;

**Additional Information**: Just a reminder and a clarification of the new NIH requirement for fellowship applications (see original notice below). The new "Additional Educational Information" requirement also applies to the Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31 - Diversity) and the Individual Predoctoral MD/PhD or Other Dual-Doctoral Degree Fellowship (F30). I added these two programs, with links clarifying their instructions, to the list below. As always, if you have any questions regarding this new requirement, please contact your SPA Project Officer. Please forward this email to predoctoral and postdoctoral fellows whom you are aware are applying for these fellowships. Thank you;

Stephanie F. Scott, M.S., CRA; Communications and Outreach Director; Sponsored Projects Administration (SPA); Columbia University; Morningside Campus Ph: 212-854-0606; Medical Center (CUMC) Ph: 212-305-1641; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu; As the next NIH deadline for Predoctoral (F31) and Postdoctoral (F32) Fellowship applications approaches August 8th, I wanted to take this opportunity to remind applicants, their mentors, and administrators of the new "Additional Educational Information" document required in the applications. All applications lacking this attachment will be considered incomplete and will not proceed to review. Please refer to the following notices regarding this new requirement: (*) NIH Notice of Clarification (F31s); (*) NIH Notice of Clarification (F32s); (*) NIH Notice of Clarification (Parent F31-Diversity); (*) NIH Notice of Clarification (F30); (*) FAQs for Fellowships; Columbia University's Office of Postdoctoral Affairs (OPA) provides template language you can include in the "Additional Educational Information" document for F32s. This language can be obtained from the OPA website at http://www.postdocs.columbia.edu/funding.html; If you have any questions regarding this new requirement, please contact your SPA Project Officer.;

Prior Announcement: As the next NIH deadline for Predoctoral (F31) and Postdoctoral (F32) Fellowship applications approaches August 8th, I wanted to take this opportunity to
remind applicants, their mentors, and administrators of the new “Additional Educational Information” document required in the applications. All applications lacking this attachment will be considered incomplete and will not proceed to review. Please refer to the following notices regarding this new requirement: NIH Notice of Clarification (F31s); NIH Notice of Clarification (F32s); FAQs for Fellowships; Columbia University’s Office of Postdoctoral Affairs (OPA) provides template language you can include in the “Additional Educational Information” document for F32s. This language can be obtained from the OPA website at http://www.postdocs.columbia.edu/funding.html. If you have any questions regarding this new requirement, please contact your SPA Project Officer. Thank you, Stephanie F. Scott, M.S., CRA; Communications and Outreach Director; Sponsored Projects Administration (SPA); Columbia University; Morningside Campus Ph: 212-854-0666; Medical Center (CUMC) Ph: 212-305-1641; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/

FULBRIGHT
NA

AHRQ RESEARCH AND DISSEMINATION

AHRQ Encourages Use of Fast Healthcare Interoperability Resources (FHIR) Standard
Sponsor: Agency for Healthcare Research and Quality
Deadline(s): 09/09/2019 (Release Date)
Contact: Please direct all inquiries to: Lisa Scott-Morrin, MS, MSHS, CRA; Director, Division for Policy, Coordination and Analysis; Agency for Healthcare Research and Quality, HHS; Office of Extramural Research, Education, and Priority Populations; Email: Lisa.Scott-Morrin@ahrq.hhs.gov

AMERICAN HEART ASSOCIATION
NA

AMERICORPS
NA

NASA
NA

SERVICE AREA COMPETITIONS

COLUMBIA
Mailman School of Public Health
RESEARCH RESOURCES
mailman.columbia.edu/r2
Deadline(s): If you are planning to submit for the May 25th, 2020 deadline to the Parent T32, then you must use PA-20-142, in addition to using the latest data tables below; Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

Contact: Scientific / Research Contact(s); See: Table of IC-Specific Information, Requirements and Staff Contacts; [As soon as more information is available] from NIH it will be passed along; [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; sfs2110@cumc.columbia.edu; [also forwarded to our attention] by Carol Shreffler; Carol Shreffler, PhD; Program Officer; Exposure, Response, and Technology Branch; Division of Extramural Research and Training; Phone: 984-287-3322; Shreffl1@niehs.nih.gov

Link(s): https://grants.nih.gov/grants/guide/pa-files/PA-20-142.html

Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35)

Sponsor: National Institutes of Health; National Center for Complementary and Integrative Health; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Biomedical Imaging and Bioengineering; National Institute on Deafness and Other Communication Disorders; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Deadline(s): Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

Contact: Scientific/Research Contact(s);


UNDERGRADUATE, PREDOCTORAL, POSTDOCTORAL, POSTBACALAUREATE FELLOWSHIPS, INTERNSHIPS, TRAINING GRANTS

Notice of Intent to Publish a Funding Opportunity Announcement for Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34 Clinical Trial Not Allowed)

Sponsor: National Institute of General Medical Sciences

Deadline(s): 05/21/2020 (First Estimated Application Due Date)

Contact: Please direct all inquiries to: Anissa J. Brown, Ph.D.; National Institute of General Medical Sciences; 301-496-7301; Email: anissa.brown@nih.gov


Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

Sponsor: National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Deadline(s): Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

Contact: Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts

Link(s): https://grants.nih.gov/grants/guide/pa-files/PA-20-245.html

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)

Sponsor: National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Deadline(s): Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

Contact: Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts

Link(s): https://grants.nih.gov/grants/guide/pa-files/PA-20-245.html
Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** Standard dates; Standard AIDS dates; 08/09/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts


**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)**

**Sponsor:** National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts


**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)**

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts


**NIH Training Grant FAQs**

Preparing Your Training Grant Proposal – SPA Webinar

**Sponsor:** NIH, SPA

**Deadline(s):** Webinar updated 04/2020

**Contact:** [email](mailto:kenneth.gibbs@nih.gov) [kenneth.gibbs@nih.gov](mailto:kenneth.gibbs@nih.gov); [Website](https://grants.nih.gov/grants/guide/pa-files/PA-20-076.html); [NH Training Grant FAQs](https://grants.nih.gov/grants/guide/pa-files/PA-20-076.html)

Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program in the Neurosciences (T32 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Institute on Aging; National Institute on Drug Abuse; National Institute of Mental Health

**Deadline(s):** 05/26/2022; 05/26/2022 (Expiration)

**Contact:** [email](mailto:kenneth.gibbs@nih.gov) [kenneth.gibbs@nih.gov](mailto:kenneth.gibbs@nih.gov); Applicants should refer to the [JSPTPN](https://prc.columbia.edu/program-coordination-planning-and-strategic-initiatives) website for each IC’s scientific/research contact for this NRSA T32 program. Applicants should contact the Chair of the JSPTPN Steering Committee with questions about this FOA or the application itself.


Postbaccalaureate Research Education Program (R25 - Independent Clinical Trial Not Allowed)

**Sponsor:** National Institute of General Medical Sciences

**Deadline(s):** 01/27/2022; 01/28/2022 (Expiration)

**Contact:** [email](mailto:kenneth.gibbs@nih.gov) [kenneth.gibbs@nih.gov](mailto:kenneth.gibbs@nih.gov); Applicants should contact the Chair of the JSPTPN Steering Committee with questions about this FOA or the application itself.

Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34)

**Sponsor:** National Institute of General Medical Sciences  
**Deadline(s):** 05/22/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Anissa J. Brown, Ph.D.; National Institutes of General Medical Sciences (NIGMS); Email: anissa.brown@nih.gov  

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs  
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022  
**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts  
**Link(s):** https://grants.nih.gov/grants/guide/files/PAR-19-191.html

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute for Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs  
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022  
**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts  

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)

**Sponsor:** National Institutes of Health; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs  
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022  
**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts  
**Link(s):** https://grants.nih.gov/grants/guide/files/PAR-19-196.html

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development;
National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022

**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts


**Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)**

**Sponsor:** National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022

**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts


**Additional Information:** The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers.

**NIH released the Fellowship (F-series) Parent Announcements for proposals due on or after April 8th, 2018 with the FORMS-E packages**

**Sponsor:** NIH

**Deadline(s):** for due dates on or after 04/08/2018

**Contact:** please see individual announcements for contact(s)

**Link(s):** [https://grants.nih.gov/grants/how-to-apply-application-guide/forms-e/fellowship-forms-e.pdf](https://grants.nih.gov/grants/how-to-apply-application-guide/forms-e/fellowship-forms-e.pdf)

**Agency for Healthcare Research and Quality (AHRQ)-sponsored National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) Synopsis 1**

**Sponsor:** HHS; Department of Health and Human Services; Agency for Health Care Research and Quality

**Deadline(s):** 08/08/2022; 09/13/2022 (Archive)

**Contact:** Jerry Calderone AHRQ Referral Officer Phone 301-427-1548; Gerald.Calderone@ahrq.hhs.gov


**http://grants.nih.gov/grants/guide/notice-files/PA-17-481.html**

**Notice of Reissuance of Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral MD/PhD or Other Dual-Doctoral Degree Fellowship (Parent F30)**

**Sponsor:** National Institutes of Health;

**Deadline(s):** NA (Announcement of Reissuance);

**Contact:** Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Programs; Office of Extramural Research; Website: [https://researchtraining.nih.gov](https://researchtraining.nih.gov); Email: NIHTrain@mail.nih.gov;


**Lilly Fellowship Program in Neurosciences**

**Sponsor:** [www.lilly.com](http://www.lilly.com); brought to our attention via [www.trialect.com](http://www.trialect.com);

**Deadline(s):** The current call for preliminary research proposals is by invitation only. Invitations were sent to Deans at selected universities around the world. Interested applicants should contact their Dean for further information.; August 2016: Funding/research begins;

**Contact:** if you would like your institution to be considered for the LIFA program, please have your Dean contact the LIFA team at LIFA@lilly.com; Thanks, Trialect Support;

**Support:** [lilly.com](http://www.lilly.com);

**Link(s):** [http://www.lilly.com/research-development/innovation-starts/Pages/Lilly-Innovation-Fellowship-Award.aspx](http://www.lilly.com/research-development/innovation-starts/Pages/Lilly-Innovation-Fellowship-Award.aspx); [https://app.trialect.com/2660/display](https://app.trialect.com/2660/display);

**AHRQ Postdoctoral Fellowship Program;**

**Sponsor:** Center for Gerontology and Healthcare Research;

**Deadline(s):** Please see announcement;

**Contact:** Brown University; Box G-5121 (6); 121 S. Main Street; Providence, RI 02912; U.S.A.; Tel: 401-863-3211; Fax: 401-863-3489; E-mail: cgchr@brown.edu;

**Link(s):** [http://brown.edu/research/projects/gerontology-healthcare-research/fellowship-programs](http://brown.edu/research/projects/gerontology-healthcare-research/fellowship-programs);

**Program URL:** [http://brown.edu/research/projects/gerontology-healthcare-research/fellowship-programs/ahrq-post-doctoral-fellowship-program](http://brown.edu/research/projects/gerontology-healthcare-research/fellowship-programs/ahrq-post-doctoral-fellowship-program);

**Postdoctoral Fellowship Program**

**Sponsor:** Mage-Womens Research Institute (MWRI);

**Deadline(s):** 6/30 and 12/31 of each year;

**Contact:** Helen Gamrod; Postdoctoral Fellowship Program; 204 Craft Ave, Room B408; Pittsburgh, PA 15213; U.S.A.; Fax: 412-641-6156; E-mail: hgamrod@mwr.magee.edu;

**Link(s):** Web Site: [http://www.mwrif.org](http://www.mwrif.org); Program URL: [http://www.mwrif.org/21/postdoctoral-trainees](http://www.mwrif.org/21/postdoctoral-trainees);
NRSA Mental Health Postdoctoral Research Fellowship Program

Sponsor: Sheps (Cecil G) Center for Health Services Research;
Deadline(s): Receipt
Contact: Lindsay McCall, Training Program Director; 919-966-8628; lmccall@email.unc.edu;

NEW ITEMS FROM THE NIH

NIH-Investigators Reminder for NIH-Investigators: eRA Commons IDs and Complete Profiles;
Deadline(s): Starting in October 2014; 
Contact: Stephanie F. Scott, M.S., CRA; Communications and Outreach Director; Sponsored Projects Administration (SPA); Columbia University; Morningside Ph: 212-854-0606; CUMC Ph: 212-305-1641; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/;
Link(s): eRA Commons Manage Personal Profile;
http://era.nih.gov/rg_accounts/manage_personal_profile.cfm;
Additional Information: Complete Profiles Required for Students and Postdocs; As we get closer to October 2014, I wanted to remind investigators and administrators of the new NIH progress reporting requirement regarding eRA Commons IDs. Postdocs, graduate and undergraduate students supported on NIH awards must have eRA Commons IDs, with complete eRA Commons Personal Profiles. Beginning with NIH progress reports due October 2014, NIH will not accept progress reports that have missing eRA Commons IDs and incomplete profiles. As you are aware, if NIH rejects a progress report, that could delay issuance of the next year’s funding. Complete eRA Commons profiles are just as important as the ID itself. NIH can reject the progress report if the following fields are not complete in the profiles: date of birth, gender, race, ethnicity, disabilities, US citizenship status and country of citizenship. Some fields have “I Do Not Wish to Provide” as one of the acceptable responses. For those who have completed undergraduate or graduate degrees (graduate students and postdoctoral researchers), the highest educational degree, the degree date, and the institution where it was earned also should be completed. Tutorials on the eRA Commons Personal Profile can be found at eRA Commons Manage Personal Profile; If you have graduate and undergraduate students supported on NIH grants who do not have eRA Commons IDs, please have them request an eRA Commons account from SPA at SPA-eBiz@columbia.edu.

The Research Performance Progress Report (RPPR);
Sponsor: NIH;
Deadline(s): starting October 17, 2014;

Contact: Stephanie F. Scott, M.S., CRA; Communications and Outreach Director; Sponsored Projects Administration (SPA); Columbia University; Morningside Ph: 212-854-0606; CUMC Ph: 212-305-1641; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/;
Link(s): NOT-OD-13-097; NOT-OD-14-092; eRA Commons Manage Personal Profile;
Additional Information: The Research Performance Progress Report (RPPR) format will be required for all Type 5 non-SNAP progress reports beginning October 17th, 2014 (the paper PHS 2590 forms are being phased out). See NOT-OD-14-092. If you are not yet familiar with the RPPR format, resources are available at http://grants.nih.gov/grants/rppr/; Please share this information with your students and postdocs who are supported on NIH grants. If you have any questions, you may contact me, or your assigned SPA Project Officer.; Step; Stephanie F. Scott, M.S., CRA; Communications and Outreach Director; Sponsored Projects Administration (SPA); Columbia University; Morningside Campus Ph: 212-854-0606; Medical Center (CUMC) Ph: 212-305-1641; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/; This is a reminder that beginning October 2014, Research Performance Progress Reports (RPPRs) lacking an eRA Commons ID for graduate and undergraduate students will receive an error and the RPPR will not be accepted by the NIH without this information. RPPRs that are not accepted could delay issuance of Notice of Grant Awards. See full NIH notice at NOT-OD-13-097; Currently, warnings appear in the eRA Commons screens to alert individuals identified as undergraduate students, graduate students, and postdoctoral researchers that the following fields should be completed in their eRA Commons profiles: date of birth, gender, race, ethnicity, disabilities, US citizenship status and country of citizenship. Some fields have “I Do Not Wish to Provide” as one of the acceptable responses. For those who have completed undergraduate or graduate degrees (graduate students and postdoctoral researchers), the highest educational degree, the degree date, and the institution where it was earned also should be completed. Beginning on October 1, 2014, those fields in the eRA Commons screens will be required for individuals identified in any of those roles.; If you have graduate and undergraduate students supported on NIH grants who do not have eRA Commons IDs, please have them request an eRA Commons account from SPA at SPA-eBiz@columbia.edu. In addition, graduate and undergraduate students, and postdoctoral researchers should complete their Personal Profiles in the eRA Commons, ensuring all fields listed above are complete. Tutorials on the Personal Profile can be found at eRA Commons Manage Personal Profile; RPPRs will be required for all Type 5 non-SNAP progress reports beginning October 17th, 2014 (the paper PHS 2590 forms are being phased out). See NOT-OD-14-092. If you are not yet familiar with the RPPR format, resources are available at http://grants.nih.gov/grants/rppr/; Therefore, if you have students supported on non-SNAP awards, now is the time to ensure they have eRA Commons profiles completed.; Please share this information with your students and postdocs who are supported on non-SNAP awards.
Thank you, Stephanie F. Scott, M.S., CRA; Communications and Outreach Director; Sponsored Projects Administration (SPA); Columbia University; Morningside Ph: 212-854-0606; CUMC Ph: 212-305-1641; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/

NIH eSUBMISSION ITEMS OF INTEREST

NIH-Investigators Reminder-eRA Commons IDs and Complete Profiles Required for Students and Postdocs

This is a reminder that beginning October 2014, Research Performance Progress Reports (RPPRs) lacking an eRA Commons ID for graduate and undergraduate students will receive an error and the RPPR will not be accepted by the NIH without this information. RPPRs that are not accepted could delay issuance of Notice of Grant Awards. See full NIH notice at NOT-OD-13-097.

Currently, warnings appear in the eRA Commons screens to alert individuals identified as undergraduate students, graduate students, and postdoctoral researchers that the following fields should be completed in their eRA Commons profiles: date of birth, gender, race, ethnicity, disabilities, US citizenship status and country of citizenship. Some fields have “I Do Not Wish to Provide” as one of the acceptable responses. For those who have completed undergraduate or graduate degrees (graduate students and postdoctoral researchers), the highest educational degree, the degree date, and the institution where it was earned also should be completed. Beginning on October 1, 2014, those fields in the eRA Commons screens will be required for anyone identified in any of those categories.

If you have graduate and undergraduate students supported on NIH grants who do not have eRA Commons IDs, please have them request an eRA Commons account from SPA at SPA-eBiz@columbia.edu. In addition, graduate and undergraduate students, and postdoctoral researchers should complete their Personal Profiles in the eRA Commons, ensuring all fields listed above are complete. Tutorials on the Personal Profile can be found at eRA Commons Manage Personal Profile.

RPPRs will be required for all Type 5 non-SNAP progress reports beginning October 17th, 2014 (the paper PHS 2590 forms are being phased out). See NOT-OD-14-092. If you are not yet familiar with the RPPR format, resources are available at http://grants.nih.gov/grants/rppr/. Therefore, if you have students supported on non-SNAP awards, now is the time to ensure they have eRA Commons profiles completed. Please share this information with your students and postdocs who are supported on NIH grants. If you have any questions, you may contact me, or your assigned SPA Project Officer.

Thank you, Stephanie F. Scott, M.S., CRA; Communications and Outreach Director; Sponsored Projects Administration (SPA); Columbia University; Morningside Ph: 212-854-0606; CUMC Ph: 212-305-1641; Email: sfs2110@columbia.edu; Website: http://spa.columbia.edu/
NOT-OD-14-093, for the NIH transition to new U.S. Department of Health and Human Services (HHS) payment policies for domestic, non-competing continuation awards and use of Payment Management System (PMS) subaccounts. It also announces a change in how competitive revisions/administrative supplements (Type-3s) awards will be processed. This Notice only applies to domestic non-competing continuation awards that have not yet transitioned to PMS subaccounts. In response to critical feedback from the grantee community, NIH requested an amendment to its subaccount implementation plan to delay the transition of domestic, non-competing continuation awards to PMS subaccounts for an additional year; e.g., now beginning October 1, 2015. HHS’s Office of the Assistant Secretary for Financial Resources recently approved the request. This additional time is provided to allow grantees to prepare their systems to accommodate the changes. Grantees with inadequate systems in place to appropriately manage this transition by October 1, 2015, may be unable to appropriately access PMS accounts and risk losing their ability to draw down funding. Grantees are advised that there will be no additional implementation delays considered and no exceptions granted to the deadline. As of October 1, 2015, NIH will utilize only subaccounts for awarding grant funds. Every grant that is awarded funding in FY 2016 (whether it be in the first, second, third or fourth quarter of FY 2016) will be in a subaccount. NIH will continue transitioning payment of grant awards with new document numbers to domestic institutions to PMS subaccounts in FY 2015 as announced in Notice NOT-OD-13-120. The administrative changes announced in NOT-OD-14-093 will now apply to the transition that will occur between October 1, 2015 and September 30, 2016. This Notice reiterates those administrative changes for non-competing, continuation awards and highlights the revised implementation timelines and T-3 award process for all domestic awards. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-103.html#sthash.0l3doSVZ.dpuf; http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-103.html#sthash.q3dFkWY2.dpuf;

TRAVEL / CONFERENCE / MEETING SUPPORT

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

Sponsor: National Institutes of Health; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Deadline(s): Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

Contact: Scientific/Research Contact(s); Scientific/Research Contact information is listed in the table at R13 Contacts and Special Interest website.


FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)

Sponsor: Food and Drug Administration

Deadline(s): 10/12/2021; 04/12/2022; 10/11/2022; 10/12/2022 (Expiration)

Contact: Application Submission Contacts; eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues); Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact); Telephone: 301-402-7469 or 866-504-9552 (Toll Free); Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace); Contact Center Telephone: 800-518-4726; Email: support@grants.gov


FEDERAL FUNDING TRAVEL POLICY

NIH-Investigators New Policy on Fly America Act: Sponsored Projects Administration (SPA) and the Accounts Payable (AP) department is happy to announce the release of an updated version of the Fly America Act policy, effective immediately. SPA and AP have partnered together on this effort, resulting in a clearer, more comprehensive policy to ensure compliance with the Fly America Act. You can find the full policy in the Administrative Policy Library at: http://policylibrary.columbia.edu/fly-america-act. This link contains: * Full policy text, including links to resources; * FAQs; * A Decision Tree Diagram; * A new form, the Fly America Exception Checklist; These resources can also be found on the SPA website at:
The Fly America Act is a Federal regulation that states that any foreign air travel that is financed by Federal funds must be booked on U.S. Flag Air Carriers, regardless of cost or convenience. Only Federally funded sponsored projects are subject to this policy. The Fly America Act is not a new policy. Rather, our offices updated our existing policies, which now live in a central location in the Policy Library. There are specific exceptions to the Fly America Act that allow travelers to use Federal funds on foreign carriers, but only under certain circumstances. These exceptions can be quite complex to interpret. Therefore, our offices created a Fly America Exception Checklist and Decision Tree Diagram to assist travelers when booking flights internationally as part of the work to be done on a Federal sponsored project. In cases of exceptions, the Fly America Exception Checklist Form will need to accompany the Columbia Travel & Business Expense Report (TBER) to be submitted to AP. Appropriate back-up documentation should accompany the Checklist. The full policy and FAQs outline this process.

Anyone planning to travel internationally as part of work to be done on a Federally sponsored project is responsible for knowing and adhering to this policy. Please share this information with all faculty, administrators, postdocs and students who may be traveling internationally.

When questions arise that are related to the Fly America Act (for example, what is allowable vs. unallowable, Open Skies Agreement exceptions, etc.) you may contact your SPA Project Officer or myself. However, if you have specific questions about reimbursement of travel expenses or regarding your supporting travel documentation, you should contact AP through the Finance Service Center or call 212-854-2122. Thank you.

Thank you, Stephanie F. Scott, M.S., CRA; Communications and Outreach Director; Sponsored Projects; Administration (SPA); CUMC


US DEPARTMENT OF EDUCATION
NA

RESEARCH EXCHANGES
NA

TEAM HEALTHCARE AND COLLABORATIONS
NA

OUTSTANDING INVESTIGATOR
NA

SELF-ADVOCACY
NA

AWARDS / PRIZES

NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35 Clinical Trial Not Allowed)
Sponsor: National Institute of Dental and Craniofacial Research
Deadline(s): 07/26/2021; 07/27/2021 (Expiration)
Contact: Scientific/Research Contact(s); Lillian Shum, PhD; National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-594-0618; Email: ShumL@mail.nih.gov; For a list of frequently asked questions, please visit our FAQ page.

Institutional Research and Academic Career Development Awards (IRACDA) (K12 - Independent Clinical Trial Not Allowed)
Sponsor: National Institute of General Medical Sciences
Deadline(s): 10/01/2021; 10/02/2021 (Expiration)
Contact: Scientific/Research Contact(s); Mercedes Rubio, Ph.D.; National Institutes of General Medical Sciences (NIGMS); Email: mercedes.rubio@nih.gov

Maximizing Investigators’ Research Award (R35 - Clinical Trial Optional)
Sponsor: National Institute of General Medical Sciences
Deadline(s): 01/18/2022; 05/17/2022; 05/18/2022 (Expiration)
**PCORI Mandates Data Sharing by Most of its Awardees**

**Sponsor:** Patient-Centered Outcomes Research Institute (PCORI)

**Deadline(s):** 09/07/2018 (Release Date)

**Contact:** https://www.pcori.org/about-us/contact-us


https://www.pcori.org/news-release/pcori-board-approves-policy-researchers-share-their-research-data

---

**PCORI FUNDING OPPORTUNITIES**

**Sponsor:** http://www.pcori.org;

**Deadline(s):** Various; please see http://www.pcori.org/funding-opportunities;

**Contact:** info@pcori.org;

**Link(s):** http://www.pcori.org/funding-opportunities;

http://www.pcori.org/research-results/research-we-support;

http://www.pcori.org/program/cer-methods-and-infrastructure;

http://www.pcori.org/research-results/pcornet-national-patient-centered-clinical-research-network;

**PAY FOR SUCCESS**

Currently, NA

**MAXIMIZING INVESTIGATOR’S RESEARCH AWARD**

NA

**LIMITED COMPETITION, LIMITED SUBMISSION**

**Limited Submissions Communications Update**

**Sponsor:** Columbia | Research;

**Deadline(s):** NA

**Contact:** Please feel free to contact me if you have any questions or feedback.; Sincerely, Greg Culler; Associate Director | Research Initiatives; COLUMBIA | RESEARCH; Office of the Executive Vice President for Research; Columbia University in the City of New York; 409 Low Memorial Library, MC 4312; 535 West 116th Street; New York, New York 10027; Phone: 212-854-6285; Email: gregory.culler@columbia.edu;

Website: https://research.columbia.edu/content/limitedsubmissions#text-6026; limitedsubmissions@columbia.edu

**Link(s):** https://research.columbia.edu/content/limitedsubmissions#text-6026

**Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03)**

**Sponsor:** National Institute of Allergy and Infectious Diseases

**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2020 (Expiration)

**Contact:** Scientific/Research Contact(s): Shawn Drew Gaillard, Ph.D. (For questions regarding application instructions and overall process); Division of Extramural Activities (DEA); National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3857; Email: Shawn.Gaillard@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/PAR-17-439.html

Young Investigator Early Investor Early Career
**NIDCD Early Career Research (ECR) Award (R21 Clinical Trial Optional)**

**Sponsor:** National Institute on Deafness and Other Communication Disorders  

**Deadline(s):** 10/28/2021; 02/24/2022; 06/23/2022; 10/27/2022; 02/23/2023; 06/29/2023; 10/26/2023; 10/27/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); For general and eligibility questions, contact the Program Coordinator: Bracie Watson, Jr.; National Institute on Deafness and Other Communication Disorders (NIDCD)  

Telephone: 301-402-3458; Email: watsonb@nidcd.nih.gov


---

**Mental Health Research Awards for Investigators Early in their Career in Low and Middle-Income Countries (R01 Clinical Trial Optional)**

**Sponsor:** National Institute of Mental Health  

**Deadline(s):** 11/15/2021; 11/16/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); For dissemination and implementation research and services research: Andrea Horvath Marques, M.D., MPH, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-646-7320; Email: andrea.horvathmarques@nih.gov


---

**REPRODUCIBILITY, RIGOR AND TRANSPARENCY**

NA

---

**ETHICS / BIOETHICS**

**Ethical, Legal and Social Implications (ELSI) Funding Opportunity Announcements**


**Sponsor:** NIH  

**Deadline(s):** 10/19/2021; 02/17/2022; 06/17/2022; 10/19/2022; 02/17/2023; 06/19/2023; 07/20/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Joy Boyer; National Human Genome Research Institute (NHGRI); Telephone: 301-402-4997; Email: boyerj@mail.nih.gov


---

**LANGUAGE AND LITERACY**

NA

---

**Dissemination and Implementation Research in Health**

**Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders**

**Sponsor:** National Heart, Lung, and Blood Institute  

**Deadline(s):** 02/05/2021 (First Available Due Date); 01/08/2024 (Expiration Date)

Contact: Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: Scientific/Research Contact(s): For Clinical Trial PAIR Applications (that target PAR-19-274 Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)); Rebecca A. Roper, MS, MPH; Center for Translation Research and Implementation Science; National Heart, Lung and Blood Institute (NHLBI); Telephone: 301-496-1051; Email:Rebecca.Roper@nih.gov


NIAID ClinicalTrial Implementation Cooperative Agreement (U01 Clinical Trial Required)

Sponsor: National Institute of Allergy and Infectious Diseases

Deadline(s): 09/13/2021; 01/14/2022; 05/13/2022; 09/13/2022; 01/13/2023; 05/13/2023; 09/14/2023; 01/13/2024; 01/14/2024 (Expiration)

Contact: Scientific/Research Contact(s); Greg Deye, M.D.; Division of Microbiology and Infectious Diseases (DMID); National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3371; Email: gregory.deye@nih.gov


[1] Dissemination and Implementation Research in Health R01 Clinical Trial Optional

[2] Dissemination and Implementation Research in Health R21 Clinical Trial Optional

[3] Dissemination and Implementation Research in Health R03 Clinical Trial Not Allowed

Sponsor: National Institutes of Health (NIH); Components of Participating Organizations: National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Human Genome Research Institute (NHGRI); National Institute on Aging (NIA); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Deafness and Other Communication Disorders (NIDCD); National Institute of Dental and Craniofacial Research (NIDCR); National Institute on Drug Abuse (NIDA); National Institute of Environmental Health Sciences (NIEHS); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Nursing Research (NINR); National Institute on Minority Health and Health Disparities (NIMHD); National Center for Complementary and Integrative Health (NCCIH); All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP); Office of Behavioral and Social Sciences Research (OBSSR); Office of Research on Women’s Health (ORWH)

Deadline(s): Standard dates; Standard AIDS dates; 05/08/2022 (Expiration)

Contact: Scientific/Research Contact(s); Lindsey Ann Martin, Ph.D.; National Institute of Environmental Health Sciences (NIEHS); Phone: (984) 287-4036; Email: Lindsey.Martin@nih.gov


Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

Sponsor: NIH, DHHS; National Cancer Institute; National Center for Complementary and Integrative Health; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; Office of Behavioral and Social Science Research; Office of Disease Prevention; Office of Research on Women’s Health

Deadline(s): Standard dates; Standard AIDS dates; 05/08/2022 (Expiration)

Contact: Scientific/Research Contact(s); Gila Neta, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-6785; Email: gila.neta@nih.gov

Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-CA-19-078.html PAR-19-274 (R01 Clinical Trial Optional)

Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

**Sponsor:** NIH, DHHS; National Cancer Institute; John E. Fogarty International Center; National Center for Complementary and Integrative Health; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; Office of Behavioral and Social Science Research; Office of Disease Prevention; Office of Research on Women’s Health

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Gila Neta, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-6785; Email: gila.neta@nih.gov


**PAR-19-275** (R21 Clinical Trial Optional)

---

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)

**Sponsor:** National Institutes of Health; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** Due dates vary by awarding IC Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts


---

EDUCATION AND DIVERSITY

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Table of IC-Specific Information, Requirements, and Staff Contacts  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-251.html

**Notice of Intent to Publish a Funding Opportunity**  
**Announcement for Support for Research Excellence (SuRE)**  
**Sponsor:** National Institute of General Medical Sciences  
**Deadline(s):** 05/25/2021 (First Estimated Application Due Date)  
**Contact:** Please direct all inquiries to: Sydella Blatch, Ph.D.; National Institute of General Medical Sciences (NIGMS); 301-827-7323; sydella.blatch@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-003.html

**Notice of Intent to Publish a Funding Opportunity**  
**Announcement for Maximizing Access to Research Careers (T34 Clinical Trial Not Allowed)**  
**Sponsor:** National Institute of General Medical Sciences  
**Deadline(s):** 05/21/2021 (First Estimated Application Due Date)  
**Contact:** Please direct all inquiries to: Sydella Blatch, Ph.D.; National Institute of General Medical Sciences; sydella.blatch@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-005.html

**Notice of Intent to Publish a Funding Opportunity**  
**Announcement for Support for Research Excellence - First Independent Research Support & Transition (SuRE-First)**  
**Sponsor:** National Institute of General Medical Sciences  
**Deadline(s):** 09/25/2021 (First Estimated Application Due Date)  
**Contact:** Please direct all inquiries to: Irina N. Krasnova, Ph.D.; National Institute of General Medical Sciences (NIGMS); 301-827-7323; irina.krasnova@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-008.html

**Notice of Intent to Publish a Funding Opportunity**  
**Announcement for a National Resource Center for the Support for Research Excellence (SuRE) Program**  
**Sponsor:** National Institute of General Medical Sciences  
**Deadline(s):** 09/25/2021 (First Estimated Application Due Date)  
**Contact:** Please direct all inquiries to: Michele McGuirl, Ph.D.; National Institute of General Medical Sciences (NIGMS); 301-594-3555; michele.mcguirl@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-GM-21-009.html

**NIDDK Education Program Grants (R25 Clinical Trial Not Allowed)**  
**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases  
**Deadline(s):** 07/28/2021; 07/28/2022; 01/31/2023; 02/01/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); For Diabetes, Endocrinology, and Metabolic Diseases: Arthur Castle, Ph.D.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-594-7719; Email: castlea@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-21-034.html

**Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)**  
**Sponsor:** National Institute of Neurological Disorders and Stroke; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Mental Health; Office of Behavioral and Social Sciences Research; Office of Research on Women's Health  
**Deadline(s):** 11/15/2020 (Expiration Date)  
**Contact:** Eric M. Hudak, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1779; Email: eric.hudak@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NS-20-107.html
Reissue of Parent Research Supplements to Promote Diversity in Health-Related Research FOA in October 2020

**Sponsor:** National Institutes of Health  
**Deadline(s):** 09/10/2020 (Release Date)  
**Contact:** Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Research  
**Website:** [https://researchtraining.nih.gov](https://researchtraining.nih.gov); Email: NIHTrain@mail.nih.gov  

**Additional Information:** Related Announcements: NOT-OD-20-128 - Notice of Requirement for Electronic Submission of all Administrative Supplements; PA-20-222 - Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Notice of Intent to Publish a Funding Opportunity Announcement for NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Coordination and Evaluation Center (U54 Clinical Trial Not Allowed)

**Sponsor:** Office of Strategic Coordination (Common Fund)  
**Deadline(s):** 11/09/2020 (First Estimated Due Date)  
**Contact:** Rina Das, Ph.D.; National Institute on Minority Health and Health Disparities (NIMHD); 301-496-3996; FIRSTNIH@nih.gov  

Notice of Intent to Publish a Funding Opportunity Announcement for NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Not Allowed)

**Sponsor:** Office of Strategic Coordination (Common Fund)  
**Deadline(s):** 11/09/2020 (First Estimated Due Date)  
**Contact:** Please direct all inquiries to: Sanya Springfield, Ph.D.; National Cancer Institute (NCI); 240-276-6170; FIRSTNIH@nih.gov  

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Institute for Occupational Safety and Health; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs  
**Deadline(s):** Due dates vary by awarding IC; Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date; 05/08/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts  

NIH Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Institute of Mental Health  
**Deadline(s):** 09/27/2021; 09/26/2022; 09/27/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Michelle Jones-London, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-451-7966; Email: jonesmich@ninds.nih.gov  

Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25)

**Sponsor:** National Institute of Biomedical Imaging and Bioengineering  
**Deadline(s):** 06/24/2022; 06/25/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Zeynep Erim, Ph.D.; National Institute of Biomedical Imaging and Bioengineering (NIBIB); Telephone: (301) 451-4797; Email: erimz@mail.nih.gov  
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

**Sponsor:** John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs; National Institutes of Health

**Deadline(s):** Due dates vary by awarding IC Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date: 05/22/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); See Table of IC-Specific Information, Requirements and Staff Contacts

**Link(s):** [https://grants.nih.gov/grants/guide/pa-files/PA-20-166.html](https://grants.nih.gov/grants/guide/pa-files/PA-20-166.html)

NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)

**Sponsor:** National Institute of General Medical Sciences

**Deadline(s):** 07/13/2022; 07/14/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Tony Beck, Ph.D.; National Institute of General Medical Sciences (NIGMS);

**Email:** beck@nigms.nih.gov


**Additional Information:** Weekly NIH Funding Opportunities and Notices; Funding Opportunities

Support of Competitive Research (SCORE) Pilot Project Award (SC2 Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health (NIH); Components of Participating Organizations: National Institute of General Medical Sciences (NIGMS); National Institute on Aging (NIA); National Institute of Allergy and Infectious Diseases (NIAID); National Institute on Deafness and Other Communication Disorders (NIDCD); National Institute of Dental and Craniofacial Research (NIDCR); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Environmental Health Sciences (NIEHS); National Heart, Lung and Blood Institute (NHLBI); National Institute on Drug Abuse (NIDA); National Human Genome Research Institute (NHGRI)

**Deadline(s):** 09/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Albert Avila, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-496-8804; Email: aavila@nida.nih.gov

**Link(s):** [https://grants.nih.gov/grants/guide/par-040.html](https://grants.nih.gov/grants/guide/par-040.html)

Support of Competitive Research (SCORE) Research Advancement Award (SC1 Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health (NIH); Components of Participating Organizations: National Institute of General Medical Sciences (NIGMS); National Institute on Aging (NIA); National Institute of Allergy and Infectious Diseases (NIAID); National Institute on Deafness and Other Communication Disorders (NIDCD); National Institute of Dental and Craniofacial Research (NIDCR); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Environmental Health Sciences (NIEHS); National Heart, Lung and Blood Institute (NHLBI); National Institute on Drug Abuse (NIDA); National Human Genome Research Institute (NHGRI)

**Deadline(s):** 09/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Albert Avila, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-496-8804; Email: aavila@nida.nih.gov

**Link(s):** [https://grants.nih.gov/grants/guide/par-039.html](https://grants.nih.gov/grants/guide/par-039.html)

NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)

**Sponsor:** National Institute on Minority Health and Health Disparities

**Deadline(s):** Standard dates; Standard AIDS dates ; 06/17/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Please use the links below to identify Scientific/Research contacts for NIMHD's three research interest areas: Community Health and Population Sciences; Clinical and Health Services Research; Integrative Biological and Behavioral Sciences
Additional Information: NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.

Notice of NIDA Participation in PAR-20-039, Support of Competitive Research (SCORE) Research Advancement Award (SC1 Clinical Trial Not Allowed)

**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 05/25/2022; 09/08/2022 (Expiration)  
**Contact:** Please direct all inquiries to: Albert Avila, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-496-8804; Email: aavila@nida.nih.gov


Notice of NIDA Participation in PAR-20-040, Support of Competitive Research (SCORE) Pilot Project Award (SC2 Clinical Trial Not Allowed)

**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 05/25/2022; 09/08/2022 (Expiration)  
**Contact:** Please direct all inquiries to: Albert Avila, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-496-8804; Email: aavila@nida.nih.gov


Notice of Intent to Publish a Funding Opportunity Announcement for Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00)

**Sponsor:** National Institute of General Medical Sciences  
**Deadline(s):** 02/12/2020 (First estimated due date)  
**Contact:** Please direct all inquiries to: Alison Gammie, Ph.D.; National Institute of General Medical Sciences (NIGMS); 301-594-3900; alison.gammie@nih.gov


Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)

**Sponsor:** Office of Disease Prevention; National Cancer Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute on Minority Health and Health Disparities

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Dionne C. Godette, PhD; Office of Disease Prevention (ODP)  
Telephone: 301-480-1161; Email: dionne.godette@nih.gov


Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health; John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** Due dates vary by awarding IC. See Table of IC-Specific Information.

**Contact:** Submission dates vary by awarding IC. See Table of IC-Specific Information. Requirements and Staff Contacts for more details; [https://grants.nih.gov/grants/guide/contacts/Diversity-Supp_contacts.html](https://grants.nih.gov/grants/guide/contacts/Diversity-Supp_contacts.html)


Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed)

**Sponsor:** Office of the Director, NIH; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Biomedical Imaging
and Bioengineering; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of General Medical Sciences; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research

**Deadline(s):** Applications are accepted on a rolling basis at any time starting 30 days after the Open Date until the expiration date; 09/05/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Michael Weingarten, MA; National Cancer Institute (NCI); Telephone: 240-276-5238; Email: weingartenm@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-18-837.html

---

**Revised: Notice of NIH’s Interest in Diversity**

**Sponsor:** National Institutes of Health

**Deadline(s):** 01/25/2018 (Release Date)

**Contact:** Please direct all inquiries to: Division of Biomedical Research Workforce; Office of Extramural Research

**Website:** https://researchtraining.nih.gov ; Email: NIHTrain@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-129.html

---

**Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)**

**Sponsor:** National Institutes of Health; John E. Fogarty International Center; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs; The Common Fund/Office of Strategic Coordination

**Deadline(s):** Due dates vary by awarding IC. See Table of IC-Specific Information, Requirements and Staff Contacts for more details.; 09/08/2021 (Expiration); 10/13/2021 (Archive)

**Contact:** Due dates vary by awarding IC. See Table of IC-Specific Information, Requirements and Staff Contacts for more details.

---

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-18-586.html

---

**Notice of Intent to Publish a Funding Opportunity Announcement for Diversity Program Consortium Dissemination and Translation Awards (U01 - Clinical Trial Not Allowed)**

**Sponsor:** NIH Roadmap Initiatives

**Deadline(s):** 01/15/2020 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Alison Gammie, Ph.D.; National Institute of General Medical Sciences 301-594-3900; alison.gammie@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notic-files/NOT-RM-18-007.html

---

**Education and Health: New Frontiers (R21)**

**Sponsor:** Department of Health and Human Services; National Institutes of Health (NIH); National Cancer Institute (NCI); National Institute on Aging (NIA); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); Division of Program Coordination, Planning and Strategic Initiatives, Office of Behavioral and Social Sciences Research (OBSSR)

**Deadline(s):** Standard dates: 01/08/2019 (Expiration)

**Contact:** Scientific/Research Contact(s): Michael Spittel, PhD; Office of Behavioral and Social Sciences Research (OBSSR); Telephone: 301-496-1428; Email: spittelm@mail.nih.gov; OBSSR does not award grants. Please contact one of the IC program contacts listed below for questions regarding funding interest; e.g.: Georgeanne Patmios, PhD; National Institute on Aging (NIA); Telephone: 301-496-3138; Email: georganne_patmios@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-16-078.html

---

**INSTITUTIONAL DEVELOPMENT AWARD**

NA

**VOICE DISORDERS**

NA

**TUBERCULOSIS TB AND ITS PREVENTION**

NA

**NEW INNOVATOR AWARD**
Notice of Special Interest (NOSI): NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training (Admin Supp Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 04/01/2021 (First Available Due Date); 04/02/2023 (Expiration)  
**Contact:** Mark Chavez, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-8942; Email: mchavez1@NIMH.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-19-040.html

NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 06/20/2022; 06/21/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Eric R. Murphy, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-9230; Email: eric.murphy@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-525.html

NCMRR Early Career Research Award (R03 Clinical Trial Optional)

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development  
**Deadline(s):** 03/30/2022; 04/01/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Theresa Hayes Cruz, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-496-9233; Email: cruzth@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-20-042.html

Notice of Intent to Publish a Funding Opportunity Announcement for Maximizing Investigators Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional)

**Sponsor:** National Institute of General Medical Sciences  
**Deadline(s):** 10/05/2020 (First Estimated Due Date); 09/08/2022 (Expiration Date)  
**Contact:** Michele McGuirl, Ph.D.; National Institutes of General Medical Sciences (NIGMS); michele.mcguirl@nih.gov  

NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Dental and Craniofacial Research  
**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); R. Dwayne Lunsford, PhD; National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-827-4635; Email: lunsfordr@nidcr.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-19-370.html

**SERIOUS ADVERSE DRUG REACTIONS**

POISON CENTER

NA

**SUBSTANCE USE DISORDERS, OPIOIDS AND ADDICTION**

Notice of Special Interest (NOSI): High-Priority Interest to Enhance Data Science Research Training in Addiction Research

**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 03/08/2021 (First Available Due Date); 12/09/2024 (Expiration Date)  
**Contact:** Scientific/Research Contact(s); Susan Wright, PhD; Program Director for Big Data and Computational Science; National Institute on Drug Abuse (NIDA); Telephone: 301-402-6683; Email: susan.wright@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-013.html

Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders

**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 05/07/2021 (First Available Due Date); 09/08/2024 (Expiration Date)  
**Contact:** Raul Mandler, MD; National Institute on Drug Abuse (NIDA); Telephone: 301-480-2541; Email: mandler@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-019.html

Notice of Intent to Publish a Funding Opportunity Announcement for Specialized Alcohol Research Centers (P50 Clinical Trial Optional)

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 11/15/2021 (First Estimated Application Due Date)
**Notice of Intent to Publish a Funding Opportunity Announcement for Comprehensive Alcohol Research Centers (P60 Clinical Trial Optional)**

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 11/15/2021 (First Estimated Application Due Date)  
**Contact:** Abraham P. Bautista, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); 301-443-9737; bautista@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AA-21-004.html

**Notice of Special Interest: Alcohol-induced Tissue-specific and Organ System Diseases (R01/R21/R03)**

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 02/05/2021 (First Available Due Date); 05/08/2024 (Expiration Date)  
**Contact:** Scientific/Research Contact(s); Li Lin; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-827-7749; Email: linli@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AA-20-024.html

**Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)**

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 10/19/2021; 02/17/2022; 11/15/2021; 07/19/2022; 11/15/2022; 07/19/2023; 11/16/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Lori Ducharme, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-827-6331; Email: ducharme@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AA-21-097.html

**Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)**

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 07/19/2021; 11/15/2021; 07/19/2022; 11/15/2022; 07/19/2023; 11/16/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Preclinical Studies and Medical Care; William Dunty, PhD; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-443-7351; Email: duntyw@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AA-21-098.html

**Notice of Special Interest: Advances in Research for the Treatment, Services, and Recovery of Alcohol Use Disorder**

**Sponsor:** National Institute on Drug Abuse and Alcoholism  
**Deadline(s):** 01/05/2021; 11/15/2021 (First Available Due Date); 09/08/2023 (Expiration Date)  
**Contact:** Scientific/Research Contact(s); Brett T. Hagman, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Division of Treatment and Recovery Research (DTRR); Telephone: 301-443-0638; Email: brett.hagman@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AA-20-022.html

**Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)**

**Sponsor:** National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 07/19/2021; 11/15/2021; 07/19/2022; 11/15/2022; 07/19/2023; 11/16/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Lori Ducharme, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-827-6331; Email: ducharme@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/PAR-21-022.html

**Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional)**

**Sponsor:** National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 07/19/2021; 11/15/2021; 07/19/2022; 11/15/2022; 07/19/2023; 11/16/2023 (Expiration)
Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)

**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 09/02/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Ivan D. Montoya, M.D., M.P.H.; National Institute on Drug Abuse (NIDA); Telephone: 301-827-5936; Email: imontoya@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-001.html

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)

**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 10/19/2021; 10/19/2022; 10/20/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Jonathan D. Pollock, Ph.D.; National Institute on Drug Abuse; Telephone: 301-435-1309; Email: jpollock@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-013.html

Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Eye Institute; National Heart, Lung and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Mental Health; Office of Behavioral and Social Sciences Research; Office of Research on Women’s Health

**Deadline(s):** 11/15/2020 (First Available Due Date); 05/15/2024 (Expiration Date)  
**Contact:** Eric M. Hudak, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1779; Email: eric.hudak@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NS-20-107.html

Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists (R25 Clinical Trials Not Allowed)

**Sponsor:** National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 08/10/2021; 11/15/2021; 03/15/2022; 08/10/2022; 11/15/2022; 03/15/2023; 08/10/2023; 11/15/2023; 11/16/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Albert Avila, PhD; National Institute on Drug Abuse (NIDA); Telephone: 301-496-8804; Email: aavila@nida.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-019.html

Notice of Intent to Publish a Funding Opportunity Announcement for Improving Health Disparities in Alcohol Health Services (R01 Clinical Trial Optional)

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 03/15/2021 (First Estimated Application Due Date)  
**Contact:** Scientific/Research Contact: Laura E. Kwako, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-451-8507; Email: laura.kwako@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AA-20-023.html

Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)

**Sponsor:** National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute on Drug Abuse  
**Deadline(s):** 03/15/2021 (First Estimated Application Due Date)  
**Contact:** Please direct all inquiries to: Michael C. Freed, Ph.D., EMT; National Institute of Mental Health; 301-443-3747; michael.freed@nih.gov  
**Link(s):**
**Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24) (Clinical Trial Optional)**

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 05/26/2021; 05/27/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Mark Egli, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-594-6382; Email: megli@mail.nih.gov  

**Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia (U01 Clinical Trial Optional)**

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 05/26/2021; 05/27/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Mark Egli, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-594-6382; Email: megli@mail.nih.gov  

**Notice of Intent to Publish a HEAL Funding Opportunity Announcement for Consortium on Co-managing Chronic Pain and Opioid Use Disorder (C3PO) (RM1)**

**Sponsor:** National Institute on Drug Abuse; National Center for Complementary and Integrative Health; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases  
**Deadline(s):** 01/04/2021 (Estimated First Application Due Date)  
**Contact:** Please direct all inquiries to: Shelley Su, Ph.D.; National Institute on Drug Abuse; 301-402-3869; C3PO_R2D2@nih.gov  

**Notice of Intent to Publish a HEAL Funding Opportunity Announcement for Research on Related DSM-5 Diagnoses (R2D2) Coordination and Dissemination Center**

**Sponsor:** National Institute on Drug Abuse; National Center for Complementary and Integrative Health; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases  
**Deadline(s):** 01/04/2021 (Estimated First Application Due Date)  
**Contact:** Please direct all inquiries to: Shelley Su, Ph.D.; National Institute on Drug Abuse; 301-402-3869; C3PO_R2D2@nih.gov  

**Notice of Special Interest: Secondary Analyses of Existing Alcohol Research Data**

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 10/05/2020 (First Available Due Date); 09/05/2023 (Expiration Date)  
**Contact:** Scientific/Research Contact(s); Wexing Zha, Ph.D. (Methodology, Measurement and Epidemiology); National Institute on Alcohol Abuse and Alcoholism (NIAAA/DEPR); Telephone: 301-443-0633; Email: zhaw@mail.nih.gov  

**Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)**

**Sponsor:** National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** 08/10/2021; 12/14/2021; 08/10/2022; 12/14/2022; 08/10/2023; 08/11/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Kevin Walton, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-827-5980; Email: kevin.walton@nih.gov  

**NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)**

**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 09/27/2021; 09/26/2022; 11/18/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Kevin Walton, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-8270-5980; Email: Kevin.Walton@nih.gov  
**Additional Information:** Reissue of PAR-18-225
Notice of Special Interest: Epidemiology and Prevention in Alcohol Research

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism

**Deadline(s):** 10/05/2020 (First Available Due Date); 09/08/2023 (Expiration Date)

**Contact:** Please direct all inquiries to: Abraham P. Bautista, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Email: bautista@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/files/NOT-DA-20-058.html

Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 10/05/2020 (First Available Due Date); 01/08/2024 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Evan S. Hermann, PhD; National Institute on Drug Abuse (NIDA); Email: evan.hermann@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/files/NOT-DA-20-058.html

**Additional Information:** Related Announcements: PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed); PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required); PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed); PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 08/02/2021; 11/15/2021; 03/01/2022; 08/02/2022; 11/15/2022; 03/01/2023; 08/02/2023; 11/15/2023; 11/16/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Aria Davis Crump, Sc.D.; National Institute on Drug Abuse (NIDA); Division of Epidemiology, Services and Prevention Research; Telephone: 301-435-0881; Email: acrump@nida.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/files/PAR-20-249.html

---

Notice of Intent to Publish a Funding Opportunity Announcement for INIA Research Project (U01 Clinical Trial Optional)

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism

**Deadline(s):** 05/18/2021 (First Anticipated Application Due Date)

**Contact:** Please direct all inquiries to: Jonathan D. Pollock, Ph.D.; National Institute on Drug Abuse; Telephone: 301-435-1309; Email: jpollock@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/files/NOT-AA-20-016.html

**Additional Information:** Related Announcements: NOT-AA-20-14 - Notice of Intent to Publish a Funding Opportunity Announcement for INIA Administrative Resource (U24 Clinical Trial Not Allowed); NOT-AA-20-15 - Notice of Intent to Publish a Funding Opportunity Announcement for INIA Research Resource (U24 Clinical Trial Not Allowed)

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 10/19/2021; 10/19/2022; 10/20/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Matthew Shire, Ph.D.; National Institute on Drug Abuse; Telephone: 301-435-1309; Email: mshire@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/files/PAR-20-225.html

**Notice of Special Interest (NOSI): Research on Co-morbid Substance Use, Substance Use Disorders, and Other Psychiatric Disorders**

**Sponsor:** National Institute on Drug Abuse; Office of Research on Women’s Health

**Deadline(s):** 10/05/2020 (First Available Due Date); 05/08/2023 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Amy B. Goldstein, PhD; National Institute on Drug Abuse; Office of Research on Women’s Health; Telephone: 301-435-1309; Email: aggoldstein@nida.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/files/NOT-DA-20-004.html

Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 08/13/2021; 08/15/2022; 08/16/2022 (Expiration)

---

Columbia Mailman School of Public Health
Research Resources
mailman.columbia.edu/re2
Notice of Special Interest (NOSI): Advancing Research on Substance Use Disorders Through Computational Neuroscience

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 10/08/2021; 10/09/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Redonna Chandler, PhD; National Institute on Drug Abuse (NIDA); Telephone: 301-402-1919; Email: redonna.chandler@nih.gov


**Additional Information:** Note: COVID-19 research related to substance abuse and substance use disorders is within scope of this FOA.

Notice of Special Interest (NOSI): SUD through Computational Neuroscience

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 06/05/2020 (First Available Due Date); 09/08/2023 (Expiration Date)

**Contact:** Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.; Scientific/Research Contact(s); Shelley Su, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-402-3869; Email: shelley.su@nih.gov


Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)

**Sponsor:** National Institute on Drug Abuse; National Cancer Institute

**Deadline(s):** 10/08/2021; 10/09/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Kelly D. Blake, Sc.D.; National Cancer Institute; Telephone: 240-281-5934; Email: kelly.blake@nih.gov


**Additional Information:** Note: COVID-19 research related to substance abuse and substance use disorders is within scope of this FOA.

Notice of Special Interest (NOSI): Cannabis, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** 06/05/2020 (First Available Due Date); 09/08/2023 (Expiration Date)

**Contact:** Please direct all inquiries to: Hemin Chin, Ph.D.; Shelley Su, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-402-3869; Email: shelley.su@nih.gov


NIDA Small Research Grant Program (R03 Clinical Trial Required)

**Sponsor:** National Institute on Drug Abuse

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Katrina L Foster, PhD; National Institute on Drug Abuse (NIDA); Division of Therapeutics and Medical Consequences; Telephone: 301-827-5815; Email: fosterkl@nih.gov


Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Partnership between on Alcohol Research Centers and Institutions serving Underserved Communities and Populations (US4 Clinical Trial Optional)

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism

**Deadline(s):** 10/07/2020 (First Estimated Application Due Date): October 07, 2020

**Contact:** Please direct all inquiries to: Hemin Chin, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); 301-443-1282; hchin@mail.nih.gov


Notice of Special Interest (NOSI): Neuroimmune Signaling and Function in Substance Use Disorders

**Sponsor:** National Institute on Drug Abuse

Deadline(s): 06/05/2020 (First Available Due Date); 09/08/2023 (Expiration Date)
Contact: Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements; Scientific/Research Contact(s): Roger G Sorensen, Ph.D., MPA; National Institute on Drug Abuse (NIDA); Email: rsorensen@nida.nih.gov

Notice of Special Interest (NOSI): Sleep and Substance Use Disorders
Sponsor: National Institute on Drug Abuse
Deadline(s): 06/06/2020 (First Available Due Date); 09/08/2023 (Expiration)
Contact: Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements; Scientific/Research Contact(s): Steven Grant, PhD; National Institute on Drug Abuse (NIDA); Telephone: (301) 444-8869; Email: sgrant@nida.nih.gov

Notice of Special Interest (NOSI): Research Training and Career Development Awards to Support Individuals Pursuing Research Focused on Developing Treatments for Substance Use Disorders and the Associated Medical Consequences of these Disorders
Sponsor: National Institute on Drug Abuse
Deadline(s): 06/12/2020 (First Available Due Date); 09/08/2023 (Expiration)
Contact: Please direct all inquiries to: Guifang Lao, MD, PhD; National Institute on Drug Abuse (NIDA); Telephone: 301-827-5931; Email: laog@mail.nih.gov.
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-037.html

NIH HEAL Initiative Announcements
Sponsor: https://heal.nih.gov/about/research-plan
Deadline(s): please see piecemeal funding announcements on open funding page; https://heal.nih.gov/funding/open
Contact: healquestion@od.nih.gov
Link(s): https://heal.nih.gov/funding/open

Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
Sponsor: National Institute on Drug Abuse
Deadline(s): 09/02/2022 (Expiration)
Contact: Scientific/Research Contact(s): Ivan D. Montoya, M.D., M.P.H.; National Institute on Drug Abuse (NIDA); Telephone: 301-827-5936; Email: imontoya@mail.nih.gov

Notice of Special Interest (NOSI): Preclinical and Clinical Studies of the Interactions of Opioids and Stimulants
Sponsor: National Institute on Drug Abuse
Deadline(s): 06/05/2023 (Expiration)
Contact: Scientific/Research Contact(s); Nathan M. Appel, Ph.D.; National Institute on Drug Abuse / Division of Therapeutics and Medical Consequences; Telephone: 301-827-5918; Email: nappel@nih.gov

Notice of Special Interest (NOSI): Modeling Social Contagion of Substance Use Epidemics
Sponsor: National Institute on Drug Abuse
Deadline(s): 01/08/2023 (Expiration)
Contact: Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: Scientific/Research Contact(s); Susan Wright, PhD; National Institute on Drug Abuse (NIDA); Telephone: (301) 402-6683; Email: susan.wright@nih.gov

Notice of Intent to Publish a Funding Opportunity Announcement Re-issuance for HEAL Initiative: Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) (UG3/UH3, Clinical Trials Optional)
Sponsor: National Center for Complementary and Integrative Health; National Center for Advancing Translational Sciences; Office of Behavioral and Social Sciences Research
Deadline(s): 03/30/2020 (First Estimated Due Date)
Contact: Please direct all inquiries to: Wendy Weber, N.D., Ph.D., M.P.H.; National Center for Complementary and Integrative Health (NCCIH); 301-402-1272; webervj@mail.nih.gov
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-AT-20-005.html
Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)
**Sponsor:** National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2021 (Expiration)
**Contact:** Scientific/Research Contact(s); Marsha F. Lopez, Ph.D., M.H.S.; National Institute on Drug Abuse (NIDA); Telephone: 301-443-6504; Email: marsha.lopez@nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-19-041.html [*]

Notice of Special Interest (NOSI): The Application of Big Data Analytics to Drug Abuse Research
**Sponsor:** National Institute on Drug Abuse
**Deadline(s):** 10/05/2019 (First Available Due Date); 09/08/2022 (Expiration)
**Contact:** Please direct all inquiries to: Susan Wright, PhD; National Institute on Drug Abuse (NIDA); Telephone: (301) 402-6683; Email: susan.wright@nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-19-038.html

Notice of Special Interest (NOSI): Gene-Environment Interplay in Substance Use Disorders (R01, R21)
**Sponsor:** National Institute on Drug Abuse
**Deadline(s):** 10/05/2019 (First Available Due Date); 09/08/2022 (Expiration)
**Contact:** Please direct all inquiries to: Naimah Weinberg, M.D.; National Institute on Drug Abuse (NIDA); Telephone: (301) 443-6504; Email: nweinber@nida.nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-19-038.html

Mechanisms of Tolerance (R21/R33 - Clinical Trial Required)
**Sponsor:** National Institute on Alcohol Abuse and Alcoholism
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)
**Contact:** Scientific/Research Contact(s); Elizabeth M Powell, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-443-0786; Email: elizabeth.powell3@nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-19-036.html

Behavioral Science Track Award for Rapid Transition (B/Start/R03 Clinical Trial Optional)
**Sponsor:** National Institute on Drug Abuse
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)
**Contact:** Scientific/Research Contact(s); Jonathan D. Pollock, Ph.D.; National Institute on Drug Abuse; Telephone: 301-435-1309; Email: jpollock@mail.nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-19-223.html

Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R01/R33 Clinical Trial Not Allowed)

**Additional Information:** This Funding Opportunity from the National Institute on Drug Abuse (NIDA) will use a NIH Small Research Grant (R03) award mechanism to support studies that apply affective, cognitive and behavioral science approaches to research questions relevant to substance use disorders (SUD).
**Friday Newsletter 07/16/2021**

**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 12/18/2020; 06/24/2021; 12/17/2021; 12/18/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s): John Satterlee Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-435-1020; Email: satterlee@nida.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/files/PAR-19-278.html

**NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)**  
**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 09/25/2021; 01/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s): Kevin Walton, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-435-0762; Email: kevin.walton@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/files/PA-19-259.html

**NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)**  
**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 07/22/2021; 09/08/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s): Belinda E. Sims, Ph.D.; Division of Epidemiology, Services and Prevention Research; National Institute on Drug Abuse (NIDA); Telephone: 301-402-1533; Email: bsims@nida.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/files/PAR-19-258.html

**NIDA Division of Neuroscience and Behavior Will Give High Programmatic Priority to Opioid Related Basic Research**  
**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 06/25/2018 (Release Date)  
**Contact:** Please direct all inquiries to: Roger Little, Ph.D.; National Institute on Drug Abuse; Telephone: 301-435-1316; Email: Roger.Little@nih.gov  

**Notice of Added Research Goals for RFA-DA-19-005 “Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment (R61/R33 Clinical Trial Required)”**  
**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 09/04/2018 (Release Date)  
**Contact:** Please direct all inquiries to: Sarah Q. Duffy, Ph.D.; National Institute on Drug Abuse (NIDA)  
Telephone: 301-451-4998; Email: duffys@nida.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/files/NOT-DA-18-037.html

**Genetics of Alcohol Sensitivity and Tolerance (R01 Clinical Trial Not Allowed)**  
**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2021  
**Contact:** Scientific/Research Contact(s): Hemin R. Chin, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-443-1282; Email: chinhh@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/files/PA-19-660.html

**Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Not Allowed)**  
**Sponsor:** National Institute on Alcohol Abuse and Alcoholism  
**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2021  
**Contact:** Scientific/Research Contact(s): Elizabeth M Powell, PhD; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-443-0786; Email: elizabeth.powell3@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/files/PA-18-659.html

**Notice of Interest in Advancing Research about the Effects of Opioids and Opioid Antagonists on the Fetal and Neonatal Brain Development**  
**Sponsor:** National Institute on Drug Abuse; Eunice Kennedy Shriver National Institute of Child Health and Human Development  
**Deadline(s):** 02/12/2018 (Release Date)  
**Contact:** Please direct all inquiries to: Da-Yu Wu, PhD; National Institute on Drug Abuse; Telephone: 301-435-4649  
Email: wudy@nida.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/files/NOT-DA-17-067.html

**CENTER CORE, PROGRAM PROJECT AND P GRANTS**  
NA

**PATIENT SAFETY**

**Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R01 - Clinical Trial Optional)**  
**Sponsor:** National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)  
**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s): Marion Kosos-Thomas, MD, MPH; Eunice Kennedy Shriver National Institute of Child and Human Development (NICHD); Telephone: 301-435-6873; Email: kosomari@mail.nih.gov
Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)
Agency for Healthcare Research and Quality
**Deadline(s):** Standard dates; 10/31/2021 (Expiration)
**Contact:** Scientific/Research Contact(s); Direct your questions about general FOA issues, including information on the inclusion of priority populations to: James Cleeman, MD; Agency for Healthcare Research and Quality; Center for Quality Improvement and Patient Safety; Division of Healthcare-Associated Infections; Telephone: (301) 427-1330; E-mail: james.cleeman@ahrq.hhs.gov
**Link(s):** http://grants.nih.gov/grants/guide/pa-files/PA-16-423.html

COLUMBIA TECHNOLOGY VENTURES (CTV)

Columbia Technology Ventures (CTV) Opportunities and News
**Sponsor:** Columbia Technology Ventures (CTV); https://techventures.columbia.edu/
**Deadline(s):** please see individual opportunities
**Contact:** https://techventures.columbia.edu/contact; techventures@columbia.edu
**Link(s):** https://techventures.columbia.edu/

NATURAL PRODUCTS

Pilot Projects Increasing the Impact of the NIH Centers for Advancing Research on Botanicals and Other Natural Products (PI2 CARBON) (R03 Clinical Trials Not Allowed)
**Sponsor:** Office of Dietary Supplements; National Center for Complementary and Integrative Health
**Deadline(s):** 02/01/2022; 09/30/2022; 10/15/2022 (Expiration)
**Contact:** Scientific/Research Contact(s); Barbara C. Sorkin, Ph.D.; Office of Dietary Supplements (ODS); Telephone: 301-435-3605; Email: orkinb@mail.nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-20-228.html

Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)
**Sponsor:** National Center for Complementary and Integrative Health
**Deadline(s):** 10/01/2021; 06/01/2022; 02/01/2023; 05/08/2023 (Expiration)
**Contact:** Scientific/Research Contact(s); Wendy Weber, ND, Ph.D, MPH; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-402-1272; Email: webewj@mail.nih.gov

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PEDIATRIC CARE (R03 - CLINICAL TRIAL OPTIONAL)
**Sponsor:** National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2021 (Expiration)
**Contact:** Scientific/Research Contact(s); Marion Kosomo-Thomas, MD, MPH; Eunice Kennedy Shriver National Institute of Child and Human Development (NICHD); Telephone: 301-435-6873; Email: kosomari@mail.nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-18-791.html [*]

DEVELOPING MEASURES OF SHARED DECISION MAKING (R01);
Synopsis 1
HHS; Department of Health and Human Services; Agency for Health Care Research and Quality
**Deadline(s):** Standard dates; 02/05/2022 (Expiration)
**Contact:** If you have difficulty accessing the full announcement electronically, please contact: Jerry Calderone AHRQ Referral Officer Phone 301-427-1548; Scientific/Research Contact(s); Direct your questions about general FOA issues, including information on the inclusion of priority populations to: Monique D. Cohen, PhD, MPH; Agency for Healthcare Research and Quality; Center for Evidence and Practice Improvement; Telephone: (301) 427-1630; E-mail: Monique.Cohen@ahrq.hhs.gov
**Link(s):** http://www.grants.gov/web/grants/view-opportunity.html?oppid=288658

ANTIMICROBIAL, ANTIBACTERIAL RESISTANCE &/OR MULTIDRUG RESISTANCE

Large Health Services Research Demonstration and Dissemination Projects for Combating Antibiotic-Resistant Bacteria (CARB)(R18)
Agency for Healthcare Research and Quality
**Deadline(s):** Standard dates; 10/31/2021 (Expiration)
**Contact:** Scientific/Research Contact(s); Direct your questions about general FOA issues, including information on the inclusion of priority populations to: James Cleeman, MD; Agency for Healthcare Research and Quality; Center for Quality Improvement and Patient Safety; Division of Healthcare-Associated Infections; Telephone: (301) 427-1330; E-mail: james.cleeman@ahrq.hhs.gov
**Link(s):** http://grants.nih.gov/grants/guide/pa-files/PA-16-422.html
NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)
Sponsor: National Center for Complementary and Integrative Health
Deadline(s): 10/01/2021; 06/01/2022; 02/01/2023; 05/08/2023 (Expiration)
Contact: Scientific/Research Contact(s); Wendy Weber, ND, Ph.D, MPH; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-402-1272; Email: weberwj@mail.nih.gov

NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
Sponsor: National Center for Complementary and Integrative Health; Office of Dietary Supplements
Deadline(s): 10/01/2021; 06/01/2022; 02/01/2023; 05/08/2023 (Expiration)
Contact: Scientific/Research Contact(s); Wendy Weber, ND, Ph.D, MPH; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-402-1272; Email: weberwj@mail.nih.gov

NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
Sponsor: National Center for Complementary and Integrative Health; Office of Dietary Supplements
Deadline(s): 10/01/2021; 06/01/2022; 02/01/2023; 05/08/2023 (Expiration)
Contact: Scientific/Research Contact(s); Wendy Weber, ND, Ph.D, MPH; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-402-1272; Email: weberwj@mail.nih.gov

Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)
Sponsor: National Center for Complementary and Integrative Health
Deadline(s): 10/01/2021; 06/01/2022; 02/01/2023; 05/08/2023 (Expiration)
Contact: Scientific/Research Contact(s); Wendy Weber, ND, Ph.D, MPH; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-402-1272; Email: weberwj@mail.nih.gov

BASIC RESEARCH, EVIDENCE BASED RESEARCH, EXPLORATORY RESEARCH, PRE-CLINICAL, INTERDISCIPLINARY, MULTIDISCIPLINARY AND TRANSFORMATIVE, AND TRANSLATIONAL RESEARCH

NCATS Announces Plans to Publish the ASPIRE 2020 Reduction-to-Practice Challenge Prize Competition
Sponsor: National Center for Advancing Translational Sciences
Deadline(s): The Announcement is expected to be published in September 2020 with an expected submission window from late November through the end of February 2021.
Contact: Please direct all inquiries to: We strongly encourage interested parties to contact NCATS ASPIRE Program staff listed below to discuss potential submissions. Inquiries may also be sent to: NCATSASPIREChallenge@mail.nih.gov (link sends e-mail).; Danilo Tagle, Ph.D.; National Center for Advancing Translational Sciences (NCATS); Telephone: 301-594-8064; Email: danilo.tagle@nih.gov

NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
Sponsor: National Cancer Institute
Deadline(s): 10/20/2021; 02/22/2022; 06/21/2022; 07/21/2022 (Expiration)
Contact: Scientific/Research Contact(s): Applications Related to Cancer Treatment/Diagnosis (Clinical Studies): William C. Timmer, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-6130; Email: william.timmer@nih.gov; [please see announcement for other contacts]

IDeA Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54 - Clinical Trial Optional)
Sponsor: National Institute of General Medical Sciences
Deadline(s): 10/07/2021; 10/07/2022; 10/08/2022 (Expiration)
Contact: Scientific/Research Contact(s); Ming Lei Ph.D.; National Institute of General Medical Sciences (NIGMS); Email: leim@mail.nih.gov
Link(s): https://grants.nih.gov/grants/guide/pa-files/PAR-20-175.html

Notice of Special Interest: Clinical and Translational Science Award (CTSA) Program Administrative Supplements
**Sponsor:** National Center for Advancing Translational Sciences  
**Deadline(s):** 09/10/2022 (Expiration)  
**Contact:** Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.  
**Link(s):** [https://grants.nih.gov/grants/guide/notice-files/NCTRI-P50-014.html](https://grants.nih.gov/grants/guide/notice-files/NCTRI-P50-014.html)

**Notice of Special Interest: Research through NCATS Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Awards (U01 and R21)**  
**Sponsor:** National Center for Advancing Translational Sciences  
**Deadline(s):** 07/10/2020 (First Available Due Date); 11/11/2021 (Expiration)  
**Contact:** Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.  
**Link(s):** [https://grants.nih.gov/grants/guide/notice-files/NCTRI-P50-007.html](https://grants.nih.gov/grants/guide/notice-files/NCTRI-P50-007.html)  
**Additional Information:** Related Announcements: PAR-19-099 Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional); PAR-19-100 Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional); Issued by National Center for Advancing Translational Sciences (NCATS)

**Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)**  
**Sponsor:** National Center for Advancing Translational Sciences  
**Deadline(s):** 10/06/2021; 10/07/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Elaine Collier, MD; National Center for Advancing Translational Sciences (NCATS); Telephone: 301-435-0794; Email: ec5x@nih.gov  
**Link(s):** [https://grants.nih.gov/grants/guide/notice-files/NCTRI-P50-007.html](https://grants.nih.gov/grants/guide/notice-files/NCTRI-P50-007.html)

**Notice of Intent to Publish a Funding Opportunity Announcement for National Centers for Translational Research in Reproduction and Infertility (NCTRI) (P50 Clinical Trial Optional)**  
**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development  
**Deadline(s):** 04/15/2020 (First Estimated Application Due Date)  
**Contact:** Please direct all inquiries to: Stuart B. Moss, PhD; NICHD; 301-435-6979; Mossstua@mail.nih.gov  

**NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)**  
**Sponsor:** National Cancer Institute  
**Deadline(s):** 10/20/2021; 02/22/2022; 06/20/2022; 06/21/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); William C. Timmer, Ph.D; National Cancer Institute (NCI); Telephone: 240-276-6130; Email: william.timmer@nih.gov  
**Link(s):** [https://grants.nih.gov/grants/guide/notice-files/NCTRI-P50-014.html](https://grants.nih.gov/grants/guide/notice-files/NCTRI-P50-014.html)

**High impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)**  
**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases  
**Deadline(s):** 11/02/2021; 11/03/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Corinne M. Silva, Ph.D.; Division of Diabetes, Endocrinology and Metabolic Diseases; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-451-7335; Email: silvacman@nih.gov  
**Link(s):** [https://grants.nih.gov/grants/guide/notice-files/NCTRI-P50-014.html](https://grants.nih.gov/grants/guide/notice-files/NCTRI-P50-014.html)

**HEALTHCARE ASSOCIATED INFECTIONS**  
NA

**BLOOD PRESSURE AND SODIUM**  
NA

**SKIN DISEASES / DERMATOLOGY**  
NA

**COMPLEMENTARY AND INTEGRATIVE MEDICINE**  

**Notice of Special Interest: NCCIH Administrative Supplements to NCATS CTSA Programs for Scholars Pursuing Complementary Health Research Career Development**  
**Sponsor:** National Center for Complementary and Integrative Health; National Center for Advancing Translational Sciences  
**Deadline(s):** 10/01/2020 (First Available Due Date); 10/04/2023 (Expiration)  
**Contact:** Lanay M. Mudd, Ph.D.; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-594-9346; Email: lanay.mudd@nih.gov  
**Link(s):** [https://grants.nih.gov/grants/guide/notice-files/NCTRI-P50-014.html](https://grants.nih.gov/grants/guide/notice-files/NCTRI-P50-014.html)
Center of Excellence for Research on Complementary and Integrative Health (P01, Clinical Trial Optional)
Sponsor: National Center for Complementary and Integrative Health
Deadline(s): Standard dates; 05/26/2023
Contact: Scientific/Research Contact(s); Craig Hopp, Ph.D.; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-496-5825; Email: hoppdc@mail.nih.gov

EPIDEMIOLOGY
NA

PUBLIC HEALTH INSTITUTES
NA

QUALITY OF CARE

AHRQ Announces Interest in Research that Uses Shared Decision Making as a Tool to Improve the Quality of Care for Low Income and Racial and Ethnic Minority Patients; Agency for Healthcare Research and Quality; Deadline(s): NA
Contact: Please direct all inquiries to: Marian James; Agency for Healthcare Research and Quality (AHRQ); Center for Evidence and Practice Improvement; Telephone: 301-427-1609; Email: sdm@ahrq.hhs.gov;
Link(s): http://grants.nih.gov/grants/guide/notice-files/NOT-HS-16-010.html;

WORLD TRADE CENTER
NA

THE ROBERT WOOD JOHNSON FOUNDATION
NA

THE ROBERT WOOD JOHNSON FOUNDATION
NA

YOUNG, FOREIGN BORN BIOMEDICAL SCIENTISTS
NA

EMERGENCY MANAGEMENT RESPONSES/PREPAREDNESS AND CHEMICAL THREATS/FEMA/DHS/DEPARTMENT OF HOMELAND SECURITY

Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)
Sponsor: National Institute of Neurological Disorders and Stroke; National Eye Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of Environmental Health Sciences
Deadline(s): 09/14/2021; 09/13/2022; 09/12/2023; 09/13/2023 (Expiration)
Contact: Scientific/Research Contact(s); For questions related to the overall CounterACT program and/or neurological injury research including threat agents of interest: David A. Jett, Ph.D.; National Institute of Neurological Disorder and Stroke (NINDS); Telephone: 301-496-6035; Email: jettd@ninds.nih.gov
Link(s): https://grants.nih.gov/grants/guide/pa-files/PAR-20-316.html

Reminder: NIH Natural Disaster Policy Hurricane Laura
Sponsor: National Institutes of Health
Deadline(s): 09/11/2020 (Release Date)
Contact: Please direct all inquiries to: Division of Grants Policy; Office of Policy for Extramural Research Administration (OPERA); GrantsPolicy@OD.NIH.gov

Notice of Special Interest (NOSI): Research in the Emergency Setting
Sponsor: National Institute of Neurological Disorders and Stroke; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of General Medical Sciences; National Institute on Mental Health; National Institute on Minority Health and Health Disparities
Deadline(s): 10/05/2020 (First Available Due Date); 09/08/2022 (Expiration Date)
Contact: Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: Jeremy Brown, MD; Office of Emergency Care Research; National Institute of Neurological Disorders and
Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Eye Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of Environmental Health Sciences

**Deadline(s):** 05/31/2022; 05/30/2023; 05/31/2023 (Expiration)

**Contact:** For questions related to the overall CounterACT Program and/or neurological injury research: Shardell Spriggs, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-443-8189; Email: shardell.spriggs@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-20-253.html

RADIATION

NA

NANOMATERIALS and Nanotechnology

NA

ENVIRONMENTAL AND OCCUPATIONAL HEALTH AND SAFETY

NA

NIOSH Centers of Excellence for Total Worker Health (U19)

**Sponsor:** National Institute for Occupational Safety and Health

**Deadline(s):** 10/29/2021; 10/28/2022; 10/30/2023; 10/31/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Maria Lioce, MD; National Institute for Occupational Safety and Health (NIOSH); Centers for Disease Control and Prevention (CDC); Telephone: 404-498-2575; Email: MLIoce@cdc.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-20-297.html

Notice of Cancellation of RFA-FD-18-024; Strengthening Global Competency and Capacity in Inspectonal Approaches and Good Manufacturing Practices (GMP) (U01)

Food and Drug Administration

**Deadline(s):** NA

**Contact:** Please direct all inquiries to: Layla I. Batarseh; Office of National Program; Telephone: 240-402-4281

**Email:** Layla.Batarseh@fda.hhs.gov


Rapid Assessment Post-Impact of Disaster (R21);
National Institute of Mental Health / NIH / DHHS

**Deadline(s):** Applications should be submitted within approximately six weeks of the identified disaster event.

**Contact:** Farris Tuma, Sc.D.; Address: Division of Adult Translational Research and Treatment Development; 6001 Executive Blvd.; Room 7111, MSC 9632; Bethesda, MD 20892-9632; U.S.A.; Tel: 301-443-3648; Fax: 301-443-4611; E-mail: ftuma@nih.gov;

**Link(s):** Program URL: http://grants1.nih.gov/grants/guide/notice-files/PAR-12-181.html

Notice Regarding New Applications for PAR-15-303: “Occupational Safety and Health Education and Research Centers (42)”

Centers for Disease Control and Prevention

**Deadline(s):** A sufficient number of high-quality Education and Research Center (ERC) applications were received in FY2018 to allow NIOSH to fund 18 ERCs. Funds to support applications for new NIOSH ERCs are not expected to be available in FY2019. As a result, NIOSH is closing the October 11, 2018 receipt date to new applications.

**Contact:** Please direct all inquiries to: Elizabeth H. Maples, PhD; Scientific Program Official; National Institute for Occupational Safety and Health (NIOSH); Telephone: 404-498-2557;

**Email:** emaples@cdc.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OH-18-008.html


http://www.grants.gov/web/grants/view-opportunity.html?oppId=277933

CARDIOVASCULAR DISEASE / CARDIOVASCULAR / HEART DISEASE OR STROKE

NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)

**Sponsor:** National Institute of Neurological Disorders and Stroke

**Deadline(s):** 10/14/2021; 02/22/2022; 06/20/2022; 10/18/2022; 02/14/2023; 06/14/2023; 07/24/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Claudia Scala Moy, PhD; National Institute of Neurological Disorders & Stroke (NINDS); Telephone: 301-496-9135; Email: moyc@ninds.nih.gov
Implementation of shared decision making for HLBS diseases and conditions (R01 Clinical Trial Optional)
National Heart, Lung, and Blood Institute; Office of Behavioral and Social Science Research
**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2022 (Expiration)
**Contact:** Scientific/Research Contact(s); Susan T. Shero, BSN, MS; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-496-1051; Email: sheros@nih.gov


**Contact:** Scientific/Research Contact(s); Donald Everett, MA; National Eye Institute (NEI); Telephone: 301-451-2020; Email: everettd@mail.nih.gov
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-19-231.html

### IMPORTANT EXTRAMURAL FUNDING OPPORTUNITIES

**PCORE = Patient Oriented Outcomes Research and Evaluation**
An ASPH YouTube Webinar on Developing A Strategic Plan For Prevention Research At NIH
An Updated Chart Of Grant Application Due Dates MSPH SPA
The Health Research Board Funding Opportunity

**Epidemiology Cohort**

**Notice of Update to PAR-17-338 "Continuation of Existing Grant Based Epidemiology Cohort Studies in Heart, Lung, Blood, and Sleep Diseases and Disorders (U01 - Clinical Trials Not Allowed)"**
National Heart, Lung, and Blood Institute; Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute
**Deadline(s):** 09/28/2017 (Release Date); 2027 (Continuation Expiration)
**Contact:** Please direct all inquiries to: Sean Coady, MS; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-1289; Email: coadys@mail.nih.gov
**Link(s):** http://www.grants.gov/web/grants/view-opportunity.html?oppId=296672

**Transformative**

**Vision, Eye Disease, Ophthalmology**

**NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)**
**Sponsor:** National Eye Institute
**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2022 (Expiration)

NIH Research Evaluation and Commercialization Hub Awards
NA

**Vision, Eye Disease, Ophthalmology**

**NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)**
**Sponsor:** National Eye Institute
**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2022 (Expiration)
CANCER / ONCOLOGY

Gateway Discovery Grant to Address Cancer Disparities in Clinical Trials
Gateway Discovery Grant Application Portal
Program Guidelines and Application Instructions
Sponsor: https://www.asco.org
Deadline(s): 03/15/2021 (LOI); 08/16/2021 (Only applicants who have received approval for their LOI will be eligible to submit a full application)
Contact: grants@conquer.org
Link(s): https://www.asco.org/research-guidelines/grants-awards/funding-opportunities/gateway-discovery-grant-address-cancer
https://asco.smapply.org/prog/DiscoveryGrant/

Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes
Sponsor: National Cancer Institute; National Institute on Aging
Deadline(s): 03/08/2021 (First Available Due Date); 01/08/2024 (Expiration Date)
Contact: Scientific/Research Contact(s): Lisa Gallicchio, Ph.D.; National Cancer Institute; Telephone: (240) 276-5741;
Email: lisa.gallicchio@nih.gov

Notice of Special Interest (NOSI): Tailoring Follow-up Care for Survivors Using Risk-Stratified Pathways
Sponsor: National Cancer Institute
Deadline(s): 02/05/2021 (First Available Due Date); 2023 (Expiration Date)
Contact: Michelle Mollica, PhD, MPH, RN, OCN; National Cancer Institute (NCI); Telephone: 240-276-7621;
Email: michelle.mollica@nih.gov

Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Support Global Cancer Stigma Research
Sponsor: National Cancer Institute
Deadline(s): 01/22/2021 (First Available Due Date); 05/16/2021 (Expiration Date)
Contact: Please direct all inquiries to: Vidya Vedham, Ph.D.; Center for Global Health; National Cancer Institute; (NCI);
Telephone: 240-276-7272; Email: vidya.vedham@nih.gov

Notice of Special Interest (NOSI): Leveraging Population-based Cancer Registry Data to Study Health Disparities
Sponsor: National Cancer Institute
Deadline(s): 02/05/2021 (First Available Due Date); 05/08/2023 (Expiration Date)
Contact: Scientific/Research Contacts: Kathy Cronin, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-6836;
Email: cronink@mail.nih.gov

Notice of Intent to Publish a Funding Opportunity Announcement: Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health
Sponsor: National Cancer Institute
Deadline(s): 06/02/2021 (First Estimated Application Due Date)
Contact: Please direct all inquiries to: Paul C. Pearlman, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-5354;
Email: paul.pearlman@nih.gov

Gateway Discovery Grant to Address Cancer Disparities in Clinical Trials
Gateway Discovery Grant Application Portal
Program Guidelines and Application Instructions
Sponsor: https://www.asco.org
Deadline(s): 03/15/2021 (LOI); 08/16/2021 (Only applicants who have received approval for their LOI will be eligible to submit a full application)
Contact: grants@conquer.org
Link(s): https://www.asco.org/research-guidelines/grants-awards/funding-opportunities/gateway-discovery-grant-address-cancer
https://asco.smapply.org/prog/DiscoveryGrant/
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)

**Sponsor:** National Cancer Institute
**Deadline(s):** 11/17/2021; 11/18/2021 (Expiration)
**Contact:** Scientific / Research Contact(s): Juli Klemm, Ph.D.; National Cancer Institute (NCI); Telephone: 301-480-5778; Email: juli.klemm@nih.gov
**Link(s):** [https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-017.html](https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-017.html)

Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

**Sponsor:** National Cancer Institute
**Deadline(s):** 11/17/2021; 11/18/2021 (Expiration)
**Contact:** Scientific / Research Contact(s): Juli Klemm, Ph.D.; National Cancer Institute (NCI); Telephone: 301-480-5778; Email: juli.klemm@nih.gov
**Link(s):** [https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-014.html](https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-014.html)

Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

**Sponsor:** National Cancer Institute
**Deadline(s):** 11/17/2021; 11/18/2021 (Expiration)
**Contact:** Scientific / Research Contact(s): Juli Klemm, Ph.D.; National Cancer Institute (NCI); Telephone: 301-480-5778; Email: juli.klemm@nih.gov

Sustained Support for Informatics Technologies for Cancer Research and Management (U48 Clinical Trial Optional)

**Sponsor:** National Cancer Institute
**Deadline(s):** 11/17/2021; 11/18/2021 (Expiration)
**Contact:** Scientific / Research Contact(s): Juli Klemm, Ph.D.; National Cancer Institute (NCI); Telephone: 301-480-5778; Email: juli.klemm@nih.gov

Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional)

**Sponsor:** National Cancer Institute
**Deadline(s):** 11/17/2021; 11/18/2021 (Expiration)
**Contact:** Scientific / Research Contact(s): Juli Klemm, Ph.D.; National Cancer Institute (NCI); Telephone: 301-480-5778; Email: juli.klemm@nih.gov
**Link(s):** [https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-017.html](https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-017.html)

Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional)

**Sponsor:** National Cancer Institute
**Deadline(s):** 11/17/2021; 11/18/2021 (Expiration)
**Contact:** Scientific / Research Contact(s): Juli Klemm, Ph.D.; National Cancer Institute (NCI); Telephone: 301-480-5778; Email: juli.klemm@nih.gov

Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trial Optional)

**Sponsor:** National Cancer Institute
**Deadline(s):** 11/18/2021; 11/19/2021 (Expiration)
**Contact:** Scientific / Research Contact(s): Juli Klemm, Ph.D.; National Cancer Institute (NCI); Telephone: 301-480-5778; Email: juli.klemm@nih.gov

Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2024 (Expiration)
**Contact:** Scientific/Research Contact(s): Jeannette F. Korczak, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-5630; Email: korczakj@mail.nih.gov

Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2024 (Expiration)
**Contact:** Scientific/Research Contact(s): Jeannette F. Korczak, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-5630; Email: korczakj@mail.nih.gov
Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute  
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); Jeannette F. Korczak, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-5630; Email: korczakj@mail.nih.gov  

Cancer Research Institute Technology Impact Award

**Sponsor:** Cancer Research Institute  
**Deadline(s):** 11/15/2020 (LOI); 03/15/2021 (Full Proposal)  
**Contact:** [https://www.cancerresearch.org/contact-us](https://www.cancerresearch.org/contact-us)  
**Link(s):** [https://www.cancerresearch.org/scientists/fellowships-grants/technology-impact-award](https://www.cancerresearch.org/scientists/fellowships-grants/technology-impact-award)

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

**Sponsor:** National Cancer Institute  
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); For Therapeutic Studies: Lori A. Henderson, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-5930; Email: hendersori@mail.nih.gov  

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

**Sponsor:** National Cancer Institute  
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2024 (Expiration)  
**Contact:** Scientific/Research Contact(s); For cancer prevention, early detection, screening, and symptom management-related clinical trials, contact: Brandy Heckman-Stoddard, Ph.D., M.P.H.; National Cancer Institute (NCI); Telephone: 240-276-7048; Email: heckmanbm@mail.nih.gov  

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 10/08/2021; 02/14/2022; 07/11/2022; 10/11/2022; 02/14/2023; 07/10/2023; 10/10/2023; 10/11/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); For inquiries related to response, resistance, and risk stratification markers for treatment trials, please contact: Tracy G. Lively, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-5944; Email: livelyt@mail.nih.gov  

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 10/08/2021; 02/14/2022; 07/11/2022; 10/11/2022; 02/14/2023; 07/10/2023; 10/10/2023; 10/11/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); For inquiries related to response, resistance, and risk stratification markers for treatment trials, please contact: Tracy G. Lively, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-5944; Email: livelyt@mail.nih.gov  

Social and Behavioral Intervention Research to Address Modifiable Risk Factors for Cancer in Rural Populations (R01 Clinical Trial Required)

**Sponsor:** National Cancer Institute; Office of Disease Prevention  
**Deadline(s):** 01/18/2022; 01/19/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Kelly D. Blake, ScD; National Cancer Institute (NCI); Telephone: 240-281-5934; Email: kelly.blake@nih.gov  

Core Infrastructure Support for Cancer Epidemiology Cohorts (U01 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 11/09/2021; 04/07/2022; 11/09/2022; 11/10/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Joanne Elena, PhD, MPH; National Cancer Institute (NCI); Telephone: 240-276-6818; Email: joanne.elena@nih.gov  

Notice of Intent to Publish a Funding Opportunity Announcement for New Cohorts to Assess Environmental Exposures and Cancer Risk (UG3/UH3 Clinical Trial Optional)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 01/29/2021 (First Estimated Application Due Date)
**Notice of Intent to Publish a Funding Opportunity**

**Announcement for Coordinating Center for New Cohorts to Assess Environmental Exposures and Cancer Risk (U24 Clinical Trial Not Allowed)**

**Sponsor:** National Cancer Institute

**Deadline(s):** 02/25/2020 (First Available Due Date); 05/09/2023 (Expiration Date)

**Contact:** Scientific/Research Contact(s); Juli Klemm, Ph.D., MPH, RN, OCN; National Cancer Institute (NCI); Telephone: 301-480-5778; Email: juli.klemm@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-027.html

**New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (U01 Clinical Trial Optional)**

**Sponsor:** National Cancer Institute

**Deadline(s):** 11/18/2021; 06/06/2022; 11/18/2022; 06/06/2023; 06/07/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); For Research Area 1 related inquiries: Angela B. Mariotto, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-6698; Email: mariotta@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-045.html

**Notice of Special Interest (NOSI): Advancing Cancer Data Repositories and Knowledgebases**

**Sponsor:** National Cancer Institute

**Deadline(s):** 04/05/2021 (Expiration Date)

**Link(s):** https://grants.nih.gov/grants/guide/files/RFA-CA-20-028.html

**Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional)**

**Sponsor:** National Institutes of Health (NIH); Components of Participating Organizations; National Cancer Institute (NCI)

**Deadline(s):** 07/30/2021; 07/31/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Michelle Mollica, Ph.D., MPH, RN, OCN; Healthcare Delivery Research Program; National Cancer Institute (NCI); Telephone: 240-276-7621; Email: michelle.mollica@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-045.html

**Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional)**

**Sponsor:** National Institutes of Health (NIH); Components of Participating Organizations; National Cancer Institute (NCI)

**Deadline(s):** 07/30/2021; 07/31/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Michelle Mollica, Ph.D., MPH, RN, OCN; Healthcare Delivery Research Program; National Cancer Institute (NCI); Telephone: 240-276-7621; Email: michelle.mollica@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-045.html
Notice of Special Interest: Alcohol and Cancer Control  
**Sponsor:** National Cancer Institute  
**Deadline(s):** 06/05/2020 (First Available Due Date); 09/09/2023 (Expiration)  
**Contact:** Scientific/Research Contacts; Tanya Agurs-Collins, Ph.D., R.D.; National Cancer Institute (NCI); Telephone: 240-276-6956; Email: collinsta@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-034.html

Notice of Intent to Publish a Funding Opportunity Announcement for Strengthening Institutional Capacity to Conduct Global Cancer Research (D43)  
**Sponsor:** National Cancer Institute  
**Deadline(s):** 06/30/2020 (First Estimated Due Date)  
**Contact:** Please direct all inquiries to: Sudha Sivaram, DrPH; National Cancer Institute (NCI); 240-276-5804; Sudha.sivaram@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-015.html

Notice of Special Interest (NOSI): Geospatial Approaches in Cancer Control and Population Sciences  
**Sponsor:** National Cancer Institute  
**Deadline(s):** 02/05/2020 (First Available Due Date); 01/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Cancer Epidemiology; Armen Ghazarian, PhD, MPH; National Cancer Institute (NCI); Telephone: 240-276-7305; Email: ghazarianaa@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-004.html

Notice of Special Interest (NOSI): Use of Biological Information to Understand How the Interplay of Environmental Exposures and Genes Influences Cancer Risk  
**Sponsor:** National Cancer Institute  
**Deadline(s):** 02/05/2020 (First Available Due Date); 01/08/2022 (Expiration)  
**Contact:** Please direct all inquiries to: Stefanie Nelson, PhD; Division of Cancer Control and Population Sciences; National Cancer Institute (NCI); Telephone: 240-276-6944; Email: nelsons@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-002.html

Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Trial Optional)  
**Sponsor:** National Cancer Institute  
**Deadline(s):** Standard dates; 01/08/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Todd S Horowitz, Ph.D; National Cancer Institute (NCI); Telephone: 240-276-6963; Email: todd.horowitz@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-021.html

Perception and Cognition Research to Inform Cancer Image Interpretation (R01 Clinical Trial Optional)  
**Sponsor:** National Cancer Institute  
**Deadline(s):** Standard dates; 01/08/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Todd S Horowitz, Ph.D; National Cancer Institute (NCI); Telephone: 240-276-6963; Email: todd.horowitz@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-025.html

Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional)  
**Sponsor:** National Cancer Institute  
**Deadline(s):** Standard Dates; 09/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Michelle Mollica, PhD, MPH, RN, OCN; National Cancer Institute (NCI); Telephone: 240-276-7621; Email: michelle.mollica@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-004.html

Neural Regulation of Cancer (R01 Clinical Trial Not Allowed)  
**Sponsor:** National Cancer Institute  
**Deadline(s):** 10/21/2021; 05/27/2022; 05/28/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Chamelli Jhappan, Ph.D.; National Cancer Institute (NCI); Telephone 240-276-6200; Email: jhappanc@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-004.html

Neural Regulation of Cancer (R21 Clinical Trial Not Allowed)  
**Sponsor:** National Cancer Institute  
**Deadline(s):** 10/21/2021; 05/27/2022; 05/28/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Chamelli Jhappan, Ph.D.; National Cancer Institute (NCI); Telephone 240-276-6200; Email: jhappanc@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-004.html

Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance (U01 Clinical Trial Not Allowed)
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional)

Sponsor: National Cancer Institute

Deadline(s): Standard dates; 09/08/2022

Contact: Scientific/Research Contact(s): Michelle Mollica, PhD, MPH, RN, OCN; National Cancer Institute (NCI); Telephone: 240-276-6956; Email: michelle.mollica@nih.gov


Notice of Intent to Publish the Reissuance of RFA-CA-18-026, "Improving the Reach and Quality of Cancer Care in Rural Populations (R01 Clinical Trial Required)"

Sponsor: National Cancer Institute

Deadline(s): 01/15/2020 (First Estimated Due Date)

Contact: Please direct all inquiries to: Shobha Srinivasan, Ph.D.; National Cancer Institute (NCI); 240-276-6938; ss688k@nih.gov


Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

Sponsor: National Cancer Institute

Deadline(s): Standard dates; Standard AIDS dates; 09/08/2022 (Expiration)

Contact: Scientific/Research Contact(s): Tanya Agurs-Collins, Ph.D., R.D.; National Cancer Institute (NCI); 240-276-6956; Email: collinsta@mail.nih.gov


Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)

Sponsor: National Cancer Institute

Deadline(s): 10/08/2021; 10/09/2021 (Expiration)

Contact: Scientific /Research Contact(s): Mukesh Verma, Ph.D.; National Cancer Institute (NCI); 240-276-6889; Email: vermam@mail.nih.gov


Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional)

Sponsor: National Cancer Institute

Deadline(s): 12/10/2021; 12/11/2021 (Expiration)

Contact: Scientific/Research Contact(s): Sudhir Srivastava, Ph.D., MPH; National Cancer Institute (NCI); 240-276-7028; Email: srivastas@mail.nih.gov


Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Optional)

Sponsor: National Cancer Institute; National Institute of Environmental Health Sciences

Deadline(s): 11/06/2020; 07/08/2021; 11/08/2021; 11/09/2021 (Expiration)

Contact: Scientific/Research Contact(s): For inquires related to cancer prevention contact: Wendy Wang, Ph.D. M.Sc.; National Cancer Institute (NCI); 240-276-7117; Email: wangw@mail.nih.gov


Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R21 Clinical Trial Optional)

Sponsor: National Cancer Institute; National Institute of Environmental Health Sciences

Deadline(s): 07/08/2021; 11/08/2021; 11/09/2021 (Expiration)

Contact: Scientific/Research Contact(s): For inquires related to cancer prevention contact: Wendy Wang, Ph.D. M.Sc.; National Cancer Institute (NCI); 240-276-7117; Email: wangw@mail.nih.gov


NIH NCI Microbial Based Cancer Therapies; [1] Microbial-based Cancer Therapy - Bugs as Drugs R21 Clinical Trial Not Allowed; [2] Microbial-based Cancer Therapy - Bugs as Drugs R01 Clinical Trial Not Allowed

Sponsor: National Institutes of Health (NIH); National Cancer Institute (NCI)

Deadline(s): Standard dates; 05/08/2022 (Expiration)

Contact: Scientific/Research Contact(s): Avi Rasooly, PhD; National Cancer Institute (NCI); 301-240-276-6196; Email: rasoolya@mail.nih.gov


Notice of NIDCR’s Participation in PAR-19-194 “Microbial-based Cancer Therapy-Bugs as Drugs (R21- Clinical Trial Not Allowed)”
Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 11/08/2021; 11/09/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Young S. Kim, PhD; National Cancer Institute (NCI); Telephone: 240-276-7115; Email: yk47s@nih.gov  

Notice of NIDCR’s Participation in PAR-19-193 "Microbial-based Cancer Therapy-Bugs as Drugs (R01 Clinical Trial Not Allowed)"

**Sponsor:** National Institute of Dental and Craniofacial Research  
**Deadline(s):** Standard dates ; 05/08/2022 (Expiration)  
**Contact:** Please direct all inquiries to: Chiayeng Wang, Ph.D.; National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-827-4647; Email: chiayeng.wang@nih.gov  

Notice of Availability of Administrative Supplements to Promote Data Sharing in Cancer Epidemiology Studies

**Sponsor:** National Cancer Institute  
**Deadline(s):** 03/12/2019 (Release Date)  
**Contact:** Please direct all inquiries to: Danielle Daee, PhD; National Cancer Institute (NCI); Telephone: 240-276-5744; Email: Danielle.Daee@nih.gov  

Notice of Availability of Administrative Supplements for Geospatial, Multilevel, and Contextual Approaches in Cancer Control and Population Sciences

**Sponsor:** National Cancer Institute  
**Deadline(s):** 03/12/2019 (Release Date)  
**Contact:** Please direct all inquiries to: Armen Ghazarian, PhD, MPH; Division of Cancer Control and Population Sciences; National Cancer Institute (NCI); Telephone: 240-276-7305; Email: ghazarianaa@mail.nih.gov;  

Notice of Availability of Administrative Supplements for NCI Grant and Cooperative Agreement Awards to Support Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 11/08/2021; 11/09/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Young S. Kim, PhD; National Cancer Institute (NCI); Telephone: 240-276-7115; Email: yk47s@nih.gov  

Notice of NIDCR’s Participation in PAR-19-193 "Microbial-based Cancer Therapy-Bugs as Drugs (R01 Clinical Trial Not Allowed)"

**Sponsor:** National Institute of Dental and Craniofacial Research  
**Deadline(s):** Standard dates ; 05/08/2022 (Expiration)  
**Contact:** Please direct all inquiries to: Chiayeng Wang, Ph.D.; National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-827-4647; Email: chiayeng.wang@nih.gov  

Notice of Availability of Administrative Supplements to Promote Data Sharing in Cancer Epidemiology Studies

**Sponsor:** National Cancer Institute  
**Deadline(s):** 03/12/2019 (Release Date)  
**Contact:** Please direct all inquiries to: Danielle Daee, PhD; National Cancer Institute (NCI); Telephone: 240-276-5744; Email: Danielle.Daee@nih.gov  

Notice of Availability of Administrative Supplements for Geospatial, Multilevel, and Contextual Approaches in Cancer Control and Population Sciences

**Sponsor:** National Cancer Institute  
**Deadline(s):** 03/12/2019 (Release Date)  
**Contact:** Please direct all inquiries to: Armen Ghazarian, PhD, MPH; Division of Cancer Control and Population Sciences; National Cancer Institute (NCI); Telephone: 240-276-7305; Email: ghazarianaa@mail.nih.gov;  

Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 11/08/2021; 11/09/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Young S. Kim, PhD; National Cancer Institute (NCI); Telephone: 240-276-7115; Email: yk47s@nih.gov  

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

**Sponsor:** National Cancer Institute  
**Deadline(s):** 08/11/2021; 08/12/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Claire Zhu, Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-7013; Email: zhucla@mail.nih.gov  

Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional)

**Sponsor:** National Cancer Institute  
**Deadline(s):** Standard dates ; 01/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Nonniekaye Shelburne, MS, CRNP, AOCN; National Cancer Institute (NCI); Telephone: 240-276-6897; Email: nshelfburne@mail.nih.gov  

Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)

**Sponsor:** National Cancer Institute  
**Deadline(s):** Standard dates ; 01/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Nonniekaye Shelburne, MS, CRNP, AOCN; National Cancer Institute (NCI); Telephone: 240-276-6897; Email: nshelfburne@mail.nih.gov  

Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)

**Sponsor:** National Cancer Institute  
**Deadline(s):** Standard dates ; Standard AIDS dates ; 09/08/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Frank M. Perna, Ed.D., Ph.D.; National Cancer Institute (NCI); Telephone: 240-276-6782; Email: perna@ncharlottesville.org  
Pediatric Cancer Control Research Across the Lifespan (Admin Supp Clinical Trial Optional)
National Cancer Institute
Deadline(s): 06/28/2018 (Release Date)
Contact: Please direct all inquiries to: Michelle Mollica, Ph.D., M.P.H., R.N., O.C.N.; National Cancer Institute; Telephone: 240-276-7621; Email: michelle.mollica@nih.gov

Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer (R21 Clinical Trial Optional)
National Cancer Institute
Deadline(s): Standard dates: 05/08/2021 (Expiration)
Contact: Scientific/Research Contact(s); Gurvaneet S. Randhawa, M.D., MPH; National Cancer Institute (NCI); Telephone: 240-276-6940; Email: gurvaneet.randhawa@nih.gov

Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer (R01 Clinical Trial Optional)
National Cancer Institute
Deadline(s): Standard dates: 05/08/2021 (Expiration)
Contact: Scientific/Research Contact(s); Gurvaneet S. Randhawa, M.D., MPH; National Cancer Institute (NCI); Telephone: 240-276-6940; Email: gurvaneet.randhawa@nih.gov

Cancer Moonshot Update: NCI Funding Opportunities
Deadline(s): please see https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding?cid=eb_govdel_en_grantees_moonshot-foa_announcement_rsr#current for currently open funding opportunities
Contact: https://www.cancer.gov/contact
Link(s): https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding?cid=eb_govdel_en_grantees_moonshot-foa_announcement_rsr
https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding?cid=eb_govdel_en_grantees_moonshot-foa_announcement_rsr#current

Notice of Correction to Scientific Merit Review Dates in PAR-17-203 "Inter-organelle Communication in Cancer (R01)"
Deadline(s): 10/11/2017 (Release Date)
NIH; NCI
Contact: Please direct all inquiries to: Michael Graham Espey, Ph.D. National Cancer Institute (NCI); Telephone: 240-276-7619; Email: SP@nih.gov


KRAS Travel Scholarship
NIH; http://pancan.org
Deadline(s): Rolling
Contact: For inquiries regarding proposed projects and/or FNLCR facilities: Dwight Nissley, PhD, Director, Cancer Research Technology Program, FNLCR at nissleyd@mail.nih.gov

FOUNDATION FUNDING

Info Emerging Leader Award
Apply The Mark Foundation Emerging Leader Award
Sponsor: https://themarkfoundation.org/
Deadline(s): 03/24/2021 (Letter of Intent Portal Opens); 05/03/2021 (Letters of Intent Due); Week of 06/13/2021 (Applications Invited); Week of 10/03/2021 (Finalists Notified)
Contact: info@themarkfoundation.org
Link(s): https://themarkfoundation.org/emerging-leader-award/

Limited Submission; 2021 W.M. Keck Foundation Science & Engineering and Medical Research Tracks
Current Limited CU Submission Opportunities
Sponsor: Keck foundation
Deadline(s): Columbia solicits one-page concept papers to be discussed with, the Keck Foundation to align potential proposals with Foundation interests. The consultations take place between January 1 – February 15 for a May 1 submission, and July 1 – August 15 for a November 1 submission. PIs do not participate in this consultation call with the Foundation; instead they need to nominate a colleague who is familiar with their proposed research and can discuss it with the foundation; 10/29/2020 (Internal Proposal Deadline); 01/01/2021_02/15/2021 (Consultations); 05/01/2021 (Application)
Contact: For additional information, please contact Dimitra Koutsantoni at dk2617@columbia.edu or 212-851-9924
Link(s): https://research.columbia.edu/keck-research-grants
https://research.columbia.edu/content/limitedsubmissions#table-6029
http://www.wmkeck.org/grant-programs/research [Current Limited CU Submission Opportunities] [Current Limited CU Submission Opportunities] [Current Limited CU Submission Opportunities]
Current Wellcome UK Funding Opportunities
Sponsor: https://wellcome.ac.uk
 Deadline(s): NA
 Contact: https://wellcome.ac.uk/about-us/contact-us [general contact email] https://wellcome.ac.uk/about-us/contact-us/funding-enquiry-enhanced?ref=1961 [contact relative to grants]
Link(s): https://wellcome.ac.uk/funding/guidance https://wellcome.ac.uk/funding/schemes

NYSCF Neuroscience - Investigator Awards;
Sponsor: NYSCF, New York Stem Cell Foundation;
Deadline(s): None Provided;
Contact: Thanks, Trialect Support; +1.805.850.6002 (USA) for technical questions; Support@trialect.com; http://www.nyscf.org/about-us/contact-us; info@nyscf.org;
Link(s): https://app.trialect.com/3139/display;
http://www.nyscf.org/grants/neuroscience-investigator-awards;

ADOLESCENT HEALTH/TEENS
NA

MENOPAUSE
NA

FERTILITY, REPRODUCTIVE HEALTH, CONTRACEPTION

Notice of Change of Key Dates for RFA-HD-22-003
"Contraception Development Research Center Program (P50 Clinical Trial Optional)"
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development
**Deadline(s):** 11/29/2021; 11/30/2021 (Expiration) [for RFA-HD-22-003]

**Contact:** Christopher C. Lindsey, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6907; Email: chris.lindsey@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-044.html

**Additional Information:** Related: RFA-HD-22-003 - Contraception Development Research Center Program (PSO Clinical Trial Optional)

Fertility Status as a Marker for Overall Health (R01 Clinical Trial Optional)

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institute of Environmental Health Sciences; Office of Disease Prevention; Office of Research on Women’s Health

**Deadline(s):** 02/19/2022; 10/19/2022; 06/19/2023; 06/20/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Susan Taymans, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-496-6517; Email: taymanss@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/PAR-20-281.html

Fertility Status as a Marker for Overall Health (R21 Clinical Trial Not Allowed)

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institute of Environmental Health Sciences; Office of Disease Prevention; Office of Research on Women’s Health

**Deadline(s):** 02/19/2022; 10/19/2022; 06/19/2023; 06/20/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Susan Taymans, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-496-6517; Email: taymanss@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/PAR-20-282.html

Notice of Special Interest: Ancillary Reproductive Health Projects to Existing Large and/or Longitudinal Studies

**Sponsor:** Issued by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute on Minority Health and Health Disparities (NIMHD); National Cancer Institute (NCI); All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.; Office of Behavioral and Social Sciences Research (OBSSR); Office of Research on Women’s Health (ORWH)

**Deadline(s):** 05/01/2020 (First Available Due Date); 05/02/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Candace Tingen, PhD; Program Official; National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6971; Email: candace.tingen@nih.gov; There may be someone in your department or unit who would like to apply but needs some suggestions about a reproductive health expert to collaborate with; Jane Waldfogel ; j.waldfogel@columbia.edu, my CPRC co-director, or I am happy to provide introductions

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-008.html

**GYNECOLOGY**

**Notice of Special Interest: Optimizing Precision Treatment of Gynecologic, Reproductive and Obstetrical Outcomes in Adolescents and Adults with PCOS and Associated Comorbid Conditions (Clinical Trial Optional)**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development Office of Research on Women’s Health

**Deadline(s):** 02/05/2021 (First Available Due Date); 09/08/2023 (Expiration)

**Contact:** Scientific / Research Contact(s); Esther Eisenberg, MD MPH; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-496-6516; Email: esther.eisenberg@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-026.html

**Additional Information:** Related Announcements; PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required); PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed); PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

**PREGNANCY**

**NA**

**ADOLESCENTS**
Multidisciplinary Research in Vulvodynia (R01 Clinical Trial Optional)

**Sponsor**: Department of Health and Human Services; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Office of Research on Women's Health (ORWH)

**Deadline(s)**: Any due dates on or after Jan 25, 2018 must use reissued FOA.

**Contact**: Scientific/Research Contact(s); Susan Meikle, M.D., M.S.P.H.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-273-8541; Email: meikles@mail.nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide NOTICE-OD-21-036.html

NHLBI Announces Plan to Fund a Women's Health Initiative Home-Based Exam in the Long Life Study 2 Cohort

**Sponsor**: National Heart, Lung, and Blood Institute

**Deadline(s)**: 01/24/2020 (Release Date)

**Contact**: Please direct all inquiries to: Shari Eason Ludlam, MPH; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-6667; Email: ludlams@mail.nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide NOTICE-HL-20-750.html

Multidisciplinary Research in Vulvodynia (R21 Clinical Trial Optional)

**Sponsor**: Department of Health and Human Services; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Office of Research on Women's Health (ORWH)

**Deadline(s)**: Standard dates; Standard AIDS dates; 05/08/2019

**Contact**: Scientific/Research Contact(s); Susan Meikle, M.D., M.S.P.H.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-273-8541; Email: meikles@mail.nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide PA-18-096.html

HUMAN MILK

Notice of Intent to Publish a Funding Opportunity Announcement for Human Milk as a Biological System (R01 Clinical Trial Optional)

**Sponsor**: Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Deadline(s)**: 11/30/2021 (First Estimated Application Due Date)

**Contact**: Andrew A. Bremer, MD, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-402-7886; Email: andrew.bremer@nih.gov

**Link(s)**: https://grants.nih.gov/grants/guide NOTICE-HD-21-005.html

Maternal and Child Health and Pediatrics

View all Active Funding Opportunity Announcements for NICHD

**Sponsor**: Eunice Kennedy Shriver National Institute of Child Health and Human Development

https://www.nichd.nih.gov/

**Deadline(s)**: please see piecemeal / individual opportunities

**Contact**: please see piecemeal / individual opportunities; also https://www.nichd.nih.gov/contact

**Link(s)**: https://www.nichd.nih.gov/grants-contracts/FOAs-notices/active-FOAs

Notice of Intent to Publish a Funding Opportunity Announcement for Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Multisite (UG3/UH3) with Coordinating Center (U24)

**Sponsor**: National Heart, Lung, and Blood Institute
Deadline(s): 06/22/2021 (First Estimated Application Due Date)

Contact: Please direct all inquiries to: Charlotte A. Pratt; National Heart, Lung, and Blood Institute (NHLBI); (301) 435-0382; NHLBI_Enrich@nhlbi.nih.gov


Notice of Special Interest (NOSI): Improving Methods to Assess Body Composition in Infants and Young Children

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Biomedical Imaging and Bioengineering

Deadline(s): 09/05/2020 (First Available Due Date); 09/05/2022 (Expiration Date)

Contact: Please direct all inquiries to: Voula Osganian, M.D., Sc.D., M.P.H.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-827-6939; Email: voula.osganian@nih.gov


Notice of Intent to Publish a Funding Opportunity Announcement for HEALthy Brain and Child Development Study

Sponsor: National Institute on Drug Abuse

Deadline(s): 03/01/2021 (First Estimated Due Date)

Contact: Michelle Freund; National Institute on Drug Abuse (NIDA); Telephone: 301-827-4128; Email: freundm@mail.nih.gov


Notice of Special Interest: Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children (R01, R21)

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Deadline(s): 07/01/2020 (Release Date); Standard dates; Standard AIDS dates; 05/08/2023 (Expiration for PA-20-185); 01/08/2021 (Expiration for PA-18-480 and PA-18-482)

Contact: Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: Scientific/Research Contact(s): Kristin M. Burns, M.D.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-451-4295; Email: robert.tamburro@nih.gov


Additional Information: Related Announcements: PA-20-185 - Research Project Grant (Parent R01 Clinical Trial Not Allowed); PA-18-480 - NICHD Research Project Grant (R01 Clinical Trial Required); PA-18-482 - NICHD; Exploratory Developmental Research Grant (R21 - Clinical Trial Optional)

Collaborative Centers in Children's Environmental Health Research and Translation (P2C Clinical Trial Optional)

If you are interested in applying for the NIEHS Limited Submission (one application from Mailman)

Notice of Special Interest (NOSI): Understanding Sudden Death in the Young Through Research

Sponsor: National Heart, Lung, and Blood Institute; National Institute of Neurological Disorders and Stroke

Deadline(s): 10/05/2020 (First Available Due Date); 01/08/2023 (Expiration Date)

Contact: Scientific/Research Contact(s): Kristin M. Burns, MD; National Heart, Lung, and Blood Institute; Telephone: 301-594-6859; Email: kristin.burns@nih.gov


NICHD Research Education Programs (R25 Clinical Trial Not Allowed)

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Advancing Translational Sciences

Deadline(s): Standard dates; 05/26/2022 (Expiration)

Contact: Scientific/Research Contact(s): Dennis A. Twombly, Ph.D.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-451-3371; Email: dtwombly@mail.nih.gov


Notice of Availability of National Childrens Study (NCS) Vanguard Biological and Environmental Sample Materials

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Deadline(s): 06/12/2020 (Release Date)
**Notice of NCATS Withdrawal from Participation in PAR-18-690, Innovative Therapies and Tools for Screenable Disorders in Newborns (R03 Clinical Trial Optional)**

**Sponsor:** National Center for Advancing Translational Sciences

**Deadline(s):** NA, withdrawal

**Contact:** Please direct all inquiries to: NCATS Referral Office; Email: ncatsreferral@mail.nih.gov


**Notice of NCATS Withdrawal from Participation in PAR-18-689, Innovative Therapies and Tools for Screenable Disorders in Newborns (R01 Clinical Trial Optional)**

**Sponsor:** National Center for Advancing Translational Sciences

**Deadline(s):** NA, withdrawal

**Contact:** Please direct all inquiries to: NCATS Referral Office; Email: ncatsreferral@mail.nih.gov


---

**Catalyzing Innovation in Pediatric Pharmacology Clinical Trial Design and Resource Access (X01 Clinical Trial Not Allowed)**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Deadline(s):** 03/17/2022; 03/17/2023; 03/18/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Perdita Taylor-Zapata, MD; Telephone: 301-496-9584; Email: taylorpe@mail.nih.gov; Telephone: 301-496-9584; Email: taylorpe@mail.nih.gov


---

**Small Research Grants for Establishing Basic Science-Clinical Collaborations to Understand Structural Birth Defects (R03 Clinical Trial Not Allowed)**

**Sponsor:** National Institutes of Health (NIH); Components of Participating Organizations: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Dental and Craniofacial Research (NIDCR); National Institute of Environmental Health Sciences (NIEHS)

**Deadline(s):** Standard dates; 01/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Reiko Toyama, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-2723; Email: toyamae.mail.nih.gov


---

**Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Dental and Craniofacial Research

**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): William Dunty, Ph.D.; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-443-7351; Email: dunnyw@mail.nih.gov


---

**Drug Repurposing for Conditions Affecting Neonates and Pregnant Women (R01 Clinical Trial Optional)**

**Sponsor:** NIH; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2021

**Contact:** Scientific/Research Contact(s): Ekaterini Tsilou, MD; Eunice Kennedy Shriver National Institute of Child Health and Human Development

Human Development (NICHD); Telephone: 301-496-6287; Email: tsiloue@mail.nih.gov


**Notice of NIEHS Participation on PAR-19-162**

**"Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)**

**Sponsor:** National Institute of Environmental Health Sciences

**Deadline(s):** 03/11/2019 (Release Date)

**Contact:** Please direct all inquiries to: Kimberly Gray; National Institute of Environmental Health Sciences (NIEHS); Telephone: 984-287-3262; Email: GRAYK@niehs.nih.gov


**Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)**

**Sponsor:** National Institute on Drug Abuse; National Center for Complementary and Integrative Health; National Cancer Institute; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; Office of Research on Women’s Health

**Deadline(s):** Standard dates; Standard AIDS dates ; 09/08/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Karen Sirocco; National Institute on Drug Abuse (NIDA); Telephone: 301-451-8661; Email: siroccok@nida.nih.gov


**Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)**

**Sponsor:** National Institutes of Health (NIH); National Institute on Drug Abuse (NIDA); National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Minority Health and Health Disparities (NIMHD); National Institute of Mental Health (NIMH); National Cancer Institute (NCI); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.; NIH Office of Research on Women’s Health (ORWH)

**Deadline(s):** Standard dates; Standard AIDS dates ; 09/08/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Karen Sirocco; National Institute on Drug Abuse (NIDA); Telephone: 301-451-8661; Email: siroccok@nida.nih.gov


**Forecasted: HRSA: Emergency Medical Services for Children Data Center**

**Sponsor:** Department of Health and Human Services; Health Resources and Services Administration

**Deadline(s):** None Provided

**Contact:** Theresa Morrison-Quinata, (301) 443-1527; tmorrisonquinata@hrsa.gov

**Link(s):** a direct link is not currently available following is the results of a grant title based grants.gov search that returns a top link to HRSA-17-092


**RFP -- Best Pharmaceuticals for Children Act (BPCA) Data Coordinating Center (DCC)**

**Sponsor:** National Institute of Child Health and Human Development/NIH/DHHS

**Deadline(s):** NA

**Contact:** Deborah Brock; 301-435-6961; Deborah.Brock@nih.gov

**Link(s):** [https://www.fbo.gov/index?s=opportunity&mode=form&id=d84ebc7c37568d7655a48c034568af0&tab=core&_cview=0](https://www.fbo.gov/index?s=opportunity&mode=form&id=d84ebc7c37568d7655a48c034568af0&tab=core&_cview=0)

**USDA**

**NA**

**OMICS**

**NA**

**DOWN SYNDROME**

**INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE)**

**Clinical Trial Readiness (R21 Clinical Trial Not Allowed)**

**Sponsor:** NIH

**Deadline(s):** 11/03/2021; 11/04/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Please direct inquiries related to specific interests of the participating NIH Institutes and Centers (IC) to the IC contacts listed on the INCLUDE Project website.


**Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome) (R61/R33 Clinical Trial Required)**
Sponsor: NIH  
**Deadline(s):** 11/03/2021; 11/04/2021 (Expiration)  
Contact: Please direct inquiries related to specific interests of the participating NIH Institutes and Centers (IC) to the IC contacts listed on the INCLUDE Project website.  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-003.html

Transformative Research Award for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project (R01 Clinical Trial Not Allowed)  
Sponsor: NIH  
**Deadline(s):** 11/03/2021; 11/04/2021 (Expiration)  
Contact: Please direct inquiries related to specific interests of the participating NIH Institutes and Centers (IC) to the IC contacts listed on the INCLUDE Project website.  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-005.html

Genetics  
Telomeres in Wellness and Disease: A Biobehavioral Approach (R21 Clinical Trial Optional)  
Sponsor: National Institute of Nursing Research  
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)  
Contact: Lois A. Tully, PhD; National Institute of Nursing Research (NINR)  
Telephone: 301-594-5968; Email: tullyla@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-073.html

Telomeres in Wellness and Disease: A Biobehavioral Approach (R01 Clinical Trial Optional)  
Sponsor: National Institute of Nursing Research  
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)  
Contact: Lois A. Tully, PhD; National Institute of Nursing Research (NINR)  
Telephone: 301-594-5968; Email: tullyla@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-074.html

ELECTRONIC HEALTH RECORDS  
NA

INFORMATIONIST SERVICES  
NA

BIOSTATISTICS  

Speed Biostatistics Consulting Sessions; First Thursday of Every Month; 3:00 – 5:00 PM  
**Sponsor:** This service is sponsored by the Biostatistics, Epidemiology and Research Design Resource (BERD).  
**Deadline(s):** NA; held first Thursday of every month.; 3:00 - 5:00pm; 722 West 168th Street Floor 6, Room 627; Department of Biostatistics; Mailman School of Public Health; Allan Rosenfield Building  
Contact: Email Dr. Martina Pavlicova at mp2370@cumc.columbia.edu with questions and/or any materials necessary for the consultation.  
**Link(s):** https://irvinginstitute.columbia.edu/resources/biostatistics.html  
https://doodle.com/poll/7m7vt5s9atwe6wy7

MATHEMATICAL MODELING OF LIVING SYSTEMS (MMLS)  
NA

BIG DATA, INFORMATICS, HEALTH INFORMATION SYSTEMS AND GENOMICS  

Biomedical Knowledgebase (U24 – Clinical Trials Not Allowed)  
**Sponsor:** Participating Organization(s): National Institutes of Health (NIH); Components of Participating Organizations: National Institute of General Medical Sciences (NIGMS); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Allergy and Infectious Diseases (NIAID); National Institute on Drug Abuse (NIDA); National Institute of Environmental Health Sciences (NIEHS); National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Minority Health and Health Disparities (NIMHD); National Cancer Institute (NCI)  
**Deadline(s):** 01/25/2023; 05/08/2023; 05/09/2023 (Expiration)  
Contact: Veerasamy Ravichandran, Ph.D.; National Institute of General Medical Sciences; Email: veerasamy.ravichandra@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-20-097.html

Biomedical Data Repository (U24 – Clinical Trials Not Allowed)
Supplemental Information to the NIH Policy for Data Management and Sharing: Selecting a Repository for Data Resulting from NIH-Supported Research

**Sponsor:** National Institutes of Health

**Deadline(s):** 10/29/2020 (Release Date)

**Contact:** Please direct all inquiries to: NIH Office of Science Policy; SciencePolicy@od.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-016.html

Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)

**Sponsor:** National Heart, Lung, and Blood Institute

**Deadline(s):** 02/05/2021 (First Available Due Date); 05/08/2023 (Expiration Date)

**Contact:**

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-823.html

Notice of Intent to Publish a Funding Opportunity Announcement for NLM Institutional Grants for Research Training in Biomedical Informatics and Data Science (T15 Clinical Trial Not Allowed)

**Sponsor:** National Library of Medicine

**Deadline(s):** 05/14/2021 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Valerie Florance, PhD; National Library of Medicine (NLM); 301-496-4621; florancev@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-LM-21-001.html

Notice of Special Interest: Small Grants for Secondary Analyses of Existing Data Sets and Stored Biospecimens

**Sponsor:** Eunice Kennedy Shriver; National Institute of Child Health and Human Development

**Deadline(s):** 10/16/2020 (First Available Due Date); 05/08/2023 (Expiration Date)

**Contact:** Scientific/Research Contact: Regina Bures, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); 301-496-9485; Email: regina.bures@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-022.html

---

**Supplemental Information to the NIH Policy for Data Management and Sharing: Allowable Costs for Data Management and Sharing**

**Sponsor:** National Institutes of Health

**Deadline(s):** 10/29/2020 (Release Date)

**Contact:** Please direct all inquiries to: NIH Office of Science Policy; SciencePolicy@od.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-015.html

---

**Research Experiences in Genomic Research for Data Scientists (R25)**

**Sponsor:** National Human Genome Research Institute

**Deadline(s):** 05/25/2022; 05/25/2023; 05/26/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Shurjo K. Sen, Ph.D.; National Human Genome Research Institute (NHGRI); Phone: 301-827-7028; Email: sensh@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-014.html

---

**Supplemental Information to the NIH Policy for Data Management and Sharing: Elements of an NIH Data Management and Sharing Plan**

**Sponsor:** National Institutes of Health

**Deadline(s):** 10/29/2020 (Release Date)

**Contact:** Please direct all inquiries to: NIH Office of Science Policy; SciencePolicy@od.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-014.html

---

**Supplemental Information to the NIH Policy for Data Management and Sharing: Allowable Costs for Data Management and Sharing**

**Sponsor:** National Institutes of Health

**Deadline(s):** 10/29/2020 (Release Date)

**Contact:** Please direct all inquiries to: NIH Office of Science Policy; SciencePolicy@od.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-015.html

---

**Notice of Special Interest: Small Grants for Secondary Analyses of Existing Data Sets and Stored Biospecimens**

**Sponsor:** Eunice Kennedy Shriver; National Institute of Child Health and Human Development

**Deadline(s):** 10/16/2020 (First Available Due Date); 05/08/2023 (Expiration Date)

**Contact:** Scientific/Research Contact: Regina Bures, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); 301-496-9485; Email: regina.bures@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-022.html

---

**Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)**

**Sponsor:** National Heart, Lung, and Blood Institute

**Deadline(s):** 02/05/2021 (First Available Due Date); 05/08/2023 (Expiration Date)

**Contact:**

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-823.html

---

**Notice of Intent to Publish a Funding Opportunity Announcement for NLM Institutional Grants for Research Training in Biomedical Informatics and Data Science (T15 Clinical Trial Not Allowed)**

**Sponsor:** National Library of Medicine

**Deadline(s):** 05/14/2021 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Valerie Florance, PhD; National Library of Medicine (NLM); 301-496-4621; florancev@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-LM-21-001.html

---

**Supplemental Information to the NIH Policy for Data Management and Sharing: Allowable Costs for Data Management and Sharing**

**Sponsor:** National Institutes of Health

**Deadline(s):** 10/29/2020 (Release Date)

**Contact:** Please direct all inquiries to: NIH Office of Science Policy; SciencePolicy@od.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-015.html

---

**Research Experiences in Genomic Research for Data Scientists (R25)**

**Sponsor:** National Human Genome Research Institute

**Deadline(s):** 05/25/2022; 05/25/2023; 05/26/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Shurjo K. Sen, Ph.D.; National Human Genome Research Institute (NHGRI); Phone: 301-827-7028; Email: sensh@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-014.html

---

**Supplemental Information to the NIH Policy for Data Management and Sharing: Elements of an NIH Data Management and Sharing Plan**

**Sponsor:** National Institutes of Health

**Deadline(s):** 10/29/2020 (Release Date)

**Contact:** Please direct all inquiries to: NIH Office of Science Policy; SciencePolicy@od.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-014.html

---

**Supplemental Information to the NIH Policy for Data Management and Sharing: Allowable Costs for Data Management and Sharing**

**Sponsor:** National Institutes of Health

**Deadline(s):** 10/29/2020 (Release Date)

**Contact:** Please direct all inquiries to: NIH Office of Science Policy; SciencePolicy@od.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-015.html
Request for Information: Data Science Challenges and Opportunities in the Field of Precision Nutrition  
**Sponsor:** Office of Strategic Coordination (Common Fund)  
**Deadline(s):** 11/15/2020 (Response Date)  
**Contact:** Please direct all inquiries to: Holly Nicastro, Ph.D., M.P.H.; Office of Nutrition Research; Telephone: 301-435-0383; Email: nutritionresearch@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-RM-21-005.html

Notice of Special Interest: Administrative Supplements to Connecting Pre-mortem Clinical Information with Post-mortem Brain Analysis  
**Sponsor:** National Institute of Neurological Disorders and Stroke  
**Deadline(s):** 10/26/2020 (First Available Due Date); 06/29/2021 (Expiration Date)  
**Contact:** Please direct all inquiries to: Debra Babcock, PhD, MD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-9964; Email: dbabcock@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-001.html  
**Additional Information:** Related Announcements: PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional)  
**Sponsor:** National Institute of Mental Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Neurological Disorders and Stroke  
**Deadline(s):** 07/14/2022; 07/14/2023; 07/15/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s): Ming Zhan, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-827-3678; Email: ming.zhan@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-600.html

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)  
**Sponsor:** National Cancer Institute; National Human Genome Research Institute; National Institute of Dental and Craniofacial Research  
**Deadline(s):** Standard dates: 09/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s): Melissa Rotunno, Ph.D.; Division of Cancer Control and Population Sciences (DCCPS), National Cancer Institute (NCI); Telephone: 240-276-7245; Email: rotunnom@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/PAR-20-276.html

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)  
**Sponsor:** National Cancer Institute; National Human Genome Research Institute; National Institute of Dental and Craniofacial Research  
**Deadline(s):** Standard dates: 09/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s): Melissa Rotunno, Ph.D.; Division of Cancer Control and Population Sciences (DCCPS), National Cancer Institute (NCI); Telephone: 240-276-7245; Email: rotunnom@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/PAR-20-277.html

Notice Announcing the National Institute of Mental Health (NIMH) Expectations for Collection of Common Data Elements  
**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 10/01/2020 (Unless NIMH stipulates otherwise during the negotiation of the terms and conditions of a grant award, this Notice applies to all grant applications involving human research participants submitted after October 1, 2020)  
**Contact:** Please direct all inquiries to: Gregory K. Farber, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-435-0778; Email: farberg@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-067.html

Notice of a Joint Veterans Health Administration/National Cancer Institute Data Science Postdoctoral Fellowship - the Big Data Scientist Training Enhancement Program (BD-STEP)  
**Sponsor:** National Cancer Institute  
**Deadline(s):** Applications should be submitted online https://service.cancer.gov/bd-step and will be accepted on a rolling
Notice of Special Interest (NOSI) of NIDCR in Supporting Dental, Oral, and Craniofacial Research Using Bioinformatic, Computational, and Data Science Approaches

**Sponsor:** National Institute of Dental and Craniofacial Research

**Deadline(s):** 08/11/2020 (First Available Due Date); 08/08/2023 (Expiration Date)

**Contact:** Scientific/Research Contact: Lu Wang, Ph.D.; National Institute of Dental and Craniofacial Research; Telephone: 301-594-4846; Email: wanglu@nidcr.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DE-20-006.html

The Agency for Healthcare Research and Quality Data Management Plan Policy

**Sponsor:** Agency for Healthcare Research and Quality

**Deadline(s):** 05/26/2020 (Release Date)

**Contact:** Please direct all inquiries to: Hope Hongzhu He, JD, MPA, MA; AHRQ Human Protections Administrator; Office for Extramural Research, Education, and Priority Populations; Agency for Healthcare Research and Quality (AHRQ); Telephone: 301-427-1905; Email: PublicAccess@ahrq.hhs.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-011.html

Biomedical Knowledgebase (U24 – Clinical Trials Not Allowed)

**Sponsor:** Participating Organization(s): National Institutes of Health (NIH); Components of Participating Organizations: National Institute of General Medical Sciences (NIGMS); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Allergy and Infectious Diseases (NIAID); National Institute on Drug Abuse (NIDA); National Institute of Environmental Health Sciences (NIEHS); National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Minority Health and Health Disparities (NIMHD); National Cancer Institute (NCI)

**Deadline(s):** 01/25/2023; 05/08/2023; 05/09/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Veerasamy Ravichandran, Ph.D.; National Institute of General Medical Sciences; Email: veerasamy.ravichandra@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-20-097.html

Advancing Genomic Medicine Research (Clinical Trial Optional) (R01)

**Sponsor:** National Human Genome Research Institute

**Deadline(s):** 11/02/2021; 08/01/2022; 03/13/2023; 03/14/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Ms. Christine Chang; National Human Genome Research Institute (NHGRI); Telephone: 301-480-2255; Email: christine.chang2@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-036.html

Advancing Genomic Medicine Research (Clinical Trial Optional) (R21)

**Sponsor:** National Human Genome Research Institute

**Deadline(s):** 11/02/2021; 08/01/2022; 03/13/2023; 03/14/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Ms. Christine Chang; National Human Genome Research Institute (NHGRI); Telephone: 301-480-2255; Email: christine.chang2@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-037.html

Columbia Mailman School of Public Health

RESEARCH RESOURCES
mailman.columbia.edu/r2
**Biomedical Data Repository (U24 – Clinical Trials Not Allowed)**

**Sponsor:** Participating Organization(s): National Institutes of Health (NIH); Components of Participating Organizations: National Institute of General Medical Sciences (NIGMS); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Allergy and Infectious Diseases (NIAID); National Institute on Drug Abuse (NIDA); National Institute of Environmental Health Sciences (NIHES); National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Minority Health and Health Disparities (NIMHD); National Cancer Institute (NCI)

**Deadline(s):** 01/25/2023; 05/08/2023; 05/09/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Veerasamy Ravichandran, Ph.D.; National Institute of General Medical Sciences; Email: veerasamy.ravichandra@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-20-089.html

**Notice of NHGRIs Participation in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)”**

**Sponsor:** National Human Genome Research Institute

**Deadline(s):** 03/31/2020 (Release Date); Earliest start dates may vary by awarding IC. See the Urgent Guide Notices for any applicable Application Due Dates.; Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. [From pa-18-935]

**Contact:** Inquiries; Please direct all inquiries to: Jennifer Troyer, Ph.D.; NIH National Human Genome Research Institute; Telephone: 301-312-3276; Email: jennifer.troyer@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HG-20-034.html

**Notice of Transfer of The National Children’s Study (NCS) Archive Materials to the NICHD Data and Specimen Hub (DASH)**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Deadline(s):** 03/27/2020 (Release Date)

**Contact:** Please direct all inquiries to: Jack Moye, Jr., MD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-594-8624; Email: john.moye@nih.hhs.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-010.html

**Notice of Information: Leveraging STRIDES for Cloud Computing Activities in Common Fund Awards**

**Sponsor:** Office of Strategic Coordination (Common Fund)

**Deadline(s):** 03/19/2020 (Release Date)

**Contact:** Please direct all inquiries to: Stephanie Courchesne-Schlink, Ph.D.; Office of Strategic Coordination (OSC); Office of the Director (OD); Telephone: 301-451-6387; Email: stephanie.courchesne@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-RM-20-009.html

**Genomic Community Resources (U24 Clinical Trial Not Allowed)**

**Sponsor:** National Human Genome Research Institute

**Deadline(s):** Standard dates: 01/26/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Christopher Wellington; National Human Genome Research Institute (NHGRI); Telephone: 301-480-3496; Email: wellingtonc@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-20-100.html

**Genomic Expert Curation Panels (U24 Clinical Trial Not Allowed)**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Eye Institute; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke

**Deadline(s):** 05/27/2022; 05/27/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Melissa A. Parisi, MD, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6880; Email: parisima@mail.nih.gov


[1] Ethical, Legal, and Social Implications (ELSI) of Genomics Research R01

[2] Ethical, Legal, and Social Implications (ELSI) of Genomics Research R03

[3] Ethical, Legal, and Social Implications (ELSI) of Genomics Research R21

**Sponsor:** NIH

**Deadline(s):** Standard dates; Standard AIDS dates 09/08/2020 (Expiration)

**Contact:** Scientific/Research Contact(s): Joy Boyer; National Human Genome Research Institute (NHGRI); Telephone: 301-402-4997; Email: boyerj@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-17-444.html R01
Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)

**Sponsor:** National Heart, Lung, and Blood Institute  
**Deadline(s):** 10/28/2021; 02/26/2022; 10/28/2022; 11/26/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Ruth Kirby, RN, BS; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-0401; Email: kirbyr@nih.nhlbi.gov  
**Link(s):** https://grants.nih.gov/grants/guide/parfiles/PA-20-078.html

Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (U01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 09/1/2021; 09/15/2022; 09/16/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Miri Gitik, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-827-3523; Email: miri.gitik@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/parfiles/PA-20-026.html

Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (Collaborative U01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 09/1/2021; 09/15/2022; 09/16/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Miri Gitik, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-827-3523; Email: miri.gitik@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/parfiles/PA-20-027.html

Omics-guided Biobehavioral Interventions for Improved Health Outcomes: A Step Forward in Translation (R01 Clinical Trial Optional)

**Sponsor:** National Institute of Nursing Research  
**Deadline(s):** Standard dates; Standard AIDS dates; 01/08/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Lois A. Tully, PhD; National Institute of Nursing Research (NINR); Telephone: 301-594-5968; Email: tullyla@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/parfiles/PA-19-377.html

ABCD Study News; The Adolescent Brain Cognitive Development (ABCD) Study

**Sponsor:** https://nda.nih.gov/abcd  
**Deadline(s):** NA  
**Contact:** https://abcdstudy.org/contact/  
**Link(s):** https://abcdstudy.org/  

Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)

**Sponsor:** National Heart, Lung, and Blood Institute  
**Deadline(s):** New and Revision Applications: 02/11/2021; 06/10/2021; 10/14/2021; 02/11/2022; 06/10/2022; 09/09/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Division of Blood Diseases and Resources; Nancy DiFronzo, PhD; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-0065; Email: difronzon@nih.nhlbi.gov  
**Link(s):** https://grants.nih.gov/grants/guide/parfiles/PA-19-330.html  
**Additional Information:** Applications must be submitted for the same due date as the collaborating CCC (UG3/UH3) application.

Computing Resources Available at Data Science Institute

**Sponsor:** CU Data Science Institute  
**Deadline(s):** NA  
**Contact:** help@datascience.columbia.edu  
**Link(s):** https://datascience.columbia.edu/columbia-data-science  
https://wikis.cuit.columbia.edu/confluence/display/rcs/Habanero+HPC+Cluster+User+Documentation

Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Allergy and Infectious Diseases  
**Deadline(s):** Standard dates; 01/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Ishwar ChandramouliSwaran M.S., M.B.A; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 301-761-7822; Email: ishwar.chandramouliSwaran@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/parfiles/PA-19-068.html

Limited Submission; NIH Data Science Research: Personal Health Libraries for Consumers and Patients (R01) – PAR-19-072

**Sponsor:** NIH; National Library of Medicine (NLM)
Friday Newsletter 07/16/2021

Deadline(s): 06/30/2021; 07/31/2021 (Expiration Date)
Contact: Scientific/Research Contact(s); Alan VanBiervliet, PhD; National Library of Medicine (NLM); Telephone: 301-594-4882; Email: vanbiervlietag@mail.nih.gov; Questions should be sent to limitedsubmissions@columbia.edu

High-Priority Areas for Research Leveraging EHR and Large-Scale Data (R01 Clinical Trial Not Allowed)
Sponsor: National Institute of Mental Health; National Institute of Neurological Disorders and Stroke
Deadline(s): Standard dates; 09/08/2022 (Expiration)
Contact: Scientific/Research Contact(s); Farris Tuma, ScD; National Institute of Mental Health; Telephone: 301-443-9232; Email: fmtuma@mail.nih.gov

New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 (Collab) Clinical Trial Not Allowed)
Sponsor: National Institute of Mental Health
Deadline(s): Standard dates; 01/08/2022 (Expiration)
Contact: Scientific/Research Contact(s); Alexander Arguello, PhD; National Institute of Mental Health; (NIMH); Telephone: 301-827-3547; Email: alexander.arguello@nih.gov

New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 Clinical Trial Not Allowed)
Sponsor: National Institute of Mental Health
Deadline(s): 01/08/2022 (Expiration)
Contact: Scientific/Research Contact(s); Alexander Arguello, PhD; National Institute of Mental Health; (NIMH); Telephone: 301-827-3547; Email: alexander.arguello@nih.gov

Columbia University Data Science Institute DSI Research (formerly Campus Connections) Program
Sponsor: http://datascience.columbia.edu
Deadline(s): NA
Contact: Rachel Fuld Cohen; Assistant Director of Student Services & Career Development; Data Science Institute; Columbia University; 500 West 120th Street; Room 432 (Mudd); New York, NY 10027; (212)854-9325; rachel.cohen@columbia.edu
Link(s): http://datascience.columbia.edu/project-submission-form

NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)
Sponsor: National Library of Medicine

Deadline(s): 09/08/2021 (Expiration)
Contact: Scientific/Research Contact(s); For Clinical and Public Health Informatics: Hua-Chuan Sim, MD; National Library of Medicine (NLM); Telephone: 301-594-4882; Email: simh@mail.nih.gov

Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)
Sponsor: National Human Genome Research Institute
Deadline(s): 11/16/2020; 07/16/2021
Contact: Scientific/Research Contact(s); Daniel Gilchrist, Ph.D.; National Human Genome Research Institute (NHGRI); Telephone: 301-496-7531; Email: daniel.gilchrist@nih.gov

Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)
Sponsor: National Human Genome Research Institute
Deadline(s): 07/16/2021
Contact: Scientific/Research Contact(s); Daniel Gilchrist, Ph.D.; National Human Genome Research Institute (NHGRI); Telephone: 301-496-7531; Email: daniel.gilchrist@nih.gov

Analyses of CALERIE Data and Biospecimens to Elucidate Mechanisms of Caloric Restriction (CR)-Induced Effects in Humans (R01 - Clinical Trial Not Allowed)
Sponsor: National Institute on Aging
Deadline(s): 09/08/2021 (Expiration)
Contact: Scientific/Research Contact(s); Giovanna Zappalà, Ph.D., M.P.H.; National Institute on Aging (NIA); Telephone: 301-827-6240; Email: Giovanna.Zappalà@nih.gov

Exploratory Analyses of CALERIE Data and Biospecimens to Elucidate Mechanisms of Caloric Restriction (CR)-Induced Effects in Humans (R21 - Clinical Trial Not Allowed)
Sponsor: National Institute on Aging
Deadline(s): 09/08/2021 (Expiration)
Contact: Scientific/Research Contact(s); Giovanna Zappalà, Ph.D., M.P.H.; National Institute on Aging (NIA); Telephone: 301-827-6240; Email: Giovanna.Zappalà@nih.gov

Analyses of Adherence Strategies and Data Sets from CALERIE to Explore Behavioral and Psychosocial Aspects
Exploratory Analyses of Adherence Strategies and Data Sets from CALERIE to Investigate Behavioral and Psychosocial Aspects of Sustained Caloric Restriction in Humans (R21 - Clinical Trial Not Allowed)

**Sponsor:** National Institute on Aging

**Deadline(s):** Standard dates; 09/08/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Giovanna Zappalà, Ph.D., M.P.H.; National Institute on Aging (NIA); Telephone: 301-827-6240; Email: Giovanna.Zappala@nih.gov


Implementation of the NIH Genomic Data Sharing Policy for NIH Grant Applications and Awards

**Sponsor:** Office of the Director, NIH

**Deadline(s):** NA

**Contact:** Genomic Data Sharing Policy Team; Office of Science Policy; Telephone: 301-496-9838; Email: GDS@nih.gov - See more at: [https://grants.nih.gov/grants/guide/pa-files/NOT-OD-14-111.html#hash.cNncFqH.dput](https://grants.nih.gov/grants/guide/pa-files/NOT-OD-14-111.html#hash.cNncFqH.dput)

**Link(s):** [NOT-OD-14-111](https://grants.nih.gov/grants/guide/pa-files/NOT-OD-14-111.html)

**DISABILITIES**

NA

**LEARNING / DEVELOPMENTAL DISABILITIES**

**Notice of Special Interest: Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities (R43/R44)**

**Sponsor:** NIH; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

**Deadline(s):** 01/05/2021 (First Available Due Date); 01/08/2022 (Expiration Date)

**Contact:** Scientific/Research Contact(s); Sujata Bardhan, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-0471; Email: sujata.bardhan@nih.gov


**AUTISM SPECTRUM DISORDERS**

**Notice of Intent to Publish a Funding Opportunity Announcement for Autism Centers of Excellence: Networks (R01 Clinical Trial Optional)**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke

**Deadline(s):** 11/30/2021 (First Estimated Application Due Date)

**Contact:** Alice Kau, Ph.D.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-496-1383; Email: kaua@mail.nih.gov


**Notice of Intent to Publish a Funding Opportunity Announcement for Autism Centers of Excellence: Centers (P50 Clinical Trial Optional)**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke

**Deadline(s):** 11/30/2021 (First Estimated Application Due Date)

**Contact:** Alice Kau, Ph.D.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-496-1383; Email: kaua@mail.nih.gov


**Identification and Management of Behavioral Symptoms and Mental Health Conditions in Individuals with Intellectual Disabilities (R01-Clinical Trial Optional)**

**Sponsor:** DHHS; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

**Deadline(s):** Standard dates; 09/08/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Tracy King, MD, MPH; Intellectual and Developmental Disabilities Branch (IDD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-402-1822; Email: tracy.king@nih.gov


Research on Autism Spectrum Disorders (R01);
Sponsor: National Institute of Mental Health/NIH/DHHS; Department of Health and Human Services;
Deadline(s): Standard Dates;
http://grants.nih.gov/grants/funding/submissionschedule.htm;
Contact: Lisa Gilotty, Ph.D.; Address: Division of Developmental Translational Research; 6001 Executive Blvd; Room 6179; MSC 9617; Bethesda, MD 20892-9617; U.S.A.; Tel: 301-443-3825; Fax: 301-480-4415; E-mail: gilottyl@mail.nih.gov;
Link(s): Program URL: http://grants1.nih.gov/grants/guide/pa-files/PA-13-216.html;

REGENERATIVE MEDICINE

DEFENSE HEALTH AGENCY

NA

VETERANS ADMINISTRATION

DEPARTMENT OF DEFENSE (DOD), and DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA)

Department of Defense, Peer Reviewed Medical Research Program (PRMRP) Anticipated Funding Opportunities for FY21
Sponsor: Department of Defense
Deadline(s): NA, Anticipated Funding Opportunities FY21
Contact: Point of Contact: CDMRP Public Affairs; usarmy.detrick.medcom-cdmrp.nbx.cdmrp-public-affairs@mail.mil

FY21 DOD Pre-Announcements
Department of Defense Neurofibromatosis Research Program Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)
Sponsor: Department of Defense
Deadline(s): NA, Pre-Announcements
Contact: help@ebrap.org

FY21 DoD DMRDP Program Announcements; Defense Medical Research and Development Program (DMRDP) being managed by the office of Congressionally Directed Medical Research Programs (CDMRP)
Sponsor: Department of Defense
Deadline(s): please see piecemeal opportunities
Contact: help@ebrap.org
https://ebrap.org/eBRAP/programSubscription/Subscribe.htm

Subscribe to FY21 Department of Defense Announcements by Field
Sponsor: Department of Defense
Deadline(s): NA, Pre-Announcements
Contact: help@ebrap.org
Friday Newsletter 07/16/2021


Department of Defense FY21 Pre-Announcements
Defense Health Program Department of Defense Military Burn Research Program (MBRP) Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)
Defense Health Program Department of Defense Autism Research Program (ARP) Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)

Sponsor: Department of Defense
Deadline(s): NA (Pre-Announcements)
Contact: help@ebrap.org

Department of Defense, New FY21 Policy on the Inclusion of Women and Minorities in Clinical Research
Department of Defense, FY21 Ovarian Cancer Research Program Pre-Announcements
Department of Defense, FY21 Breast Cancer Research Program Pre-Announcements
Department of Defense, FY21, Currently Available Funding Opportunities

Sponsor: Department of Defense
Deadline(s): NA; New FY21 Policy; Updated July 2020
Contact: help@ebrap.org
Link(s): https://ebrap.org/eBRAP/public/ViewFileTemplate.htm?fileTemplateId=8266800&fileType=pdf

Department of Defense FY21 Pre-Announcements
Department of Defense FY21 Funding Opportunities: Breast Cancer Research Program (BCRP)

Sponsor: Department of Defense
Deadline(s): For Pre-Announcements, NA; for BCRP please see Department of Defense FY21 Funding Opportunities: Breast Cancer Research Program (BCRP)
Contact: help@ebrap.org
https://cdmrp.army.mil/funding/bcrp [Department of Defense FY21 Funding Opportunities: Breast Cancer Research Program (BCRP)]

[1] Department of Defense; Ovarian Cancer Research Program; Anticipated Funding Opportunities
[2] Department of Defense; Breast Cancer Research Program; Anticipated Funding Opportunities
[3] CDMRP Website
Sponsor: Department of Defense
Deadline(s): NA, Pre-Announcements
Contact: Point of Contact: CDMRP Public Affairs; 301-619-9783; usarmy.detrick.medcom-cdcmp.mbx.cdmrp-public-affairs@mail.mil
https://cdmrp.army.mil [CDMRP Website]

Department of Defense, DOD, FY 2020 Pre-Announcements; Combat Readiness—Medical Research Program; Rapid Development and Translational Research Award
Sponsor: Department of Defense
Deadline(s): NA, Pre-Announcements
Contact: help@ebrap.org; CDMRP Public Affairs; 301-619-9783; usarmy.detrick.medcom-cdcmp.mbx.cdmrp-public-affairs@mail.mil
Link(s): https://cdmrp.army.mil/pubs/press/2020/20crrp_ann [Department of Defense Pre-Announcements; Combat Readiness—Medical Research Program; Rapid Development and Translational Research Award]

Department of Defense; United States Army Medical Research Materiel Command; Congressionally Directed Medical Research Programs; CDMRP Research Funding for 2020
Sponsor: Department of Defense
Deadline(s): Anticipated, please see piecemeal announcements
Contact: Point of Contact: CDMRP Public Affairs; 301-619-7783; usarmy.detrick.medcom-cdcmp.mbx.cdmrp-public-affairs@mail.mil
JUST RELEASED! FY20 ARP, BMFRP, MBRP, NFRP, OCRP, PRARP, and TSCRP Pre-Announcements

**Sponsor:** Department of Defense  
**Deadline(s):** Pre-Announcements, NA  
**Contact:**  
**Point of Contact:** CDMRP Public Affairs; 301-619-7783; usarmy.detrick.medcom-cdmrpx.mbx.cdmrp-public-affairs@mail.mil  
**Link(s):** https://cdmrp.army.mil/pubs/press/cdmrp_presses

Defence Health Program; Department of Defense Breast Cancer Research Program; Anticipated Funding Opportunities for Fiscal Year 2020

**Sponsor:** Department of Defense  
**Deadline(s):** NA, Pre-Announcements  
**Contact:**  
**Point of Contact:** CDMRP Public Affairs; 301-619-9783; usarmy.detrick.medcom-cdmrpx.mbx.cdmrp-public-affairs@mail.mil  
**Link(s):** https://cdmrp.army.mil/pubs/press/2020/20bcrppreann

URGENT: EXTENSIONS / VARIANCES IN SUBMISSION DEADLINES FOR CDMRP FUNDING OPPORTUNITIES DUE TO HURRICANE DORIAN

**Sponsor:** Department of Defense  
**Deadline(s):** Pre-applications will not be accepted [post deadline] if you do not submit an appeal with an explanation to the eBRAP Helpdesk at Help@eBRAP.org; Approval must be received from the appropriate program for a submission extension  
**FULL APPLICATION DEADLINES:** A Grace Period has been added to the Grants.gov submission deadline, but the application will not be accepted if you do not submit an appeal with an explanation to the eBRAP Helpdesk at Help@eBRAP.org. Approval must be received from the appropriate program for a submission extension  
**Contact:** Help@eBRAP.org  
**Link(s):** https://cdmrp.army.mil/funding/prgdefault

US DEPARTMENT OF STATE  
NA  
USAID  
NA  
RENAI/KIDNEY RESEARCH  
NA  
CANNABIS / CANNABINOIDS  
NA  
LUPUS AND AUTOIMMUNITY  
NA  
IMMUNITY

Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease
**Clinical Trial Optional**

**Announcement for Tobacco Regulatory Science (R01 Notice of Intent to Publish a Funding Opportunity**

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; National Institute of Dental and Craniofacial Research; Office of Research on Women’s Health

**Deadline(s):** Spring 2021 (First Estimated Application Due Date)

**Contact:** TRSP@nih.gov


**Notice of Intent to Publish a Funding Opportunity**

**Announcement for Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2) (Clinical Trials Not Allowed)**

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; National Institute of Dental and Craniofacial Research; Office of Research on Women’s Health

**Deadline(s):** Spring 2021 (First Estimated Application Due Date)

**Contact:** TRSP@nih.gov


**TOBACCO, NICOTINE AND E-CIGARETTES**

**Notice of Intent to Publish a Funding Opportunity**

**Announcement for Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)**

Sponsor: Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environmental Health Sciences

**Deadline(s):** 10/08/2021 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Tobacco Regulatory Science Program; Office of Disease Prevention; 301-451-7464; TRSP@nih.gov


**Notice of Intent to Publish a Funding Opportunity**

**Announcement for Tobacco Regulatory Science (R01 Clinical Trial Optional)**

Sponsor: Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environmental Health Sciences

**Deadline(s):** 07/14/2021 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Tobacco Regulatory Science Program; Office of Disease Prevention 301-451-7464; TRSP@nih.gov


**Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)**

Sponsor: National Institute on Drug Abuse

**Deadline(s):** 10/29/2021; 04/29/2022; 10/31/2022; 04/28/2023; 11/01/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Heather L. Kimmel, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-443-6504; Email: heather.kimmel@nih.gov


**Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional)**

Sponsor: Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environmental Health Sciences

**Deadline(s):** Standard dates; 09/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Bob Vollinger, DrPH, MSPH; National Cancer Institute (NCI); Telephone: 240-276-6919; Email: Bob.Vollinger@nih.gov


**Tobacco Control Policies to Promote Health Equity (R21 Clinical Trial Optional)**

Sponsor: National Cancer Institute; Office of Disease Prevention

**Deadline(s):** 11/12/2020; Standard dates; 09/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Bob Vollinger, DrPH, MSPH; National Cancer Institute (NCI); Telephone: 240-276-6919; Email: Bob.Vollinger@nih.gov


Sponsor: Office of Disease Prevention; National Institute on Drug Abuse

**Contact:**

**Link(s):**
HEPATITIS

NA

LYME DISEASE / TICKBORNE DISEASES

NA

PALLIATIVE / END OF LIFE CARE / HOSPICES / SURVIVORSHIP

End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21- Clinical Trial Optional)
Sponsor: National Institute of Nursing Research
Deadline(s): Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)
Contact: Scientific/Research Contact(s); Karen A. Kehl, Ph.D.; National Institute of Nursing Research (NINR); Telephone: 301-594-8010; Email: kehlka@nih.gov

End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional)
Sponsor: National Institute of Nursing Research
Deadline(s): Standard dates; Standard AIDS dates; 01/08/2022 (Expiration)
Contact: Scientific/Research Contact(s); Karen A. Kehl, Ph.D.; National Institute of Nursing Research (NINR); Telephone: 301-594-8010; Email: kehlka@nih.gov

MUSCULOSKELETAL ISSUES/ORTHOPEDICS/ARTHRITIS

Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Telephone: 301-451-3884; Email: wangx1@mail.nih.gov

PAIN AND PAIN MANAGEMENT

HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Required)
Sponsor: National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research
Deadline(s): 09/08/2021; 01/06/2022; 04/06/2022; 09/08/2022; 09/09/2022 (Expiration)
Contact: Scientific/Research Contact(s); Stephanie Fertig, MBA; National Institute of Neurological Disorders and Stroke (NINDS); Phone: 301-496-1778; Email: fertigs@ninds.nih.gov
Link(s): https://grants.nih.gov/grants/guide/notice-files/RFA-NS-20-008.html

HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
Sponsor: National Institute of Neurological Disorders and Stroke; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
**Deadline(s):** 09/08/2021; 01/06/2022; 04/06/2022; 09/08/2022; 09/09/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Stephanie Fertig, MBA; National Institute of Neurological Disorders and Stroke (NINDS); Phone: 301-496-1778; Email: fertigs@ninds.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-009.html

**HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)**

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute on Deafness and Other Communication Disorders; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research

**Deadline(s):** 09/08/2021; 01/06/2022; 04/06/2022; 09/09/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Stephanie Fertig, MBA; National Institute of Neurological Disorders and Stroke (NINDS); Phone: 301-496-1778; Email: fertigs@ninds.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-010.html

**HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)**

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research; National Library of Medicine; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** 09/08/2021; 01/06/2022; 04/06/2022; 09/08/2022

**Contact:** Scientific/Research Contact(s); Stephanie Fertig, MBA; National Institute of Neurological Disorders and Stroke (NINDS); Phone: 301-496-1778; Email: fertigs@ninds.nih.gov


**HEAL/NINDS Early Phase Pain Investigation Clinical Network (EPPIC-Net): Opening to applications for non-addictive pain therapeutics**

**Sponsor:** National Institute of Neurological Disorders and Stroke

**Deadline(s):** The application form and information packet can be found at https://www.ninds.nih.gov/Current-Research/Trans-Agency-Activities/NINDS-Role-HEAL-Initiative/NINDS-Role-HEAL-Initiative-EPPIC. EPPIC-Net will open for applications on September 3, 2019.

**Contact:** Please direct all inquiries to: Barbara I. Karp, MD; National Institute of Neurological Disorders and Stroke; Telephone: 301-496-0150; Email: barbara.karp@nih.gov; Rebecca Hommer, MD; National Institute of Neurological Disorders and Stroke; Telephone: 301-827-2257; Email: rebecca.hommer@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NS-19-075.html

**Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional)**

**Sponsor:** National Center for Complementary and Integrative Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; Office of Behavioral and Social Science Research; Office of Research on Women’s Health

**Deadline(s):** Standard dates; 05/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Inna Belfer, M.D., Ph.D.; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-435-1573; Email: inna.belfer@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-200.html

**Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional)**

**Sponsor:** National Center for Complementary and Integrative Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; Office of Behavioral and Social Science Research; Office of Research on Women’s Health

**Deadline(s):** Standard dates; 05/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Inna Belfer, M.D., Ph.D.; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-435-1573; Email: inna.belfer@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-19-201.html
Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional)

**Sponsor:** National Institute on Drug Abuse; National Center for Complementary and Integrative Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Yu (Woody) Lin, MD, PhD; National Institute on Drug Abuse (NIDA); Telephone: 301-435-1318; Email: ylin1@nida.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/PA-18-917.html

Anorexia Nervos and Bulimia

NA

FOOD, DIGESTIVE, NUTRITION, METABOLITES, OBESITY, DIETARY, SUPPLEMENTS, SAFETY

Columbia Digestive Disease and Liver Research Center Pilot and Feasibility Program

**Sponsor:** https://www.columbiaidrdc.org

**Deadline(s):** 03/19/2021 (LOI); The LOI should be emailed to Seetha Srinivasan svs2113@columbia.edu

**Contact:** If you have any questions concerning this opportunity, please email Kara Gross Margolis kmg2133@columbia.edu or Utpal Pajvani up2104@columbia.edu

**Link(s):** https://www.columbiaidrdc.org/funding/

Notice of Special Interest (NOSI): Obesity Policy Evaluation Research (R01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Office of Behavioral and Social Sciences Research; Office of Disease Prevention

**Deadline(s):** 09/08/2023 (Expiration Date)

**Contact:** Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: Scientific/Research Contact(s); Mary Evans, Ph.D.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-594-4578; email: evansmary@niddk.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-035.html

Additional Information: Related Announcements: PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

NIDDK 2020-2030 Strategic Plan for NIH Nutrition Research

**Sponsor:** NIDDK

**Deadline(s):** 05/2020 (Release Date)

**Contact:** healthinfo@niddk.nih.gov

**Link(s):** https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/strategic-plan-nih-nutrition-research


Administrative Supplement for Research on Dietary Supplements (Admin Supp-Clinical Trial Not Allowed)

**Sponsor:** Office of Dietary Supplements; John E. Fogarty International Center; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Institute on Minority Health and Health Disparities; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Deadline(s):** 10/15/2021; 01/15/2022; 04/15/2022; 10/15/2022; 01/15/2023; 04/15/2023; 04/16/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Cindy Davis; Office of Dietary Supplements (ODS); Telephone: 301-496-0168; Email: davisci@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/PA-20-227.html

Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...
Cancer Institute (NCI); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP); Office of Behavioral and Social Sciences Research (OBSSR)

**Deadline(s):** 08/10/2021; 09/10/2021; 09/11/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Mary Evans, Ph.D.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-594-4578; Email: evansmary@mail.nih.gov


Role of Environmental Chemical Exposures in the Development of Obesity, Type 2 Diabetes and Metabolic Syndrome (R21);

**Sponsor:** NIH; National Institute of Environmental Health Sciences (NIEHS); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH/DHHS;

**Deadline(s):** Standard Dates; AIDS Dates/NA;

**Contact:** Scientific/Research Contact(s); Jarrod Heindel, PhD; National Institute of Environmental Health Sciences (NIEHS); Telephone: 919-541-0781; Email: heindelj@niehs.nih.gov

[Link(s):](http://grants.nih.gov/grants/guide/pa-files/PA-12-184.html)

Exploratory/Developmental Clinical Research Grants in Obesity (R21)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Cancer Institute (NCI); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Office of Dietary Supplements (ODS)

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2018 (Expiration)

**Contact:** Scientific/Research Contact(s); Robert J. Kuczmarski, Dr.P.H.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-451-8354; Email: kuczmarskr@mail.nih.gov


**VACCINES / IMMUNIZATIONS**

**Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional)**

**Sponsor:** National Cancer Institute

**Deadline(s):** Standard dates; 09/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Sarah Kobrin, Ph.D., MPH; National Cancer Institute (NCI); Telephone: 240-276-6931; Email: kobrins@mail.nih.gov


**Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 Clinical Trial Optional)**

**Sponsor:** National Cancer Institute

**Deadline(s):** Standard dates; 07/17/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Sarah Kobrin, Ph.D., MPH; National Cancer Institute (NCI); Telephone: 240-276-6931; Email: kobrins@mail.nih.gov

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)

**Sponsor:** National Cancer Institute  
**Deadline(s):** Standard dates; 09/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Sarah Kobrin, Ph.D., MPH; National Cancer Institute (NCI); Telephone: 240-276-6931; Email: kobrins@mail.nih.gov


**ALZHEIMER’S DISEASE / DEMENTIA**

Alzheimer’s Drug Discovery Foundation | Harrington Scholar Program

**Sponsor:** [https://www.alzdiscovery.org](https://www.alzdiscovery.org) ; [www.harringtondiscovery.org](www.harringtondiscovery.org)

**Deadline(s):** 04/23/2021 (LOI); 07/20/2021 (Application)

**Contact:** We encourage you to contact us if you would like to discuss your proposed project and receive initial feedback.; For scientific inquiries, please contact: Alzheimer’s Drug Discovery Foundation

Meriel Owen, PhD; Assistant Director, Scientific Affairs; mowen@alzdiscovery.org; Harrington Discovery Institute; Bronwyn J. Monroe; Director, Programs; bronwyn.monroe@harringtondiscovery.org;

Website: [www.harringtondiscovery.org/addf](www.harringtondiscovery.org/addf); For application submission inquiries, please contact: Grants and Contracts Team grants@alzdiscovery.org

**Link(s):** [https://www.alzdiscovery.org/research-and-grants/funding-opportunities/harrington](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/harrington)

Notice of Special Interest (NOSI): Sensory and Motor System Changes as Predictors of Preclinical Alzheimers Disease

**Sponsor:** National Institute on Aging

**Deadline(s):** 03/11/2021 (First Available Due Date); 11/13/2021 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Coryse St. Hillaire-Clarke, Ph.D.; National Institute on Aging (NIA); Phone: 301-827-6944; Email: sthillaireclacn@mail.nih.gov


Notice of Special Interest: Basic and Translational Research on Affective, Motivational, and Social Function in Normative Aging and/or Alzheimers Disease and Related Dementias (AD/ADRD)

**Sponsor:** National Institute on Aging

**Deadline(s):** 10/05/2020 (First Available Due Date); 01/08/2022 (Expiration Date)

**Contact:** Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: Scientific/Research Contact(s): Janine Simmons, M.D., Ph.D.; National Institutes on Aging (NIA); Telephone: 301-480-8959; Email: janine.simmons@nih.gov


Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer’s Dementia (R01 Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health

**Deadline(s):** Standard dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Jovier Evans, PhD; National Institute of Mental Health (NIMH); Telephone: 301-443-1369; Email: jevans1@mail.nih.gov


Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer’s Dementia (R21 Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health

**Deadline(s):** Standard dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Jovier Evans, PhD; National Institute of Mental Health (NIMH); Telephone: 301-443-1369; Email: jevans1@mail.nih.gov


Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease (R01 Clinical Trial Optional)

**Sponsor:** National Institute on Aging

**Deadline(s):** Standard dates; 05/08/2023 (Expiration)
Harmonization of Alzheimers Disease and Related Dementias (AD/ADRD) Genetic, Epidemiologic, and Clinical Data to Enhance Therapeutic Target Discovery (U24 Clinical Trial Not Allowed)

**Sponsor:** National Institute on Aging  
**Deadline(s):** Standard dates apply, 05/25/2020 (First standard due date); 01/26/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Marilyn Miller, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-9350; Email: millerm@nia.nih.gov  
Notice of Special Interest: High-Priority Research Topics for PAR-19-071
Sponsor: National Institute on Aging
Deadline(s): 11/12/2021; 11/13/2021 (Expiration) [for PAR-19-071]
Contact: Submissions should indicate that they are in response to NOT-AG-19-007 in Field 4.b on the SF 424 form.; Please direct all inquiries to: Austin Yang, Ph.D.; National Institute on Aging (NIA); Television: 301-496-9350; Email: yangj13@mail.nih.gov

Notice to Specify High-Priority Research Topic for PAR-19-070 and PAR-19-071
Sponsor: National Institute on Aging
Deadline(s): 11/12/2021; 11/13/2021 (Expiration)
Contact: Please direct all inquiries to: Elena Fazio; National Institute on Aging (NIA); Television: 301-496-3136; Email: elena.fazio@nih.gov

Notice to Specify High-Priority Research Topic for PAR-19-070 and PAR-19-071
Sponsor: National Institute on Aging
Deadline(s): 02/02/2019 (Release Date); 11/12/2021; 11/13/2021 (Expiration)
Contact: Please direct all inquiries to: Elena Fazio; National Institute on Aging (NIA); Television: 301-496-3136; Email: elena.fazio@nih.gov

Research on Current Topics in Alzheimer’s Disease and Its Related Dementias (R01 Clinical Trial Optional)
Sponsor: National Institute on Aging; National Institute of Neurological Disorders and Stroke
Deadline(s): 11/12/2021; 11/13/2021 (Expiration)
Contact: Scientific/Research Contact(s); Robin A. Barr, D.Phil.; National Institute on Aging (NIA); Telephone: 301-402-7715; Email: BarrR@mail.nih.gov

Research on Current Topics in Alzheimer’s Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)
Sponsor: National Institute on Aging

Deadline(s): 11/12/2021; 11/13/2021 (Expiration)
Contact: Scientific/Research Contact(s); Robin A. Barr, D.Phil.; National Institute on Aging (NIA); Telephone: 301-402-7715; Email: BarrR@mail.nih.gov

Small Business Alzheimer's Disease Research (R41/R42)
Sponsor: National Institute on Aging
Deadline(s): Standard dates, by 5:00 PM local time of applicant organization.; http://grants.nih.gov/grants/funding/submissionschedule.htm;
Contact: Scientific/Research Contact(s); Partha Bhattacharyya, Ph.D.; National Institute of Aging (NIA)
Division of Behavioral and Social Research (DBSR); Telephone: 301-496-3138; Email: bhattacharyyap@mail.nih.gov;
Link(s): http://grants.nih.gov/grants/guide/pa-files/PA-16-092.html;

PATHOLOGY
NA

CLINICAL TRIALS

Chia, A Large Annotated Corpus of Clinical Trial Eligibility Criteria
Sponsor: Co-authored by Irving Institute faculty Chunhua Weng and lab support staff Alex Butler
Deadline(s): 08/27/2020 (Publication Date)
Contact: chunhua@columbia.edu

NIH PHS Human Subjects and Clinical Trials Information Form Walk-through and
CU SPA NIH Proposal Information
Sponsor: NIH
Deadline(s): NA
Contact: [brought to our attention by] Stephanie F. Scott, MS, CRA; Director of Policy and Research Development; Columbia | Research ; Sponsored Projects Administration; sfs2110@cumc.columbia.edu ; Website: https://spa.columbia.edu/
Link(s): https://www.youtube.com/watch?v=FNgOHQmk0rY&feature=youtu.be
https://research.columbia.edu/nih-proposal-information
Additional Information: [SPA News] new NIH PHS HS/CT form walk-through video; NIH just posted a new walk-through video of their PHS Human Subjects and Clinical Trials Information form to align with the new FORMS-F. See video here, it’s only 6 minutes
long.; This, plus other resources related to helping you with NIH/AHRQ FORMS-F, are posted on our website at https://research.columbia.edu/nih-proposal-information.

NIAID Clinical Trial Planning Grant (R34 Clinical Trials Not Allowed)

**Sponsor:** National Institute of Allergy and Infectious Diseases

**Deadline(s):** 09/14/2021; 01/12/2022; 05/13/2022; 09/14/2022; 01/13/2023; 05/12/2023; 05/13/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Greg Deye, M.D.; Division of Microbiology and Infectious Diseases (DMID); National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3371; Email: gregory.deye@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-20-270.html

Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)

**Sponsor:** National Heart, Lung, and Blood Institute

**Deadline(s):** New and Revision Applications: 10/14/2021; 02/11/2022; 06/10/2022; 09/09/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Division of Blood Diseases and Resources; Nahed El Kassar, MD National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-0065; Email: nahed.elkassar@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-19-328.html

Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)

**Sponsor:** National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)

**Deadline(s):** New and Revision Applications: 06/10/2021; 10/14/2021; 02/11/2022; 06/10/2022; 09/09/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Division of Blood Diseases and Resources; Nancy DiFronzo, PhD National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-0065; Email: difronzon@nhlbi.nih.gov


Major Regulatory and Policy Changes Related to Clinical Trials Announced

**Sponsor:** NIH

**Deadline(s):** NA; Released 09/16/2016; Effective Date: The target effective date for the NIH Policy on Funding Opportunity Announcement (FOA) for Clinical Trials is September 27, 2017. All applications with receipt dates on or after the effective date with plans to conduct clinical trials must be submitted in response to a clinical trial-specific FOA. After that date, applications planning a clinical trial that are submitted to a non-clinical trial FOA will be returned without review.

**Contact:** Inquiries: Please direct all inquiries to: Clinical Trials Program; Office of the Director; Office of Extramural Programs; Office of Extramural Research; National Institutes of Health; oepmailbox@od.nih.gov


**LYMPHATICS**

**NA**

**CHOLESTEROL**

**NA**

**INFLAMMATION**

Notice of Special Interest: Promoting Fundamental and Applied Research in Inflammation Resolution

**Sponsor:** National Institute of Environmental Health Sciences; National Heart, Lung, and Blood Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases

**Deadline(s):** 10/05/2020 (First Available Due Date); 05/31/2024 (Expiration Date)

**Contact:** Scientific/Research Contact(s); Srikanth S Nadadur, PhD National Institute of Environmental Health Sciences (NIEHS); Telephone: 984-287-3296; Email: nadadurs@niehs.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-018.html

**BLOOD / HEMATOLOGIC / CARDIOLOGY** Heart, Lung, Blood
Notice of Special Interest: Competitive Supplements for Implementation Science Research as Part of NHLBI-funded Phased Awards (R61/R33 and UG3/UH3)

**Sponsor:** National Heart, Lung, and Blood Institute  
**Deadline(s):** 11/23/2020 (First Available Due Date); 11/24/2022 (Expiration Date)  
**Contact:** Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: Cheryl Anne Boyce, Ph.D.; National Institute of Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-496-1051; Email: cheryl.boyce@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-795.html

Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders

**Sponsor:** National Heart, Lung, and Blood Institute  
**Deadline(s):** 02/05/2021 (First Available Due Date); 01/08/2024 (Expiration Date)  
**Contact:** Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: Scientific/Research Contact(s): For Clinical Trial PAIR Applications (that target PAR-19-274 Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)); Rebecca A. Roper, MS, MPH; Center for Translation Research and Implementation Science ; National Heart, Lung and Blood Institute (NHLBI); Telephone: 301-496-1051; Email: Rebecca.Roper@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-815.html

Notice of Intent to Publish a Funding Opportunity Announcement for Serological Sciences Centers of Excellence

**Sponsor:** National Cancer Institute  
**Deadline(s):** 07/20/2020 (First Estimated Due Date)  
**Contact:** Please direct all inquiries to: Juli Klemm, Ph.D.; National Cancer Institute (NCI); 301-480-5778; klemmj@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-066.html

Pragmatic clinical trial on efficacy of managing reduced iron stores on risk of clinically important events in older adults with heart failure and anemia (U01 Clinical Trial Required)

**Sponsor:** National Institute on Aging  
**Deadline(s):** Standard dates; 07/06/2022 (Expiration)  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-066.html

**Contact:** Scientific/Research Contact(s); Sergei Romashkan, MD, Ph.D.; National Institute on Aging (NIA); Telephone: 301-435-3047; Email: romashks@nia.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-795.html

New Directions in Hematology Research (SHINE-II) (R01)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS  
**Deadline(s):** Standard Dates;  
**Contact:** E-mail: daniel.wright@nih.gov;  
**Link(s):** Program URL: http://grants1.nih.gov/grants/guide/pa-files/PAS-13-006.html

SICKLE CELL DISEASE

NA

HEMOPHILIA

NA

INFLUENZA / FLU

NA

SWINE RESEARCH

NA

SEX DIFFERENCES

NA

SEX AND GENDER

**The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional)**

**Sponsor:** National Institutes of Health (NIH); Office of Research on Women’s Health (ORWH)  
**Deadline(s):** 11/26/2021; 11/27/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Rebecca DelCarmen-Wiggins, Ph.D.; Office of Research on Women’s Health (ORWH); Telephone: 301-451-8689; Email: rdelcarm@mail.nih.gov  
R²report
Friday Newsletter 07/16/2021


Advancting Science for the Health of Women; The Trans-NIH strategic Plan for Women’s Health Research 2019-2023

**Sponsor:** NIH National Institutes of Health; Office of Research on Women’s Health

**Deadline(s):** 11/27/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Rebecca DelCarmen-Wiggins, Ph.D.; Office of Research on Women’s Health (ORWH); Telephone: 301-451-8689; Email: rdelcarm@mail.nih.gov

**Link(s):** https://orwh.od.nih.gov/sites/orwh/files/docs/ORWH_Strategic_Plan_2019_02_21_19_V2_508C.pdf [Advancing Science for the Health of Women; The Trans-NIH strategic Plan for Women’s Health Research 2019-2023]

LGBTI AND SEXUAL AND GENDER MINORITIES

NA

DIET/PHYSICAL ACTIVITY

INSURANCE

NA

PATHOGENS

NA

NIDDK, DIABETES AND PANCREAS

**Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed)**

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases

**Deadline(s):** 11/03/2021; 11/04/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Teresa L.Z. Jones, MD; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-435-2996; Email: teresa.jones@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-001.html

**Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care (R34 Clinical Trial Required)**

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases

**Deadline(s):** 06/22/2021; 06/22/2022; 06/22/2023; 06/23/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Henry B. Burch, M.D. (for health behaviors and policy effects diabetes research); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-827-0827; Email: henry.burch@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-032.html

**Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional)**

**Sponsor:** National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases

**Deadline(s):** 10/15/2021; 10/16/2021 (Expiration)

**Contact:** Scientific/Research Contact(s); Nicole Redmond, MD, PhD, MPH; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-0379; Email: nicole.redmond@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-014.html

**Notice of Special Interest: Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Diseases**

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases

**Deadline(s):** 02/03/2021 (First Available Due Date); 02/04/2023 (Expiration Date)

**Contact:** Please direct all inquiries to: Carol R. Haft, PhD; Division of Diabetes, Endocrinology and Metabolic Diseases; National Institute of Diabetes and Digestive and Kidney Disease (NIDDK); Telephone: 301-594-7789; Email: haftc@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-040.html

**Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)**

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases

**Deadline(s):** Standard dates; Standard AIDS dates : 05/08/2023

**Contact:** Scientific/Research Contact(s); Susan Mendley, M.D.; Division of Kidney, Urologic and Hematologic Diseases; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-827-1861; Email: susan.mendley@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAS-20-160.html

**Notice of Intent to Publish a Funding Opportunity Announcement for Institutional Network Award for**
Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1 - Clinical Trial Not Allowed)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases

**Deadline(s):** 09/28/2020 (First Estimated Due Date)

**Contact:** Please direct all inquiries to: Victoria Spruance, Ph.D.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 301-827-5091; victoria.spruance@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-024.html

GASTROINTESTINAL / DIGESTIVE

NA

HHMI, Howard Hughes Medical Institute

NA

NATIONAL SCIENCE FOUNDATION (NSF)

Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science

**NSF Smart Health website**

**Sponsor:** NIH, NSF

**Deadline(s):** 11/24/2020 (Release Date); 11/10/2021; 11/10/2022 [NSF Deadlines]

**Contact:** Inquiries are encouraged and NIH Scientific/Research contacts are listed below. Please see the NSF Smart Health website for names and contact information of participating NSF Directorates

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-011.html


New NSF PAPPG 18-1 effective 1/29/18

**Sponsor:** NSF

**Deadline(s):** 01/29/2018 (effect date for proposals submitted on, or due on or after)

**Contact:** https://www.nsf.gov/help/contact.jsp

**Link(s):** https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf18001

LOAN REPAYMENT PROGRAM

Next Window will be in the Fall of 2020, from 09/01/2021 11/20/2021

ENGINEERING

NA

COLUMBIA UNIVERSITY INTERNAL FUNDING OPPORTUNITIES
A survey to learn about your interest in our Community Based Participatory Research Training and Pilot Awards Program

**Sponsor:** http://irvinginstitute.columbia.edu

**Deadline(s):** NA

**Contact:** https://cumc.co1.qualtrics.com/SE/?SID=SV_6gmz5qJ79DmVff

**Link(s):** We appreciate your time in completing this short questionnaire accessible here: https://cumc.co1.qualtrics.com/SE/?SID=SV_6gmz5qJ79DmVff

http://www.irvinginstitute.columbia.edu/resources/cbpr_pilot_award.html

---

**Pilot and Collaborative Studies Resource**

**Sponsor:** Irving Institute

**Deadline(s):** Please see individual announcements

**Contact:** For more information, contact: Nancy King Reame, MSN, PhD, FAAN; Mary Dickey Lindsay Professor of Nursing; Director, Pilot and Collaborative Studies Resource (PCSR); Columbia University Medical Center; nr2188@columbia.edu

**Link(s):** http://irvinginstitute.columbia.edu/research_ops/pcsr.html

**Additional Information:** Internal Columbia University Seed Funding Programs: For translational and clinical projects in the biomedical sciences, the Pilot and Collaborative Studies Resource, run through the Irving Institute for Clinical and Translational Research.

---

**Seed Funding for cancer-focused NIH Program Grants;**

**Sponsor:** Columbia University; Herbert Irving Comprehensive Cancer Center (HICCC);

**Deadline(s):** Application deadline: Applications may be submitted any time before or shortly after submission of the NIH Program grant (but HICCC seed funding may not begin until after NIH submission.

**Contact:** Applications should be submitted as a single pdf file to: Richard Arjune (dra2112@columbia.edu) and Sadie Maloof (maloof@icg.cpmc.columbia.edu); Link(s): http://hiccc.columbia.edu/

---

**PRIONS**

NA

---

**VIROLOGY**

---

**Notice of Intent to Publish a Funding Opportunity Announcement for Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)**

**Sponsor:** National Cancer Institute

**Deadline(s):** 12/14/2020 (First Estimated Application Due Date)

---

**Contact:** Please direct all inquiries to: Rebecca Liddell Huppi, Ph.D.; National Cancer Institute (NCI); 240-781-3324; Email: liddellr@exchange.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-098.html

---

**Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract**

**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Office of Research on Women’s Health**

**Deadline(s):** 10/05/2020 (First Available Due Date); 07/16/2023 (Expiration)

**Contact:** Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.;

**Scientific/Research Contact(s):** Stuart B. Moss, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6979; Email: mossstua@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-021.html

---

**IMMUNOLOGY/IMMUNOTHERAPY**

---

**Pre-Solicitation Notice: Immunology Quality Assessment (IQA) Program, RFP: 75N93020R00007**

**Sponsor:** National Institute of Allergy and Infectious Diseases

**Deadline(s):** Any responsible offeror may submit a proposal, which will be considered by the Agency. This RFP will be available electronically, on/about April 16, 2020, and may be accessed through SAM. http://beta.sam.gov/. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.; For this solicitation, the NIAID requires proposals to be submitted online via the NIH’s electronic Contract Proposal Submission (eCPS) website at https://ecps.nih.gov. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website https://ecps.nih.gov and then click on "How to Submit."

**Contact:** Please direct all inquiries to: Christopher Weaver; Contracting Officer; AIDS Research Contracts Branch; Office of Acquisitions; Division of Extramural Activities; National Institute of Allergy & Infectious Diseases; National Institutes of Health, DHHS; Telephone: 240-627-3219; Email: christopher.weaver@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-020-042.html
Notice of Intent to Publish a Funding Opportunity Announcement for Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Research Hubs (U54 Clinical Trial Optional)

**Sponsor:** Office of Strategic Coordination (Common Fund)

**Deadline(s):** 11/24/2020 (First Estimated Due Date)

**Contact:** Please direct all inquiries to: Brad Newsome, Ph.D.; Fogarty International Center (FIC); 301-480-8389; brad.newsome@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-RM-20-010.html

Notice of Intent to Publish a Funding Opportunity Announcement for Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Research Training Program (U2R Clinical Trial Optional)

**Sponsor:** Office of Strategic Coordination (Common Fund)

**Deadline(s):** 11/24/2020 (First Estimated Due Date)

**Contact:** Please direct all inquiries to: Laura Povlich, Ph.D.; Fogarty International Center (FIC); 301-827-2227; Email: laura.povlich@nih.gov


Notice of Intent to Publish a Funding Opportunity Announcement for Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa): Ethical, Legal, and Social Implications Research (U01 Clinical Trial Not Allowed)

**Sponsor:** Office of Strategic Coordination (Common Fund)

**Deadline(s):** 11/24/2020 (First Estimated Due Date)

**Contact:** Please direct all inquiries to: James D. Churchill, Ph.D.; National Institute of Mental Health (NIMH); 301-443-3621; churchillj@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-RM-20-012.html

Notice of Intent to Publish a Funding Opportunity Announcement for Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Open Data Science Platform and Coordinating Center (U2C Clinical Trial Not Allowed)

**Sponsor:** Office of Strategic Coordination (Common Fund)

**Deadline(s):** 11/24/2020 (First Estimated Due Date)

**Contact:** Please direct all inquiries to: Tiffani Lash, Ph.D.; National Institute Biomedical Imaging and Bioengineering; (NIBIB); 301-451-4772; tiffani.lash@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-RM-20-013.html

HEMATOLOGY

NA
BIOMARKERS

COMMUNITY HEALTH

Soon to be Issued Funding Opportunity for All of Us Research Program Community Engagement (OT2)
Sponsor: National Institutes of Health
Deadline(s): First Quarter 2017 (Estimated First Application Due Date)
Contact: Please direct all inquiries to: All of Us Partner Engagement Team; Email: PMICFOAInquiries@mail.nih.gov
Link(s): http://grants.nih.gov/grants/guide/notice-files/NOT-PM-17-001.html

STDs SEXUALLY TRANSMITTED DISEASES / HIV / AIDS / IMMUNODEFFICIENCY

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)
Sponsor: National Institute on Drug Abuse
Deadline(s): 07/15/2022 (Expiration)
Contact: Scientific/Research Contact(s); Shang-Yi Anne Tsai, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-827-5842; Email: stsa@nih.gov

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed)
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases
Deadline(s): Standard AIDS dates ; 01/08/2024 (Expiration)
Contact: Scientific/Research Contact(s); For Division of Digestive Diseases and Nutrition-related inquiries: Peter J. Perrin, Ph.D.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-451-3759; Email: peter.perrin@nih.gov
Link(s): https://grants.nih.gov/grants/guide/notice-files/NOT-DK-17-062.html

Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
Sponsor: National Institute of Mental Health
Deadline(s): 08/25/2021; 08/25/2022; 08/25/2023; 09/14/2023 (Expiration)
Contact: Scientific/Research Contact(s); Christopher Gordon, PhD; National Institute of Mental Health (NIMH); Telephone: 240-627-3867; Email: cgordon1@mail.nih.gov

AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
Sponsor: National Institute of Mental Health
Deadline(s): 08/25/2021; 08/25/2022; 08/25/2023; 09/14/2023 (Expiration)
Contact: Scientific/Research Contact(s); Christopher Gordon, PhD; National Institute of Mental Health (NIMH); Telephone: 240-627-3867; Email: cgordon1@mail.nih.gov

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)
Sponsor: National Cancer Institute
Deadline(s): 12/14/2021; 12/15/2021 (Expiration)
Contact: Scientific/Research Contact(s); Rebecca Liddell Huippi, Ph.D.; National Cancer Institute (NCI); Telephone: 240-781-3324; Email: liddellr@exchange.nih.gov

Using Syndemics to Understand HLBS Disease Emergence and Progression in People with HIV (PWH)(R01 Clinical Trial Not Allowed)
Sponsor: National Heart, Lung, and Blood Institute
Deadline(s): 12/14/2021; 12/15/2021 (Expiration)
Contact: Scientific/Research Contact(s); Fassil Ketema, M.S.; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-496-5468; Email: fossil.ketema@nih.gov

Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed)
Sponsor: National Heart, Lung, and Blood Institute
Deadline(s): 01/07/2022; 05/07/2022; 01/07/2023; 01/08/2023 (Expiration)
Contact: Scientific/Research Contact(s); Shimian Zou, Ph.D.; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-827-8301; Email: zouss@mail.nih.gov

HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)
Sponsor: National Institute of Allergy and Infectious Diseases
Deadline(s): 03/15/2022; 03/16/2023 (Expiration)
New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial Required)

**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 08/11/2021; 11/18/2021; 08/11/2022; 11/18/2022; 08/11/2023; 08/12/2023 (Expiration)  
**Contact:** Minnjuan Flournoy Floyd, PhD; National Institute on Drug Abuse (NIDA); Telephone: 301-827-6474; Email: Minnjuan.flournoyfloyd@nih.gov  

Toward Elucidating Mechanisms of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases  
**Deadline(s):** 11/17/2021; 11/18/2021 (Expiration)  
**Contact:** For Division of Digestive Diseases and Nutrition-related inquiries: Peter J. Perrin, Ph.D.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-451-3759; Email: Peter.Perrin@nih.gov  

HIV Infection of the Central Nervous System (R01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Mental Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Neurological Disorders and Stroke  
**Deadline(s):** Standard AIDS dates; 05/08/2023 (Expiration)  
**Contact:** Jeymohan Joseph, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 240-627-3869; Email: jeymohan@mail.nih.gov  

Notice of Additional Topic Area for support under the Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11) Program PAR-19-285

**Sponsor:** Fogarty International Center  
**Deadline(s):** 08/20/2021; 08/21/2021 (Expiration)  
**Contact:** Geetha P. Bansal, Ph.D.; Program Officer; Division of International Training and Research; Fogarty International Center; National Institutes of Health; 31 Center Drive, Room B2C58; Bethesda, MD 20892; Telephone: 301-496-1492; Email: geetha.bansal@nih.gov  

Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Allergy and Infectious Diseases  
**Deadline(s):** AIDS Application Due Date(s); 07/28/2021; 07/29/2022; 07/28/2022 (Expiration)  
**Contact:** Jon Warren, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3032; Email: JWarren@niaid.nih.gov  
Pre-Solicitation Notice: Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents, RFP: 75N93019R00023

**Sponsor:** National Institute of Allergy and Infectious Diseases  
**Deadline(s):** 05/08/2023 (Expiration Date)  
**Contact:** Please direct all inquiries to: Patrick Finn; Contracting Officer; AIDS Research Contracts Branch, Office of Acquisitions; Division of Extramural Activities; National Institute of Allergy and Infectious Diseases; National Institutes of Health, Email: patrick.finn@nih.gov  

**Notice of Special Interest: Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults**

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 05/08/2023 (Expiration Date)  
**Contact:** Please direct all inquiries to: Patrick Finn; Contracting Officer; AIDS Research Contracts Branch, Office of Acquisitions; Division of Extramural Activities; National Institute of Allergy and Infectious Diseases; National Institutes of Health, Email: allisonsu@mail.nih.gov  

**Notice of Special Interest (NOSI): Mental Health Comorbidities in HIV Prevention and Treatment**

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 05/08/2023 (Expiration Date)  
**Contact:** Scientific/Research Contact(s); Teri Senn, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-761-7852; Email: teri.senn@nih.gov  

**Additional Information:** Weekly NIH Funding Opportunities and Notices; Notice of Changes to Funding Opportunities

**Notice of Special Interest: Stigma or Other Social Determinants of Health (SDOH) in HIV Prevention and Treatment**

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 05/08/2023 (Expiration Date)  
**Contact:** Scientific/Research Contact(s); Gregory Greenwood, PhD, MPH; National Institute of Mental Health (NIMH); Telephone: 240-669-5532; Email: gregory.greenwood@nih.gov  

**Additional Information:** Weekly NIH Funding Opportunities and Notices; Notice of Changes to Funding Opportunities

**Notice of Special Interest (NOSI): Strengthening the HIV Care Continuum**

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 05/08/2023 (Expiration Date)  
**Contact:** Scientific/Research Contact(s); Gregory Greenwood, PhD, MPH; National Institute of Mental Health (NIMH); Telephone: 240-669-5532; Email: gregory.greenwood@nih.gov  

**Additional Information:** Weekly NIH Funding Opportunities and Notices; Notice of Changes to Funding Opportunities

**Notice of Special Interest (NOSI): Implementation Science to Advance the United States HIV Prevention and Treatment Goals and the Global HIV Prevention and Treatment Targets**

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 05/08/2023 (Expiration Date)  
**Contact:** Scientific/Research Contact(s); Christopher Gordon, Ph.D; Telephone: 240-627-3867; Email: cgordon1@mail.nih.gov  

**Additional Information:** Weekly NIH Funding Opportunities and Notices; Notice of Changes to Funding Opportunities

**Notice of Special Interest (NOSI): Strengthening the HIV Prevention Continuum**
Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Christopher Gordon, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 240-627-3867; Email: cgordon1@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-144.html

Notice of Intent to Publish a Funding Opportunity Announcement for Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)

**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 07/13/2020 (First Estimated Application Due Date); 04/01/2021 (Earliest Estimated Award Date); 04/01/2021 (Earliest Estimated Start Date)

**Contact:** Please direct all inquiries to: Redonna Chandler, Ph.D.; National Institute on Drug Abuse (NIDA); 301-402-1919; rchandle@nida.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-045.html

Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01 Clinical Trial Not Allowed)

**Sponsor:** National Institute on Drug Abuse  
**Deadline(s):** 10/13/2021; 03/15/2022; 10/13/2022; 03/15/2023; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); John Satterlee Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-435-1020; Email: satterleej@nida.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-147.html

Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** Standard AIDS dates; 01/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Christopher Gordon, Ph.D.; Telephone: 240-627-3867; Email: cgordon1@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PA-20-147.html

Notice of Special Interest (NOSI): The HIV-HCV-Substance Use Disorder Syndemic: Therapeutic Approaches

**Sponsor:** National Institute on Drug Abuse
Deadline(s): 06/05/2020 (First Available Due Date); 09/08/2023 (Expiration)
Contact: Scientific/Research Contact(s); Raul Mandler, MD; FAAN; FANA; National Institute on Drug Abuse (NIDA); Telephone: 301-480-2541; Email: mandller@nih.gov

Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D43 Clinical Trial Optional)
Sponsor: National Institutes of Health (NIH); Components of Participating Organizations: Fogarty International Center (FIC); National Cancer Institute (NCI); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Deadline(s): 08/20/2021; 08/21/2021 (Expiration)
Contact: Scientific/Research Contact(s); Geetha P Bansal Ph.D.; Fogarty International Center (FIC); Telephone: 301-496-1492; Email: geetha.bansal@nih.gov
Link(s): https://grants.nih.gov/grants/guide/pa-20-036.html

Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)
Sponsor: National Institutes of Health (NIH); Components of Participating Organizations: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Mental Health (NIMH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Deadline(s): Standard AIDS dates; 09/08/2022
Contact: Scientific/Research Contact(s); Robin E. Huebner, Ph.D., M.P.H.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone 240-627-3216; Email: rhuebner@niaid.nih.gov
Link(s): https://grants.nih.gov/grants/guide/pa-20-036.html

Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 Clinical Trial Optional)
Sponsor: National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Deadline(s): Standard dates; Standard AIDS dates; 09/08/2021 (Expiration)
Contact: Scientific/Research Contact(s); Ravi Ravindranath, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6889; Email: ravindrm@mail.nih.gov

Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 Clinical Trial Optional)
Sponsor: National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Deadline(s): Standard dates; Standard AIDS dates; 09/08/2021 (Expiration)
Contact: Scientific/Research Contact(s); Ravi Ravindranath, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6889; Email: ravindrm@mail.nih.gov

Planning Grant for Global Infectious Disease Research Training Program (D71 No Clinical Trials Allowed)
Sponsor: John E. Fogarty International Center
Deadline(s): 10/28/2021; 10/29/2021 (Expiration)
Contact: Scientific/Research Contact(s); Barbara Sina, Ph.D.; Fogarty International Center (FIC); Telephone: 301-402-9467; Email: sinabi@mail.nih.gov

Notice of Intent to Publish a Funding Opportunity Announcement for U.S. and Low- and Middle-Income Country (LMIC) HIV Malignancy Research Networks (US4)
Sponsor: National Cancer Institute
Deadline(s): 06/18/2019 (Release Date); 01/10/2020 (First Estimated Application Due Date)
Contact: Please direct all inquiries to: Geraldina Dominguez, Ph.D.; National Cancer Institute (NCI); 240-781-3291; dominguez@nih.gov

Control of Sexually Transmitted Infections (STIs) Through a Comprehensive Understanding of the Natural History of Infection (R01 Clinical Trial Not Allowed)
Sponsor: National Institute of Allergy and Infectious Diseases
Deadline(s): Standard dates; 01/08/2022 (Expiration)
Contact: Scientific/Research Contact(s); Leah R. Vincent, Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 301-761-7365; Email: leah.vincent@nih.gov

Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-infection (R01 Clinical Trial Not Allowed)
Sponsor: National Institute of Allergy and Infectious Diseases
Deadline(s): Standard dates; Standard AIDS dates; 01/08/2022

COLUMBIA
RESEARCH RESOURCES
mailman.columbia.edu/r2
**Contact:** Scientific/Research Contact(s): Chris Lambros, Ph.D (HIV/HHV co-infection); Division of AIDS (DAIDS); National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3093; Email: clambros@niaid.nih.gov

**Link(s):** https://grants.nih.gov/grants_guide/pa-files/PAS-19-097.html

**Engaging Men in HIV Testing, Prevention, and Care (R21 Clinical Trial Optional)**
**Sponsor:** National Institute of Allergy and Infectious Diseases; National Institute of Mental Health
**Deadline(s):** Standard AIDS dates; 09/08/2021 (Expiration)
**Contact:** Scientific/Research Contact(s): Adeola Adeyeye, M.D.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-669-5005; Email: adeyeyeao@niaid.nih.gov

**Link(s):** https://grants.nih.gov/grants_guide/pa-files/PAS-19-050.html

**HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)**
**Sponsor:** National Institute on Drug Abuse
**Deadline(s):** Standard AIDS dates; 09/08/2021 (Expiration)
**Contact:** Scientific/Research Contact(s): Richard A. Jenkins, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-443-1923; Email: jenkinsr@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants_guide/pa-files/PAS-18-915.html

**AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)**
**Sponsor:** National Institute on Drug Abuse
**Deadline(s):** Standard AIDS dates; 09/08/2021 (Expiration)
**Contact:** Scientific/Research Contact(s): Richard A. Jenkins, Ph.D.; National Institute on Drug Abuse (NIDA); Telephone: 301-443-1923; Email: jenkinsr@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants_guide/pa-files/PAS-18-916.html

**NHLBI Interest in Administrative Supplements to Enhance HIV-related Heart, Lung, Blood, and Sleep Research**
**Sponsor:** National Heart, Lung, and Blood Institute; National Institute on Aging
**Deadline(s):** NA
**Contact:** Please direct all inquiries to: Shimian Zou, PhD; National Heart, Lung, and Blood Institute (NHLBI); Telephone: 301-435-0065; Email: shimian.zou@nih.gov


**Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 - Clinical Trial Optional)**
**Sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development
**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2021 (Expiration)

**Contact:** Scientific/Research Contact(s): Ravi Ravindranath, PhD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Telephone: 301-435-6889; Email: ravindr@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants_guide/pa-files/PA-18-838.html

**Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional)**
**Sponsor:** National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institute of Mental Health
**Deadline(s):** Standard AIDS dates; 05/08/2021 (Expiration)
**Contact:** Scientific/Research Contact(s): Rosemary McKaig, M.P.H., Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 240-627-3214; Email: rmk34n@nih.gov

**Link(s):** https://grants.nih.gov/grants_guide/pa-files/PA-18-764.html

**Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01 - Clinical Trials Optional)**
**Sponsor:** National Institute on Alcohol Abuse and Alcoholism; NIH
**Deadline(s):** Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Standard dates; Standard AIDS dates; 05/08/2020 (Expiration)
**Contact:** Scientific/Research Contact(s): Tatiana Balachova, PhD; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Telephone: 301-443-5726; Email: balachovta@mail.nih.gov

**Multidisciplinary Studies of HIV/AIDS and Aging (R01)**
**Synopsis 1**
**Sponsor:** HHS; Department of Health and Human Services; National Institutes of Health; National Institute on Aging; National Center for Complementary and Integrative Health; National Cancer Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute on Drug Abuse; National Institute of Allergy and Infectious Diseases (NIAID); Telephone: 301-443-5726; Email: balachovta@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants_guide/pa-files/PA-18-764.html
R²report
Friday Newsletter 07/16/2021

DENTAL/ORTAL/CRANIOFACIAL

Notice of Special Interest: Administrative Supplements to Support Dentist Scientists Post Specialty or Residency to Develop Expertise in Dental, Oral and Craniofacial Research
Sponsor: National Institute of Dental and Craniofacial Research
Deadline(s): 11/02/2020 (First Available Due Date); 07/24/2023 (Expiration Date)
Contact: Lynn Mertens King, PhD; National Institute of Dental and Craniofacial Research; Telephone: 301-594-5006; Email: lynn.king@nih.gov
Additional Information: Related Announcements; PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

National Dental Practice-Based Research Network Clinical Trial or Observational Study Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Optional)
Sponsor: National Institute of Dental and Craniofacial Research
Deadline(s): 10/08/2021; 02/09/2022; 06/09/2022; 10/07/2022; 02/09/2023; 06/09/2023; 09/08/2023 (Expiration)
Contact: Scientific/Research Contact(s): Dena Fischer, DDS, MSD, MS, National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-594-4876; Email: dena.fischer@nih.gov

Notice of Special Interest (NOSI): Defining Mechanisms of Disease Recurrence in Dental, Oral, and Craniofacial Tissues
Sponsor: National Institute of Dental and Craniofacial Research
Deadline(s): 06/05/2020 (First Available Due Date); 05/08/2022 (Expiration)
Contact: Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.
Additional Information: Related Announcements: PAR-19-172 Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R01 Clinical Trial Not Allowed); PAR-19-173 Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed)

ENVIRONMENTAL MEDICINE

NA

MUSIC AND HEALTH

Music and Health: Understanding And Developing Music Medicine (R21 Clinical Trial Optional)
Sponsor: National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute of Nursing Research; Office of Behavioral and Social Sciences Research
Deadline(s): 02/16/2022; 02/16/2023; 02/17/2023 (Expiration)
Contact: Scientific/Research Contact(s): NINDS; Robert Riddle, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-5745; Email: riddler@ninds.nih.gov

Music and Health: Understanding And Developing Music Medicine (R01 Clinical Trial Optional)
Sponsor: National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Cancer Institute; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute on Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research
Disparities; National Institute of Nursing Research; Office of Behavioral and Social Sciences Research

**Deadline(s):** 02/05/2022; 02/05/2023; 02/06/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): NINDS; Robert Riddle, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-5745; Email: riddler@ninds.nih.gov

**Link(s):** [https://grants.nih.gov/grants/guide/notice-files/PAR-21-100.html](https://grants.nih.gov/grants/guide/notice-files/PAR-21-100.html)

**Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional)**

**Sponsor:** National Center for Complementary and Integrative Health; National Cancer Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Mental Health; Office of Behavioral and Social Sciences Research

**Deadline(s):** 10/04/2021; 06/02/2022; 10/03/2022; 06/02/2023; 06/20/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Wen G. Chen, Ph.D.; National Center for Complementary and Integrative Health (NCCIH); Telephone: 301-451-3989; Email: chenw@mail.nih.gov

**Link(s):** [https://grants.nih.gov/grants/guide/notice-files/PAR-20-266.html](https://grants.nih.gov/grants/guide/notice-files/PAR-20-266.html)

**HEARING, DEAFNESS AND COMMUNICATION DISORDERS**

**Notice of Special Interest (NOSI): Improving Outcomes for Disorders of Human Communication**

**Sponsor:** National Institute on Deafness and Other Communication Disorders

**Deadline(s):** 06/16/2020 (First Available Due Date); 01/10/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Kelly King, Au.D, Ph.D.; NIDCD/Division of Scientific Programs; Telephone: 301-402-3458; Email: kingke@nidcd.nih.gov


**MULTIPLE SCLEROSIS**

**NA**

**CHRONIC FATIGUE SYNDROME**

**Notice of NCATS Withdrawal from Participation in PAR-20-165, "Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)"

**Sponsor:** National Center for Advancing Translational Sciences

**Deadline(s):** Effective Immediately (distributed 12/18/2020)

**Contact:** Please direct all inquiries to: Erica Rosemond, Ph.D; National Center for Advancing Translational Sciences (NCATS); Email: Erica.Rosemond@nih.gov


**Additional Information:** Related Announcements: PAR-20-165 - Research on Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)

**Notice of NCATS Withdrawal from Participation in PAR-20-168, "Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trials Not Allowed)"

**Sponsor:** National Center for Advancing Translational Sciences

**Deadline(s):** 12/17/2020 (Release Date)

**Contact:** Erica Rosemond, Ph.D; National Center for Advancing Translational Sciences (NCATS); Email: Erica.Rosemond@nih.gov


**Additional Information:** Related Announcements: PAR-20-168 - Research on Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trials Not Allowed)

**Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)**

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Library of Medicine; Office of Behavioral and Social Sciences Research

**Deadline(s):** Standard dates; 03/06/2023 (Expiration)

**Contact:** Scientific/Research Contact(s): Vicky Whittemore, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1917; Email: vicky.whittemore@nih.gov

Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trials Not Allowed)

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Center for Advancing Translational Sciences; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health; Office of Behavioral and Social Sciences Research

**Deadline(s):** Standard dates; 05/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Vicky Whittemore, PhD; National Institute of Neurological; Disorders and Stroke (NINDS);
Telephone: 301-496-1917; Email: vicky.whittemore@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/PAR-20-168.html

MUSCULAR DYSTROPHY

**Muscular Dystrophy Association’s Venture Philanthropy**

**Sponsor:** https://www.mda.org

**Deadline(s):**
https://www.mda.org/sites/default/files/2019/02/2019_MDA_grant_dates.png; 03/01/2020 (MDA Venture Philanthropy Program)

**Contact:** For any questions, further information, or suggestions for content please contact: Dimitra Koutsantoni, Director of University Corporate and Foundation Relations | dk2617@columbia.edu

**Link(s):** https://www.mda.org/science/funding-opportunities

PARKINSON'S DISEASE

**NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional)**

**Sponsor:** National Institute of Neurological Disorders and Stroke

**Deadline(s):** 09/28/2021; 09/28/2022; 09/29/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Beth-Anne Sieber, PhD; National Institute of Neurological Disorders and Stroke (NINDS);
Telephone: 301-496-5680; Email: Beth-Anne.Sieber@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-001.html

**Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional)**

**Sponsor:** National Institute of Neurological Disorders and Stroke

**Deadline(s):** 09/25/2020 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Beth-Anne Sieber, PhD; National Institute of Neurological Disorders and Stroke (NINDS); (301) 496-5680; Beth-Anne.Sieber@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NS-20-057.html

**Additional Information:** Related Announcements: NOT-NS-20-058

**Notice of Intent to Publish a Funding Opportunity Announcement for NINDS Exploratory Grant Program in Parkinson's Disease Research (P20- Clinical Trial Optional) (P20 Clinical Trial Optional)**

**Sponsor:** National Institute of Neurological Disorders and Stroke

**Deadline(s):** 09/25/2020 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Beth-Anne Sieber, PhD; National Institute of Neurological Disorders and Stroke (NINDS); (301) 496-5680; Beth-Anne.Sieber@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NS-20-058.html

**Progression Markers for Cognitive Impairment in Parkinson's Disease Dementia (R01 Clinical Trial Not Allowed)**

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Institute on Aging

**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s); Debra Babcock, PhD, MD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-9964; Email: dbabcock@mail.nih.gov


AMYTROPIC LATERAL SCLEROSIS (ALS)

**NA**

NEUROSCIENCES, NEUROLOGY, NEUROLOGICAL, BRAIN DISORDERS, CONCUSSION AND COGNITION

**COLUMBIA UNIVERSITY**

**RESOURCES**

mailman.columbia.edu/r2
Notice of Clarification to Career Stages Supported for PAR-20-240 "NIH Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)"

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Institute of Mental Health  
**Deadline(s):** 09/27/2021; 09/26/2022; 09/27/2022 (Expiration) [for PAR-20-240]  
**Contact:** Michelle Jones-London, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-451-7966; Email: jonesmiche@ninds.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-019.html  
**Additional Information:** PAR-20-240 - NIH Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)

**Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)**  
**Sponsor:** National Institute of Neurological Disorders and Stroke  
**Deadline(s):** 02/22/2022; 06/22/2022; 02/22/2023; 06/22/2023; 09/08/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Carol Taylor-Burds, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1779; Email: carol.taylor-burds@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-056.html

**Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)**  
**Sponsor:** National Institute of Neurological Disorders and Stroke  
**Deadline(s):** 02/22/2022; 06/22/2022; 02/22/2023; 06/22/2023; 09/08/2023 (Expiration)  
**Contact:** Scientific/Research Contact(s); Carol Taylor-Burds, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1779; Email: carol.taylor-burds@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-059.html

**BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)**  
**Sponsor:** National Institute of Mental Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Neurological Disorders and Stroke; Office of Behavioral and Social Sciences Research  
**Deadline(s):** 12/09/2020; 08/10/2021; 04/11/2022; 12/09/2022; 12/10/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Ashlee Van’t Veer, PhD; National Institute of Mental Health (NIMH); Telephone: 301-443-3107; Email: Brain.Initiative.Training@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-620.html

**Collaborative Research in Computational Neuroscience (CRCNS) NSF Innovative Approaches to Science and Engineering Research on Brain Function**  
**Sponsor:** National Institute of Mental Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; National Institute on Drug Abuse; National Institute
Notice of Participation in PA-18-358, "NINDS Exploratory Neuroscience Research Grant (R21- Clinical Trial Optional)"

**Sponsor:** National Institute of Mental Health; National Institute of Neurological Disorders and Stroke  
**Deadline(s):** Standard dates; Standard AIDS dates; 05/08/2021 (Expiration)  
**Contact:** Please direct all inquiries to: Susab Koester, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-3563; Email: koesters@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NNS-20-034.html

**Additional Information:** Related Announcements: PA-18-358, NINDS Exploratory Neuroscience Research Grant (R21- Clinical Trial Optional)

BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Biomedical Imaging and Bioengineering; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Deafness and Other Communication Disorders; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; Office of Behavioral and Social Sciences Research  
**Deadline(s):** 09/03/2021; 09/04/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s): Shumin Wang, Ph.D.; National Institute of Biomedical Imaging and Bioengineering (NIBIB); Telephone: 301-594-9001; Email: shumin.wang@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/RFA-EB-20-001.html

BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Biomedical Imaging and Bioengineering; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Deafness and Other Communication Disorders; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; Office of Behavioral and Social Sciences Research  
**Deadline(s):** 09/15/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s): Grace C.Y. Peng, PhD; National Institute of Biomedical Imaging and Bioengineering (NIBIB); Telephone: 301-451-4778; Email: BRAINTheoriesFOA@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/RFA-EB-20-002.html

Notice of Intent to Publish a Funding Opportunity Announcement for "BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)"

**Sponsor:** National Institute of Mental Health; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Deafness and Other Communication Disorders; National Institute of Neurological Disorders and Stroke  
**Deadline(s):** 12/08/2020 (First Estimated Due Date)  
**Contact:** Please direct all inquiries to: Ashlee Van’t Veer, PhD; National Institute of Mental Health (NIMH); 301-443-3107; BRAIN.Initiative.Training@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NTO-MH-20-062.html
Notice of Special Interest: Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program (BRCP) - U.S. Entity (Admin Supp)

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Center for Advancing Translational Sciences; National Center for Complementary and Integrative Health; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; National Institute on Drug Abuse; National Institute of Dental and Craniofacial Research; National Institute of Environmental Health Sciences; National Institute of Mental Health

**Deadline(s):** 09/08/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Stacey D. Chambers; Telephone: 301-496-0690; Email: chambers@ninds.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NCT-09-024.html

---

BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP (U01 Clinical Trials Optional)

**Sponsor:** National Institute of Neurological Disorders and Stroke; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; Office of Behavioral and Social Sciences Research; Office of Research on Women's Health

**Deadline(s):** 07/15/2021; 07/16/2021 (Expiration)

**Contact:** Scientific/Research Contact(s): Karen K David, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-9964; Email: BRAINcircuits@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/RFA-NS-20-029.html

---

BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)

**Sponsor:** National Institutes of Health (NIH); Components of Participating Organizations; National Institute of Neurological Disorders and Stroke (NINDS); National Eye Institute (NEI); National Institute on Aging (NIA); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Biomedical Imaging and Bioengineering (NIBIB); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Deafness and Other Communication Disorders (NIDCD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH); National Center for Complementary and Integrative Health (NCCIH)

**Deadline(s):** 06/01/2021; 10/01/2020; 02/01/2022; 06/01/2022; 10/03/2022; 10/04/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Sathana N. Kukke, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1447; Email: BRAIN-FOAs@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/RFA-NS-20-006.html

---

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)

**Sponsor:** National Institutes of Health (NIH); Components of Participating Organizations; National Institute of Neurological Disorders and Stroke (NINDS); National Eye Institute (NEI); National Institute on Aging (NIA); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Biomedical Imaging and Bioengineering (NIBIB); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Deafness and Other Communication Disorders (NIDCD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH); National Center for Complementary and Integrative Health (NCCIH)

**Deadline(s):** 10/06/2021; 02/10/2022; 06/08/2022; 10/11/2022

**Contact:** Scientific/Research Contact(s): For project relevance or scientific questions: Edmund (Ned) Talley, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1917; Email: BRAINnDIVERSITYK99R00@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/RFA-NS-19-043.html

---

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)

**Sponsor:** National Institutes of Health (NIH); Components of Participating Organizations; National Institute of Neurological Disorders and Stroke (NINDS); National Eye Institute (NEI); National Institute on Aging (NIA); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Biomedical Imaging and Bioengineering (NIBIB); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Deafness and Other Communication Disorders (NIDCD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH); National Center for Complementary and Integrative Health (NCCIH)

**Deadline(s):** 09/08/2022; 07/15/2021; 07/16/2021 (Expiration)

**Contact:** Scientific/Research Contact(s): Edmund (Ned) Talley, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1917; Email: BRAINnDIVERSITYK99R00@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/RFA-NS-20-006.html
Publically Available Data from the NCAA-DOD Concussion Assessment Research Education (CARE) Consortium

Sponsor: NCAA, Department of Defense
Deadline(s): NA
Contact: http://www.careconsortium.net/contact/
Link(s): https://fitbir.nih.gov/study_profile/310
http://www.careconsortium.net/
http://www.ncaa.org/sport-science-institute/topics/ncaa-dod-care-consortium

Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)

Sponsor: National Institute of Neurological Disorders and Stroke; National Institute on Aging
Deadline(s): 07/19/2021; 02/14/2022; 03/08/2022 (Expiration)
Contact: Scientific/Research Contact(s); Mary Ann Pelleymounter, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1779; Email: mary.pelleymounter@nih.gov

BRAIN Initiative: Development of Next Generation Human Brain Imaging Tools and Technologies (U01 Clinical Trial not allowed)

Sponsor: National Institute of Biomedical Imaging and Bioengineering; National Center for Complementary and Integrative Health; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke
Deadline(s): 09/03/2021; 09/04/2022 (Expiration)
Contact: Scientific/Research Contact(s); Shumin Wang, Ph.D.; National Institute of Biomedical Imaging and Bioengineering (NIBIB); Telephone: 301-594-9001; Email: shumin.wang@nih.gov

Notice to Allow Requests for Budget Increases for NINDS Research Program Award (R35)

Sponsor: National Institute of Neurological Disorders and Stroke
Deadline(s): NA; 06/12/2019 (Release Date)
Contact: Please direct all inquiries to: Anna Taylor, Ph.D.; National Institute of Neurological Disorders and Stroke (NINDS) / Division of Extramural Activities (DEA); Telephone: 301-827-3565; Email: Anna.Taylor@nih.gov

Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)

Sponsor: National Institute of Neurological Disorders and Stroke
Deadline(s): 10/14/2021; Standard AIDS dates; 01/08/2022
Contact: Scientific/Research Contact(s); Adam L. Hartman, MD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-9135; E-mail: adam.hartman@nih.gov

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR/R44 Clinical Trial Not Allowed)

Sponsor: National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute on Drug Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Alcohol Abuse and Alcoholism; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke
Deadline(s): Standard dates; Note new SBIR/STTR Standard Due Dates: 01/06/2021 (Expiration)
Contact: Scientific/Research Contact(s); Margaret Grabb, PhD; National Institute of Mental Health (NIMH); Telephone: 301-443-3563; Email: mgrabbe@mail.nih.gov

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed)

Sponsor: National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke
Deadline(s): Standard dates; Note new SBIR/STTR Standard Due Dates: 01/06/2021 (Expiration)
Contact: Scientific/Research Contact(s); Edmund (Ned) Talley, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Telephone: 301-496-1917; Email: EDMUND@NIH.GOV
Contact: Scientific/Research Contact(s); Margaret Grabb, PhD; National Institute of Mental Health (NIMH)
Telephone: 301-443-3563; Email: mgrabb@mail.nih.gov


POST TRAUMATIC SYNDROMES AND TRAUMA
NA

DELIRIUM
NA

MUSCULOSKELETAL DISORDERS

REHABILITATION
NA

MOOD / MENTAL HEALTH / ILLNESS / PSYCHIATRY / PSYCHIATRIC DISORDERS / INTELLECTUAL DISABILITIES

Notice of Special Interest (NOSI): Supporting Research Education in High-Priority Intervention and Services Research Areas for Mentoring Networks for Mental Health Research Education and Short Courses for Mental Health Related Research

Sponsor: National Institute of Mental Health
Deadline(s): 05/26/2022 (Expiration)
Contact: Scientific/Research Contact(s); Lauren D. Hill; National Institute of Mental Health (NIMH); Telephone: 301-443-2638; Email: hillla@mail.nih.gov


AGRICULTURE

Change in Application Types for PAR-15-353 "NIOSH Centers for Agricultural Safety and Health (US4)"

Sponsor: Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (NIOSH)
Deadline(s): 10/11/2017 (Release Date)
Contact: Scientific/Research Contact; Steve Dearwent, PhD; Telephone: 404-498-6382; Email: SDearwent@cdc.gov


NON-COMMUNICABLE DISEASES

SUICIDE PREVENTION

Notice of Intent to Publish a Funding Opportunity Announcement for Systems-Level Risk Detection and Interventions to Reduce Suicide Ideation and Behaviors in Black Children and Adolescents (R01 Clinical Trial Optional)

Sponsor: National Institute of Mental Health
Deadline(s): 06/29/2021 (First Estimated Application Due Date)
Contact: Please direct all inquiries to: Denise Juliano-Bult, MSW; National Institute of Mental Health (NIMH); 301-443-1638; djuliano@mail.nih.gov


Notice of Intent to Publish a Funding Opportunity Announcement for Systems-Level Risk Detection and Interventions to Reduce Suicide Ideation and Behaviors in Black Children and Adolescents (R34 Clinical Trial Optional)

Sponsor: National Institute of Mental Health
Deadline(s): 04/30/2021 (First Estimated Application Due Date)
Contact: Please direct all inquiries to: Denise Juliano-Bult, MSW; National Institute of Mental Health (NIMH); 301-443-1638; djuliano@mail.nih.gov


Notice of Intent to Publish a Funding Opportunity Announcement for Systems-Level Risk Detection and Interventions to Reduce Suicide Ideation and Behaviors in Youth from Underserved Populations (R01 Clinical Trial Optional)

Sponsor: National Institute of Mental Health
Deadline(s): 04/30/2021 (First Estimated Application Due Date)
Contact: Please direct all inquiries to: Denise Juliano-Bult, MSW; National Institute of Mental Health (NIMH); 301-443-1638; djuliano@mail.nih.gov
Notice of Intent to Publish a Funding Opportunity Announcement for Systems-Level Risk Detection and Interventions to Reduce Suicide Ideation and Behaviors in Youth from Underserved Populations (R34 Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 06/29/2021 (First Estimated Application Due Date)  
**Contact:** Please direct all inquiries to: Denise Juliano-Bult, MSW; National Institute of Mental Health (NIMH); 301-443-1638; djuliano@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-21-188.html

Notice of Special Interest (NOSI) in Research on Risk and Prevention of Black Youth Suicide

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 08/25/2020 (First Available Due Date); 07/31/2022 (Expiration Date)  
**Contact:** Scientific/Research Contact(s); Stacia Friedman-Hill, PhD; Division of Translational Research; National Institute of Mental Health (NIMH); Telephone: 301-443-8458; Email: friedmans@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-055.html

Notice of Intent to Publish a Funding Opportunity Announcement for Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 01/26/2022; 01/27/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Joel Sherrill, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-2477; Email: jsherril@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-286.html

Notice of Intent to Publish a Funding Opportunity Announcement for Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide RPG (R01 Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 02/14/2021 (First Estimated Application Due Date)  
**Contact:** Please direct all inquiries to: Stephen O'Connor, Ph.D.; National Institute of Mental Health (NIMH); (301) 480-8366; stephen.o'connor2@nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-069.html

Notice of Intent to Publish a Funding Opportunity Announcement for Pilot Effectiveness Trials for Rapid-Acting Interventions for Severe Suicide Risk (R01 Clinical Trial Required)

**Sponsor:** National Institute of Mental Health  
**Deadline(s):** 02/25/2020 (First Estimated Due Date)  
**Contact:** Please direct all inquiries to: Joel Sherrill, Ph.D.; NIMH; 301-443-2477; jsherril@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-065.html

**Additional Information:** Related Announcements: NOT-MH-20-069 - Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R34 Clinical Trial Optional)

Notice of Intent to Publish a Funding Opportunity Announcement for Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R34 Clinical Trial Optional)

**Sponsor:** National Institute of Mental Health

**Deadline(s):** 02/14/2021 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Matthew Rudorfer, M.D.; National Institute of Mental Health (NIMH); (301) 443-8458; Email: mrudorfe@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-044.html

**Notice of Intent to Publish a Funding Opportunity Announcement for Systems-Level Risk Detection and Interventions to Reduce Suicide Ideation and Behaviors in Youth from Underserved Populations (R34 Clinical Trial Optional):**

Sponsor: National Institute of Mental Health

Deadline(s): 06/29/2021 (First Estimated Application Due Date)

Contact: Please direct all inquiries to: Denise Juliano-Bult, MSW; National Institute of Mental Health (NIMH); 301-443-1638; djuliano@mail.nih.gov


Notice of Special Interest (NOSI) in Research on Risk and Prevention of Black Youth Suicide

Sponsor: National Institute of Mental Health

Deadline(s): 08/25/2020 (First Available Due Date); 07/31/2022 (Expiration Date)

Contact: Scientific/Research Contact(s); Stacia Friedman-Hill, PhD; Division of Translational Research; National Institute of Mental Health (NIMH); Telephone: 301-443-8458; Email: friedmans@mail.nih.gov


Notice of Intent to Publish a Funding Opportunity Announcement for Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional)

Sponsor: National Institute of Mental Health

Deadline(s): 01/26/2022; 01/27/2022 (Expiration)

Contact: Scientific/Research Contact(s); Joel Sherrill, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-2477; Email: jsherril@mail.nih.gov


Notice of Intent to Publish a Funding Opportunity Announcement for Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional)

Sponsor: National Institute of Mental Health

Deadline(s): 01/26/2022; 01/27/2022 (Expiration)

Contact: Scientific/Research Contact(s); Joel Sherrill, Ph.D.; National Institute of Mental Health (NIMH); Telephone: 301-443-2477; Email: jsherril@mail.nih.gov


Notice of Intent to Publish a Funding Opportunity Announcement for Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide RPG (R01 Clinical Trial Optional)

Sponsor: National Institute of Mental Health

Deadline(s): 02/14/2021 (First Estimated Application Due Date)

Contact: Please direct all inquiries to: Stephen O'Connor, Ph.D.; National Institute of Mental Health (NIMH); (301) 480-8366; stephen.o'connor2@nih.gov


Notice of Special Interest (NOSI) in Research on Risk and Prevention of Black Youth Suicide

Sponsor: National Institute of Mental Health

Deadline(s): 08/25/2020 (First Available Due Date); 07/31/2022 (Expiration Date)

Contact: Scientific/Research Contact(s); Stacia Friedman-Hill, PhD; Division of Translational Research; National Institute of Mental Health (NIMH); Telephone: 301-443-8458; Email: friedmans@mail.nih.gov


Notice of Intent to Publish a Funding Opportunity Announcement for Pilot Effectiveness Trials for Rapid-Acting Interventions for Severe Suicide Risk (R01 Clinical Trial Required)

Sponsor: National Institute of Mental Health

Deadline(s): 02/25/2020 (First Estimated Due Date)

Contact: Please direct all inquiries to: Joel Sherrill, Ph.D.; NIMH; 301-443-2477; jsherril@mail.nih.gov


**Additional Information:** Related Announcements: NOT-MH-20-069 - Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R34 Clinical Trial Optional)

Notice of Intent to Publish a Funding Opportunity Announcement for Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R34 Clinical Trial Optional)

Sponsor: National Institute of Mental Health

Deadline(s): 02/14/2021 (First Estimated Application Due Date)

Contact: Please direct all inquiries to: Matthew Rudorfer, M.D.; National Institute of Mental Health (NIMH); (301) 443-8458; Email: mrudorfe@mail.nih.gov


**TRANSFUSIONS**

NA
**VETERINARY MEDICINE**

**Notice to extend the 2020 Application Due Date for PAR-20-132 "Development and Maintenance of the Animal Feed Regulatory Program Standards with Optional Coordinated Preventive Control Regulatory Activities and Capacity Building (U18)"**

**Sponsor:** Food and Drug Administration; Notices of Special Interest

**Deadline(s):** 12/01/2021; 02/16/2022 (Expiration)

**Contact:** Please direct all inquiries to: Gordana Zuber; Office of Acquisitions & Grants Services (OAGS); Food and Drug Administration; Telephone: 301-348-1747; Email: gordana.zuber@fda.hhs.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-FD-20-023.html; Related Announcements; PAR-20-132

---

**HEALTH CARE PROVIDERS**

**NA**

**AFFORDABLE CARE ACT AND EXCHANGES**

**NA**

**MEDICARE MEDICAID**

**NA**

**CENTERS OF EXCELLENCE**

**NA**

**AGE / AGING**

**Notice of Special Interest: Integrative Studies of Neural Mechanisms Underlying Fundamental Affective Processes in Aging**

**Sponsor:** National Institute on Aging

**Deadline(s):** 02/05/2021 (First Available Due Date); 01/08/2024 (Expiration Date)

**Contact:** Please direct all inquiries to: Luci Roberts, Ph.D.; Division of Neuroscience; National Institute on Aging (NIA); Email: robertlu@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AG-21-012.html

**Notice of Special Interest: Advancing the Science of Geriatric Palliative Care**

**Sponsor:** National Institute on Aging; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Minority Health and Health Disparities; National Institute of Nursing Research; Office of Research on Women’s Health

**Deadline(s):** 10/05/2020 (First Available Due Date); 09/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Diane St. Germain; National Cancer Institute (NCI); Telephone: 240-276-7082; Email: dstgermain@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-041.html

**Notice of Special Interest: Alcohol and Aging**

**Sponsor:** National Institute on Alcohol Abuse and Alcoholism

**Deadline(s):** 10/05/2020 (First Available Due Date); 09/08/2023 (Expiration Date)

**Contact:** Scientific/Research Contact(s): Andras Orosz, Ph.D.; Division of Metabolism and Health Effects; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Phone: 301-443-2193; Email: orosza@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-AA-20-019.html

**Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Required)**

**Sponsor:** National Institute on Aging

**Deadline(s):** 10/22/2021; 10/21/2022; 10/22/2022 (Expiration)

**Contact:** Scientific/Research Contact(s): Shahrooz Vahedi, Ph.D.; National Institute on Aging (NIA); Telephone: 301-496-9322; Email: shahrooz.vahedi@nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-021.html

**Notice of Special Interest to Highlight High Priority Opportunities for Intervention Development Research in Geriatric Mental Health**

**Sponsor:** National Institute of Mental Health

**Deadline(s):** 09/08/2023 (Expiration)

**Contact:** Scientific/Research Contact(s); Jovier D. Evans, PhD.; NIMH/Division of Translational Research; Telephone: {301-443-1369}; Email: jevans1@mail.nih.gov

**Link(s):** https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-027.html
Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)

**Sponsor:** National Institute on Aging  
**Deadline(s):** Standard dates; 11/17/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Winifred K. Rossi; National Institute on Aging (NIA); Telephone: 301-496-3836;  
**Email:** rossiw@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-20-070.html

Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)

**Sponsor:** National Institute on Aging  
**Deadline(s):** Standard dates; 11/17/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Winifred K. Rossi; National Institute on Aging (NIA); Telephone: 301-496-3836;  
**Email:** rossiw@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-20-071.html

Could where you live influence how long you live?

**Sponsor:** RWJF  
**Deadline(s):** NA  
**Contact:** https://www.rwjf.org/en/manage-your-subscriptions.html [subscribe to RWJF emails]  
**Link(s):** https://www.rwjf.org/en/library/interactives/whereyouliveaffectshowlongyouliv e.html

National Academy of Medicine Launches Global Competition Seeking Solutions for Improving Healthy Longevity

**Sponsor:** National Academy of Medicine  
**Deadline(s):** The first cycle of the Catalyst Phase of the Healthy Longevity Global Competition opens in January 2020. Proposals will be accepted for approximately 6 weeks  
**Contact:** Don’t see your location? New Global Collaborators will be added in the coming years. If your organization is interested in becoming a Global Collaborator, contact HealthyLongevity@nas.edu  

Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)

**Sponsor:** National Institute on Aging  
**Deadline(s):** Standard dates; 09/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Sanoj Suneja, Ph.D.; National Institute on Aging (NIA); Telephone: 301-402-7710;  
**Email:** suneja@nai.nih.gov  

NIA Program Project Applications (P01 Clinical Trial Optional)

**Sponsor:** National Institute on Aging  
**Deadline(s):** Standard dates; Standard AIDS dates; 05/26/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Robin A. Barr; D. Phil.; National Institute on Aging (NIA); Telephone: 301-496-9322;  
**Email:** BarrR@mail.nih.gov  

Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional)

**Sponsor:** National Institute on Aging  
**Deadline(s):** Standard dates; 07/12/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Chhanda Dutta, Ph.D.; Division of Geriatrics and Clinical Gerontology; National Institute on Aging (NIA); Telephone: 301-496-4161;  
**Email:** duttac@nia.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-19-305.html

Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional)

**Sponsor:** National Institute on Aging  
**Deadline(s):** Standard dates; 07/17/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); Chhanda Dutta, Ph.D.; Division of Geriatrics and Clinical Gerontology; National Institute on Aging (NIA); Telephone: 301-496-4161;  
**Email:** duttac@nia.nih.gov  

Clinical Research to Improve the Oral Health of Older Adults (R01 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Dental and Craniofacial Research  
**Deadline(s):** Standard dates; Standard AIDS dates 09/07/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); For questions related to general clinical research, contact: Darien Weatherspoon, DDS, MPH; National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-594-5394;  
**Email:** darien.weatherspoon@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-19-239.html

Clinical Research to Improve the Oral Health of Older Adults (R21 Clinical Trial Not Allowed)

**Sponsor:** National Institute of Dental and Craniofacial Research  
**Deadline(s):** Standard dates; Standard AIDS dates 09/08/2022 (Expiration)  
**Contact:** Scientific/Research Contact(s); For questions related to general clinical research, contact: Darien Weatherspoon, DDS, MPH; National Institute of Dental and Craniofacial Research (NIDCR); Telephone: 301-594-5394;  
**Email:** darien.weatherspoon@mail.nih.gov  
**Link(s):** https://grants.nih.gov/grants/guide/pa-files/PAR-19-239.html
Notice to Specify High-Priority Research Topic for PAR-19-070 and PAR-19-071

**Sponsor:** National Institute on Aging  
**Deadline(s):** 11/12/2021; 11/13/2021 (Expiration)  
**Contact:** Please direct all inquiries to: Elena Fazio; National Institute on Aging (NIA); Telephone: 301-496-3136; Email: elena.fazio@nih.gov  

**Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)**

**Sponsor:** National Institute of Nursing Research; National Institute on Aging  
**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Mary C. Roary, Ph.D.; National Institute of Nursing Research (NINR)  
Phone: 301-594-2154; Email: mary.roary@nih.gov  

**Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional)**

**Sponsor:** National Institute of Nursing Research; National Institute on Aging  
**Deadline(s):** Standard dates; Standard AIDS dates; 09/08/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Mary C. Roary, Ph.D.; National Institute of Nursing Research (NINR)  
Phone: 301-594-2154; Email: mary.roary@nih.gov  

**Making Health Care Safer in Ambulatory Care Settings and Long Term Care Facilities (R18)**

**Sponsor:** Agency for Healthcare Research and Quality  
**Deadline(s):** Standard dates; 09/08/2021 (Expiration)  
**Contact:** Scientific/Research Contact(s); Barbara A. Bartman, MD, MPH; Agency for Healthcare Research and Quality; Center for Quality Improvement and Patient Safety; Telephone: 301-427-1515; Email: barbara.bartman@ahrq.hhs.gov  

**Policy on Charging and Documentation of Personnel Costs Charged to Sponsored Projects**

**Sponsor:** COLUMBIA UNIVERSITY  
**Deadline(s):** Information Sessions are offered to ensure clear understanding of this policy. Attendance is strongly encouraged. Information sessions will be held in October on both the CUMC and Morningside campuses: (*) CUMC – Alumni Auditorium, Black Building, 650 W. 168 St; (**) Tuesday, October 11, 11:00-12:30; (**) Thursday, October 13, 10:30-12:00; (*) Morningside - Schapiro Center, Davis Auditorium, 412 CEPSR, 530 W. 120 Street; (**) Thursday, October 13, 2-15-3:45; (***) Tuesday, October 18, 9:00-10:30;  
**Contact:** For questions, please contact research-compliance@columbia.edu  
**Link(s):** [http://policylibrary.columbia.edu/policy-charging-and-documentation-personnel-costs-charged-sponsored-projects](http://policylibrary.columbia.edu/policy-charging-and-documentation-personnel-costs-charged-sponsored-projects)

**Institutional Review Board Walk In Hours;**

Columbia | Research; Human Research Protection Office;  
**Sponsor:** Institutional Review Board;  
**Deadline:** [http://www.cumc.columbia.edu/dept/irb/](http://www.cumc.columbia.edu/dept/irb/);  
**Contact:** For questions, please contact  
**Link(s):** [http://www.cumc.columbia.edu/dept/irb/](http://www.cumc.columbia.edu/dept/irb/)

**Additional Information:** Dear Colleagues: At the start of the New Year, in response to requests from the research community, we are pleased to announce that beginning Monday January 4th an additional hour will be established. Walk-in hours are available for researchers at the IRB Liaison office in PH10 to meet with Rui Ferreira, IRB Specialist. Rui will be available to assist researchers with understanding and addressing IRB requirements and requests. He will also be able to help navigate Rascal IRB 2.0.; Scheduled walk-in hours are on Monday, Wednesday and Thursdays: (*) Time: (*) Mondays 3-4 pm; (**) Wednesdays and Thursdays 10:00 – 11:00 am; (***) Location: 622 West 168 St, PH-10-402 D; (**) Attendees will be asked to sign in, and will meet with Rui in order of arrival. If other people are waiting, individual consultations may be limited to 30 minutes; (*) Consultation is available to Columbia faculty researchers, who may be accompanied by student or trainee/mentees; Researchers may also call Rui at during working hours for assistance: 212-342-5136; To learn more or to request an appointment outside walk-in hours, contact Rui by phone or email: (*) 212-342-5136; (**) rf2554@columbia.edu; We thank you for your continued commitment to the ethical conduct of human research.; Columbia | Research; Human Research Protection Office; Institutional Review Board;
Notice of Intent to Publish a Funding Opportunity
Announcement for Chronic Kidney Diseases of Uncertained Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium Renal Analytic Core (U01 - Clinical Trial Not Allowed)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences

**Deadline(s):** 11/10/2020 (First Estimated Due Date)

**Contact:** Please direct all inquiries to: Susan R. Mendley, MD; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 301-827-1861; susan.mendley@nih.gov


**Additional Information:** Related Announcements: NOT-DK-20-028: Notice of Intent to Publish a Funding Opportunity Announcement for Chronic Kidney Diseases of Uncertained Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium – Field Site (U01 - Clinical Trial Not Allowed); NOT-DK-20-030: Notice of Intent to Publish a Funding Opportunity Announcement for Chronic Kidney Diseases of Uncertained Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium - Scientific Data Coordinating Center (SDCC) (U24 - Clinical Trial Not Allowed)

---

Notice of Intent to Publish a Funding Opportunity Announcement for Chronic Kidney Diseases of Uncertained Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium - Field Site (U01 - Clinical Trial Not Allowed)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases; John E. Fogarty International Center; National Institute of Environmental Health Sciences

**Deadline(s):** 11/10/2020 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Susan R. Mendley, MD; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 301-827-1861; susan.mendley@nih.gov


**Additional Information:** Related Announcements: NOT-DK-20-028: Notice of Intent to Publish a Funding Opportunity Announcement for Chronic Kidney Diseases of Uncertained Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium – Field Site (U01 - Clinical Trial Not Allowed); NOT-DK-20-029: Notice of Intent to Publish a Funding Opportunity Announcement for Chronic Kidney Diseases of Uncertained Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium - Scientific Data Coordinating Center (SDCC) (U24 - Clinical Trial Not Allowed)

---

Quarterly Financial Reviews Relative to Uniform-Guidance

**Sponsor:** CU Uniform-Guidance; National Institute of Environmental Health Sciences

**Deadline(s):** NA

**Contact:** uniform-guidance@columbia.edu;

**Link(s):** [https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-027.html](https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-027.html);

From the Columbia University Executive Vice President's Office:

**NA**

**UROLOGY**, **Kidney**

[1] Notice of Pre-Application Webinar and Frequently Asked Questions (FAQs) for PAR-20-220 " Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1 - Clinical Trial Not Allowed) "

[2] PAR-20-220 pre submission Webinar Registration Link

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases

**Deadline(s):** 09/28/2021; 09/28/2022; 09/29/2022

(Expiration for PAR-20-220)

**Contact:** Please direct all inquiries to: Victoria Spruance, Ph.D.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Telephone: 301-827-5091;

Email: victoria.spruance@nih.gov


**Additional Information:** Related Announcements: PAR-20-220 - Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C-Clinical Trial Not Allowed)

---

Notice of Intent to Publish a Funding Opportunity Announcement for Chronic Kidney Diseases of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium - Field Site (U01 - Clinical Trial Not Allowed)

**Sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases; John E. Fogarty International Center; National Institute of Environmental Health Sciences

**Deadline(s):** 11/10/2020 (First Estimated Application Due Date)

**Contact:** Please direct all inquiries to: Susan R. Mendley, MD; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 301-827-1861; susan.mendley@nih.gov


**Additional Information:** Related Announcements: NOT-DK-20-028: Notice of Intent to Publish a Funding Opportunity Announcement for Chronic Kidney Diseases of Uncertained Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium – Field Site (U01 - Clinical Trial Not Allowed); NOT-DK-20-030: Notice of Intent to Publish a Funding Opportunity Announcement for Chronic Kidney Diseases of Uncertained Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium - Scientific Data Coordinating Center (SDCC) (U24 - Clinical Trial Not Allowed)
Contact Us
Dr. Pam Factor-Litvak
Associate Dean for Research Resources
Associate Professor of Clinical Epidemiology
Mailman School of Public Health
722 West 168th Street, Room 1614 New York, NY 10032
Phone: 212-305-7851
prf1@cumc.columbia.edu
mailman.columbia.edu/r2

Craig Kandell
Project Coordinator
212-305-3615
ckk7@cumc.columbia.edu

END